<SEC-DOCUMENT>0001437749-24-005894.txt : 20240228
<SEC-HEADER>0001437749-24-005894.hdr.sgml : 20240228
<ACCEPTANCE-DATETIME>20240228160107
ACCESSION NUMBER:		0001437749-24-005894
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240228
DATE AS OF CHANGE:		20240228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CASSAVA SCIENCES INC
		CENTRAL INDEX KEY:			0001069530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				911911336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41905
		FILM NUMBER:		24695034

	BUSINESS ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731
		BUSINESS PHONE:		512-501-2444

	MAIL ADDRESS:	
		STREET 1:		6801 N CAPITAL OF TEXAS HIGHWAY
		STREET 2:		BUILDING 1; SUITE 300
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78731

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PAIN THERAPEUTICS INC
		DATE OF NAME CHANGE:	20000309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sava20231231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:sava="http://www.cassavasciences.com/20231231" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>sava20231231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 2/28/2024 4:04:02 AM -->
  <meta http-equiv="Content-Type" content="text/html"/></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001069530</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:AmendmentFlag" format="ixt:fixed-false" id="ixv-12670">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-12671">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-12672">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-12673">2023</ix:nonNumeric>
<ix:nonFraction id="c107483662" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c107483663" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c107483667" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c107483668" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c107483669" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c107483670" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c107483671" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107483673" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107483672" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107483674" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107483677" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c107483678" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c107483679" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c107483680" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">120,000,000</ix:nonFraction>
<ix:nonFraction id="c107483681" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c107483683" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction>
<ix:nonFraction id="c107483682" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction>
<ix:nonFraction id="c107483684" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction>
<ix:nonFraction id="c107483920" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c107483964" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c107483965" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c107484158" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c107484343" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484346" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484349" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484352" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484355" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484358" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c107484403" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction>
<ix:nonFraction id="c107484422" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:OpenTaxYear" id="c107484425">2019 2020 2021 2022</ix:nonNumeric>
<ix:nonFraction id="c107484574" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c107484575" contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c107484576" contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c107484579" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c107484580" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c107484582" contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3</ix:nonFraction>
<ix:nonFraction id="c107484588" contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">4</ix:nonFraction>
<ix:nonFraction id="c107484590" contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="sava:ClassOfWarrantOrRightIssuedDuringPeriod" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.9</ix:nonFraction>
<ix:nonFraction id="c107484592" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c107484606" contextRef="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="sava:RedemptionPercentageOfWarrants" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.1</ix:nonFraction>
<ix:nonFraction id="c107484615" contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="sava:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">659,000</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c107484626" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c107484634" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c107484635" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c107484636" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="sava-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2023-01-01_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-02-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-22</xbrli:startDate><xbrli:endDate>2022-11-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2021RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2021RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:CarryforwardSubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:IndefiniteLifeCarryforwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_LeaseContractualTermAxis-LeaseForOfficeSpaceInAustinTexasMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:LeaseForOfficeSpaceInAustinTexasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-28</xbrli:startDate><xbrli:endDate>2021-10-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-04</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-05</xbrli:startDate><xbrli:endDate>2022-07-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-22</xbrli:startDate><xbrli:endDate>2023-12-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-01-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-01-03_ClassOfWarrantOrRightAxis-BonusShareFractionMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:BonusShareFractionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001069530</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#160;
  </div>
  <div><div>
 &#160;
</div>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><a href="#toc" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt">Table of Contents</a></p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="font-family: Times New Roman; font-size: 14pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Form <ix:nonNumeric name="dei:DocumentType" contextRef="d_2023-01-01_2023-12-31" id="ixv-13877">10-K</ix:nonNumeric></b></p>
<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;<b>(Mark One)</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:5.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13878">&#9745;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:94.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Fiscal Year Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" contextRef="d_2023-01-01_2023-12-31" id="ixv-13879">December 31, 2023</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or</b></p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:5.2%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13880">&#9744;</ix:nonNumeric></p> </td><td style="vertical-align:top;width:94.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from </b><b><span style="text-decoration: underline; ">_____</span></b><b> to </b><b><span style="text-decoration: underline; ">_____</span></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2023-01-01_2023-12-31" id="ixv-13881">000-29959</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>Cassava Sciences, Inc.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2023-01-01_2023-12-31" id="ixv-13882">Delaware</ix:nonNumeric> </b></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2023-01-01_2023-12-31" id="ixv-13883">91-1911336</ix:nonNumeric> </b></p> </td></tr>
<tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State or other jurisdiction of</i></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(I.R.S. Employer</i></p> </td></tr>
<tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>incorporation or organization)</i></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Identification Number)</i></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2023-01-01_2023-12-31" id="ixv-13884">6801 N. Capital of Texas Highway, Building 1; Suite 300</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2023-01-01_2023-12-31" id="ixv-13885">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2023-01-01_2023-12-31" id="ixv-13886">TX</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2023-01-01_2023-12-31" id="ixv-13887">78731</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2023-01-01_2023-12-31" id="ixv-13888">512</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2023-01-01_2023-12-31" id="ixv-13889">501-2444</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Address, including zip code, of registrant's principal executive offices and</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>telephone number, including area code)</i></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:15pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title of each class</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange on which registered</b></p> </td></tr>
<tr><td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-13890">Common Stock, $0.001 par value</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 18%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-13891">SAVA</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember" id="ixv-13892">NASDAQ</ix:nonNumeric> Capital Market</p> </td></tr>
<tr><td style="width:288px; padding:.33px .33px .33px .33px" valign="top"> <p style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
    <div style="font-size:12pt">
     <div style="font-family:&quot;Times New Roman&quot;,serif">
      <div style="font-size:10.0pt">
       <div style="color: black; text-align: center;">
        <ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-13893">Warrants, exercisable for shares of Common Stock</ix:nonNumeric>
       </div>
      </div>
     </div>
    </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> </td><td style="width:7px; padding:.33px .33px .33px .33px" valign="bottom"> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> </td><td style="width:130px; padding:.33px .33px .33px .33px" valign="bottom"> <p style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
    <div style="font-size:12pt">
     <div style="font-family:&quot;Times New Roman&quot;,serif">
      <div style="font-size:10.0pt">
       <div style="color: black; text-align: center;">
        <ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-13894">SAVAW</ix:nonNumeric>
       </div>
      </div>
     </div>
    </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> </td><td style="width:7px; padding:.33px .33px .33px .33px" valign="bottom"> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> </td><td style="width:288px; padding:.33px .33px .33px .33px" valign="bottom"> <p style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
    <div style="font-size:12pt">
     <div style="font-family:&quot;Times New Roman&quot;,serif">
      <div style="font-size:10.0pt">
       <div style="color: black; text-align: center;">
        <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember" id="ixv-13895">NASDAQ</ix:nonNumeric> Capital Market
       </div>
      </div>
     </div>
    </div> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> </td></tr>
<tr><td style="vertical-align: top; width: 40%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 18%;">&#160;</td><td style="vertical-align: bottom; width: 1%;">&#160;</td><td style="vertical-align: bottom; width: 40%;">&#160;</td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities registered pursuant to Section 12(g) of the Act: None</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2023-01-01_2023-12-31" id="ixv-13896">Yes</ix:nonNumeric>&#160;&#9745; No&#160;&#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2023-01-01_2023-12-31" id="ixv-13897">No</ix:nonNumeric>&#160;&#9745;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2023-01-01_2023-12-31" id="ixv-13898">Yes</ix:nonNumeric>&#160;&#9745; No&#160;&#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2023-01-01_2023-12-31" id="ixv-13899">Yes</ix:nonNumeric>&#160;&#9745; No&#160;&#9744;.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
    1
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2023-01-01_2023-12-31" id="ixv-13900">Large accelerated filer</ix:nonNumeric> &#9745;</p> </td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p> </td></tr>
<tr><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Non-accelerated filer &#9744;</p> </td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13901">&#9744;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:49.9%;">&#160;</td><td style="vertical-align:top;width:49.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13902">&#9744;</ix:nonNumeric></p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the&#160;Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13903">&#9745;</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160; <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13904">&#9744;</ix:nonNumeric></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2023-01-01_2023-12-31" id="ixv-13905">&#9744;</ix:nonNumeric> No&#160;&#9745;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" contextRef="i_2023-06-30" id="ixv-13906">967</ix:nonFraction>&#160;million computed by reference to the last sales price of $24.52&#160;as reported on the Nasdaq Capital Market, as of the last business day of the Registrant's most recently completed second fiscal quarter, June&#160;30, 2023. The number of shares outstanding of the Registrant's common stock, par value $0.001 per share, on February 26, 2024&#160;was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:num-dot-decimal" contextRef="i_2024-02-26" id="ixv-13907">43,225,211</ix:nonFraction>.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Portions of the Registrant's proxy statement for its 2024&#160;Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference to Part III of this Annual Report on Form 10-K.&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    2
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></div>
  <div>
    &#160;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="toc" title="toc" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 10-K</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align:top;width:7.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Page</span></b></p> </td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1" style="-sec-extract:exhibit;">Business</a></p> </td>
      <td style="vertical-align:bottom;width:7.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#item1">6</a></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1a" style="-sec-extract:exhibit;">Risk Factors</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1a">33</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 1B.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item1b" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1b">77</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">Item 1C.</td>
      <td style="vertical-align:top;width:81.7%;"><a href="#item1c" style="-sec-extract:exhibit;">Cybersecurity</a></td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item1c">77</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 2.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item2" style="-sec-extract:exhibit;">Properties</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item2">77</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 3.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item3" style="-sec-extract:exhibit;">Legal Proceedings</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item3">77</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 4.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item4">79</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 5.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;"><a href="#item5" style="-sec-extract:exhibit;">Market for Registrant<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item5">79</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 6.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item6" style="-sec-extract:exhibit;">[Reserved]</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item6">80</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 7.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item7" style="-sec-extract:exhibit;">Management<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item7">81</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 7A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item7a" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures About Market Risk</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item7a">89</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 8.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item8" style="-sec-extract:exhibit;">Consolidated Financial Statements and Supplementary Data</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item8">89</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9" style="-sec-extract:exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9">110</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9A.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9a" style="-sec-extract:exhibit;">Controls and Procedures</a>&#160;</p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9a">111</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9B.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9b" style="-sec-extract:exhibit;">Other Information</a>&#160;</p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9b">113</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 9C.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item9c" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspection</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item9c">113</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART III</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 10.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item10" style="-sec-extract:exhibit;">Directors and Executive Officers and Corporate Governance</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item10">113</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 11.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item11" style="-sec-extract:exhibit;">Executive Compensation</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item11">115</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 12.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item12">115</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 13.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item13">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 14.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#itme14" style="-sec-extract:exhibit;">Principal Accountant Fees and Services</a></p> </td>
      <td style="vertical-align: bottom; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#itme14">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;">&#160;</td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;">&#160;</td>
     </tr>

     <tr>
      <td colspan="3" style="vertical-align:top;width:99.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV</b></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 15.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item15" style="-sec-extract:exhibit;">Exhibits and Consolidated Financial Statement Schedules</a></p> </td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item15">116</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Item 16.</p> </td>
      <td style="vertical-align:top;width:81.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#item16" style="-sec-extract:exhibit;">Form 10-K Summary</a></p> </td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#item16">118</a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:10.3%;"><a href="#sigs" style="-sec-extract:exhibit;">Signatures</a></td>
      <td style="vertical-align:top;width:81.7%;">&#160;</td>
      <td style="vertical-align: top; width: 7.4%; text-align: center;"><a class="tocPGNUM" href="#sigs">119</a></td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        3
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b>PART I</b></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORWARD-LOOKING STATEMENTS AND NOTICES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This Annual Report on Form 10-K, including the portions of our definitive Proxy Statement incorporated by reference herein, contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Reform Act of 1995. We intend that such forward-looking statements be protected by the safe harbor created thereby.&#160; All statements other than statements of present or historical facts contained in this Annual Report, including statements anticipating or otherwise relating to our future results of operations and financial position, future results of ongoing clinical trials, business strategy, plans and objectives for future operations, and anticipated events or trends, are forward-looking statements. In some cases, forward-looking statements are identified by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;drive,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;future,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;will&#8221; and &#8220;would&#8221; or the negatives of these terms or other comparable terminology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Examples of forward-looking statements include, but are not limited to, statements about:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the expected safety profile or treatment benefits, if any, of simufilam for people with Alzheimer&#8217;s disease in our on-going Phase 3 studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;">our reliance on third-party contractors to conduct all of our clinical and non-clinical trials and to make drug supply on a large-scale for our Phase 3 clinical program, or their ability to do so on-time or on-budget;</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">limitations around data interpretation from results of any of the three clinical phases of our 2-year safety study of simufilam in patients with Alzheimer&#8217;s disease, as compared to clinical&#160;results from randomized controlled trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of clinical scales to assess cognition or health in our trials of Alzheimer&#8217;s disease;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any significant changes we may make, or anticipate making, to the design of any of our on-going Phase 3 studies of simufilam in patients with Alzheimer&#8217;s disease;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to initiate, conduct or analyze additional clinical and non-clinical studies with our product candidates targeted at Alzheimer&#8217;s disease and other neurodegenerative diseases;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the impact of pre-clinical findings on our ability to develop our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the interpretation of results from our pre-clinical or early clinical studies, such as Phase 1 and Phase 2 studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans to further develop SavaDx, our investigational blood-based diagnostic product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability or willingness to expand therapeutic indications for simufilam outside of Alzheimer&#8217;s disease;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the safety, efficacy, or potential therapeutic benefits of our product candidates;</p> </td>
    </tr>

    <tr style="font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our use of exploratory &#8216;research use only&#8217; non-safety related biomarkers in our clinical studies;</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to file for and obtain regulatory approval of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our strategy and ability to establish an infrastructure to commercialize any product candidates, if approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the potential future revenues of our product candidates, if approved and commercialized;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the market acceptance of our product candidates, if approved and commercialized;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the pricing and reimbursement of our product candidates, if approved and commercialized;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the utility of protection, or the sufficiency, of our intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our potential competitors or competitive products for the treatment of Alzheimer&#8217;s disease;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our need to raise new capital from time to time to continue our operations or to expand our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our use of multiple third-party vendors and collaborators, including a Clinical Research Organization (CRO), to conduct clinical and non-clinical studies of our lead product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding trade secrets, technological innovations, licensing agreements and outsourcing of certain business functions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our expenses or incurred costs increasing by material amounts in excess of budgeted amounts due to unexpected cost overruns, inflation, imperfect forecasting, increased scope of activities or other causes;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">fluctuations in our financial or operating results;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our operating losses, anticipated operating and capital expenditures and legal expenses;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expectations regarding the issuance of shares of common stock, options or other equity to employees or directors pursuant to equity compensation awards, net of employment taxes;</p> </td>
    </tr>

    <tr style="font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">expectations regarding the issuance of shares of common stock to holders of outstanding warrants that are exercised for cash;</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the development and maintenance of our internal information systems and infrastructure;</p> </td>
    </tr>

    <tr style="font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;">&#9679;</td>
     <td style="width: auto; font-size: 10pt;">our ability to minimize the likelihood and impact of adverse cybersecurity incidents in our information systems and infrastructure;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our need to hire additional personnel and our ability to attract and retain such personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">existing or emerging regulations and regulatory developments in the United States and other jurisdictions in which we operate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans to expand the size and scope of our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the sufficiency of our cash&#160;resources to continue to fund our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential future agreements with third parties in connection with the commercialization of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">assumptions and estimates used for our disclosures regarding stock-based compensation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the expense, timing and outcome of pending or future litigation or other legal proceedings and claims, including U.S. government inquiries; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The forward-looking statements in this Annual Report are based on our beliefs, assumptions and expectations of our future performance, events and developments, based on currently available information and plans. Forward-looking statements involve risks and uncertainties, and our actual results and the timing of events may differ materially from those discussed in the forward-looking statements. Such forward-looking statements include, but are not limited to, those described in &#8220;Item 1A. Risk Factors&#8221;, and investors should consider such risks before investing in our Company.&#160; Accordingly, you should not place undue reliance upon any forward-looking statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will affect us or our operations in the way we expect.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The forward-looking statements included in this Annual Report on Form 10-K are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by law.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In addition, statements that &#8220;we believe&#8221; or similar statements reflecting our beliefs, views, and opinions on the relevant subject are based upon information available to us as of the date of this Annual Report.&#160; While we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and involve a number of assumptions and limitations, and you are cautioned not to unduly rely upon these statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our research programs in neurodegeneration have historically benefited from scientific and financial support from the National Institutes of Health (NIH). The contents of this Annual Report are solely our responsibility and do not represent any views of NIH, the Department of Health and Human Services, or any other agency of the United States government, or any of our vendors, collaborators or unrelated third-parties<i>.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 16pt;">All our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates are approved or available for sale anywhere in the world.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">All of our earlier-stage clinical trials, i.e., all studies that are not in Phase 3 stage of development, involve a relatively small number of patients and limited data. Information and results generated from our early-stage studies do not constitute, and should not be interpreted as, evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. Rigorous evidence for drug safety and efficacy is required for regulatory approval and is derived from one or more large, randomized, placebo-controlled Phase 3 studies. The design and limited size of our early-stage studies may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects, if any, placebo effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our early-stage clinical studies add complexity or limitations to the scope of data interpretation. In addition, &#8216;top-line results&#8217; is a summary of the clinical data prior to the completion of a full and final audit or quality-control of the clinical database. We generally communicate top-line results so that our stakeholders have timely access to a summary of a study&#8217;s findings prior to us receiving the final dataset. Final data may change from initial top-line data.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Unless otherwise noted, all clinical data in this Annual Report is statistically non-significant at a standard probability level of p&lt;0.05. In addition, from time to time, our scientific research may include the use of exploratory biomarkers, typically labelled &#8216;research use only.&#8217; They are understood to mean non-safety-related, investigational diagnostic products that are in the research phase of development and have not been approved by any regulatory agency to be effective, sensitive, specific, accurate, predictive or linked to a specific diagnosis or indication. At present there is no sufficiently reliable evidence that any observed treatment effect on such biomarkers is reasonably likely to predict clinical benefit.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">National Clinical Trial (&#8220;NCT&#8221;) is an eight-digit identification number that http://www.ClinicalTrials.gov assigns a clinical study when it is registered with the National Library of Medicine, which is operated by the United&#160;States government.</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1" title="item1" href="#"></a>Item 1.</b>&#160;&#160;&#160;&#160;<b><i>Business</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the Alzheimer&#8217;s brain. Our lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer&#8217;s disease dementia in Phase 3 clinical studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For over 12 years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for treating neurodegenerative diseases, such as Alzheimer&#8217;s&#8212;a degenerative disease of the brain, where a patient&#8217;s cognition and health functions decline over time as the disease progresses and the patient moves from mild to moderate to, eventually, severe Alzheimer&#8217;s disease.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: -18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress <i>both</i> neurodegeneration and neuroinflammation. We believe our ability to potentially improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our lead product candidate, simufilam, is a proprietary small molecule drug. Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer&#8217;s brain. Published studies have demonstrated that the altered form of FLNA causes neuronal dysfunction, neuronal degeneration and neuroinflammation. Specifically, we&#160;believe&#160;simufilam disrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR), which underlies our drug&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. More recent data also suggest a meaningful impact of simufilam on mTOR signaling. Because mTOR contributes to age-related cellular changes, simufilam&#8217;s suppression of mTOR overactivation, concurrent with improved insulin sensitivity, may slow certain aging processes and attenuate this pathological feature, potentially benefiting brain function and memory in Alzheimer&#8217;s disease and in aging.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We own exclusive, worldwide rights to our drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes nine&#160;issued U.S. patents. Corresponding foreign filings have been made for each of the U.S. filings.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 19pt;">We are currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer&#8217;s disease dementia.&#160;Both trials are fully enrolled. The trials have randomized a total of approximately 1,900 patients with mild to moderate Alzheimer&#8217;s disease at baseline. All efficacy data from our Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of simufilam 100 mg tablets versus placebo over 52 weeks (NCT04994483). Top-line results of our 52-week Phase 3 study are anticipated approximately year-end 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks (NCT05026177). Top-line results of our 76-week Phase 3 study are anticipated approximately mid-year 2025.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risk is Fundamental to the Drug Development Process</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We are in the business of new drug discovery and&#160;development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read this Annual Report in its entirety, including &#8220;Item 1A. Risk Factors&#8221;. <i>Because risk is fundamental to the process of drug discovery and&#160;development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>About Alzheimer</b>&#8217;<b>s Disease</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Alzheimer&#8217;s is a degenerative disease of the brain that affects cognition, function and behavior. Over time, a patient&#8217;s cognition and health functions decline as the disease takes its toll. With disease progression, patients move from mild to moderate to, eventually, severe Alzheimer&#8217;s disease. Cognitive decline becomes more pronounced, and presumably more difficult to treat, in advanced stages of the disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">An estimated 6.7 million Americans age 65 and older were&#160;living with Alzheimer's dementia in 2023, according to the Alzheimer&#8217;s Association. According to the same source, in 2011, the largest ever demographic generation of the American population &#8212; the baby-boom generation &#8212; started reaching age 65. By 2030, the segment of the U.S. population age 65 and older will have grown substantially, and the projected 74 million older Americans will make up over 20% of the total population. Because age is a well-known risk factor for Alzheimer&#8217;s dementia, new cases of Alzheimer&#8217;s dementia are expected to climb with the growth in the number of elderly Americans.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Our Scientific Approach is Different</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Given the biopharmaceutical industry&#8217;s challenging track record in Alzheimer&#8217;s research and drug development, we believe there is an urgent need to consider innovative approaches to combat this disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For more than twelve years, we have developed a new and promising scientific approach for the treatment and diagnosis of neurodegenerative diseases, such as Alzheimer&#8217;s disease. Importantly, we do not seek to clear amyloid out of the brain. Rather, our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our scientific approach is to treat neurodegeneration by targeting an altered form of a scaffold protein called FLNA. Through years of basic research, we and our academic collaborators identified FLNA as a structurally altered protein that enables neurodegeneration and neuroinflammation pathways in the Alzheimer&#8217;s brain. We have shown that the altered form of FLNA is pervasive in the Alzheimer&#8217;s brain and essentially undetectable in healthy control brains.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Using scientific insight and lab techniques, we believe we have elucidated this protein dysfunction. Through this work, we have produced experimental evidence that altered FLNA plays a critical role in Alzheimer&#8217;s disease. We engineered a family of high-affinity, small molecules to target this structurally altered protein and restore its normal shape and function. This family of small molecules, including our lead therapeutic product candidate, simufilam, was designed in-house and characterized by our academic collaborators.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our lead drug candidate, simufilam, is a small molecule (oral) drug with a novel mechanism of action. The target of simufilam is altered FLNA, the structurally altered protein in the brain that we seek to stabilize. Importantly, since simufilam has a unique mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with existing drug treatments for Alzheimer&#8217;s disease dementia.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Our science is based on stabilizing a critical protein in the brain</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Proteins are essential for cell function because they participate in virtually every biological process. If protein function is impaired, the health consequences can be devastating. Technological advances in medicine and improvements in lifestyle are making our lives longer. But with age, genetic mutations and other factors conspire against healthy cells, resulting in altered proteins. Sometimes a cell can rid itself of altered proteins. However, when disease changes the shape and function of critical proteins, multiple downstream processes are impaired. There are many clinical conditions in which proteins become structurally altered and impair the normal function of cells, tissues and organs, leading to disease. Conversely, restoring altered proteins back to health &#8211;called proteostasis &#8211; is a well-accepted therapeutic strategy in clinical medicine.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For over 100 years, scientists have ascribed various neurodegenerative diseases to proteins that misfold and are rendered pathological. In Alzheimer&#8217;s disease, certain proteins, such as amyloid and tau, lose their normal shape and function. Such misfolded proteins can break down or aggregate in clumps and form plaque or tangles in the brain. Destruction of neuronal synapses, accelerated death of neurons, and dysfunction of the brain support cells, are all widely believed to be direct consequences of misfolded proteins.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">FLNA is a scaffolding protein found in high levels in the brain. A healthy scaffolding protein brings multiple proteins together, coordinating their interaction. However, an altered form of FLNA protein is found in the Alzheimer&#8217;s brain. Our experimental evidence shows that altered FLNA protein contributes to Alzheimer&#8217;s disease by disrupting the normal function of neurons, leading to neurodegeneration and brain inflammation. Our product candidate, simufilam, aims to counter the altered and toxic form of FLNA in the brain, thus restoring the normal function of this critical protein.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>One drug, multiple effects </i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Simufilam binds to altered FLNA with very high (femtomolar) affinity. We believe simufilam&#160;improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering downstream toxic effects of altered FLNA. This drug effect restores the normal function of key brain receptors, including: the alpha-7 nicotinic acetylcholine receptor; the N-methyl-D-aspartate (NMDA) receptor; and the insulin receptor. These receptors have pivotal roles in brain cell survival, cognition and memory. In addition, recent data suggest a beneficial&#160;impact of simufilam on mTOR signaling.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We have generated and published experimental evidence of improved brain health by restoring altered FLNA with simufilam. In animal models, treatment with simufilam resulted in dramatic improvements in brain health, such as reduced amyloid and tau deposits, improved receptor signaling and improved learning and memory. In addition, simufilam has another beneficial treatment effect of significantly reducing inflammatory cytokines in the brain. In animal models of disease, treatment with simufilam greatly reduced levels of IL-6 and suppressed TNF-alpha and IL-1beta levels by 86% and 80%, respectively, illustrating a powerful anti-neuroinflammatory effect.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">By restoring function to multiple receptors and exerting powerful anti-inflammatory effects, we believe our approach has potential to slow the progression of Alzheimer&#8217;s disease in patients. We also believe our scientific approach may broaden the range of possible treatment approaches for this complex disease.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our science is published in multiple peer-reviewed journals. In addition, our research has been supported by NIH under multiple research grant awards. Each grant was awarded following an in-depth, peer-reviewed evaluation of our approach for scientific and technical merit by a panel of outside experts in the field.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Publication Confirming Mechanism of Action of Simufilam</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">In September 2023, we&#160;announced the publication of new research that confirms the biological activity of simufilam. Researchers at the Cochin Institute (Paris, France) used a highly precise cell-based assay based on TR-FRET to show that simufilam interrupts amyloid binding to the &#945;7 nicotinic acetylcholine receptor (&#945;7nAChR). We&#160;believe&#160;disruption of amyloid binding to &#945;7nAChR underlies simufilam&#8217;s primary mechanism of action in Alzheimer&#8217;s disease. The research paper was co-authored by Hoau-Yan Wang and Zhe Pei of the City University of New York, Erika Cecon, Julie Dam and Ralf Jockers of the Institut Cochin, and Lindsay Burns of Cassava Sciences, and appeared in a special<i> </i>issue of <i>International Journal of Molecular Sciences, </i>a peer-reviewed journal. See Figure 1.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">Figure 1. Experiment conducted by Erika Cecon, Universit&#233; Paris Cit&#233;, Institut Cochin in an assay she developed: Cecon et al 2019; <i>Br J Pharmacol;</i> 176:3475-3488. Data shown are means of pooled data from 4 separate experiments &#177;SEM.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="cab1ac4300e0img001.jpg" src="cab1ac4300e0img001.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><i>Publication Showing Simufilam Suppresses Overactive mTOR</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 18pt;">In June 2023, we&#160;announced the publication of new research that showed the effects of simufilam on the mechanistic Target of Rapamycin&#160;(mTOR). Scientific literature shows overactive mTOR plays a key role in aging, Alzheimer&#8217;s disease and other conditions. When functioning normally, mTOR monitors cellular needs and is activated by insulin. The new published research shows mTOR is overactive in lymphocytes isolated from blood collected from Alzheimer's patients versus healthy controls. After oral administration of simufilam 100 mg twice daily to Alzheimer's patients for 28 days, lymphocytes showed normalized mTOR activity and restored&#160;sensitivity to insulin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">These data suggest a meaningful impact of simufilam on mTOR signaling. The suppression of overactive mTOR signaling and its improved responsiveness to insulin represents a mechanistic benefit of simufilam beyond the disruption of pathogenic signaling pathways of soluble amyloid. These improvements in mTOR signaling may also result from reversing an altered conformation of FLNA, allowing FLNA to dissociate from the insulin receptor when insulin binds and initiates signaling. Because mTOR contributes to age-related cellular changes, simufilam&#8217;s suppression of mTOR overactivation, concurrent with improved insulin sensitivity, may slow certain aging processes and attenuate this pathological feature of Alzheimer&#8217;s disease, potentially benefiting brain function and memory in Alzheimer&#8217;s disease and in aging. This mTOR research paper was co-authored by Hoau-Yan Wang, Zhe Pei and Kuo-Chieh Lee of the City University of New York, Boris Nikolov, Tamara Doehner and John Puente, who are investigators in the clinical trial protocols, and Lindsay Burns of Cassava Sciences, and appeared in <i>Frontiers in Aging</i>, a peer-reviewed journal.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 7pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Simufilam Drug Development</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>IND submission to FDA, Drug Safety in Early Clinical Studies</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">For over a decade, we conducted basic research, in vitro studies and preclinical studies in support of a successful Investigational New Drug (IND) submission to FDA for simufilam, including requisite studies around safety pharmacology, toxicology, genotoxicity and bioanalytical methods. In 2017 we filed an IND with FDA for simufilam.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Following FDA acceptance of our IND in 2017, we investigated the safety, dosing and pharmacokinetic profile of simufilam in healthy human volunteers. The design of our first-in-human Phase 1 study was based on regulatory feedback, clinical and scientific rationale and observations from previously conducted preclinical and in vitro studies. In a Phase 1 study, simufilam was evaluated in 24 healthy human volunteers (18 simufilam, 6 placebo) in a single site in the U.S. for safety, tolerability and pharmacokinetics. Study subjects were administered a single oral dose of 50, 100 or 200 mg of simufilam or placebo. Drug appeared&#160;safe and well-tolerated. Importantly, simufilam showed no treatment-related adverse effects and no dose-limiting safety findings. Pharmacokinetic measurements demonstrated that simufilam, a small molecule, was rapidly absorbed. Dose-proportionality was observed over the full dose range of 50 to 200 mg.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Phase 2 Clinical Studies</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In 2019, we completed a first-in-patient, clinical-proof-of-concept, open-label Phase 2a study of simufilam in the U.S., with substantial support from the National Institute on Aging (NIA), a division of the NIH. In this small study of&#160;thirteen patients with mild-to-moderate Alzheimer&#8217;s disease,&#160;treatment with simufilam for 28 days significantly improved certain exploratory biomarkers of Alzheimer&#8217;s pathology, neurodegeneration and neuroinflammation (p&lt;0.001). Drug was safe and well-tolerated. Biomarkers effects were seen in all patients in both cerebrospinal fluid (CSF) and plasma.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In September 2020, we reported final results of a Phase 2b study with simufilam in Alzheimer&#8217;s disease. In this clinical study funded by the NIH, Alzheimer&#8217;s patients treated with 50 mg or 100 mg of simufilam twice-daily for 28 days showed statistically significant (p&lt;0.05) improvements in CSF biomarkers of disease pathology, neurodegeneration and neuroinflammation, versus Alzheimer&#8217;s patients who took placebo. Simufilam treatment also significantly reduced levels of plasma P-tau181 in sample testing conducted by Quanterix Corporation, a third-party vendor. In addition, Alzheimer&#8217;s patients treated with simufilam showed improvements in validated tests of episodic memory and spatial working memory, versus patients on placebo. Cognitive improvements correlated most strongly with decreases in levels of P-tau181. Drug was safe and well-tolerated.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Given the absence of observable dose-limiting effects in our&#160;Phase 1 or Phase 2 studies, and in light of the strong scientific rationale and multiple peer-reviewed publications and research grant awards, we determined that simufilam demonstrated favorable proof-of-principle for further evaluation as an investigational drug for the treatment of Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>24-Month Clinical Safety</b> <b> Study</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Much of the strategic value of our 24 month clinical safety study&#160;is to support simufilam&#8217;s long-term safety profile in patients. We believe a well-designed, long-term, safety study is a prudent risk-management undertaking. Clinical results may serve to help inform and manage the inherent risks and uncertainties of drug development while we undertake a large, expensive Phase 3 clinical testing program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In March 2020, we initiated a clinical safety study of&#160;simufilam, our lead drug candidate,&#160;in patients with Alzheimer&#8217;s disease (NCT04388254).&#160;This study&#160;was funded in part by a research grant award from NIH. This study was designed to evaluate the long-term clinical safety and tolerability of&#160;simufilam&#160;in patients with Alzheimer&#8217;s disease over 24 months. The study &#160;included a pre-specified exploratory efficacy endpoint of mean change in ADAS-Cog11 scores, a cognitive scale widely used in Alzheimer&#8217;s clinical research. This study enrolled over 200 patients with mild-to-moderate Alzheimer&#8217;s disease ((Mini-Mental State Examination (MMSE) 16-26) who were recruited from 16 U.S. clinical sites. Alzheimer&#8217;s is a progressive disease, with severity of disease typically assessed by MMSE score. In this study, mild patients are MMSE 21-26, and moderate patients are MMSE 16-20.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">We conducted the 24-month safety study in three continuous phases:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="font-size: 10pt;">
     <td style="width: 34pt; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">a 12-month, open-label treatment phase, followed by</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="font-size: 10pt;">
     <td style="width: 34pt; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">a 6-month randomized, placebo-controlled withdrawal phase (previously referred to as the &#8220;Cognition Maintenance Study&#8221; or CMS), followed &#160;by</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt;">
   <tbody>
    <tr style="font-size: 10pt;">
     <td style="width: 34pt; font-size: 10pt;">&#160;</td>
     <td style="vertical-align: top; width: 18pt; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p> </td>
     <td style="vertical-align: top; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">6 additional months of open-label treatment.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 18pt; text-align: justify;">Study participants received simufilam oral tablets 100 mg twice-daily in the open-label treatment phases, and simufilam or matching placebo during the randomized withdrawal phase. In an open-label study design, both the health providers and the patients are aware of the drug treatment being given.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 18pt; text-align: justify;">All study participants who completed 12 months of open-label simufilam treatment were eligible to participate in the 6-month randomized, placebo-controlled withdrawal phase. Likewise, all study participants who completed the randomized, placebo-controlled withdrawal phase were eligible for 6 additional months of open-label treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Study Results for the 12-month, Open-label Treatment Phase </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">In January 2023, we announced positive top-line results for the 12-month, open-label treatment phase of the safety study. The pre-specified, exploratory efficacy endpoint was change in baseline on ADAS-Cog11, a cognitive scale widely used in Alzheimer&#8217;s clinical research. Other exploratory endpoints included the Mini-Mental State Examination (MMSE) to assess disease stage by cognitive impairment; the Neuropsychiatric Inventory (NPI) to assess dementia related behavior; and the Geriatric Depression Scale (GDS). Endpoints were measured at baseline (study entry) and month 12.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Top-line Results </b>&#8211;<b> mean scores, baseline to month 12 </b>(<i>lower is better, except for MMSE)</i><b>:</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: -18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ADAS-Cog11 scores changed from 19.1 (&#177;9.2) to 19.6 (&#177;13.3)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">MMSE scores changed from 21.5 (&#177;3.6) to 20.2 (&#177;6.4)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">NPI10 scores changed from 3.2 (&#177;4.6) to 2.9 (&#177;4.6)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">GDS scores changed from 1.8 (&#177;1.8) to 1.4 (&#177;1.9)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><b>Response Analysis </b>&#8211;<b> baseline to month 12</b></i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 14pt;text-indent:-14pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ADAS-Cog scores improved in 47% of patients; this group had a mean change of -4.7 (&#177;3.8) points (lower is better).</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In an additional 23% of patients, ADAS-Cog declined less than 5 points; this group had a mean change of 2.5 (&#177;1.4) points.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients with an NPI10 score of zero increased from 42% to 54%, indicating reduced dementia-related neuropsychiatric symptoms after 1 year on simufilam.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Full Analysis Set (FAS) population (N=216) was used for the statistical analysis of efficacy endpoints. Mild and moderate sub-groups showed notable differences on changes in ADAS-Cog mean scores, baseline to month 12 (lower is better):</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: -18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the <i>mild</i> sub-group (MMSE 21-26), mean&#160;ADAS-Cog scores improved, from 15.0 (&#177;6.3) to 12.6 (&#177;7.8)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the <i>moderate</i> sub-group (MMSE 16-20), mean ADAS-Cog scores worsened, from 25.7 (&#177;9.2) to 30.1 (&#177;13.1)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe the improvement in ADAS-Cog over 1 year in mild patients taking simufilam is well outside the expected range of historic placebo decline rates from numerous other studies. Figure 2: historical declines on ADAS-Cog in early disease (MCI + mild) and mild disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="pic1.jpg" src="pic1.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Figure 1:</i></b><i> Statistical model of simufilam versus historical 1-year placebo declines on ADAS-Cog in early disease and mild disease. Forest plot by Pentara Corporation, independent biostatisticians</i><i>. Data was sourced from non-randomized studies (i.e., ADNI) and randomized, controlled trials conducted by other sponsors in patients with early (i.e., MCI + mild) and mild Alzheimer</i>&#8217;<i>s disease.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><b>Safety Data</b></i>&#160;- Simufilam 100 mg tablets twice daily appeared safe and well tolerated in this treatment phase of the open-label study. There were no drug-related serious adverse events. Three treatment-emergent adverse events (TEAEs) occurred in 7% or more of study patients: COVID-19 (12%), urinary tract infection (10%) and headache (9%). Reported TEAEs are based on all study patients who received at least one dose of drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i><b>Biomarker Data</b></i>&#160;- In this open-label treatment phase of the study, exploratory biomarkers were analyzed from CSF collected from 25 patients who agreed to undergo a lumbar puncture at baseline and again after 6 months of treatment. CSF samples were analyzed blind to timepoint by our academic collaborator at City University of New York.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">P-values shown below are baseline vs. 6-month levels by paired t-test:</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 36pt; text-indent: -18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CSF biomarkers of disease pathology, t-tau and p-tau181, decreased 38% and 18%, respectively (both p&lt;0.00001)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CSF biomarkers of neurodegeneration, neurogranin and neurofilament light chain (NfL), decreased 72% and 55%, respectively (both p&lt;0.00001)</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CSF biomarkers of neuroinflammation, sTREM2 and YKL-40, decreased 65% and 44% (both p&lt;0.00001)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Study Results for the 6-month,&#160;Randomized Withdrawal Study Phase&#160;("Cognition Maintenance Study")</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2021, we initiated the randomized, withdrawal phase of the 24 month safety study, which has been previously referred to as the &#8216;Cognition Maintenance Study' or CMS. The CMS has a randomized, withdrawal study design. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) explains that in a randomized withdrawal study,<i> </i>&#8220;<i>subjects receiving a test</i>&#160;<i>treatment for a specified time are randomly assigned to continued treatment with the test treatment or to placebo (i.e., withdrawal of active therapy) </i>&#8230;&#160;<i>Any difference that emerges between the group receiving continued treatment and the group randomized to placebo would demonstrate the effect of the active treatment</i>.&#8221;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">The design of randomized, withdrawal phase of the study was intended to evaluate simufilam&#8217;s effects on cognition and health outcomes in Alzheimer&#8217;s patients who continue with drug treatment versus patients who discontinue drug treatment. This was a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease. Study patients were randomized (1:1) to simufilam or placebo for six months. To enroll in the CMS, patients must have previously completed 12 months or more of open-label treatment with simufilam. Final enrollment was 157 patients. See Figure 3.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Figure 3. Design&#160;of the Randomized Withdrawal Phase (CMS) </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="pic2.jpg" src="pic2.jpg"/></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><i><b>Top-line Results</b></i>&#160;- Simufilam treatment for 6 months slowed cognitive decline by 38% compared to placebo in mild-to-moderate Alzheimer&#8217;s disease (MMSE 16-26) patients. The placebo arm declined 1.5 points on ADAS-Cog, and this arm declined at all measured timepoints. The simufilam arm declined 0.9 points on ADAS-Cog, a 38% difference in favor of drug at month 6 (95% CI, &#8211; 2.1 to 1.0; not significant for sample sizes). See Table 1 and Chart 1.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Table 1: Results of Randomized Withdrawal Study </b>&#8211;<b> cognitive change, full analysis set (FAS)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80%;margin-left:0pt;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Full Analysis Set</i></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N = 78)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N = 77)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Numerical</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6-month Change in</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.9 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.5 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#8211;0.6</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">38% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><img alt="deccog.jpg" src="deccog.jpg"/></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">Upon randomization into the randomized, withdrawal phase, mean baseline MMSE scores were 18.6 and 18.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores were 19.3 and 21.9 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b><i>Simufilam Drug Effects Favored Patients with Mild Alzheimer</i></b><i>&#8217;</i><b><i>s Disease </i></b>&#8211;<b><i>&#160;</i></b>Simufilam treatment for 6 months slowed cognitive decline &gt; 200% compared to placebo in mild Alzheimer&#8217;s disease. Patients with mild Alzheimer&#8217;s (MMSE 21-26) on placebo declined 0.6 points on ADAS-Cog over 6 months as a group. Patients with mild Alzheimer&#8217;s on simufilam improved 0.6 points over 6 months as a group, a 205% difference in favor of drug (95% CI, &#8211; 2.6 to 0.4; not significant for sample sizes). See Table 2 and Chart 2.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b>Table 2: Results of Randomized Withdrawal Study </b>&#8211;<b> cognitive change, mild patients</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80%;margin-left:0pt;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Mild Patients</i></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Simufilam 100 mg</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N= 40)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Placebo</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(N= 36)</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Numerical</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Difference</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percent Difference</b></p> </td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">6-month Changes in</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">ADAS-Cog</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.6 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Improvement</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.6 point</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Decline</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#8211;1.1</p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:middle;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">205% in favor of drug</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="alz.jpg" src="alz.jpg"/></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">Upon randomization into the randomized, withdrawal phase of the study, mean baseline MMSE scores for mild patients were MMSE 24.0 and MMSE 24.1 for the simufilam and placebo arms, respectively. Mean baseline ADAS-Cog scores for mild patients were 11.0 and 11.2 for the simufilam and placebo arms, respectively.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><b><i>Simufilam for 18 months stabilized cognition in mild Alzheimer</i></b><i>&#8217;</i><b><i>s disease </i></b>&#8211;<b><i>&#160;</i></b>After taking open-label simufilam for 12 months, 76 patients with mild Alzheimer&#8217;s disease (MMSE 21-26) enrolled in the randomized, withdrawal phase and were randomized to receive either simufilam (N=40) or placebo (N=36) for 6 months. Mild patients randomized to simufilam in the CMS showed no material decline in ADAS-Cog scores over 18 months as a group, indicating stable cognition. Mild patients randomized to placebo in the randomized, withdrawal phase (and therefore withdrawn from simufilam treatment for 6 months) declined by 0.8 points in ADAS-Cog over 18 months as a group. See Figure 4.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt -37pt;"><b>Figure 4. Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="chgbsl.jpg" src="chgbsl.jpg"/></div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Figure 4</b>: Forest plot by Pentara Corporation, independent biostatisticians. Data was sourced from the placebo groups in randomized, controlled trials of monoclonal antibodies conducted by other sponsors in Alzheimer&#8217;s disease (MMSE 20-30). Results shown for CLARITY P3 trial of lecanemab; EMERGE and ENGAGE P3 studies of aducanumab; and TRAILBLAZER P3 trial of donanemab; in this figure, the randomized, withdrawal phase is referred to as the &#8216;PTI-125-04&#8217; study; &#8216;Simufilam100mg-Simufilam100mg&#8217; refers to patients who received simufilam in both the open-label phase and the randomized, withdrawal phase; &#8216;Simufilam100mg-Placebo&#8217; refers to patients who received simufilam in the open-label phase and placebo in the randomized, withdrawal phase.</p>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i><b>Safety Data</b></i>&#160;&#8211; Simufilam 100 mg tablets twice daily appeared safe and well tolerated in the 6-month the randomized, withdrawal phase of the 24 month safety study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><b><i>Discussion</i></b>&#160;&#8211;Patients who completed 12 months of open-label simufilam treatment were invited to participate in the randomized, withdrawal phase. It is not known how long a washout period may be needed to remove lingering drug effects, if any, from prior treatment with open-label simufilam for 12 months. In this small randomized, withdrawal study phase in patients with mild-to-moderate Alzheimer&#8217;s disease, simufilam slowed cognitive decline by 38% on ADAS-Cog over six months (not statistically significant), with good drug safety. Effects were pronounced in mild patients. Mean baseline MMSE and ADAS-Cog scores were approximately balanced given the small size of each arm.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Study Results for the 24-Month Safety Study</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In February 2024, we reported top-line results of the 24-month clinical safety study. Average changes in ADAS-Cog scores, baseline to month 24, indicate the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:34pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with mild Alzheimer&#8217;s disease who received simufilam treatment continuously for two years (n=47) had no decline in ADAS-Cog scores (&#177;&#160;1.51 SE) as a group.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:34pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with mild Alzheimer&#8217;s who received simufilam treatment non-continuously (n=40) declined 1 point on ADAS-Cog (&#177;&#160;1.65 SE) as a group. Non-continuous treatment consisted of one year on open-label drug, six months on placebo and six months back on open-label drug.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:34pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In patients with mild Alzheimer's, the largest separation between the continuous and non-continuous treatment groups occurred at the end of the 6-month randomized, placebo-controlled withdrawal phase.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:34pt;">&#160;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patients with moderate Alzheimer&#8217;s who received simufilam treatment continuously for two years (n=32) declined 11.05 points on ADAS-Cog (&#177;&#160;1.91 SE) as a group.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Patients with mild Alzheimer&#8217;s disease (n=87) started the 24 months study with MMSE 21-26, with ten exceptions. Patients with moderate Alzheimer&#8217;s started the 24 months study with MMSE 16-20, with one patient who entered with MMSE 15.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The pre-specified cognition endpoints were analyzed on the Full Analysis Set (FAS) by an independent consulting firm that specializes in complex statistical analysis of clinical trial results. The FAS population consists of all study participants who received at least one dose of treatment and have both baseline and at least one post-baseline assessment. (Because FAS data is specific to each phase of a study, the FAS for the&#160;24-month study&#160;may differ from the FAS for other study phases).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Mild patients who received simufilam for 24 continuous months (n=47) showed an average change of 0.07 points on ADAS-Cog11 (&#177; 1.51 SE), baseline to month 24, as a group.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Mild Alzheimer&#8217;s patients who received 12 months of open-label simufilam, followed by placebo in the 6-month randomized, placebo-controlled withdrawal phase, followed by an additional 6 months of open-label simufilam (n=40), declined by an average of 1.04 points on ADAS-Cog11 (&#177; 1.65 SE), baseline to month 24, as a group. See Figure 4B.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <div style="text-align: center;">
   <div>
    <img alt="slide02.jpg" src="slide02.jpg"/></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Mean ADAS-Cog scores at baseline were approximately balanced in the group of mild Alzheimer&#8217;s patients who received drug continuously versus non-continuously (15.2 and 14.6, respectively).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Safety Data&#160;</i></b>&#8211; Oral simufilam 100 mg tablets twice daily appeared safe and well tolerated in this study. There were no drug-related serious adverse events. The most common treatment-emergent adverse events (TEAEs) were Covid-19 and urinary tract infection.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>End-of-Phase 2 (EOP2) Meeting with FDA</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In January 2021, we held an End-of-phase 2 (EOP2) meeting for simufilam with the U.S. Food and Drug Administration (FDA). The purpose of this EOP2 meeting was to gain general agreement around key elements of a pivotal Phase 3 program to treat Alzheimer&#8217;s disease dementia. FDA attendees included Robert Temple, MD, Deputy Center Director for Clinical Science and Senior Advisor in the Office of New Drugs; Billy Dunn, MD, Director, Office of Neuroscience; Eric Bastings, MD, Director, Division of Neurology, and others.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In February 2021, we announced the successful completion of our EOP2 meeting. Official meeting minutes confirm that we and FDA are aligned on key elements of a Phase 3 clinical program for simufilam. FDA agreed that the completed Phase 2 program, together with an ongoing and well-defined Phase 3 clinical program, are sufficient to potentially show evidence of clinical efficacy for simufilam in Alzheimer&#8217;s disease. There was also agreement that the use of separate clinical scales to assess cognition (ADAS-cog<sup style="vertical-align:top;line-height:120%;">1</sup>) and function (ADCS-ADL<sup style="vertical-align:top;line-height:120%;">2</sup>) are appropriate endpoints of efficacy. iADRS<sup style="vertical-align:top;line-height:120%;">3</sup> is an efficacy endpoint that combines scores for ADAS-cog and ADCS-ADL, and thereby provide a single composite measure of cognition and health function. Other endpoints include the NPI<sup style="vertical-align:top;line-height:120%;">4</sup>.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;"><i><sup style="vertical-align:top;line-height:120%;">1</sup></i><i> ADAS-Cog = The Alzheimer</i>&#8217;<i>s Disease Assessment Scale </i>&#8211;<i> Cognitive Subscale, a measure of cognition </i></p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; margin: 0pt;"><i><sup style="vertical-align:top;line-height:120%;">2</sup></i><i> ADCS-ADL = Alzheimer</i>&#8217;<i>s Disease Cooperative Study </i>&#8211;<i> Activities of Daily Living, a measure of health function</i></p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;"><i><sup style="vertical-align:top;line-height:120%;">3</sup></i><i>iADRS = integrated Alzheimer</i>&#8217;<i>s Disease Rating Scale, a composite measure of cognition and health function</i></p>
  <p style="font-family: Times New Roman; font-size: 9pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i><sup style="vertical-align:top;line-height:120%;">4</sup></i><i>NPI = Neuropsychiatric Inventory, a clinical tool that assesses the presence and severity of dementia-related behavior </i></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Special Protocol Assessments</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2021, we announced we had reached agreement with FDA under a Special Protocol Assessment (SPA) for both Phase 3 studies. These SPA agreements document that FDA has reviewed and agreed upon the key design features of our Phase 3 study protocols of simufilam for the treatment of patients with Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">An SPA agreement indicates concurrence by the FDA with the adequacy and acceptability of specific critical elements of overall protocol design (e.g., entry criteria, dose selection, endpoints, etc.). These elements are critical to ensure that our planned Phase 3 studies of simufilam in Alzheimer&#8217;s disease can</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">potentially be considered adequate and well-controlled studies in support of a future regulatory submission and marketing application.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The first clinical study protocol under the SPA is titled &#8220;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer</i>&#8217;<i>s Disease</i>.&#8221;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The second clinical study protocol under the SPA is titled &#8220;<i>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer</i>&#8217;<i>s Disease</i>.&#8221;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Phase 3 Clinical Program Overview</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Phase 3 program consists of two large, double-blind, randomized, placebo-controlled studies of simufilam in patients with mild-to-moderate Alzheimer&#8217;s disease dementia. Both studies are designed to measure changes in cognition and function during their treatment period. Some highlights of this clinical program are summarized in Figure 5.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Premier Research International is the&#160;CRO supporting the&#160;conduct of our Phase 3 clinical program. Our Phase 3 clinical sites are currently located in the United States, Canada, Puerto Rico, Australia, and South Korea.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b>Figure 5. Summary of Our Phase 3 Clinical Program&#160;</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div style="text-align: center;">
   <img alt="slide03.jpg" src="slide03.jpg"/></div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RETHINK-ALZ and REFOCUS-ALZ</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In Fall 2021, we announced initiation of&#160;two Phase 3 studies of simufilam in mild-to-moderate Alzheimer&#8217;s disease dementia. In&#160;November 2023, we had announced the completion of patient enrollment in both Phase 3 studies. A total of approximately 1,900 patients are randomized&#160;into these studies.&#160;Approximately 70% of randomized patients entered our Phase 3 studies with mild Alzheimer&#8217;s disease (MMSE 20 to 27).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg over 52 weeks (NCT04994483).&#160;Details of the RETHINK-ALZ Phase 3 study include:</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-size: 10pt;">Approximately 800&#160;patients are randomized into this study.</td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-size: 10pt;">
     <td style="width: 18pt; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients are randomized (1:1) to simufilam 100 mg tablets or matching placebo twice daily.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patients are&#160;treated for 52 weeks.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Efficacy endpoints are ADAS-Cog12, a cognitive scale, and ADCS-ADL, a functional scale and iADRS, (which is a combination of scores from ADAS-Cog &amp; ADCS-ADL). All three clinical measurements are standard psychometric assessment tools in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other endpoints include plasma biomarkers of disease and NPI, a clinical tool that assesses the presence and severity of dementia-related behavior.</td>
    </tr>

    <tr>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;">&#9658;</td>
     <td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">No interim analyses on efficacy are planned.</td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 76 weeks (NCT05026177). Details of the REFOCUS-ALZ Phase 3 study include:</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Approximately 1,100 patients are randomized into this study.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Patients are randomized (1:1:1) to simufilam 100 mg tablets, 50 mg tablets, or matching placebo twice daily.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Patients are treated for 76 weeks.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Efficacy endpoints are ADAS-Cog12, a cognitive scale, and ADCS-ADL, a functional scale and iADRS, (which is a combination of scores from ADAS-Cog &amp; ADCS-ADL). All three clinical measurements are standard psychometric assessment tools in trials of Alzheimer&#8217;s disease.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Other endpoints include biomarkers of disease, MRI imaging and NPI, a clinical tool that assesses the presence and severity of dementia-related behavior.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt; text-align: justify;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#9658;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">No interim analyses on efficacy are planned.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 3 Entry Criteria </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In our Phase 3 clinical studies, eligibility criteria are the requirements that patients must meet to be included in a study. These requirements help make sure that study participants are substantially and closely matched as a group in terms of specific factors such as age, disease or stage of disease, general health, and other key factors. Eligibility criteria can consist of inclusion criteria, which are required for a person to participate in the study, or exclusion criteria, which prevent a person from participating. See Figure 5A.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div style="text-align: center;">
   <div>
    <img alt="slide04.jpg" src="slide04.jpg"/></div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b>Use of Plasma Phosphorylated-tau181 (p</b>&#8208;<b>tau181) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We believe plasma p&#8208;tau181 is a biomarker qualifier of Alzheimer&#8217;s neuropathology. RETHINK-ALZ and REFOCUS-ALZ Phase 3 studies use a &#8216;research use only&#8217;, non-safety related exploratory p-tau181 plasma assay to qualify mild-to-moderate Alzheimer&#8217;s patients. The plasma assay we use does not rely on age, APOE-gene status or complex algorithms to provide a result. P-Tau181 testing was performed by an independent commercial laboratory.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: -9pt;"><b>Data and Safety Monitoring Board (DSMB)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In September 2023, we announced that a&#160;routine, scheduled meeting of a DSMB&#160;recommended that both of our&#160;Phase 3 studies continue as planned, without modification. This DSMB only reviewed&#160;patient safety. It did&#160;not assess drug efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b>Interim MRI Safety Data</b>&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In October&#160;2023, we announced&#160;a potentially significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer&#8217;s patients who are enrolled in a Phase 3 clinical trial of simufilam. These MRI data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities, or ARIA. MRIs were all analyzed for ARIA by independent, board-certified neuroradiologists.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">ARIA is a medical term used to describe a spectrum of brain MRI imaging abnormalities, such as brain swelling&#160;and brain bleeds. ARIA is&#160;a known risk factor for Alzheimer&#8217;s patients taking the class of drugs known as monoclonal antibodies directed against&#160;amyloid. In contrast to that&#160;class of drugs, simufilam is a&#160;small-molecule (oral) drug candidate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The new safety finding is based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer&#8217;s patients enrolled in&#160;REFOCUS-ALZ, our&#160;on-going 76-week Phase 3 clinical trial of simufilam in mild-to-moderate Alzheimer&#8217;s. Final MRI data is expected at the conclusion of this Phase 3 study.&#160;See Figure 6.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div style="text-align: center;">
   <div style="margin-left: -9pt;">
    <img alt="slide05.jpg" src="slide05.jpg"/></div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><b>Status of Phase 3 Clinical Program</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 19pt;">Our Phase 3 trials have randomized a total of approximately 1,900 patients with mild to moderate stages of Alzheimer&#8217;s disease at baseline (MMSE 16-27), with approximately 800 patients randomized&#160; in the 52-week study (RETHINK-ALZ) and approximately 1,100 patients randomized&#160; in the 76-week study (REFOCUS-ALZ).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">Approximately 70% of patients enrolled in our Phase 3 trials are diagnosed with mild Alzheimer&#8217;s disease (MMSE 20-27), with remaining patients entering the study with moderate disease (MMSE 16-19). Since the distribution of patients randomized&#160;in these trials is numerically&#160;skewed towards mild patients, we expect to rely predominantly on outcomes from mild patients to evaluate drug safety and efficacy.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">Over 340 patients have completed the 52-week RETHINK-ALZ study. Over 215 patients have completed the 76-week REFOCUS-ALZ study, for a total of over 555 completers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">All efficacy data from our Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 19pt;">We anticipate top-line data readout for our 52-week study (RETHINK-ALZ) approximately year-end 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We anticipate top-line data readout for our 76-week study (REFOCUS-ALZ) approximately mid-year 2025.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We have initiated a discussion with the FDA to finalize a statistical analysis plan (SAP), which is a formal document defining the detailed analysis that our independent biostatisticians will undertake as to efficacy data collected in our Phase 3 trials. The SAP includes in-depth technical details and descriptions on the intended clinical trial analysis, the statistical methods and models that will be used, the population being analyzed, the data variables that will be analyzed, how missing data will be accounted for, descriptions of covariates to be included in the statistical model, and other statistical factors, all of which will be prospectively defined, documented and finalized prior to unblinding of any efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Open-label Extension Study for the Phase 3 Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In October 2022, we announced the initiation of an open-label extension study for our Phase 3 program. This study is designed to provide no-cost access to oral simufilam for up to one year to Alzheimer&#8217;s patients who have successfully completed a Phase 3 study of simufilam and who meet other entry criteria.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">We expect the open-label extension study to generate additional long-term clinical safety data for oral&#160;simufilam 100 mg twice daily over 52 weeks. There is no obligation for a patient or a physician to participate in the open-label extension study. Each clinical investigational site and each patient chooses whether to participate in this open-label extension study.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Patient enrollment for this study began in November 2022. To date, over 500 patients entered the open-label extension study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Phase 3 Drug Supply</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We have a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik supplies and is expected to continue to supply us with large-scale, clinical-grade quantities of simufilam. Evonik is one of the world&#8217;s largest contract development and manufacturing organizations for pharmaceutical ingredients. Other vendors supply excipients, the finished dosage form (i.e., simufilam tablets), drug packaging, package labeling and other critical components of&#160;the supply chain for Phase 3 drug supply.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>SavaDx</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our investigational product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. For business, technical and personnel reasons, we continue to prioritize the development of simufilam, our novel drug candidate, over SavaDx, our novel diagnostic candidate. SavaDx is a research-use only, non-safety related exploratory biomarker.&#160;Development activity related to SavaDx accounts for less than 1% of our research budget.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">Working with third parties, we continue to evaluate the use of mass spectrometry to detect FLNA or other proteins of interest. The data and information generated from these evaluations continues to be under review for potential intellectual property rights.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The regulatory pathway for SavaDx may eventually include formal analytical validation studies and clinical studies that support evidence of sensitivity, specificity and other variables in various healthy and diseased patient populations. We have not conducted such studies and do not expect to conduct such studies in 2024.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA). Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA, i.e., without the use of antibodies. These evaluations are on-going.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Over the past twelve&#160;years, we discovered that altered FLNA is a hallmark feature of brain pathology in patients with Alzheimer&#8217;s disease. We believe SavaDx may reveal early traces of the disease, potentially even before the overt appearance of disease symptoms, such as memory loss.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A diagnostic test usually measures one or more biomarkers, which are biological indicators of disease. A deep understanding of the biology of disease is required to identify and develop a diagnostic. A valid diagnostic has certain baseline characteristics to be functional and useful for clinical practice. It must detect disease in patients (sensitivity) and, conversely, not detect disease in healthy subjects (specificity); and it is preferably quantitative, giving some indication of severity or stage of disease. Collectively, the ability to selectively detect disease indicators can be useful to provide diagnostic information (i.e., detect the disease) or prognostic information (i.e., predict the disease or its future course).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Currently, the most definitive method to diagnose Alzheimer&#8217;s disease is through autopsy after death, which is not particularly helpful. Methods to detect Alzheimer&#8217;s disease during its course can be expensive, invasive, subjective, risky and/or uncomfortable. Importantly, because of the expense and invasiveness of current tests, most people are not tested until they show obvious cognitive decline.<i> </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Current approaches for diagnosing Alzheimer&#8217;s disease include measurement of amyloid-&#946; (specifically, A&#946;<sub>42</sub>), total tau (T-tau) or phosphorylated tau (P-tau) levels in CSF or plasma; structural neuroimaging techniques, including magnetic resonance imaging (MRI) or computerized tomography (CT); positron-emission tomography (PET) imaging of brain amyloid (AmyVid&#174;); and batteries of cognitive tests. Usually, a combination of more than one test is necessary to provide a working diagnosis. When such tests and techniques are used together, the totality of data can be sensitive and specific for the detection of Alzheimer&#8217;s disease. In practice, however, such tests and techniques are only used after overt symptoms of impaired memory.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe there is a profound need for a blood-based diagnostic test for Alzheimer&#8217;s disease. A quick, simple, inexpensive test may benefit the medical community in many ways. Advantages may include confirming the presence of Alzheimer&#8217;s disease earlier, when lifestyle changes and potential therapeutics may have the most impact, or conversely, to rule out Alzheimer&#8217;s disease at such early stages. Other potential benefits include discriminating Alzheimer&#8217;s disease from other causes of dementias; helping to identify stage of Alzheimer&#8217;s disease; selection and enrollment of appropriate patients into clinical studies of experimental product candidates; and better alignment of a patient&#8217;s specific diagnosis with a targeted therapeutic.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">It is widely accepted that in Alzheimer&#8217;s disease, pathological changes in the brain occur at least 10-15 years before clinical symptoms appear. These &#8220;pre-symptomatic&#8221; changes include deposits of certain misfolded or impaired proteins in the brain. Our long-term goal with SavaDx is to identify people with Alzheimer&#8217;s disease, potentially long before clinical symptoms occur. Early detection may be critical for any intervention to cease &#8211; or at least slow down &#8211; brain damage before it is too late. Importantly, a non-invasive screen for latent Alzheimer&#8217;s disease prior to overt symptoms could be conducted as a general health screen, not just in patients at risk by family history or in patients already showing cognitive impairment. Once a disease-modifying treatment is found, early detection is likely to be critically important. Early detection and treatment may also be critical in identifying such a disease-modifying treatment, as many believe one reason for clinical study failures in Alzheimer&#8217;s disease is that treatment has routinely started too late in the course of disease to make any impact.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Moreover, with repeat measurements over time, SavaDx may provide a probability of cognitive decline or disease progression. Even if SavaDx does not provide a precise numerical cutoff value for Alzheimer&#8217;s disease, we believe it may be important to incorporate data from SavaDx into the overall diagnostic framework for neurodegeneration, and Alzheimer&#8217;s disease in particular. As with any diagnosis of disease, some people may embrace a way to detect Alzheimer&#8217;s disease long before clinical symptoms appear, while others may prefer not to know &#8211; at least until better&#160;treatments are&#160;found.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Diagnostic development program.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Diagnostic development differs from drug development in many important ways. As a result, diagnostic development requires substantial differences in planning, study design and study execution.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Some of the ways that diagnostic development differs from drug development include the following:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may need to choose among a wider range of regulatory pathways for approval of SavaDx, depending on factors such as intended use and user, test type and complexity and role in patient-care decisions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Drug studies usually deal primarily with one office within FDA, but the regulatory pathway for SavaDx may require us to consider the policies of multiple federal or state regulatory agencies and offices;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unlike drug programs, statistical analysis with SavaDx does not focus on efficacy and safety endpoints. Rather, study endpoints for SavaDx will focus on sensitivity (true positives), specificity (true negatives), positive predictive value (percentage of correct positive diagnoses of known positive cases) and negative predictive value (percentage of correct negative diagnoses of known negative cases).</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">SavaDx is an investigational diagnostic product candidate that has not yet been reviewed by FDA. Early clinical testing consisted&#160;of collecting blood samples on a limited scale to test and validate SavaDx using antibodies or&#160;mass spectrometry. Our ability to test such samples and generate accurate results depends&#160;on multiple factors, many of which are&#160;beyond our control. For example, optimal sample collection depends on risk of sample degradation, storage requirements to preserve samples, cost of sample storage and actual vs. predicted time of assay validation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have conducted four early validation tests using SavaDx. In three blinded studies of test samples, SavaDx detected more than a 10-fold separation between Alzheimer&#8217;s patients and normal healthy control subjects (N=232 test samples). In these three proof-of-concept studies, SavaDx demonstrated nearly 100% accuracy and specificity. The three studies deployed a research grade antibody manufactured by an outside vendor.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A fourth blinded study of SavaDx failed to generate meaningful diagnostic data. We believe the fourth study deployed a faulty research antibody sourced from an outside vendor. Commercially available research antibodies can present certain technical flaws, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize results of studies and experiments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In July 2021, we announced positive clinical data with SavaDx when used to measure plasma levels of altered filamin A before and after simufilam treatment in patients with Alzheimer&#8217;s disease. In a Phase 2b randomized, controlled trial sponsored by the National Institutes of Health (NIH), simufilam significantly reduced a plasma marker of altered filamin A in Alzheimer&#8217;s patients treated for 28 days. Plasma levels of p-tau181 also dropped significantly in these same patients, as measured by Quanterix Corporation, a third-party vendor.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">SavaDx is currently designed as an antibody-based detection system for filamin A (FLNA). Working with third parties, we are evaluating the use of mass spectrometry to detect&#160;FLNA, i.e., without the use of antibodies. These evaluations are on-going.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The legal system for intellectual property around diagnostic methods is highly complex and uncertain. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Generally, a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#8220;laws of nature&#8221;. However, different outcomes from different courts, including Federal Circuit, district court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent claims. Furthermore, claims for diagnostic methods can be complicated to enforce.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have no issued patents in the United States with respect to SavaDx.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Expansion of Our Science to Other Indications</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Protein misfolds occur in a wide variety of biological processes and diseases. We may leverage our scientific insights in neurodegeneration and neuroinflammation and advanced tools in molecular biology, biochemistry, and imaging to expand our science to other diseases. New indications and new drug development approaches may complement our initial focus on Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Preclinical programs are always visionary, sometimes innovative and often of high biomedical potential. By definition, such programs are exploratory and risky. Most preclinical programs fail for scientific or other reasons, regardless of the amount of effort or resources that are brought to bear. For these reasons, we do not intend to disclose our preclinical programs until&#160;they become material to our pipeline of product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>We Own Worldwide Rights to Our Neurodegeneration Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent applications with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to those drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer&#8217;s disease and other neurodegenerative diseases currently runs through 2039 and includes nine&#160;issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2033. Our patent estate further includes patents and patent applications for related compounds and treatments. Corresponding foreign filings have been made for each of the U.S. filings.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Development Team </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product development team is led by seasoned professionals with a proven track record of innovation in drug discovery and development, as well as substantial business expertise.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Founder and Chief Executive Officer, Remi Barbier, has over 25&#160;years of biopharmaceutical industry experience and has led teams responsible for pioneering several pharmaceutical innovations, including abuse-deterrent technology for opioid drugs; the clinical development of multiple pain drug candidates; an innovative antibody program in cancer; and other programs in neuroscience and other therapeutics areas. Before founding Cassava Sciences, he held leadership roles and was founder or co-founder of three life science companies, all of which are now either publicly traded or were acquired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Our Chief Medical Officer, James Kupiec, MD, has participated in research programs that led to two FDA drug approvals prior to Cassava Sciences. He previously served at Pfizer, Inc. as VP, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit. Dr. Kupiec also held leadership roles at Sanofi and Ciba-Geigy Pharmaceuticals and before that was a practicing neurologist.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Lindsay Burns, PhD, SVP, Neuroscience, reports to Dr. Kupiec and has worked on the development of several product candidates in neuroscience and other therapeutics areas while at Neurex (acquired by Elan Pharmaceuticals) and Abgenix (acquired by Amgen).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Michael Zamloot, SVP of Technology Operations, has participated in research programs that led to four FDA drug approvals prior to Cassava Sciences. He previously worked in drug operations and supply chain management at Boehringer Mannheim (acquired by Roche Diagnostics), Athena Neuroscience (acquired by Elan Pharmaceuticals) and Ciba-Geigy (acquired by Novartis).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Michael Marsman, PharmD, SVP of Regulatory Affairs previously held senior positions at Impax Laboratories, Millennium Pharmaceuticals, and Syntex, where he had shared responsibility for the regulatory approval of several high-profile drugs. He also previously led regulatory affairs for our Company for nearly a decade until 2019.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">George (Ben) Thornton, PhD, SVP of Technology, has led research and development teams at Johnson &amp; Johnson as well as translated basic science to the clinical setting at biotechnology start-ups such as GeneMedicine and Apovia.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management team is further supported by scientific advisors who are leading experts in the field and share our commitment to advancing new treatments for neurodegenerative diseases, including Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Strategy </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our goal is to develop product candidates to diagnose and treat neurodegeneration, such as Alzheimer&#8217;s disease. Key elements of our business strategy to achieve this mission include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">building a lean company that is narrowly focused on developing innovative product candidates for Alzheimer&#8217;s disease and other areas of neurodegeneration;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">validating our unique scientific approach with competitive research grants and publishing our scientific data in peer-reviewed journals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">applying our development capabilities to advance our product candidates through clinical proof-of-concept studies and beyond;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">using our expertise and experience to continue to focus on discovering new indications and product candidates, validated by experimental evidence and leading experts in the field; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continuing to outsource preclinical studies, clinical studies and formulation development activities in order to allow more efficient deployment of our resources</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also conduct basic research and development in collaboration with academic and other partners. Our research and development expenses were $89.4&#160;million, $68.0&#160;million and $24.8&#160;million for the year ended December 31, 2023, 2022 and 2021, respectively. See &#8220;<i>Item 7. Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations</i>&#8221; for additional details regarding our research and development activities.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The drug discovery and development industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize, such as simufilam or SavaDx, may compete with existing therapies and new therapies that may become available in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Historically, the drug industry has attempted to treat Alzheimer&#8217;s disease by developing drugs that block the synthesis of, or remove or disaggregate, beta amyloid and, more recently, another protein in the brain called tau. Essentially, the prevailing doctrine holds that amyloid (or tau) must be cleared out of the brain. This scientific approach has been repeatedly tested by our competitors in late-stage clinical studies using a variety of antibody backbones, epitopes and target conformations in various stages of disease. More recent competitors in Alzheimer&#8217;s research are focused on modulating proteins in the brain that have anti-inflammatory or other properties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In contrast, our scientific approach seeks to simultaneously improve neurodegeneration and neuroinflammation. We believe improving multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Regardless of scientific approach, improvement or stability in cognition and health function remains a key criterion for a new drug in Alzheimer&#8217;s disease to receive full, unconditional marketing approval from the FDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our competitors may have significantly greater financial resources, an established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing-approved products. These competitors compete with us in recruiting and retaining qualified scientific and technical personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring or developing technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, significant financial backing from large investors and/or access to intellectual property from large established companies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The key competitive factors affecting the success of simufilam, and any other product candidates that we develop to address neurodegenerative disorders, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, patient and physician acceptance and the availability of reimbursement from government and other third-party payors. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our competitors may develop and obtain FDA approval for their products more rapidly than us. For example, the FDA approved Biogen&#8217;s aducanumab (human monoclonal antibody) for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway, although its development and commercialization was subsequently discontinued by Biogen in January 2024. More recently, in January 2023, lecanemab (humanized version of a mouse monoclonal antibody, marketed as Leqembi&#174;), which is a proprietary drug of Eisai R&amp;D Management Co., Ltd. and Biogen, Inc., received marketing approval from the FDA for the treatment of Alzheimer&#8217;s disease using an accelerated approval pathway and in July&#160;2023, the FDA granted lecanemab full approval for the treatment of Alzheimer&#8217;s disease. In addition, we believe Eli Lilly&#8217;s donanemab drug is poised for a potential FDA approval in the first half of 2024 in patients with early Alzheimer&#8217;s disease. Each of the foregoing drugs is&#160;currently delivered by infusion.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Other currently marketed drugs, called cholinesterase inhibitors, focus solely on treating symptoms mostly in patients with mild-to-moderate Alzheimer's disease. The Alzheimer&#8217;s brain has low levels of a neurotransmitter called acetylcholine. Cholinesterase inhibitors prevent an enzyme in the brain, called&#160;acetylcholinesterase,&#160;from breaking down acetylcholine. Currently marketed cholinesterase inhibitors include donepezil (marketed by Eisai&#160;Co.,&#160;Ltd. and Pfizer,&#160;Inc. as Aricept&#174;), rivastigmine (marketed by Novartis AG as Exelon&#174;) and galantamine (marketed by Janssen Pharmaceuticals, Inc. as Razadyne&#174;). Cholinesterase inhibitors may benefit some patients for several months, after which the targeted brain receptors are desensitized, and drug efficacy is lost. Another approved medication for treating the symptoms of Alzheimer&#8217;s disease is memantine, a non-competitive antagonist of NMDA receptors (marketed by Lundbeck as Namenda&#174;).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, we have observed ramped-up worldwide efforts aimed at developing blood-based techniques to detect and monitor Alzheimer&#8217;s disease. The key competitive factors affecting the success of SavaDx, and any other product candidates that we develop to diagnose neurodegeneration, if approved, are likely to be their measure of accuracy, such as specificity and sensitivity, as well as their convenience, patient acceptance, price and the availability of reimbursement from government and other third-party payors. Our competitors in the diagnostic area are pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Despite increased research effort, the field has generally been hampered by lack of reproducibility and an unclear path on how to move academic discoveries into clinical utilization.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to blood-based techniques to detect Alzheimer&#8217;s disease, competitors are examining the use of novel tracing agents and imaging techniques to map the course of neurodegeneration. In 2012, FDA approved Amyvid&#174; (Eli Lilly Pharmaceuticals), which is a radioactive diagnostic agent for brain imaging of amyloid plaque. Amyvid can rule out Alzheimer&#8217;s disease but does not confirm its presence. That is, a negative scan means little or no plaque is present; however, a positive scan does not necessarily indicate Alzheimer&#8217;s disease. In addition, Amyvid cannot be used to stage Alzheimer&#8217;s disease because some people take years to show cognitive decline after amyloid plaque develops, while other others rapidly develop advanced Alzheimer&#8217;s disease within months.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Manufacturing</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Simufilam and any future product candidates must be manufactured for clinical trial use in compliance with current good manufacturing practices (cGMP) regulations. These regulations are extensive, stringent and complex, and may include requirements regarding the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Our manufacturing vendors must have facilities to make our product candidates in strict compliance with cGMP requirements and the FDA&#8217;s or comparable foreign regulatory authorities&#8217; satisfaction. Our third-party vendors may also be subject to periodic and unannounced inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of simufilam to assess compliance with applicable regulations. Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of simufilam. Our suppliers may be forced to stop producing, storing, shipping or testing our drug product candidates if they fall out of compliance with government regulations and standards.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Although we are ultimately responsible for the manufacture of simufilam and any other future product candidates, we have limited or no control over our suppliers&#8217; compliance, or lack thereof, with the multitude of regulations and standards that affect our drug products. We cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not own or lease any manufacturing facilities. We outsource formulation, manufacturing and related activities to third parties. For the foreseeable future, we will continue to rely on third parties to conduct certain quality control and assurance testing, shipping or storage of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We currently rely on one non-affiliated contract development and manufacturing organization (CDMO)&#8212;Evonik Corporation&#8212;to manufacture simufilam and expect to continue to do so.&#160; In 2021, we entered into an agreement with Evonik Corporation to supply large-scale, clinical-grade quantities of drug substance for simufilam.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We believe our manufacturing strategy will continue to provide sufficient drug supply for our Phase 3 program, including both drug substance (i.e., active ingredient) and drug product (i.e., oral tablets).&#160; The goal of our manufacturing strategy is to ensure the integrity of the supply chain for drug substance&#160;in compliance with FDA standards. We believe raw materials for our drug product are readily available from reliable sources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations are subject to various levels of governmental controls and regulations in the United States and in other countries where we operate, including Canada, South Korea and Australia. We attempt to comply with all legal requirements in the conduct of our operations and employ business practices that we consider to be prudent under the circumstances in which we operate.&#160;Government authorities in the U.S. (federal, state and local), Canada, South Korea, Australia and other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and diagnostic products. Generally, before a new drug or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy and/or specificity must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by each regulatory authority.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>U.S. Drug Development </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the U.S., FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA). Both drugs and diagnostics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product candidates must be approved by FDA before they may be commercialized in the U.S. The drug approval process generally includes the following sequence of steps:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Submission to FDA of an IND, which must become effective before human clinical studies may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Approval by an independent institutional review board (IRB) or ethics committee before each study may be initiated;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Performance of adequate and well-controlled human clinical studies in accordance with applicable IND regulations, code of good clinical practice (cGCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Submission to FDA of a new drug application&#160;(NDA);</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A determination by FDA within 60 days of its receipt of an NDA to accept the filing for review;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Potential FDA audit of the preclinical study and/or clinical study sites that generated the data in support of the NDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the U.S.; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Compliance with any post-approval requirements, including the potential requirement to conduct post-approval studies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Preclinical Studies and IND </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. As sponsor, we must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to FDA as part of the IND. An IND is a request for authorization from FDA to administer an investigational product to humans and must become effective before human clinical studies may begin.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as<i> </i>in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including cGCP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to FDA as part of an IND. Some long-term preclinical testing, such as long-term toxicity tests, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by FDA, unless before that time FDA raises concerns or questions about any aspect of the program. In such a case, the IND sponsor and FDA must resolve any outstanding concerns before the clinical study can begin.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical Studies </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control, in accordance with cGCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to FDA as part of the IND. Furthermore, each clinical study must be reviewed and approved by an IRB for each institution at which the clinical study will be conducted to ensure that the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until completed. There also are requirements governing the reporting of ongoing clinical studies and completed clinical study results to public registries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A sponsor who wishes to conduct a clinical study outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical study under an IND. If a foreign clinical study is not conducted under an IND, the sponsor may submit data from the clinical study to FDA in support of an NDA. The FDA may accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with cGCP requirements and FDA is able to validate the data through an onsite inspection if deemed necessary. We currently have clinical sites outside of the U.S. in Canada, Puerto Rico, South Korea and Australia.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical studies in the U.S. generally are conducted in three sequential phases, known as Phase&#160;1, Phase&#160;2 and Phase&#160;3, and may overlap.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 1 clinical studies generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical studies is to assess the absorption, metabolism, pharmacologic action, tolerability and safety of a drug candidate.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 2 clinical studies involve studies in disease-affected patients to determine the proper dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy may be observed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Phase 3 clinical studies generally involve enrolling many patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These studies may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Post-approval studies, sometimes referred to as Phase&#160;4 clinical studies, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase&#160;4 clinical studies as a condition of approval of an NDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Progress reports detailing the results of the clinical studies, among other information, must be submitted at least annually to FDA. Written safety reports and the investigations&#160;for serious and unexpected adverse events, or any other findings suggesting a significant risk to humans exposed to the drug must be submitted to FDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Phase&#160;1, Phase&#160;2, and Phase&#160;3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical studies are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a Data and Safety Monitoring Board (DSMB). This group provides authorization for whether a study may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical studies, companies usually complete additional animal studies and must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>NDA Review Process</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Following completion of the clinical studies, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical studies are then submitted to FDA as part of an NDA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA is a request for approval to market a drug for one or more specified indication and must contain proof of safety and efficacy for a drug&#8217;s purity and potency. The application may include both negative and ambiguous results of preclinical studies and clinical studies, as well as positive findings. Data may come from company-sponsored clinical studies intended to test the safety and efficacy of a product&#8217;s use or from several alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the U.S.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to FDA&#8217;s fiscal year 2024&#160;fee schedule, effective through September&#160;30, 2024, the user fee for an application requiring clinical data, such as an NDA, is approximately $4.0&#160;million. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accept the NDA for filing. The FDA must decide whether to accept an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by FDA under PDUFA, FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Before approving an NDA, FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities fully comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical studies to ensure compliance with cGCP requirements. Additionally, FDA may refer applications for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical study data, which could result in extensive discussions between FDA and the applicant during the review process. After FDA evaluates an NDA, it will issue either an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A CRL indicates that FDA&#8217;s review of the application is complete and the application cannot be approved in its present form. A CRL usually describes the specific deficiencies in the NDA identified by FDA. The CRL may require additional clinical data, additional pivotal Phase&#160;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical studies, preclinical studies or manufacturing. If a CRL is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identified in the CRL, or withdraw the application. Even if such data and information are submitted, FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and FDA may interpret data differently than we interpret the same data.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Commercialization Plan</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our product candidates have not received marketing approval from the FDA, and we do not expect to have any approved product candidates in the near term. We currently have no company experience in marketing drugs and have no personnel, capabilities or infrastructure in sales, marketing, third-party payor programs or commercial product distribution. When and if any of our product candidates are approved for commercialization, we will need to develop a commercialization infrastructure for any such product in the U.S. and potentially in certain other key markets. As a matter of strategy, we may also rely on partnerships or collaborations with larger biopharmaceutical companies to provide commercialization infrastructure, such as sales and marketing and commercial distribution.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Advertising and Promotion</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. None of our product candidates can be commercially promoted before receiving FDA approval. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#160;&#8212; that is, uses not approved by FDA and therefore not described in the drug&#8217;s labeling&#160;&#8212; because FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers&#8217; communications regarding off-label uses. Failure to comply with applicable FDA requirements and restrictions in this area may subject us to adverse publicity and enforcement action by FDA, the U.S. Department of Justice, or the Office of the Inspector General of Health and Human Services, as well as state authorities. This could subject us to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which we promote or distribute our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Post-Approval Requirements</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">After a product candidate receives regulatory approval, it is often subject to pervasive and continuing regulation by FDA, including, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion restrictions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-market testing, known as Phase 4 testing, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging, and labeling procedures must continue to conform to cGMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies. Registration may result in periodic announced or unannounced inspections by FDA or these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, other regulatory actions may be taken, including, among other things, warning letters, the seizure of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations, refusal to approve pending applications or supplements to approved applications, civil penalties, and criminal prosecution.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA may require post-approval clinical studies to help assure continued safety or effectiveness of the approved drug. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to the FDA, manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the U.S., including the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, the Affordable Care Act (ACA) and state and local governments.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">For example, in the United States, sales, marketing and scientific and educational programs must also comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling, if and when approved; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The Hatch-Waxman Amendments</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i><span style="text-decoration: underline; ">Orange Book Listing</span></i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In seeking approval for our product candidates through an NDA, we will be required to list with FDA each patent whose claims cover the drug product. Upon receiving regulatory approval, each of the patents listed in the application for this drug is then published in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221;&#160;Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated NDA, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredient in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or efficacy of their drug product. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The ANDA applicant is required to make certain certifications to FDA concerning any patents listed for the approved product in FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i)&#160;the required patent information has not been filed; (ii)&#160;the listed patent has expired; (iii)&#160;the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv)&#160;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&#160;viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than make certifications concerning a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph&#160;IV certification. If the ANDA applicant has provided a Paragraph&#160;IV certification to FDA, the applicant must also send notice of the Paragraph&#160;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&#160;IV certification. The filing of a patent infringement lawsuit within 45&#160;days of the receipt of a Paragraph&#160;IV certification automatically prevents FDA from approving the ANDA until the earlier of 30&#160;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. The ANDA application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Disclosure of Clinical Study Information</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Sponsors of clinical studies of FDA-regulated products, including drugs, are required to register and disclose certain clinical study information. Information related to the product, patient population, phase of investigation, clinical study sites and investigators, and other aspects of the clinical study is then made public as part of the registration. Sponsors are also obligated to post certain information regarding the results of their clinical studies after completion. Disclosure of the results of these studies can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Other Regulatory Requirements</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to federal, state and local environmental laws and regulations, including the Environmental Protection Act and the Clean Air Act. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may also be subject to regulations under other federal, state, and local laws, including the Occupational Safety and Health Act, national restrictions on technology transfer, and import, export, and customs regulations. It is possible that any portion of the regulatory framework under which we operate may change and that such change could have a negative impact on our current and anticipated operations. Failure to comply with these requirements could result, among other things, in suspension of regulatory approval, recalls, injunctions or civil or criminal sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Third-Party Payor Coverage and Reimbursement</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The commercial success of our product candidates, if approved, will depend, in part, upon the availability of coverage and adequate reimbursement from third-party payors at the federal, state and private levels. Third-party payors include governmental programs such as Medicare or Medicaid, private insurance plans and managed care plans. These third-party payors may deny coverage or reimbursement for our product candidates in whole or in part if they determine that our product candidates are not medically appropriate or necessary. Also, third-party payors attempt to control costs by limiting coverage through the use of formularies and other cost-containment mechanisms and the amount of reimbursement for particular procedures or drug treatments.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Some third-party payors also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future&#160;these requirements or any announcement or adoption of such proposals could have a material adverse effect on our ability to obtain adequate prices for our approved product candidates to operate profitably.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Human Capital</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our approach to human capital resource management starts with our mission to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our industry exists in a complex regulatory environment. The unique demands of our industry, together with the challenges of running an enterprise focused on the discovery, development, manufacture and commercialization of innovative medicines, require talent that is highly educated and/or has significant industry experience. Additionally, for certain key functions, we require specific scientific expertise to oversee and conduct research and development activities and the complex manufacturing requirements for biopharmaceutical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">Our employees are an essential asset, and we consider our ability to recruit, train, retain and motivate our employees to be critical to our success. We are an equal opportunity employer, and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law. By focusing on employee retention and engagement, we also improve our ability to support our clinical trials, our pipeline, business and operations, and also protect the long-term interests of our stockholders. Our success also depends on our ability to attract, engage and retain a diverse group of employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our base pay program aims to compensate management and staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform each position, as well as the experience brought to the job. We also provide cash incentive programs to reward our management team and staff members in alignment with achievement of Company-wide goals that are designed to drive aspects of our strategic priorities that support and advance our strategy across our Company. Our management team and staff members are eligible for the grant of equity awards under our long-term incentive program that are designed to align their long-term interests with that of our stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our benefit programs are generally broad-based, promote health and overall well-being and emphasize saving for retirement. All management team and regular staff members are eligible to participate in the same core health and welfare and retirement savings plans. Other employee benefits may include medical plans, dental plans, vacation and sick-pay plans, flexible spending accounts, life and accident insurance and short and long-term disability benefits.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our Compensation Committee provides oversight of our executive compensation plans, policies and programs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2023, we had 29&#160;full-time employees. None of our employees is&#160;represented by a labor union or covered under a collective bargaining agreement. We also engage numerous consultants to perform services on retainer, per diem or an hourly basis.&#160;We&#160;consider our relationship with our employees to be good.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Lawsuit Against Perpetrators of </b>&#8220;<b>Short and Distort</b>&#8221;<b> Campaign</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 3, 2022, we announced that we had filed a lawsuit in federal court against certain individuals who executed a &#8220;short and distort&#8221; campaign against Cassava Sciences. The 150+ page complaint alleges that the defendants&#8217; disinformation campaign caused a precipitous decline in Cassava Sciences&#8217; stock price, a multi-billion dollar decline in its market capitalization, and delayed the Company&#8217;s work in developing a treatment for Alzheimer&#8217;s disease. The complaint identifies over 1,000 false and defamatory statements made by the defendants in submissions to the U.S. Food and Drug Administration as well as &#8220;reports&#8221; and presentations that defendants published online or on social media. Between January 3 and 23, 2024, the Magistrate Judge assigned to the case recommended that the District Court grant defendants&#8217; various motions to dismiss the complaint. The Company has timely filed objections to those recommendations with the District Court. The matter is pending in federal district court for the Southern District of New York.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Internal Investigation</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Beginning in August 2021, certain individuals, later revealed to be short sellers of the Company&#8217;s securities, publicly alleged that the Company and certain of its employees and third-party collaborators had engaged in research misconduct in connection with the development of simufilam.&#160;These allegations related in part to research that was conducted at the City University of New York (&#8220;CUNY&#8221;) pursuant to research contracts with the Company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The Company takes allegations of research misconduct seriously. Accordingly, the Company&#8217;s Board of Directors engaged the law firm Orrick Herrington &amp; Sutcliffe LLP to investigate these allegations. The investigation had access to Company personnel, communications, documents, data, and information, and counsel was assisted by technical experts with relevant experience and knowledge. The investigation has found no evidence to substantiate allegations that the Company or its employees engaged in or were aware of research misconduct.</p>
  <p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Publication Corrections</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">An erratum or corrigendum is a correction of a published text, generally a human, production or author's error, that was not caught in proofing. Such errors generally do not impact data conclusions. We note the following corrections in our published works.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In July 2021, we presented clinical data for SavaDx in a poster presentation titled, &#8220;<i>SavaDx, a Novel Plasma Biomarker to Detect Alzheimer</i>&#8217;<i>s Disease, Confirms Mechanism of Action of Simufilam</i>&#8221; at the Alzheimer&#8217;s Association International Conference (AAIC) in Denver, CO and virtually. Publication correction: The AAIC data and data analysis are correct, however, visual errors that were not caught in proofing were disclosed by the Company in September 2021. This error does not impact data conclusions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In 2017, we published in Neurobiology of Aging an article titled &#8220;<i>PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer</i>&#8217;<i>s disease pathogenesis</i>&#8221; (Vol 55, July 2017, Pages 99&#8211;114). Publication correction: Figure 12 contains an image showing 12 control bands. It should show 13. The data analysis was based on all 13 control bands. Other human errors in this publication have been noted and corrected. These errors do not impact data conclusions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In 2012, we published in the Journal of Neuroscience an article titled<i>, </i>&#8220;<i>Reducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A</i>&#8221;<i> </i>(JNeurosci 2012;32:9773-9784)<i>. </i>Publication correction: A duplicated panel appears in Figure 8B of the article. This error does not impact data conclusions and the publisher printed a correction.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Information</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We were incorporated as a Delaware corporation in May 1998 under the name Pain Therapeutics, Inc. In March 2019, we changed our company name to Cassava Sciences, Inc. Our principal offices are located at 6801 N. Capital of Texas Highway, Building 1; Suite 300, Austin, TX, 78731. Our telephone number is 512-501-2444. Our website address is www.CassavaSciences.com. Information contained on our website is not a part of this Annual Report on Form 10-K and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We use Cassava Sciences, the Cassava Sciences logo, artwork and other marks as trademarks in the United States and other countries. Solely for convenience, trademarks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the &#174; or TM&#160;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We file electronically with the Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of the site is <span style="text-decoration: underline; ">http://www.sec.gov</span>.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">You may obtain a free copy of our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports on the day of filing with the SEC on our website at <span style="text-decoration: underline; ">http://www.cassavasciences.com</span>, by contacting our corporate offices by calling 512-501-2450 or by sending an e-mail message to <span style="text-decoration: underline; ">IR@cassavasciences.com</span>.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1a" title="item1a" href="#"></a>Item 1A. </b>&#160;&#160;&#160;&#160;<b><i>Risk Factors</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>RISK FACTORS </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Investing in our securities involves a high degree of risk. This section includes a discussion of what we believe to be the material factors that make an investment in our Company speculative or risky. The risks described in this section are not the only risks we face.</i><i>&#160;Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our securities.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;"><i>You should carefully consider the risks described below, as well as other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and the section titled </i>&#8220;<i>Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations,</i>&#8221;<i> before deciding whether to invest in our securities. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our securities could decline, and you may lose all or </i> <i>part of your investment. </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have concentrated a substantial portion of our research and development efforts on the treatment of Alzheimer&#8217;s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We are heavily dependent on the success of simufilam, our lead product candidate which is still under development. If this product candidate fails one or both of our ongoing Phase 3 trials, or does not receive regulatory approval, we will be unable to generate product revenue and our business will be harmed.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have a limited operating history in our business targeting Alzheimer&#8217;s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We cannot give any assurance that we will file for regulatory approval for any of our product candidates, or that if we file for approval, our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>There can be no assurance that promising results of smaller Phase 1 and Phase 2 clinical trials or 24-month safety study with simufilam will be reproduced in our large Phase 3 studies.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Clinical results observed in our smaller Phase 1 and Phase 2 clinical trials or 24-month safety study with simufilam are not regulatory evidence of drug safety or efficacy.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We currently have no in-house capabilities to manufacture or commercialize our product candidates, and we rely on a third-party commercial drug manufacturing organization for clinical drug supplies. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We may need to rely on clinical results generated predominately, or even solely, from patients with mild Alzheimer&#8217;s disease to show&#160;evidence of efficacy in our Phase 3 clinical trials, if any, and this may present more or different challenges in our efforts to develop simufilam.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Government Regulation and Other Legal Compliance Matters</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims, many of which arose following a short selling attack campaign against our Company that commenced in 2021.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</i></p> </td>
    </tr>

    <tr>
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"><i>&#9679;</i></td>
     <td style="width: auto;"><i>Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates.</i></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are unable to obtain and maintain sufficient patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be materially harmed.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Operations </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our reputation and operations could be adversely impacted by allegations of wrongdoing, regardless of their merits.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our ability to continue to operate without any significant disruptions will, in part, depend on our ability to source materials and clinical supplies via our product supply chains.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We expect to significantly grow the size and capabilities of our organization and we may experience difficulties in effectively managing this growth.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are&#160;and may continue to be unknown to us.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Financial Condition and Capital Requirements </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have broad discretion in the use of our capital resources, including the net proceeds from</i> <i>any of our financing transactions</i> <i>and may not use them effectively.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We have no product revenues and may never achieve revenues or profitability based on product revenues.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Ownership of Our Common Stock </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The market price of our common stock has historically been highly volatile and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#9679;</i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Short sellers of our stock may be manipulative and may drive down the market price of our common stock.</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have concentrated a substantial portion of our research and development efforts on the treatment of Alzheimer</i></b>&#8217;<b><i>s disease, an area of research that has seen significant failure rates. Further, our product candidates are based on new scientific approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and likelihood of success.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have concentrated substantially all of our research and development efforts on experimental methods for the treatment of Alzheimer&#8217;s disease. Prior efforts by biopharmaceutical companies in the field of neurodegenerative diseases, including efforts to develop new treatments for Alzheimer&#8217;s disease, have seen many failures and very limited clinical success. Since 2003, many new types and classes of drugs have been developed and tested in Alzheimer&#8217;s disease, including monoclonal antibodies, gamma secretase modulators and inhibitors, &#946;-site amyloid precursor protein cleaving enzyme (BACE) inhibitors, receptor for advanced glycation end-products (RAGE) inhibitors, nicotinic partial agonists and allosteric modulators, serotonin subtype receptor (5HT6) antagonists, and others, but virtually all of these scientific programs have failed in Phase 3 or earlier testing. Developing and, if approved, commercializing a novel treatment for Alzheimer&#8217;s disease subjects us to many challenges, including obtaining regulatory approval from FDA and other regulatory authorities who have only a limited set of precedents to rely on. Notwithstanding the substantial challenges historically associated with the development of new treatments for Alzheimer&#8217;s disease, we seek to improve brain health by addressing the neurodegeneration and neuroinflammation components of Alzheimer&#8217;s disease. Our lead drug candidate for Alzheimer&#8217;s disease is based on a new approach of stabilizing&#8212;but not removing&#8212;a critical protein in the brain. We cannot be certain that our novel technologies will yield clinical results that support the approval of a safe and effective therapeutic product or, if approvable, that such a product will be marketable. In addition, because FDA has limited comparators to evaluate our lead drug candidate, we could experience a longer than expected regulatory review process and increased development costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are heavily dependent on the success of simufilam, our lead product candidate which is still under development. If this product candidate </i></b><b><i>fails one or both of our on-going Phase 3 clinical trials, or</i></b> <b><i>does not receive regulatory approval, we will be unable to generate product revenue and our business will&#160;be harmed. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, we have invested a significant portion of our efforts and financial resources in the development of simufilam and, to a much lesser extent, SavaDx, for the treatment and detection of Alzheimer&#8217;s disease, respectively. Our business is substantially dependent on our ability to successfully complete clinical development and obtain regulatory approval for simufilam, which may never occur. The results of clinical studies are subject to a variety of factors, and there can be no assurance that simufilam will advance to regulatory approval, be approved by applicable regulatory agencies, or be successfully commercialized.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect that a substantial portion of our efforts and expenditures over the next few years will continue to be devoted to simufilam and, to a much lesser extent, SavaDx. This will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in one or more national jurisdictions and obtaining commercial-scale manufacturing supply. Substantial investment and significant efforts will be required before we can generate any revenues from any commercial sales of our product candidates. We cannot be certain that we will be able to successfully complete any of these activities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have a limited operating history in our business targeting Alzheimer</i></b>&#8217;<b><i>s disease and no history of product approvals for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are a clinical-stage biopharmaceutical company with a limited operating history in our business targeting Alzheimer&#8217;s disease. Since we commenced operations in 1998, we have had no product candidates approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have not completed a pivotal Phase 3 clinical study in Alzheimer&#8217;s disease, obtained marketing approval for any product candidates, or conducted sales and marketing activities necessary for successful product commercialization. Our long operating history as a company without product revenue makes any assessment of our future success and viability subject to significant uncertainty.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We will continue to encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields. We have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not successfully address these risks and difficulties, our business, results of operations and financial condition will suffer materially.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To date, we have invested substantial effort and financial resources to identify, procure intellectual property for, and develop our programs in neurodegeneration, including conducting preclinical and clinical studies for our product candidates, simufilam and SavaDx, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following: &#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our product candidates may not successfully complete preclinical studies or clinical studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be safe or effective or otherwise does not meet applicable regulatory criteria;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our competitors may develop products or therapies that render our product candidates obsolete or less attractive;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the product candidates that we develop may not be sufficiently covered by intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the product candidates that we develop may be challenged by third parties&#8217; patents or other intellectual property or exclusive rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the market for our product candidates may change so that the continued development of a product candidate is no longer reasonable or commercially attractive;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">our product candidates may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a product candidate may not be accepted as safe, effective or useful by patients, the medical community or third-party payors, if applicable.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may not be successful in our efforts to further develop our product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. SavaDx is in the early stages of development. Simufilam, our late-stage product candidate, will require successful completion of our ongoing Phase 3 program, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have never completed a product development program in neurodegeneration. Further, we cannot be certain that any of our product candidates will be successful in clinical studies, and we may terminate existing or future clinical studies&#160;prior to their completion.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If any of our product candidates successfully complete clinical studies, we may seek regulatory approval to market our product candidates in the U.S., Japan, Canada, the United Kingdom or the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We may never receive regulatory approval to market any product candidates anywhere even if such product candidates successfully complete clinical studies, which would adversely affect our viability. To obtain regulatory approval in countries outside the U.S., we would need to comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment or diagnosis of neurodegenerative diseases or other diseases, we cannot provide assurance that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>There can be no assurance that promising results of smaller Phase 1 and Phase 2 </i></b><b><i>clinical trials or a 24-month Safety Study with simufilam will be reproduced in our large Phase 3 studies.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Results of our Phase 1, Phase 2 and 24-month Safety Study with simufilam are not predictive of the future results of Phase 3 clinical trials. Simufilam may fail to show the desired safety and efficacy in Phase 3 clinical trials despite having progressed successfully through preclinical studies and initial clinical trials. Many biopharmaceutical companies have suffered significant setbacks in Phase 3 clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. We cannot be certain that our product candidates will not face similar setbacks.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, conclusions based on data from analyses of Phase 1 and Phase 2 clinical studies and open-label results may not be reproduced when implemented in large, well-controlled, randomized clinical trials. Particular caution should be exercised when interpreting preliminary data, data relating to a small number of patients and data from open-label uncontrolled studies, which are generally not capable of providing interpretable evidence of efficacy. Results of our small, &#8220;first-in-human&#8221; Phase 1 study was designed to assess the initial safety characteristics of simufilam in healthy human volunteers and this study was not designed to, and did not, evaluate safety, tolerability and efficacy of simufilam in patients. Similarly, our Phase 2 clinical studies with simufilam were designed to assess the safety characteristics of simufilam in patients. Our Phase 2 program was not designed to, and did not, evaluate large-scale or long-term safety, tolerability and efficacy of simufilam in patients. There can be no assurance that future large, well-controlled, multi-dose studies will demonstrate the safety, tolerability or efficacy of simufilam to treat patients with any indication, including Alzheimer&#8217;s disease.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Even if our clinical trials for simufilam are completed as planned, we cannot be certain that their results will support the substantial evidence of safety and efficacy needed to obtain regulatory approval. The failure of simufilam to show safety, tolerability or efficacy in any future clinical studies would significantly harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Clinical results observed </i></b><b><i>our smaller Phase 1 and Phase 2 clinical trials or 24-month Safety Study with simufilam are&#160;not regulatory evidence of drug safety or efficacy.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Data results from our non-Phase 3 studies&#160;do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for simufilam in Alzheimer&#8217;s disease. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The size and open-label design of portions of our non-Phase 3 studies may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our non-Phase 3 studies add complexity or limitations to the scope of data interpretation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may encounter substantial delays in our clinical studies or may not be able to conduct or complete our clinical studies on the timelines we expect, if at all. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned, enroll patients as planned or be completed on schedule, if at all. Moreover, even after our studies begin, safety or other issues may arise that could suspend or terminate such clinical studies. A failure of one or more clinical studies can occur at any stage of testing, and our ongoing or future clinical studies may not be successful. Events that may prevent successful or timely initiation or completion of clinical studies include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">inability to generate sufficient or necessary preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical studies or to support the filing of a New Drug Application for simufilam;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in reaching a consensus with regulatory agencies on study design;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in reaching an agreement on acceptable terms with prospective clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical study sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in identifying and recruiting suitable clinical investigators;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in obtaining required IRB approval for each clinical study site or adverse action by one or more IRBs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a new safety finding that presents unreasonable risk to clinical study participants;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">a negative finding from an inspection of our clinical research organization (CRO), clinical study operations or study sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the finding that the investigational protocol or plan is deficient to meet its stated objectives;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical studies, and delays caused by patients withdrawing from clinical studies, or failing to return for post-treatment follow-up;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays caused by disease epidemics, pandemics, such as COVID-19, or other health crises;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">difficulty collaborating with patient groups and investigators;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">failure by our CRO or other third parties, or us to adhere to clinical study requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">failure to perform in accordance with FDA&#8217;s or any other regulatory authority&#8217;s Code of Good Clinical Practice (GCP) requirements, or other regulatory guidelines in other countries;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">changes in the standard of care on which a clinical development plan was based, which may require new or additional studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">the cost of clinical studies of our product candidates being greater than we anticipate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any inability to successfully initiate or complete clinical studies could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to, or we may elect, to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates or the termination of such clinical studies prior to their completion, either of which could adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We have conducted, and continue to conduct, portions of our Phase 3 clinical trials outside the United States, and the FDA may not accept data from trials conducted in foreign locations. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 25pt;">We have conducted, and we expect to continue to conduct, portions of our Phase 3 clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials we conduct&#160;outside the United States must be representative of the population for which we intend to label the product in the United States. In addition, while Phase 3 clinical trials conducted outside the United States are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. We cannot assure you that the FDA will accept data from portions of our Phase 3 trials conducted outside the United States. If the FDA does not accept such data from such clinical trials, we would likely need to conduct additional trials, which would be costly and time-consuming and delay or permanently halt our development of simufilam, our lead investigational product.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The FDA or other regulatory agencies&#160;may put a clinical hold on our clinical studies, which would cause our business to suffer.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">A clinical hold is an order issued by FDA or another regulatory agency to suspend an ongoing clinical trial, typically due to newly identified deficiencies with, or the need for additional information regarding, the subject study or drug candidate. For example, we are aware that in 2022, FDA placed clinical holds on drug candidates for Alzheimer&#8217;s disease from two competitors, Cortexzyme Inc. and Denali Therapeutics Inc. The grounds for imposition of a clinical hold are complex, variable and fact specific. If FDA imposes a clinical hold on us, no new patients may be enrolled in the subject study and study patients already in such study may be taken off our drug candidate unless treatment is specifically permitted by FDA in the interest of patient safety.&#160; If we are issued a clinical hold, FDA would expect us to address the cited deficiencies or provide the requested additional information, in each case, through the submission of a detailed, written response. A clinical hold would require us to spend significant resources, potentially over an extended period of time, to address the root causes of FDA&#8217;s concerns, even if we disagreed with the FDA&#8217;s assessment of asserted deficiencies.&#160;If we were unable to find and successfully address such root causes or if our response were deemed inadequate to lift the clinical hold, this could adversely affect our business. If we were subjected to a clinical hold that remained in effect for one&#160;year or longer, the FDA may consider the IND for the affected product candidate to fall into Inactive Status, which may result in termination of the corresponding clinical program.&#160; To the extent we are not successful in lifting any clinical hold that the FDA might impose, our results of operations and business will be materially adversely affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If physicians and patients do not accept and use our drugs, we will not achieve sufficient product revenues and our business will suffer.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if FDA approves our drugs, physicians and patients may not accept and use them. Acceptance and use of our drugs will depend on a number of factors including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">when the drug is launched into the market and related competition;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">approved label claims;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">perceptions by members of the healthcare community, including physicians, about the safety, side effects and effectiveness of our drugs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">perceptions by physicians regarding the cost-benefit of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">published studies demonstrating the cost effectiveness of our drugs relative to competing products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">availability of reimbursement for our products from government or healthcare payers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">effectiveness of marketing and distribution efforts by us and other licensees and distributors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because we expect to rely on sales generated by our current lead product candidates for substantially all of our revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in developing our product candidates in neurodegeneration. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In addition to the risks associated with our Phase 3 clinical trials for simufilam, SavaDx and our future product candidates in neurodegeneration are still in development. Such early stage product candidates will take several&#160;years to develop and must undergo extensive clinical and scientific validations.<b><i> </i></b>Even if we are successful in developing any of our product candidates through clinical and scientific validation, we may not be able to develop a drug or a diagnostic that:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">meets applicable regulatory standards, in a timely manner or at all;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">successfully competes with other technologies and tests;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">avoids infringing the proprietary rights of others;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">is adequately reimbursed by third-party payors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">can be performed at commercial levels or at reasonable cost; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">can be successfully marketed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To the extent we are not successful in developing our new product candidates in neurodegeneration, our results of operations and business will be materially adversely affected.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Interim, </i></b>&#8220;<b><i>top-line</i></b>&#8221;<b><i> and preliminary data from our clinical trials that we announce or publish from time to time are likely to change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final dataset.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">From time to time, we may publish &#8220;top-line&#8221; or preliminary data from our clinical trials. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data at the time of its initial release. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Such data from clinical trials may materially change as more study data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary top-line data should be viewed with caution until the final data is available. Differences between preliminary or top-line data and final data could significantly harm our business prospects and may cause the trading price of our securities&#160;to fluctuate significantly.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, other parties, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently than us, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from later, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We currently have no in-house capabilities to manufacture or commercialize our product candidates and we rely on third-party commercial drug manufacturers for clinical drug supplies. If we are unable to develop our own manufacturing, sales, marketing and distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms, or at all, our product revenues could be adversely impacted. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We rely on various third parties to manufacture, fill, label, store, test and ship our product candidates. We plan to continue to outsource formulation, manufacturing and related activities. These suppliers must comply with cGMP regulations enforced by FDA and other government agencies, and are subject to ongoing periodic unannounced inspection, including preapproval inspections by FDA and corresponding state and foreign government agencies to ensure strict compliance with cGMP and other standards. These manufacturers may subsequently be stopped from producing, manufacturing, filling, labeling, storing, testing and shipping our product candidates due to their non-compliance with federal, state or local regulations. We do not have control over our suppliers&#8217; compliance with these regulations and standards and we cannot control decisions by our suppliers that affect their ability or willingness to continue to supply us on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Disputes in the past have arisen with some of these third parties with respect to fulfilling certain conditions and obligations. There can be no guarantee that such disputes will not arise again in the future, which may lead to termination of an agreement. If an agreement is terminated, we would not be able to commercialize our product candidates until another manufacturer is identified and we have entered into a manufacturing agreement with such manufacturer. We may not be able to replace a commercial supplier on commercially reasonable terms, or at all. Replacing any of our commercial suppliers would be expensive and time consuming. Failure by any of our suppliers to perform as expected could delay or prevent the commercialization or potential regulatory approval of our product candidates for an extended period of time, result in shortages, cost overruns or other problems and would materially harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have no sales, marketing or distribution capabilities. We have not established commercial strategies regarding any of our product candidates. In order to commercialize our products, if any are approved by FDA, we will either have to develop such capabilities internally or collaborate with third parties who can perform these services for us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we decide to commercialize any of our drugs ourselves, we may not be able to</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">hire and retain the necessary experienced personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">build sales, marketing and distribution operations in a cost-effective manner which are capable of successfully launching new drugs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain access to adequate numbers of physicians to prescribe our products; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">generate sufficient product revenues.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, establishing such operations on our own will take time and involve significant expense. If our commercial operations lack complementary products, we may not be able to compete in a cost-effective manner with competitors with more products to sell. If we engage third-party collaborators to perform any commercial operations, our future revenues may depend significantly upon the performance of those collaborators. If we decide to enter into new co-promotion or other licensing arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators is limited and because of competition from others for similar alliances. Even if we are able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable terms, or at all.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, due to the nature of the market for our product candidates, it may be necessary for us to license all or substantially all of our product candidates to a single collaborator, thereby eliminating our opportunity to commercialize these other products independently. If we enter into any such new collaborative arrangements, our revenues are likely to be lower than if we marketed and sold our products ourselves.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, any revenues we receive would depend upon our collaborators&#8217; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change of strategic focus, business combinations or other factors outside of our control. Depending upon the terms of our collaboration, the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may be difficult or impossible to find a replacement collaborator on acceptable terms, or at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We rely on third parties to conduct our studies and some aspects of our research, and such third parties may not perform satisfactorily, which could delay or harm our studies, research, and testing. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We substantially rely and expect to continue to rely on third parties, such as contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical studies.&#160;For example, Pentara Corporation, an independent consulting firm that specializes in complex statistical analysis of clinical trials, has conducted statistical analysis relating to cognition endpoints in our clinical studies.&#160;Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it will delay our product development activities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that all of our clinical studies are conducted in accordance with the general investigational plan and protocols for the trial. Moreover, FDA requires us to comply with the norms of Good Clinical Practice (GCPs) for conducting, recording, and reporting the results of clinical studies to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of study participants are protected. We also are required to register ongoing clinical studies and post the results of completed clinical studies on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">If our third-party vendors do not successfully carry out their contractual duties, meet expected deadlines, or conduct studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. For example, one of our vendors failed to fully comply with certain Good Laboratory Practice (GLP) norms in its research facility, which required us to repeat a lab study at a different research site.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">We also rely on other third parties to label, store and distribute drug supplies for our clinical studies. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in our efforts to expand our technology or product candidates in other indications. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in Alzheimer&#8217;s disease dementia, our primary indication. We may expand our research efforts outside of this primary indication and into other areas of clinical medicine based on genetic, biological or mechanistic overlap with the primary indication. Conducting clinical studies for additional indications for our product candidates will require substantial technical, financial and human resources and is prone to the inherent risks of failure in drug development. We cannot provide any assurance that we will be successful in our effort to expand our technology or our product candidates in additional indications, even if we obtain approval for our product candidate in Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to successfully identify and develop additional product candidates, our commercial opportunity will be limited to Alzheimer</i></b>&#8217;<b><i>s disease or other neurodegenerations. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Identifying, developing, obtaining regulatory approval for, and commercializing additional product candidates requires substantial expertise and funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any additional product candidates through the development process, or assemble sufficient resources to identify, acquire, or develop additional product candidates. If we are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have never obtained FDA approval for a diagnostic test and we may not be able to secure such approval in a timely manner or at all. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are developing an investigational blood-based diagnostic test for Alzheimer&#8217;s disease, called SavaDx, which will require FDA approval prior to commercialization. Our diagnostic product candidate, marketing, sales and development activities and manufacturing processes are subject to extensive and rigorous regulation by FDA pursuant to the FDCA, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Under the FDCA, a diagnostic must receive FDA clearance or approval before it can be commercially marketed in the United States. The process of obtaining marketing approval or clearance from FDA or by comparable agencies in foreign countries for new products could:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">take a significant period of time;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">require the expenditure of substantial resources;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">involve rigorous preclinical testing, as well as increased post-market surveillance;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">require changes to products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">result in limitations on the indicated uses of products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not compete effectively with scientific and commercial competitors, we may not be able to successfully develop our diagnostic test for Alzheimer</i></b>&#8217;<b><i>s disease.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The field of clinical laboratory testing is highly competitive. Diagnostic tests are characterized by rapid technological change. Our competitors in the United States&#160;and abroad are numerous and include, among others, major diagnostic companies, reference laboratories, molecular diagnostic firms, universities and other research institutions. Most of our potential competitors have considerably greater financial, technical, marketing and other resources than we do, which may allow these competitors to discover important biological markers and determine their function before we do. We could be adversely affected if we do not discover proteins or biomarkers and characterize their function, develop diagnostic and pharmaceutical and clinical services based on these discoveries, obtain required regulatory and other approvals and launch these tests and their related services before our competitors. We also expect to encounter significant competition with respect to any diagnostic tests that we may develop or commercialize. Those companies that bring to market new diagnostic tests before we do may achieve a significant competitive advantage in marketing and commercializing their tests. We may not be able to develop additional diagnostic tests successfully and we may not obtain or enforce patents, if any, covering these tests that provide protection against our competitors. Moreover, our competitors may succeed in developing diagnostic tests that circumvent our technologies or tests. Furthermore, our competitors may succeed in developing technologies or tests that are more effective or less costly than those developed by us or that would render our technologies or tests less competitive or obsolete. We expect competition to intensify in the fields in which we are involved as technical advances in these fields occur and become more widely known and changes in intellectual property laws generate challenges to our intellectual property position.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We will need to develop our own proprietary antibodies or find alternative approaches that do not involve antibodies to advance our SavaDx and our diagnostic program.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To date, most of our tests with SavaDx have relied on the use of commercially available antibodies, which are complex molecules that can recognize and bind to an intended protein. Commercially available antibodies can present technical challenges, such as improper validation, significant batch-to-batch variations or inconsistent storage, any of which can jeopardize our studies and experiments. We are also evaluating an alternative approach to detect Alzheimer&#8217;s disease using mass spectrometry to detect FLNA, i.e., without the use of antibodies. The complexity of such an alternative approach also gives rise to many technical issues that are challenging to solve. We cannot be certain that we will be able to successfully complete the development of a detection system for Alzheimer&#8217;s disease that does or does not involve antibodies.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our Phase 2 clinical studies with simufilam in patients with Alzheimer</i></b>&#8217;<b><i>s disease are generally not designed to show a statistically meaningful difference in cognition or other health functions between those patients who receive placebo and those who receive drug.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Clinical research data is often analyzed with statistical probability (p-value) to address the question of whether a clinical observation is related to a treatment effect, a random effect or something else. This, in turn, requires a clinical study to incorporate a sufficiently large sample patient population to infer the appropriate statistical analysis. By design, our Phase 2 clinical studies with simufilam generally do not include a sufficiently large patient population to generate statistical probability on measures of cognition or other health functions. This feature may make it difficult for investors to properly interpret whether clinical observations in those Phase 2 studies with simufilam are important or meaningful. Conversely, our clinical studies may generate statistically significant data (i.e., p&lt;0.05) on exploratory biomarkers, or other endpoints, that have unknown or no clinical importance. In general, the distinction between statistically significant data and clinically meaningful data is a complex area of research that continues to evolve and may be subject to differences of opinion among scientists, clinicians, biostatisticians and other professionals, as well as among government regulators.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>In our open-label study, we observed apparent differences in treatment effects by stage of disease. These observations may or may not replicate in any of our subsequent clinical studies.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Alzheimer&#8217;s dementia is a progressive, degenerate disease. Severity of disease is typically assessed by stage of disease progression, a continuum that ranges from, approximately, mild cognitive impairment (MCI), to early stage, to mild, to moderate and finally to severe disease. Over time, cognition progressively worsens in the mild-to-moderate stages of Alzheimer&#8217;s as the disease takes its toll. However, we do not have a clear understanding of how our drug candidate simufilam may impact&#160;patients by stage of disease, if at all. For example, in our open-label and small placebo-controlled studies, we observed apparent differences in treatment effects by stage of disease. While we believe our data in mild patients may emphasize the importance of treating patients early in the disease, such observations may or may not replicate in any of our subsequent clinical studies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We expect to rely on clinical results generated predominately, or even solely, from patients with mild Alzheimer</i></b>&#8217;<b><i>s disease to show evidence of efficacy in our Phase 3 clinical trials, if any. Our reliance on patients with mild disease may narrow our ability to broadly market simufilam to the Alzheimer's disease community, if our drug candidate receives regulatory approval.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 19pt;">Our Phase 3 trials have randomized a total of approximately 1,900 patients with mild to moderate stages of Alzheimer&#8217;s disease at baseline (MMSE 16-27). Approximately 70% of these patients are diagnosed with mild Alzheimer&#8217;s disease (MMSE 20-27). Since the distribution of patients randomized into these trials is numerically skewed towards mild patients, we expect to rely predominantly, or even solely, on outcomes from mild patients to show evidence of drug efficacy, if any, in our Phase 3 trials. Our reliance on mild Alzheimer&#8217;s patients to show evidence of drug efficacy in our Phase 3 trials may not allow us to meet the regulatory standards required to gain a broad label indication in Alzheimer&#8217;s disease, and this may limit our ability to broadly market simufilam to the Alzheimer's disease community, if our drug candidate receives regulatory approval and becomes commercially available.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may encounter </i></b><b><i>difficulties keeping patients enrolled in our Phase 3 clinical studies, and our clinical development activities could thereby be delayed or otherwise adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The successful completion of clinical studies in accordance with their protocols depends, among other things, on our ability to keep patients enrolled in our Phase 3 studies until study conclusion. Patients who are enrolled in our Phase 3 studies may terminate their participation for a many&#160;reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">moving away from a clinical site;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability to keep appointments due to loss of mobility or caregiver;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">perceptions as to the efficacy of treatment, or lack thereof, including those who are randomized to placebo;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">side-effects associated with treatment;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">loss of interest or motivation to continue participation in clinical research;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patient non-compliance or protocol deviations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">interest in other available therapies and product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">withdrawal of patient consents; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the emergence of severe or debilitating health issues unrelated to study participation, such as a fall resulting in a fractured hip.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>&#160;Our clinical studies may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Before obtaining regulatory approvals for any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical experiments and clinical studies that our product candidates are both safe and effective for use in an intended population. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use, as determined by the FDA in the United States.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">New drug discovery, development and commercialization involves a high degree of risk. The process is expensive and complex and can take many years to complete, and its outcome is inherently uncertain. It can take over 10 to 15 years and cost over $1 to $2 billion for each new drug candidate to achieve regulatory approval. Only a small number of research and development programs achieve regulatory approval and subsequent commercialization of a drug product.&#160;We believe that in recent decades about 90 to 95% of novel drug candidates under development by the biopharmaceutical industry have failed to achieve regulatory approval and subsequent commercialization. Failure can occur at any time during the drug discovery and development process and such failures may be due to lack of clinical efficacy, adverse safety profile, regulatory hurdles, excessive costs, lack of perceived market opportunity, lack of resources, insufficient reimbursement from insurers, inability to compete or for other reasons. Many biopharmaceutical companies have suffered significant setbacks in Phase 3 clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Seasoned professionals with a prior track record of innovation in drug discovery and development, as well as substantial business expertise, routinely fail to achieve regulatory approval of new product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The results of our preclinical studies with our product candidates may not be predictive of the results of early-stage or later-stage clinical studies, and results of early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. The results of clinical studies in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical studies of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical study protocols and the rate of dropout among clinical study participants. Our open-label extension study may also extend the timing and overall cost of our clinical development program substantially. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We may suffer significant setbacks in our ongoing Phase 3 clinical studies due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier studies. Clinical trials in neurodegenerative diseases, including Alzheimer&#8217;s disease, have much higher historically failure rates than in many other disease areas. Most new product candidates for neurodegeneration that begin clinical studies are never approved by regulatory authorities for commercialization.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have limited experience in designing clinical studies in neurodegeneration and may be unable to design and execute a clinical study to support marketing approval. We cannot be certain that our current clinical studies or any other future clinical studies will be successful. Additionally, any safety concerns observed in any one of our clinical studies in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, even if such clinical studies are successfully completed, we cannot guarantee that FDA or foreign regulatory authorities will interpret the results as we do, and more studies could be required before we submit our product candidates for approval. To the extent that the results of the studies are not satisfactory to FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional studies in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>If our drug candidate causes or contributes to a death or a serious injury before or after approval, we will be subject to medical reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our drug candidate in Alzheimer&#8217;s disease is aimed at elderly patients with dementia, some of whom may be frail due to advanced age or underlying health issues. Under FDA medical reporting regulations, we are required to report to the FDA information that our drug candidate has or may have caused or contributed to a death or serious injury. Any such serious adverse event involving our drug could result in future FDA action, such as an inspection, enforcement action or warning, or in more serious cases, a complete shutdown of our clinical program. In the context of our ongoing clinical trials, we report adverse events to the FDA in accordance with applicable national and local regulations. Any corrective action, whether voluntary or involuntary, and either pre- or post-market, needed to address any serious adverse events will require the dedication of our time and capital, distract management from operating our business, and may harm our reputation and financial results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market opportunities for simufilam and SavaDx, if approved, may be smaller than we anticipate.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If our clinical development programs succeed, we expect to seek regulatory approval of simufilam and SavaDx for patients with Alzheimer&#8217;s disease. Our projections of the number of patients with Alzheimer&#8217;s disease is based on our beliefs and estimates. These estimates have been derived from a variety of outside sources, including scientific literature, patient foundations and market research, and may prove to be incorrect. The actual number of patients may turn out to be lower than expected. Additionally, the potential patient population for our current programs or future product candidates may be limited. Even if we obtain regulatory approval and capture significant market share for any product candidate, the potential target populations may be smaller than anticipated, and we may never achieve profitability without obtaining marketing approval for additional indications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that additional competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, any of which may harm our business operations. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Drug discovery and development is highly competitive. Moreover, the neurodegenerative field is characterized by intense and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to Biogen, Eisai and Eli Lilly, several pharmaceutical and biotechnology companies are currently pursuing the development of products for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical studies, obtaining regulatory approvals, and marketing approved products than we do.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our commercial opportunity could be reduced or eliminated if other competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient, achieve greater acceptance among physicians and patients, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant advantages over any of our product candidates. Competitors other than Biogen, Eisai and Eli Lilly may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Government Regulation and Other Legal Compliance Matters</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings, government investigations or allegations and other claims, many of which arose following a </i></b><b><i>short selling attack campaign against our Company that commenced in 2021</i></b><b><i>.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are, and may in the future be, subject to various investigations and legal proceedings.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, there has been a trend of increasing government investigations, legal proceedings and law enforcement activities against companies, executives and others operating in our industry, including those arising from whistleblower programs operated by the SEC and DOJ and the <i>qui tam</i> provisions of the False Claims Act.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are currently managing inquiries from U.S. government agencies, as well as civil claims under federal and state laws, relating to and/or arising out of research and development of our product candidates, including grant applications, securities disclosures and other aspects of our business. For additional information regarding legal proceedings, see "Item 8. Financial Information&#8212;8.A. Consolidated Statements and Other Financial Information&#8212;Legal Proceedings".&#160; New claims or inquiries may arise in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In response to government document requests and other claims asserted against us, we established a comprehensive document retention policy that strictly governs how we handle, store and protect our documents and data. Failure to comply with our document retention policy would expose us to risk of enforcement actions and penalties under applicable laws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Legal proceedings are inherently unpredictable, and large judgments or penalties sometimes occur. As a consequence, we may in the future incur judgments or penalties that could involve large cash payments, including the potential repayment of amounts allegedly obtained improperly and other penalties, including enhanced damages. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, such proceedings against us or against third parties with whom we collaborate or otherwise do business may affect our reputation, inhibit our ability to raise fund in the capital markets, create a risk of potential exclusion from government reimbursement or grant programs and may lead to additional civil litigation. Even meritless claims could subject us to adverse publicity, hinder us from securing insurance coverage in the future or require us to incur significant legal costs. As a result, having taken into account all relevant factors, we may in the future enter into settlements of such claims without bringing them to final legal adjudication by courts or other such bodies, despite having potentially significant defenses against them, in order to limit the risks they pose to our business and reputation. Such settlements may require us to pay significant sums of money and to enter into corporate integrity or similar agreements intended to regulate company behavior for a period of years, which can be costly to operate under.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As a result, significant claims or legal proceedings to which we are a party, any judgments or settlements against us or involving third parties associated with us relating to such claims or proceedings, and any accruals that we may take with respect to potential judgments or settlements, could have a material adverse impact on our business, financial condition or results of operations, as well as on our reputation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Additional future litigation involving&#160;us could be costly and time-consuming to defend. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Innovative drug development is highly litigious, and we may, from time to time, become subject&#160;to or involved in additional legal proceedings, claims and allegations that arise in the ordinary course of business or pursuant to governmental or regulatory enforcement activity. Regardless of merit, any lawsuits against or involving us, individually or in the aggregate, may have a material adverse effect on our business, financial condition, results of operations or cash flows. In addition, any litigation to which we subsequently become a party might result in substantial costs and divert management's attention, time and resources, which might seriously harm our business, financial condition, results of operations and cash flows. Our insurance policies might not cover such claims, might not provide sufficient payments to cover all of the costs to resolve one or more such claims, and might not continue to be available on terms acceptable to us. In particular, any claim could result in potential liability for us if the claim is outside the scope of the indemnification agreement we have with our third-party partners, or our third-party partners do not abide by the indemnification agreement as required, or the liability exceeds the amount of any applicable indemnification limits or available insurance coverage. A claim brought against us that is uninsured or underinsured could result in unanticipated costs and could have a material adverse effect on our financial condition, results of operations, cash flows or reputation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are ultimately unable to file for and obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The time required to obtain approval by FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not obtained regulatory approval for any product candidate, including our product candidates aimed at Alzheimer&#8217;s disease, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may disagree with the design, implementation, or results of our clinical studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be unable to demonstrate to FDA or comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio when compared to the standard of care is acceptable;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA), or other submission or to obtain regulatory approval in the United States or elsewhere;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the approval policies or regulations of FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our ability to market and promote our product candidates will be determined and limited by FDA-approved labeling. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The commercial success of our product candidates will depend upon our ability to obtain FDA-approved labeling&#160;effectively describing their features. If a product receives regulatory approval, the approval may be significantly limited to specific disease stages, patient populations and dosages, or the indications for use may otherwise be limited, which could restrict the availability of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling or a commitment to conduct one or more post-market studies or clinical trials.&#160;For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug&#8217;s safety and effectiveness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our failure to achieve FDA approval of product labeling containing appropriate information will prevent us from advertising and promoting the key features of our product candidates in order to differentiate them from other similar products. On the other hand, limitations required by the FDA for the product labeling of our product candidates may restrict the patient populations to which our product candidate is available.&#160;Either of these results would make our products less competitive in the market the commercial value of the product.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with the laws of FDA and other comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide true, complete, and accurate information to FDA and other comparable foreign regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with manufacturing standards we have established;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">comply with healthcare fraud and abuse laws in the U.S. and similar foreign fraudulent misconduct laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">report financial or clinical information or data accurately or to disclose unauthorized activities to us; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">otherwise comply with applicable criminal, civil or regulatory laws governing their conduct.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Activities subject to laws also involve the improper use of information obtained in the course of patient recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. Further, it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we fail to comply or stay in compliance with the complex set of federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are obligated to comply with the laws of all countries and jurisdictions in which we operate. These laws cover an extremely wide and growing range of activities. Such legal requirements can vary from country to country, and new requirements may be imposed on us from time to time as government and public expectations regarding acceptable corporate behavior change, and enforcement authorities modify interpretations of legal and regulatory provisions and change enforcement priorities. In addition, we rely on numerous associates, independent contractors, consultants, commercial partners and vendors who may put our reputation, business and&#160;operations at risk of material impairment if they engage, or are alleged to engage, in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, in violation of such laws and public expectations.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The laws and regulations that govern our operations include, among others:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Clinical Laboratory Improvement Amendments (CLIA) of 1988, which are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, requires that laboratories obtain certification from the federal government, and state licensure laws;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FDA laws and regulations , including those relating to off-label marketing;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Health Insurance Portability and Accountability Act (HIPAA), which imposes comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, including penalties for violators, enforcement authority to state attorneys general and requirements for breach notification;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state laws regulating testing and protecting the privacy of test results, as well as state laws protecting the privacy and security of health information and personal data and mandating reporting of breaches to affected individuals and state regulators;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal anti-kickback law, or the Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal health care program;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal False Claims Act (FCA), which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government and which, under its <i>qui tam</i> provisions, allows private litigants (called &#8220;relators&#8221;) to file claims under seal on behalf of the government and to receive a percentage of recoveries obtained as a result;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the Foreign Corrupt Practices Act (FCPA) and other worldwide anti-bribery laws, including those that prohibit companies and their intermediaries from making improper payments to government officials or other third parties for the purpose of obtaining or retaining business, and laws that prohibit commercial bribery;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">import, export control and economic sanctions laws and regulations in the U.S. and elsewhere;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Federal securities laws, including provisions of the Exchange Act and Dodd-Frank Act under which whistleblowers that report alleged violations of wrongdoing can obtain up to 30% of related recoveries;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Physician Payments Sunshine Act, which requires manufacturers to track and report to the federal government certain payments and other transfers of value made to physicians and teaching hospitals and ownership or investment interests held by physicians and their immediate family members;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">section 216 of the federal Protecting Access to Medicare Act of 2014 (PAMA), which requires applicable laboratories to report private payer data in a timely and accurate manner every three years (and in some cases annually);</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state laws that impose reporting and other compliance-related requirements; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">similar foreign laws and regulations that will apply to us in foreign countries in which we may choose to operate in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Government agencies may establish and promulgate usage guidelines that could limit the use of our product candidates. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Government agencies, professional and medical societies, and other groups may establish usage guidelines that apply to our product candidates. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the clinical use or commercial appeal of our product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the conduct of clinical trials, study participants report changes in their health to their doctor, including illnesses, injuries and discomforts. Often, it is not possible to determine whether our product candidate caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur. In addition, we have not yet completed long-term safety studies with simufilam to determine if this product candidate is safe for humans. Adverse events or other undesirable side effects caused by simufilam could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by FDA or other comparable foreign regulatory authorities. Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential claims.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to legal liability associated with clinical trials.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our business requires us to engage in the conduct of clinical studies in human volunteers and in patients in the United States and abroad. There are circumstances under which a participant in one of our clinical trials could impose liability on us. For example, a clinical investigator who is a participant in one of our studies may intentionally or unintentionally deviate from a clinical protocol and cause harm to a clinical trial participant, or a clinical trial participant may seek to compel us to continue to supply drug to them after the completion of a study but prior to FDA approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Claims may be brought against us for negligence, breach of contract, harm, injury or death, or other legal theories based on the nature of a study. Clinical trial liability is a complex and somewhat unsettled area of law and may vary by state and by country where we conduct clinical studies. Furthermore, claims may be brought against us by a clinical investigator, a clinical trial participant, or another party associated with a clinical study, long after the completion of a clinical study. Defense of such actions is a fact-intensive process that could be costly and involve significant time and attention of our management and other resources, may result in monetary liabilities or penalties, and may require us to change our business in an adverse manner.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we may&#160;need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. We do not carry a separate cybersecurity commercial insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are and will be required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical study participants, costs due to related litigation, distraction of management&#8217;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our product candidates receive regulatory approval, we and our collaborators will be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we and our collaborators may also be subject to additional FDA post-marketing obligations or new regulations, all of which may result in significant expense and limit our and our collaborators</i></b>&#8217;<b><i> ability to commercialize our potential drugs. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any regulatory approvals that our product candidates receive may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition, if FDA approves any of our product candidates, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping for the drug will be subject to extensive regulatory requirements. The subsequent discovery of previously unknown problems with the drug, including but not limited to adverse events of unanticipated severity or frequency, or the discovery that adverse events previously observed in preclinical research or clinical studies that were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. Any of these events could prevent us from marketing our products and our business could suffer.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Enacted and future legislation may increase the difficulty and cost for us to commercialize our product candidates and may reduce the prices we are able to obtain for our product candidates.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Legislative and regulatory changes and future changes regarding the healthcare system could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities or affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the U.S., the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the Medicare Modernization Act) established the Medicare Part&#160;D program and provided authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare Modernization Act, including its cost reduction initiatives, could limit the coverage and reimbursement rate that we receive for any of our approved products. Private payors may follow Medicare coverage policies and payment limitations in setting their own reimbursement rates resulting in similar limits in payments from private payors.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, among other things, imposes a significant annual fee on companies that manufacture or import branded prescription product candidates. It also contains substantial provisions intended to, among other things, broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, and impose additional health policy reforms, any of which could have a material adverse effect on our business. A significant number of provisions are not yet, or have only recently become, effective, but the Affordable Care Act may result in downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Affordable Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue, attain profitability or commercialize our products. The Affordable Care Act is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the Affordable Care Act on our business or on our drugs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The purported goal of the Inflation Reduction Act (IRA) of 2022 is to lower healthcare costs for Americans, and includes several provisions aimed at reducing drug spending and increasing access to pharmaceuticals. Specifically, the IRA introduces drug-price negotiations by requiring the federal government to negotiate &#8220;maximum fair prices&#8221; with drug manufacturers for certain brand-name, single-source drugs covered under Medicare Part B and Part D. In addition, the IRA penalizes price increases and expands required discounts on branded, single-source drugs. The IRA is a highly complex piece of legislation that continues to evolve. We do not and cannot understand or anticipate the full impact and potential implications of the IRA on our business or on our drugs, however, we currently believe the IRA may reduce the prices we are able to obtain for our product candidates, if approved in the United States.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our relationships with customers and payors will be subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Healthcare providers, physicians and payors play a primary role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our current or future arrangements with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we may obtain marketing approval. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients' rights are and will be applicable to our business. Restrictions under applicable federal, state and foreign healthcare laws and regulations may affect our ability to operate and expose us to areas of risk, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute to defraud any healthcare benefit program or specific intent to violate it in order to have committed a violation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, commonly known as the Sunshine Act, as well as other state and foreign laws regulating marketing activities; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state and foreign equivalents of each of the above laws, including state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; state laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Nonetheless, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to obtain and maintain sufficient patent protection for any product candidates, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. Given that our product candidates are in early or clinical stages of development, our intellectual property portfolio with respect to certain aspects of our product candidates is also at an early stage. We have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in some cases, we have filed only provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>U.S. intellectual property rights around diagnostic methods is a complex, evolving area of law and effective patent claims may not be available to us for our investigational diagnostic product candidate, SavaDx, in the United States.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The legal system for intellectual property around diagnostic methods is highly complex, remains uncertain and continues to evolve. In the U.S., patent courts have struggled to define a clear means of patent eligibility for modern age diagnostics. Case law interpretations from the U.S. Supreme Court have left certain important scientific advances in the area of diagnostics without effective patent claims. In 2012, the Supreme Court held that a simple process involving correlations between blood test results and patient health is not eligible for patent claims because such processes incorporate &#8220;laws of nature&#8221;. Since then, different outcomes from different courts, including Federal Circuit, District Court and Patent Trial and Appeal Board decisions, have continued to create a sometimes vague or conflicting legal framework for determining the eligibility of patent claims for diagnostic methods. As a result, we cannot be certain how SavaDx fits into the current U.S. legal framework for obtaining effective patent protection. We currently have no U.S. patents or patent applications with respect to SavaDx, and we believe it may be protected in the United States only by trade secrets, know-how and other proprietary rights technology. Furthermore, claims for diagnostic methods can be complicated to enforce. For patent infringement to occur with a protected diagnostic, the patented method must generally either be performed by one person in its entirety or performed by multiple parties all under the control or direction of a single party. Accordingly, even if effective patent claims are issued for SavaDx, it may be impractical, impossible or even undesirable to enforce potential infringement claims.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that the asserted patent is invalid or unenforceable. In patent litigation in the U.S. and in other jurisdictions, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, <i>inter partes</i><b><i> </i></b>review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the U.S. and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants as well as train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If any of our patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in either the patent laws or their interpretation in the U.S. and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents with respect to our product candidates. With respect to our intellectual property related to our product candidates, we cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, or enforce all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and <i>inter partes </i>review, or interference proceedings or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be able to protect our intellectual property and proprietary rights throughout the world. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Changes in either the patent laws or interpretation of the patent laws in the U.S. could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September 2011, the U.S. transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The America Invents Act also significantly affects the way patent applications are prosecuted and as well as patent litigation. This includes allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i><b><i> </i></b>review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings as compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Various U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to claims challenging the inventorship of our patents and other intellectual property. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to claims that former employees, scientific collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may not be successful in obtaining necessary rights to our product candidates or other technologies. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many pharmaceutical companies, biotechnology companies, and academic institutions that compete with us in the field of neurodegeneration therapy may have patents filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owner&#8217;s interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property which may prevent or delay the development of our product candidates. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The field of developing innovations for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, the intellectual property landscape in this field is in flux, and it may remain uncertain in the future. Additionally, no products utilizing our underlying science and technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our commercial success depends in part on our ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including <i>inter partes</i> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. Although we believe that we do not infringe on any third parties&#8217; patents or other intellectual property, we cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued to a third party, such as a competitor in the fields in which we are developing product candidates, who might assert infringement of patents it may hold by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Competitors may infringe on our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intellectual property rights do not necessarily address all potential threats. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we may own;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we might not have been the first to make the inventions covered by the issued patent or pending patent application that we own now or in the future;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we might not have been the first to file patent applications covering certain of our inventions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">it is possible that our current or future pending patent applications will not lead to issued patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may not develop additional proprietary technologies that are patentable;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the patents of others may harm our business; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business and Operations </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our reputation and operations could be adversely impacted by allegations&#160;</i></b><b><i>of wrongdoing</i></b><b><i>, regardless of their merits. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe that our reputation has significantly contributed to the success of our business. We also believe that maintaining and enhancing our reputation is critical to many of our core operations, such as conducting studies, working with outside vendors, attracting qualified employees, members of our Board of Directors and&#160;science collaborators, raising funds for future operations, and&#160;working with potential industry and government collaborators. Maintaining and enhancing our reputation will depend largely on our ability to develop innovative drug products, continue to generate credible scientific data and respond appropriately to our critics, which we may not do successfully.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our reputation may be injured by the dissemination of false statements purporting to be fact, mischaracterizations of our scientific data, or by hostile actions made by or paid for by parties associated with market participants who seek a decline in the price of our securities (&#8220;short-sellers&#8221;) as well as media coverage of the foregoing. Allegations, mischaracterizations and similar statements may be disseminated directly to third parties with whom we interact, published in forums over which we have no control, such as through online social media channels or publicized as a result of media coverage, and may be adopted by the editors of scientific or technical journals that have published our research, potentially resulting in retractions or expressions of concern by the journals. For example, although no journal has asserted that we or any of our employees or consultants has inappropriately manipulated data or engaged in any misconduct, public short-seller allegations have prompted several journals to reassess certain peer-reviewed articles previously published by researchers associated with us and to retract articles or issue expressions of concern.&#160;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Regardless of merit, allegations, mischaracterizations and false statements may spread quickly and erode confidence in our reputation. Maintaining and enhancing our reputation may require us to make substantial investments in legal actions or other activities, and these investments could be expensive, time consuming, and unsuccessful. If we fail to successfully maintain our reputation, or if we incur excessive expenses in this effort, our business, operations, future prospects, cash flows, and financial position may be adversely affected.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Our current dependence on single source suppliers for our drug substance and drug product could materially adversely affect our ability to manufacture our product candidates and materially increase our costs.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We rely on single source suppliers for materials that are critical to the manufacturing of simufilam, our lead product candidate. This reliance subjects us to risks related to our potential inability to obtain an adequate supply of required materials. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct their activities in accordance with regulatory requirements, or if there are disagreements between us and these third parties, we may not be able to complete, or may be delayed in completing, the clinical studies required to support future regulatory submissions and approval of the product candidates we develop. Our operating results could be materially adversely affected if we were unable to obtain adequate supplies of simufilam in a timely manner or if their cost increased significantly due to inflation or other factors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Further, under certain circumstances, service providers that have contracted with us may be entitled to terminate their engagements with us. In such circumstances, product development activities could be delayed while we seek to identify, validate, and negotiate an agreement with a replacement service provider. In some such cases an appropriate replacement may not be readily available or available on acceptable terms, which could cause additional delays to our development process. It would likely result in production and delivery delays if we needed to find alternative suppliers for simufilam, which could lead to delays in our clinical trials and have a material adverse effect on our business, results of operations and financial condition</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Inadequate Congressional funding for the FDA, the SEC and other U.S. government agencies or comparable foreign regulatory authorities, including from government shut downs, or other disruptions to these agencies</i></b>&#8217;<b><i> operations, could hinder these agencies</i></b>&#8217;<b><i> ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent government agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 32pt;">The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and enact statutory, regulatory and policy changes. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 32pt;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid, unpredictable and entirely beyond our control.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 32pt;">Disruptions at the FDA and other agencies may also slow the time necessary for us and the FDA to communicate and continue discussions&#160;on key aspects of our Phase 3 clinical analysis, or for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in prior years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA or SEC to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-indent: 9pt;"><b><i>The FDA may change the statutory requirements for drug approval.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">FDA Guidances for Industry are non-binding policy documents that are issued by FDA from time to time to assist sponsors, such as our Company, with the clinical development of drug candidates. Even though such guidance documents do not set legal standards or impose binding requirements they are nonetheless broadly followed by sponsors, including us. In addition, sponsors who adhere in good faith with earlier guidance documents have no assurance or recourse against enforcement actions if the guidance documents are later replaced with conflicting guidance. We have relied heavily on current FDA guidance and meetings with the FDA to advance simufilam through the drug development process. Any future changes to existing FDA Guidance for Industry for Alzheimer&#8217;s disease may have a material adverse effect on our business, may add significant time, cost or complexity to our drug development program for simufilam, or could cause us to cease or delay development of some or all our product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In addition, changes in FDA regulations, statutes or the interpretation of existing regulations and statutes could impact our business by requiring, for example: (i) changes to our manufacturing arrangements for simufilam; (ii) additions or modifications to product labeling, if and when our product candidates are approved for sale; (iii) the recall or discontinuation of our product candidates from investigational clinical sites; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they may have a material adverse effect on our business, may add significant time, cost or complexity to our drug development program for simufilam, or could cause us to cease or delay development of some or all our product candidates.&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our reliance on third parties for both the supply and manufacture of materials for our product candidates carries the risk that we will not have sufficient quality or quantities of such materials or product candidates, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We do not have any manufacturing facilities. We currently rely on CDMOs for all of the manufacture of our materials for preclinical studies and clinical studies and expect to continue to do so for preclinical studies, clinical studies, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the possible breach of the manufacturing agreement by the third party;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the inability to produce required volume in a timely manner and to quality standards.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the U.S. Our failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our studies, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures, or recalls of product candidates or product candidates, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business, financial condition, results of operations, and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also rely on third-parties for the supply of the raw materials required for the production of our product candidates, and we expect to continue to rely on third party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 1pt;"><b><i>Our employees, principal investigators, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and vendors. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violate (i) the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, clinical and business arrangements in the biotechnology and healthcare industries are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of financial arrangements, incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the conduct of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or furnish under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple mistake or human error. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Failure to comply with laws regarding data privacy could expose us to risk of enforcement actions and penalties under such laws.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may be subject to privacy and security laws in the various jurisdictions in which we operate, obtain or store personally identifiable information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Our ongoing efforts to comply with evolving laws and regulations may be costly and require ongoing modifications to our policies, procedures and systems. Failure to comply with laws regarding data protection by us or our partners or service providers would expose us to risk of enforcement actions and penalties under such laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Within the U.S., there are numerous federal and state laws and regulations related to the privacy and security of personal information. For example, at the federal level, the Health Insurance Portability and Accountability Act of 1996, as amended (&#8220;HIPAA&#8221;), and its implementing regulations establish privacy and security standards that limit the use and disclosure of personally identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information. While we have determined that we are neither a &#8220;covered entity&#8221; nor a &#8220;business associate&#8221; directly subject to HIPAA, many of the U.S. health care providers with which we interact are subject to HIPAA, and we may have assumed obligations related to protecting the privacy of personal information. States are increasingly regulating the privacy and security of personal information. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which took effect in 2020, gives California consumers (defined to include all California residents) certain rights, including the right to ask covered companies to disclose the types of personal information collected, the categories of sources from which such information was collected, the business purpose for collecting or selling the consumer&#8217;s personal information, the categories of third parties with whom a covered company shares personal information, and specific pieces of information collected by a covered company. The CCPA imposes several obligations on covered companies to provide notice to California consumers regarding their data processing activities. The CCPA also gives California consumers the right to ask covered companies to delete a consumer&#8217;s personal information and it places limitations on a covered company&#8217;s ability to sell personal information, including providing consumers a right to opt out of sales of their personal information. Additionally, the California Privacy Rights Act (&#8220;CPRA&#8221;), which became operational in 2023, significantly modifies the CCPA, including expanding consumers&#8217; rights with respect to certain sensitive personal information, and creates a new state agency vested with authority to implement and enforce the CCPA and CPRA. The Virginia Consumer Data Protection Act (&#8220;CDPA&#8221;) went into effect on January 1, 2023. The CDPA provides consumers with new rights to access, correct, delete and obtain a copy of the personal information a covered business holds about them, and to opt out of certain data processing activities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="color:#000000;"><b><i>Because we are </i></b></span><b><i>developing our lead product candidate for the treatment of Alzheimer</i></b>&#8217;<b><i>s disease, a condition for which there are few recent examples of new drug molecules that have received full FDA approval, and all Phase 3 trials in Alzheimer</i></b>&#8217;<b><i>s disease employ cognitive and functional efficacy endpoints or methodologies that may be considered subjective, there is a heightened risk that the FDA or other regulatory authorities may not consider our Phase 3 clinical trials, or the endpoints of our clinical trials, as evidence of clinically meaningful results or that our clinical results may be difficult to analyze.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If our product candidates advance to the FDA review process, we will need to demonstrate the achievement of success criteria and endpoints such that the FDA will be able to determine the clinical efficacy and safety profile of our product candidates. Because we are developing a novel treatment for Alzheimer&#8217;s disease, a condition in which there are very few examples of new drug approvals, and our trials employ endpoints or methodologies that may be considered subjective, there is heightened risk that the FDA or other regulatory bodies may not consider our clinical trials, or the endpoints of our clinical trials, as evidence of clinically meaningful results to patients. In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a threshold of statistical significance (i.e., p-value &lt;0.05). Even if we believe the data collected from clinical trials of our lead product candidates are promising, these data may not be sufficient to support approval by the FDA or foreign regulatory authorities. Pre-clinical and clinical data can be interpreted in different ways. Accordingly, the FDA or foreign regulatory authorities could interpret these data in different ways from us, which could delay, limit or prevent regulatory approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If data from one or both of our Phase 3 trials do not adequately demonstrate the safety or efficacy of our lead product candidate, the regulatory approval for such product candidate could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approvals could be denied.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are evaluating two doses (50 mg and 100 mg) of simufilam in on-going Phase 3 trials. If data from one dose in our Phase 3 trials does not adequately demonstrate safety or efficacy, the regulatory approval for the other dose could be significantly delayed as we work to meet approval requirements, or, if we are not able to meet these requirements, such approval could be denied.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We expect to significantly grow the size and capabilities of our organization and we may experience difficulties in effectively managing this growth. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As our development plans and strategies develop, we expect to add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">identifying, recruiting, integrating, retaining, and motivating additional employees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">increasing employee headcount;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to contractors and other third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expanding our operational, financial and management controls, reporting systems, and procedures; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">managing increasing operational and managerial complexity.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical studies may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and, accordingly, may not achieve our research, development, and commercialization goals.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Ownership of our corporate headquarters and property leasing are subject to numerous risks and uncertainties.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In 2021, we made an all-cash purchase of an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. Title to this property is held by Austin Innovation Park, LLC, a Texas limited liability company wholly owned by Cassava Sciences. The purchase required a substantial upfront cash investment and may require further commitments of our resources in the future. We have assumed or entered into lessor commitments with independent third parties for portions of our office complex and expect to&#160;continue to do so in the future. Commercial property ownership and related leasing activity are subject to many factors that pose substantial financial risks and uncertainties, including tenant default or non-payment of lease obligations by tenants. Macro-economic or other factors outside of our control could have an adverse effect on the demand for leased office space in our locale or may cause a decline in the market value of our corporate headquarters.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">At December 31, 2023, we occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to third parties.&#160;Virtually all existing tenant&#160;leases will expire&#160;in 2024. We believe tenant leases that expire in 2024 will likely&#160;not be extended, renewed or re-leased beyond their expiry date, in which case we will no longer receive rental payments or reimbursement for shared expense for such office space. If we fail to lease unoccupied office space at favorable rates, or if we incur excessive expenses in this effort or incur excessive leasehold improvements or property ownership expenses, our business, operations, future prospects, cash flows, and financial position may be adversely affected. In addition, our property is located in a semi-rural, wooded area of Austin, Texas that is subject to natural disasters such as extreme weather conditions, including but not limited to floods, tornadoes, wildfires, winter storms, lighting, heat waves and drought. Such natural disasters could damage, destroy or impair the value of our property or reduce the number of tenants who are willing or able to continue to lease office space in our property. We may incur substantial expenses as a result of our property&#8217;s exposure to natural disasters, which could have a material adverse effect on our business and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our internal computer systems, or those used by third parties on whom we rely, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In the ordinary course of our business, we collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems, as well as extensive cloud-based applications and data storage. These applications and data encompass a wide variety of business-critical information including research and development information, commercial information and business and financial information. Despite the implementation of security measures, our internal computer systems and those of our current or future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these cyberattacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical study data from completed, ongoing, or future clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates,&#160;to conduct clinical studies, and to analyze our clinical study data and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our reliance on third parties requires us to share our proprietary information, which increases the possibility that a competitor will discover this information or that our proprietary information will be misappropriated or inadvertently disclosed.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our reliance on third-party vendors requires us to disclose our proprietary information to these parties, which could increase the risk that a competitor will discover this information or that our proprietary information will be misappropriated or disclosed without our intent to do so. If any of these events were to occur, then our ability to obtain patent protection or other intellectual property rights could be irrevocably jeopardized, and costly, distracting litigation could ensue. Furthermore, if these third-party vendors cease to continue operations and we are not able to quickly find a replacement provider or we lose information or items associated with our products or product candidates, our development programs may be delayed. Although we carefully manage our relationships with our third-party collaborators and CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, clinical operations, financial condition and prospects.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business involves environmental risks that may result in liability for us.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In connection with our research and development activities, we, and our collaborators and vendors, are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens, chemicals and wastes. Although we believe that we comply with such applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may incur significant costs to comply with environmental and health and safety regulations in the future. Although we believe that our safety procedures for handling and disposing of controlled materials comply with the standards prescribed by state and federal regulations, accidental contamination or injury from these materials may occur. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business disruptions and lack of appropriate levels of commercial insurance could seriously harm our future revenue and financial condition and increase our costs and expenses. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, disease epidemics or pandemics, such as COVID-19, and other natural or man-made disasters or business interruptions, for which we are partly or entirely uninsured. In addition, we rely on third parties for conducting certain research and development activities relating to our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any such business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our day-to-day operations are located in a single office facility in Austin, Texas. Damage or extended periods of interruption to our corporate, development, or research facilities could cause us to cease or delay development of some or all our product candidates. Our insurance might not cover losses under such circumstances and our business may be seriously harmed by such delays and interruption.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Social media platforms have significantly altered the dynamics of corporate communications and present risks and challenges, some of which are&#160;and may continue to be unknown to us.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As social media continues to expand, it also presents us with new challenges. The inappropriate or unauthorized use of our confidential information on media platforms could cause brand damage or information leakage, which would cause legal or regulatory issues for us. In addition, negative, inappropriate or inaccurate posts or comments about us or our product candidates on social media internet sites could quickly and irreversibly damage our reputation, image and goodwill. Further, the accidental or intentional disclosure of non-public sensitive information by our workforce or others through media channels could lead to information loss or could lead to legal or regulatory issues for us. In addition, there is a risk of a fraudulent third-party hijacking our information technology systems without our knowledge to access our confidential documents or to use our company name, logo or brand without authorization. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm and costs to our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We also rely on other third parties to label, store and distribute drug supplies for our clinical studies. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our product candidates, producing additional losses and depriving us of potential product revenue.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We are a small company with a limited number of employees. We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our President and Chief Executive Officer, Remi Barbier, and our scientific and technical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region in Austin, Texas, and doing so may be costly and difficult.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity option grants that vest over time and/or a cash bonus plan. The value to employees of these equity grants that vest over time or cash bonus plans may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may need to cease our operations if we are unable to attract and retain key personnel.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are engaged in developing early- and clinical-stage technologies and will continue to do so for the foreseeable future. Unlike larger organizations, we rely on a very small number of highly skilled, and highly sought after, employees to continue the advancement of our development stage technologies. The knowledge and skills contributed by our key employees may be irreplaceable and the loss of a key employee may cause substantial negative financial, operational and scientific consequences for our business. As an example, in the past, we have received research grant awards from NIH, which depended in part on the continued participation of certain key employees, known as Principal Investigators. When such NIH grant awards are in place, the loss of a Principal Investigator may result in the loss of one or more of such research grant awards. Likewise, the intellectual property that is intended to protect our development stage technologies is still evolving and its evolution remains highly dependent on a small number of employees with specific expertise. The loss of a key employee may jeopardize our existing or pending intellectual property or may prevent us from accessing the technical information and knowledge necessary to extend our portfolio of intellectual property. Furthermore, we believe the adverse effects that may result from losing a key employee&#8217;s participation cannot be compensated with any specific insurance policies, such as &#8220;key person&#8221; or &#8220;business life&#8221; insurance. If we are not successful in retaining key employees, our business and financial condition will suffer, and we may need to cease our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If our current research collaborators or scientific advisors terminate their relationships with us or develop relationships with a competitor, our ability to continue our business operations could be adversely affected.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have relationships with unaffiliated research collaborators at academic and other institutions who conduct research at our request. These research collaborators are not our employees. As a result, we have limited control over their activities and, except as otherwise required by our collaboration agreements, can expect only limited amounts of their time to be dedicated to our activities. Our ability to discover drugs and biomarkers involved in human disease and validate and commercialize diagnostic tests may&#160;depend in part on the continuation of these collaborations. If any of these collaborations are terminated, we may not be able to enter into other acceptable collaborations. In addition, our existing collaborations may not be successful. Our research collaborators and scientific advisors may have relationships with other commercial entities, some of which could compete with us. Our research collaborators and scientific advisors sign agreements which provide for the confidentiality of our proprietary information and the results of studies conducted at our request. We may not, however, be able to maintain the confidentiality of our technology and other confidential information related to all collaborations. The dissemination of our confidential information could have a material adverse effect on our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties beyond our control.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">War, terrorism, geopolitical uncertainties and other business interruptions could cause damage to, disrupt or cancel the conduct of our clinical studies on a global or regional basis, which could have a material adverse effect on our business, clinical sites or vendors with which we do business. Such events could also decrease patient demand to enroll in our clinical studies or make it difficult or impossible for us to deliver products and services to our clinical investigational sites. In addition, territorial invasions can lead to cybersecurity attacks on technology companies, such as ours, located far outside of the conflict zone. In the event of prolonged business interruptions due to geopolitical events, we could incur significant losses, require substantial recovery time and experience significant expenditures in order to resume our business or clinical operations. We have no operations in Israel,&#160;Russia or the Ukraine, but we do not and cannot know if the current uncertainties in these geopolitical areas may escalate and result in broad economic and security conditions or rationing of medical supplies, which could limit our ability to conduct clinical trials outside the U.S. or result in material implications for our business. In addition, our insurance policies typically contain a war exclusion of some description and we do not know how our insurers are likely to respond in the event of a loss alleged to have been caused by geopolitical uncertainties.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our efforts to minimize the likelihood and impact of a cybersecurity incident may not be successful and our business could be negatively affected by a data breach or other cybersecurity threat or other disruption to our operations, which could result in legal claims against us or could give rise to substantial financial costs to redress any such cybersecurity incident and could harm our relationship with vendors,&#160;clinical study participants or regulators.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our business operation is data-intensive and relies extensively on the use of information technology. In addition, biopharmaceutical firms have been subject to an increasing number of cyberattacks in recent years, particularly cyberattacks targeting the theft of intellectual property and unauthorized access to proprietary clinical research data or sensitive patient information. Given the nature of our business, we are subject to a variety of evolving cybersecurity threats to our information technology infrastructure, including ransomware, unauthorized attempts to gain access to our operations or to sensitive patient information, denial-of-service attacks or various other methods of attacks. As discussed below, similar security threats may be faced by our vendors, consultants, suppliers, subcontractors, clinical investigational sites and non-clinical research labs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Such cybersecurity threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, nation states and rogue nation-state actors. We could also be impacted by the improper cyber conduct of our employees or others working on behalf of us who have access to our proprietary information or sensitive patient information, which could adversely affect our business and reputation. The occurrence of any material cybersecurity incident could cause substantial disruptions to our business operations. In addition to cyber threats, we may face threats to the security of our facilities or executives, which could materially disrupt our business if carried out.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We also work cooperatively with numerous vendors, consultants, suppliers, subcontractors, clinical investigational sites and non-clinical research labs, which have access to our proprietary or sensitive information. These third parties, which are typically outside our control, may have varying levels of cybersecurity expertise and safeguards and our ability to monitor their cybersecurity practices is limited. These third parties may not have adequate cybersecurity measures in place, and incidents or other interruptions suffered by them could cause us to experience adverse consequences. In particular, cybersecurity incidents in our drug supply chain could have an adverse impact on our ability to timely deliver product candidates to patients and physicians participating in our clinical studies, which could cause us to delay or cancel the completion of our ongoing clinical and non-clinical studies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">If cybersecurity threats materialize and we or third-parties that we rely upon are unable to defend against them or to protect sensitive information, including through complying with evolving information security and data protection/privacy regulations, this could cause vendors, clinical study participants, clinical study investigation sites, patients, or governmental authorities to question the adequacy of the threat mitigation and detection processes and procedures that we and our vendors employ. Moreover, depending on the severity of an incident, our proprietary clinical research data, sensitive patient information, intellectual property, including trade secrets and research, development and technical know-how, could be compromised.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Nearly all of our operations carry cybersecurity risks, including risks that they could be breached or that we could fail to detect, prevent or combat attacks, which could result in financial losses and claims against us, and could harm our relationships with our vendors or clinical study participants. The costs and expenses to respond to a material cybersecurity incident or other security threat or disruption may be substantial for a company of our size. Further, we do not carry a separate cybersecurity commercial insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Financial Condition and Capital Requirements </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable future. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have incurred net losses in each reporting period since our inception, including a net loss of $97.2&#160;million for the year ended December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $380.8&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have invested significant financial resources in research and development activities for product candidates. We do not expect to generate revenue from product sales for several years, if at all. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect to continue to incur significant expenses and higher operating losses for the foreseeable future. We anticipate our expenses will remain substantial as we: &#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue our research and discovery activities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">advance our current and any future product candidates through preclinical and clinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">work with our CDMO&#8217;s to scale up the manufacturing processes for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seek regulatory approvals and marketing authorizations for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtain, maintain, protect, defend and enforce our intellectual property portfolio;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attract, hire, and retain qualified personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">experience any delays or encounter other issues related to our operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">meet the requirements and demands of being a public company; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">defend against litigation, claims or other uncertainties that may arise from allegations made against us or our collaborators.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. In any quarter, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have broad discretion in the use of </i></b><b><i>our capital resources, including </i></b> <b><i>the net proceeds from any of our financing transactions, and we may not use them effectively. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have broad discretion in the application of our capital resources, including the net proceeds from our financing transactions, and investors will not have the opportunity to opine on whether such resources are being used appropriately. We could spend such capital resources in ways that vary substantially from their initially communicated intended use, do not improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest available capital resources, including net proceeds from our financing transactions, in a manner that does not produce income or that loses value</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We have no product revenues and may never achieve revenues or profitability based on product revenues. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing product candidates with significant commercial value. This is a significant endeavor that few early-stage biopharmaceutical companies can successfully achieve. Our ability to generate revenue and achieve profitability depends on many factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">completing research and preclinical and clinical development of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">identifying, assessing, acquiring, and/or developing new product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">addressing any competing technological and market developments;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attracting, hiring, and retaining qualified personnel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our clinical studies or the development of any of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may require additional capital to fund our operations and to complete the development of our product candidates. A failure to obtain this necessary capital on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to remain substantial for the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities, research grants and payments received from prior third-party collaborations. Developing our product candidates and conducting clinical studies for the treatment of neurodegenerative diseases, including Alzheimer&#8217;s disease, will require substantial amounts of capital. We will also require a significant amount of capital to commercialize any approved products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2023, we had cash and cash equivalents of $121.1&#160;million. In addition, from January 3, 2024 to February 26, 2024, we&#160;received&#160;gross proceeds&#160;of approximately $21.8&#160;million from the exercise of outstanding warrants. See Note 13 to the consolidated financial statements for more information.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our projected operations for at least the next 12&#160;months. Our estimate as to how long we expect our existing cash and cash equivalents to be available to fund our operations is a forward-looking statement, based on assumptions that may prove inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of currently unanticipated circumstances, which may be beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We may require additional capital for the further development of our product candidates. Additional capital may not be available when we need it, or on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, limit, reduce or terminate our research and development programs or the commercialization of product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Global credit and financial market conditions and inflation could negatively impact the value of our portfolio of cash equivalents and our ability to meet our financing objectives.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our cash and cash equivalents are generally maintained in highly liquid investments with original maturities of three months&#160;or less at the time of purchase. While, as of the date of this filing, we are not aware of any downgrades, material losses, or other significant deterioration in the fair value of our cash equivalents since December 31, 2023, no assurance can be given that deterioration in conditions of the global credit and financial markets, including inflationary pressure, would not negatively impact our current portfolio of cash equivalents or our ability to meet our financing objectives.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our operations are subject to the effects of rising inflation.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The United States has experienced historically high levels of inflation over the last three years. According to the U.S. Department of Labor, the annual inflation rate for the United States was approximately 3.4% for the 12 months ended December 31, 2023, after being&#160;between 6.5% - 7.0% in each of 2022 and 2021. If the inflation rates continue&#160;at historically high levels, for example due to increases in the costs of labor and supplies, it may affect our expenses, such as employee compensation and research and development charges. Research and development expenses account for a significant portion of our operating expenses. Additionally, the U.S. is experiencing a continuing&#160;workforce shortage, which in turn has created a very competitive wage environment that may increase our operating costs. To the extent inflation results in further interest rate increases and has other adverse effects on the market, inflation may adversely affect our consolidated financial condition and results of operations or business prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Ownership of Our Common Stock<i>&#160;</i>and Warrants</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We do not know whether a sufficient market will continue to </i></b><b><i>develop for our securities or what the market price of our securities will be, and, as a result, it may be difficult for investors to sell shares of our common stock or outstanding warrants. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">If a market for our common stock is not sustained, it may be difficult to sell shares of our common stock at an attractive price or at all. Similarly, if an active and stable market for our outstanding warrants is not sustained, it may be difficult to sell such warrants at an attractive price or at all.&#160;The trading market for our securities may lack adequate size, liquidity or price transparency.&#160; We cannot predict the prices at which our common stock or warrants will trade. Moreover, features of our warrants, such as our redemption right or the 9.9% ownership limitation on exercisability, may affect the trading price of such warrants.&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our trading securities may fall.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>The market price of our common stock has historically been highly volatile, and we expect it to continue to be volatile, which could result in substantial losses for investors who purchase our shares. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">The market price of our common stock has historically been highly volatile.&#160;For example, the closing price of our common stock has fluctuated from a low of $12.64&#160;to a high of $30.11&#160;over the 12 months preceding the filing date of this Annual Report on Form 10-K. Some of the factors that may cause the market price of our common stock to fluctuate include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success of existing or new competitive products or technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the timing and results of clinical studies for our current product candidates and any future product candidates that we may develop;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure or discontinuation of any of our product development and research programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">results of preclinical studies, clinical studies, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory or legal developments in the United States and other countries;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">developments or disputes concerning patent applications, issued patents, or other proprietary rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the recruitment or departure of key personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the results of our efforts to develop additional product candidates or products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">actual or anticipated changes in estimates as to financial results or development timelines;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">announcement or expectation of additional financing efforts;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">sales of our common stock by us, our insiders, or other stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">market conditions in the pharmaceutical and biotechnology sectors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">general economic, industry, and market conditions; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">securities litigation, regardless of merit.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In recent years, the stock market in general, Nasdaq, and the markets for early-stage companies and pharmaceutical and biotechnology companies&#160;have&#160;experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we are currently and may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Hedging arrangements relating to our warrants may affect the value and volatility of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In order to hedge their financial positions, certain warrant holders may enter into hedging transactions with respect to our common stock, may unwind or adjust hedging transactions and/or may purchase or sell large blocks of our common stock in one or more market transactions. The effect, if any, of these activities on the trading price of our common stock will depend in part on market conditions and cannot be known in advance, but any of these activities could adversely affect the value and price volatility of our common stock.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The trading price for our warrants may bear little or no relationship to traditional valuation methods, or to the market price of our common stock, and therefore the trading price of the warrants may fluctuate significantly.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The trading price of our warrants may have little or no relationship to, and may be significantly lower, or at times higher, than the price that would otherwise be established using traditional indicators of value, such as our future prospects and those of our industry in general; future potential revenues, earnings, cash flows, and other financial and operating information, or multiples thereof; market prices of securities and other financial and operating information of companies engaged in drug development activities similar to ours; and the views of research analysts. Potential investors should not buy warrants in the open market unless they are willing to take the risk that the trading price of the warrants could fluctuate and decline significantly.&#160;In order for warrant holders to recover the value of an investment in the shares of common stock received upon exercise of a warrant (after taking into account the bonus share fraction during any bonus share period) at the exercise price, the value of such shares of common stock must be more than the exercise price of the warrants.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In addition, we may redeem all unexercised warrants at our sole option at any time on or after April 15, 2024, and upon meeting certain other conditions. If we redeem unexercised warrants, they will cease to be outstanding after the redemption date, they will cease to trade, and they will have no value.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If securities analysts do not publish research or reports about our business, or we are the subject of negative publicity, the price of our stock could decline. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The trading market for our securities depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not control these analysts. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our securities could decline. If one or more of these analysts cease coverage of our company or fail to publish reports covering our company regularly, our stock may lose visibility in the market, which in turn could cause the price of our securities to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, social media, industry group or the general or financial press, the price of our securities may decline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Short sellers of our stock may be manipulative and may drive down the market price of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Short selling&#8212;also known as &#8220;shorting,&#8221; &#8220;selling short&#8221; or &#8220;going short&#8221;&#8212;refers to the sale of a security or financial instrument that the seller has borrowed from a third party. A short seller hopes to profit from a decline in the value of the securities they are shorting. As it is in the short seller&#8217;s financial interest for the price of our stock to decline, some short sellers may publish misrepresentations, falsehoods or mischaracterizations regarding our business operations, including our pre-clinical or clinical results, that are intended to create and spread negative publicity about us. Since negative information can travel fast in the media, short seller activity can lead to a sudden, sharp decline in the market value of the market price of our securities, which is sometimes known as a &#8220;short attack.&#8221; Issuers, like us, with securities that have historically had limited trading volumes and relatively high volatility, together with the challenges of engaging in new and complex scientific endeavors, can make us particularly vulnerable to such short seller attacks. Short selling may also lead to fluctuations of our stock price, particularly if other investors holding &#8220;long&#8221; positions in our common stock seek to counter short selling activity by purchasing additional shares, thus making it more difficult and more expensive for short sellers to profit. No assurances can be made that declines in the market price of our common stock will not occur in the future in connection with such activity.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>General Risk Factors</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As a public company, we are subject to reporting and other obligations under the Exchange Act including the requirements of Section&#160;404(a) of the Sarbanes-Oxley Act (&#8220;SOX&#8221;), which require annual management assessments of the effectiveness of our internal control over financial reporting. Section 404(b) of SOX also requires our independent auditors to attest to, and report on, the effectiveness of our internal control over financial reporting.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by SOX. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with accounting principles generally accepted in the U.S. Any failure to maintain effective internal controls, or if our independent registered public accounting firm is unable to attest to the effectiveness of our internal control over financial reporting, could have an adverse effect on our business, financial position, and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Anti-takeover provisions in our charter documents and Delaware law may prevent or delay removal of incumbent management or a change of control. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Anti-takeover provisions of our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law may have the effect of deterring or delaying attempts by our stockholders to remove or replace management, engage in proxy contests and effect changes in control. The provisions of our charter documents include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a classified board so that only one of the three classes of directors on our Board of Directors (the &#8220;Board&#8221;) is elected each year;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">elimination of cumulative voting in the election of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">procedures for advance notification of stockholder nominations and proposals;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of the Board to amend our bylaws without stockholder approval; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of the Board to issue up to 10,000,000 shares of preferred stock without stockholder approval upon the terms and conditions and with the rights, privileges and preferences as the Board may determine.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In addition, as a Delaware corporation, we are subject to Delaware law, including Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder unless certain specific requirements are met as set forth in Section 203.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">These provisions, alone or together, could have the effect of deterring or delaying changes in incumbent management, proxy contests or changes in control.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Laws of 1933, which could limit our stockholders</i></b>&#8217;<b><i> ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our amended and restated bylaws provide that the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">While the Delaware courts have determined that such choice of forum provisions are valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Changes in our ownership could limit our ability to utilize net operating loss carryforwards.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of December 31, 2023, we had aggregate federal net operating loss carryforwards of approximately $158.7&#160;million, which begin to expire in 2029. Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in our ownership may limit the amount of our net operating loss carryforwards that could be utilized annually to offset our future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of our company of more than 50% within a rolling three-year period. Any such limitation may significantly reduce our ability to utilize our net operating loss carryforwards and tax credit carryforwards. Any such limitation, whether as the result of past offerings, sales of our common stock by our existing stockholders, the issuance of shares of common stock&#160;as a result of the exercise of warrants or additional sales of our common stock by us in the future could have a material adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for purposes of Section 382 has occurred.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>We may sell additional equity or debt securities to fund our operations, and have outstanding securities exercisable for our common stock, which may result in dilution to our stockholders and impose restrictions on our business.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In order to raise additional capital to support our operations, we may sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock which could result in dilution our stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in prior offerings, and investors purchasing our shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional shares of our common stock or securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per share in prior offerings. You may also be diluted upon the exercise of outstanding stock options as of December 31, 2023 to purchase approximately 3.0 million&#160;shares of our common stock at a weighted average price of $15.13 per share, the future issuance of up to approximately 2.9 million&#160;compensatory equity awards authorized under our 2018 Omnibus Incentive Plan, and the potential issuance of up to 25.3 million shares of our common stock from exercises of our outstanding warrants, initially issued in January 2024. The issuance of such additional shares of common stock or the perception that issuances could occur, could result in significant downward pressure on our stock price.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The estimates and judgments we make, or the assumptions on which we rely, in preparing our consolidated financial statements could prove inaccurate.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. Such estimates and judgments include development expenses, valuation of stock-based awards and income tax. We base our estimates on historical experience, facts and circumstances known to us and on various other assumptions that we believe to be reasonable under the circumstances. We cannot provide assurances, however, that our estimates, or the assumptions underlying them, will not change over time or otherwise prove inaccurate. If this is the case, we may be required to restate our consolidated financial statements, which could, in turn, subject us to securities class action litigation. Defending against such potential litigation relating to a restatement of our consolidated financial statements would be expensive and would require significant attention and resources of our management. Moreover, our insurance to cover our obligations with respect to the ultimate resolution of any such litigation may be inadequate. As a result of these factors, any such potential litigation could have a material adverse effect on our financial results and cause our stock price to decline, which could in turn subject us to securities class action litigation.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1b" title="item1b" href="#"></a>Item 1B. </b>&#160;&#160;&#160;&#160;<b><i>Unresolved Staff Comments</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item1c" title="item1c" href="#"></a>Item 1C. </b>&#160;&#160;&#160;&#160;<b><i>Cybersecurity</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">In the normal course of business, we collect and store sensitive information, including proprietary and confidential business information, intellectual property, information regarding clinical and non-clinical trials, sensitive third-party information and employee information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We have processes designed to protect our information systems, data, assets, infrastructure, and computing environments from cybersecurity threats and risks. Our cybersecurity strategy includes the use of managed detection and response services to monitor our network infrastructure and associated endpoints for possible cybersecurity threats. In addition, we use multi-factor authentication, perform periodical penetration testing and other logical, physical and technical controls designed to deter, prevent, mitigate and respond to cybersecurity threats. Further, our information systems include continuous alert plans, and we provide periodical cybersecurity reminders to our employees to emphasizes the importance of adherence to our security policies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">We conduct organizational risk assessment, which help management in identifying data assets and recognizing and assessing potential threats, and investigating potential vulnerabilities. We are in the process of reviewing and implementing incremental information technology strategies to mitigate cybersecurity risks and their possible impacts. Risk assessments enable management to make risk management decisions and assign resources to mitigate risk. We also periodicly engage third parties to assess the effectiveness of our cybersecurity practices.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">As of the date of this Annual Report, we do not believe that any past cybersecurity incidents that have been detected have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition. We do not carry a separate cybersecurity commercial insurance policy covering the potential financial losses that may occur in the event we experience a cybersecurity incident.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">See &#8220;Risk Factors - Risks Related to Our Business and Operations&#8221; for additional information about the risks to our business associated with cybersecurity or a breach or compromise to our information security systems.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item2" title="item2" href="#"></a>Item</b>&#160;<b>2. </b>&#160;&#160;&#160;&#160;<b><i>Properties</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;We occupied approximately 25% of the property as of December 31, 2023.</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item3" title="item3" href="#"></a>Item</b>&#160;<b>3. </b>&#160;&#160;&#160;&#160;<b><i>Legal Proceedings</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are and, from time to time, we may become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA.&#160;In addition, we have received, and from time to time, we may receive inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. At this time, no assessment can be made as to their likely outcome or whether the outcome will be material to us. We&#160;believe&#160;that our&#160;total provision&#160;for legal matters are adequate based upon currently available information.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Government Investigations</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 15, 2021, we disclosed that certain government agencies had asked us to provide&#160;corporate information and documents. These were confidential requests. We have been voluntarily cooperating and intend&#160;to continue to cooperate with these inquiries. No government agency has informed us that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors.&#160;No government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency may pursue an enforcement action against us or others.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Between August 27, 2021 and October 26, 2021, four putative class action lawsuits were filed alleging violations of the federal securities laws by us and certain named officers. The complaints rely on allegations contained in Citizen Petitions&#160;submitted to FDA&#160;and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On June 30, 2022, a federal judge consolidated the four class action lawsuits into one case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on August 18, 2022 on behalf of a putative class of purchasers of our securities between September 14, 2020 and July 26, 2022. On May 11, 2023, the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on July 3, 2023.&#160;On February 22, 2024, plaintiffs filed a motion to supplement their complaint to extend the putative class period through October 12, 2023.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 4, 2021, a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does not seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between November 4, 2021 and June 20, 2023, four additional shareholder derivative actions were filed alleging substantially similar claims, two in the U.S. District Court for the Western District of Texas, one in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On July 5, 2022, the three federal court actions were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On November 9, 2023, another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On February 2, 2024, a putative class action lawsuit was filed alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an October 12, 2023 journal article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between August 18, 2022 and October 12, 2023.</p>
  <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify; text-indent: 18pt;">We believe&#160;the foregoing claims are without merit and intend&#160;to defend against these lawsuits vigorously. We are unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On August 19, 2022, a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the 2020 Cash Incentive Bonus Plan in August 2020. The complaints seek unspecified compensatory damages and other relief. On January 6, 2023, the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on March 10, 2023, and moved to partially dismiss the amended complaint on March 14, 2023. On January 25, 2024, the parties entered into a binding settlement term sheet with respect to this action. The settlement is subject to certain conditions, including the filing of a Stipulation of Settlement and final court approval. The proposed settlement resolves the claims asserted against the Company and the individual defendants and would contain provisions that the settlement does not constitute an admission, concession, or finding of any fault, liability, or wrongdoing of any kind by any defendant. There can be no assurance that the final settlement agreement will be executed or that such agreement will be approved by the court.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="item4" title="item4" href="#"></a>Item 4. </b>&#160;&#160;&#160;&#160;<b><i>Mine Safety Disclosures</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART II</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item5" title="item5" href="#"></a>Item 5.</b>&#160;&#160;&#160;&#160;<b><i>Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our common stock is quoted on Nasdaq, under the symbol "SAVA."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Holders</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of February 20, 2024, there were approximately 28&#160;registered holders of record of our common stock. We believe the actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Sales of Non-Registered Securities</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Purchases of Equity Securities by the Issuer</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Dividend Policy</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and, notwithstanding our special non-dividend distributions in December 2012 (of $0.75 per share of common stock totaling $34.0&#160;million) and December 2010 (of $2.00 per share of common stock totaling $85.7&#160;million), we do not anticipate paying any cash dividends in the foreseeable future.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stock Performance Graph</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:28pt;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on January 1, 2019&#160;and its relative performance is tracked through December 31, 2023. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no cash dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div style="text-align: center;">
   <div>
    <img alt="pg01.jpg" src="pg01.jpg"/></div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>This performance graph shall not be deemed soliciting material or to be filed with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of the Company</i>&#8217;<i>s filings under the Securities Act or the Exchange Act.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item6" title="item6" href="#"></a>Item 6.</b>&#160;&#160;&#160;&#160;<b><i>[Reserved]</i></b></p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item7" title="item7" href="#"></a>Item 7.</b>&#160;&#160;&#160;&#160;<b><i>Management</i></b>&#8217;<b><i>s Discussion and Analysis of Financial Condition and Results of Operations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>This discussion and analysis</i> <i>of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and accompanying notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations, and intentions, that are based on the beliefs of our management. Operating results are not necessarily indicative of results that may occur in future periods. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the </i>&#8220;<i>Risk Factors</i>&#8221;<i> section of this Annual Report on Form 10-K.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer&#8217;s disease. Our novel science is based on stabilizing &#8211; but not removing &#8211; a critical protein in the brain. Our lead therapeutic drug candidate, simufilam, is being evaluated for the proposed treatment of Alzheimer&#8217;s disease dementia in fully-enrolled, on-going Phase 3 clinical studies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Over the past 12&#160;years, we have combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer&#8217;s disease and other neurodegenerative diseases. Our strategy is to leverage our unique scientific/clinical platform to develop a first-in-class program for treating neurodegenerative diseases, such as Alzheimer&#8217;s.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We currently have two biopharmaceutical assets under development:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead therapeutic product candidate, called simufilam, is a novel oral treatment for Alzheimer&#8217;s disease dementia; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our lead investigational diagnostic product candidate, called SavaDx, is a novel way to detect the presence of Alzheimer&#8217;s disease from a small sample of blood.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our scientific approach for the treatment of Alzheimer&#8217;s disease seeks to simultaneously suppress <i>both</i> neurodegeneration and neuroinflammation. We believe our ability to improve multiple vital functions in the brain represents a new, different and crucial approach to address Alzheimer&#8217;s disease.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe simufilam improves brain health by reverting altered FLNA back to its native, healthy conformation, thus countering the downstream toxic effects of altered FLNA. We have generated and published experimental or&#160;clinical evidence of improved brain health with simufilam. Importantly, simufilam is not dependent on clearing amyloid from the brain. Since simufilam has a unique drug mechanism of action, we believe its potential therapeutic effects may be additive or synergistic with those of other therapeutic candidates aiming to treat neurodegeneration.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 19pt;">We are currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer&#8217;s disease dementia.&#160;Both trials are fully enrolled. The trials have randomized a total of approximately 1,900 patients with mild to moderate Alzheimer&#8217;s disease at baseline. All efficacy data from our Phase 3 program remain blinded. There are no interim analyses on efficacy outcomes.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our first Phase 3 study, called RETHINK-ALZ, is designed to evaluate the safety and efficacy of simufilam 100 mg tablets versus placebo over 52 weeks (NCT04994483).&#160;Top-line results of our 52-week Phase 3 study are anticipated approximately year-end 2024.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">Our second Phase 3 study, called REFOCUS-ALZ, is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg tablets versus placebo over 76 weeks (NCT05026177). Top-line results of our 76-week Phase 3 study are anticipated approximately mid-year 2025.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Our investigational diagnostic product candidate, called SavaDx, is an early-stage program focused on detecting the presence of Alzheimer&#8217;s disease from a small sample of blood. The goal is to make the detection of Alzheimer&#8217;s disease as simple as getting a blood test.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Financial Overview</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have yet to generate any revenues from product sales. We have an accumulated deficit of $380.8&#160;million at December 31, 2023. These losses have resulted principally from costs incurred in connection with research and development activities, salaries and other personnel-related costs and general corporate expenses. Research and development activities include costs of preclinical and clinical studies as well as clinical supplies associated with our product candidates. Salaries and other personnel-related costs include stock-based compensation associated with options and other equity awards granted to employees and non-employees. Our operating results may fluctuate substantially from period to period as a result of the timing of preclinical activities, enrollment rates of clinical studies for our product candidates and our need for clinical supplies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We believe that our cash and cash equivalents at December 31, 2023, will enable us to fund our operating expenses for at least the next 12 months. In addition, we may seek in the future to fund our operations through additional public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain financing or reach profitability, the related lack of liquidity will have a material adverse effect on our operations and future prospects, and we may have to significantly delay, scale back or discontinue the development and commercialization of simufilam, our lead drug candidate, or delay our efforts to expand our product pipeline.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect to continue to use significant cash resources in our operations for the next several years. Our cash requirements for operating activities and capital expenditures may increase in the future as we:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue our ongoing Phase 3 program with simufilam;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manufacture large-scale supplies for simufilam;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">conduct other preclinical and clinical studies for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seek regulatory approvals for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">develop, formulate, manufacture and commercialize our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">implement additional internal systems and develop new infrastructure;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">acquire or in-license additional products or technologies, or expand the use of our technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintain, defend and expand the scope of our intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expend resources related to legal proceedings and claims, including U.S. government inquiries; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">hire additional personnel.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. If our development efforts result in regulatory approval and successful commercialization of our product candidates, we expect to generate revenue from direct sales of our drugs and/or, if we license our drugs to future collaborators, from the receipt of license fees and royalties from sales of licensed products. We conduct our research and development programs through a combination of internal and collaborative programs. We rely on arrangements with universities, certain collaborators, CDMOs, CROs and clinical research sites for a significant portion of our product development efforts.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Components of Operating Results</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Operating Expenses</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We focus substantially all of our research and development efforts in the development of simufilam. Research and development expenses for our investigational diagnostic product candidate, SavaDx, represented less than 1% of total research and development expenses for the periods presented. The following table summarizes expenses by category for research and development efforts (in thousands):</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Phase 2 and Phase 3 clinical trials</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,087</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,149</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,322</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Pre-clinical and Phase 1 studies</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,425</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,966</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">927</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Chemical, Manufacturing and Controls costs (&#8220;CMC costs&#8221;)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,910</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,573</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">4,606</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Personnel related</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,723</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,631</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">4,633</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Stock-based compensation</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,050</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,631</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,302</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,228</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,082</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,023</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">89,423</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">68,032</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,813</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Clinical trial costs include the costs of our CRO. CMC costs include costs related to our contract development and manufacturing organizations. Research and development expenses include compensation, contractor fees and supplies as well as allocated common costs such as facilities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year&#160;ended December 31, 2023, we did not receive reimbursement from NIH research grants. During the years ended&#160;December 31, 2022 and 2021, we received $0.9 million and&#160;$3.9&#160;million in research grants from the NIH, respectively. When applicable, the proceeds from grants are recorded as reductions&#160;to&#160;our research and development expenses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our technology has been applied across certain of our portfolio of product candidates. Data, know-how, personnel, clinical results, research results and other matters related to the research and development of any one of our product candidates also relate to, and further the development of, our other product candidates. As a result, costs allocated to a specific product candidate may not necessarily reflect the actual costs surrounding research and development of such product candidate due to cross application of the foregoing.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Estimating the dates of completion of clinical development, and the costs to complete development, of our product candidates would be highly speculative and&#160;subjective. Pharmaceutical products take a significant amount of time to research, develop and commercialize. The clinical study portion of the development of a new drug alone usually spans several years. We expect our research and development expenses to decrease modestly in&#160;2024 as a result of decreased spending for our Phase 3 program, as patient screening and enrollment are now complete for the Phase 3 clinical studies. The decrease in Phase 3 program costs is expected to be partially offset by increased enrollment in the open-label study as well as higher stock-based compensation expense. We expect to reassess our future research and development plans based on our review of data we receive from our current research and development activities. The cost and pace of our future research and development activities are linked and subject to change.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Estimates</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of our consolidated financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and interest income in our consolidated financial statements and accompanying notes. We evaluate our estimates on an ongoing basis, including those estimates related to agreements and research collaborations. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our significant accounting policies are described in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, and we believe that the accounting policies discussed below involve the greatest degree of complexity and exercise of significant judgments and estimates by our management. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations and, accordingly, we believe the policies described below are the most critical for understanding and evaluating our financial condition and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research Contracts, Prepaids and Accruals. We have entered into various research and development contracts with research institutions and other third-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. We record prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of prepaid expenses and&#160;accrued liabilities, we analyze progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant&#160;judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from our estimates. Our historical prepaid and accrual estimates have not been materially different from actual costs.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Legal and other contingencies. The Company is subject to lawsuits, claims, allegations and investigations regarding simufilam and SavaDx. The Company believes the claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits. However, litigation is subject to inherent uncertainties, and unfavorable rulings could occur. If an unfavorable ruling were to occur, it may cause a material adverse impact on the results of operations, cash flows, or financial condition for the period in which the ruling occurs, or future periods. Refer to Note 12 to the Consolidated Financial Statements for further information on contingencies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2020 Cash Incentive Bonus Plan. In 2020, we established the 2020 Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under Accounting Standards Codification (ASC) 718, &#8220;Stock-based Compensation&#8221;. The fair value of each potential Plan award will be determined once a grant date occurs and will be remeasured each reporting period. Compensation expense associated with the Plan will be recognized over the expected achievement period for each Plan award, when a Performance Condition is considered probable of being met.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in our market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;our market capitalization increases&#160;significantly and (1) we complete a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan, to render payment (each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which may ever occur. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, we have concluded that&#160;a&#160;Plan&#160;grant date has not occurred&#160;as of December 31, 2023. No actual cash payments were authorized or made to participants under the Plan through December 31, 2023.</p>
  <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock-based Compensation. We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. Significant judgments and estimates are made in determining inputs to the Black-Scholes option valuation model. See Note 7 to our Consolidated Financial Statements for significant assumptions regarding stock-based compensation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recent Accounting Pronouncements</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">See Note 2. Summary of Significant Accounting Policies, in Notes to the Consolidated Financial Statements in Item 8 of Part II of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Results of Operations </b>&#8211;<b> Comparison of years ended December 31, 2023 and 2022</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Expense</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses consist primarily of costs of drug development work associated with our product candidates, including:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical studies,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">preclinical testing,</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">clinical supplies and related formulation and design costs, and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">compensation and other personnel-related expenses.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Research and development expenses increased to $89.4&#160;million in&#160;2023 from $68.0&#160;million in 2022, representing a 31% increase. This increase was due primarily to costs related to conducting the ongoing Phase 3 clinical program of simufilam, costs of a&#160;cognition maintenance study and an ongoing open-label study in simufilam compared to the prior year. Higher pre-clinical study costs also contributed to the increase.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect research and development expense to decrease modestly in future periods as patient screening and enrollment is complete for our Phase 3 clinical program. The decrease in Phase 3 program costs is expected to be partially offset by increased enrollment in the open-label study as well as higher stock-based compensation expense due to new grant awards in 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>General and Administrative Expense</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. Allocated expenses consist primarily of existing facility costs. We incur insurance, audit, investor relations, SOX compliance and other administrative and professional services expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq. General and administrative expense increased to $16.5&#160;million in 2023 from $12.0&#160;million in 2022. The 38% increase was due primarily to higher legal fees, stock-based compensation&#160;due to new grant awards and personnel costs compared to the prior year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Interest Income</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Interest and other income, net, was $7.8 million in 2023 compared to $2.8 million&#160;in 2022. The increase in interest income was due to increases in interest rates in 2023 compared to the prior year.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We expect interest income to decrease in&#160;2024 compared to&#160;2023 as we use&#160;cash balances in operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other income, net </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We record the activities related to leasing office space to third parties in buildings we own as other income, net, as leasing is not core to the Company&#8217;s operations. Other income, net, was $0.9&#160;million during the year ended December 31, 2023 compared to $1.0 million&#160;during 2022. We expect other income, net, to decrease in 2024 as higher vacancy rates are expected to lower rental income.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation and amortization for the office complex is included in general and administrative and research and development expense, and thus not reflected in other income, net.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comparison of the years ended&#160;December 31, 2022 and 2021</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2022 Annual Report on Form 10-K for a discussion of the results of operations for the year ended December 31, 2022 compared to the year ended December 31, 2021.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Since inception, we have financed our operations primarily through public and private stock offerings, payments received under collaborative agreements and interest earned on our cash and cash equivalents balances. We intend to continue to use our capital resources to fund research and development activities, capital expenditures, working capital requirements and other general corporate purposes. As of December 31, 2023, cash and cash equivalents totaled $121.1&#160;million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><b><i>2024 Common Stock Warrant Distribution and On-going Offering</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On January 3, 2024, we&#160;completed&#160;a distribution of approximately 16.9 million&#160;warrants&#160;to purchase shares of our common stock to holders of record of our&#160;common stock as of the close of business on December 22, 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">From January 3, 2024 to February 26, 2024, a total of approximately 659,000&#160;warrants were exercised at an exercise price of $33.00 per warrant resulting in gross proceeds to the Company of approximately $21.8&#160;million and the issuance of approximately 989,000&#160;shares of our common stock, including Bonus Share Fractions.&#160;After the first $20 million of gross proceeds, the Company is&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock in the offering to&#160;our&#160;financial advisor for the warrant distribution.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">Until the Bonus Share Expiration Date (described below), a holder exercising its warrants will receive an additional 0.5 shares of common stock for each warrant exercised, without the payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire upon the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period (commencing on or after January 3, 2024) in which the daily volume weighted average price (the &#8220;VWAP&#8221;) of the shares of common stock has been at the then applicable trigger price, initially $26.40, for at least 20 trading days (whether or not consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon not less than 20 business days&#8217; public notice (either condition being the &#8220;Bonus Share Expiration Date&#8221;). Any warrant exercised with an exercise date after the Bonus Share&#160;Expiration Date will not be entitled to the Bonus Share Fraction. The Company&#160;will make a public announcement of the Bonus Share Expiration Date (i) at least 20 business days prior to such date, in the case of the Company&#160;setting a Bonus Share Expiration Date and (ii) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Unless earlier redeemed, the warrants will expire and cease to be exercisable&#160;on November 15, 2024. The warrants are redeemable at the Company&#8217;s sole option at any time with a redemption date on or after April 15, 2024. We&#160;will provide at least 20 calendar days&#8217; notice by press release&#160;of the date selected, if any, for a redemption. The warrant offering is ongoing as of the date of filing of this Annual Report on Form 10-K.&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>2022 Registered Direct Offering</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On November 22, 2022, we completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>2021 Registered Direct Offering</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On February&#160;12, 2021, we completed a common stock offering pursuant to which certain investors purchased 4,081,633 shares of common stock at a price of $49.00 per share. Net proceeds of the offering were approximately $189.7&#160;million after deducting offering expenses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 18pt; text-align: justify;">On May 1, 2023, we entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the SEC on May 1, 2023 and became effective immediately upon filing. We are obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. We are not obligated to sell any shares in the offering.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -9pt; text-indent: 36pt;">There were&#160;no&#160;common stock sales under the ATM during the year&#160;ended December 31, 2023.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">In March 2020, we entered into&#160;an at-the-market offering program (&#8220;2020 Program&#8221;) to sell, from time to time, shares of our common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on May 5, 2020. We gave notice of termination for the 2020 Program effective on April 26, 2023, which was effective May 1, 2023. There were no common stock sales under the 2020 Program through its termination.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>NIH Research Grant Awards</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our research has been previously supported by NIH under multiple research grant awards. Strong, historical&#160;support from NIH has allowed us to advance our two lead product candidates, simufilam and SavaDx, into clinical development.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In May 2021, we were awarded a new research grant award from NIH of up to $2.7 million to support clinical readiness activities for a Phase 3 program with simufilam. This&#160;non-dilutive research grant&#160;is&#160;intended to strengthen our clinical program of simufilam, our investigational drug to treat Alzheimer&#8217;s disease. All of our NIH research grant awards are paid out on a reimbursement basis and require milestone-based technical progress. There were no remaining funds for NIH grant awards&#160;as of December 31, 2023.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>2020 Cash Incentive Bonus Plan Obligations</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In August 2020, the Board approved the <i>2020 Cash Incentive Bonus Plan</i> (the Plan). The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;not receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;not&#160;be paid&#160;any cash bonuses unless (1) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (2) the Compensation Committee&#160;determines the Company has sufficient cash on hand, as defined in the Plan. Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">As of December 31, 2022, the Company&#8217;s independent directors were participants in the Plan. However, effective March 16, 2023, the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will not be allocated to any other participant under the Plan. The Company's&#160;independent directors have not received, and as a result of such amendment will never receive, any payments under the Plan.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization, including all outstanding stock options, was $89.4&#160;million at the inception of the Plan in August 2020. If the Company were to exceed a $5&#160;billion market capitalization&#160;for no less than 20 consecutive trading days, and conditions noted above for payment are met, all&#160;Plan milestones would be deemed achieved, in which case total cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Any warrants outstanding are excluded from the determination of market capitalization.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s potential financial obligation to Plan participants at&#160;December 31, 2023&#160;totaled $6.5&#160;million (after the March 2023 Plan amendment), based upon the achievement of one Plan milestone in the Company&#8217;s market capitalization in 2020. No actual cash bonus payments have been made to any Plan participant, as the Company has not yet satisfied all the conditions necessary for amounts to be paid under the Plan. During the year ended December 31, 2021, the Company&#8217;s market capitalization increased substantially. These increases triggered the achievement of 11 additional Plan milestones. Collectively, the achievement of such milestones could trigger potential Company obligations to Plan participants ranging from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million, with exact amounts to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">No valuation milestones were achieved during the years ended December 31, 2023 or 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the Plan as of December 31, 2023, or through the filing date of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       87
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table sets forth a summary of the primary sources and uses of cash for each of the periods presented below (in thousands):</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years ended December 31,</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2023</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2022</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
     <td>&#160;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(82,025</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(77,514</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(30,196</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash used in investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(414</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,712</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(22,214</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net cash provided by financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,560</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47,804</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">192,341</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net (decrease) increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(79,879</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(32,422</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">139,931</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $82.0&#160;million for the year ended&#160;December 31, 2023, resulting primarily from the net loss reported of $97.2&#160;million partially offset by&#160;an increase in accounts payable of $6.9&#160;million and accrued development expense of $0.8 million,&#160;a decrease in in prepaid and other assets of $1.7&#160;million, stock-based compensation expense of $4.6&#160;million and depreciation and amortization of $1.0 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in operating activities was $77.5 million for the year ended December 31, 2022, resulting primarily from the net loss reported of $76.2 million, a decrease in accounts payable of $3.4 million, accrued compensation and benefits of $1.7 million and a decrease in accrued developmental expenses of $0.5 million, partially offset by a decrease in in prepaid and other assets of $1.2 million, and stock-based compensation expense of $2.1 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the year ended&#160;December 31, 2023&#160;was $0.4 million as final payment was made on renovations and fixtures for our corporate headquarters.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash used in investing activities during the year ended&#160;December 31, 2022 was $2.7 million related to renovations and fixtures for our corporate headquarters.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the year ended&#160;December 31, 2023&#160;was $2.6&#160;million from the exercise of stock options.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Net cash provided by financing activities during the year ended&#160;December 31, 2022 was $47.8 million, consisting of $47.3&#160;million in proceeds from our registered direct offering of common stock in November 2022 and $0.5&#160;million from the exercise of stock options.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Cash </i></b>&#8211;<b> </b><b><i>Comparison of the years ended December 31, 2022 and 2021</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">Refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Results of Operations&#8221; in our 2022&#160;Annual Report on Form 10-K for a discussion of use of cash for the year ended December 31, 2022 compared to the year ended December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and Leases</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We own an office complex in Austin, Texas, a portion of which serves as our corporate headquarters. This property is intended to accommodate our anticipated growth and expansion of our operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet. At December 31, 2023, we occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to third parties.&#160;Virtually all existing tenant&#160;leases will expire&#160;in 2024. We believe tenant leases that expire in 2024 may likely not be extended, renewed or re-leased beyond their expiry date, in which case we will no longer receive rental payments or reimbursement for shared expense for such office space.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We leased approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, Texas expiring in April 2024. We terminated this lease on February 22, 2023 with no continuing obligations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       88
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt;"><i><b>Future Funding Requirements</b></i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have an accumulated deficit of $380.8&#160;million at December 31, 2023. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We believe that our current resources should be sufficient to fund our operations for at least the next 12 months. We may seek additional future funding through public or private financing in the future, if such funding is available and on terms acceptable to us.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If we raise additional funds by issuing equity or equity-linked securities, our stockholders will experience dilution, which may be substantial. If we raise additional funds through the issuance of preferred equity securities or through debt financing, the terms of such future preferred equity or debt into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our drug candidates in certain territories or indications that we would prefer to develop and commercialize ourselves.</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item7a" title="item7a" href="#"></a>Item 7A.</b>&#160;&#160;&#160;&#160;<b><i>Quantitative and Qualitative Disclosures about Market Risk</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to market risks in the ordinary course of our business, primarily related to interest rate sensitivities and, to a lesser extent, currency fluctuations related to our clinical operations outside the U.S.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Interest Rate Sensitivity</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We are exposed to market risk related to changes in interest rates. We had cash and cash equivalents of $121.1&#160;million as of December 31, 2023, which consisted primarily of U.S. Treasury securities and money market accounts.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain investment vehicles with high credit quality and short-term duration, in accordance with our board-approved investment policy. Such interest-earning instruments carry a degree of interest rate risk. However, due to the generally short-term maturities and low risk profile of our cash equivalents, an immediate 100 basis point increase or decrease in interest rates during any of the periods presented would increase or decrease our annual net loss by less than $2 million in our condensed consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p>
  <div>
    &#160;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item8" title="item8" href="#"></a>Item 8.</b>&#160;&#160;&#160;&#160;<b><i>Consolidated Financial Statements and Supplementary Data</i></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:92.9%;">&#160;</td><td style="vertical-align:top;width:6.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Page</span></b></p> </td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a style="-sec-extract:exhibit;" href="#report">Report of Independent Registered Public Accounting Firm</a>&#160;(PCAOB ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2023-01-01_2023-12-31" id="ixv-13908">42</ix:nonNumeric>)</p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#report">90</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#balance_sheet">Consolidated Balance Sheets</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#balance_sheet">92</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#state_of_op">Consolidated Statements of Operations</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#state_of_op">93</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#equity">Consolidated Statements of Stockholders<span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">&#160;Equity</span></a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#equity">94</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#cash_flows">Consolidated Statements of Cash Flows</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#cash_flows">95</a></td></tr>
<tr><td style="vertical-align:top;width:92.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="#notes">Notes to Consolidated Financial Statements</a></p> </td><td style="vertical-align: top; width: 6.7%; text-align: center;"><a class="tocPGNUM" href="#notes">96</a></td></tr>
</tbody></table>
<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    89
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="report" title="report" href="#"></a>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Opinion on the Financial Statements </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We have audited the accompanying consolidated balance sheets of Cassava Sciences, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes&#160;(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework),&#160;and our report dated February 28, 2024 expressed an unqualified opinion thereon.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Basis for Opinion</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Critical Audit Matters</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;"><tbody><tr><td style="vertical-align:top;width:16.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Description of the Matter</i></p> </td><td style="vertical-align:top;width:84.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prepaid and Accrued Development Expenses Related to CRO Pass Through Costs for Clinical Trials</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As explained in Note 2 to the consolidated financial statements, the Company contracts with a contract research organization (CRO) to assist the Company in conducting clinical trials, the costs for which are recorded as research and development expenses as incurred. A portion of these costs are pass through costs, which are costs incurred by third parties contracted by the CRO to perform certain services for clinical trials. These costs are passed through to the Company by the CRO. Depending on the timing of CRO payments, the Company records these costs as either prepaid or accrued development expenses. These prepaid or accrued development expenses are based on management&#8217;s determination of pass through costs incurred by the third parties based on the status of the clinical trials. At December 31, 2023, based on timing of invoicing and costs incurred, prepaid and accrued development expenses for CRO pass through costs were $317 thousand and $182 thousand, respectively.&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Auditing the Company&#8217;s prepaid and accrued development expenses related to CRO pass through costs for clinical trials was challenging because the recorded amounts involved management&#8217;s validation of the completeness and accuracy of costs incurred for services provided but not yet billed by third parties to the CRO.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> </td></tr>
</tbody></table>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    90
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;"><tbody><tr><td style="vertical-align:top;width:16.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>How We Addressed the Matter in Our Audit</i></p> </td><td style="vertical-align:top;width:84.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process of accounting for prepaid and accrued development expenses related to CRO pass through costs for clinical trials, including management&#8217;s review of the progress of clinical trial activity in comparison to budgets and invoices received from the CRO.&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To evaluate the adequacy of the Company&#8217;s prepaid and accrued development expenses related to CRO pass through costs for clinical trials, our audit procedures included, among others, testing the completeness and accuracy of the underlying data used by management to determine the prepaid and accrued development expenses. To evaluate completeness and accuracy of the data, on a sample basis, we: (i) obtained confirmation directly from the CRO of key clinical trial contract terms and conditions and any amendments thereto, as well as pass through costs incurred to date, (ii) agreed data used in the calculation to the contracts with the CRO, and any amendments thereto, and/or the data obtained from the CRO, (iii) corroborated the progress of clinical trials through inquiry of Company personnel who oversee clinical trials, and (iv) obtained and reviewed subsequent invoices received from the CRO to corroborate the prepaid and accrued development expenses at the end of the reporting period.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> </td></tr>
<tr><td style="vertical-align:top;width:16.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Description of the Matter</i></p> </td><td style="vertical-align:top;width:84.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Loss Contingencies</b>&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is subject to lawsuits, claims, allegations, and investigations regarding simufilam and SavaDx. As described in Note 12 to the consolidated financial statements, such allegations and claims could result in adverse consequences. At December 31, 2023, the Company was unable to determine the likelihood of a loss, if any, associated with these lawsuits and investigations and therefore was unable to reasonably estimate a loss or range of loss.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Auditing management&#8217;s accounting for, and disclosure of, loss contingencies related to the lawsuits and investigations was challenging because management&#8217;s evaluation of the likelihood of loss required judgment.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> </td></tr>
</tbody></table>
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;"><tbody><tr><td style="vertical-align:top;width:16.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>How We Addressed the Matter in Our Audit</i></p> </td><td style="vertical-align:top;width:84.5%;"> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process of evaluation of the accounting for and disclosure of these matters. This included controls over management&#8217;s assessment of the likelihood of incurrence of a loss and whether the loss or range of loss was reasonably estimable, and the development of related disclosures.</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p> <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">Our audit procedures included gaining an understanding of the status of ongoing lawsuits and investigations, reading the meeting minutes of the board of directors and of the committees of the board of directors, reading summaries of the proceedings and related correspondence, requesting letters from internal and external legal counsel, meeting with internal and external legal counsel to discuss developments related to the lawsuits and investigations together with our forensic professionals, and obtaining written representations from the Company on these matters. We also evaluated the Company&#8217;s disclosures in relation to these matters.</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ <ix:nonNumeric name="dei:AuditorName" contextRef="d_2023-01-01_2023-12-31" id="ixv-13909">Ernst &amp; Young LLP</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since 2002.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2023-01-01_2023-12-31" id="ixv-13910">Austin, Texas</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 28, 2024</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    91
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
    <a style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" href="#toc">Table of Contents</a>
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></div>
  <div>
    &#160;
  </div>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="balance_sheet" title="balance sheet" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except share and par value data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">ASSETS</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483626" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483627" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483628" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483629" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483630" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">129,633</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483631" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">211,226</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483632" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483633" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:num-dot-decimal" decimals="-3">122</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483634" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483635" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483636" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483637" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" format="ixt:num-dot-decimal" decimals="-3">622</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483638" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483639" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:num-dot-decimal" decimals="-3">234,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="8" style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; text-align: center;"><b><em style="font: inherit;"><em style="font: inherit;">LIABILITIES AND STOCKHOLDERS' EQUITY</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accounts payable and other accrued expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483643" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483644" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,017</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued development expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483645" contextRef="i_2023-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,037</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483646" contextRef="i_2022-12-31" unitRef="USD" name="sava:AccruedDevelopmentExpenseCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,280</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accrued compensation and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483647" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-5">200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483648" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Operating lease liabilities, current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483649" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483650" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">104</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483651" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">385</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483652" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">492</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483653" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483654" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,063</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating lease liabilities, non-current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483655" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483656" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">35</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other non-current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483657" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483658" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">197</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483659" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">14,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483660" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,295</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Commitments and contingencies (Notes 10, 11 and 12)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c107483662">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;<span style="-sec-ix-hidden:c107483663">&#160;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stockholders' equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c107483667"><span style="-sec-ix-hidden:c107483668">0.001 </span></span>par value; <span style="-sec-ix-hidden:c107483669"><span style="-sec-ix-hidden:c107483670">10,000,000 </span></span>shares authorized, <span style="-sec-ix-hidden:c107483671"><span style="-sec-ix-hidden:c107483673"><span style="-sec-ix-hidden:c107483672"><span style="-sec-ix-hidden:c107483674">none </span></span></span></span>issued and outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483665" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483666" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c107483677"><span style="-sec-ix-hidden:c107483678">0.001 </span></span>par value; <span style="-sec-ix-hidden:c107483679"><span style="-sec-ix-hidden:c107483680">120,000,000 </span></span>shares authorized; <span style="-sec-ix-hidden:c107483681"><span style="-sec-ix-hidden:c107483683">42,236,919 </span></span>and <span style="-sec-ix-hidden:c107483682"><span style="-sec-ix-hidden:c107483684">41,735,557 </span></span>shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483675" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483676" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483685" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483686" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483687" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483688" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483689" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483690" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483691" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">151,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483692" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">234,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       92
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="state_of_op" title="state of op" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except per share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Operating expenses:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Research and development, net of grant reimbursement</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483700" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">89,423</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483701" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">68,032</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483702" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,813</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483703" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">16,534</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483704" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">11,988</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483705" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,055</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Total operating expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483706" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">105,957</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483707" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-4">80,020</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483708" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">32,868</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483709" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">105,957</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483710" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-4" sign="-">80,020</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483711" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,868</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483712" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">7,833</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483713" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,777</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483714" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">49</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other income, net</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483715" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">907</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483716" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">997</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483717" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">434</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483718" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483719" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483720" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483721" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483722" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483723" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.82</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Shares used in computing net loss per share, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483724" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483725" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483726" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,405</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       93
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="equity" title="equity" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands, except share data)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common stock</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>stockholders'</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Par value</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>paid-in capital</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>deficit</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>equity</b></p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2020</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483727" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,237,987</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483728" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">35</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483729" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">267,086</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483730" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">174,921</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483731" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-5">92,200</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483734" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483735" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,706</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483736" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483737" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,706</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483739" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483740" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">53</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483741" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483742" contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">53</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483743" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">143,153</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483744" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483745" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,824</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483746" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483747" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,824</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of warrants</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483748" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">554,019</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483749" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">1</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483750" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">691</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483751" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483752" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="sava:StockIssuedDuringPeriodValueWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">692</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock issued in conjunction with registered direct offering, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483753" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,081,633</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483754" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483755" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">189,821</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483756" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483757" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">189,825</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483759" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483760" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483761" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483762" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2021</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483763" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">40,016,792</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483764" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-4">40</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483765" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">461,181</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483766" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">207,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483767" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">253,915</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483770" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483771" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,972</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483772" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483773" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,972</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483775" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483776" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483777" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483778" contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">94</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expiration of restricted stock Performance Awards</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483779" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483780" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483781" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483782" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483783" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483784" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">109,241</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483785" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483786" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483787" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483788" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock issued in conjunction with registered direct offering, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483789" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,666,667</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483790" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">2</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483791" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,327</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483792" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483793" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,329</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483795" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483796" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483797" contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483798" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2022</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483799" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">41,735,557</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483800" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483801" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">511,049</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483802" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">283,552</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483803" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">227,539</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation for:</p> </td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483806" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483807" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,493</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483808" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483809" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,493</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock options for non-employees</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483811" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483812" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">93</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483813" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483814" contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" format="ixt:num-dot-decimal" decimals="-3">93</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common stock pursuant to exercise of stock options</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483815" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">501,362</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483816" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483817" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483818" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483819" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#8212;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483821" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483822" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483823" contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483824" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
      <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance at December 31, 2023</b></p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483825" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,236,919</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483826" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">42</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483827" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">518,195</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107483828" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">380,769</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483829" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:num-dot-decimal" decimals="-3">137,468</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       94
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b><a id="cash_flows" title="cash flows" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>(In thousands)</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from operating activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483837" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483838" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483839" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,385</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Stock-based compensation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483841" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,586</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483842" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,066</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483843" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,759</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483844" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,084</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483845" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-3">804</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483846" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="3" format="ixt:num-dot-decimal" decimals="-4">310</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Amortization of intangible assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483847" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">446</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483848" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">497</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483849" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">224</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Prepaid and other assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483851" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,714</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483852" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,189</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c107483853" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,956</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Operating lease right-of-use assets and liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483854" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">17</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483855" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">9</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483856" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">28</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accounts payable and other accrued expenses</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483857" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,896</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483858" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">3,449</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483859" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,215</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accrued development expense</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483860" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">757</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483861" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">523</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483862" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="sava:IncreaseDecreaseInDevelopmentExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,084</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Accrued compensation and benefits</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483863" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-4">30</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483864" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">1,707</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483865" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,794</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: -9pt;">Other liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483866" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">304</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483867" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">136</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483868" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">731</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483869" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">82,025</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483870" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">77,514</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483871" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">30,196</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from investing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Purchase of property and equipment</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483873" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">414</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483874" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,712</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c107483875" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,214</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash used in investing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483876" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">414</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107483877" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">2,712</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c107483878" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">22,214</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Cash flows from financing activities:</b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Proceeds from issuance of common stock upon exercise of stock options</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483880" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483881" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">475</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107483882" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,824</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Proceeds from issuance of common stock upon exercise of 2018 warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107483883" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107483884" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107483885" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="3" format="ixt:num-dot-decimal" decimals="-3">692</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Proceeds from common stock offering, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483886" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483887" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,329</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483888" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:num-dot-decimal" decimals="-3">189,825</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483889" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,560</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483890" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">47,804</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483891" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:num-dot-decimal" decimals="-3">192,341</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net (decrease) increase in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483892" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">79,879</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107483893" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,422</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107483894" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" format="ixt:num-dot-decimal" decimals="-3">139,931</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cash and cash equivalents at beginning of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483895" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107483896" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">233,437</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107483897" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">93,506</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Cash and cash equivalents at end of period</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483898" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">121,136</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483899" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">201,015</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483900" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:num-dot-decimal" decimals="-3">233,437</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Supplemental cash flow information:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">Non-cash investing activities</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom">
      <td style="font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt 0pt 0pt 9pt; font-size: 10pt; font-family: Times New Roman;">Purchases of property and equipment included in accounts payable</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483903" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483904" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:num-dot-decimal" decimals="-4">340</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107483905" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;">&#160;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.<br/> &#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       95
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="notes" title="notes" href="#"></a>CASSAVA SCIENCES, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="c2560565" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b> <b>General, Liquidity and Basis of Presentation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $<ix:nonFraction id="c107483907" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">380.8</ix:nonFraction>&#160;million at <em style="font: inherit;"> December 31, 2023. </em>The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2560566" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:UseOfEstimates" id="c107485577" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="c107485578" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2023,</em> there were <em style="font: inherit;"><span style="-sec-ix-hidden:c107483920">no</span></em> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> and <em style="font: inherit;">2021,</em> the Company received $<ix:nonFraction id="c107483928" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.9</ix:nonFraction> million and&#160;$<ix:nonFraction id="c107483931" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.9</ix:nonFraction> million&#160;of reimbursement, respectively, from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its research and development expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">96</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c107485579" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c107485580" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c107485581" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business Segments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to <ix:nonFraction id="c107483963" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:NumberOfOperatingSegments" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> business segment: the development of novel drugs and diagnostics.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="c107485582" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c107483964">three</span> or <span style="-sec-ix-hidden:c107483965">four</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">97</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c107485583" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
    <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="c2560567" escape="true">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484008" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">97,217</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484009" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">76,246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484010" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:num-dot-decimal" decimals="-3" sign="-">32,385</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484012" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">41,932</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484013" contextRef="d_2022-01-01_2022-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">40,202</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484014" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" format="ixt:num-dot-decimal" decimals="-3">39,405</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107484015" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.32</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107484016" contextRef="d_2022-01-01_2022-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.90</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c107484017" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">0.82</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484018" contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,123</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484019" contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,055</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484020" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options and warrants outstanding, along with <ix:nonFraction id="c107483968" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction> restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;would have been anti-dilutive. The <ix:nonFraction id="c107483969" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction> restricted stock awards expired during the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c107485584" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c107485585" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c107485586" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">98</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c107485587" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities.&#160;As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c107485588" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of <ix:nonNumeric contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c107483980" format="ixt-sec:duryear">39</ix:nonNumeric> years and approximately <ix:nonNumeric contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c107483981" format="ixt-sec:duryear">10</ix:nonNumeric> years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately <ix:nonNumeric contextRef="i_2023-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c107483982" format="ixt-sec:duryear">0.4</ix:nonNumeric> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c107485589" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates <ix:nonNumeric contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c107483984" format="ixt-sec:duryear">0.3</ix:nonNumeric> years at <em style="font: inherit;"> December 31, 2023.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c107485590" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">99</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="sava:PrepaidExpensesAndOtherCurrentAssetsTextBock" id="c2560568" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid and other current assets at&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> consisted of the following (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c2560569" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484027" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">759</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484028" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="3" format="ixt:num-dot-decimal" decimals="-3">874</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484029" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,489</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484030" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DepositContractsAssets" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,177</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484031" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">962</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484032" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:InterestReceivableCurrent" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484033" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">287</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484034" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-4">160</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484035" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,497</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484036" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:num-dot-decimal" decimals="-3">10,211</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:RealEstateOwnedTextBlock" id="c2560570" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em> Real Property and Other Income, Expense</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately <ix:nonFraction id="c107484039" contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="SquareFoot" name="us-gaap:NetRentableArea" scale="0" format="ixt:num-dot-decimal" decimals="INF">90,000</ix:nonFraction> rentable square feet.&#160;At <em style="font: inherit;"> December 31, 2023, </em>the Company&#160;occupied approximately <ix:nonFraction id="c107484040" contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="Pure" name="sava:PercentageOfOccupancy" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="c2560571" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484055" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,283</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484056" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,459</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484057" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="3" format="ixt:num-dot-decimal" decimals="-3">911</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484058" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,376</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484059" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,462</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c107484060" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">477</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484061" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">907</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484062" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">997</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484063" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">434</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company had accrued property taxes related to the building totaling $<ix:nonFraction id="c107484045" contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">338,000</ix:nonFraction> and $<ix:nonFraction id="c107484046" contextRef="i_2022-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX" unitRef="USD" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="INF">433,000</ix:nonFraction> at&#160;<em style="font: inherit;"> December 31, 2023 </em>and&#160;<em style="font: inherit;">2022,</em> respectively, included in other current liabilities.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">100</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2560572" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">5.</em> Property and Equipment</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2560573" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484077" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484078" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,734</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484079" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484080" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">15,980</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484081" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">494</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484082" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">470</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484083" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,062</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484084" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">3,016</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484085" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">868</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484086" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">851</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107484087" contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484088" contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484089" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,138</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484090" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">24,064</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484091" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,284</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484092" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:num-dot-decimal" decimals="-5">1,200</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484093" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">21,854</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484094" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">22,864</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$<ix:nonFraction id="c107484066" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,084,000</ix:nonFraction>, $<ix:nonFraction id="c107484067" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">804,000</ix:nonFraction>&#160;and&#160;$<ix:nonFraction id="c107484068" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="INF">310,000</ix:nonFraction>&#160;for the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c2560574" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c2560575" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484108" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484109" contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,053</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484110" contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">293</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484111" contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-4">290</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484112" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,346</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484113" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,343</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484114" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-4">1,170</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484115" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" format="ixt:num-dot-decimal" decimals="-3">721</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484116" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484117" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">622</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $<ix:nonFraction id="c107484097" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">446,000</ix:nonFraction>, $<ix:nonFraction id="c107484098" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">497,000</ix:nonFraction> and $<ix:nonFraction id="c107484099" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="INF">224,000</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c2560576" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484119" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" format="ixt:num-dot-decimal" decimals="-3">172</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484120" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" format="ixt:num-dot-decimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484121" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">176</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">101</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="c2560577" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">7.</em> Stockholders' Equity and Stock-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in <em style="font: inherit;">one</em> or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased <ix:nonFraction id="c107484127" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,666,667</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction id="c107484128" contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">30.00</ix:nonFraction> per share. Net proceeds of the offering were approximately $<ix:nonFraction id="c107484129" contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">47.3</ix:nonFraction>&#160;million after deducting offering expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2021</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">12,</em> <em style="font: inherit;">2021,</em> the Company completed a common stock offering pursuant to which certain investors purchased <ix:nonFraction id="c107484133" contextRef="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">4,081,633</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction id="c107484134" contextRef="i_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">49.00</ix:nonFraction> per share. Net proceeds of the offering were approximately $<ix:nonFraction id="c107484135" contextRef="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">189.8</ix:nonFraction>&#160;million after deducting offering expenses.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c107484137" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction> million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to <ix:nonFraction id="c107484138" contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Pure" name="sava:EquityOfferingPercentageOfCommission" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were&#160;<ix:nonFraction id="c107484140" contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;common stock sales under the ATM during the year&#160;ended <em style="font: inherit;"> December 31, 2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#8220;2020</em> Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $<ix:nonFraction id="c107484143" contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember" unitRef="USD" name="sava:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">100</ix:nonFraction> million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were <em style="font: inherit;">no</em> common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2008</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Company&#8217;s <em style="font: inherit;">2008</em> Equity Incentive Plan, or <em style="font: inherit;">2008</em> Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The <em style="font: inherit;">2008</em> Equity Plan expired in <em style="font: inherit;"> December 2017. </em>Share-based awards generally expire <em style="font: inherit;">ten</em> years from the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan (the <em style="font: inherit;">2018</em> Plan) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and performance awards. Share-based awards generally expire <span style="-sec-ix-hidden:c107484158">ten</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended on <em style="font: inherit;"> May 5, 2022, </em>provides for issuance of up to <ix:nonFraction id="c107484160" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction id="c107484161" contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction> per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company <em style="font: inherit;"> may </em>then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">102</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock Options</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock option activity during <em style="font: inherit;">2023:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2560578" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484194" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,529,448</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484195" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">12.13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c107484196" format="ixt-sec:duryear">3.94</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484197" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-5">49.60</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"><ix:nonFraction id="c107484198" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,162,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484199" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.91</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(<ix:nonFraction id="c107484202" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">602,420</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484203" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(<ix:nonFraction id="c107484206" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">49,999</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484207" contextRef="d_2023-01-01_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">32.59</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484210" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,039,029</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484211" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484214" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,039,029</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484215" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c107484216" format="ixt-sec:duryear">6.21</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484217" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" format="ixt:num-dot-decimal" decimals="-4">30.28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484218" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,836,174</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484219" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">11.09</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c107484220" format="ixt-sec:duryear">3.98</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484221" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" format="ixt:num-dot-decimal" decimals="-4">26.18</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Of the stock options exercised during the year ended <em style="font: inherit;"> December 31, 2023, </em><ix:nonFraction id="c107484165" contextRef="d_2023-01-01_2023-12-31" unitRef="Share" name="sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">101,058</ix:nonFraction>&#160;stock options were net settled in satisfaction of the exercise price, with <em style="font: inherit;">no</em> cash proceeds received.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock options at <em style="font: inherit;"> December 31, 2023 </em>by a range of exercise prices:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c2560579" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484264" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.95</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484265" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.24</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484266" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">804,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484267" format="ixt-sec:duryear">4.8</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484268" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.17</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484269" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">804,834</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484270" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">2.17</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484271" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.09</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484272" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">13.02</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484273" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">656,230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484274" format="ixt-sec:duryear">2.9</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484275" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.33</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484276" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">647,167</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484277" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.34</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484278" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">14.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484279" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.94</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484280" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">62,634</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484281" format="ixt-sec:duryear">1.9</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484282" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484283" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">62,634</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484284" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484285" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484286" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484287" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">800,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484288" format="ixt-sec:duryear">9.8</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484289" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484290" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">44,442</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484291" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">17.54</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484292" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">21.11</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484293" contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">77.00</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484294" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">715,331</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484295" format="ixt-sec:duryear">7.2</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484296" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.20</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484297" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">277,097</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484298" contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">41.29</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484301" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,039,029</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c107484302" format="ixt-sec:duryear">6.2</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484303" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.13</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484304" contextRef="i_2023-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,836,174</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484305" contextRef="i_2023-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:num-dot-decimal" decimals="INF">11.09</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;<em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2560580" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484315" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">152</ix:nonFraction>% to <ix:nonFraction id="c107484317" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">155</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484318" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">151</ix:nonFraction>% to <ix:nonFraction id="c107484320" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">154</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484321" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">147</ix:nonFraction>% to <ix:nonFraction id="c107484323" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">151</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484324" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.82</ix:nonFraction>% to <ix:nonFraction id="c107484326" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.37</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484327" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.98</ix:nonFraction>% to <ix:nonFraction id="c107484329" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.69</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484330" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.12</ix:nonFraction>% to <ix:nonFraction id="c107484332" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">1.42</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c107484334" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c107484337" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c107484340" format="ixt-sec:duryear">7</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484343">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484346">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484349">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484352">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484355">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484358">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484361" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484364" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">35.16</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484367" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">65.83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Volatility is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is <ix:nonFraction id="c107484169" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">zero</ix:nonFraction> because the Company does <em style="font: inherit;">not</em> anticipate paying cash dividends in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2023, </em>the Company expects to recognize compensation expense of $<ix:nonFraction id="c107484171" contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">24.2</ix:nonFraction>&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c107484172" format="ixt-sec:duryear">2.8</ix:nonNumeric>&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">103</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Performance Awards</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about performance award activity during <em style="font: inherit;">2023:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c2560581" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of Performance Awards</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484369" contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484370" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484371" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c107484372" contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:fixed-zero" decimals="INF" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484373" contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">7,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>a total of <ix:nonFraction id="c107484175" contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" scale="0" format="ixt:num-dot-decimal" decimals="INF">57,143</ix:nonFraction> shares of restricted stock awards expired as performance criteria related to these Performance Awards were <em style="font: inherit;">not</em> attained. These shares of restricted stock were returned to the <em style="font: inherit;">2008</em> Equity Incentive Plan, which expired in <em style="font: inherit;"> December 2017, </em>and thus were retired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If and when outstanding Performance Awards vest, the Company would recognize $<ix:nonFraction id="c107484178" contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:num-dot-decimal" decimals="INF">101,000</ix:nonFraction> in stock-based compensation expense. These performance awards expire in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock-based compensation expense, in thousands:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2560582" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484380" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-4">2,050</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484381" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,631</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484382" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,302</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484383" contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,536</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484384" contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">435</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484385" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">457</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484386" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">4,586</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484387" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,066</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484388" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,759</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="c2560583" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">8.</em> Employee <em style="font: inherit;">401</em>(k) Benefit Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has a defined-contribution savings plan under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the <em style="font: inherit;">first</em> day of the month after hire and <em style="font: inherit;"> may </em>contribute up to the current statutory limits under Internal Revenue Service regulations. The <em style="font: inherit;">401</em>(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through <em style="font: inherit;"> December 31, 2023, </em>the Company has <em style="font: inherit;">not</em> made any matching contributions to the <em style="font: inherit;">401</em>(k) plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">104</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2560584" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">9.</em> Income Taxes</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2560585" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484438" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484439" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484440" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484441" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484442" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484443" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484444" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3">0.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484445" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484446" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3">1.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484447" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3">5.1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484448" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484449" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484450" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484451" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.2</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c107484452" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484453" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">2.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c107484454" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">1.8</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c107484455" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.2</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484456" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="2" sign="-">24.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484457" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">23.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484458" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">23.8</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484459" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484460" contextRef="d_2022-01-01_2022-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484461" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:fixed-zero" decimals="0">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Deferred tax assets and valuation allowance</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were valued at the corporate tax rate of <ix:nonFraction id="c107484401" contextRef="d_2023-01-01_2023-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21</ix:nonFraction>%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2560586" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484467" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">33,322</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484468" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:num-dot-decimal" decimals="-3">28,017</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484469" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,561</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484470" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:num-dot-decimal" decimals="-3">2,706</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484471" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">12,557</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484472" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:num-dot-decimal" decimals="-3">9,681</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484473" contextRef="i_2023-12-31" unitRef="USD" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-3">27,538</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c107484474" contextRef="i_2022-12-31" unitRef="USD" name="sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" scale="3" format="ixt:num-dot-decimal" decimals="-4">12,690</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484475" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,371</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484476" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:num-dot-decimal" decimals="-3">934</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484477" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">77,349</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484478" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:num-dot-decimal" decimals="-3">54,028</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484479" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">77,349</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484480" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:num-dot-decimal" decimals="-3">54,002</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484481" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484482" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="3" format="ixt:num-dot-decimal" decimals="-3">26</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484484" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484485" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" format="ixt:num-dot-decimal" decimals="-3">26</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484486" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c107484487" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:num-dot-decimal" decimals="-3">26</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484488" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484489" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The valuation allowance increased by $<ix:nonFraction id="c107484402" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:num-dot-decimal" decimals="-2">23.3</ix:nonFraction>&#160;million and $<ix:nonFraction id="c107484404" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" format="ixt:num-dot-decimal" decimals="-2">17.8</ix:nonFraction>&#160;million in&#160;<em style="font: inherit;">2023</em> and <em style="font: inherit;">2022,</em> respectively, due primarily to continuing operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s net operating loss carryforwards of $<ix:nonFraction id="c107484407" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">158.7</ix:nonFraction>&#160;million are federal, of which $<ix:nonFraction id="c107484408" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.1</ix:nonFraction>&#160;million expires between <em style="font: inherit;">2029</em> and <em style="font: inherit;">2037</em> and $<ix:nonFraction id="c107484411" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">84.6</ix:nonFraction>&#160;million carries forward indefinitely. As of <em style="font: inherit;"> December 31, 2023, </em>the Company had federal research and development tax credits of approximately $<ix:nonFraction id="c107484412" contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">21.1</ix:nonFraction>&#160;million, which expire in the years <em style="font: inherit;">2024</em> through <em style="font: inherit;">2043.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">105</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Unrecognized tax benefits</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company has unrecognized tax benefits related to tax credits of $<ix:nonFraction id="c107484418" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction>&#160;million, $<ix:nonFraction id="c107484419" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million and $<ix:nonFraction id="c107484420" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction>&#160;million, respectively. <ix:nonFraction id="c107484421" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" format="ixt-sec:numwordsen" decimals="-3">None</ix:nonFraction> of the unrecognized tax benefits as of <em style="font: inherit;"> December 31, 2023, </em>if recognized, would impact the effective tax rate due to the valuation allowance and <span style="-sec-ix-hidden:c107484422">no</span> interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="c2560587" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484496" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484497" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107484498" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-5">4,500</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(<ix:nonFraction id="c107484499" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:num-dot-decimal" decimals="-4">50</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484500" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><ix:nonFraction id="c107484501" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484502" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,967</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484503" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">1,495</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c107484504" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:num-dot-decimal" decimals="-3">501</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484505" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">8,413</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484506" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">6,496</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c107484507" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:num-dot-decimal" decimals="-3">5,001</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of <em style="font: inherit;"> December 31, 2023, </em>there were <em style="font: inherit;">no</em> unrecognized tax benefits that we expect would change significantly over the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after <span style="-sec-ix-hidden:c107484425">2019</span>&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the <em style="font: inherit;">2020</em>&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are <em style="font: inherit;">not</em> under audit in any taxing jurisdiction at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="sava:LeasesAndCommitmentsDisclosureTextBlock" id="c2560588" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">10.</em> Leases and Commitments</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Right-of-use Asset and Liability</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company had an operating lease for approximately <ix:nonFraction id="c107484509" contextRef="i_2022-12-31_LeaseContractualTermAxis-LeaseForOfficeSpaceInAustinTexasMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:num-dot-decimal" decimals="INF">6,000</ix:nonFraction> square feet of office space in Austin, Texas expiring <em style="font: inherit;"> April 30, 2024. </em>The Company terminated this lease on <em style="font: inherit;"> February 22, 2023 </em>with <em style="font: inherit;">no</em> continuing obligations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cash paid for operating lease liabilities totaled $<ix:nonFraction id="c107484511" contextRef="d_2023-01-01_2023-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">24,000</ix:nonFraction>, $<ix:nonFraction id="c107484513" contextRef="d_2022-01-01_2022-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">155,000</ix:nonFraction> and $<ix:nonFraction id="c107484514" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="INF">109,000</ix:nonFraction> during the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="sava:CashIncentiveBonusPlanTextBlock" id="c2560589" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> December 31, 2023.&#160;</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">106</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the Company&#8217;s closing price&#160;of <em style="font: inherit;">one</em> share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160; &#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The Plan specifies <ix:nonFraction id="c107484538" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;incremental&#160;amounts&#160;between&#160;$<ix:nonFraction id="c107484539" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-8">200</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction id="c107484540" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c107484542" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately <ix:nonFraction id="c107484543" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" scale="-2" format="ixt:num-dot-decimal" decimals="2">67</ix:nonFraction>% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $<ix:nonFraction id="c107484546" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="9" format="ixt:num-dot-decimal" decimals="-9">5</ix:nonFraction>&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" name="sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" id="c107484548" format="ixt-sec:durday">20</ix:nonNumeric> consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$<ix:nonFraction id="c107484549" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">111.4</ix:nonFraction>&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$<ix:nonFraction id="c107484550" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:CashIncentiveBonusAwardExceedsMaximum" scale="6" format="ixt:num-dot-decimal" decimals="-5">289.7</ix:nonFraction>&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the <ix:nonFraction id="c107484554" contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">14</ix:nonFraction>&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$<ix:nonFraction id="c107484557" contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:CashIncentiveBonusAward" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.5</ix:nonFraction>&#160;million&#160;in total&#160;for&#160;all Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company achieved <ix:nonFraction id="c107484558" contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="Pure" name="sava:CashBonusIncentiveIncrementalAmounts" scale="0" format="ixt:num-dot-decimal" decimals="INF">11</ix:nonFraction> additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $<ix:nonFraction id="c107484559" contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">74.9</ix:nonFraction>&#160;million up to a hypothetical maximum of $<ix:nonFraction id="c107484560" contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember" unitRef="USD" name="sava:PerformancePlanValuationMilestoneAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">202.3</ix:nonFraction>&#160;million (after taking into account the <em style="font: inherit;"> March 2023 </em>Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;<ix:nonFraction id="c107484561" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction>&#160;compensation expense has been recorded&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years&#160;ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><ix:nonFraction id="c107484567" contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember" unitRef="USD" name="sava:PaymentsForCashIncentiveBonus" scale="6" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> actual cash payments were authorized or made to participants under the Plan through <em style="font: inherit;"> December 31, 2023&#160;</em>and the date of filing of this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">107</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:LossContingencyDisclosures" id="c2560590" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">12.</em> Contingencies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. <em style="font: inherit;">No</em> government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. <em style="font: inherit;">No</em> government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c107484574">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c107484575">four</span> class action lawsuits into <span style="-sec-ix-hidden:c107484576">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023.&#160;</em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em><ix:nonFraction id="c107484578" contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">four</ix:nonFraction> additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c107484579">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c107484580">one</span> in Texas state court (Travis County District Court) and <ix:nonFraction id="c107484581" contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember" unitRef="Pure" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c107484582">three</span> federal court actions were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">108</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>journal article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023. </em>On <em style="font: inherit;"> January 25, 2024, </em>the parties entered into a binding settlement term sheet with respect to this action. The settlement is subject to certain conditions, including the filing of a Stipulation of Settlement and final court approval. The proposed settlement resolves the claims asserted against the Company and the individual defendants and would contain provisions that the settlement does <em style="font: inherit;">not</em> constitute an admission, concession, or finding of any fault, liability, or wrongdoing of any kind by any defendant. There can be <em style="font: inherit;">no</em> assurance that the final settlement agreement will be executed or that such agreement will be approved by the court.&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2560591" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">13.</em> Subsequent Event - Warrant Dividend Distribution</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;completed&#160;a distribution&#160;to the holders of record of the Company&#8217;s shares of common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c107484588">four</span> warrants for every <ix:nonFraction id="c107484589" contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt-sec:numwordsen" decimals="INF">ten</ix:nonFraction> shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c107484590">16.9</span> million&#160;warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Each warrant entitles the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $<ix:nonFraction id="c107484591" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.00</ix:nonFraction> per warrant, <span style="-sec-ix-hidden:c107484592">one</span> share of common stock plus, to the extent described below, the Bonus Share Fraction. Payment for shares of common stock upon exercise of warrants must be in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">A Bonus Share Fraction entitles a holder to receive an additional <ix:nonFraction id="c107484593" contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-BonusShareFractionMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.5</ix:nonFraction> of a share of common stock (rounded down for any fractional share) for each warrant exercised (the &#8220;Bonus Share Fraction&#8221;) without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire upon the earlier of (i) the <em style="font: inherit;">first</em> business day following the last day of the <em style="font: inherit;">first</em> <em style="font: inherit;">30</em> consecutive trading day period (commencing on or after <em style="font: inherit;"> January 3, 2024) </em>in which the daily volume weighted average price (the &#8220;VWAP&#8221;) of the shares of common stock has been at the then applicable trigger price, initially $<ix:nonFraction id="c107484597" contextRef="i_2023-12-22" unitRef="USDPerShare" name="sava:VolumeWeightedAveragePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">26.40</ix:nonFraction>, for at least <em style="font: inherit;">20</em> trading days (whether or <em style="font: inherit;">not</em> consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon <em style="font: inherit;">not</em> less than <em style="font: inherit;">20</em> business days&#8217; public notice (either condition being the &#8220;Bonus Share Expiration Date&#8221;). Any warrant exercised with an exercise date after the Bonus Share&#160;Expiration Date will <em style="font: inherit;">not</em> be entitled to the Bonus Share Fraction. The Company&#160;will make a public announcement of the Bonus Share Expiration Date (i) at least <em style="font: inherit;">20</em> business days prior to such date, in the case of the Company&#160;setting a Bonus Share Expiration Date and (ii) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">109</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
       <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#160;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Unless earlier redeemed, the warrants will expire and cease to be exercisable&#160;on <em style="font: inherit;"> November 15, 2024 (</em>the &#8220;Expiration Date&#8221;). The warrants are redeemable at the Company&#8217;s sole option at any time with a redemption date on or after <em style="font: inherit;"> April 15, 2024. </em>The Company will provide at least <em style="font: inherit;">20</em> calendar days&#8217; notice by press release&#160;of the date selected for redemption (the &#8220;Redemption Date&#8221;). The redemption price upon any redemption shall equal to <span style="-sec-ix-hidden:c107484606">1/10</span> of $<ix:nonFraction id="c107484607" contextRef="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="sava:WarrantRedemptionPrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.01</ix:nonFraction> per warrant. The warrants <em style="font: inherit;"> may </em>be exercised at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the earlier of (<em style="font: inherit;">1</em>) the Expiration Date and (<em style="font: inherit;">2</em>) the business day prior to the Redemption Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The number of shares of Common Stock issuable upon exercise is subject to certain anti-dilution adjustments, including for share dividends, splits, subdivisions, spin-offs, consolidations, reclassifications, combinations, non-cash distributions and cash dividends. Terms of the warrants prohibit ownership by warrant exercise&#160;of <em style="font: inherit;">9.9%</em> or more of the Company's common stock by a single or affiliated group of stockholders without the Company's prior written consent.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The right to exercise warrants shall be automatically suspended&#160;in a circumstance while&#160;there is <em style="font: inherit;">no</em> effective registration statement registering the shares of common stock issuable upon exercise of the warrants.&#160;Such registration statement was declared effective by the SEC on <em style="font: inherit;"> May 1, 2023.&#160;</em>The warrant Expiration Date or the Redemption Date, as the case <em style="font: inherit;"> may </em>be, shall be extended by the number of days comprised in the event of a suspension.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company <em style="font: inherit;"> may </em>from time to time&#160;and in its sole discretion amend warrants for <em style="font: inherit;">one</em> or more of the following purposes: (i) to cure any ambiguity, omission, defect or inconsistency; (ii) to provide for the assumption by a successor company in any business combination; (iii) to postpone the Expiration Date; (iv) to decrease the warrant exercise price or increase the basic warrant exercise rate or the Bonus Share Fraction; (v) to reinstate a Bonus Share Period after the Bonus Share Expiration Date;&#160;(vi) to provide for net share settlement upon exercise of the warrants; (vii) to make any change that does <em style="font: inherit;">not</em> adversely affect the rights of any warrant holder in any material respect; (viii) to provide for a successor warrant agent or calculation agent; (ix) in connection with any business combination, to provide that the warrants are exercisable for appropriate consideration; or (<em style="font: inherit;">x</em>) other conforming changes.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt; text-align: justify;">The warrants are listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 9pt; text-align: justify;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> February 26, 2024, </em>a total of approximately <span style="-sec-ix-hidden:c107484615">659,000</span>&#160;warrants were exercised resulting in gross proceeds to the Company of approximately $<ix:nonFraction id="c107484616" contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:num-dot-decimal" decimals="-5">21.8</ix:nonFraction>&#160;million. The Company issued approximately <ix:nonFraction id="c107484617" contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="sava:StockIssuedDuringPeriodSharesWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="INF">989,000</ix:nonFraction>&#160;shares of common stock, including Bonus Share Fractions, from the exercise of warrants through <em style="font: inherit;"> February 26, 2024. </em>After the <em style="font: inherit;">first</em> $<ix:nonFraction id="c107484619" contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission" scale="6" format="ixt:num-dot-decimal" decimals="-7">20</ix:nonFraction> million of gross proceeds, the Company is&#160;obligated to pay a commission of&#160;<ix:nonFraction id="c107484621" contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Pure" name="sava:CommissionPercentageOfGrossProceeds" scale="-2" format="ixt:num-dot-decimal" decimals="3">2.5</ix:nonFraction>% of the gross proceeds from the sale of shares of common stock in the offering to the Company's financial advisor for the warrant distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  </ix:nonNumeric>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9" title="item9" href="#"></a>Item 9.</b>&#160;&#160;&#160;&#160;<b><i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       110
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9a" title="item9a" href="#"></a>Item 9A.</b>&#160;&#160;&#160;&#160;<b><i>Controls and Procedures</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Evaluation of disclosure controls and procedures.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission, or SEC, rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosures.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><i>Management</i>&#8217;<i>s annual report on internal control over financial reporting.</i> Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Our management has assessed the effectiveness of internal control over financial reporting as of December 31, 2023. Our assessment was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-Integrated Framework (2013 Framework).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and board of directors; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the consolidated financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Based on it&#8217;s assessment under the COSO framework, management concluded that our internal control over financial reporting as of&#160;December 31, 2023 was effective.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Changes in internal control over financial reporting.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2023&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       111
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">To the Stockholders and the Board of Directors of Cassava Sciences, Inc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Opinion on Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We have audited Cassava Sciences, Inc.&#8217;s internal control over financial reporting&#160;as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our&#160;opinion, Cassava Sciences, Inc. (the Company) maintained, in all material respects, effective&#160;internal control over financial reporting&#160;as of December 31, 2023, based on the COSO criteria.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes&#160;and our report dated February 28, 2024 expressed an unqualified opinion thereon.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Basis for Opinion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">The Company&#8217;s management is responsible for maintaining effective&#160;internal control over financial reporting&#160;and for its assessment of the effectiveness of&#160;internal control over financial reporting&#160;included in the accompanying Management's annual report on internal control over financial reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective&#160;internal control over financial reporting&#160;was maintained in all material respects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Our audit included obtaining an understanding of&#160;internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our&#160;opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Definition and Limitations of</b>&#160;<b>Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Ernst &amp; Young LLP</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Austin, Texas</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 28, 2024</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       112
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <ix:nonNumeric contextRef="d_2023-01-01_2023-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c2560592" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9b" title="item9b" href="#"></a>Item <em style="font: inherit;">9B.</em></b>&#160;&#160;&#160;&#160;<b><i>Other Information</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> December 31, 2023, </em><span style="-sec-ix-hidden:c107484626"><span style="-sec-ix-hidden:c107484634"><span style="-sec-ix-hidden:c107484635"><span style="-sec-ix-hidden:c107484636">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
  </ix:nonNumeric>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item9c" title="item9c" href="#"></a>Item 9C. </b><b><i>Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">None<b>.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART III</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item10" title="item10" href="#"></a>Item 10.</b>&#160;&#160;&#160;&#160;<b><i>Directors and Executive Officers and Corporate Governance </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information regarding our directors (other than the biographies below), executive officers, director nomination process and the audit committee of the Board is incorporated by reference from "Directors and Executive Officers" in our Proxy Statement for our 2024&#160;Annual Meeting of Stockholders.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Biographies of Directors and Executive Officers</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>&#65279;Remi Barbier</i>, the Company&#8217;s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company&#8217;s inception in 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc., a publicly-traded drug development company, ArQule, Inc., a drug development company acquired by Merck &amp; Co., and EnzyMed, Inc., a chemistry company acquired by Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington, the Santa Fe Institute, the Advisory Board of the University of California Institute for Quantitative Biosciences and a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>R. Christopher Cook</i> has served as Senior Vice President and General Counsel since October 2022. He previously served, since 2017, as the Global Head of Litigation and Government Investigations for Alcon, a publicly traded medical device and pharmaceutical company, as well as the Vice President and division General Counsel for Walmart Central America in San Jose, Costa Rica. Mr. Cook&#160;also spent seventeen years at Jones Day, where he was a litigation partner in the firm's Washington, DC and Chicago offices. He&#160;served as an Assistant United States Attorney in Chicago and graduated from Harvard Law School.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>James W. Kupiec, M.D.</i> joined the Company in January 2021 as Chief Clinical Development Officer and has served as our Chief Medical Officer since December 2022. Dr. Kupiec joined the Company after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as Vice President, Global Clinical Leader for Parkinson&#8217;s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before transitioning to the pharmaceutical industry.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Eric Schoen</i> has served as Chief Financial Officer since 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspira Women&#8217;s Health Inc. (formerly Vermillion, Inc.), a publicly-held women&#8217;s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       113
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Robert Anderson, Jr.</i>&#160;has served as a director since December 2023.&#160;Mr. Anderson has decades of operational experience in cybersecurity, counterintelligence, economic espionage and critical incident response and management. Mr. Anderson previously led more than 20,000 FBI employees as the bureau&#8217;s Executive Assistant Director of the Criminal, Cyber, Response and Services Branch&#8212; the No. 3 position in the organization. Mr. Anderson is currently Chairman of the Board and Chief Executive Officer of Cyber Defense Labs, an advisory firm focused on cybersecurity, where he has served as CEO since March 2019 and Chairman since January 2022. Mr. Anderson holds a Bachelor of Science and a Master in Public Administration from Wilmington University.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Richard J. Barry</i> has served as a director since June 2021. Since June 2015, Mr. Barry has also served as a director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Mr. Barry has extensive experience in the investment management business. He was a founding member of Eastbourne Capital Management LLC, and served as a Managing General Partner and Portfolio Manager from 1999 to its close in 2010. Prior to Eastbourne, Mr. Barry was a Portfolio Manager and Managing Director of Robertson Stephens Investment Management. Mr. Barry holds a Bachelor of Arts from Pennsylvania State<b> </b>University.&#65279;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Pierre Gravier</i>&#160;has served as a director since December 2023. Since&#160;July 2023, Mr. Gravier has been the&#160;Chief Financial Officer of PTC Therapeutics, Inc., a publicly traded biotechnology company. From 2013 to July 2023, Mr. Gravier was previously Managing Director in the healthcare group of Perella Weinberg Partners, a leading global independent advisory firm that provides strategic, financial, and tactical advice in connection with executing mergers, acquisitions and other corporate&#160;strategies.&#160;Mr. Gravier holds a Master&#8217;s Degree in Finance from ESCP Business School and a Master of Science in Bioengineering from the University of Technology of Compi&#232;gne.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Robert Z. Gussin, Ph.D</i>. has served as a director since 2003. Dr. Gussin worked at Johnson &amp; Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Claude Nicaise, M.D.</i>&#160;has served as a director since December 2023.&#160;Since June 2015, Dr. Nicaise has also served as a director of Sarepta Therapeutics, Inc., (Nasdaq: SRPT). Since January 2021, Dr. Nicaise has served as a member of the board of directors of Gain Therapeutics. Since March 2021, Dr. Nicaise has served as a member of the board of directors of Chemomab Therapeutics Ltd. Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals in various diseases areas, including neuroscience. Dr. Nicaise is the founder of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies.&#160;Dr. Nicaise served&#160;as Executive Vice President, Regulatory at Ovid Therapeutics Inc., a company that develops medicines for orphan diseases of the brain, from 2015 to March 2023.&#160;Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development and Vice-President of Worldwide Regulatory Science and Strategy.&#160;Dr. Nicaise received his M.D. from the Universit&#233; Libre de Bruxelles in Belgium.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Michael J. O</i>&#8217;<i>Donnell, Esq</i>. has served as a director since 1998. Mr. O&#8217;Donnell has been a partner in the law firm of Orrick, Herrington &amp; Sutcliffe LLP since June 2021. Orrick, Herrington &amp; Sutcliffe LLP&#160;provides legal services to the Company. Previously, Mr. O&#8217;Donnell was a member of Morrison &amp; Foerster LLP from 2011 to 2021. Mr. O&#8217;Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Previously, Mr. O&#8217;Donnell was a member of Wilson Sonsini Goodrich &amp; Rosati. Mr. O&#8217;Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Sanford R. Robertson</i> has served as a director since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens &amp; Company, a technology investment bank sold to BankBoston in 1998. Mr. Robertson was previously&#160;the lead director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:14pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"><i>Patrick J. Scannon, M.D., Ph.D.</i> has served as a director since 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016, Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA.&#160;Dr. Scannon retired from XOMA and resigned from XOMA&#8217;s board of directors in 2016.&#160;Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       114
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Section 16(a) Beneficial Ownership Reporting Compliance</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Section 16(a) of the Exchange Act requires our executive officers and directors and persons who own more than ten percent (10%) of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten percent (10%) stockholders are required to furnish us with copies of all Section 16(a) forms they file. We believe all of our executive officers and directors complied with all applicable filing requirements during 2023.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Code of Ethics </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. We publicize the Code of Ethics through posting the policy on our website, <span style="text-decoration: underline; ">http://www.cassavasciences.com</span>. We will disclose on our website any waivers of, or amendments to, our Code of Ethics.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item11" title="item11" href="#"></a>Item 11.</b>&#160;&#160;&#160;&#160;<b><i>Executive Compensation</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Executive Compensation and Other Matters."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item12" title="item12" href="#"></a>Item 12.</b><b><i> Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Security Ownership of Certain Beneficial Owners and Management."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following table summarizes the securities authorized for issuance under our equity compensation plans as of&#160;December 31, 2023:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Securities to be</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Securities</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Issued Upon</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Exercise Price of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Remaining Available</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Exercise of</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;for Future Issuance</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Outstanding</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Options,</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Under Equity</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Options, Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Warrants</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Compensation</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;and Rights</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>&#8206;Plans</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans approved by stockholders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,046,171</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">(1)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.10</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">(2)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,966,705</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">(3)</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans not approved by stockholders</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

    <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,046,171</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15.10</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,966,705</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Includes outstanding stock options and awards for 1,131,382&#160;shares of our common stock under the 2008 Plan and 1,914,793</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&#160;shares of our common stock under the 2018 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Includes the weighted average stock price for outstanding stock options of $11.18&#160;under the 2008 Plan and $17.45&#160;for the 2018 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">Represents 2,908,688 shares of our common stock for the 2018 Plan and 58,017 for the Employee Stock Purchase Plan. No future awards shall occur under the 2008 Plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       115
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item13" title="item13" href="#"></a>Item 13.</b>&#160;&#160;&#160;&#160;<b><i>Certain Relationships and Related Transactions and Director Independence</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading "Certain Relationships and Related Transactions."</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="itme14" title="itme14" href="#"></a>Item 14.</b>&#160;&#160;&#160;&#160;<b><i>Principal Accountant Fees and Services</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The information required by this Item is incorporated by reference from our definitive Proxy Statement referred to in Item 10 above where it appears under the heading &#8220;Principal Accountant Fees and Services.&#8221;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART IV</b></p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item15" title="item15" href="#"></a>Item 15.</b>&#160;&#160;&#160;&#160;<b><i>Exhibits and Financial Statement Schedules</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(a) The following documents are filed as part of this Form 10-K:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<i> </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Consolidated Financial Statements (included in Part II of this report):</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Report of Independent Registered Public Accounting Firm</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Balance Sheets</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Operations</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Stockholders' Equity</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Cash Flows</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Notes to Consolidated Financial Statements</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<i> </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Consolidated Financial Statement Schedules:</i></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><i>Management Contracts, Compensatory Plans and Arrangements</i>.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#160;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Management contracts, compensatory plans and arrangements are indicated by the symbol &#8220;*&#8221; in the applicable exhibits listed in Item 15(b), below.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       116
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(b) <i>Exhibits </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The exhibits listed below are filed as part of this Form 10-K other than Exhibit 32.1, which shall be deemed furnished.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 52%;">&#160;</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td colspan="5" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporated by Reference</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center; border-bottom: 1px solid black;"><b>Exhibit</b><br/> &#8206;<b>No.</b></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: bottom; width: 52%; border-bottom: 1px solid black;"><b>Description</b></td>
     <td style="vertical-align: bottom; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 5%; text-align: center; border-bottom: 1px solid black;"><b>Form</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 15%; text-align: center; border-bottom: 1px solid black;"><b>Filing</b><br/> &#8206;<b>Date</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 7%; text-align: center; border-bottom: 1px solid black;"><b>Exhibit</b><br/> &#8206;<b>No.</b></td>
     <td style="vertical-align: top; width: 1%; border-bottom: 1px solid black;">&#160;</td>
     <td style="vertical-align: bottom; width: 8%; text-align: center; border-bottom: 1px solid black;"><b>Filed</b><br/> &#8206;<b>Herewith</b></td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312505152582/dex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2005</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953017000028/ptie-20170508xex3_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/8/2017</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000019/sava-20181231xex3_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of Restated Certificate of Incorporation.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/29/2019</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm" style="-sec-extract:exhibit;">3.4</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000047/sava-20230908xex3_4.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of Cassava Sciences, Inc.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">9/13/23</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">3.4</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953019000032/sava-20190630xex4_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen Common Stock Certificate.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/12/2019</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_630601.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.2</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_630601.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Description of Registrant&#8217;s Securities.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315224000209/ex4-1.htm" style="-sec-extract:exhibit;">4.3</a></td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315224000209/ex4-1.htm" style="-sec-extract:exhibit;">Warrant Agreement (including Form of Warrant), dated January 3, 2024, between the Company, Computershare Inc., a Delaware corporation, and Computershare Trust Company, N.A., as Warrant Agent.</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">1/3/24</td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">4.1</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.1</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000011/sava-20211231xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement between Registrant and each of its directors and officers.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/1/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.5</span></a>*</p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312509027574/dex1012.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, dated July&#160;</span><span style="text-decoration: underline; ">1, 1998 and amended December</span><span style="text-decoration: underline; ">&#160;</span><span style="text-decoration: underline; ">17, 2008, between Registrant and Remi Barbier.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2/13/2009</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.12</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.6</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312510170701/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2000 Employee Stock Purchase Plan, as amended and restated.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">7/29/2010</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.7</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312508124661/dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2008 Equity Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/29/2008</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.8</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment Number 1 to the 2008 Equity Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/1/2013</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.9</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000119312513315094/d547249dex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment No. 2 to Employment Agreement between Registrant and Remi Barbier.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/1/2013</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.10</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000025/ptie-20180511xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2018 Omnibus Incentive Plan.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/11/2018</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.11</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000149315223015041/ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Capital On Demand<sup style="vertical-align:top;line-height:120%;">TM</sup>&#160;Sales Agreement, dated as of May 1, 2023, between Cassava Sciences, Inc. and JonesTrading Institutional Services LLC</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5/1/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.12</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan</span>&#160;(As Amended March 16, 2023).</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/3/2023</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.13</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953018000058/ptie-20181011xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on October&#160;</span><span style="text-decoration: underline; ">9, 2018, by and between Registrant and Eric Schoen.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/11/2018</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.14</span></a></p> </td>
     <td style="vertical-align: top; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><sup style="vertical-align:top;line-height:120%;">*</sup></p> </td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000002/sava-20210106xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on January&#160;</span><span style="text-decoration: underline; ">1, 2021, by and between Registrant and Dr. James Kupiec.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1/6/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.15</span></a>+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000011/sava-20210311xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Master Services Agreement between Cassava Sciences, Inc. and Evonik Corporation, dated February 22, 2021.</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3/11/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.16</span></a>+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000045/sava-20210630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Master Services Agreement between Cassava Sciences, Inc. and Premier Research International LLC, dated June 11, 2021</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/4/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       117
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.17</span></a>+</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953021000050/sava-20210930xex10_4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Agreement of Sale and Purchase Between DWF IV Lakewood, LP and Cassava Sciences, Inc. dated July 2, 2021</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">11/15/2021</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.18</span></a>*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000033/sava-20220630xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment 1 to 2018 Omnibus Incentive Plan</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8/4/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19</span></a>*</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement, executed on October 13, 2022, by and between Registrant and R. Christopher Cook</span></a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">8-K</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10/27/2022</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953022000051/sava-20221013xex10_1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19</span></a>*</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="http://www.sec.gov/Archives/edgar/data/1069530/000106953023000039/sava-20230630xex10_3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Cassava Sciences Non-Employee Director Compensation Plan</span></a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%; text-align: center;">8/3/2023</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%; text-align: center;">10.3</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_573342.htm" style="-sec-extract:exhibit;">21.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_573342.htm" style="-sec-extract:exhibit;">Subsidiaries of the Registrant.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_573343.htm" style="-sec-extract:exhibit;">23.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_573343.htm" style="-sec-extract:exhibit;">Consent of Independent Registered Public Accounting Firm.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_573344.htm" style="-sec-extract:exhibit;">31.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_573344.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.&#160;</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_573345.htm" style="-sec-extract:exhibit;">31.2</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_573345.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.&#160;</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a href="ex_573346.htm" style="-sec-extract:exhibit;">32.1</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_573346.htm" style="-sec-extract:exhibit;">Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%; text-align: center;"><a href="ex_611641.htm" style="-sec-extract:exhibit;">97</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"><a href="ex_611641.htm" style="-sec-extract:exhibit;">Policy Regarding Recovery of Erroneously Awarded Compensation</a></td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%; text-align: center;">X</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Instance Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: middle; width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">X</p> </td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 8%; text-align: center;">104</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 52%; text-align: justify;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, formatted in Inline XBRL (included in Exhibit 101).</td>
     <td style="vertical-align: bottom; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 5%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 15%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 7%;">&#160;</td>
     <td style="vertical-align: top; width: 1%;">&#160;</td>
     <td style="vertical-align: top; width: 8%; text-align: center;">X</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">* Management contract, compensatory plan or arrangement.</p>
  <p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">+ Confidential portions of this document have been redacted as permitted by applicable regulations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 16pt;text-indent:-16pt;">(c)<i> Consolidated Financial Statement Schedules </i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">All consolidated financial statement schedules are omitted because the information is inapplicable or presented in the notes to the consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a id="item16" title="item16" href="#"></a>Item 16.</b>&#160;&#160;&#160;&#160;<b><i>Form 10-K Summary</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company has elected not to include summary information.</p>
  <p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#8206;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       118
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink" style="display: inline-block; text-align: left;">
      <a href="#toc" style="font-weight: initial; font-style: initial; font-variant: initial; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Table of Contents</a>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#160;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="sigs" title="sigs" href="#"></a>SIGNATURES</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 45%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Principal Executive</p> </td>
     <td style="vertical-align: top; width: 35%;">&#160;</td>
     <td style="vertical-align: top; width: 20%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cassava Sciences, Inc.</p> </td>
     <td style="vertical-align: top; width: 20%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ REMI BARBIER</p> </td>
     <td style="vertical-align: top; width: 20%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Remi Barbier,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chairman of the Board of Directors,</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 45%;">&#160;</td>
     <td colspan="2" style="vertical-align: top; width: 35%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">President and Chief Executive Officer</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dated: February 28, 2024</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b>&#160;</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title </b></p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: middle; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: middle; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ REMI BARBIER</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">President, Chief Executive Officer and</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remi Barbier</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chairman of the Board of Directors</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ERIC J. SCHOEN</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Eric J. Schoen</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ROBERT ANDERSON, JR.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Anderson, Jr.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ RICHARD J. BARRY</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Richard J. Barry</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ PIERRE GRAVIER</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pierre Gravier</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ ROBERT Z. GUSSIN, PH.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Z. Gussin, Ph.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ CLAUDE NICAISE, M.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Claude Nicaise, M.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ MICHAEL J. O'DONNELL, ESQ.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Michael J. O'Donnell, Esq.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ SANFORD R. ROBERTSON</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Sanford R. Robertson</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

    <tr>
     <td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ PATRICK SCANNON, M.D., PH.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%; text-align: center;">February 28, 2024</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 40%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Patrick Scannon, M.D., Ph.D.</p> </td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 40%;">&#160;</td>
     <td style="vertical-align: middle; width: 2%;">&#160;</td>
     <td style="vertical-align: top; width: 16%;">&#160;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       119
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex_630601.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html><head>
	<title>ex_630601.htm</title>
	<!-- Generated by ThunderDome Portal - 2/26/2024 5:15:19 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 72pt;text-indent:36pt;"><b>Exhibit 4.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>DESCRIPTION OF THE REGISTRANT</b>&#8217;<b>S SECURITIES</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following is a brief description of (i) the common stock, $0.001 par value per share ( &#8220;Common Stock&#8221;), of Cassava Sciences, Inc. (the &#8220;Company&#8221;) and (ii) the warrants, each whole warrant exercisable for shares of Common Stock (&#8220;Warrants&#8221;), of the Company, each of which is registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Description of Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><b>General</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following summary of the material features of our Common Stock and certain provisions of Delaware law do not purport to be complete and is subject to, and qualified in its entirety by, the provisions of our amended and restated certificate of incorporation, our bylaws, the Delaware General Corporation Law (&#8220;DGCL&#8221;) and other applicable law. For additional detail about our capital stock, please refer to our amended and restated certificate of incorporation and bylaws, each as amended, copies of which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of the date of this Exhibit to the Form 10-K, our authorized capital stock consists of 130,000,000 shares. The Company is authorized to issue two classes of shares to be designated, respectively, Common Stock and Preferred Stock. The total number of shares of Common Stock which this Company is authorized to issue is 120,000,000, with a par value of $0.001, and the total number of shares of Preferred Stock which we is authorized to issue is 10,000,000, with a par value of $0.001. As of December 31, 2023, there were 42,236,919 shares of Common Stock issued and outstanding. Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SAVA.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Liquidation Rights </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of our liquidation, dissolution or winding up, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock then outstanding. The Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Voting Right</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Dividends </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Common Stock are entitled to receive ratably any dividends that may be declared from time to time by the board of directors out of funds legally available for that purpose. However, the Company is not currently paying any dividends.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No Preemptive or Similar Rights </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Common Stock has no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Limitation on Rights of Holders of Common Stock </b>&#8211;<b> Preferred Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We currently have no shares of preferred stock outstanding. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of the Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could negatively affect the voting power and other rights of the holders of Common Stock. Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or make it more difficult to remove our management. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Certain Anti-Takeover Matters</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation requires that certain amendments of the amended and restated certificate of incorporation and certain amendments by the stockholders of our bylaws require the approval of at least 66 2/3% of the voting power of all outstanding stock. These provisions could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could delay changes in our management.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. At an annual meeting, stockholders may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors. Stockholders may also consider a proposal or nomination by a person who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our Secretary timely written notice, in proper form, of his or her intention to bring that business before the meeting. The bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting of the stockholders. However, our bylaws may have the effect of precluding the conduct of business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of our company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our bylaws provide that only our board of directors, the chairman of the board, the president or the chief executive officer may call a special meeting of stockholders. Because our stockholders do not have the right to call a special meeting, a stockholder could not force stockholder consideration of a proposal over the opposition of the board of directors by calling a special meeting of stockholders prior to such time as a majority of the board of directors believed or the chief executive officer believed the matter should be considered or until the next annual meeting provided that the requestor met the notice requirements. The restriction on the ability of stockholders to call a special meeting means that a proposal to replace the board also could be delayed until the next annual meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Director Classification</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation provides for our board of directors to be divided into three classes serving staggered terms. Approximately one-third of the board of directors will be elected each year. The provision for a classified board could prevent a party who acquires control of a majority of the outstanding voting stock from obtaining control of the board of directors until the second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company and could increase the likelihood that incumbent directors will retain their positions. Our amended and restated certificate of incorporation provides that directors may be removed with cause by the affirmative vote of the holders of the outstanding shares of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Limitation of Liability and Indemnification Matters</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Our amended and restated certificate of incorporation provides that to the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended, a director of the Company or any subsidiary of the Company will not be held personally liable to the Company or its stockholders and will otherwise be indemnified by the Company for monetary damages for breach of fiduciary duty as a director of the Company, any predecessor of the Company or any subsidiary of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The Company, under the amended and restated certificate of incorporation, also indemnifies to the fullest extent permitted by law any person made or threatened to be made a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of the fact that he, his testator or intestate is or was a director or officer of the Company, any predecessor of the Company or any subsidiary of the Company or serves or served at any other enterprise as a director or officer at the request of the Company, any predecessor to the Company or any subsidiary of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Section 203 of the Delaware General Corporation Law</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">We are subject to the provisions of Section 203 of the DGCL. Under Section 203, we would generally be prohibited from engaging in any business combination with any interested stockholder for a period of three years following the time that this stockholder became an interested stockholder unless:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">prior to this time, the board of directors of the Company approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">upon consummation of the transaction that resulted in the stockholder&#8217;s becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the Company outstanding at the time the transaction commenced, excluding shares owned by persons who are directors and also officers, and by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#183;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2&#8260;3% of the outstanding voting stock that is not owned by the interested stockholder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under Section 203, a &#8220;business combination&#8221; includes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any merger or consolidation involving the Company and the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any merger or consolidation involving the Company and the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the Company involving the interested stockholder;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any transaction that results in the issuance or transfer by the Company of any stock of the Company to the interested stockholder, subject to limited exceptions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">any transaction involving the Company that has the effect of increasing the proportionate share of the stock of any class or series of the Company beneficially owned by the interested stockholder; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the Company</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, Section 203 defines an interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the Company and any entity or person affiliated with or controlling or controlled by such entity or person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description of the Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>&#65279;General</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of the material features of our Warrants and certain provisions of Delaware law do not purport to be complete and is subject to, and qualified in its entirety by, the provisions of our amended and restated certificate of incorporation, our bylaws, the warrant agreement, dated as of January 3, 2024 (the &#8220;Warrant Agreement&#8221;), between the Company and Computershare Inc. and Computershare Trust Company, N.A., as warrant agents, the DGCL and other applicable law. For additional detail about our Warrants, please refer to our amended and restated certificate of incorporation and bylaws, each as amended from time to time, copies of which are included as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&#65279;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of the date of distribution of the Warrants, January 3, 2024 , there were 16,894,704 Warrants issued and outstanding. Our Warrants are listed on the Nasdaq Capital Market under the symbol &#8220;SAVAW.&#8221;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrant Exercise Rate</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Each Warrant represents the right to purchase from the Company one share of Common Stock (the &#8220;Basic Warrant Exercise Rate&#8221;) plus the Bonus Share Fraction (as defined below), if any as described below, for the applicable exercise date for cash at an initial exercise price of $33.00 (the &#8220;Exercise Price&#8221;) per Warrant, payable in U.S. dollars.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Until the Bonus Share Fraction Expiration Date (as defined below), a holder exercising its Warrants will receive, in addition to the Basic Warrant Exercise Rate, initially, an additional 0.5 of a Common Share for each Warrant exercised (subject to adjustment as described herein, the &#8220;Bonus Share Fraction&#8221;) without payment of any additional Exercise Price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The right to receive the Bonus Share Fraction will expire at 5:00 p.m. New York City time (the &#8220;Bonus Share Expiration Date&#8221;) upon the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period commencing on or after the distribution date in which the daily VWAPs (as defined in the Warrant Agreement) of the shares of Common Stock has been at least equal to the then applicable Bonus Share Expiration Trigger Price (as defined in the Warrant Agreement) for at least 20 trading days (whether or not consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon not less than 20 business days&#8217; notice. Any Warrant exercised with an exercise date after the Bonus Share Expiration Date will not be entitled to any Bonus Share Fraction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The &#8220;Bonus Share Expiration Trigger Price&#8221; is initially $26.40, subject to certain adjustments described in the Warrant Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Basic Warrant Exercise Rate plus any Bonus Share Fraction is referred to as the Warrant Exercise Rate. The Basic Warrant Exercise Rate, the Bonus Share Fraction and the Bonus Share Expiration Trigger Price are each subject to certain adjustments described in the &#8220;Anti-Dilution Adjustments&#8221; section below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company will make a public announcement of the Bonus Share Expiration Date (i) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition and (ii) at least 20 Business Days prior to such date, in the case of the Company setting a Bonus Share Expiration Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Expiration</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Except as described below, the Warrants will expire and cease to be exercisable at 5:00 p.m. New York City time on November 15, 2024 (the &#8220;Expiration Date&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Redemption</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Warrants are redeemable at the Company&#8217;s sole option at any time with a redemption date on or after April 15, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">By public announcement only, the Company will provide at least 20 calendar days&#8217; notice (the &#8220;Redemption Notice&#8221;) of the date selected for redemption (the &#8220;Redemption Date&#8221;). The redemption price upon any redemption shall equal to 1/10 of $0.01 per Warrant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of a redemption of the Warrants, Warrants will be exercisable until 5:00 p.m. New York City time on the business day immediately preceding the Redemption Date. The Warrants will not be exercisable after 5:00 p.m. New York City time on the business day immediately preceding the Redemption Date and will cease to be outstanding after the Redemption Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Exercise</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All or any part of the Warrants may be exercised prior to the earlier of (x) 5:00 p.m. New York City time on the Expiration Date and (y) 5:00 p.m. New York City time on the Business Day prior to the Redemption Date by delivering a completed form of election to purchase shares of Common Stock, which contains certain representations by the holder of the Warrants, and payment of the Exercise Price in cash. Any such delivery that occurs on a day that is not a Business Day or is received after 5:00 p.m., New York City time, on any given Business Day will be deemed received and exercised on the next succeeding Business Day. Record owners of Warrants may exercise Warrants through the process established by the Warrant Agent. Indirect, &#8220;street name&#8221; holders of Warrants should contact their broker, bank or other intermediary for information on how to exercise Warrants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If a registration statement is not effective at any time or from time to time, the right to exercise Warrants shall be automatically suspended until such registration statement becomes effective as described under &#8220;Registration and Suspension&#8221; below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon delivery of Warrant Shares upon exercise of Warrants, the Company will issue such whole number of Warrant Shares as the exercising Warrant holder is entitled to receive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Without the prior written consent of the Company (which consent may be withheld in the Company&#8217;s sole discretion), a holder will not be permitted to exercise Warrants for any shares of Common Stock, and the Company shall not be obligated to effect such exercise if, following such exercise, the holder (together with such holder&#8217;s affiliates, and any other persons acting as a group with such holder and its affiliates) would beneficially own 9.9% or more of the shares of Common Stock outstanding, including without limitation, through synthetic or derivative financial instruments that give effect to a direct or indirect ownership in the common stock of the Company (the &#8220;Ownership Limitation&#8221;). No consideration or repayment will be made to any holder as a result of an inability to exercise a Warrant in whole or in part because of such ownership limitations. The terms &#8220;beneficial ownership&#8221; and &#8220;group&#8221; shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of determining whether the Ownership Limitation has been reached, a holder may rely on the number of outstanding shares of Common Stock reflected in (x) the Company&#8217;s most recent periodic or annual report filed with the SEC or (y) any more recent notice published on the Company&#8217;s website.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Registration and Suspension</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Company has agreed in the Warrant Agreement to use commercially reasonable efforts to cause a shelf registration statement (including, at the Company&#8217;s election, an existing registration statement), to be filed pursuant to Rule 415 (or any successor provision) of the Securities Act, covering the issuance of shares of Common Stock to the Warrant holders upon exercise of the Warrants to remain effective until the earlier of (i) such time as all Warrants have been exercised and (ii) the earlier of the Expiration Date and the Redemption Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Anti-Dilution Adjustments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Basic Warrant Exercise Rate shall be subject to adjustment, without duplication, upon the occurrence&nbsp;of certain events, including, among others, stock dividends payable in shares of Common Stock, stock splits, reclassifications and combinations, certain rights offerings to holders of shares of Common Stock, other distributions and spin-offs of securities to holders of shares of Common Stock, and cash dividends on shares of Common Stock, each as more fully described in the Warrant Agreement, except that the Company shall not make any such adjustments if each holder has the opportunity to participate, at the same time and upon the same terms as holders of the shares of Common Stock and solely as a result of holding the Warrants in any of the transactions described below, without having to exercise such holder&#8217;s Warrants, as if such holder held a number of shares of Common Stock equal to the product (rounded down to the nearest whole multiple of a share of Common Stock) of (i) the Warrant Exercise Rate in effect on the record date for such transaction and (ii) the number of Warrants held by it on such record date. The Bonus Share Fraction and the Bonus Share Expiration Trigger Price will be proportionately adjusted for any adjustment to the Basic Warrant Exercise Rate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All adjustments to the Basic Warrant Exercise Rate shall be made by the Calculation Agent to the nearest whole multiple of 0.00001 (with 0.000005 being rounded upwards) share of Common Stock. Any adjustments described above shall be made successively whenever an event referred to therein shall occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business Combinations and Reorganizations</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the event of a merger, consolidation, amalgamation, statutory share exchange or similar transaction that requires the approval of the Company&#8217;s shareholders (a &#8220;Business Combination&#8221;) or reclassification of Common Stock, other than a reclassification of Common Stock referred to in &#8220;Anti-Dilution Adjustments&#8221; above, the right of a Warrant holder to receive Common Stock upon exercise of a Warrant will be converted into the right to exercise a Warrant to acquire, per each Warrant, the number of shares or other securities or property (including cash) that a number of shares of Common Stock equal to the Warrant Exercise Rate (in effect at the time of such Business Combination or reclassification) immediately prior to such Business Combination or reclassification would have been entitled to receive upon consummation of such Business Combination or reclassification (the amount of such shares, other securities or property in respect of a share of Common Stock being herein referred to as a &#8220;Unit of Reference Property&#8221;). If the Business Combination causes the Common Stock to be converted into, or exchanged for, the right to receive more than a single type of consideration (determined based in part upon any form of shareholder election), then the composition of the Unit of Reference Property into which the Warrants will be exercisable will be deemed to be the weighted average of the types and amounts of consideration actually received by the holders of Common Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex_573342.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Cassava Sciences, Inc. Subsidiaries</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 0pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u>Subsidiary</u></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u>State/Country of Incorporation/Formation</u></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Austin Innovation Park, LLC</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 46%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Texas</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_573343.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 134pt;text-indent:-18pt;">EXHIBIT 23.1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We consent to the incorporation by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Registration Statement (Form S-8 No. 333-265540) pertaining to the 2018 Omnibus Incentive Plan of Registrant,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2)</p>
			</td>
			<td style="width: auto; font-size: 10pt;">Registration Statement (Form S-3 No. 333-271542) and related Prospectus of Cassava Sciences, Inc.,</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">3)</p>
			</td>
			<td style="width: auto; font-size: 10pt;">Registration Statement (Form S-8 No. 333-168390) pertaining to the 2000 Employee Stock Purchase Plan of Registrant,</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">4)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Registration Statement (Form S-8 No. 333-225708) pertaining to the 2018 Omnibus Incentive Plan of Registrant,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">5)</p>
			</td>
			<td style="width: auto; font-size: 10pt;">Registration Statement (Form S-8 No. 333-147336) pertaining to the 2000 Employee Stock Purchase Plan of Registrant, and</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">6)</p>
			</td>
			<td style="width: auto; font-size: 10pt;">Registration Statement (Form S-3 No. 333-152676) pertaining to the 2008 Equity Incentive Plan of Registrant;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">of our reports dated February 28, 2024, with respect to the consolidated financial statements of Cassava Sciences, Inc. and the effectiveness of internal control over financial reporting of Cassava Sciences, Inc. included in this Annual Report (Form 10-K) of Cassava Sciences, Inc. for the year ended December 31, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">/s/ Ernst &amp;Young LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Austin, Texas</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">February 28, 2024</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex_573344.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>

	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: col-resize;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;">EXHIBIT 31.1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">PRINCIPAL EXECUTIVE OFFICER CERTIFICATION PURSUANT TO</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">I, Remi Barbier, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Cassava Sciences, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ REMI BARBIER</u></td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Remi Barbier,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chairman of the Board of Directors,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">President and Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">(Principal Executive Officer)</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 350pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Date: February 28, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex_573345.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 80pt;">EXHIBIT 31.2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">PRINCIPAL FINANCIAL OFFICER CERTIFICATION PURSUANT TO</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">I, Eric J. Schoen, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Cassava Sciences, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">4.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">c.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">d.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">5.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">b.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ ERIC J. SCHOEN</u></td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Eric J. Schoen,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chief Financial Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">(Principal Financial Officer)</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Date: February 28, 2024</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex_573346.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 476pt;">EXHIBIT 32.1</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">CERTIFICATIONS OF THE CHIEF EXECUTIVE OFFICER AND THE</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Cassava Sciences, Inc. (the &#8220;Company&#8221;), hereby certifies that to the best of such officer&#8217;s knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and to which this certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">The information contained in this Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Date: February 28, 2024</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ REMI BARBIER</u>&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Remi Barbier,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chairman of the Board of Directors,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">President and Chief Executive Officer</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;"><u>/s/ ERIC J. SCHOEN</u>&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Eric J. Schoen,</td>
		</tr>
		<tr>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 55%;">Chief Financial Officer</td>
		</tr>

</table>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>8
<FILENAME>ex_611641.htm
<DESCRIPTION>EXHIBIT 97
<TEXT>
<html><head>
	<title>ex_611641.htm</title>
	<!-- Generated by ThunderDome Portal - 2/27/2024 5:51:40 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 97.</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><img alt="ex_611641img001.jpg" src="ex_611641img001.jpg" style="width:470;height:123;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;">Policy Regarding Recovery of Erroneously Awarded Compensation<br>
<b>Effective October 2, 2023</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy Regarding Recovery of Erroneously Awarded Compensation (the &#8220;<b><i>Policy</i></b>&#8221;) is established by Cassava Sciences, Inc. (the &#8220;<b><i>Company</i></b>&#8221;), a Delaware corporation, effective as of October 2, 2023 (the &#8220;<b><i>Effective Date</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>1. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Purpose</b>.<b> </b>The Company is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules, and regulations. In accordance with the applicable rules of The Nasdaq Stock Market (the &#8220;<b><i>Nasdaq Rules</i></b>&#8221;) and Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;) (&#8220;<b><i>Rule 10D-1</i></b>&#8221;), this Policy explains when the Company will be required to seek recovery of Incentive Compensation erroneously awarded to a Covered Person.&nbsp; All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section 11, below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>2. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Miscalculation of Financial Reporting Measure Results</b>. In the event of a Restatement, the Company will seek to recover, reasonably promptly, all Recoverable Incentive Compensation from a Covered Person in accordance with this Policy, the Nasdaq Rules, and Rule 10D-1. Such recovery, in the case of a Restatement, will be made without regard to any individual knowledge or responsibility related to the Restatement.&nbsp; Notwithstanding the foregoing, if the Company is required to undertake a Restatement, the Company will not be required to recover the Recoverable Incentive Compensation if the Compensation Committee determines it Impracticable to do so, in the reasonable exercise of its business judgment after reviewing all the relevant facts and circumstances.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If such Recoverable Incentive Compensation was not awarded or paid on a formulaic basis, the Company will seek to recover the amount of Recoverable Incentive Compensation that the Compensation Committee determines in good faith should be recouped pursuant to this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>3. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Actions</b>. The Compensation Committee may, subject to applicable law, seek recovery in the manner it chooses, including by seeking reimbursement from the Covered Person of all or part of the compensation awarded or paid, by electing to withhold unpaid compensation, by set-off, or by rescinding or canceling unvested stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the reasonable exercise of its business judgment under this Policy, the Compensation Committee may in its sole discretion determine whether and to what extent additional action is appropriate to address the circumstances surrounding a Restatement to minimize the likelihood of any recurrence and to impose such other discipline as it deems appropriate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>4. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>No Indemnification or Reimbursement. </b>Notwithstanding the terms of any other policy, program, agreement, or arrangement, in no event will the Company or any of its affiliates indemnify or reimburse a Covered Person for any loss under this Policy and in no event will the Company or any of its affiliates pay premiums on any insurance policy that would cover a Covered Person&#8217;s potential obligations with respect to Recoverable Incentive Compensation under this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>5. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Administration and Interpretation of Policy. </b>The Compensation Committee shall have the sole and exclusive authority to administer this Policy in accordance with and subject to the Nasdaq Rules and Rule 10D-1. The Compensation Committee is authorized to make such determinations and interpretations and to take such actions as it deems necessary, appropriate, or advisable for the administration of this Policy and for the Company&#8217;s continued compliance with Nasdaq Rules, Section 10D, Rule 10D-1, and any other applicable law, regulation, rule, or interpretation of the U.S. Securities and Exchange Commission (&#8220;<b><i>SEC</i></b>&#8221;) or Nasdaq promulgated or issued therewith.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>6. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Claims and Rights. </b>The remedies under this Policy are in addition to, and not in lieu of, any legal and equitable claims the Company or any of its affiliates may have or any actions that may be imposed by law enforcement agencies, regulators, administrative bodies, or other authorities. Further, the exercise by the Compensation Committee of any rights pursuant to this Policy will not impact any other rights that the Company or any of its affiliates may have with respect to any Covered Person subject to this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Policy has been established for the exclusive benefit of the Company. This Policy does not confer any rights, remedies, or authority upon, nor shall this Policy be enforced by, any person or entity other than the Company, the Board, and the Compensation Committee as set forth in this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>7. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Acknowledgement by Covered Persons; Condition to Eligibility for Incentive Compensation. </b>The Company will provide notice to and seek acknowledgement of this Policy from each Covered Person, provided that the failure to provide such notice or obtain such acknowledgement will have no impact on the applicability or enforceability of this Policy. After the Effective Date, the Company must be in receipt of a Covered Person&#8217;s acknowledgement as a condition to such Covered Person&#8217;s eligibility to receive Incentive Compensation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>8. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Amendment; Termination</b>. The Board or the Compensation Committee may in its discretion amend or terminate this Policy at any time as it deems necessary. Notwithstanding anything in this Section 8 to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal securities laws, SEC rule, or Nasdaq Rule.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>9. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Effectiveness. </b>Except as otherwise determined in writing by the Compensation Committee, this Policy will apply to any Incentive Compensation that is Received by a Covered Person on or after the Effective Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>10. </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Disclosure Requirements.</b> The Company shall file all disclosures with respect to this Policy required by applicable SEC filings and rulings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Definitions. </b> For purposes of this Policy, the following capitalized terms shall have the meanings set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.1</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Applicable Period</i></b>&#8221; means the three completed fiscal years of the Company immediately preceding the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes (or reasonably should have concluded) that a Restatement is required or (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare a Restatement. The &#8220;Applicable Period&#8221; also includes any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.2</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Board</i></b>&#8221; means the Board of Directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.3</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Company</i></b>&#8221; shall refer solely and exclusively to Cassava Sciences, Inc. and shall not include any other person or entity, including any successor company or acquiror.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.4</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Compensation Committee</i></b>&#8221; means the Company&#8217;s committee of independent directors responsible for executive compensation decisions, or in the absence of such a committee, a majority of the independent directors serving on the Board of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.5</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Covered Person</i></b>&#8221; means any person who is, or was at any time, during the Applicable Period, an Executive Officer of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.6</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Executive Officer</i></b>&#8221; means each individual who is currently or was previously designated as an &#8220;officer&#8221; of the Company as defined in Rule 16a-1(f) under the Exchange Act. For the avoidance of doubt, the identification of an executive officer for purposes of this Policy shall include each executive officer who is or was identified pursuant to Item 401(b) of Regulation S-K or Item 6.A of Form 20-F, as applicable, as well as the principal financial officer and principal accounting officer (or, if there is no principal accounting officer, the controller).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.7</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Financial Reporting Measure</i></b>&#8221; means a measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements (including but not limited to &#8220;non-GAAP&#8221; financial measures, such as those appearing in the Company&#8217;s earnings releases or Management Discussion and Analysis), and any measure that is derived wholly or in part from such measure. Stock price and total shareholder return (and any measures derived wholly or in part therefrom) shall be considered Financial Reporting Measures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.8</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Impracticable.</i></b>&#8221; The Compensation Committee may determine in good faith that recovery of Recoverable Incentive Compensation is &#8220;Impracticable&#8221; if: (i) pursuing such recovery would violate home country law of the jurisdiction of incorporation of the Company where that law was adopted prior to November 28, 2022 and the Company provides an opinion of home country counsel to that effect acceptable to the Company&#8217;s applicable listing exchange; (ii) the direct expense paid to a third party to assist in enforcing this Policy would exceed the Recoverable Incentive Compensation and the Company has (A) made a reasonable attempt to recover such amounts and (B) provided documentation of such attempts to recover to the Company&#8217;s applicable listing exchange; or (iii) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.9</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Incentive Compensation</i></b>&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive Compensation does not include any base salaries (except with respect to any salary increases earned wholly or in part based on the attainment of a Financial Reporting Measure performance goal); bonuses paid solely at the discretion of the Compensation Committee or Board that are not paid from a &#8220;bonus pool&#8221; that is determined by satisfying a Financial Reporting Measure performance goal; bonuses paid solely upon satisfying one or more subjective standards and/or completion of a specified employment period; non-equity incentive plan awards earned solely upon satisfying one or more strategic measures or operational measures; and equity awards that vest solely based on the passage of time and/or attaining one or more non-Financial Reporting Measures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.10</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Received.</i></b>&#8221; Incentive Compensation is deemed &#8220;Received&#8221; in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.11</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Recoverable Incentive Compensation</i></b>&#8221; means the amount of any erroneously awarded Incentive Compensation (calculated on a pre-tax basis) Received by a Covered Person during the Applicable Period that is in excess of the amount that otherwise would have been Received if the calculation were based on the Restatement. For the avoidance of doubt Recoverable Incentive Compensation does not include any Incentive Compensation Received by a person (i) before such person began service in a position or capacity meeting the definition of an Executive Officer, (ii) who did not serve as an Executive Officer at any time during the performance period for that Incentive Compensation, or (iii) during any period the Company did not have a class of its securities listed on a national securities exchange or a national securities association. For Incentive Compensation based on (or derived from) stock price or total shareholder return where the amount of Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in the applicable Restatement, the amount will be determined by the Compensation Committee based on a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was Received (in which case, the Company will maintain documentation of such determination of that reasonable estimate and provide such documentation to the Company&#8217;s applicable listing exchange).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>11.12</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<b><i>Restatement</i></b>&#8221; means an accounting restatement of any of the Company&#8217;s financial statements filed with the Securities and Exchange Commission under the Exchange Act, or the Securities Act of 1933, as amended, due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as &#8220;Big R&#8221; restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as &#8220;little r&#8221; restatements).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>sava-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:29PM UTC 2024-02-28--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sava="http://www.cassavasciences.com/20231231" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cassavasciences.com/20231231">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sava-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-liquidity-and-basis-of-presentation" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-and-other-current-assets" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Prepaid and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Real Property and Other Income, Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-employee-401k-benefit-plan" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Employee 401(k) Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-leases-and-commitments" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Leases and Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-2020-cash-incentive-bonus-plan" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-contingencies" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-event-warrant-dividend-distribution" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-and-other-current-assets-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 6 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-and-other-income-expense-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-real-property-acquisitions-components-of-other-income-net-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-components-of-property-and-equipment-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-components-of-intangible-assets-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995487 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995488 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995489 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995490 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995491 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995492 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995493 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-leases-and-commitments-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995494 - Disclosure - Note 10 - Leases and Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-2020-cash-incentive-bonus-plan-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995495 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-contingencies-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995496 - Disclosure - Note 12 - Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995497 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sava_AccruedDevelopmentExpenseCurrent" name="AccruedDevelopmentExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_AtthemarketCommonStockOfferingMember" name="AtthemarketCommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_BonusShareFractionMember" name="BonusShareFractionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_CarryforwardSubjectToExpirationMember" name="CarryforwardSubjectToExpirationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashBonusIncentiveIncrementalAmounts" name="CashBonusIncentiveIncrementalAmounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAward" name="CashIncentiveBonusAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_CashIncentiveBonusAwardExceedsMaximum" name="CashIncentiveBonusAwardExceedsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_CashIncentiveBonusPlanMember" name="CashIncentiveBonusPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CashIncentiveBonusPlanTextBlock" name="CashIncentiveBonusPlanTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_CommissionPercentageOfGrossProceeds" name="CommissionPercentageOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_EquityOfferingMaximumAmount" name="EquityOfferingMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_EquityOfferingPercentageOfCommission" name="EquityOfferingPercentageOfCommission" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_IncreaseDecreaseInDevelopmentExpense" name="IncreaseDecreaseInDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_IndefiniteLifeCarryforwardsMember" name="IndefiniteLifeCarryforwardsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LeaseForOfficeSpaceInAustinTexasMember" name="LeaseForOfficeSpaceInAustinTexasMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_LeasesAndCommitmentsDisclosureTextBlock" name="LeasesAndCommitmentsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_LeasingCommissionsAndOtherMember" name="LeasingCommissionsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PaymentsForCashIncentiveBonus" name="PaymentsForCashIncentiveBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_PercentageOfOccupancy" name="PercentageOfOccupancy" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" name="PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" name="PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_PerformancePlanValuationMilestoneAmount" name="PerformancePlanValuationMilestoneAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" name="PrepaidExpensesAndOtherCurrentAssetsTextBock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" name="ProceedsFromWarrantsExercisedThatObligatedToPayCommission" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeFiveMember" name="RangeFiveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeFourMember" name="RangeFourMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeOneMember" name="RangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeThreeMember" name="RangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_RangeTwoMember" name="RangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_RedemptionPercentageOfWarrants" name="RedemptionPercentageOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsDelawareCourtMember" name="ShareholderDerivativeActionsDelawareCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsMember" name="ShareholderDerivativeActionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasCourtMember" name="ShareholderDerivativeActionsTexasCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ShareholderDerivativeActionsTexasStateCourtMember" name="ShareholderDerivativeActionsTexasStateCourtMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodSharesWarrantExercises" name="StockIssuedDuringPeriodSharesWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockIssuedDuringPeriodValueWarrantExercises" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" name="StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2018EquityIncentivePlanMember" name="The2018EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2021RegisteredDirectOfferingMember" name="The2021RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_The2022RegisteredDirectOfferingMember" name="The2022RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_ViolationsOfFederalSecuritiesLawsMember" name="ViolationsOfFederalSecuritiesLawsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="sava_VolumeWeightedAveragePrice" name="VolumeWeightedAveragePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="sava_WarrantRedemptionPrice" name="WarrantRedemptionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="sava_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" name="statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" name="statement-statement-note-2-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" name="statement-statement-note-3-prepaid-and-other-current-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" name="statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" name="statement-statement-note-4-real-property-and-other-income-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" name="statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" name="statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-6-intangible-assets-tables" name="statement-statement-note-6-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" name="statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" name="statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" name="statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="sava_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>sava-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:29PM UTC 2024-02-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:href="sava-20231231.xsd#statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:href="sava-20231231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>sava-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:29PM UTC 2024-02-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan" xlink:href="sava-20231231.xsd#statement-note-8-employee-401k-benefit-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-and-other-current-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information" xlink:href="sava-20231231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="sava-20231231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:href="sava-20231231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2021RegisteredDirectOfferingMember" xlink:label="sava_The2021RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2021RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments" xlink:href="sava-20231231.xsd#statement-note-10-leases-and-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:href="sava-20231231.xsd#statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies" xlink:href="sava-20231231.xsd#statement-note-12-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:href="sava-20231231.xsd#statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_BonusShareFractionMember" xlink:label="sava_BonusShareFractionMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_BonusShareFractionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies" xlink:href="sava-20231231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:href="sava-20231231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2021RegisteredDirectOfferingMember" xlink:label="sava_The2021RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_The2021RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual" xlink:href="sava-20231231.xsd#statement-note-10-leases-and-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20231231.xsd#statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual" xlink:href="sava-20231231.xsd#statement-note-12-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:href="sava-20231231.xsd#statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_BonusShareFractionMember" xlink:label="sava_BonusShareFractionMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_VolumeWeightedAveragePrice" xlink:label="sava_VolumeWeightedAveragePrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sava_BonusShareFractionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_VolumeWeightedAveragePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:href="sava-20231231.xsd#statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:href="sava-20231231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeThreeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFourMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sava_RangeFiveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>sava-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:29PM UTC 2024-02-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_DocumentAndEntityInformation" xlink:label="sava_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="sava_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DocumentAndEntityInformation" xlink:to="sava_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="sava_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="sava_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="sava_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid and Other Current Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:to="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property and Other Income, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="sava_statement-statement-note-4-real-property-and-other-income-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="sava_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeiture rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="sava_statement-statement-note-6-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-tables" xlink:label="sava_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-tables" xlink:to="sava_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:to="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Components of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Components of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of option (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:to="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatements" xlink:label="sava_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatements" xlink:to="sava_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="sava_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="sava_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/canceled, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2023 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at December 31, 2023 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022, weighted average contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding as of December 31, 2022, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value of stock options granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyNewClaimsFiledNumber</link:label>
    <link:label xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GranteeStatusAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Acquired-in-Place [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAcquiredInPlaceMember" xlink:to="us-gaap_LeasesAcquiredInPlaceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsNet</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDisclosures" xlink:to="us-gaap_LossContingencyDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercises (in shares)</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of stock issued attributable to warrant exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of warrants</link:label>
    <link:label xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares of stock issued attributable to exercises of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateOwnedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate Owned [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateOwnedTextBlock" xlink:to="us-gaap_RealEstateOwnedTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetRentableArea</link:label>
    <link:label xlink:label="us-gaap_NetRentableArea-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Rentable Area (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:label xlink:label="sava_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeOneMember" xlink:to="sava_RangeOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</link:label>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)</link:label>
    <link:label xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of stock options exercised net settled in satisfaction of the exercise price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2021RegisteredDirectOfferingMember" xlink:label="sava_The2021RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2021RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="sava_The2021RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the 2021 Registered Direct Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2021RegisteredDirectOfferingMember" xlink:to="sava_The2021RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_IndefiniteLifeCarryforwardsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Life Carryforwards [Member]</link:label>
    <link:label xlink:label="sava_IndefiniteLifeCarryforwardsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to indefinite life tax carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IndefiniteLifeCarryforwardsMember" xlink:to="sava_IndefiniteLifeCarryforwardsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CarryforwardSubjectToExpirationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carryforward Subject to Expiration [Member]</link:label>
    <link:label xlink:label="sava_CarryforwardSubjectToExpirationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to tax carryforwards subject to expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CarryforwardSubjectToExpirationMember" xlink:to="sava_CarryforwardSubjectToExpirationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label xlink:label="sava_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeThreeMember" xlink:to="sava_RangeThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label xlink:label="sava_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeTwoMember" xlink:to="sava_RangeTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label xlink:label="sava_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFiveMember" xlink:to="sava_RangeFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:label xlink:label="sava_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label xlink:label="sava_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to range four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RangeFourMember" xlink:to="sava_RangeFourMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases And Commitments Disclosure [Text Block]</link:label>
    <link:label xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure regarding leases and commitments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:label xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized research and development expenses</link:label>
    <link:label xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease for Office Space in Austin, Texas [Member]</link:label>
    <link:label xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Relating to the lease for office space in Austin, Texas.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:to="sava_LeaseForOfficeSpaceInAustinTexasMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation for stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock pursuant to exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expiration of restricted stock Performance Awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/canceled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in conjunction with registered direct offering, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued in conjunction with registered direct offering, net of issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RetainedEarningsAccumulatedDeficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development, net of grant reimbursement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_VolumeWeightedAveragePrice" xlink:label="sava_VolumeWeightedAveragePrice" xlink:type="locator"/>
    <link:label xlink:label="sava_VolumeWeightedAveragePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_VolumeWeightedAveragePrice</link:label>
    <link:label xlink:label="sava_VolumeWeightedAveragePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volume Weighted Average Price (in dollars per share)</link:label>
    <link:label xlink:label="sava_VolumeWeightedAveragePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average price of common stock under warrant agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_VolumeWeightedAveragePrice" xlink:to="sava_VolumeWeightedAveragePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_WarrantRedemptionPrice</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Redemption Price (in dollars per share)</link:label>
    <link:label xlink:label="sava_WarrantRedemptionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price of warrants if they are redeemed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantRedemptionPrice" xlink:to="sava_WarrantRedemptionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_RedemptionPercentageOfWarrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption Percentage of Warrants</link:label>
    <link:label xlink:label="sava_RedemptionPercentageOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Percent of the cost for redemption of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_RedemptionPercentageOfWarrants" xlink:to="sava_RedemptionPercentageOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CommissionPercentageOfGrossProceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission Percentage of Gross Proceeds</link:label>
    <link:label xlink:label="sava_CommissionPercentageOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of commission required to be paid from gross proceeds.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CommissionPercentageOfGrossProceeds" xlink:to="sava_CommissionPercentageOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_AccruedDevelopmentExpenseCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued development expense, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AccruedDevelopmentExpenseCurrent" xlink:to="sava_AccruedDevelopmentExpenseCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 120,000,000 shares authorized; 42,236,919 and 41,735,557 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset (liability)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInDevelopmentExpense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued development expense</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in development expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInDevelopmentExpense" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities</link:label>
    <link:label xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Bock]</link:label>
    <link:label xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Common Stock [Member]</link:label>
    <link:label xlink:label="sava_WarrantsToPurchaseCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants used to purchase common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_WarrantsToPurchaseCommonStockMember" xlink:to="sava_WarrantsToPurchaseCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right Issued During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants or rights exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:label xlink:label="stpr_TX-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TEXAS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_TX" xlink:to="stpr_TX-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_BonusShareFractionMember" xlink:label="sava_BonusShareFractionMember" xlink:type="locator"/>
    <link:label xlink:label="sava_BonusShareFractionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bonus Share Fraction [Member]</link:label>
    <link:label xlink:label="sava_BonusShareFractionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the bonus share fraction member.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_BonusShareFractionMember" xlink:to="sava_BonusShareFractionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfOperatingSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfOperatingSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageOfOccupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Occupancy</link:label>
    <link:label xlink:label="sava_PercentageOfOccupancy-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of occupancy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageOfOccupancy" xlink:to="sava_PercentageOfOccupancy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Warrants Exercised That Obligated to Pay Commission</link:label>
    <link:label xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Dollar amount required to be paid for commission from warrants exercised during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LandMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNonoperatingExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositContractsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract research organization and other deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsAssets" xlink:to="us-gaap_DepositContractsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 10, 11 and 12)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Text Block]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanTextBlock" xlink:to="sava_CashIncentiveBonusPlanTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violations of Federal Securities Laws [Member]</link:label>
    <link:label xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the violations of federal securities laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanValuationMilestoneAmount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Valuation Milestone Amount</link:label>
    <link:label xlink:label="sava_PerformancePlanValuationMilestoneAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of valuation milestone for performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanValuationMilestoneAmount" xlink:to="sava_PerformancePlanValuationMilestoneAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts" xlink:type="locator"/>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashBonusIncentiveIncrementalAmounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Bonus Incentive, Incremental Amounts</link:label>
    <link:label xlink:label="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of incremental amounts for cash bonus incentive.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashBonusIncentiveIncrementalAmounts" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:type="locator"/>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</link:label>
    <link:label xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum number of days valuation milestone must be achieved and maintained in performance plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Plan [Member]</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cash incentive bonus plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusPlanMember" xlink:to="sava_CashIncentiveBonusPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas Court</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsMember" xlink:to="sava_ShareholderDerivativeActionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Delaware Court [Member]</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Delaware court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholder Derivative Actions, Texas State Court Member</link:label>
    <link:label xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents shareholder derivative actions in Texas State Court.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Common Stock Offering [Member]</link:label>
    <link:label xlink:label="sava_AtthemarketCommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the At-the-Market Common Stock Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_AtthemarketCommonStockOfferingMember" xlink:to="sava_AtthemarketCommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2022 Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="sava_The2022RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2022 Registered Direct Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2022RegisteredDirectOfferingMember" xlink:to="sava_The2022RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingPercentageOfCommission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Percentage of Commission</link:label>
    <link:label xlink:label="sava_EquityOfferingPercentageOfCommission-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingPercentageOfCommission" xlink:to="sava_EquityOfferingPercentageOfCommission-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_EquityOfferingMaximumAmount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Amount</link:label>
    <link:label xlink:label="sava_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount to be issued in the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_EquityOfferingMaximumAmount" xlink:to="sava_EquityOfferingMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAwardExceedsMaximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award, Exceeds Maximum</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award if the maximum milestone is exceeded.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAwardExceedsMaximum" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:type="locator"/>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</link:label>
    <link:label xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the percentage of valuation milestone cash bonus award subject to approval and adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus" xlink:type="locator"/>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_PaymentsForCashIncentiveBonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Cash Incentive Bonus</link:label>
    <link:label xlink:label="sava_PaymentsForCashIncentiveBonus-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of payments for cash incentive bonus.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_PaymentsForCashIncentiveBonus" xlink:to="sava_PaymentsForCashIncentiveBonus-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward" xlink:type="locator"/>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">sava_CashIncentiveBonusAward</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Incentive Bonus Award</link:label>
    <link:label xlink:label="sava_CashIncentiveBonusAward-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash incentive bonus award.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_CashIncentiveBonusAward" xlink:to="sava_CashIncentiveBonusAward-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing Commissions and Other [Member]</link:label>
    <link:label xlink:label="sava_LeasingCommissionsAndOtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents leasing commissions and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_LeasingCommissionsAndOtherMember" xlink:to="sava_LeasingCommissionsAndOtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="sava_The2018EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2018 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sava_The2018EquityIncentivePlanMember" xlink:to="sava_The2018EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of 2018 warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from common stock offering, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAmount</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:label xlink:label="srt_OfficeBuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive securities excluded from net loss per share, diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 162(m) limitation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average contractual life (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, exercise price, upper limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options, exercise price, lower limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>sava-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:29PM UTC 2024-02-28--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan" xlink:href="sava-20231231.xsd#statement-note-8-employee-401k-benefit-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-and-other-current-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:label="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_PrepaidExpensesAndOtherCurrentAssetsTextBock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information" xlink:href="sava-20231231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="sava-20231231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:href="sava-20231231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstateOwnedTextBlock" xlink:label="us-gaap_RealEstateOwnedTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RealEstateOwnedTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2021RegisteredDirectOfferingMember" xlink:label="sava_The2021RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2021RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments" xlink:href="sava-20231231.xsd#statement-note-10-leases-and-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:label="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_LeasesAndCommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:href="sava-20231231.xsd#statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanTextBlock" xlink:label="sava_CashIncentiveBonusPlanTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="sava_CashIncentiveBonusPlanTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies" xlink:href="sava-20231231.xsd#statement-note-12-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDisclosures" xlink:label="us-gaap_LossContingencyDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LossContingencyDisclosures" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:href="sava-20231231.xsd#statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_BonusShareFractionMember" xlink:label="sava_BonusShareFractionMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NotesToFinancialStatementsAbstract" xlink:label="sava_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_BonusShareFractionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies" xlink:href="sava-20231231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-significant-accounting-policies-policies" xlink:label="sava_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:label="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-and-other-current-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:label="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-and-other-income-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-5-property-and-equipment-tables" xlink:label="sava_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-tables" xlink:label="sava_statement-statement-note-6-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-tables" xlink:label="sava_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:href="sava-20231231.xsd#statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:href="sava-20231231.xsd#statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageOfOccupancy" xlink:label="sava_PercentageOfOccupancy-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX" xlink:label="stpr_TX" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_OfficeBuildingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="stpr_TX" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetRentableArea-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageOfOccupancy-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AtthemarketCommonStockOfferingMember" xlink:label="sava_AtthemarketCommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingMaximumAmount" xlink:label="sava_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_EquityOfferingPercentageOfCommission" xlink:label="sava_EquityOfferingPercentageOfCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice" xlink:label="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2018EquityIncentivePlanMember" xlink:label="sava_The2018EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2021RegisteredDirectOfferingMember" xlink:label="sava_The2021RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_The2022RegisteredDirectOfferingMember" xlink:label="sava_The2022RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2022RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_The2021RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="sava_AtthemarketCommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_The2018EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_EquityOfferingPercentageOfCommission-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CarryforwardSubjectToExpirationMember" xlink:label="sava_CarryforwardSubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IndefiniteLifeCarryforwardsMember" xlink:label="sava_IndefiniteLifeCarryforwardsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_CarryforwardSubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="sava_IndefiniteLifeCarryforwardsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual" xlink:href="sava-20231231.xsd#statement-note-10-leases-and-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:label="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="sava_LeaseForOfficeSpaceInAustinTexasMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:href="sava-20231231.xsd#statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashBonusIncentiveIncrementalAmounts" xlink:label="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAward" xlink:label="sava_CashIncentiveBonusAward-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusAwardExceedsMaximum" xlink:label="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CashIncentiveBonusPlanMember" xlink:label="sava_CashIncentiveBonusPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PaymentsForCashIncentiveBonus" xlink:label="sava_PaymentsForCashIncentiveBonus-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment" xlink:label="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained" xlink:label="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_PerformancePlanValuationMilestoneAmount" xlink:label="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="sava_CashIncentiveBonusPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashBonusIncentiveIncrementalAmounts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanValuationMilestoneAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAwardExceedsMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CashIncentiveBonusAward-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_PaymentsForCashIncentiveBonus-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual" xlink:href="sava-20231231.xsd#statement-note-12-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:label="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsMember" xlink:label="sava_ShareholderDerivativeActionsMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:label="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ViolationsOfFederalSecuritiesLawsMember" xlink:label="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ViolationsOfFederalSecuritiesLawsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasCourtMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsTexasStateCourtMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsDelawareCourtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="sava_ShareholderDerivativeActionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:href="sava-20231231.xsd#statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_BonusShareFractionMember" xlink:label="sava_BonusShareFractionMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_CommissionPercentageOfGrossProceeds" xlink:label="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_NoteToFinancialStatementDetailsTextual" xlink:label="sava_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission" xlink:label="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RedemptionPercentageOfWarrants" xlink:label="sava_RedemptionPercentageOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_VolumeWeightedAveragePrice" xlink:label="sava_VolumeWeightedAveragePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantRedemptionPrice" xlink:label="sava_WarrantRedemptionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_WarrantsToPurchaseCommonStockMember" xlink:label="sava_WarrantsToPurchaseCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_WarrantsToPurchaseCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="sava_BonusShareFractionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_VolumeWeightedAveragePrice-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_RedemptionPercentageOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_WarrantRedemptionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_CommissionPercentageOfGrossProceeds-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInDevelopmentExpense" xlink:label="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet" xlink:label="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sava_IncreaseDecreaseInDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:href="sava-20231231.xsd#statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:label="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsAssets" xlink:label="us-gaap_DepositContractsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepositContractsAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:href="sava-20231231.xsd#statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:label="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingImprovementsMember" xlink:label="us-gaap_BuildingImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember" xlink:label="us-gaap_LandMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:href="sava-20231231.xsd#statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_LeasingCommissionsAndOtherMember" xlink:label="sava_LeasingCommissionsAndOtherMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:label="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAcquiredInPlaceMember" xlink:label="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LeasesAcquiredInPlaceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="sava_LeasingCommissionsAndOtherMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="sava-20231231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:label="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:href="sava-20231231.xsd#statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:label="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:href="sava-20231231.xsd#statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:label="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="sava-20231231.xsd#statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:label="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:href="sava-20231231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_AccruedDevelopmentExpenseCurrent" xlink:label="sava_AccruedDevelopmentExpenseCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sava_AccruedDevelopmentExpenseCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:href="sava-20231231.xsd#statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFiveMember" xlink:label="sava_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeFourMember" xlink:label="sava_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeOneMember" xlink:label="sava_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeThreeMember" xlink:label="sava_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_RangeTwoMember" xlink:label="sava_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="sava-20231231.xsd#sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:label="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeThreeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeFourMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="sava_RangeFiveMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>alz.jpg
<TEXT>
begin 644 alz.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P =M5^ /Q,^ FK>!=?TW2?#OCJ\\.:G\5/%7Q%\4K8:QX1BTO[)+:+X$O\
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MO%,-_97FF7NL7,%L]E=07,LD43@U]C MDCWQQC _3_ZXZD'I0!)17YV>+O\
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MPG\#_C;\-?C1KGQ ^&NH? [Q1<?%+Q#XJ\,Z590^#[;P[X2N?"\WQ*,,FOW
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M)'B<?#?X<>-?B3:^ _AYJ[*NE^-_B#>>#]%U2V\&^&]01O/M-1UN6U26W4W
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M4U\4_M;ZUY7B?59(V^$VL7$4MG#9R'PQ$;GQ?M0F?1I([>Q1C\NL,.G[P44
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M)&F^,M9UK_A+?B9JOPQU&]N?@]\/!>V'DR:S;:7H^G)+97*VUA=S7HFO8_[
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M@KQ7/X[U'37U*77-?N)XM+FO7GETR_=6CK^AA((HRS1QHA=MSE$53(W'S.0
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MUO4R_CGQ3X9^-VL_&#23X.MSX;CAUFT,.J6OAJ0:@VC*+;2XW,313M&OTO\
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M$;+I"67]JF^V+]HFLE*A?W/HH _"KXW?\$S/C9\7;[]ON>V\1> M"/Q^U/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_;K^(GC2;X"^)?B)\#M \"?"[]HNW\?V_@;Q)H?Q.E\8>)[#6/A_P"']?\
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M2W?BO1(+JXT;0_#9\1VVBZQI=U+J%_J>G:A'#;U[#\'?V4_"?P0U'2/^$/\
MB-\:[OP7X7L]0T[P1\*/$?Q#GU?X:>"=,OHY+>'2]#T8:;;:I>:;HME*^G^'
M+'Q/KGB&V\/V7EQ:5';-! \74>./V>O"7CCXL^!_C--XA\<>'/%_@KP_J?@Z
M:'POKMK8:#XU\#ZQK&FZ_J/@OQUI-[I6I1ZSX?N-7TFRO&CLY=+U#*2PC4/L
M]Q<0R@'R]\/?VU/B)XDF_9^\;>,/@?I/A+X%?M2>+;?PA\)?%]A\1Y->\?:?
M=>(M#UWQ+\.=1^('@9O".FZ5I-AXZT7P[=7,2Z'XMU^XT)KNPAU*,DSF'PW_
M (* ?%+XT?#3]IOX!^*?AKXU\8V/A;X4?"+XF_'7XD?#31M:U&V\.?$KP/X%
M\:?#_3_'^G^(-!MW^PZS?:;\/]=\1ZMX?FO+>YET_4]/AEL$2Y=%E^P?AU^P
MW\(_AMXC\$:OIWB/XJ^(?#?PKU35]:^$/PP\8>.)-<^&GPIU75X=0LVOO!V@
M?V=:WS3Z5INK:II?AP^)=8\1)X<L-0N(M%2S;RY(_8_%/P%\ ^,_BKX=^+_B
M"+5+WQ'X;^'7C?X6VVF&\A'AJ_\ "?Q!N=(N?$<&JZ6;1IKJZE.C6T-M,E[#
M'#;RW2/!,TJN@!^</Q9^-GCGXD_M?_ '6_A?\1O$VE_ KX??'?X7_!?6K'PO
MKU_8^%_BUXW^*GPG^(OQ4\50>(K>QN([#Q%H_@CPCI?PXCT^UODN8;77/$>J
ME0)X0T/L&E?MS>.[VR\%_%JY^">D6G[,'C[XV0?!3P_X]'Q&EG^)<<VH>/;_
M .&&B_$#5?AN/!\>E6_A#5?&EB\ M+?QI<^([31[FUU:72GWR6L7M'PW_8@^
M!WPH^'/P;^%W@R#Q39>&O@?\69/C3X3DN==2\U?4O&LFG^+M*\WQ1J,U@6U?
M3HM-\97]A#9QQV3Q6FG:+ EP([!EGS="_83^#OA_Q1I.K6VO_%.[\$>'/B3>
M?%_PO\$=0\<2W/P9\-?$F[UB^\2?\)-I/A4:='J8-GXGU/4/$NF:'?\ B"^\
M,Z;KUTVHV6BPS16YA /*?#O[;?Q/U#Q/X>OM<^!GAW2/@]XF_:E\>_LGZ;XT
MM?BA-J?C%O&GAGQEXV\%:#XKG\$+X,MK.#PCK>L>#C97X/B@ZYI5Q=O<Q:7>
MZ?%'=7'R?XD^,G[4?C7]B[]HSQ)\2K#POJ%_X5_:O\,>&?!-SX1\?7L6O7=[
MX<_;-^'FB#X?EY?!?A33=,\+:=9QQ^']'\37.I7M_J^ES/<:[86I:97_ $\B
M_9/^%\/A_P .>&EN?%AT[PM^T5K'[3^F,VLVQNF^)6M^-?$_CV\ANI_[- F\
M,KKGBS4UM])6.*XCL4L[=M1=H'FEYI_V*_A>^F?%;PZ?%'Q/'@WXN?$G0OBU
MJ_@C_A*;%O"_AKQOHWQ'T/XJW6I>#+1]!:\T>'Q'XO\ #]C<Z_9W5_J=O+:2
M7=KI::4MP74 U_@/\=/''Q!\>_&3X3?%/X?:%\/OB+\(G\#ZC>0>$O&=WXZ\
M+:[X9^(NCWNJ^'M2L-;OO#/A*_MM2M)M*U/3=9TVYT:-(;BVCN+&ZO+6X65?
MSZ_X7CXSNOBS\3_C5\5M#_:-D^$/PY_:[N_@+HGB?X<?&NP\)?"WP-IN@^.O
M#WPL\/'7?@UH?B&QUSX@V7B#QKJ,,OCK6_$^F:FT*Z^EII-F-'TDR5^KGA[X
M1>%/#/Q2^)/Q>TZ35F\6?%/2? VC>)DNKV*;2([/X?6NK6F@_P!E6*VL<EI*
M\>M7AU"26YN?M+^28U@$95O"]5_8?^$&L?$#6/&EWK7Q+3P_XD^)6D_&3Q-\
M';?QD\/P<\1_%31I-+NK+QQJ_A,:>;V?4FU70]&UV\T^/7(?#U_KVFVNK7NB
MSWBO(X!]BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Q/B?P:_B75?#NIKXN\:^'1X?O!=MIWAC68=-TK70)[>
M?[)XBM9-/O&U"T(M_)\J.:U8P3W,8D!D5E^?OA=X*^,.C?M)_'/XC^*_!?A'
M2O _Q0T;X:Z3H]_I7Q!NM<UZR;X8VOB^Q@GU#09?!6D6R)XAC\3Q7");:W.V
ME_99HIC=%XW/UO10 ULY7 /)YQZ?U_F!DCI7Y5_\$CO&OQ"_:1_X)X?LZ?&K
MXT?$CQUXX^)OCBS^)=SXH\4W6OS:5/JTND?&7XB>'M,9]/T&/2](M5L]%TG3
M=.ABL=/MHA!9Q$HTA>1_U5/4?7^AK\B/^"#?_*)S]D?_ +!?Q;_]7[\5: /U
M!_X02P_Z#OC/_P *_7?_ ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/
M^@[XS_\ "OUW_P"3*/\ A!+#_H.^,_\ PK]=_P#DRNWHH XC_A!+#_H.^,__
M  K]=_\ DRC_ (02P_Z#OC/_ ,*_7?\ Y,KMZ* .(_X02P_Z#OC/_P *_7?_
M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M ),H_P"$$L/^@[XS_P#"OUW_ .3*[>B@#B/^$$L/^@[XS_\ "OUW_P"3*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@%+X6_&WQ!XO\;>._AEX_P#A];_#[X@>!_"?@?QY)INE>,H/'.AZIX3\?_\
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M$1?_ !='VZR_Y_+7_P "(O\ XNN<_P"$!\$?]"CX<_\ !/8?_&*/^$!\$?\
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MMUE_S^6O_@1%_P#%USG_  @/@C_H4?#G_@GL/_C%'_" ^"/^A1\.?^">P_\
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M=<W_ ,(%X'_Z%+PW_P"">P_^,4O_  @7@?I_PB7AS/I_8]A_\8H Z/[=9?\
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ME;1>!?C#\2+SQ5X1@U1[K3-+:T\01Z7/&NLZ=!%=VME>%H;?4;U!YS']=?\
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M>O\ 45]+@N&N'LM26 R/*,)R[2H9?A:<^FO.J7M+Z+[=^MSU,/EF783_ ';
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MD?O+?&XC*74?^"W?[1*'[+I_A']FWP_>,0'E@T#PUJL5G<*=A8W;^,O%L<L
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M4^_X-R=$"BQ_:1_8[(3I]NTG5M6/&#R=5\-7I;G^]G/U))]&TO\ X++_ /!
MS0P/[%_:U_9 TC:<K_9GAD6(!]1]F\%1<X)YS2> \4*R2GG_  I@TWK]5R7'
MXE]$]<7BVEY7;5]UT%[#BN=N;,<FH?\ 7G XBHUMJG5Q&MK76B/4[C_@KM\/
M+H[?#/P1^)VN,3M7?<:#;JS'H!_9LNM/@Y&?W>\'HIK+/_!3OXJ:RYC\)?L?
M>.;QF8"-KG4/$-V7!Z'R;'P-"O/^S='/054M_P#@O!_P1/LL?9/V[_V<+7'W
M?LR:Q"%],"'PNF".Q_2M-?\ @OY_P1J7 7_@H/\  55Y&!J'B4 #Z?\ ".84
M_EZ#BG_JWQY6M[?Q!5#NL#PSET+;:1G5KSEMU<7LA_V;G\]*O$?*NU#+,-#:
MW\\YZ=->9V1 /VUOV]=:.SP[^QA?VL<JYBFU'P_X[=0'/RMY]W_9=J01CJ0.
MYPIX0?&3_@J]X@;.E? ?PEX?AEX5KW3]"A:$'H3_ &OX[CFXP3AK4XR,J1C-
MD_\ !?O_ ((TG'_&P?X"<'.?MWB,G/\ X3G^>]'_  _[_P""-0Q_QL(^ O\
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M5_TD'^ O_@P\2?\ S.T?\/\ [_@C5_TD'^ O_@P\2?\ S.T ?L)17X]_\/\
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M-C'XJEM4MM:^)OB7R]?^(6O8W&0W7B"[C#Z=:R,S$:5H<6FZ9&NU1:N=SO\
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MVU@L+BTU'0[B]\(/_!?S_@C43G_AX1\!?_!AXD],?]"[Z=:/^'_?_!&G)/\
MP\(^ W.>E_XC'_NNXR#WQW8'()KL6FG;N?.'L/[(:0_$#XW_ !:_:$UCX<_$
M3X.ZYXJ\ ^#/A-X ^$_BSX+?$SX90^#_ (*_"W7_ !'+X>O?%.N^)?!/AKP5
MK'C_ ,7ZSXFO]:A\)>%=5UJ+P%X-&B:%;7%W=0^)+L_2_P"TA^RA\!OVM/ M
MQ\/OCU\.=%\;Z,4E_LN^N8VM/$7AJ[E3 U+PSXCLWAUC1+^)@K,UC=)#=>6L
M=[#<VS-"?@;_ (?]?\$:<D_\/"/@+R,<7_B/OU.?^$=S].PP/?,G_#_[_@C5
M_P!)!_@+_P"##Q)_\SM88G#8;&T*N%QF'HXK#5X.E7P^(I4ZM"M3DK.G5I3B
MX5(OM)/74]7(\\SKAG-L!G_#N:YCD6=Y7B88O+<WRC&8C+LRP&)I24H5\)C<
M)4I8C#U(R5U.E4C+5ZV/RV\:?L/_ /!1#_@D7XGU;XN?L'^-]<^/_P"S@U[)
MJ_BWX+:S:R:SJ]EI<;++=G7?!ELT::N8X0ZCQE\/ET[Q+ I#WVCRVR3O-^J?
M[!O_  6)_9K_ &S3I_@G6[Q/@A\>PQLK[X5>-]0B@AUG4[=?+NU\#>([B.SM
M-=VSK+_Q);J.Q\26X1UFTMPC352?_@OW_P $:F(_XV$_ 88Z8O\ Q'U['_D7
M.W;/3MUK\@?V\?C5_P &[/[9']H^.O#7_!0#X _ WX_'_2['XF^"CKUK8:[J
M<.Z2V;QWX;M/#UG;:RQF(W:[93:=XDMSLD&HW*0BUD_.)\+Y[PG*>)X(Q"Q>
M6*3J5N#<VKREA'=IRED685)2J9965WRX>OSX)S;?[J_,?VA0\=?"?Z0F'HY'
M]*;)9</\<NE3PF6?21\/LHP]+B+VD4H4/^(J<'8.&'P'&^!A:"Q&=9;#!<34
MJ$(P@\8W.3_L#WKZ_P">GYYX^O% 8$9S_7K]/\GM7\-W[%'_  7U\3?LU>.9
M/@-\4OC7\/\ ]NOX*^&YK.ULOB?\+?%MQK_CK1="D+I;W^D:KXDLM U;Q99P
MPC-SH7B^SM==L?*$$&LB)H1/_0[=?\%W/^"2^C66D77BW]M7X7^";O6-/M=3
MBT7Q?;^*]%UJS2YB$@M+^RD\.R);WEN2T5W LTGDRHR%CMR?HN'^,<JS^I4P
M-J^5YYADUC<AS2E]5S+#2C;FE&E)\F*P[^*GB<+4JTI0<92<'+E7X_XP_1KX
M_P#"+!X'BERRSCSPMSV7/PQXL\!XEYYP1G-&32IT,3C:4?;Y#G$6_9XG)<\H
MX+'4<1&I2IT\1"G[>?Z[45^/0_X+^_\ !&H?\Y!_@)]!J'B3KGKG_A':7_A_
M]_P1J_Z2#_ 7_P &'B3_ .9VOK#^>C]A**_'O_A_]_P1J_Z2#_ 7_P &'B3_
M .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'O_A_]_P1J_Z2#_ 7_P &
M'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'O_A_]_P1J_Z2#_ 7
M_P &'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'O_A_]_P1J_Z2
M#_ 7_P &'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'O_A_]_P1
MJ_Z2#_ 7_P &'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'O_A_
M]_P1J_Z2#_ 7_P &'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A**_'
MO_A_]_P1J_Z2#_ 7_P &'B3_ .9VC_A_]_P1J_Z2#_ 7_P &'B3_ .9V@#]A
M**\4_9\_:-^!W[5GPMT#XV?L[?$SPQ\6_A7XHFUBWT'QKX2NI;K2-1G\/ZYJ
M7AO6(4^TP6MW#+8:WI&I:?,ES;0LTMJ[Q!X621O:Z "BBB@ HHHH **** "B
MBB@ HHHH **** "ORJ_;5_X)P_%W]K3XK:9\2? __!2_]NK]D+1]/\'Z7X6D
M^&'[-OCS1/"_@._OK#4=6O9O%=Y8WVCWMU-XAU*+4H;&^N&N6B:TTO3Q%''L
MD,GZJTA_K0!_+/\ LF?\$:_V@O&OP#^'OBK3O^"U_P#P5,\&65__ ,)(+?PO
MX9^*_ANUT'3$TWQGXATQDL;6?0KK8EV]DU[.LC2H]S=3MMV,$']0FC6,^EZ7
MIFF3W][JTNFZ=96$NJ:BZR7^IRV=K#;R:C>R(JK)>7KQM<W+!0K32NR@<J/E
M7]@S_DU3X9KV2^^)$2#LL<7Q6\<1QJ/9(T51[ 5]?T ?G=^V_P#&/XI_"CQY
M^SK9^#_CK\-/V=O GC5_BWIGCWXC?&#P=;^+? ,6L:3H7A?6/ NBW'GZ_P"#
MO[/U_5&A\3_V,'\9:);7D%OJHD@U>ZM[&R'Q;\%O^"@?Q1^-'QB^%.HV?QC^
M'J:2?&GP;^$7B;X%^$],\.W]E\1Y/B&GQ0M_&7Q8TG4-22?XCZ+'X>D\(:!X
MFT73;:^CTO1_#]U=V'BFWN[R[@O4^Z?VU/%WC>?Q;^SM\!O"OC[PA\(M+^/'
MB;QU9^(_BAXP\'>&_'"::/ ?ABVU_1_!WAG1/&A_X1!O%_C6]O)?[*GU>*[G
MAM-!U1]*LI[X(8^:_9#@^T_&+X]?#GQY??"CXT^,/V>=8\%3>%?VA/#_ ,,?
M _A+QC.GQ?\ #>L:MXE\)>(I?"=JVE6'C/0I-%0^(+S09].EUG1_$.BS:Y8I
M>R2&8 _1&\LX-1M;FPO85N+2]MI[.[@DW%)K6ZB:"XA8KL;;)%(R/@JV&)!R
M-U?+WP>_98TKX4>)/!NMS^._%?C>S^%/@'5_A7\&]%\06>@6EM\/? &MZCH]
MY>:6U[I&G6E_XHU1-/\ #'A/P[;:YK4IN(=%T")1"U]J&JWU[]7 8_\ U8_E
M2T ?+7[7_P"SC=?M2_"'_A5UGX\NOAS<#Q7X<\4)X@M]"MO$D4Q\/SSS#2;_
M $FYO],\_3]0,^VY:WU"SNXO+22UN(Y0&'\\/[&O_!-8?\%$_P!C+X7?M(>*
M?CYXT^#VJ_$W2/&=SH?A?X9Z3!%I7AO5_#7Q&\4^!Q<Z[J&I:G/J'BZRO+3P
ML;G[ KZ"MF^H,L,IF@6ZE_K"/5?J?Y&OR&_X(/+N_P""3O[(Y[?V7\7,@]_^
M+_?%7&0/SZ]0/2OD,[X#X2XDQW]I9WDU',,;'#T\+&M4K8J%J%.564(<E*O"
MFW!UZKC)TW).2:E>,;?1\-<59OPCGF3<29#'*,/GF05,34RK,\7P[P_FV)PK
MQCH_6%?-\LQT*\7&BHTX8F-:%",Z\:$::Q.(]I_/M\2?^"/?[:W[(7B35O&E
MC\ _@!_P4/\ AQ)-)<ZEIOC7P);^/O$-S8PJ6,LWA'Q%>Q>-=*F\E-C6W@SQ
M!KML)#D6=PRB8=1\!OCC_P $(O$6N?\ "#?M?_\ !)C]GS]F;XBVTL=EK&HZ
ME\ =!\4>%$U#>8I9+^&7PS:>-O#L+2*[D:CH6H0VX^5]2G57G']JYC]#@<G@
MG)SZ_CTQTXKYM^/W['W[-?[4&D/H_P =?@YX'^(*B*2.SU?5-&A@\3Z69.LF
MD^*;#[+X@TV0'YO]$U&-'8 RI( %'@T^",ZX=7-P3Q'4PN'BVXY!Q!2_M;*>
M56M1HXI*&:8*&BM[/$5H1UO"=U;^L:?TC/!SQ/C'"_2,\ LAQ.;U:=.C4\5?
M WZEX9<=4Y)*#QN:\-4</5X"XIQ"24FL1E63SERJ,*])7O\  OPK_P""7O\
MP0X^.'AN#Q?\(/V*_P!@SXD^&KA$=-7\'?"[X<:[:H9!N6.X^Q64LEE-C.;>
MZCAF'*L@92*]/'_!%7_@D?W_ ."<O['W(Z#X(>!R?UTOOD8QGZ]*_-OXI_\
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M$5/^"1X_YQR_L?\ _ACO _X_\PKKCI49_P""*O\ P20!Q_P[F_8^Y X/P/\
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M>$IY]P'Q?@91C&K@N(^&,<Y8#&0J03IQQ=*&&S+#*3^JXR@TF?Q2_L?^)/\
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M.IX?>,.48?C_ (:6'CI[+ 2S=RSK(G"',J%3(<VRV6'E)U*7+/WC^:7X2?\
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ME0XZX:I5ZC2C#"U\\P6$IM)TVJ?M#^C $>HSZ<>^.Y]*,@]"*_E-_P"&D/\
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MIWEA,E52+?+*I[?%TW[\5![?T3]2^BW]')N69U\!]*WQ>PON_P!F9?6QN6>
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MZ=17T?Z]]?Z]#\8ZWZ_/YZ?+KKYV"BBB@84444 %%%% !1110 4444 %%%%
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ME?#.UU'P=X<T#PMX/FM+KQ<FE:YXUOM5MK*XU"WL*][^%WP=_;>_: _:K_9
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M '&.&PO&? 688>2M4P^)X5XCHYAE=*G67NU9X&EA,0TE:LGJOY7=(_X*U_\
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M;P7'XB\7QA@B7\1+5]K_ +'G_!"3]G_X-:K;_%']IG6+G]J?XWW5W'K5_?\
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MJTY_VB_V)OV1_&^C^+O$7PJ^)5I\'/"WPZ\"? 3Q7HGAGQ!X9U*[L;S4]/\
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M$CXI_P#E/1_PL'P[_P \_$/_ (2/BG_Y3UV]% '$?\+!\._\\_$/_A(^*?\
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M'P[_ ,\_$/\ X2/BG_Y3UV]% '$?\+!\._\ //Q#_P"$CXI_^4]'_"P?#O\
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M_$/_ (2/BG_Y3T?\+!\._P#//Q#_ .$CXI_^4]=O10!Q'_"P?#O_ #S\0_\
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M;4=8U+7)K'1-':ZOCHOAO1Y=3?1O#&C"\N1I/A^PTW3Q-(+?=7N]% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !2'M]?\X_STS2TA[?48_K^F: /D?\
M8UX\"_%J/DB+]JO]JB,$]2!\<?&;9..,Y8]*^N:^1OV.?^10^-*CHG[6_P"U
M4JC^Z/\ A=GBUL8[<L3CWKZYH **** "BBB@!#U'U_H:_(C_ ((-_P#*)S]D
M?_L%_%O_ -7[\5:_7<]1]?Z&OR(_X(-_\HG/V1_^P7\6_P#U?OQ5H _7BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T
M=Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"
M_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG
M9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)P
MO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )
MV7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17
M#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0
MI^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\
MX_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I
M^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X
M_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\
M"<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./
M_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_
MPG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_
M  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W
M%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_
M -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E
M_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_
M]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9
M?_C] '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</
M_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GXX_\ "=E_^/T =Q17#_\ "<+_ -"G
MXX_\)V7_ ./T?\)PO_0I^./_  G9?_C] '<45P__  G"_P#0I^./_"=E_P#C
M]'_"<+_T*?CC_P )V7_X_0!W%%</_P )PO\ T*?CC_PG9?\ X_1_PG"_]"GX
MX_\ "=E_^/T =Q17#_\ "<+_ -"GXX_\)V7_ ./T?\)PO_0I^./_  G9?_C]
M '<45P__  G"_P#0I^./_"=E_P#C]'_"<+_T*?CC_P )V7_X_0!W%%</_P )
MPO\ T*?CC_PG9?\ X_1_PG"_]"EXX_\ "<E_^/T =Q16?IFH?VG9QW@L[^P\
MPR#[+J5L;2]C\N1X\S6Y9RF_9YD?S'?$R/QNP-"@ HHHH **** "BBB@ HHH
MH **** "BBB@ K"\3^'-"\8^'->\(^*=(L]?\,>*=&U7PYXCT+4H%N=.UG0M
M;L+C3-7TK4+9\I<6.HZ?=7%I=PN-LL$SH>H!W:* /PH_X(K_ /!%KP#_ ,$D
MT_:NO],U6P\7^*/CG\;-?NO!?B-5EGU/PU^SCX>O[B3X1^ =2NKBVMY#X@ME
MU'5-4\87%L6LM0U-]-*;UT^';^Z]%% !1110 F >HKR#P/\  7X5?#?Q;XD\
M=>#?#,^D^+/%X4>*-9D\2^*]6FUTQB%+>34H=:US4;2YGLH+>&TT^X>W,^G6
M"#3[&2WLBT!]@HH 0]1]?Z&OR(_X(-_\HG/V1_\ L%_%O_U?OQ5K]=SU'U_H
M:_(C_@@W_P HG/V1_P#L%_%O_P!7[\5: /UXHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\76>J7_AG3M1\,>.O"_C.'^V[31F75)+*['AUK*4V!^T1_:5E0'80?F?Q/\
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M<_X)\_$WX.?LU?L$>$8?%FC>.O$W[ MM\<_&&N:;X7T.Y>_^+%[XN^!/QP\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]#7Y$?\ !!O_ )1.?LC_ /8+^+?_ *OWXJT ?KQ1110 4444 %%%% !1110
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MJD2PZ;XDL[6Z2\MHG6^@N5C$D BFD_0TX/7''3/8]?S[T CH,<8X';/3\^U
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MH XG^V/'/_0E:;_X5\?_ ,HJ/[8\<_\ 0E:;_P"%?'_\HJ[:B@#B?[8\<_\
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MS_T)6F_^%?'_ /**C^V/'/\ T)6F_P#A7Q__ "BKMJ* .)_MCQS_ -"5IO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cab1ac4300e0img001.jpg
<TEXT>
begin 644 cab1ac4300e0img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 FX# 2(  A$! Q$!_\0
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MT(.10%QU%)D>M&1ZT +13!+&S,JNI9>H!Z4[(]: %HHI,CUH 6BDR/6C(]:
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MM_$&CO')+>OY$TT)215.<,A/O6S\-)=<\/:C>>$-9LKAK>V8FROEA_=NOH6
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MJS.BI<5SG_"52_\ 0"U+_OV*/^$JE_Z 6I?]^Q3Y&.QT16C'O7._\)5+_P!
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MC%8'_"3R?] 74/\ O@4?\)/)_P! 74/^^!2YT5]6J]CH,8H-<_\ \)/)_P!
M74/^^!1_PD\O_0%U#_O@4<\0^K5>QOX]Z,<U@?\ "3R_] 74/^^!4UKK\ES<
M+$=*O8L_QNHP*7M(H3P]1:M&SSZT8]ZK_:SC_42?E2_:C_SPD_*I^L4^YFX,
ML 4M5OM1_P">$GY4?:V_YX2?E1]8I]PY66:*K?:V_P">$GY4?:S_ ,\)/RH]
MO3[ARLLTAI$;<H.",]C2FM4[ZHD,4E.HH ;12XHQ3 2C-+BC% "9-*.E+BB@
M!**6B@!**6B@!*.M+10 VC\#3J* &_@:/P-.HH 3 HI:* "BBB@ HHHH *3%
M*:\];Q]=V&L:Q;7%G)>[-6CT^R@@"JQ+1;^2>.N>: /03Q29->777Q&U"?4]
M#O-/TRZE@EBO%NM.#('$D) ;+'C YZ=:A\0_$"[DLKF^T>XN55K*RNHH#$G
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M[Z"Q&I:>(0"JPOD*K8[J<9^M;GP^US5;O5=6TW5;Z>?[/'!-#]KA$<I#K\S
M#@Q[NAZT >@44T,&) ()'45YMI?CZ]M-=U*TU2SN9K$ZTUA#?+M"0D@;$(ZG
MGO[T >E49KS.T^)DMII%ONTV_P!5N6MYKN1U$<96*.0JQ(SCCMCK3?%?Q&N&
MTZY30+*Y/DBU::_^79#YS*0I4\G(.#CIF@#T_-&:\]'CV:RNKBU2RO=5NIM3
MN;2VA01Q[?*0,1G/W<'J>:9=_%FRAL;"YMM*N;AKNV6X,7F*C*#)Y84 _>;=
MG@=N:- /1<T9KD/%GBG5-!O?#L%CI0NCJ=V()5,@!4;2< YZ\$YZ<5#9?$2"
M\U>VMQI=TFGW5V]E;Z@679).N<KMZ@9! /M1H!VM'-<7XC^(<7A_4+ZW&E7=
MY%IT"37T\++B$/G8,'ELX[=*SO$&M>)X=4T%M-U2"+^V9HA'ILMH&:*/;ND9
MGSG@>W>@#T7FCFN(TSXCPZCKEM8'2;N"WN;F>UAO'9=CRQ9W#'7& 3FL#1?B
M=>3:KK$EX]M-I[6EQ>:9'#CS-D+%2K]\D#//:@#U7)I>:\KO];\86?PYG\4W
M.KVK&YMXIH;>WM0/(+NN K9^;Y3CFI-=^(U\NC-Y$$NCWMMJ<%G=_:(A.R1R
M+N#A5^\<=J /4.:.:Y3X?Z]J'B'PV;Z_:.0?:)(X+A$\OSXE. Y3^$^HKJ\4
M '-'-&*,4 '-'-&*,4 %'XT8HQ0 4F:=10 W-&:=10 VEHQ2XH 2BEHHT 2B
MEHHT 2DIU% #:6EHQ0 E%&*7% "44M%*P""@TM(:8"T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5SA\%:2VIMJ+
M"?SVU!-1/[SCS538./3':NDHH Y:V\!Z-9W$4L0N-\?VK&9/^>YS)_\ 6]*J
MO\-/#\EBUH?M?E-:PVIQ,00D3;E(/KD]:[.B@#E+'X?Z18O;S"6\GN(;W[<9
MYYB[R2;=HW'N . *;9_#[1;(6T2M=R0VL\T\$,LVY$\U2KH!_=Y/'O76TF!Z
M4 <5!\,-"AL[BU>:_GCEM?L<?G7!8V\.X-LC]!D#\JZ"PT&ST[5K[4X/,-Q>
M)%'+N;(Q&NU<#Z5K44 <C9_#[1K+5Q?QO=LL<LD\-J\Q,,$L@(9T7L3D_3-7
M5\(::/!O_"+JUP-.,1B)$F'*DY(W5T-% '#>(?AQI5[IUU_8]M#8WSV,EFAC
M&R-U?'WP/O8QQ6?J/P[NK;PU=P:1>2W&J7<$<%Q->7+%FC13B)&'W1NQ7I-%
M '">&M%U6V\5RW]_I[6P%C';B2*X#K.X W,PSG.1@>PJY_PKS1O[=.JF2\9F
MNS>M;-.?):;& ^WU':NOHH Y*V^'VB6L)BC^T[?L<UGS*<^7(VYOQR>#5:Z^
M&.A73J3-?1QF*&.2&.X*I+Y6/+9QW(Q7;48'I0!S</@O2H-4BU!//\Z.[GO!
MF3CS)4V/QZ8Z"N-U3X8:A%JEI)X>O8[>"UM5@MI))6\RW/F%RV,$/G)&.*]5
MP/2EP/2@#$UKPW:Z];6*WLTZSV4RW$-Q;OL=9 ,9'UR>/>LZR\ :-8ZW'J4;
MW;"*9[F&T>8F"*5OO.J]CR?S-=910!R>O_#_ $?Q#?3W=W)>1-<Q+%<I;SE$
MG"_=W#N1VJ]:>%;*UUBSU5Y;FYO+2S^QPO/)NVIG)/\ O'C)K>HH Y/_ (0#
M1A;P0JUTH@N+BX1EF(97F!#G/XG%*GP\\-0'33!8) VGJ55H@%,JE=I60_Q@
M@\YKJZ* .*B^&FC0Z=<:;]MU22QE0(EL]T62%0P;"#MR!^%7Y_!6D7.HRW[_
M &@327D-ZV)#CS(AA?P]1WKIL48H R=&T&ST(WHLO,6.[N6NGC9LJCM][:.P
M)YQZUK444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %(:6D- "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !VKB/%FIZY8>+/#45M+##I5U?+!,!S)*2K'!]%&*
M[<]*HWVE6>I36<MU ))+.83P,21L?!&?R)H \JN_%FNZ7X@UF]O+K4!!F[&F
M6X$36LAB3A21\X/4\^E;'ACQ1J.FR:I#J]W>:S%;VEI>+)!;AI09P<H%3J!C
M(]C760^#/#T&KW&J1Z5"+NX#"1SD@[N&^7H">YQS5C0O#6D>&X9HM)LDMEF;
M<^"26/;D]AV% $'A[Q7I_B1KR.SBNX9;-U2:*Z@,3J2,C@^U;HKC?#'_ "4'
MQG_UUM?_ $579T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4F1C.: %HI,@=Z,B@!:*3(]:7- !11D4F1ZT +129%+0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F10>E<;XI
MU[6],\5>'+2UAACTR]O%AGF8[G<E6.U5[#CK0!V611FO.I-;\4V7BZYMVN[2
M^ME@N)YK6V@/^AH%)AR_=V/\/XU#X*\8WL6FW\_BS4+DW5O'#+):OIYC:%7S
M@KMR74GO[4 ;/AC_ )*#XS_ZZVO_ **KLZX#P)J=KK'C'QA?63N\#S6P4NA0
MY$6#P0#7?T %%%% !112;A0 'I7%>*-$MYO$NCN;B^C^VW#1SI%=.BL!&2.
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M%22$08&2<G]:GS0 M%)FEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D-+2&@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *YO4/'.BZ5K%SIEX\\<\$0E+>42C9!8*&Z;L#I71DUX[\0&T
MZ]\:3V%S%HMLT<$3M-J-Y+$9\YQA4XXZ9//- 'J&AZY:^(-*CU"T29(V)5HY
MTV2(P/(9>QK3K+\/Z/::'I$-G9;C%S(69RY9FY)+'DUJ4 %9VI:+9ZK<6$UT
MK,]A.+B#:V,. 1D^O!-:-% '(VOPYT*TU>ZU)&OGENV=KB-[MS'*7!!W+T/!
M_"M#P]X0TGPQYQTY)B\P57DGF:5MJ_=4%NBCL*W<TM '&>&/^2@>,_\ KK:_
M^BJ[.N,\,?\ )0?&?_76U_\ 15=E0 M%)FC)H 6N8\93ZQI^F?;]+U&*V$;(
MCQR6XD#[G"YSGC&:Z;/M7'?$+5[>S\/M;2QW#22O$R^5"S@ 2+U(&!0!TVGP
M7=O:*E]=B[G!),HC$8/IP*Q/$<J+XB\,!W52;R0 ,V,_NVK;L-0AU.S6Y@$J
MQL2 )8S&W'L>:\W\46MO#XCUA=8T&XU2;5(UBT>2-=X4A.4!_P"61#9;=0!Z
MF#FEK-T&WN[70K"WOY#)>16Z),^<Y<#GGO6E0 4444 %%%% !1110 4444 5
MK^XEMK5I8;62Y<' CC(!^O->6Z7XMUJ1-(U5]5-Q/?W:PRZ5LCVJ"Y5D4#YP
MZ ;B3QBO6B,]ZH1:'I<&HOJ,.G6L=X_WIUA4.?QZT 70,=Z\OFUS5X-0ET])
M;UK^WUJ><Q%&(-H$++SC!0\<9ZUZCM]Z-H)SWH \I7Q#XDNO[/DU-&W0W%O<
MYM('7*O"[,A7^+! _'%9MQXR\0W:6E^TS6XM;N94G-HY21#"&4.@[[OE'O7M
M.WW_ $I-@QCC\J /)]1\6>*+_P#M*R>S2R3^SR_E ,)LF+=O0CK\QQCVJ.U\
M2>)-*FBM((LI<7LC&>]#%3CRP(P<<9!)KUW:,YI-@QS@_A0!YKX=U[5M5\?-
M+J+/%!;VERK6J0NJP%9 %#,>'8J,@BN;NO$OB"+3]9N-1&HVMIJJ+/;/*,+"
MHF"E$V\J#&0><'/2O;MH_P BH;NQMK^V:WNX4FA8@E'&02#D?J!0!P7@SQ/%
MINCV^FWK7$]U+/<_9CR1)$A)5@7PP4C@;N>#7<Z7J,6K:;;W\"2)%.@=1(NU
M@/<5!J/A_2M7VF_L89W52JNR_, 1@@'J.#5VTM8K*VCMH%*Q1+M122<#ZF@"
M:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &-WQ7B>L:K?
MF\NUNK7Q$K:=$KW39M6VH22K'<,]/T%>W$5X[\0);"Y\<M:W<&AVS06\3BXU
M 3$W )/RD1D @>ASUH ]4EU.SL-&74+NY2&T2)7:5SP 1UXKG5^)_A@OAKB[
MBB_Y[RV4JQ_]]%<5U4:1RV<:ND3H47@+\IX[#TKC/B5=W=II=G]DN;V#,C&3
M[(@8% !D-D@ <_7TH [>.59HUDC8,C@,K#N#7+>(O%&H:3XFT+3+?3MUK?W0
MAFO)#\HR"=JC.2W%='9X-C;D+M!B4@>G JAJ^@P:S=:7<32RHVG70NH@F/F8
M*1@^W)H X@_$O4;:ZN+VZLK8Z.[7D=J$+>=OMQ_'VPV#TZ5J>'?'%P6OX?%#
M6-FUM!;W8GB8B,1S#Y5.?X@1CWJPGPYT@:K=7<UQ=S6TPGV63N/*A,PQ(RC&
M<GZ\5<\.>";#0([D/<7&I27"QQO+>E7/EH,(F,8P!0!E>"=0L]4\:>,+RPN8
M[FW>6V"RQG*G$7-=-XEU^U\+^'KS6;P,T-LFXJO5CT 'U.*Y_P )Q10>//&4
M<,:1QB6VPJ* !^Z]!73:WHUEX@T>ZTK4(S):W*;)%!P?P/K0!YMX ^(EI\0=
M3O+ '4=/NDC>5%6X#*RL1G''!7M]36O\0]3OO#FE0G3M1DCNKR21%GN[@+%"
M-NXGIUPORCU-1>'?@YH_A>XDN=+U358+F0%#*LJ@[,_=Z54^(W@H:CX4EM;G
M7M9F8N&A5H_/7> < JJY /3/O0!9^'NLZAXLTZZ&H:BQN(</Y]C.#&RRJ"!R
M/E9<=/4UF?%$S02)9ZAJ^HVVDS1B2*6,X7S_ #%&UF49P%RP!ZFG?##P7)IO
MA?R;77=6M+AW\RZC%N(E#D= '7)P!U%9GQA@\8:-H5JNFZI?7]A+,/M!:)"T
M; @IR%S@G]: .X\'R>()O#B327?VE!)*+=[Z,K++%N_=NQ'<C)Z<\5G>(=3U
MY_%FAP)864)%S(;?[1*WS_(1R0,<]0!S5OPW=^/$\-Z?=:I9V%W<O"#+;EC#
M./3)Y4G&/2J'B#Q9H=[K/A^UU&<Z;=I=-YMM=_)+"3&P5@>G7HPXH ]%MS*8
M(S.J+,5&\(<J#WQ4M9FEW4IDELKK!N+?&' .)4/1@3U.,9]ZTZ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(: %HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!K?YYKQWQ5=/9ZM/#;WVM7<&G0)
M->3QZA#'A6)(VJRDN0/3'85[$0#D'O7DOVGX52WEQ'%H)N9H)C',T-A*^UP>
M<D>] 'JMM(K6<,BEMAC5@7X.,=_>N&\=3'4IM(M-.F2Z+.\DMO!*&9TQPVT,
M"P!S75ZQ9-J?AF\L;6;[,US;-''(P(V9&!FO.O#_ ,,M9TO7+.\D;088(;J.
MX8VD#B0!$VE%)/"MU(]: /58,B&,$$?*,@CIQ4N**0T &!Z4M<$?%OB.U\47
M>GZAI.GK96UK+>2307+,Z1+G9N&."Q'3ZU)X'\<S>)=,N=1U-M)M+>/81Y%W
MN9-W:3<!M/2@";PQ_P E!\9_]=;7_P!%5V=<1X1N8+OQUXQFMIHYHFEML/&P
M93^Z]17;T %&.<T44 %<;\0M0FM= >&/3KNY5WB)EA4%4Q*O!R1UKLJQ-<\.
M6WB%%CNKN^BB&,QV\VQ6(.02,=B* +^GW3WUFL\EG/:,Q(,4X 88^A->)?%S
MX?ZEXF\<V%W90[?M*BV#/,,.54MD#JOH<U[986?]GVBVXN;FX )/F7#[W.>Q
M.*Y?Q/K$,'B311]EOY!9W#23-#:.ZJIC('('/)[4 2:;?FYT6UOA!]FU#2L6
MU];EE+(  &4N?X>C9[X%==&P=0ZL&1@"I'0BN4U7R]/UJSUY5VV%^BV=^KKC
MAO\ 5.0>X)VG/9O:DTWQKX=M"=+N=>L_M4$QMPAF#.><+G@<^U '7T4@I: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $/6O#M<76=2\27%Y+X?U+0H;
M><[;O2H1Y]PH/5I-P7!Z\@U[@:\1U?1=5U+6K:ZGNU\46DMX\\5LMVT3>0C$
M/&(CA&P<<Y[4 >NW^F6^MZ&]A=-/Y-Q$H9E?;(.A!R.AKR_PPRZ5KEJ/M?B2
M;2WU.2UBO)KQ#%+/N/RM%][:2",]SS7J\UU!8::UU*CQP0Q[F4+DHH'3 ]*X
M59_ T?CBQN;;3UEU"\*RQ7<7,0=\@'&<;CSD@<=Z /1J0]*6B@#GX?#*)>:_
M<274K/JY4%U #1(J;0%/MR?QK-T/P#;V+WLNKW7]LS7<<<+_ &BW14\N/[@V
MC@GODUV.1ZTM '"^#+&TT[QMXPM;&VAMK=);8K%"@503%SP*[JN,\,?\E!\9
M_P#76U_]%5V= !1110 4444 %%%% %35-/AU73+BPN 3%.A1L=1GN/<=:^>X
M+O['XEL]:N5TJ6[+-9R6)LQF1XYM@]Q*P^?=7T<:^==5U/1G^,\B)J#G4%D"
M"Y:S7RUN$;*J .>GRENI- 'T2#@$DX[\]JC6ZMW8*EQ$S'H X.:9&T=Y9JYC
MS'-'DHZX.".A%<EX;\/Z1;>*]>D@TZWC>VGB$)"_<S&,X]* .VHJI??;?LC_
M &#R#<_P>?G9^..:Q?"VJZQK%JUYJ$%A#;[GC1;=G+;E8J2<C&.* .EHHI,B
M@!:*YCQ;?:YI=LEYID]DL.^.)H[B)F)9G"@@@CCFMS3TO8[1%U"6&6Y&=SPH
M54^F : +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2&EI#0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 )CFO-=5^'FEV&KV-Q!+JT<$DTQFG34&
MC2T5LN2.P#-QBO2LC.*YOQD;>Y\/RVWE6EY,\B^5:7%P(UF<,#MSW/'2@"UK
M>H16?AJ^F@U".!H8,"Y;,@C)'RLV,^H.?QKSCPY/HFC/%K-WXIT<7IG9IHUE
M6?S(SUVX (?KRH'7!!KL? &GS6^D7DUQIHT][JZ=S;;F8*!\HX;[HXZ=*Z"/
M0M)AG\^+2[%)NOF+;H&S]<4 789HYX8Y8R2DBAE)&,@C-/;I2!<4XT <#'\2
M$DUW6;0V$0T_2?-,]R+M"_[L9.(OO<GC-:GA;QC_ &])=V][8/IEU;QQ3F.6
M57#12#*-D?D1VK$N?AE+J&MW,]_J4#V+?:#$L-HL<V9EP0[C[RC.1^M7="\
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M\1>'TAU_Q!-#)-,)9C/DP#R^"#CC)XYK>_X0.3_H;/$?_@6/_B: .RHKC?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TAH
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M:NNFBU6$^8VZ(.&W9[$XKG+;6KOQ3J%[-J-Y;71D\/73-:P(5^S,'^XW/+#
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M>UE@M+VX>>$W!A2+#Q1@X+,#CH>U"3"Z.IS1FN"U?QI=1W.H/ISP/:QZ2E[
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MK/SX;F]N;R:=(1;P!2?+8C&,_K5P>.K"2SLY;>TO)KFZE>)+1(QYH9/O9&<
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M\2Z=H3*EWYY+*9"(86?:HZLV.@HN[A96,63P??V=PTFCW]M L]D+2X66$D<
MX9 #@'D\5H0^&G7P(/#LEPN_[*8#*J\9]<5J3:M:Q:*=50O-;>6)5\I-S.#T
MP/6N?TSQ5JVJZ'>W=OHP-[%=FWCM2^-O3ES[=3BE=L+(A3PKKEL8KNSU*RCO
M7M%L[G="QC95X5E&<AL?A6LGAB*'P6_AV&<[6MVB\YAR2>K8^M-\.:Y=:I<Z
ME8WT$"W5A*J.]LQ:-\C/&><CN*9#XZT2>[2!99QNG-OYC0,(Q(#C:6Q@$]J'
MS-@K&#=> +Z[%K--/ILMTEJ+67S8&9 J_=91G[V/7BK6J>"+N\EA%G=64,<4
M:1QS?9RL\&WJ492.OH<XK0M_&-K':W,U[(I*7KVL4=M$[.Y';&,D^N.*L-XS
MT9=.M;U)9I5NF*1110LTK%?O#9C/'>G>060FG:%=Z=XGU#4!<Q26E\J%T93Y
M@=5 !STP<5DZOX-U2X;68-/U*WAL]6823)-&6='Z':1Q@XK4E\<:)'#:2++-
M-]K5C"L,+.S%?O+@=&'I2V'C?0]2O+>VM[B0FX4F)WB94)'5=Q&,CN*5V&A6
M@\(R+;Z];S72[-4144HIS& FWOUYK+E\':D\:2ZK?0SPV^G26?E6D)#E2.",
MGEN*WK;QGI%]<&WMII-[*_D/)$RQS%1SL8\'%4-/\>6O_"/V>H:G#(DTZ/(R
M6T32+&JM@DGL*=Y!9&!X;EOM4\3Z&[327$6GVLB.WV1X1&, +NW=6..W%=-J
MWAW4Y-;GU+1M0@M9+N!8+CSHR^,'AD]_KQ5IO&.D_;X;.-KB>::-)D$,+,-C
M="2.@I-6\1G2O$%O921)]D:RFNI9,G<NSTH=VQZ'/ZKX!O\ 4+J\E_M.WD^T
M"(^=/"6E0ICA2#A5/MS5^X\'74UEXA@%Y"K:K(CQG:<1[0.OKTJ*P\4>)KJ>
MSNI?#JC2+QPL;1R;ID4]'8>E)9>-+B_\2W-A'-I<5O!<-$$D+^=(JCDK_"3[
M47D+09?^"M5DM]4L['4[:.RU(*\RRQ$LL@ !VGT.*?-X'N9&OIH[Z*.X>Y@N
M;5MA(1HU"X8=P<5+I'C&]OM1T_[39P16&J-(MHR.3(I3^^.G(YXK8UGQ1INA
M2+'=^>6V>8WE0LX1?5B. *+N]@TW.;N_!&L7YO[B[U*T:YNI89=JQ,(CLXV,
M,Y*FE_X06_CLI5CO;,7/]HI?Q8A(C4@8*[1T'TK:O?&^BV-P\,CW$CI"LY\F
M!G'EMR&X'2FZIXUTJP@S%(\\S6OVE!'$S*JX^4N1]T&B\@LC(@\ -'K?VIVL
M7MGN?M3%X"90W7:ISC;NY!QFK5IX0OX?$L>I->6D:1RM([6T)CEG!_ADP=I'
MX5>/B.4> TU^1((IC;K,RD,R*2?;DT\^,M*BO%M)'F:8",2O'"S1QLXR S8X
MS[TKR"R+GB/29-;T*ZTZ&X-N\RX$@[<YP?8]ZY%OA_J+VM^@O;&&2Z^SE?)A
M*I&T39X'?/\ .NG\1ZW<:4EC!90137E]<"WA\UB$4D9RV.<8':LJS\4:QJEA
M&-/TVW^V)<207;RR'R8"G?/4@]J%<':Y7OO!>IZI%J4U_J-LU[=)%%&T<9"(
MB,&Y'7)]:?<>";J:>[D%[%^_U""[ VGA8Q@K]34,/CN]N;73YHM/C_?DJXRQ
M$K"0(1&?S;GM74:/J4NJ->2A$%I',8H''63;PS?3/3Z4[R063.,U_1YM%T36
MHY9Q,E[=_:K!8(6:5)R01G'&..M=?X8THZ1X>M+20?OMF^<GJ9&Y;]32:QXH
MTW0I1'>&<L5WMY4+.$7U8@8 JO<>--%MKL0&6:4[$D>2&%G2,/\ =+$#C-+5
MH+*YC6_@G4K2"(PZC;">RNWN;)S$2,.3N60=^O45O:#H4FFQWTM[<+<7NH2F
M6X>-=JCC "CT J]J>JV>D6/VR\DVQDA5"J69V/15 ZDUS6N>/([32H+C2[9Y
M[B6Y^SF.:)AY3#J& Y!YX'>C5AHBO%X*U:)+&Q74[9M-L;T7,*&(^81DG:3T
MXS2GP/>KHZ6(N-/N"+F69DNH"RD.<C!!W CV--TOQ^]S>WS7ULMM96H5 1#)
MYLDIQ@ 'N3T7K6Z?&&CKIIOFDF $OD& PMYOF?W=G7/>G>2#0IZ/X5NM-U73
M;RXU#[4;6R>W8N#N9F;.0?0=*SD\$:I$MO:C4K;^SK;4/ML:>4=YY)PQ_&KE
MUX^M%N=)2Q@FN(KVX:&0^4VZ(KU&W'WL]O2K>D>++>^N1:7$D8N)9YHX3&C!
M"(^H);^+%'O;AH<UH'A_4]7TOR)KI(-+75)9W@>$B4[9"0 3QM/7I74Z%H=]
MHLFK+]HMY+>ZG>X@ 4[D9NN[U'3I37\;:,MG#<*UQ*LQ?8D4#,Y5#AGVCG;G
MO6JVJV8TG^U!,K69C\P2)DY7Z"DVPT.-;X86LFER227+'77<S?; [;1+NR#M
MJJVAZOJ^N>)+6.>"$3I!',TL#%6.P9>,^M=/'XXT1[.ZN7EGA%KM\R.:%E?Y
MONX4]<G@5I:3K5IK,<C6HF1HGV21SQ&-T/N#3O);A9,Y?4/AO9W$5K]EN9TF
M6>.6XD>=_P!Z%&"0,\-[]JEB\,:[%XGDUAKS3K@Y"0">-V:"(=EYQN/<ULGQ
M7I2V,EYYDGDI=?8V/EG/F9QCZ9[U6?QSHD=Y);/)<!HKC[-))Y#>6C^[8P*5
MY!9#O$.A7^IZEI5_I]W!!-8.[CSD+!\C&.*R[?P3=I=6=Y-?0O=)?27ETRH0
MKEEVA5'8 >M6[7QD@75'OX"JVM\;2%;>-G:3 ST'>H;GQ[:I=:2]JC36-YYJ
MN1&QE5T_A"COFA<P:#(/!5Q#I&DV+7<3&ROFN7(4@.I)^4>AYJ&'P5JT/]G6
MG]IVSZ9I]Y]HA0Q'S&7).TGIQGM6R?&FC_V?#=QR32^<[1I!'"S3%E^\-F,C
M'>H&\7POK.F06S0MIUY:RSO<,2"FSM_,&G[P:%32O!EUI]UI$TEY"XL)KF1P
M%(W^:<@#Z5CW^D3>%KBPO1=LMTMW<.LRVKRPB.0YVN%Y!]ZZNU\8Z-=Q7$@G
MDA2&+SR9XF3='_?7/WA]*JZ;XR35O$\&FVD#+;/:M.S3QM'(#D8P#U!%%Y!9
M$?@*TG7PY=&Y#@W5U-*K.FPNK'AMO;/I5*R\%ZMIUO8O;:C:"]T]Y!;,T3%'
MB<DD/SG//:K_ (L\73>'[ZU@MK1;D$>==DD_N800-WUY[^E2Z]XDN;.^M;'3
M([5Y9[=[HS73E8UC4>W.31KN&A>\.:(^B6<RS7 N+FYG:XGD"[07;T'H*VZX
MN_\ '1M/!=MK(LB+ZZC+0VCYYQU)_P!D 9S]*?J?B;7+;3EO[;3K7[)%9K=3
MS3R%58D9*)CO]:FS'='8T55TZ\&H:=;7@0H)XED"-U&1FK5(84AI:0T +111
M0 AZ5P.J^$M:E.L6FGR61LM2G6Y+SEA)&XQE0 ,$$CKVKOZ3 ]*:=@.=31[R
M3QA#JUR8?(AL1#&BDDK(3\Q ]*Q[KPAJ4VDZ]:*UOOO]16ZB)<X" J>>.O%=
MUQZ44<S%9'GMU\.I-:EU*]U6^F2[N7(C2WE(C"*,(&&.>E3GP_XHM9+35=/N
M;+^UOLBVM['/DQR[3\K @9!KN^*.*?,PLCBU\-Z[.VA3:CJ$-W<6=ZUS.Q&
M%(X1..<>]4YO UW=ZANNEM9K1]7>\DC9B=T13&",=<UZ!Q11S,+(X:+1]6\(
MVNKC14M7LGQ+9QR*=\;D_,IP.1Z<UM^(=+N=8T1;=+>TFE!5WBN<A2>^"O*G
MT-;U'X4KL+(X*#PGK9M]/6YN8G^S:B+A8C*S^5$!C8'898YYYIVG^#]1M8-
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JHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chgbsl.jpg
<TEXT>
begin 644 chgbsl.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M6FV\=W>0C4H3):0R8,<LB[LHCAEVLV <C&<TOA3XN^%?'6H"TT7Q-X?UBZ:
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M'?@[K6DWWC3XH>"_A_K%MX=T]Y+C5M?T*UOI+.UCW.P#R1LVT98A5ZD\ DT
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M_P#\9H'[ 'P'!_Y(G\(__"/T_P#^,T ;/_#7'PI_Z*9\/?\ PH[/_P".4?\
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MV31VT>IL5LF=_(V@2''4_+N7=MR*],'[ 7P'/_-$_A'_ .$?I_\ \9H VO\
MAKGX4?\ 13OA[_X4=G_\<I/^&N/A3_T4SX>_^%'9_P#QRL;_ (8 ^ __ $1/
MX1_^$?I__P 9H_X8 ^ __1$_A'_X1^G_ /QF@#9_X:X^%/\ T4SX>_\ A1V?
M_P <I1^UM\*FZ?$SX?'O_P C'9__ !RL7_A@#X#_ /1$_A'_ .$?I_\ \9KR
M_P#:P_8:^">B>#/"\EG\'/A5:O-XRT&"0Q>$[!"\;ZC"K(<1#*LI((/!!(H
M]I_X:X^%/_13/A[_ .%'9_\ QRC_ (:X^%/_ $4SX>_^%'9__'*QO^& /@/_
M -$3^$?_ (1^G_\ QFC_ (8 ^ __ $1/X1_^$?I__P 9H V?^&N/A3_T4SX>
M_P#A1V?_ ,<H_P"&N/A3_P!%,^'O_A1V?_QRL;_A@#X#_P#1$_A'_P"$?I__
M ,9H_P"& /@/_P!$3^$?_A'Z?_\ &: -G_AKCX4_]%,^'O\ X4=G_P#'*/\
MAKCX4_\ 13/A[_X4=G_\<K&_X8 ^ _\ T1/X1_\ A'Z?_P#&:/\ A@#X#_\
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M ()!?##2[O28I9-=U+0[6"/^U=)O[QKF#7KM+:\MA>RLQWQS%+Z<GR2B@["
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M_P#L=_#W_IR@KUJO)/VPSGP/X3X_YG?P]P/^PE!0!ZK<W*VT;,[+'&@+,S'
M4#DDGL*Y7PM\=/"WC$7C6.NZ=)'9ZE_9'FM,J17%UY:2".)B<2961<;,\Y'4
M&F_'KX8R?&;X1>(/"\=XVG/K5JUNMQL+K&<@C<N1N0XVL,C*DC/-?,OB/_@F
MIKWBS4+K4;C5/"MC/JE[>R7&EZ?;W%OIEG%<I:J9(54AFF4VQZ[0^_JF.>7$
M5*L6O9QN>WE>#R^O3D\97=-]-&^WYZKI:WF?47B_XO\ A_P/$6OM2AWK?6VF
MR10'SY89[APD*NBY*;B1RP QSTJUX;^)>C^*4M%MM0MENKV#[1'9S2+'=!,
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M8NK?&.6TNM8\865C>1Z3/X=NQ##>:C]MTN>2XDN+5YKNY>8K(TEN2"Q"_9@
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M/T?\,:?#W_H$:I_X/]0_^/UZE12]G'L/ZYB/YY?>SRW_ (8S^'G_ $"=4_\
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M(/[05_K&@M:^-IM+M['5'EU62'Q3<W$FKRF5&_M )+$8X(_*5X_LB@I^\)[
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MZT+2HU\8R1Z?!#:VQU1=)N+Q]25(0Z7LF3NTCB;$J$W1/4_=S]??\)?XZ/\
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M(2S);S3WPC 4H_D$DL%S7V7_ ,)OXX_Z$>W_ /!W'_\ $4?\)QXX'_,CV_\
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M8M]=_P#"<>. /^1'MO\ P=Q__$4H\<>./^A'M_\ P=1__$4?VO1_EG_X!/\
MR#ZG/O'_ ,"C_F?-?A#XI?M#>/=$\,S:U:7FAW=KXJ\.7%]%IWAUK=;_ $^[
MC_TRUF\UI"D<#C+R(0V"%.T D^=Z;\3/CV8=/_??%Q]T43QF70MK2^*<VOGV
M,W[GY=) -UB3B+*G$IVKG[7_ .$W\<?]"/;_ /@ZC_\ B*#XW\<?]"/;_P#@
M[C_^(H_M>C_+/_P"?^0?4Y]X_P#@4?\ ,^5=6_:L_:*\&6EWJVM:%I,>B^3%
M))(?"]S;C2UN+62=I2S7!\W[*\:Q^7A6F:0+E6*BOHW]B[XQZE\??V>M,\3:
MK-;W5S=7VHVB74.G2:>M]#;WT]O%/]GD9GB,D<2.5+'!8XXP*U=6\0^+M>TV
M>ROOA[I]Y9W2&.:"XU:*2*53U5E*$$'T-+I'B'Q=H.F065C\/=/L[.U01PP0
M:M%'%"@X"JJH  /0"C^UZ/\ +/\ \ G_ )!]3GWC_P"!1_S)?B5_R4_X?G_I
M_N?_ $E>N[7[WXUYN]KXJ\9?$#PS>:CX=M]'L]%GFGDD&HI<,^^%D "A1W(K
MTA*C+)<]2M52:4I*UTUM&*V=F5BERPA"ZNEK9I]7V/,_VQ/%MQX$_9S\3ZM:
M+XR:XLX(V2/PI:?:M8GS*@,5NNQ]K."5,FTF-69QRN:\B^ _BCXN66H>$=2O
MKK7O'NGW7P_EGETZ33QI,9U1;Z +YDUS'')YWD.Z_O53<L#.$!<U]5DXHS7K
MG&?G'\2?C)\;-6\1>*)O!MY\7&T.SUZ:UN+?4_#UU%J#SQQ7;0/;>7:A8[2X
MN!#;($\Q L4<TS*LQ4_HAH$TUSH]K)<PM;W,D*--$S!FC<J-RDKP2#D9''I5
MS-&<T %%%% !7FO[6VJ>(-'^!6K7'AIM8COEGM%N9=)@,^H06)NHA>26Z ,6
MF6V,S*%5FR!M!.!7I5&<4 ?+%GXQ^)VM_LY> I+*^\7V_B/3?%VE)K,=QHF+
M[5=&EU38HG+H!&38E))FC =2&#;"6%>J_LZ?\)A#XI^)EOXLU'4M5@M_%3_V
M'/=6*6L:V#VELZQ0A  T4<C2IO)9F96).>!ZEFC- !39/NTZB@#Y_P#!_P 0
MO'OQ N?B9IMLMY9W<.N:KI=KJ2?9Y!X72"WA^Q,MK)S.TX83 G*YD&?EP*\_
M^-'Q*^(MC^S'\,_[-F^):_$6WL],GU%+'1'D2_O&BA:2&\986"LZ^> ,) )<
M"5HP%!^N$L(;>ZEFCBBCDG(:5U4!I"!@9/4X''/:K&: /EO]BKXH^-I_'6L:
M7\0)O%GG:MY4<,6M:8T$<.L*UY)?6]DPC -FEO':LCY:,EB%=F+ 7O&&M_$K
MP_X:^/=BVM>)IM1O+MX_!%_;^'3<_P!FQOI<4N+>*$#SA#)YF&=MSR*5SN*I
M7TF8PTBMQE>GM3\T ?GUX)^+_P 1#X@\/Z5JGB/XK>&8]+T+5KJ^UK5-(NCI
M-_91+??9[@--;;H[J;;#<D74B&W2&.(!S-BOMOX&^)M4\:_!;PCK6N6G]GZY
MK&BV5]J-KL*?9KF6!'ECP>1M=F&#TQ727]E#J5J\%Q'%/#*"KQR*&1QZ$'@B
MI$X% &+XDN_$$5S'_8]KI,\)3]X;NX>)@V>P5&R,5F_VAXX_Z!OAG_P/F_\
MC===10!R/]H>./\ H&^&?_ ^;_XW7BG_  4!U3XC0?LZ33:)IGA^3Q5;ZOIT
MOAN%+EI8[G5EN4-E%*'"*(FG$:N2PPI)KZ9KR7]L7_D1_"?_ &._A[_TY04
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M0_";XJ6OE^,M!ES-9V #E=1A(08NS\S=!VR1R* /?QXW\0D?\B9J'_@?:_\
MQ=?.?_!0+]M[XV?LOGX='X<?L]Z[\3O^$LUW^S=96WNC(=$MOD_?MY"R8!W-
MR^U?DZUZV/VI]4/_ #1WXN?^ 6G_ /R91_PU-JG_ $1WXN?^ .G_ /R90!V;
M^,_$$;LJ^#M0=5. PO[7YAZ_?I/^$V\0_P#0F:A_X'VO_P 77G6D?ML2:[X@
MU;2[7X2_%N6^T*2**^B%A8#R&DC$J#/VS!RC \9QFM3_ (:GU3_HCOQ<_P#
M+3__ ),H ['_ (3;Q#_T)FH?^!]K_P#%U-IOB[7+O488I_"M]:0R. \S7MNR
MQ#U(5R3^%>:>-?VV7^'GA+4==UCX2_%RSTO28&N;J<Z?8-Y4:C+-A;LDX]A6
MI_PU/JG_ $1WXN?^ 6G_ /R90!ZX#D45Y'_PU/JG_1'?BY_X!:?_ /)E947[
M;;3^-;CPZOPF^+C:Q:V,6I2V_P#9]AE()))(T?/VO'+12#&<_+0![C17D?\
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MLH=@" QST] %77-8MO#VD75]>3);V=E$]Q/*_P!V*-%+,Q]@ 3^%</\ LO\
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D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>deccog.jpg
<TEXT>
begin 644 deccog.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @  @$2  ,
M   !  $  (=I  0    !    )@       9*&  <    F    .     !53DE#
M3T1%  !, $4 00!$ %0 3P!/ $P 4P @ '8 ,@ P "X ,/_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( ?4#
M( ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_
MQ "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($
M! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *;,<1-SMQSGTIU-E :,Y&1]
M,T ?//[1W_!1_P %?LZ?%*W\!QZ#X^^(GCN>V%[/X>\%:+_:E]8PGD2R@NBJ
M"#NV[B^W#%0&4M5L?^"F?@'5)?A.L.D>. WQ<UBZT/3HIM,BMY-*N[:2..5+
MU995:/#R#_5B0GGTKYU^ _Q:\+?LC?\ !7/]H1?BKK6D>$9?'$%IJ.@ZOK$\
M=O:W5H #L^TR$*O&Q "0I-NR]4%5_P#@H[\3+#]J?XV_LIZI\+_'4-DNJ>*=
M4T_2_$UO8+=);74<MG&9HX9PJ3JK@^J-V)'- 'V7X@_:V\.>'/VM]!^#-Q8^
M()/$WB'1I-:MKQ(8?[/CA3S<J[^8)/,/DM@+&1TY';C_ (C?\%)_A[\-_P!K
MO2/@S?V?B2;Q%JKVMN=1@MH6TFRN+G>8;>:1I0ZRL$W8$;<,#GKCY<T'PKXP
M^ ?_  6(\%R_$_XJ'XE7MGX U#4I=8GT&VT-;.T1;LF,Q6^495*N^]L'YB.P
MKP'Q1I7Q<_:&_9G^)'Q0L_@_=:CI_C#Q2/'UIXV/BBUAN--M=.9HX8UL&'G2
M!(%EC^5@6[+\H! /TJ_:Z_X* ^'?V0O'7A3PW?\ @SXC^-=>\:17,VFV/A/2
MX=0F80&,.#&\\;$_O!C:&X!R1BN7\,?\%6?"/CKX8ZIX@\._#_XR>(M7\/ZF
MFE:MX4TWPTL_B'27=2RR36PFVB+Y2"P<X. 0,C/S/^U)\0]8_;!_:,_8[\1>
M"O%?_"%ZYXNT+4KFUUM--AU(:?<9MA+BWE)B?]XKJ-QXZ]1BO4/^"14PT?Q+
M\=M!\876H:A\9]-UTCQ5J-[<^9_:L8C*V\T*;5$<>S;\H!P&09P   >E?LQ?
M\%4?#_[6'CFUT?P[\*_CA:V=Q<2V<VMZAX<@71]/FC'SQSW$5Q((V!X*D9!/
M(%=Y^U_^W)X(_8J\+1ZEXN77M0GN(GG@T[2-/^UW4D49 DD))6*-%R,M+(B\
MX'/%>%_\$,SG]G[Q]C_H>]4Z?]=#7<?\%?\ XH^&O"'[!OQ&T'5O$FAZ7KGB
M+0YHM*T^ZU&*"[U1PR$I!&[!I"!U"@T ?0'PB^)%C\8/AQH7BK38;RWL?$-F
ME[!'=HBSHCC(#[68!A[,1[UTDS;8^_X UX9_P3L^)/ASX@_L?^!ET#7=%UO^
MR=(MK._73[V*Y^PSA 6BEV$['']U@#[5/X1C_:+_ .&@[DZ]-\%#\*?M,WD+
M81:F/$/DX_=;B[?9]^?O8&,=* ,_]K3]O_P[^R+XV\+>&]0\'_$3QIK_ (Q2
M5]-L/"FEP:A=/Y0)8>6TT;L=H9OD#8"DG J?]E+_ (*#>!?VL/%VL>&=+L_%
MGA3QEH*"?4/#?BG2FTW4[>,X&_R]S*0"P!VL2,C(Y&? O^"AWC;1_AQ_P4X_
M9BUSQ!JVFZ%H6FMJ+W>H:A<K:VEJIMYT#22.0J@LRKEB!E@.I%<KKOQ8L?VH
M_P#@J;)XV^#-Q'XFM?AW\.=1MM1UK3XM]I/?LDQM8UD VSL7:( 9(/E'LM '
MZ/4V09 ]CGZU^$_[+7A&^\8>/OAWX]7XI?!KPW\0+WQC;)>7%UK^N-XYU*5[
MT1-:7%K^\@:.0-MW+$$VD;I -Q'OGP_M?@W\3?VHOC5KG[17C#4-#^*7AGQV
M+7PL#K%Q:W>GV,<B&V&GPHQ$P9PR,HCDQ&%;C>6(!]A>&O\ @HG)K#_&YS\-
M/%^M?\*;\1)H"V/A9?[;U77][$>;';%(@F,;BGF-A<G/&*^C]"U!M9TRUOC!
M=6@O($F^SW,>R:WW*#L=<G:PS@CU'7BOR._:1BCO/V6O^"A2S1JZ?\)[IH.0
M&Z:G!@#MZ'ZFO3=?_9@\'_M<_P#!6"U\(^-[?4K[P]_PI.PU2YL;>\DM(]0F
MBNX(XO.:,AF5#.7"9QOCC)R%P0#],:CN&V1$XSC)_2OPY/Q3\7W_ /P2P^'7
MAEM>\GP2OQ2N_#FJW.JW=R=.^R)''-;VU]) PE6S#R2LZ1G.V$;<%5!^OO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444;J
M"B@'-% !1103B@ HHS10 44$XHS0 449H)Q0 449XH!S0 444%MM !11FC-
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M-_PAL)?V3?C[K?@[Q%JWB]=?MO#UK=6>F^%/[(TMKJ"_B.^"!!EK@0E/-95
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M]OF^\3?%"QU-_!/B+P;!;Z;>0?;/)AO+6X<R02?9OFWE)0Z@_*06QD]/8O\
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M\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\ Q5&W6O\
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M !5&W6O^>FE_]^I/_BJ -6BLK;K7_/32_P#OU)_\51MUK_GII?\ WZD_^*H
MU:*RMNM?\]-+_P"_4G_Q5&W6O^>FE_\ ?J3_ .*H U:*RMNM?\]-+_[]2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!GZOIDE_IMU:P75SITUQ"\<5U
M;)&TMJ2N Z>8C1[E8[E#JRY'*D<5\AG_ ((YV,GPX;PO)\?/CM)8)X^3XF12
MF#PMYT&NKJ4FJ-<JPT0 J]]()C&P*9144+'NC;[,HH ^/_'G_!(?3/B!H_Q(
MT^Z^-GQHAM?BAXQT_P <ZRD$'AH;=0L1;"V$);1R5B7[#894EBWV-,D^9/YW
ME_PA_P"">OC#X[_M'_M%Q_%*#XT>%?AG\0/%.F:D=*N-2\,/I'Q$L[/2].LF
M%XMJ;B\@:6:QE=T@:S66"6-7&<PQ_HA10!\SZ=_P3#\'W.F_'#3?%OBKQQX^
MT'X^7GV[Q'I6LC38;>VG^SQ6RR6DEC96UQ&R006\:EI7(\E7_P!87=NB_9]_
M8:T_X(^/;/Q5KWCOXA_%KQ7I.A?\(SI&L^,Y=/ENM*TYFC>6!#96ELLC2O%$
MTDTZR3/Y:YDQN!]VHH ^=O#O_!.#PIX)_9K\??"S0?$WCC1]#\?W-])<7B3V
M5Q>:3;7<DDDEE9F>UDACME::?8CQ.4\]R&S@CB-(_P""15EHEW!-!\</C9YU
MOX"_X5M&[6_A;Y=&'W8_^0-S(,#YSDX SGFOL"B@#\R?C]_P33U[1O%G@[PS
M-X5^.'Q8\&?#7P_9Z9X1U;2K7X8:Q-;&-F+&>W\0V,"VL\>V)5ELT?S456D<
M.NVOT ^ &F>*M)^#?AVW\;7=UJ'BB&S1=0N;A[9[B1^H\TVL45N9,8#^3$D>
MX-L!7!/;44 %%%% !1110 4444 %?/O[8?\ R<3^R?\ ]E5OO_4'\55]!5\^
M_MA_\G$_LG_]E5OO_4'\54 ?05%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !FD#@GJ*-P_7%?EIXC_P"#@G2=&_X+Y:?^SH+RR;X:_8SX
M9NK]5'R^)9661#Y@SF-<"WZA0TKDC*B@#]3**0NH[TM !1110 4444 %%%%
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M&VBMWOKK;]HNV1 IEDV@+O<C<=H R3@ <#4HHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E
M"%@*^8/$4P'_  64\%?-]_X-:YCW_P")UI->'_\ !=W_ (+8ZM_P1^\/_#^Z
MT7P+I/CB3QE<W4,T=YJ<EG]D$2J1@HC;LEL<^E?D[K'_  =Z^+]5_:UT'XL?
M\*3\+K>:'X4O_"HL!X@G,<\=U=VER9M_DY!4VH4+@YWDY&!0!_3CN -+7P#_
M ,$)/^"R6L?\%@_AAX]\0:UX'TGP3)X-U:UTZ*WLM2DO1=^="\A9BZ)M(V8
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MWQ_TCU\3?^!]W_\ &* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\
M2/7Q-_X'W?\ \8H _7RBOR#_ .'V?[?'_2/7Q-_X'W?_ ,8H_P"'V?[?'_2/
M7Q-_X'W?_P 8H _7RBOR#_X?9_M\?](]?$W_ ('W?_QBC_A]G^WQ_P!(]?$W
M_@?=_P#QB@#]?**_(/\ X?9_M\?](]?$W_@?=_\ QBC_ (?9_M\?](]?$W_@
M?=__ !B@#]?**_(/_A]G^WQ_TCU\3?\ @?=__&*/^'V?[?'_ $CU\3?^!]W_
M /&* /U\HK\@_P#A]G^WQ_TCU\3?^!]W_P#&*/\ A]G^WQ_TCU\3?^!]W_\
M&* /U\HK\@_^'V?[?'_2/7Q-_P"!]W_\8H_X?9_M\?\ 2/7Q-_X'W?\ \8H
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MW_@?=_\ QB@#]?**_(/_ (?9_M\?](]?$W_@?=__ !BC_A]G^WQ_TCU\3?\
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MKNB1DRSZ1N'VH1C!*R0G]W<+QC(&_ KV+]B__@O;X7^(>JP>%/C)IK_#OQ=
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M^)ZLO_!7OX3R+]UOAOXB1O\ P-TXU]15\M_%=V7_ (*Z?!W _=R?#_Q(A/\
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MX"7PXBB^>FU_>M=TWW4M$]$VSW6BF^<O]Z@2*>]>\?E ZBBB@ HHHH ****
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M_P"3B?V3_P#LJM]_Z@_BJOH*OGW]L/\ Y.)_9/\ ^RJWW_J#^*J /H*BBB@
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M_P"&?$G@W43I/B3PSKT$5OJN@W6T.J3+#++"RO&0Z/%+)&RGAB00/B_X _\
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MMTT^@ZBBBJ,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(<U]#_L._P#!>7X=_'NZM?#OQ*BA^&?C$D0^;=2'^Q[R3H=LS<VYR#\LV .
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M^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\ @MN/_B*
M-:BLG_A,K7_GWU;_ ,%MQ_\ $4?\)E:_\^^K?^"VX_\ B* -:BLG_A,K7_GW
MU;_P6W'_ ,11_P )E:_\^^K?^"VX_P#B* -:BLG_ (3*U_Y]]6_\%MQ_\11_
MPF5K_P ^^K?^"VX_^(H UJ*R?^$RM?\ GWU;_P %MQ_\11_PF5K_ ,^^K?\
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M1>F#E1V!KD_UAS;*O=SJASTU_P O:2;5N\H;KS:T[(Z?]7\JS1<V2U^2H_\
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M (3*U_Y]]6_\%MQ_\10!K45D_P#"96O_ #[ZM_X+;C_XBC_A,K7_ )]]6_\
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MQJK2;7RS90=:]P_+SU3QE^U?#I7QBG\$^'O".O>--6TM[1=;>PO=/M8=&-R
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MV!G_ -NRC+_(/^(3\'XC_D7\4X=]E5I5:7WMW2/UC,R@]S]!2^:M?DR?"?\
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M@F53XHU;3V8#_C[T>>-1_P " (KLI<3954^&O'YNWYV/FL=X(<?83^-E-?\
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M_'7B[2U[!X8;@#\\5^E%%>?4X7RF?Q4(_)6_*Q]E@?'GQ!PG\+-JS_Q24_\
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M3+L4 ?4E%%% !1110 4444 %%%%  3@4U9-_3UIQY%>,VOQG\96_[;UG\/\
M4-/\+VOA/5/">I:_I\MM-/<ZC*]I=Z; 'E9A''$KB^E7R563'DH_G'>8U /9
MJ^??VP_^3B?V3_\ LJM]_P"H/XJKZ"8X'K]*^>?VS;F.R_:!_93EFD6*./XJ
M7S.[G:J@>!_%?))XH ^AJ*R?^$]T7_H+:7_X%Q__ !5'_">Z+_T%M+_\"X__
M (J@#6HK)_X3W1?^@MI?_@7'_P#%4?\ ">Z+_P!!;2__  +C_P#BJ -:BLG_
M (3W1?\ H+:7_P"!<?\ \51_PGNB_P#06TO_ ,"X_P#XJ@#6HK)_X3W1?^@M
MI?\ X%Q__%4?\)[HO_06TO\ \"X__BJ -:BLG_A/=%_Z"VE_^!<?_P 51_PG
MNB_]!;2__ N/_P"*H UJ*R?^$]T7_H+:7_X%Q_\ Q5'_  GNB_\ 06TO_P "
MX_\ XJ@#6HK)_P"$]T7_ *"VE_\ @7'_ /%4?\)[HO\ T%M+_P# N/\ ^*H
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M_@7'_P#%4?\ ">Z+_P!!;2__  +C_P#BJ -:BLG_ (3W1?\ H+:7_P"!<?\
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M +1I:* $V_[1HV_[1I:* $V_[1HV_P"T:6B@!-O^T:-O^T:6B@!-O^T:-O\
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M[8?_ "<3^R?_ -E5OO\ U!_%5 'T%1110 4444 %%%% !1110 4444 %%%%
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M$XHE#!9M9*&+2M2KO91Q$5I&3V5167>R2@_U2CD\U<BG5\'?\$VO^"TOA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI8&>7=D8QT-2T4 ?%
M?_!23_@CKX/_ &S+:\\2^&5M_"/Q._UJ:E&I6UU1AT6Y5?XNF)0-P[[AC'S+
M^R7_ ,%3?B)_P3_^)5O\&?VF-,U#^S=.86UGX@DW37-G%T1F<9^TV^.CC+ =
M=W;]:IH?-->4_M:?L;^!?VR_AI-X:\;Z4EXJJ7L[Z$!+S3I.</#)C(Z\J<J>
MXKYG,,AFJWU[+)>SK=5]F?E)=_/_ (<_<.#_ !6PT\NCPMQO1>+R_:$K_OL.
M]E*C-Z\J_D>C6BT]U]]X#\>Z/\0_"-CK>@ZE9ZSH^I1">UO+2420SH>058?Y
M%;44HE7<*_&2XTSX\?\ !!SXF--9FX\>?!/4KH[E.?LI#'^(<_9;@#O]QB._
M;].?V.OVXO /[:_PXCU[P;JBRS1 "^TR8A+S37[K(G7'HP^4CH:Z,KSR&)F\
M+B(^SK1WB^OG%]5_7F>3Q]X4XC),/'/,HK+&995?N5X=+_8JQWIS6S323?9^
MZO9**;%)YJ;L$?6G5[Q^2A1110 4444 %%%% !1110 5^=/[+?[3/C3]G;7O
MVD=9F_9T^/VL7WQ#^(UUXM\,V,?AV.$7\#:/I=I$DLS3;;<M/9R@[\[4VL<Y
MQ7Z+5&MOL'WCU).><T ?DWJ7_!,OQ]\*_A=X)U7XC:3XT\40^,O'GC#QY\2?
M#_PVEANWTK5]<:&2U>&&X1EO+>V2!X&RN0UT95^X*ZS0?V3=+^"NN^!8?$GP
M-^*'Q6^!+?#VY\+:%H&LV<?B'7/"=T^I37$CW5N[CROM%O)$B2(2UNMLD0*J
M:_3@PMZ]\\T&VR!\S?+C&#Z4 ?F9^T)\)-:\0_M;^/U_X4K\3KKP+J7[.TG@
MNU2RL6GA:^$BW,=@DZS*[.J*J;L@%QMW'//E'PK_ &8)I?&WP?UGQC^S?\3]
M6F\(?LX2^#]66^\.?:[==9C$"16P@:<Q.VV*XVG9MR\9R#M*_L5Y1]?S["E,
M6<_IQ0!^.7@'X&^,+.[_ &>KW7_@7\9KF3PO\$M8\"^*6&E.TL<LENL5M:C%
MQGJ& :/!P5RV,8L_LO? 6]^ $?[/,_\ PI/XH> ;?P[\.?$>B>-]9BTF.SEL
MY9[=C%Y]VTQ8A65BC,66-BI&W)Q^P?V?/7\*I^(/#-CXKT2[TO4K2WO]-U"!
MK>ZMYT\R.>-AAE93P002"#0!^5W_  2I^ UMX._:5^''BSQI\+[SPCJ>C^$6
M\*^']23P =-75'E?[0+J_O79B]XT:XW1 AV,C%@#BOUAKQ[X(?L#_"/]F_Q<
M=>\$^"['0]6\DVRW"W-Q,8HSU5!+(RIT ^4#CCI7L- !1110 4444 %%%% !
M7S[^V'_R<3^R?_V56^_]0?Q57T%7S[^V'_R<3^R?_P!E5OO_ %!_%5 'T%11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8[74W7@^26^Z_!S&W.>F:^W3<X)^7I[U\._\%(/^"-7AK]JQKKQAX(:'P?\
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M?@C^SSH/P$LM671Y-6OM0\07O]H:KJFK7KWVH:E,(TB0RS2$LP2..-%'150
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MU% &3_P@^D_] ^U_[]BC_A!])_Z!]K_W[%:U% &3_P (/I/_ $#[7_OV*/\
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M:F7B/VB2UFMXCI@P\\<D"$()-BA1LS7V=4:P[3GY=W?Y?SJ2@ HHHH ****
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M'V==^[:N[&,@<X^M "Q?,S-N+;OR_"GTBKM%+0 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex_611641img001.jpg
<TEXT>
begin 644 ex_611641img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ![ =8# 2(  A$! Q$!_\0
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MN>')684445V$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV:/[3O\ _G\G_P"^S7D_5GW/1_LR?\R/0**\_P#[3O\ _G\G_P"^S1_:=_\
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MYLY#8)S#*4S\[]0.#3JI5)J*%#W(W9[W17S':_%OQI:H$_M1)P/^>]NC'\P
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MG;W,?]V:,./UKE[KX6^"[LL6T.&-F[PN\>/P!Q78T4*36S!I/<X+_A3O@O\
MZ!T__@5)_C6QIGP_\*:1*LMGH=JLJ]))%,C#Z%LXKI:*;G)[L.5+H%4[_2M.
MU2+R]0L;:Z3&,3Q*^/SJY14C.-NOA5X+NLDZ)'$Q[PRNGZ XJK_PIWP7_P!
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MG'<_+0E"4G"P-R24KGLWC3QG8>"])6[ND::>5MEO;H<&1N_/8#N:\P@^*/Q
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M,N&GMEM[ZT<+,D9)1@V=K+GD=#Q[5-2+Y;V7R'%Z[G:4445SFH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?('_"[?B'_T,/\
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MXH?#F;Q;'!J.EF,:E;IY1BD.U9H\Y SV().,\<UX1_PNWXA_]##_ .25O_\
M&Z/^%V_$/_H8?_)*W_\ C=4ZTKIK2PN16LSTFPUKXNZ+9IIZZ-/<I"NQ'FMA
M(P Z?,K<_C70:_;^+/$/P>ECU33I7UJ6Y5C;11 -L$@(^4'TKQ;_ (7;\0_^
MAA_\DK?_ .-T?\+M^(?_ $,/_DE;_P#QNAU=4[(.3I<]Z^%.@W=IX N],UK3
MYK<SW,P>&==I9&51^1YKB3X+\=_#W69[GPL&O;.7@% KEU["2,]QGJ/TKSO_
M (7;\0_^AA_\DK?_ .-T?\+M^(?_ $,/_DE;_P#QNA57=ON'(K(]3'BGXO7#
M)&F@F+) +?8\?CEFQ74_&#2=2UGP?:V^FV4]W.MZCM'"NX@!7R?IR*\#_P"%
MV_$/_H8?_)*W_P#C='_"[?B'_P!##_Y)6_\ \;I>TU32V#ETLV?1WPOT^\TO
MP!86E_:RVURCREHI5PPS(Q''TKSSQ[X8UZ_^+$>H6>D7<]F)+4F>./*84KNY
M]J\T_P"%V_$/_H8?_)*W_P#C='_"[?B'_P!##_Y)6_\ \;HC4:DY=QN":L?0
M_P 2O A\::3"UI(D6I6A9H"_W7!ZHQ[9P,'L17GFDW?Q8\*6BZ5;Z/-<6\/R
MQB2$3!!Z*RMT^M>=_P#"[?B'_P!##_Y)6_\ \;H_X7;\0_\ H8?_ "2M_P#X
MW1&JTN5JZ$X7=SZ!T"SU_P 8^"M4L/&MLUM+=2%(E6,(43:I5@,GD-D\^E<!
M9:%\2_AY<SV^C6YO;*5]W[I!+&Y_O;20RG &?ZUY[_PNWXA_]##_ .25O_\
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pg01.jpg
<TEXT>
begin 644 pg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M.-^SS,[<\9QC->FV<T=Q8P30W"74<D:ND\9!64$9# CC!Z\5YG_S=A_W*?\
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MQY?(&[)Q715070M(6\^UKI=D+GSS<^<+=-_FE=IDW8SNV_+NZXXJ_0 4444
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MOO#PK@3.2(E:-@=H;.%R30!ZW<>&_#,-K++=Z-I,<"7!U"5Y;6,*LP',Y)&
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M0 4444 %%%% &/K7A;3/$+J=6%Y+&$\MK=+^>*&5<\J\2.$<'H0P.1P>.*V
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MWMD[35[4/$6IOK=SI7AG2;?49[&)'NY+N]-K'&7&4C4B.0LY R>  ".<G%8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG$I\Q2H"; ".&;/7CI76Z];0/#;W+0QM/'=VP24H-R SH" >HR": -6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7/^
M0?%_U^6O_H^.M&L[7/\ D'Q?]?EK_P"CXZ -&BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L[7/^0?%_U^6O\ Z/CK1K.U
MS_D'Q?\ 7Y:_^CXZ -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2%4EB
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MYUZ%V@MY1<2HB7=L#"H7:_[].N1G\B*UJSM<_P"0?%_U^6O_ */CH T:***
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MKT%%>TIN\'^'D_/\Q)]&;5%%%<A04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:Y_P @^+_K
M\M?_ $?'6C6=KG_(/B_Z_+7_ -'QT :-%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !11575-2M='TFZU+4)1%:VD332N>RJ,F
MFDV[(#SCXV^-+K2-&MO"WAT/+X@\0'[/"D?WHXF.UF]B?N@_[Q[5U/P\\$VG
M@+P;:Z/;!'G \R[G48\Z8_>;Z=A[ 5YW\(=,NO'7C/5/BAX@BP)9&M](A<<1
M1CY2P^@^7/<ES7ME=V):HP6&CTUEZ]OD2M=0HHHK@*"BBB@ HHHH **** $9
M5="CJ&5A@@C((KPGQ+X=U3X*>*)/&/@J!KGPS=,/[5TI3Q",_>7T'/!_A/'W
M37N]-EBCGA>*9%DCD4JZ.,A@>"".XKHH5W1;TO%[KO\ UT$U<S?#?B/3/%F@
MV^L:)<">TN%R#T9#W5AV8=Q6I7@6K6.H? 3QJ=;T6*6Y\$ZK*%O+1?F^R.>F
M/3'\)[CY3S@U[GIFIV>LZ7;ZCI=PES:7*"2*6,Y#*?\ /3M58B@J=IP=X/9_
MH_-"3OHRU1117*4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5G:Y_R#XO^ORU_]'QUHUG:Y_R#XO\
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M)X0GLI/&/X6XZ$$>YU->@Z,K;I[/NAIW"BBBN<84444 %%%% !1110 4444
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MQ#&<?0!$S_LMZU[37=BW[-1PZ^SOZO?[MB8ZZA1117 4%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"N76>GR6_P![)WD;-%%%<!04444 %%%% !1110 4444 %%%% !1110 4444
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M %9VN?\ (/B_Z_+7_P!'QUHUG:Y_R#XO^ORU_P#1\= &C1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5XA\23_P +"^-7A_P'$?,T_3#]NU0#IT!V
MG_@. /\ KK7L.N:O;:!H-]JU^VVWLH'FD]2%&<#W/0>YKRSX!Z3=7]KK7CS6
M5_T_Q!=.8B?X858YQ[%LCZ(M=^%_=0E7?31>K_R6I,M=#V$    8 Z 4445P
M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5SGCWQ9_PA/@ZZUO[+]I,31QJK/L16=P@9VYVJ"PR<5@S_$/6[7X>VWB>7PU
M;-"+.2\O)#JT:PJB8V^4RABYD!RJD+Z$@XR >@T5S6N^+9=/CT2+2-/6^O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_*N ><GFNDUS_D'Q?]?EK_Z/CK1K.US_ )!\7_7Y:_\ H^.@#1HHHH ****
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MHH **** "BBB@ HHHH *SM<_Y!\7_7Y:_P#H^.M&L[7/^0?%_P!?EK_Z/CH
MT:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \_^-'C)O!_P]N39N1J>I'['
M9A?O!F'S,/HN?Q*^M7OA5X,7P/\ #ZQTV1 M[*/M%Z>YE8#(_P" C"_\!KSW
M3_\ B[7Q^EU!OWOAWPE\D'=)I\]??+ GZ1KZU[I7?7_<T8T.KU?Z+Y+\R5J[
MA1117 4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6=KG_(/B_Z_+7_T?'6C6=KG_(/B_P"ORU_]'QT
M:-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCU[OO^B$N["BBBN(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A<7-V/7-2UK2]&A\W6-2M+"/&=US.L8_P#'B*X36?CY\/\ 2-RKJSZA*O\
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M&^EK)_\ $U /A78CH+ ?]N"5(OPS@3[LMHOTLE%+ZWF7_/C\5_\ )"^K5/\
MG_#_ ,!D-;XS^#EZ7=RWTMFJ)OC;X17H]ZWTM_\ Z]7%^'NS[MY"OTM0/ZU*
MO@:=/NZFJ_2#']:/K68_\^?QC_\ )!]5G_T$1_\  9&2WQR\*+TAU)OI O\
M\541^._ACHMCJS?2&/\ ^.5T"^$+Y/N:VZ_2,C_V:I1X9U5?N^(;@?0-_P#%
M4?6,Q_Y]/_R7_P"2#ZG+_H)C_P" ,YG_ (7GH3?ZO2=6;_MDG_Q='_"[M-;_
M %>@:LW_ &S7_&NG_P"$:U?_ *&*X_)O_BJ/^$;U?_H8KC\F_P#BJ/K&8?\
M/I_^2_\ R0?4G_T%+_P!G,?\+HA;_5^&-6;_ ( */^%Q2'[GA#5F_P" G_XF
MNG_X1O6/^ABG_)O_ (JC_A'-8_Z&&?\ )O\ XJCZQF'_ #Z?_DG^8?4G_P!!
M2_\  7_D<Q_PN"X[>#=6_P"^3_\ $T?\+?NNW@O5O^^3_P#$UT__  CFL_\
M0PS_ )-_\51_PCNL_P#0PS?DW_Q5'UC'_P#/J7_DG^8?47_T%+_P%_Y',?\
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MJ=/AELZ6FB_C:(?YI1]?QG_/B7W+_P"2%]4Q'_/VG_Y-_D:#_%[P2G36&?\
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M^P_\ 7_^.T>3K7_/_8?^ +__ !VM&B@#.\G6O^?^P_\  %__ ([1Y.M?\_\
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M6C10!G>3K7_/_8?^ +__ !VCR=:_Y_[#_P  7_\ CM:-% &=Y.M?\_\ 8?\
M@"__ ,=H\G6O^?\ L/\ P!?_ ..UHT4 9WDZU_S_ -A_X O_ /':/)UK_G_L
M/_ %_P#X[6C10!G>3K7_ #_V'_@"_P#\=J*YL=8N8@C:E9H!(DF4LG!RK!@/
M];T.,'VS60OCZ";XDMX1M=.NI7CLY;B2[8;$+H4_=)N&'.)!DY &0.><4+?X
MBWL<FKV>L:%%9ZII]M;3K:1:@)PS7#E(XG<( DF[ ( 888$$T =7Y.M?\_\
M8?\ @"__ ,=H\G6O^?\ L/\ P!?_ ..US4GQ"FTWQ++IGB/1O[/C^R7%[ T-
MU]IF:&%PNYXD7Y=^X%0K/GD'!&*U? _BS_A-/#"ZP-/ET[=<30_9YFRZ^7(R
M?-P,'Y>1S@\9/6@#0\G6O^?^P_\  %__ ([1Y.M?\_\ 8?\ @"__ ,=K1HH
MSO)UK_G_ +#_ , 7_P#CM'DZU_S_ -A_X O_ /':T:* ,[R=:_Y_[#_P!?\
M^.T>3K7_ #_V'_@"_P#\=K1HH SO)UK_ )_[#_P!?_X[1Y.M?\_]A_X O_\
M':T:* ,[R=:_Y_[#_P  7_\ CM'DZU_S_P!A_P" +_\ QVM&B@#.\G6O^?\
ML/\ P!?_ ..T>3K7_/\ V'_@"_\ \=K1HH SO)UK_G_L/_ %_P#X[1Y.M?\
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M)W#H4^[CG/45S?A;X8WN@P+#J.N6NI>9J*:C>7/]GNES>RH2R^9(TSC ;80
MH V=,DFO1** .)\)^!=2\/>+=6UW4=:M-6GU20M+*^GND\:?P0H_G,JQK_="
M<]SP,;/A#PW_ ,(IH<FG?:_M>^[N+GS/+V8\V5I-N,GINQGOCM6[10 4444
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M/#VE2QW<_P!IN$DLHV$TO/[QP5^9N3\QYY-:L44<$*0P1K'%&H5$1<*H'
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M?Q5XJN];MKO4K^2V4ZU::?/I!MHUC19=/29P25\P,LC$CYN,8.172>-K0_\
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pic1.jpg
<TEXT>
begin 644 pic1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #, E8# 2(  A$! Q$!_\0
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MT4 > ?\ ",_M0_\ 0\_ 3_PAM6_^6M'_  C/[4/_ $//P$_\(;5O_EK7O]%
M'@'_  C/[4/_ $//P$_\(;5O_EK1_P (S^U#_P!#S\!/_"&U;_Y:U[_10!X!
M_P (S^U#_P!#S\!/_"&U;_Y:T?\ ",_M0_\ 0\_ 3_PAM6_^6M>_T4 > ?\
M",_M0_\ 0\_ 3_PAM6_^6M'_  C/[4/_ $//P$_\(;5O_EK7OI?'_P"NC?\
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MA33IGTN6]\8K/?Z!;PV!G?4/]%DFDEB"H<%H=_)P7W%1DMBA#T)?V:_CI/\
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M8C_A'?$1P<9%M'S_ .1*E/Q1\-'KKVC_ /@4G^-)_P +/\,_]!W1O_ I/\:
M(O\ A8,W_0N>(_\ P&B_^.4?\+!F_P"A<\1_^ T7_P <J5?B=X;9PHUS1V9C
M@ 74?)_.N#^!_P"W9\'?VD[?69? OQ$\)>)X_#]Y]@U%K&^5Q9SX)\M\XYPK
M?D: .X_X6%/_ -"YXD_\!HO_ (Y2?\+!F_Z%SQ'_ . T7_QRI?\ A:'AD_\
M,=T;_P "D_QH_P"%G^&?^@[HW_@4G^- $0^($[,!_P ([XB&3C)MH\#_ ,B5
MXU^QI_P4(_X;'\,^(M2M_A'\8_ H\.ZJVE-;^*]!33YKXA WG0*9/GBYQN]:
M]I/Q.\,G_F.Z-_X%)_C1_P +/\,Y_P"0[HY^MVA_K0!'_P +!G_Z%WQ)_P"
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M&!Z 4\-C_P#57-)\)=$4?\>]U_X'W'_Q=+_PJC1/^>%U_P"!]Q_\70!TF_\
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MFNW_ /9NO?;KG0; 7$<-P-0B$"^1=1)(9?)!;<L,PSE,G+\9?\%2[[P9X_\
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M<<7B$_>::^9]#B/[&E']S":E_BC;X;;<U_BUW^]:&'X,_P""A^GZMH]G)?\
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M-V$A^1A&Q#':<+X1_9(^$'@^S,>D^%M$ABO7$9*W#R^<RR6SA06D))#V5L<
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M28N!3ZCA&!4E '"_'3XX:=\ /!LFOZO8:O=Z7;,OVJ:QB23[&A./,?>Z<9(
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M^^HS^%:'VR'_ )[)_P!_!2Q2+*,JVX>N<B@"4'(I:** "BBB@ HHHH ****
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M7);S6TT5I:V\=J\-[:70,$:1A8-XLXXY/+QO$DI/S.37=6?[-K#XSZ[XKO\
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MC0 O_"L/#A_Y@.C?^ :?X5J:9I-OHUDEO:00VUO$"$CB0(BYY. .*LH,"G4
M%%%% !1110 4444 %%%% #&C '05Q'Q;\4>*?"]II;^&/#47B62?4(X;Z-]0
M6S^R6Q^_,"0=Q7LO4^]=P_W:XKXC?&K1OA?KWAW3]2^W^?XGO?L%D;:PEN%\
MW;GYV12$7H,M@98>^)GMO8Z,+&4JB4(<[[:ZZ>5GYG.?M)?%3QC\.?#VD_\
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M_!07P]\%;'XB7'B31-:TD> ;>SECCNKBUB?7GNH+B:-(,R[4XMI03,R?<8]
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MBB@ HHHH *0]*6D/2@#QOX&?\G/_ !M_Z_\ 1_\ TUQ5[+7C7P,_Y.?^-O\
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MS'_"QC_T ?$G_@#_ /94Z#X@F>X1/[#\0IO8+N>RPJY/4G=TH Z6BFH<K10
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MGB;2?M"OX&:SET.U\1LW]CKM.GW<-S)!.1Y6<21171"XW8#Y4;N>B\.?L7^
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MP"W)]*]#CF7;D$%<]<\?G0)[Z%JBJ#Z_9KYG^E6H\F00R$RK^[<XPAYX8Y&
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M@_[X%:<N(_GC_P" _P#VQP^VR;_GQ5_\&Q_^4GA7_#T/]G__ **YX+_\#?\
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MU>[?9+;^[#_WP*1K2V ^Y#_WP*.7$?SK_P !_P#M@]MDW_/BK_X-C_\ *3Y
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M%_\ #T/]G_\ Z*YX+_\  W_ZU(?^"H7P _Z*YX+_ / W_P"QKW;[);?W(?\
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MI/BWP1<>*=/\2RV"Z*Y\5VXT:U-KYNPB*:W,2^896DQO3=N ?_5 !F6OX?\
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M'AO_ , 6_P#C](9UF:,UR?G:]G_D8/#?_@"W_P ?I?-U_P#Z#_AO_P  6_\
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M5_\ (%?0E%'U.CV?WO\ S#_6/']X_P#@NG_\B?/?_##WB+_HX;X\?^!^E?\
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M;U;?3]-O])&BV;1:0\2SRH=OE_*\J7(+>H1*[E?V6?AD1_R3KP'_ .$_:?\
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M#WNFV\%K=WD,9VK(88VD^QRNQ2,,A:-9#EEKZQ@.11MN+9V9P_\ PRQ\,O\
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M]M((C) N]?+601@#>>7SM4 FG_$7PE\</'<6HJ%U+3[6YU6";2K:SU*Q@-K
ME^KR+=N"693;* HB8G.\,3D&OJ@1*.PH\I?05'U96W9K#.I1<7[*%UY>=^Y\
MS:9X9^/-O>VT4FIVMM;II<48-K#:3QQR"QVR!E>1"9OM?S*PRFP*. 6QZS\
M8/%D/@C;XQ63^TUNI0C2W$4LCPY&PMY8VJ3S\NY\?WCG [_R5/84HC [5I"E
MR]6<N*Q\J\>64(KT5@04Z@#%%:G %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(1FEHH 9Y7^<US[_"/PQ+=7DS>'
M-":;4 5NI&T^$O<@D,?,.W+Y(!^;/(!KHZ* ,N/P=I<-WYZ:=8I-M1/,6W0/
MM3&P9QG"X&!VP,=*CU#P#HNK0B.YTG3+B-2I"2VL;J"N=IP5(XW-CTW''4UL
M44 9-OX)TFTU&*[CTVP2ZA+F.9;>,2)O.7PP7(W$9.#SWS6HB;33J* "BBB@
C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pic2.jpg
<TEXT>
begin 644 pic2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #- G$# 2(  A$! Q$!_\0
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M>=)^$K?]Q;45_P#;<UZ_BDD&%H^OK_GU'[G_ )A]7?\ /+[_ /@'D \2?'.
MX_X13X4W/?>OBJ^A_#;]A;^=*/%7QS/_ #)GPL_\+&^_^5U>.^"/'/Q'W_'F
MWU2S\7'5K'2]:N=,O(I[LP6S)=7J6$$$#IY8F-LMO(C6I.Y6'F?O.3XQ\!OC
M5^T/X+^(.BW'B.+QC>Z9I'AU/"MY-JUC=75H'COK!I=>FB0*9Y!;WFT896/D
M3'[JMCH52+O^ZA_Y-_\ )&-FK>_+\/\ (^R?^$J^.8_YDSX6?^%C??\ RNH'
MBKXYG_F3/A9_X6-]_P#*ZO!-?_; ^/6K^%-2>Q\&6^EW4EDUO9;/#UY+-Y[Z
M1J=W%=KO?:%,UG:J(74E?M81CO #4O"W[2?QK\%'Q5-!:'Q5!JT]Y=:;<:OH
MFH0PV+P:=HC@@IN*6\CW-YB/9A9(G._ <*O:+_GS#_R;_P"2"W]^7X?Y'T3_
M ,)3\=/^A,^%G_A8WW_RNH_X2?XZ?]"7\+?_  L+[_Y75T'[-WQ#U7XK?!3P
M[K^NZ;<Z1JVI6Y>YM)[%K-XW5V3/E,\A56"@CYVR&!!P:[Y0,5B\933M[&'_
M )-_\D:JA)J_M)?A_D>0_P#"3_'3_H2_A;_X6%]_\KJ/^$G^.G_0E_"W_P +
M"^_^5U>O8HQ2^NT_^?,/_)O_ )(?U>7_ #\E^'^1Y#_PD_QT_P"A+^%O_A87
MW_RNH_X2?XZ?]"7\+?\ PL+[_P"5U>O8HQ1]=I_\^8?^3?\ R0?5Y?\ /R7X
M?Y'D/_"3_'3_ *$OX6_^%A??_*ZC_A)_CI_T)?PM_P#"POO_ )75Z]BC%'UV
MG_SYA_Y-_P#)!]7E_P _)?A_D>0_\)/\=/\ H2_A;_X6%]_\KJ/^$G^.G_0E
M_"W_ ,+"^_\ E=7KV*,4?7:?_/F'_DW_ ,D'U>7_ #\E^'^1Y#_PD_QT_P"A
M+^%O_A87W_RNH_X2?XZ?]"7\+?\ PL+[_P"5U>O8HQ1]=I_\^8?^3?\ R0?5
MY?\ /R7X?Y'D/_"3_'3_ *$OX6_^%A??_*ZC_A)_CI_T)?PM_P#"POO_ )75
MZ]BC%'UVG_SYA_Y-_P#)!]7E_P _)?A_D>0_\)/\=/\ H2_A;_X6%]_\KJ1_
M$_QSQSX+^%G_ (6%]_\ *ZO7\4CKD4?7:?\ SYA_Y-_\D'U>7_/Q_A_D?)WP
MP\6_%JR_:C^*+Q>"O!%YJLEAH0NX8_%,Z6\"B*[\HI(UGN<L"VX;1MP,%L\>
M_P#COQ#XWTW0M.D\.>'= U?49<?;8+W67LXK;Y03L=8)#)\V1RJ\#/M4OA/X
M2V_A7XK^*?%:7<\MSXJM["WF@90(X!:+,JE3U^;SCG/H,5UV*VQ^.I5:T9PI
MQLE%?:UM%)KXNC6EK?,SPV'G"#C*3U;[=V^QQ<_B'QNOPP6\C\.Z WB_Y=VF
M-K+BQ'[S!Q<^1N/R?-_JN3Q[TO@G7_&^H>$M0GU_P[H.F:U$7^Q6EGK#W=O<
M?)E2\Q@0IEN#A&P.>>E=GBC%<'MH\KCR+5WOKIY;[?CYG3[-WOS/\/OV.%^&
M/B3Q_K%]<KXN\,>'-"MUC4P2:;K<FH-*^?F5E:"+: .0<G/H*K>$_%'Q*O/&
MOD:WX5\(Z?X?WR@WEIX@EN;H*-WEGR6MD7+87(\SY<GKCGT/%<!^T]IFNW_P
M \8#PSJ^HZ'KJZ3<26=YI\"S72.D9;;$K*PWMMV@[206R!D"K]M"4G^[BKZ?
M:T\U[WYW)]G))>\]/37\"/7/%/Q)M_'GV?3O"WA"[\-^?&HOIO$,L-WY1V[V
M\@6K+N'S87S.<#D9XF^)WB3XAZ1J\">$?#/A;6[%H=TTNIZ[+ITJ2[C\JHEO
M*"-N#N+#DD8[U\Q_#WXG?$?6OC=X>LO#T?BF34=%\"P7FOP^*;R]M].\0:I-
MI\/DV=LC1-&IB97FFG&&,CB(MRVW5_;&\??&G1?@3\)?$-CI.J:7XTL=5CUC
MQ)HOAJ66[@O([:PFN9[&3:N"DK1F,(2P\QD4._#'=<JG%<D=O[VOF_>_*R,G
M?E;YG^&GIH?1_CW7_'%CH.GR>&=!\-:IJ,G_ !_0:CK$ME%;_*,^7(D$A?YL
MCE5XY[XHFUWQP/A>MTFA>&3XPXW:<VL2C3Q^\P?])\C?]SG_ %7WN.G-?'7[
M,G[0GQV^'^G3Z/XDTG6?$6H7/B%[B%M7TZ\GFU1+F_C66TMYAMCMHK.VD,H9
MPRL!M& K&E\8_M6_'GQ;X!M-^EW'AU[O2VN;F72_"]ZDS/<^'M0N(K=2[N\<
ML=]!"@<8.^2,, ?E=*G:T>6.CO?77RWV]+/S#GOK=Z]--/P/L7P1KWCB^\)Z
MC-XAT+PSIVM1[_L-M8:S+=VT_P F5\R5K>-DR_!PC8'//2H?A?K_ ,0=6U"Z
M7Q?X=\*Z+:K$IMWTG7)M1>1\_,&5[:(* .003]!7S/X8_:X^,OA.X\*:1J7A
MA=6MHM8M]'U&^&@W_P!NOX7@TUEFCC+B/<INKD2OYI(\@L(SM=:^SH.GXFLJ
MDE%.\(^]MOIZ:_G<N"O;WGIZ:_A^1P/A77_B;<^-_)UKPSX*L_#N^4&[LO$%
MQ<W@49\H^2UHBY;Y=P\SY<G!;'+?$.O_ !,@\>&'3O#/@JY\,>?&/MEQXAN(
M+[ROE\QO(%HR;A\VU?-P<#)&>/1,4V1-PI?6(\W-[..UK>];U^*]_G;R*]E*
MUN=_A]VQ\I>/OB%\8-'_ &T?[(^%NGCQ9X+:"*3Q)'KDC0Z;H]X7.Y;:[VEU
M<Q[':)!*H9ONKDBO2O\ @GXY?]C3X<$X!.B0D@=CEJ]AAM_*4 >N>!CK7(?L
M_P#PF_X4;\&_#GA/[;_:/]@626?VD1>5YVTD[MN3CKTR:]#$9C3K8/V*@HR3
MAJMY64KN73JNB=N^YRTL+.G7]HY-I\WHKN.B^[_ACM****\4] 0C(I!&%/:G
M44 %%%% !1110 4444 %%%% "%<TGE\TZB@!OET"/ IU% #3'FA4VTZB@ HH
MHH **** "BBB@ HHHH **** &[!FG#@444 %%%% !1110 4444 %%%% !111
M0 4444 %(1D4M% #?*!_I[4&/-.HH ;Y=&RG44 -V4ZBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I",BEHH :8\^_UH\O%.HH :8\
MT;,__KIU% #3'FE5=O2EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF#)YDR*HPP&TG@KSA2A16D+/;=]+;_>4IU'\5_Z9>^)7[=7QAOOVO?B/\.?
MVG?!:UT_X?KI[M=^,-<NM.FNQ=0>8-GEAE;:5;. , KZU]0? 7Q/XG\3?"+2
M=1\9+X5_X2*X1WNO^$9NY+W3&&]MAAD<!W&S;GC[V0*^%/CG^RCKTO[>_P 6
MO&/B#]ER+X\>&?%,>E+H5S<ZEI<26+06VR=E6YDW#>2JGY1_JNX(K[0_95TN
M;3_V>-%L(OARGP<^PQS6MKX7$UM=)I$:R.(RIMR8BK?ZS:I_BP>:RKJ"A'DM
MT_+U_0JDY.3YO/\ ,^4_A'_P5.^+/[0.L:AK?@?X=> O$?AK3-<DTVX\+P^)
M_*\;);1R^6]R;:0+#P,OMW=B,\$UW/\ P47_ &P_CA^QQ:S>*M!\,_##5O $
ME[I^F6KZA?WJ:L;FY81G?%&HC""0]0Y.WL37SA\>OV)_C#\:K6^T[5/V??"<
M7Q?_ +4+67Q@\-^((-$LP@GW+>26T;^>9!&,%2I)//7K]0?\%0OV>/''QW_8
MPTCPKX:L9O%GB:TUW0[JZ\N2*W:X6WF5IY_WCJHZ%L9SSP#6S5%5(Z*W7^K_
M .1FG4<97O?^OZZB6G[6_P 8_AG^T3\'?A[\1_#OPW@O_B9?ZNEQ-X?O;RYB
MM;:UMHY82C3*G[QG,@8%2 H7')-6/B/^WOXC\&?&[]H3PQ#HFB36?P?\!P>*
M].FD>7S+^=[9YC%, <! 4 ^7!P:/V_O@IX_U7XU_!OXL?#KPY;^--4^%VH7Y
MOO#[ZC'8S:C:W<(C)ADD^0.I!X8C.1Z&O,M'_9G^+/Q?D_:@^(WB7P2G@_6_
MBEX'_P"$6\.^%O[4M[V\D,-G+&KRS(WDJSNR@#=CDYP!DQ%4FE)VV_'F_P B
MVYI\JO\ \"W^8_2?^"DWQL^&'PO\ ?%#XF?#_P"'A^%7C:6PCGOO#>L73ZCH
MJ7N!#--#,FTJ"PW!6/INSC/;?$#_ (*<2_LP_&/XJ>&/B[IFDZ-;^&]%/B?P
M;>V#R;?%=CG9Y $A.+H2E$*KP<L<8%>*ZE\"/CS^TY^R9\./V?\ 5_@_<_#[
MP]HQTB#Q%XHU3Q%8W2O:V11G%O;P,SEY&48#'CN>I'O/_!1?]EC5OV@OB5^S
M_?:3X5M_$-IX/\=6]]K4DGD?Z%IH7+EA(P+)N2,E%#$E1\M4XT>;EE;KL_NZ
M]=B4ZG+>-^FZ^\]G_9+\=>._B7\!O#_B#XBZ)I/AOQ/K<'VV72K R,NGQ2?-
M%&YD)8RA""_0 G&.*],IB$8I]>>W=W1UK16"BBBD,**,TFZ@!:* <T$XH **
M3-&: %HI-U - "T4A.* <T +1129H 6BD!S2T %%%% !17E7[4'[8O@?]C_1
M]%OO&]]J-G#XAO3IU@MCI-SJ,MQ.(VE*".!';[BL>G:O)?\ A\S\$?\ GZ^(
M'_A :W_\C5VT<MQ=:'M*5.37=)LPGBJ,)<LYI/U/J^BOE#_A\S\$?^?KX@?^
M&_UO_P"1J/\ A\S\$?\ GZ^('_AO];_^1JU_L;'_ //F7_@+_P B/KV&_P"?
MB^]'U<W2O,OCMXXU?1_%'@SP[I6H?V'_ ,);J<MK/JIMTG:V2*W>?RHED!C\
MZ4IM4N&  ?"L<8\>_P"'S'P1_P"?KX@?^&_UO_Y&K-\4_P#!6;]GOQQH\NGZ
MS!XSU6PG(:2VO/ASK$T3$'*DJUJ1D'D'L:<<GQR=_8R_\!?^0GCL/_S\7WHZ
M8_MA^(? >K^(="N=,L?%S^$8]7O;K61J$>F"ZLM/%DTFV,(Z/<@WGEL 4CWP
M-DQ[MJVK7]O*^UFQ>]TWP#K$^F76H)INE7EU</:0W4C:E%I_[YGAQ'\TI<",
MS';&ROL; /D6I?M[?LK:MXFT+4KC1_%D@\-6,UAIMBWPTU4V5HLLT4S.D7V3
M DWPKAACJV<YK83_ (*6?LPQ:_=ZJ-!\0#4[^5)[F[_X5?JOGSR)(LBNS_9,
ME@Z(V>NY%/4"MGE.*_Y\3_\  69_7*/_ #\7WH]7\4?M;/=?#FQN+;9HOB'_
M (26TTF]MBCW=O'&FMII]ULG:-(R&42%2=K ,#M!%<HG[=7B#QW\0-!T'PYH
M>F17=SJE@ZM-J,JV6K6%W;:DR,DTEJK##V:L)(HY5D'",P)-8A_X*O?L\-I1
ML3:^,#9&Z^W&W/PWUCRC<>=Y_G;?LN/,\[]YNQG?\V<\USA_;\_9+-M+"?!^
MHF.=TDD4_"C4_G9-Q0G_ $3JN]]O]W>V,9-)93B_^?$__ 6'URC?2HOO1WM]
M_P %!=1\9^ -9O\ PWX/UF&&UT:61]4DS-%IE[_9KW:EL1^3) A\I2WFAGW@
MK&4^:NV^,/BKQ5'IGPRO-+\5W^BGQ5JEAI=_%!8VDR,)[>65Y%\V)RKY10.=
MH&?E/6O&K_\ X*1?LN:IJD5]<^'=<GO(+3^SXYY/A;JC21VVQH_)!-IQ'L9E
MV] K,.A-;=W_ ,%;/V?KZ*R2:+QI*FF2I/9J_P .=886LB*51XP;7Y6520".
M@)Q0\IQFG+0E_P" O_(?UR@]ZB^\ZZ?]MW6K 006_@74-:N9FUEX([.\DGFN
M+;2[T64LC".VV1RRRD%$)$:@_/(G K-^(/[=VL)K%_HGAS0M.:^W*]C?SW<[
MVLJ1ZS8Z=<(Q^SA&E7[8/]2\JHZLK'<NT\7KG_!2O]F#Q/86]KJ.@Z_?VMI<
M2W<$-Q\+]5ECAFE8O+(JFT(#.Q)8_P 1))S5>3_@HG^RK-J%_=OX7UA[K559
M+R9OA7JADNE9E=@[?9,D%U5B.[*#U&::RG%7N\//[F)XRC:WM8_>CTJP_;SU
M"?51]H\&PP:7N25[A-<\R9;=M8;2=PB\@9D\X"39OQL)^8.-IDT#]N?6/%D&
MBO8_#W4(4\4W]I:Z-/?WSVEM/'<>>5:1V@)#*L(8K$LJXD #DJ17 )_P4^_9
MIC50NC^)5"JJ#'PQU8859_M '_'IT$_[T?[?S=>:@TC_ (*5_LP>']6FO['0
M-?L[ZXNA?2W$'POU5)7G&\B4L+3._,DASUR['N:7]DXKIAY?<P^N4O\ G['[
MT>T_LL?M(ZQ^T)XK\12SZ?9Z?H5MINDWFGQI.TMRCW,$CS)*VT*VUTPI4] .
M!FO;J^-O#?\ P51_9Q\'7K7&DZ?XKTR=[>.S:2U^&NKPLT,98QQDK:CY5+N0
M.@W''6MK_A\S\$?^?KX@?^&_UO\ ^1JSGE&-;O&A*W^%EQQN'2UJ+[T?5]%?
M*'_#YGX(_P#/U\0/_#?ZW_\ (U'_  ^9^"/_ #]?$#_PW^M__(U3_8V/_P"?
M,O\ P%_Y%?7L-_S\7WH^KZ*^4#_P69^"/_/U\0/_  W^M_\ R-4V@?\ !:']
MG#64N/M'Q&MM$N+68P26NL:7>Z?<JP /^KDB#8YQ]01VJ995C8J\J4O_  %_
MY#6-P[=E-?>CZIHKYG_X?#?LU?\ 17O"_P#Y,?\ QND_X?#_ +-6?^2O>%__
M "8_^-UC]1Q/_/N7W,OZS1_F7WH^F:*^9C_P6'_9IQ_R5[PO^5Q_\;KUK]G_
M /:8\#_M1^$[K7? /B33_$^DV5VUA-=6:OLCG5$<QG>JG.V1#T_B%1/"UH+F
MG!I>:94:U.3M&2?S._ILAVH37/?$3XJ>'?A)H@U3Q1K^B^'-,:9+<7>J7D=I
M 9&SM3>Y W'!P,Y.#7%_\-O_  :F4X^+/PVZ=O$EH?\ VI7#4Q="G+EJ32?F
MTCLI82O5CS4X-KR39XI\2_\ @IOK_P //'_Q$ ^#>LZQ\/OA5K*:9XD\467B
M"UWV*-%#*\XLG42N$2968*QX!.>,5Z_+^W5\*K7XD2^$I/%*'5X9C:,PL;EK
M,W0@-S]D%V(_(-SY(+^0)/,Q_#7RA\1_@_X'^(7COXE+%^UQX$T?X>?%G6$U
M/Q)X<LX],:YN8Q%#$\*WSSEXPZ0JI*IT9N,G-;DOP:^#=UXP>U_X:%\#+\,F
M\6R>.5\+I=V(N(M3>)EP+[S\_9@[&01^5NW8'F%?EK=X_+6E^]BOGZ?COY&:
MR[,;_P &7_@+/9?CA_P4M^'GPN^#%OXNTFY?Q&=0T"W\5:?9K'-9?:]+EO+>
MU:Y,CQ$1A&N%)1AO(!X[B35O^"C'@B?Q+X0L?#_G:Q_;_BQO"NIM=QS:3<>'
MY!937HFG@N8ED*-%%N4X4,K;@V!7RY/^R#\/]:\ VWAZ^_:J\ 7%OI/@^+P7
MH\D-M91/8VL6H6U[%,X^UL)9O]'",3A3\I"K@JW9ZM\ ?AG\1O'O_"4^,?VB
M/ >OZ[?^)(]9U62T:TL8+NUBTJ?3(;2*,7+F(B.=W:4L^Y^BJ, 'U_+$OXT>
MOVE\@_L[,O\ GS+_ ,!9]8_ S]JCP)^T?)>Q^$M7EU&:PAAN72;3KFS>:VFW
M>3=0B>-#-;2;'V31[HVVG#<5YE\/_P#@I?X)\9:SXDT2_BNM#\2:/KNLZ%96
M,T<[V^K3:<'8HMWY(@2>2-#(("YD"\X->'_ _P#8J_9[\#>!]7T'Q3\5_ WB
M:QO[.PTZ&72=5_L"\$%G(TD9FN(;QY9)&9@7V-'%E?EB7)JQX3_9>\ :!J5O
M82?M%>"KSP3IOBO4?&=AHH2V%S;W]Q#-!"KWC73-)%$LQ8@H&D<9+@';4_VA
MEB;7MX_>BO[-S+3]S+_P%GJWPO\ ^"IO@KQ+X2A\0>*XH_"&ESZ!H&M-^_GU
M&XADU=I4@@:.*WZ;H\!U9MV3E4P,]EJ?_!1WX16G@^UU:/Q!>3O?7U[IL%@N
MB7_]HK<V:[KE);7R#/"L0*EWD150.I)P17S1X9_8K^&N@^']+L!^T!X.F_LN
MP\'V>\"W'F?V!<23AL?:>//\S;C_ )9[<_/G%=+??LX>#M/^*NJ^-_#/[0?@
M_1/$FIZ_K>I>;-#:WMNEEJL-LDUJ8S<+F1&MD=)MP&20T;#BF\QRN^E:/_@2
M["66YG;6C+_P%GU-^RS\<8OVF/V>_"'CZ/36TB/Q9IL6HI9/<"X-L'S\OF *
M&Z=0!7#6_P#P4M^#EYX-GU^WUS7+K2(+A[47$'A7591/)&)3,(@MN3((A#(9
M&3*QX&XC<,\C^QM=Z;^S+HUGX,NOBYX,U_P/X8\,Z7I6D,UQ9VTTEY$9_M4Y
MVR,^UPT&%=L*0=HQR?.?$'['W@?6_P!G[X>> 8OCIX2%MX&N]5GN1=0V]W8:
MTE^TY)EM#<A#+#YQ,3.TB*XW-&V=M0LQRWG:=:-K_P RV+_LS,>56H2_\!9[
MUKW_  4E^"WAO5+>UN?%Y;[58Z=J8N+?2+VXM8[34"!:7$DZ0M''%(2!N=E"
ME@&P3BLOQK_P4A\!:+\</#7@;1GEUV]U;Q)<>&]2O%BFM;'29(+6:XG87#Q>
M1<&+R@LB1R90OEL8->(Z9^P_X(L_A/XH\,?\+R\,NWB3P=X=\)BZ$4'^C#2)
M3(+C9]H^8R@@%,C;R<MG%6]4_8H\':YXEL[*X^./AV;X=6'B?5O$T'A[[/;_
M &L/J=O<PW,!O1/DH&NI&C/E KG#;^"-%C\L_P"?R_\  EV_S,WEV9?\^9?^
M L]OL_\ @IA\$+CPGJ6M?\)CY6G:3':SRRSZ/?0M/;W,_P!G@NH$:$-<6SR_
M*)H@\>?XJ9IW_!2CX1^*;V73]'\0SW.LA+]8K*\T>_L ;FRA>::TEDEMP(9U
M2-G\IAYFSY@A!&?!]6_80\/>-=!TZW\2?'OP_K5YX:TS2/#_ (>N4T^VMAI^
MFV-_!>%9D2X_?W$OV>)&E!15"Y$>2<]-K7['?@[6]>FOA\7]!C,WCS7O&VP1
MQ'']IZ<]C]ESY_\ RSW[]_\ %C&U>M/ZYEO2JOO0OJ.8?\^G_P" L].\%_\
M!2+X;:JO@*SUJ]O]$UOX@V=K<Z9%_8^HS:=<-/;K<;(KXVR0R!(SN=LKL .\
M)@@:EK_P41^#VH>!]7\0)XJ>/3-%%H[F72+V*:\2ZD,5I):0M")+N.>162)X
M%=9""%)KY_\ A]^P_9>#O&GAR\NOCKX,U[1?#O@^V\#6^GWVBH9++3A L5XU
MG*+T"WN+G!+3%)& VKRHP<WP!_P33\"_#SP>T%G\6_"<'B72)](G\.:W;:9"
MDMB=-G,T+7:/=/\ :C(3B0*T,?=$C8DTWB\M_P"?R^]$K!9A_P ^G]S/I'X)
M_MM^'/C%\-?B5XP^RW&D^'?AOK%_IMQ<W(=9+F&TM8KB2=HG1'A;$C*8G&Y2
MASUP.7T3_@HG:ZI\0O@_X8E\#^(+?5?BG;6]U<R.3]A\/B>SFNX87N"@6>X:
M.)B8H_N $L1\N[#T'X Z1I'[-7QK\':G\5/#?B36OC!=:MJ,VH*L.FQVT]Y9
MQVX18Q+)\BM$"#NS@X.2"3?\+Z!I/Q8\#_L^:[K_ (HTKPGKOPP,&IZCI%Q-
M!(\MQ_9DEE);EEEVH TC.&&X$*..<B?KN!U?M(V_Q+M_F5]1QNB]G+_P%]S4
M_:._X*0^$O@;\.H]<TS1_$'C"6779M -O:6,UK#:S6]Y%:74D\\D>V**-YE"
MO@B5BH3=DL/3O GQWM_&?QS\>> Y]/?3]5\$K8W2R-,)$U*SNXF:.=!@%<21
MS1LIS@Q@Y^88\Q^-G@2P^/O[/'B'P-XC^,'ARZN-8UM-1MM26VMXOL5I%?QW
M<%IY2R@2;$B$7FE@6^\1GBN)U^;6M2_:S^(?CGPUXI\.^'?MC>%O#]E=7=W9
MRIJ6G6L\MUJ4@5W.%*W+1*P&_?&VT=&$K&8%QM[6-_\ $O+_ ()7U'&I_P *
M5O\ "_/_ (![?\<_VV/AI^S;XI71/%VM7=AJATIM;,%MHU[?>78K(8WN7-O$
MX2-&!W,Q 4<G YKD++_@HKX*L_%'CVWUB*\LM)\':K8Z99W^GV\^KG7?M6GK
M?K+%#;1.ZHL3$EOF7:I8D#BO*OVG/!]]\:_VR[R\\._$3P_X.\-ZK\+[CPO?
M:Y)':ZE#(9[_ #):JC3(R3B%O,1^5!'S*XXK!\0_L!^ VENHM(^-GARSTJ75
M].OH]+U&"#4+*>WM-'72Q#=1?:$6Y;:OG(SC8K]8W JHXW+E%<]6-_\ $A/
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MLUUO<^7KU ,\#IZ5AZC$&/;\JWK\<FL/4#C\Z\N.AZLC]@O^#?4?\8D^(?\
ML8F'_DM#7U9X\N6M/V@_";*S+N\/ZSRIQ_R\:57YZ?\ !(C]L?1?V9OV8+NP
MU/PM\2_$$NIZW+<++X9\*W6L0PA884VR/""$8GHIYQS7MG[(G_!2;2_V\OB[
MI<EOX2\2>&;_ ,/:3K%M=&YMVEL9B;G3P/+N  -X\L[HW 9"R@YR"?Z=X$H3
M>4T)VTY9?^W'\L<>U8K.<1&^O,ORB?87]K2?\]9?^_A_QH_M:3_GK+_W\/\
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M,L' R>K  '(&*^EK?_@A_:P?\U+O2?7^PD'_ +6J[#_P15M(L?\ %QKQL?\
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M7XZ4O_QRN"IPKQ3]A2WYOXD?B[_%OYG=2XNX2^VX_#R_PY?"OL_#MY;'Q_\
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M7_JOQ;)ISYM-OWB[I_S=TG\EV(7%?!T4XPY$GO\ NI=FOY.S:]&^Y\5_&?\
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M0_TZ#YO^6J_S%7?V0FW_ +/WA\_[-P?_ ":FKE[/4<WL'_75?YBNF_8X;?\
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M/^P*K^!?%-EJ%_9^*=/>[TN8^1J%HH\]=[0M\Q0GI(NY#D8:OS*L!TK]3?\
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M:CJ<S5_0_/\ _P"&C_B)_P!&O_'7_OC3/_DBC_AH_P"(G_1K_P =?^^-,_\
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M?^^-,_\ DBOT \I?[J_E1Y2_W5_*C^WU_P ^5]\O\P_L>/\ ._P_R/S_ /\
MAH_XB?\ 1K_QU_[XTS_Y(H_X:/\ B)_T:_\ '7_OC3/_ )(K] /*7^ZOY4>4
MO]U?RH_M]?\ /E??+_,/['C_ #O\/\C\_P#_ (:/^(G_ $:_\=?^^-,_^2*/
M^&C_ (B?]&O_ !U_[XTS_P"2*_0#RE_NK^5'E+_=7\J/[?7_ #Y7WR_S#^QX
M_P [_#_(_/\ _P"&C_B)_P!&O_'7_OC3/_DBC_AH_P"(G_1K_P =?^^-,_\
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MA;@%_P OI_\ DO\ D0_%G,'_ ,N8?^3?YGX&7O\ P3D^/,B\?"?Q@?I#%_\
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MOJOR$_NC\J/(3^Z/RH_MB7\OXA_9,/YCY4_M:X_Z%+Q__P"$S<_X4?VM<?\
M0I>/_P#PF;G_  KZK\A/[H_*CR$_NC\J/[8E_+^(?V3#^8^5/[6N/^A2\?\
M_A,W/^%']K7'_0I>/_\ PF;G_"OJOR$_NC\J/(3^Z/RH_MB7\OXA_9,/YCY7
MMM8G2ZB8^$O'^%=2?^*9N>!GZ5[#^R7H=]X;^ 'AJSU*QNM.NX[=VDM[F,QS
M1;II' =?X3M8$@],UZ/Y"?W1^5."XKEQ68.O#D:MK<Z<-@HT9<R=Q:***\\[
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH YCQS_R,GA+_L+G_P!([JNF3[M<%\5O&VD>&?%?A*+4=5TRPE;5
M#(D=S=1Q,R_9;E-P#,#C<RKGU('4BNX@DW_G7'AZD75JQ3U37_I*.W$PDJ5*
M36C3M_X$R:BBBNPX@HI&Z5YI\1OCKJ.A_%&T\%^&/#T7B+Q%-IK:S<BZU :?
M9V-H)?)5GE\N1B\D@8*BH?N.6*@#+2;V$VEN>F45X/'^W5I'AOQ;%H_C/0-=
M\%W/]BVNK7(NK:2[%@9KVYLRL[0(Z1Q"2W#+.S!&693Q@UT>K?MD> =!U#5(
M+[5KNS72;>_NI+F?2;N.UG2QS]L\B8Q^7.8<'<L;,?E. <&J]E-=!<\>YZK1
M7DUO^VAX!O+1WBU+4I+E;Z/3UT\:'>_VC-+)";B/R[7RO.=&@5I0ZJ5V*QSP
M:BTW]N'X:ZO8Z1=VWB%YK'6K>VO(;I=,NO(MX;B5H8'N)/+VVPDD1E7SBF2/
M3FCV<^S#GCW/7JX/]J*TFO\ ]FSXA06\4L]Q-X9U*.**)"[R.;24!549)).
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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K3O)W_P"!HOP"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>slide02.jpg
<TEXT>
begin 644 slide02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $> <<# 2(  A$! Q$!_\0
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M/S-N_;N&=OKCTI8I8YXQ)#(DB'HR,"#^- #Z*8)XC,81*GF@;BFX;@/7%/H
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M\--?V[3ZE<R31S!6VH&*G!'7^&F3?#O68-8TG5=*UFTANK;3(M.F-Q:^<%"
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M5;"G@^QK#\2>%;G6_%7AO5X;F**+29GDDC=26D# =/RKH-2M6OM*O+1&"M/
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MBBO%3$MRCMGJ(\5:HKG^K1[O_P "?^9HZK:M9?<B#9<?\]E_[XHV7'_/9?\
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MRL-.BRK!ADGJ'9_7^\['\:7[-KW_ $$['_P";_XY1]FU[_H)V/\ X!-_\<H
MK0^"O#D$#01Z7&(V5E(+L<AD"$<GIM4#Z 4DO@CPW/.TTFE1-(P<,=S#.[?N
MSSW\Q_\ OHU:^S:]_P!!.Q_\ F_^.4?9M>_Z"=C_ . 3?_'* )[71=.LKQKN
MVM4CN&#AG!.3O8,WYD U?K.T2[N+W3?,NC&9EFEB9HU*J=DC*#@DXX'K6C0
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M0!1110 4444 %%%% &1X<_Y!<O\ U^7/_HYZUZR/#G_(+E_Z_+G_ -'/6O0
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M<)LOXGY[X)XITXJ4DF#=E<UJ***@9D>'/^07+_U^7/\ Z.>M>LCPY_R"Y?\
MK\N?_1SUKT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !65XE%NWAV]2Z6P:%TV,NH-M@.2  Y[#/ZXK5J"\\C[%/]IC66 (3(C)
MN#*!R,=_I0!YWX#^V:;J=F-533+22[TN&+;;L@,DJ$A5QUW!.R_**[O6M*76
M=,>S,[P-O26.:, F-T8.K8/!P5'!ZUR'@'5?"VJWUPVC>';/3;D1>:7A2$DH
M6( )C^Z3P<>_L:[^@#C)?"^G6,OA_3F+3?,\4C.0&E 5Y"2!_M<\>N*WKZSD
MAM6:U8;@?X@. <=#^ _*H=5,/_"0Z"#Y?G^=+MSC=M\ILX[XZ9_"MET61"C#
M(-363J0Y6^F@X6A*Z13C6*-5^T6X1Q@E\97.<YSVY)-3K:VQ0;8D*XP,#C&,
M?R)%3U";9-VZ,F)O5.A^HZ4K2CYCT8T06TA<>4IP2&X^A_H/RI_V:#=N\I<Y
MSG'?.?YDFJ-G)=137)NANCW\,H'''<#VQ6DK*ZAE(93T(-32J<ZOLPE'E9$+
M2W P(4QC'3MC'\B16=K.DV4^EW1\A8W*%M\8PV0/7OT%:](Z+(C(ZAE88(/<
M552"G%Q8Z<W"29EPZ?)811I B7$* ;4DX<8.>&Z'GGG\ZF@:QE;R?*$<H&/*
MD7:V,$=._!(XJ_4<UO%<)LFC5U[9'3Z5*A*"]Q_)_P!?YC<U+XE\QIM+<YS$
MG/7CZ?X#\J/(MQ(/D3>?F'KP<Y_,Y_&H/(NK;FWE\Z/_ )Y3'G\&Z_GFJ4FK
MVRZW:P7&ZWF,3C;(,#DC'/3L:F==02Y]-4M?\RHT7-^[J:@M+<# A3 &.GL1
M_(D4&TMR#F%.>O'T_P !^52@AAD$$'H12UN8D7V:'=GRESG.<=\[OY\U!;6B
M;9!+%%PY";1_#R!^A(_&KE5+ PLDYAWX\]PV[^]GG'MF@"*.RB_M.Y9H!L:)
M%!(X/7(_1?TJW]FAW9\I<YSG'?.[^?-0Q$_VK<C)QY4?'XM5NDI\^OR^[0;C
MRZ?UKJ5WL+5X_+>!"G'!'IT_F:<;2W.<Q)SP>/8#^@_*IJ*8B+[-!NW>4N<Y
MSCOG=_/FD%I;@ "%, 8Z>Q'\B?SJ:B@#*^Q6QUUR8(^;4 G:,]<?R _*KCZ=
M92-N>T@8DYR8P>^?Y\T@\G^U3]_S_(&?[NW<?US5JJYF+E11;1[!O^795_W"
M5_D:H:CX4T_4(@'\X21\Q2>8=T9P!P>H' XSSBMVBJC5J1=TR7"+Z'':=X<U
M!["*2/7)XP23Y:QIC[V>I!(Y&:F/AVZ0CS;S59% QF&\0>O;8OJ>_>NCL;=K
M6SCA<@LN<D=.I-6*VGB9.;>GW$PI\L4D<I_8FEXQ=7>MID8/FW4JCH!U4XZ
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MMZ_<24445N8D/[[[:>%\GR^O?=G^6*FJJ/)_M4\MYWD#CMMW']<U:H ****
M"BBB@ JO=0-/Y.T@;)5<Y]!5BBFFT[H35U8****0S(\.?\@N7_K\N?\ T<]:
M]9'AS_D%R_\ 7Y<_^CGK7H **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPHIN=/"D,YDPQ!6-&Q(2.Q&4X[ALUU=S/#:VTL]PP2&-2SL1G '6J":_H\A
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M?\@N7_K\N?\ T<]:]9'AS_D%R_\ 7Y<_^CGK7H **** "BBB@ HHHH ****
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M*L^#]&O-!T%;&]DC9EE9HXXG+K"AZ('8 MCU([X[4 6?LNN_]!6S_P# $_\
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MX5!0M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0
<M%)N%&X4 +12;A1N% "T4FX4;A0 M%)FB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>slide03.jpg
<TEXT>
begin 644 slide03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 ?L# 2(  A$! Q$!_\0
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M8XQ8Z@D8MV60%CM SD=J[>BBL)2<G=EI6"BBBI&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!G?V?=_]!2;_OA:3^SKS_H*3_\ ?"UI45S_ %6G
MY_>_\S;V\_+[E_D9O]G7G_04G_[X6C^SKS_H*3_]\+6E11]5I^?WO_,/;S\O
MN7^11ALKF-R7U"608Q@J*G\B7_GX?\A4]%'U:GY_>_\ ,AS;=V0>1+_S\/\
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M?\CF_P#A'=8_Z&J]_P"_,?\ A1_PCNL?]#5>_P#?F/\ PKI**+L/K=7R_P#
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M*Y_\&$5']M:__P!"N?\ P814>S?]-!S(Z*BN=_MK7_\ H5S_ .#"*C^VM?\
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M_#=P[:?<O)&8G:_N6:,G.PF4Y'X5R$2FPU^7[%#KTEO)/=3:Q;7<1,$L97^
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M_ .9&_\ V/J/_0UZI_WZ@_\ B*/['U'_ *&O5/\ OU!_\16==^.- LEMVEU
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M!XZ5V5C%'8:?;641)CMXEB4MU(48JC_;=A_SSU#_ ,%\W_Q-']MV'_//4/\
MP7S?_$TG=[AJ:WG>]'G>]9/]MV'_ #SU#_P7S?\ Q-']MV'_ #SU#_P7S?\
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M@TBHW549RRC\%(%;=%%9MW=RDK*P4444AA1110 4444 %%%% !1110 4444
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M+M R2".O2O*QX1FFU".YN-(B=G\0O=3.X0EK8KQGGE<_P_I6[H.E7-GX)O\
M2KJQSOFN?+M?-\L/&S$JH9<[00?PJ72BNH<[-R/QSISZ4=2>UU."W)C$7G6C
M*UP7^Z(QGYB:T],U^RU;3?M]M*RP!F5_.7RVB93AE<'[I'>O,H_#NHQNU[I^
MCR6%G;W5I<0Z4]PK-(T>1(P.2H)!XR><<XK:M=+U >"O$,,MOLO=4DNITMMX
M)3S,[4)Z9]>U-TH] YV=S_:UB1D7UK@,$SYZ_>/0=>I]*=)J5K%+Y4MW!'(
M"4>50V#P."<UY#<^"9C:7ZPZ+#O;0X(8,!/^/H$;L<_>Q_%^M4-8C2*6_MI[
M6UNM0DU6UD%X)T:2,?(/*VYWY'/ &,<TU0B]F'M&>ZI-\Z\]ZJ^"/^15@_Z[
MW'_HYZA$_P"]'/>I? W/A*V/_3:?_P!'/7/4C:'S_P S2G*\CHJ***YS<***
M* "BN'^)#S&UTN"#4$@:2X8FV>[>T%T ARHF7[A'W@"<''>N=C^(MS8^')GC
MNT;R-"BN[9]0 \V:8R.C;L$!ONCIUZ]ZUC1<HW1#FD[,]:HKRC2?%>J6.O72
MF^M;JWGUYK9[%MS7*JT8;<GS<*,?=QCKS5WQ)\0]1L+NRFM+9;.PV>9<IJ$!
M6XQO"_ZO<&"D=& ;GMQ3]A*]D'.K7/2J*\KTGQ5JFG^([J&^U:TEM+C7Y;5A
M,NUH8Q#N7!+?*#@ #'8^M9.J?$#6M6\*W:I>Z?8?\2RXN3,0RM<8E>-5A(;Y
M6 4'//)'%/ZO*XO:(]JHKQ^3QKJ^E0SV]@D;W$^H^5YUP^Y55;6)S]^15!)/
M3<!U.":T8_B%K!U_1TN4TZWL;M+998T83/YDN>,J^5&<;3M*D=2*7L)#]HCT
M^BJ>F/.]J3<7EO=/YCCS+=-J@;CA<9/('!YZCM5RL66%%%% !1110 4444 %
M%%% !1110 4444 %%':N2;3DU+Q!K+W4,]P(A$L5N+@JJG9]X8(&3ZT =;5>
M]OK;3[8W%U*(XP0,X)))Z  <DGT%<;;BZU6ZO/MNBW5S]FE\B. WJJ(5"C!Q
MN&6.<[ORIT<VH1MIBR6SW)AU&58(FN4=]HB;AFSC*DD<\X [T ==8ZA!J$32
M0>9\K;662-D93Z$$ U:KFY-^LZU'8ZE');PK:^?]D\W_ %K%B#N*GD* ./\
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M$M;-<""./>?E;;LW?=W=_ID]JI^T>C(C"G%W21OW5U':0^8^22=JHHRSL>@
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MBB4N%)9O7)X'>CDG>P^9&Q_8,W_0R:W_ -_H_P#XBC^P9O\ H9-;_P"_T?\
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M7_[3C_Z!FL_^"Z7_  KN;U=CDLRMX?TJXTJYOKZ^O([F^O6C,C0Q&- $7:H
M))SCJ<UA)X!CCLO$, O1OU20/;OL/^B@.7 Z\X8YXQ73?VG'_P! S6?_  72
M_P"%']IQ_P#0,UG_ ,%TO^%',PLSD[GX=12I9+'=6Q,5FEI/]H@9PVTY+H P
MPQR?O9'-65\!V\?B%K]);<VK3BX\N2$M*K!<;5;=M"Y /W<^]='_ &G'_P!
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MX!P,\=J33/"KV&KVT[WZRV%C-//9VXBPZ-+][<V>0,G& *V/[3C_ .@9K/\
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M:=%16SM):PNQRS("3[XJ6I&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M-;_Z&./_ ,%R?_%4?\(QK?\ T,<?_@N3_P"*KJZ*/;3_ *2#V<3E/^$8UO\
MZ&./_P %R?\ Q5'_  C&M_\ 0QQ_^"Y/_BJZNBCVT_Z2#V<3E/\ A&-;_P"A
MCC_\%R?_ !5'_",:W_T,<?\ X+D_^*KJZ*/;3_I(/9Q.4_X1C6_^ACC_ /!<
MG_Q5'_",:W_T,<?_ (+D_P#BJZNBCVT_Z2#V<3E/^$8UO_H8X_\ P7)_\51_
MPC&M_P#0QQ_^"Y/_ (JNKHH]M/\ I(/9Q.4_X1C6_P#H8X__  7)_P#%4?\
M",:W_P!#''_X+D_^*KJZ*/;3_I(/9Q.4'AG6P<_\)''Q_P!0Y/\ XJMG0=*.
MB:-#8&X-P8R[&4IMW%F+'CMUK2HJ95)25F-0BG=!1114%!1110!4U'3;+5K,
MVE_;I/;EE<H_3*D$'\P*BFT33I]0%]+:AK@,K%MQ 9E^Z2N<$CL2,BM"BG=H
M5D8W_"*:)^YQ8@"(1A5$C@?(VY,C."5/0G.*E'AW21 8!9)Y9MWM=NX_ZICE
MEZ]S6I13YI=PLC+/AS23-)*;-29 P92S;?F&UB%S@$C@D#)YI8_#^EQQA%M0
M5$R3_,[,2Z*%5B2<G  'X5IT4N9]PLBA8Z-8::6^R0F,,H3!D9@JCHJ@DA1S
MT&!5<>&-%";!I\>/LZ6W4Y\I&W*N<] >:UZ*.9]PLC/?1--DLS:M:J8?/^TA
M<D$2[M^X'.0=W/%0+#+!8265CI;0QMOQOE4*"Q))X)/4DUKT4U)H&B.",Q6\
M<9.2B!21["I***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>slide04.jpg
<TEXT>
begin 644 slide04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\ A<# 2(  A$! Q$!_\0
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M67.[&2?S%;FH>*M TF_CL=0UBRMKI\;8I9@K<],^GXUY?HYV_M):TP7)%JQ
M]?W<=5/A+X>TGQ@_B/5O$-I%J%[)=["+@;M@())'H><9[;>*4J4;<SV26WF-
M3>R/9!JME=K=PV&H6DUU;H=Z),K&,\XW 'CGUKSVW\4^*;3X9:]K&H:CI-SJ
M5HP-O)8NDL:CY>&VG&>37-?"BTAL/$GCJSMV+0P(T4;$Y)57<#GOP*R/!_'P
M&\8_]=A_*.J5%1;6^J_$7.W^)ZGX5^(.F3>$]'N?$6M6%OJ=Y$79'=8\_,0#
MCL.*T_'&HZM9>&/M6@7NG6]T94VS7LJI$4/7EN,GM7G/AKP-X;OO@G)J5Q90
MM?2VD]PUVWWXW3=C![ ;1Q7/7%Y<7O[-T(N69O(U$0Q%N?D#$@?ADC\*7LH.
M=X][!SNVO8[KQ]XU\0^&?#WA:XM;FT-W?86[=4$D;G:I)0],9)Y%=!KFJ>(;
M?Q[HUG8W^E1:5,JFY@GF1;ASN;.Q2<GC'3WKS3XE_P#(@_#W_KG'_P"BTK9\
M< ?\+X\'<?\ +./_ -#>FJ:LM/Y@YG?[CHKKXF01_$VW\-K-8Q::D;-<WKSC
M!?:2$!SA<'@YYSQQ7<66K:=J+RI8ZA:W3Q<2+!,KE/J >.AKQ*Z\*Z'<?M!?
MV1+IT3:?- 9Y("3AI#&6+=<YW<UJ8B\ _'5G8K!I6NVY8D\*K=3_ ./+_P"/
MU,Z4&DH[VN-2:W[GK2ZGI[:BVGK?6QO5&YK82KY@'7)7.>XI-5U.VT;2;K4K
MQMMO:Q-+(1UP!T'O7F/PAM7UO6?$7C:Z3Y[^Y:&W)[1@Y./_ !P?\!KI_BO#
M-/\ #+6U@R66)78 =55U+?H#63II5%#T*4FXW.(T[7?B?X^CFU709K+2=+#L
ML"2JI,F.V2K$GU/ S73?#KQOK&LZEJ/AWQ+:"'6-/Y:1$PL@!P<XXR,CIP0:
MN?"*ZM[GX9Z2L#*3"KQ2J#RKAR3G\P?QK8T[QCH6J>(K[0K.YWZC:9\Y!&<<
M8!(;H<$@=>M74DKRBH[$Q6SN37/B_P -VEL+B?7=.6$R^2'^T*1OZ[>#UK#M
MM8UT_$BZM)M3T@Z D!D2!9T^T+\BG<5SNQDDY],5Y;\*/ NC^+)M:NM8CDFC
MM+D)#$LA502223CKT K?L(8YOVD=5AD0-&]FR,OJ#$@Q^54Z4(N45K9"4VTF
M=-X>^)<.N>/]4T9I;&#3[5?+M9//!-U)NQE3G!R.@&:ZO5?%?A_1+E;;4]8L
M[2=AD1RR@-CUQVKQ_P  ^&M&;XN>)K9M.C:'2I#)91Y.(663@CG^=8?@[?K=
MUKVHZAX+G\3W-S<%9)A,B^1G)P W0].1T &*J5"#;MLDOQ!3D?1;:A9+8?;V
MNX!9[=_V@R#R]OKNZ8JD/%&@M?VMBNL6375TN^")9U)D'8K@\]#7CVEZ7K^B
M?!KQ?INM6-Q:0(/,LTF96PK$9 P3T('XDUN?"'P'HX\/Z3XIN(I)M48R/&[2
M';&,L@ 7IT'ZUFZ,(Q;;\BE-MI6.H\ :GX@U%-3.O7^E79BE40?V?,C[%YR'
MV]#TZUI-X[\*)>_8V\0Z<+C=MV_:%Z^F>E>2_"JYTZR\)>.)]5DDBL%D G:$
MD/M(<84CG)S@?6N>UF"RG^'\LVB> GM-*0AQK-Y,#,07QQZ@_=[BM'04JC3)
M]HU&Y]-@@@$$$'D$4M<S\/)'E^'>@/(Q9C91Y)//2NFKCDK-HU3N@HHHI#"B
MBB@ HHHH **** "BBB@ HK/>ZU$.P33@R@\'S@,TGVO4_P#H&K_W_%<_UF'9
M_P#@+_R-?8R[K[U_F:-%9WVO4_\ H&K_ -_Q1]KU/_H&K_W_ !1]9AV?_@,O
M\A^QEW7WK_,T:*SOM>I_] U?^_XIR76HM(H?3PJD\GS@<4?68=G_ . R_P A
M.C+NOO7^9?HJ#S)_^> _[[%'F3_\\!_WV*/K,.S_ / 7_D1RLGHJ#S)_^> _
M[[%'F3_\\!_WV*/K,.S_ / 7_D'*R>BH/,G_ .> _P"^Q4<D]VN-EH']?W@&
M*N%:,Y<J3^::_-$R]U79R^O^ VUOQ]HOB<:B(1IJJIM_)W>9AF;[V>/O>AZ5
M8\>^![7QSHB64LPMKF&3S(+C9NV=F&,C((]_3TK=^TW_ /SX#_OZ*/M-_P#\
M^ _[^BNI2FFG?;T,N:/9_<SD[WX<#6_ ]GX?US4WN;JR.;;4(H]CKC@9!)SQ
MP>><#O5#2_A9=KKMEJ?B#Q5?:Q]A(-M"RF,#'(W'<<\@?7'-=W]IO_\ GP'_
M ']%'VF__P"? ?\ ?T52J5$K7_(5X=G]S/)?CAKV@7^EKH4<S3:];72%((XV
MRFX<Y.,<@CIGG%>B> O#_P#PC'@O3=-= LZQ^9/_ -=&Y;\B<?A5LV@:^^W-
MH5H;O_GN=GF?]]8S6@LUT5!:U /<>8*)3_=J"_,(M<S?Z,BUK3CJ^AW^FB7R
MC=6[P^9MSMW*1G'?K6/X$\)MX+\-+I#7@NRLKR>:(]GWNV,FM[S;C_GW'_?8
MH\VX_P"?<?\ ?8K.\N7EZ%W5[C=3L_[0TJ\L@_E_:('BWXSMW*1G'XUS7@KP
M2WA'PC<:$U^+HS22/YPBV8W*!TR>F/6NG\VX_P"?<?\ ?8H\VX_Y]Q_WV*$Y
M)<J"ZO<X#2?A+;6G@"^\*WVHM<I<W'VA+B.+88V 7& 2<_=_6LNX^#%]J&AC
M3=1\8WMTEN ME&T7[J #U7=\QQD#D8KU"6>[6)VCM [@$JOF 9/IFL[^TM>_
MZ 2_^!:UK&I5>J?Y"Y8=CG-=^&$.N6.C2_VI+9:WI4"0Q:A;)C<%'&5SZ\C!
MXR:9H7PRFMO$MOX@\0^(;K6[^U7%OYB;%CZX.,GID\<<\UTW]I:]_P! )?\
MP+6C^TM>_P"@$O\ X%K1S5+6NOO06C>]CF-<^&$MQXDN->\.^(;K0[V[&+D1
M)O60]SC(QGKWYYK;\$^";;P983Q)>7%[=7+[Y[B8\L>>@SP.3]<U<_M+7O\
MH!+_ .!:T?VEKW_0"7_P+6DW4<>5M6]4-**=RWKNB67B+1;K2=0C+VUPNUMI
MP5/4$'L00#7F=M\#5,]O!J?B:^O=(MGW16)4J![9W$#/? 'X5Z =2U\=- 4_
M]O:TG]I^(?\ H7T_\#%_PHA*I!6B_P 4-P4M6;<4:0Q)%$H2-%"JH'  Z"O.
MO&/PPO/$WBV/7[+Q"^F3QPK$GEPDNI&>0P88R&KJO[3\0_\ 0OI_X&+_ (4?
MVGXA_P"A?3_P,7_"E#G@[Q:_ ;@I*S.%7X5^+ RD_$C4R 0<8DY_\B5T>L>
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MXF!$.S9@'CJ<]:;:^ FMOB=<^,?[1#+/$8_LODX(^55SNS_L^E;7]HZY_P!
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M ,"B<X6]WMV!)]39HHHKG- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ<W<=MI=[<(#;P%@\K&$LWF'IM!X"_B:P[[6]93XA33+JNH"PBUN*S\]9/\
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MVK6-M=28V0S3JK'/3@FH]2\4Z!HUT+74]9L;.<J'$<\ZHQ!Z'!/3@UYG#?\
MAS1F\86?BZQ%QJEUJ$LB6\D):6\A8#REB/?T&#Q5V;5?#VD?$B5M=^SV-H^@
M6R1P7JABOSM\F.<D#CO6_L5YF?.>A7_B31-+MK>YO]6LK:"XYAEEF4+)W^4Y
MP>M6--U;3M9MOM.F7UO>0 [3)!(' /ID=Z\3T_3M1EL?!-M;.MDT^H:A)8?:
MK?S1' 5)0&,XX(Z>F0:Z/P)-J%A;>(S!8)=^*Q?*-0L6E6VB  PCQX4C:5YS
MC)-$J*4='K_P; IML]$U3Q!H^B>7_:NJ6=D9/N"XF5"WTR:E.K:<#9@WUO\
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MS+N /X5,Z?+%-#4KNQ,]]:17T-B]S$MW,K/'"7&]U7J0.N!D58KSJ?2H-/\
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M_A./#J:RMZ^F&SNC/':^9DXV8)$?S$9_I7J%4)]'L;G6;35I8B;VTC>.%]Y
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MKV#DTL>7PZ3K&J?$C4I(=1N]#D_LJT,GV:%'4M\V4RZD?*?2O3D4K&JLQ8@
M%CU/O3J*SG/F*2L%%%%0,**** "BBB@ HK-U_1XO$&A7FE33SP1W,>QI8&VN
MO?@U-I6GII.DVFG1RS3);1+$LDS;G8 8R3ZT]+!U.7N_B586D^I*=&UJ:VTV
M9H;J[AME:*,K@L<[LX (/2ND.N:2HM3)J5I$;M%>W6294:13T*@G)KQ_5_"^
MH37GBJ-_#>OW%S?7TLEE/:W:QVQ! VEU+@$9&3E3Q5OQ=H'BO4;.\M)-(\V=
M].M%6:Q@AQ/(A!D$CL=RA3G:JXS72Z4':SL9<TD>M3:II]O>Q6<]]:Q74O\
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M;6"8PR22RJ@!!P#R> <<9ZTE_P"+]'T[4-+M9[E/+U))7AN@Z^2JQKN)9\X
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MIHM]K>I:7;7/F/IL'G7,RX,2#)R-P/)&.:@^'VB_V%X(TJTDL4M+P6Z?:4"
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M;FWO+>*XA)!,<J!E)!R#@^A&:GK$TOQ;HNM7BVMA=M)*\9FCW0NBRH#@LC,
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M19VYUV)4;9BWP\66Q@[B<?05KZUX&U;4-7UW4+>6T226]L;VQ64DH[0*05D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>slide05.jpg
<TEXT>
begin 644 slide05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %F K<# 2(  A$! Q$!_\0
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M>-;GQAXKN+<Z@Z%(H+<Y"Y 7)/3 7@#GUKB_AGX0TCQ5XA\4'68&N8+>Z8)
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M\5TGC+X>V_BKPU8Z3'?36KV#*T$[YE/ Q\V3DY]<UV'GP_\ /5/^^A1Y\/\
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M?F@NIK&QC:2"W&,N(P &;_:(/O79?#[Q"==MK[/B&/5O*D&P-:_9YX5/:1>
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MQ\;]:FGFM)OLFG+,@EM Y5/X54D_*P)^]W]*UI/@[HCHT*ZGJZ6@N1=0VHN
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MV=C+<YA@8_W1C/X$TY_AGI36DL27M]',VJ-JL5PCJ'AF/]WY<8]B#3YZ=_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(Y>/5]7-]#I^FRV=FUWKE[;R2"V!PB*6W8&,OQU/7O3+GQ?K5G;C2I)O-U
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MW=/:K';S.TL!"EE+G&WM@@<C/>B\>P6EW.O\K_II-_W^?_&CRA_STF_[_/\
MXUP-IK6MS>#YKW6/L\H&IK!&;69XW_X^=F"<#Y1V]0.:FNOB'LU:[C@2T>VM
M+\63P%G^TRG<%9T &T $]#U /2B\>P>_W.X\H?\ /2;_ +_/_C1Y0_YZ3?\
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M,VDS)97YL60,,LPD6/</;+9K*N/"FL:G<W&IW\EE'?SSV>(H68QQ0P2%R-Q
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M %%%% !1110 4444 (0""",@]0:%544*H"J!@ #@4M% !1110 4444 %%%%
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M$'KFN@_X1>X_=_\ %2ZK^Z_U?[NW^3_=_=<?A4UIX?N+6Z@F;7]2G6$\12)
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MK45%:)I2=YFC1116!TA1110 4444 <WKGC;2] \1Z3H=XEP;K4VVQ-&F57G
MW'/<^F:Z2H9;2VGGBGEMXI)H23%(Z LA/7:>WX5-5.UE86IYIXG\32VWBN:_
MAU00V6@M"EQ:"8#[3YA_>_+GYMB%"/?-6/$]VC>/(8+AM;GLO[)\Y8M*DE^]
MYI&\B,CMQFMW3_!.EPZ7/;ZE;VVH75U)+)<74ENNYVD))QG)  ( Y[4F@>%)
M]'O[.[N-2-V]MI@T[)BVEU5]RL3D\XP/PS6W/!;=".61R<6H7Y\"^(M3L;W4
M!I+M&VF274Y:X7! D^;)8#=P QR.:T/'>L77]IQ6.G:H+.;3;5M3D'G!//8'
M$<)YY#8?(^E:MSX(\R'7[2VO_(L=799O(\K(@FR"[+ST; R/7FKUIX3L1J.I
M7^I16VH7%[.) TUNI\J,*%5!G/  Z]R31SPO?^N@N66Q=M=?TRZTZRO?MMO%
M'>1++")954L& /<^]<EH/BY[.;6[>ZL=<OVCU:Y5)+>SDG14#<*&'3'IVK<T
MCP9INGV7V2[M[2_BAN))+/S[96:WC9MPC!.> 2>1CMZ5>T+1CHJ7ZFX\[[7?
M2W>=NW;O.=O7G'K47@DUN5[SL9WP]NY[SP#I-U=3RS321,SR2L68_,W4GFLB
MU\2ZG'I&GZG! +RXU[46C@BFF*)!'A]G8X 5 3QR2:ZCPUHG_"/>&[/2#/\
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MUVOB.#[>P_MFWC@#-'N,6V/9D\_,3U[4NI^#8-6GS<W3B$Z6VGE47# ET82
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M'B'69-&LH&M[87-W=7"6MM$S[5,C9QN/90 2>.U<Q+\.;AX9[5-7A6UDO1>
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M-J/Q&C1117.=04444 %%%% !1110!335M-DGD@34+5IHE+R1K,I9%!P21G@
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M 59TG[EU_P!=S_Z"M5JLZ3]RZ_Z[G_T%:RJ_";4?B-&BBBN<Z@HHHH ****
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M<+*A8X^@)-8?C30-2U75=9%C:R,)=)ME5UPHE:.X9VC#'C=M]?45$(1:U?\
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MI56E8AT4W<P?-'_/.;_OR_\ A2^;_P!,Y_\ OR_^%;M%'MF'L(F%YW.=D_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881313328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001069530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CASSAVA SCIENCES INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-29959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1911336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6801 N. Capital of Texas Highway, Building 1; Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">501-2444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 967,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,225,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Austin, Texas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, exercisable for shares of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVAW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SAVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880959664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 121,136<span></span>
</td>
<td class="nump">$ 201,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,497<span></span>
</td>
<td class="nump">10,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">129,633<span></span>
</td>
<td class="nump">211,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,854<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">151,663<span></span>
</td>
<td class="nump">234,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accrued expenses</a></td>
<td class="nump">10,573<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_AccruedDevelopmentExpenseCurrent', window );">Accrued development expense</a></td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">2,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">385<span></span>
</td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,195<span></span>
</td>
<td class="nump">7,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,195<span></span>
</td>
<td class="nump">7,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 10, 11 and 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 120,000,000 shares authorized; 42,236,919 and 41,735,557 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">518,195<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(380,769)<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">137,468<span></span>
</td>
<td class="nump">227,539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 151,663<span></span>
</td>
<td class="nump">$ 234,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_AccruedDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued development expense, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_AccruedDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880329664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,236,919<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,236,919<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880885840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, net of grant reimbursement</a></td>
<td class="nump">$ 89,423<span></span>
</td>
<td class="nump">$ 68,032<span></span>
</td>
<td class="nump">$ 24,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,534<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
<td class="nump">8,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">105,957<span></span>
</td>
<td class="nump">80,020<span></span>
</td>
<td class="nump">32,868<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(105,957)<span></span>
</td>
<td class="num">(80,020)<span></span>
</td>
<td class="num">(32,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">7,833<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="nump">434<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
<td class="num">$ (32,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
<td class="nump">39,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299877273792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Employee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Employee [Member]</div></th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Share-Based Payment Arrangement, Nonemployee [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Share-Based Payment Arrangement, Nonemployee [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,237,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 267,086<span></span>
</td>
<td class="num">$ (174,921)<span></span>
</td>
<td class="nump">$ 92,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodValueWarrantExercises', window );">Issuance of common stock pursuant to exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with registered direct offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with registered direct offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">189,821<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">189,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,385)<span></span>
</td>
<td class="num">(32,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,016,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">461,181<span></span>
</td>
<td class="num">(207,306)<span></span>
</td>
<td class="nump">253,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued in conjunction with registered direct offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued in conjunction with registered direct offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">47,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
<td class="num">(76,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Expiration of restricted stock Performance Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,735,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">511,049<span></span>
</td>
<td class="num">(283,552)<span></span>
</td>
<td class="nump">$ 227,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation for stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,493<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock pursuant to exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(97,217)<span></span>
</td>
<td class="num">(97,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,236,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 518,195<span></span>
</td>
<td class="num">$ (380,769)<span></span>
</td>
<td class="nump">$ 137,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to exercises of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299875089408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,217,000)<span></span>
</td>
<td class="num">$ (76,246,000)<span></span>
</td>
<td class="num">$ (32,385,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,586,000<span></span>
</td>
<td class="nump">2,066,000<span></span>
</td>
<td class="nump">1,759,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,084,000<span></span>
</td>
<td class="nump">804,000<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">446,000<span></span>
</td>
<td class="nump">497,000<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">1,714,000<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
<td class="num">(10,956,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet', window );">Operating lease right-of-use assets and liabilities</a></td>
<td class="num">(17,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other accrued expenses</a></td>
<td class="nump">6,896,000<span></span>
</td>
<td class="num">(3,449,000)<span></span>
</td>
<td class="nump">6,215,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_IncreaseDecreaseInDevelopmentExpense', window );">Accrued development expense</a></td>
<td class="nump">757,000<span></span>
</td>
<td class="num">(523,000)<span></span>
</td>
<td class="nump">2,084,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="num">(1,707,000)<span></span>
</td>
<td class="nump">1,794,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(304,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
<td class="nump">731,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(82,025,000)<span></span>
</td>
<td class="num">(77,514,000)<span></span>
</td>
<td class="num">(30,196,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(414,000)<span></span>
</td>
<td class="num">(2,712,000)<span></span>
</td>
<td class="num">(22,214,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(414,000)<span></span>
</td>
<td class="num">(2,712,000)<span></span>
</td>
<td class="num">(22,214,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="nump">1,824,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock upon exercise of 2018 warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,329,000<span></span>
</td>
<td class="nump">189,825,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,560,000<span></span>
</td>
<td class="nump">47,804,000<span></span>
</td>
<td class="nump">192,341,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(79,879,000)<span></span>
</td>
<td class="num">(32,422,000)<span></span>
</td>
<td class="nump">139,931,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">233,437,000<span></span>
</td>
<td class="nump">93,506,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">121,136,000<span></span>
</td>
<td class="nump">201,015,000<span></span>
</td>
<td class="nump">233,437,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease right of use assets and liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882906432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - General, Liquidity and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">1.</em></b> <b>General, Liquidity and Basis of Presentation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#8220;Company&#8221;) discovers and develops proprietary pharmaceutical product candidates that <em style="font: inherit;"> may </em>offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Consolidation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#65279;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Liquidity </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $380.8&#160;million at <em style="font: inherit;"> December 31, 2023. </em>The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#8217;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company <em style="font: inherit;"> may </em>seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are <em style="font: inherit;">no</em> assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#8217;s working capital needs for at least the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882760704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2023,</em> there were <em style="font: inherit;"><span style="-sec-ix-hidden:c107483920">no</span></em> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> and <em style="font: inherit;">2021,</em> the Company received $0.9 million and&#160;$3.9 million&#160;of reimbursement, respectively, from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its research and development expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business Segments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c107483964">three</span> or <span style="-sec-ix-hidden:c107483965">four</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(32,385</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options and warrants outstanding, along with 57,143 restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;would have been anti-dilutive. The 57,143 restricted stock awards expired during the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities.&#160;As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.4 years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates 0.3 years at <em style="font: inherit;"> December 31, 2023.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i></i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881200704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock', window );">Prepaid Expenses and Other Current Assets [Text Bock]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid and other current assets at&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> consisted of the following (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">962</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PrepaidExpensesAndOtherCurrentAssetsTextBock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PrepaidExpensesAndOtherCurrentAssetsTextBock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882815824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstateOwnedTextBlock', window );">Real Estate Owned [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">4.</em> Real Property and Other Income, Expense</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company owns a <em style="font: inherit;">two</em>-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#8217;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;At <em style="font: inherit;"> December 31, 2023, </em>the Company&#160;occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to <em style="font: inherit;">third</em> parties.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company records the net income from building operations and leases as other income, net, as leasing is <em style="font: inherit;">not</em> core to the Company&#8217;s operations. Building depreciation and amortization for space <em style="font: inherit;">not</em> occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,462</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">434</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company had accrued property taxes related to the building totaling $338,000 and $433,000 at&#160;<em style="font: inherit;"> December 31, 2023 </em>and&#160;<em style="font: inherit;">2022,</em> respectively, included in other current liabilities.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateOwnedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateOwnedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882812304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">5.</em> Property and Equipment</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of property and equipment, net, as of&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,016</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Depreciation expense for property and equipment was&#160;$1,084,000, $804,000&#160;and&#160;$310,000&#160;for the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882897584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">6.</em> Intangible assets</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The components of intangible assets, net, as of&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for intangible assets was $446,000, $497,000 and $224,000 for the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299884067264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity and Share-Based Payments [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">7.</em> Stockholders' Equity and Stock-Based Compensation</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Preferred Stock</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) has the authority to issue preferred stock in <em style="font: inherit;">one</em> or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2022</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> November&#160;</em><em style="font: inherit;">22,</em> <em style="font: inherit;">2022,</em> the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2021</em> Registered Direct Offering</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> February&#160;</em><em style="font: inherit;">12,</em> <em style="font: inherit;">2021,</em> the Company completed a common stock offering pursuant to which certain investors purchased 4,081,633 shares of common stock at a price of $49.00 per share. Net proceeds of the offering were approximately $189.8&#160;million after deducting offering expenses.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>At the Market (ATM) Common Stock Issuance </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">On <em style="font: inherit;"> May 1, 2023, </em>the Company entered into an&#160;at-the-market offering program (&#8220;ATM&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on <em style="font: inherit;"> May 1, 2023 </em>and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. The Company is <em style="font: inherit;">not</em> obligated to sell any shares in the offering.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">There were&#160;no&#160;common stock sales under the ATM during the year&#160;ended <em style="font: inherit;"> December 31, 2023.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> March 2020, </em>the Company entered into an at-the-market offering program (<em style="font: inherit;">&#8220;2020</em> Program&#8221;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on <em style="font: inherit;"> May 5, 2020. </em>The Company gave notice of termination for the <em style="font: inherit;">2020</em> Program on <em style="font: inherit;"> April 26, 2023, </em>which was effective <em style="font: inherit;"> May 1, 2023. </em>There were <em style="font: inherit;">no</em> common stock sales under the <em style="font: inherit;">2020</em> Program through its termination.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2008</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Under the Company&#8217;s <em style="font: inherit;">2008</em> Equity Incentive Plan, or <em style="font: inherit;">2008</em> Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The <em style="font: inherit;">2008</em> Equity Plan expired in <em style="font: inherit;"> December 2017. </em>Share-based awards generally expire <em style="font: inherit;">ten</em> years from the date of grant.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i><em style="font: inherit;">2018</em> Equity Incentive Plan </i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s Board or a designated Committee of the Board is responsible for administration of the Company&#8217;s <em style="font: inherit;">2018</em> Omnibus Incentive Plan (the <em style="font: inherit;">2018</em> Plan) and determines the terms and conditions of each option granted, consistent with the terms of the <em style="font: inherit;">2018</em> Plan. The Company&#8217;s employees, directors, and consultants are eligible to receive awards under the <em style="font: inherit;">2018</em> Plan, including grants of stock options and performance awards. Share-based awards generally expire <span style="-sec-ix-hidden:c107484158">ten</span> years from the date of grant. The <em style="font: inherit;">2018</em> Plan, as amended on <em style="font: inherit;"> May 5, 2022, </em>provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the <em style="font: inherit;">2018</em> Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company <em style="font: inherit;"> may </em>then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock Options</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock option activity during <em style="font: inherit;">2023:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,529,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">1,162,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">18.91</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(602,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(49,999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">32.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,836,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.98</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Of the stock options exercised during the year ended <em style="font: inherit;"> December 31, 2023, </em>101,058&#160;stock options were net settled in satisfaction of the exercise price, with <em style="font: inherit;">no</em> cash proceeds received.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock options at <em style="font: inherit;"> December 31, 2023 </em>by a range of exercise prices:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">804,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">804,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">656,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">647,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">800,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">77.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">715,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">7.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">33.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">277,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">41.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,836,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#8217;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;<em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021</em> were as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">152% to 155%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 154%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">147% to 151%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.82% to 4.37%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.98% to 3.69%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.12% to 1.42%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484343">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484346">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484349">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484352">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484355">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484358">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Volatility is based on reviews of the historical volatility of the Company&#8217;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because the Company does <em style="font: inherit;">not</em> anticipate paying cash dividends in the foreseeable future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2023, </em>the Company expects to recognize compensation expense of $24.2&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of 2.8&#160;years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Performance Awards</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about performance award activity during <em style="font: inherit;">2023:</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of Performance Awards</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2022, </em>a total of 57,143 shares of restricted stock awards expired as performance criteria related to these Performance Awards were <em style="font: inherit;">not</em> attained. These shares of restricted stock were returned to the <em style="font: inherit;">2008</em> Equity Incentive Plan, which expired in <em style="font: inherit;"> December 2017, </em>and thus were retired.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If and when outstanding Performance Awards vest, the Company would recognize $101,000 in stock-based compensation expense. These performance awards expire in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-Based Compensation Expense</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The following summarizes information about stock-based compensation expense, in thousands:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,586</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299887590960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Employee 401(k) Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Compensation and Employee Benefit Plans [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">8.</em> Employee <em style="font: inherit;">401</em>(k) Benefit Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has a defined-contribution savings plan under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the <em style="font: inherit;">first</em> day of the month after hire and <em style="font: inherit;"> may </em>contribute up to the current statutory limits under Internal Revenue Service regulations. The <em style="font: inherit;">401</em>(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through <em style="font: inherit;"> December 31, 2023, </em>the Company has <em style="font: inherit;">not</em> made any matching contributions to the <em style="font: inherit;">401</em>(k) plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299887357600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">9.</em> Income Taxes</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company did <em style="font: inherit;">not</em> provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate for periods presented was as follows:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Deferred tax assets and valuation allowance</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#8217;s deferred taxes assets at&#160;<em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022</em> were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,538</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,690</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The valuation allowance increased by $23.3&#160;million and $17.8&#160;million in&#160;<em style="font: inherit;">2023</em> and <em style="font: inherit;">2022,</em> respectively, due primarily to continuing operations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s net operating loss carryforwards of $158.7&#160;million are federal, of which $74.1&#160;million expires between <em style="font: inherit;">2029</em> and <em style="font: inherit;">2037</em> and $84.6&#160;million carries forward indefinitely. As of <em style="font: inherit;"> December 31, 2023, </em>the Company had federal research and development tax credits of approximately $21.1&#160;million, which expire in the years <em style="font: inherit;">2024</em> through <em style="font: inherit;">2043.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Unrecognized tax benefits</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">As of <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the Company has unrecognized tax benefits related to tax credits of $8.4&#160;million, $6.5&#160;million and $5.0&#160;million, respectively. None of the unrecognized tax benefits as of <em style="font: inherit;"> December 31, 2023, </em>if recognized, would impact the effective tax rate due to the valuation allowance and <span style="-sec-ix-hidden:c107484422">no</span> interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,495</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">As of <em style="font: inherit;"> December 31, 2023, </em>there were <em style="font: inherit;">no</em> unrecognized tax benefits that we expect would change significantly over the next <em style="font: inherit;">12</em> months.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after <span style="-sec-ix-hidden:c107484425">2019</span>&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the <em style="font: inherit;">2020</em>&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are <em style="font: inherit;">not</em> under audit in any taxing jurisdiction at this time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882619520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Leases and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_LeasesAndCommitmentsDisclosureTextBlock', window );">Leases And Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">10.</em> Leases and Commitments</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Right-of-use Asset and Liability</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas expiring <em style="font: inherit;"> April 30, 2024. </em>The Company terminated this lease on <em style="font: inherit;"> February 22, 2023 </em>with <em style="font: inherit;">no</em> continuing obligations.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Cash paid for operating lease liabilities totaled $24,000, $155,000 and $109,000 during the years ended <em style="font: inherit;"> December 31, 2023, </em><em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#8217;s obligations under these contracts are largely based on services performed.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_LeasesAndCommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding leases and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_LeasesAndCommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882619232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - 2020 Cash Incentive Bonus Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusPlanTextBlock', window );">Cash Incentive Bonus Plan [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em></b>&#160;<b> <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;"> August 2020, </em>the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#8220;at-risk&#8221; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#8217;s market capitalization. The Plan is considered &#8220;at-risk&#8221; because Plan participants&#160;will&#160;<em style="font: inherit;">not</em> receive a cash bonus&#160;unless&#160;the Company&#8217;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;<em style="font: inherit;">not</em>&#160;be paid&#160;any cash bonuses unless (<em style="font: inherit;">1</em>) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (<em style="font: inherit;">2</em>) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has <em style="font: inherit;">not</em> occurred&#160;as of <em style="font: inherit;"> December 31, 2023.&#160;</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company&#8217;s independent directors were participants in the Plan. However, effective <em style="font: inherit;"> March 16, 2023, </em>the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#8217; share of potential benefits under the Plan were completely forfeited to the Company and will <em style="font: inherit;">not</em> be allocated to any other participant under the Plan. The Company&#8217;s independent directors have <em style="font: inherit;">not</em> received, and as a result of such amendment will never receive, any payments under the Plan.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company&#8217;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (<em style="font: inherit;">1</em>) the Company&#8217;s closing price&#160;of <em style="font: inherit;">one</em> share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (<em style="font: inherit;">2</em>) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160; &#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#8217;s market capitalization increases significantly, up to a maximum&#160;<em style="font: inherit;">$5</em>&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#8220;Valuation Milestone&#8221;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for <em style="font: inherit;">no</em> less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;<em style="font: inherit;">not</em> awarded by the Compensation Committee&#160;are&#160;<em style="font: inherit;">no</em> longer available for distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If the Company were to exceed a $5&#160;billion market capitalization&#160;for <em style="font: inherit;">no</em> less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(<em style="font: inherit;">1</em>)&#160;the Company completes a Merger Transaction, or&#160;(<em style="font: inherit;">2</em>)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#8220;Performance Condition&#8221;),&#160;neither&#160;of which <em style="font: inherit;"> may </em>ever occur. Accordingly, there can be <em style="font: inherit;">no</em> assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#8217;s market capitalization increases&#160;significantly.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">In <em style="font: inherit;"> October 2020, </em>the Company&#160;achieved&#160;the <em style="font: inherit;">first</em>&#160;Valuation&#160;Milestone.&#160;Subsequently in <em style="font: inherit;">2020,</em> the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all Plan participants (after taking into account the <em style="font: inherit;"> March 2023 </em>Plan amendment), subject to future satisfaction of a Performance Condition.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after taking into account the <em style="font: inherit;"> March 2023 </em>Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense has been recorded&#160;since <em style="font: inherit;">no</em>&#160;grant date has occurred and <em style="font: inherit;">no</em>&#160;Performance Conditions are considered probable of being met.&#160;There is <em style="font: inherit;">no</em> continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><em style="font: inherit;">No</em> Valuation Milestones were achieved during the years&#160;ended <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">No actual cash payments were authorized or made to participants under the Plan through <em style="font: inherit;"> December 31, 2023&#160;</em>and the date of filing of this Annual Report on Form <em style="font: inherit;">10</em>-K.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the cash incentive bonus plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882897584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">12.</em> Contingencies</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Government Investigations</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. <em style="font: inherit;">No</em> government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. <em style="font: inherit;">No</em> government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c107484574">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c107484575">four</span> class action lawsuits into <span style="-sec-ix-hidden:c107484576">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs&#8217; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#8217; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023.&#160;</em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#8217;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#8217;s alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em>four additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c107484579">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c107484580">one</span> in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c107484582">three</span> federal court actions were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>journal article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#8217;s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#8217;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023. </em>On <em style="font: inherit;"> January 25, 2024, </em>the parties entered into a binding settlement term sheet with respect to this action. The settlement is subject to certain conditions, including the filing of a Stipulation of Settlement and final court approval. The proposed settlement resolves the claims asserted against the Company and the individual defendants and would contain provisions that the settlement does <em style="font: inherit;">not</em> constitute an admission, concession, or finding of any fault, liability, or wrongdoing of any kind by any defendant. There can be <em style="font: inherit;">no</em> assurance that the final settlement agreement will be executed or that such agreement will be approved by the court.&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-20/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450-30/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882786368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Event - Warrant Dividend Distribution<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><em style="font: inherit;">13.</em> Subsequent Event - Warrant Dividend Distribution</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> January 3, 2024, </em>the Company&#160;completed&#160;a distribution&#160;to the holders of record of the Company&#8217;s shares of common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on <em style="font: inherit;"> December 22, 2023 </em>received <span style="-sec-ix-hidden:c107484588">four</span> warrants for every ten shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately <span style="-sec-ix-hidden:c107484590">16.9</span> million&#160;warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Each warrant entitles the holder to purchase, at the holder&#8217;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, <span style="-sec-ix-hidden:c107484592">one</span> share of common stock plus, to the extent described below, the Bonus Share Fraction. Payment for shares of common stock upon exercise of warrants must be in cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">A Bonus Share Fraction entitles a holder to receive an additional 0.5 of a share of common stock (rounded down for any fractional share) for each warrant exercised (the &#8220;Bonus Share Fraction&#8221;) without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire upon the earlier of (i) the <em style="font: inherit;">first</em> business day following the last day of the <em style="font: inherit;">first</em> <em style="font: inherit;">30</em> consecutive trading day period (commencing on or after <em style="font: inherit;"> January 3, 2024) </em>in which the daily volume weighted average price (the &#8220;VWAP&#8221;) of the shares of common stock has been at the then applicable trigger price, initially $26.40, for at least <em style="font: inherit;">20</em> trading days (whether or <em style="font: inherit;">not</em> consecutive) (the &#8220;Bonus Price Condition&#8221;) and (ii) the date specified by the Company upon <em style="font: inherit;">not</em> less than <em style="font: inherit;">20</em> business days&#8217; public notice (either condition being the &#8220;Bonus Share Expiration Date&#8221;). Any warrant exercised with an exercise date after the Bonus Share&#160;Expiration Date will <em style="font: inherit;">not</em> be entitled to the Bonus Share Fraction. The Company&#160;will make a public announcement of the Bonus Share Expiration Date (i) at least <em style="font: inherit;">20</em> business days prior to such date, in the case of the Company&#160;setting a Bonus Share Expiration Date and (ii) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Unless earlier redeemed, the warrants will expire and cease to be exercisable&#160;on <em style="font: inherit;"> November 15, 2024 (</em>the &#8220;Expiration Date&#8221;). The warrants are redeemable at the Company&#8217;s sole option at any time with a redemption date on or after <em style="font: inherit;"> April 15, 2024. </em>The Company will provide at least <em style="font: inherit;">20</em> calendar days&#8217; notice by press release&#160;of the date selected for redemption (the &#8220;Redemption Date&#8221;). The redemption price upon any redemption shall equal to <span style="-sec-ix-hidden:c107484606">1/10</span> of $0.01 per warrant. The warrants <em style="font: inherit;"> may </em>be exercised at any time starting on <em style="font: inherit;"> January 3, 2024&#160;</em>until the earlier of (<em style="font: inherit;">1</em>) the Expiration Date and (<em style="font: inherit;">2</em>) the business day prior to the Redemption Date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The number of shares of Common Stock issuable upon exercise is subject to certain anti-dilution adjustments, including for share dividends, splits, subdivisions, spin-offs, consolidations, reclassifications, combinations, non-cash distributions and cash dividends. Terms of the warrants prohibit ownership by warrant exercise&#160;of <em style="font: inherit;">9.9%</em> or more of the Company's common stock by a single or affiliated group of stockholders without the Company's prior written consent.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The right to exercise warrants shall be automatically suspended&#160;in a circumstance while&#160;there is <em style="font: inherit;">no</em> effective registration statement registering the shares of common stock issuable upon exercise of the warrants.&#160;Such registration statement was declared effective by the SEC on <em style="font: inherit;"> May 1, 2023.&#160;</em>The warrant Expiration Date or the Redemption Date, as the case <em style="font: inherit;"> may </em>be, shall be extended by the number of days comprised in the event of a suspension.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company <em style="font: inherit;"> may </em>from time to time&#160;and in its sole discretion amend warrants for <em style="font: inherit;">one</em> or more of the following purposes: (i) to cure any ambiguity, omission, defect or inconsistency; (ii) to provide for the assumption by a successor company in any business combination; (iii) to postpone the Expiration Date; (iv) to decrease the warrant exercise price or increase the basic warrant exercise rate or the Bonus Share Fraction; (v) to reinstate a Bonus Share Period after the Bonus Share Expiration Date;&#160;(vi) to provide for net share settlement upon exercise of the warrants; (vii) to make any change that does <em style="font: inherit;">not</em> adversely affect the rights of any warrant holder in any material respect; (viii) to provide for a successor warrant agent or calculation agent; (ix) in connection with any business combination, to provide that the warrants are exercisable for appropriate consideration; or (<em style="font: inherit;">x</em>) other conforming changes.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt; text-align: justify;">The warrants are listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#8220;SAVAW&#8221;.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 9pt; text-align: justify;">From <em style="font: inherit;"> January 3, 2024 </em>to <em style="font: inherit;"> February 26, 2024, </em>a total of approximately <span style="-sec-ix-hidden:c107484615">659,000</span>&#160;warrants were exercised resulting in gross proceeds to the Company of approximately $21.8&#160;million. The Company issued approximately 989,000&#160;shares of common stock, including Bonus Share Fractions, from the exercise of warrants through <em style="font: inherit;"> February 26, 2024. </em>After the <em style="font: inherit;">first</em> $20 million of gross proceeds, the Company is&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock in the offering to the Company's financial advisor for the warrant distribution.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880919168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><a href="#" id="item9b" title="item9b"></a>Item <em style="font: inherit;">9B.</em></b>&#160;&#160;&#160;&#160;<b><i>Other Information</i></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;">During the quarter ended <em style="font: inherit;"> December 31, 2023, </em><span style="-sec-ix-hidden:c107484626"><span style="-sec-ix-hidden:c107484634"><span style="-sec-ix-hidden:c107484635"><span style="-sec-ix-hidden:c107484636">none</span></span></span></span> of our directors or officers (as defined in Rule <em style="font: inherit;">16a</em>-<em style="font: inherit;">1</em>(f) of the Exchange Act) informed us of the adoption or termination of a &#8220;Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement&#8221; or &#8220;non-Rule <em style="font: inherit;">10b5</em>-<em style="font: inherit;">1</em> trading arrangement,&#8221; as those terms are defined in Regulation S-K, Item <em style="font: inherit;">408.</em></p>
  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880497120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Proceeds from Grants</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">During <em style="font: inherit;">2023,</em> there were <em style="font: inherit;"><span style="-sec-ix-hidden:c107483920">no</span></em> reimbursements received pursuant to National Institutes of Health (&#8220;NIH&#8221;) research grants. In <em style="font: inherit;">2022,</em> and <em style="font: inherit;">2021,</em> the Company received $0.9 million and&#160;$3.9 million&#160;of reimbursement, respectively, from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its research and development expenses.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents and Concentration of Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of <em style="font: inherit;">three</em> months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at <em style="font: inherit;">one</em> financial institution.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value Measurements </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;">The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a <em style="font: inherit;">three</em>-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">1</em> includes quoted prices in active markets.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">2</em> includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from <em style="font: inherit;">third</em>-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">2</em> inputs.</p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;">&#160;</td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em style="font: inherit;">3</em> includes unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity. The Company does <em style="font: inherit;">not</em> have any financial instruments where the fair value is based on Level <em style="font: inherit;">3</em> inputs.</p> </td></tr>
</tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level <em style="font: inherit;">1</em> inputs at <em style="font: inherit;"> December 31, 2023 </em>and <em style="font: inherit;">2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Business Segments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#8217;s operations are confined to one business segment: the development of novel drugs and diagnostics.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b><b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#8220;Black-Scholes&#8221;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#8217;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally <span style="-sec-ix-hidden:c107483964">three</span> or <span style="-sec-ix-hidden:c107483965">four</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#8220;Performance Awards&#8221;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is <em style="font: inherit;">no</em> difference between the Company&#8217;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(32,385</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
     <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company excluded common stock options and warrants outstanding, along with 57,143 restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;would have been anti-dilutive. The 57,143 restricted stock awards expired during the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Financial instruments include accounts payable, accrued expenses and other liabilities. The estimated fair value of certain financial instruments <em style="font: inherit;"> may </em>be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are <em style="font: inherit;">not</em> necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies <em style="font: inherit;"> may </em>be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research Contracts, Prepaids and Accruals</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company has entered into various research and development contracts with research institutions and other <em style="font: inherit;">third</em>-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical prepaid and accrual estimates have <em style="font: inherit;">not</em> been materially different from actual costs.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Incentive Bonus Plan</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">In <em style="font: inherit;">2020,</em> the Company established the <em style="font: inherit;">2020</em> Cash Incentive Bonus Plan (the &#8220;Plan&#8221;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC&#160;<em style="font: inherit;">718</em> &#8220;<i>Stock-based Compensation</i>&#8221;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note <em style="font: inherit;">11</em> for further discussion of the Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does <em style="font: inherit;">not</em> recognize right-of-use assets or lease liabilities.&#160;As the Company`s leases do <em style="font: inherit;">not</em> provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Property and equipment</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.4 years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Intangible assets</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates 0.3 years at <em style="font: inherit;"> December 31, 2023.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company accounts for uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> &#8220;Income Taxes&#8221;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#8217;s financial statements only if that position is more likely than <em style="font: inherit;">not</em> of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881150448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Numerator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(97,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(76,246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(32,385</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Denominator:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Shares used in computing net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,932</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,202</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">39,405</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Net loss per share, basic and diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2.32</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.90</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(0.82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Dilutive common stock options excluded from net loss per share, diluted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,123</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,055</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td><td style="padding: 0; margin: 0">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880884272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Prepaid and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">874</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">962</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">160</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299883323680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,459</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">911</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Property operating expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,376</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,462</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(477</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Other income, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">907</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">997</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">434</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299887321728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Land</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,734</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Buildings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,980</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Site improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tenant improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,062</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,016</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Furniture and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Construction in progress</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross property and equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,138</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,064</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated depreciation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,200</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,854</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882620048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lease-in-place agreements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,053</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Leasing commissions and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">293</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">290</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Gross intangible assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,346</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,170</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(721</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Intangible assets, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">622</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b><span style="text-decoration: underline; ">For the year ending December 31,</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">176</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880892016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term in Years</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">in Millions</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,529,448</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49.60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">1,162,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">18.91</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(602,420</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">8.38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Options forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0">(49,999</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">32.59</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Vested and expected to vest at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">30.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Exercisable at December 31, 2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,836,174</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.98</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26.18</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Options outstanding</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Options exercisable</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">remaining</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Number of</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Range of exercise prices</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">outstanding</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">vested</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">exercise</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">From</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">To</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">life (in years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">options</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.95</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.24</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">804,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">804,834</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.17</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13.02</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">656,230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">647,167</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.34</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.94</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">800,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">44,442</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">21.11</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">77.00</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">715,331</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">7.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">33.20</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">277,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">41.29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,039,029</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,836,174</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">152% to 155%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">151% to 154%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">147% to 151%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Risk-free interest rates</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.82% to 4.37%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.98% to 3.69%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.12% to 1.42%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Dividend yield</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484343">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484346">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484349">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Forfeiture rate</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484352">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484355">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="-sec-ix-hidden:c107484358">zero</span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Weighted average fair value of stock options granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18.21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35.16</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">65.83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Number of Performance Awards</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Forfeited/canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Outstanding as of December 31, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Years ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,050</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,536</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">435</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">457</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,586</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,066</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299875053248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Tax at federal statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">21</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">State tax, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Research and development credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(1.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(0.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(24.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33,322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,017</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,706</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development credit carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,557</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,681</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capitalized research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,538</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">12,690</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,371</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">934</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,028</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(77,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(54,002</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(26</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred tax asset (liability)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Income Tax Contingencies [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Year ended December 31,</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2022</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Beginning balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,500</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Expired research and development tax credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">(50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">&#160;</td></tr>
<tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Additions based on tax positions related to the current year</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,495</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">501</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,413</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,001</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299883011344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - General, Liquidity and Basis of Presentation (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">$ (380,769)<span></span>
</td>
<td class="num">$ (283,552)<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882170688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds from Insurance Settlement, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government Assistance, Amount</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life (Year)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="nump">57,143<span></span>
</td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882216752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (97,217)<span></span>
</td>
<td class="num">$ (76,246)<span></span>
</td>
<td class="num">$ (32,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">41,932<span></span>
</td>
<td class="nump">40,202<span></span>
</td>
<td class="nump">39,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.32)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities excluded from net loss per share, diluted (in shares)</a></td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">2,055<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299874796304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsAssets', window );">Contract research organization and other deposits</a></td>
<td class="nump">6,489<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,497<span></span>
</td>
<td class="nump">$ 10,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483081/340-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483054/340-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299980558208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Real Property and Other Income, Expense (Details Textual) - Office Building [Member] - TEXAS<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageOfOccupancy', window );">Percentage of Occupancy</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrual for Taxes Other than Income Taxes, Current | $</a></td>
<td class="nump">$ 338,000<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageOfOccupancy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageOfOccupancy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299883212240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Lease revenue</a></td>
<td class="nump">$ 2,283<span></span>
</td>
<td class="nump">$ 2,459<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Property operating expenses</a></td>
<td class="num">(1,376)<span></span>
</td>
<td class="num">(1,462)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 907<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881166400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 1,084,000<span></span>
</td>
<td class="nump">$ 804,000<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880444464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 24,138<span></span>
</td>
<td class="nump">$ 24,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,284)<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,854<span></span>
</td>
<td class="nump">22,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,734<span></span>
</td>
<td class="nump">3,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">15,980<span></span>
</td>
<td class="nump">15,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">868<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299883302176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 446,000<span></span>
</td>
<td class="nump">$ 497,000<span></span>
</td>
<td class="nump">$ 224,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881134464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(721)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember', window );">Leases, Acquired-in-Place [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember', window );">Leasing Commissions and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross intangible assets</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeasesAcquiredInPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sava_LeasingCommissionsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299881159280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total amortization</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299876690304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 22, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 47,329,000<span></span>
</td>
<td class="nump">$ 189,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice', window );">Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember', window );">The 2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember', window );">The 2022 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 47,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2021RegisteredDirectOfferingMember', window );">The 2021 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember', window );">At-the-market Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_EquityOfferingPercentageOfCommission', window );">Equity Offering, Percentage of Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount to be issued in the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_EquityOfferingPercentageOfCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_EquityOfferingPercentageOfCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stock options exercised net settled in satisfaction of the exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_The2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_The2022RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_The2021RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_The2021RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sava_AtthemarketCommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880298080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares) | shares</a></td>
<td class="nump">2,529,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">3 years 11 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding as of December 31, 2022, aggregate intrinsic value | $</a></td>
<td class="nump">$ 49,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">1,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(602,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited/canceled (in shares) | shares</a></td>
<td class="num">(49,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited/canceled, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 32.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, options (in shares) | shares</a></td>
<td class="nump">3,039,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, options, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at December 31, 2023 (in shares) | shares</a></td>
<td class="nump">3,039,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at December 31, 2022, aggregate intrinsic value | $</a></td>
<td class="nump">$ 30,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at December 31, 2023 (in shares) | shares</a></td>
<td class="nump">1,836,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at December 31, 2022, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at December 31, 2022, weighted average contractual term (Year)</a></td>
<td class="text">3 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at December 31, 2022, aggregate intrinsic value | $</a></td>
<td class="nump">$ 26,180<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880390560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">3,039,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,836,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">804,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">804,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">4.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 13.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">656,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">647,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">14.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 16.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">62,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">62,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">17.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 17.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">44,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember', window );">Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options, exercise price, lower limit (in dollars per share)</a></td>
<td class="nump">21.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options, exercise price, upper limit (in dollars per share)</a></td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">715,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average contractual life (Year)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">277,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 41.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sava_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299980598960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years) (Year)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 18.21<span></span>
</td>
<td class="nump">$ 35.16<span></span>
</td>
<td class="nump">$ 65.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">152.00%<span></span>
</td>
<td class="nump">151.00%<span></span>
</td>
<td class="nump">147.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">155.00%<span></span>
</td>
<td class="nump">154.00%<span></span>
</td>
<td class="nump">151.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rates</a></td>
<td class="nump">4.37%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299883350768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details) - Performance Shares [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited/canceled, awards (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, awards (in shares)</a></td>
<td class="nump">7,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299887246720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,586<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="nump">$ 1,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,536<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="nump">$ 457<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299877312832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">8,413,000<span></span>
</td>
<td class="nump">$ 6,496,000<span></span>
</td>
<td class="nump">$ 5,001,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2019 2020 2021 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 158,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">21,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Carryforward Subject to Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">74,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Indefinite Life Carryforwards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 84,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sava_CarryforwardSubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sava_CarryforwardSubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sava_IndefiniteLifeCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sava_IndefiniteLifeCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299876969328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Section 162(m) limitation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="num">(23.40%)<span></span>
</td>
<td class="num">(23.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880297632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,322<span></span>
</td>
<td class="nump">$ 28,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">12,557<span></span>
</td>
<td class="nump">9,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalized research and development expenses</a></td>
<td class="nump">27,538<span></span>
</td>
<td class="nump">12,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">77,349<span></span>
</td>
<td class="nump">54,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(77,349)<span></span>
</td>
<td class="num">(54,002)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset (liability)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882216976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 6,496<span></span>
</td>
<td class="nump">$ 5,001<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expired research and development tax credits</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 8,413<span></span>
</td>
<td class="nump">$ 6,496<span></span>
</td>
<td class="nump">$ 5,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299876976704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Leases and Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments | $</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 109,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sava_LeaseForOfficeSpaceInAustinTexasMember', window );">Lease for Office Space in Austin, Texas [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sava_LeaseForOfficeSpaceInAustinTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sava_LeaseForOfficeSpaceInAustinTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299880285968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual) - Cash Incentive Bonus Plan [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashBonusIncentiveIncrementalAmounts', window );">Cash Bonus Incentive, Incremental Amounts</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained', window );">Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment', window );">Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAward', window );">Cash Incentive Bonus Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-Based Payment Arrangement, Expense, after Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PaymentsForCashIncentiveBonus', window );">Payments for Cash Incentive Bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">111,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_PerformancePlanValuationMilestoneAmount', window );">Performance Plan, Valuation Milestone Amount</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 202,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CashIncentiveBonusAwardExceedsMaximum', window );">Cash Incentive Bonus Award, Exceeds Maximum</a></td>
<td class="nump">$ 289,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashBonusIncentiveIncrementalAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of incremental amounts for cash bonus incentive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashBonusIncentiveIncrementalAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CashIncentiveBonusAwardExceedsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash incentive bonus award if the maximum milestone is exceeded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CashIncentiveBonusAwardExceedsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PaymentsForCashIncentiveBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for cash incentive bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PaymentsForCashIncentiveBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the percentage of valuation milestone cash bonus award subject to approval and adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum number of days valuation milestone must be achieved and maintained in performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_PerformancePlanValuationMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation milestone for performance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_PerformancePlanValuationMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sava_CashIncentiveBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299882183792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">20 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 05, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Oct. 26, 2021</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember', window );">Violations of Federal Securities Laws [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember', window );">Shareholder Derivative Actions, Texas Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember', window );">Shareholder Derivative Actions, Texas State Court Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember', window );">Shareholder Derivative Actions, Delaware Court [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember', window );">Shareholder Derivative Actions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ViolationsOfFederalSecuritiesLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsTexasStateCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsDelawareCourtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=sava_ShareholderDerivativeActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299877404320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2024</div></th>
<th class="th"><div>Dec. 22, 2023</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_VolumeWeightedAveragePrice', window );">Volume Weighted Average Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_RedemptionPercentageOfWarrants', window );">Redemption Percentage of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_WarrantRedemptionPrice', window );">Warrant Redemption Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_StockIssuedDuringPeriodSharesWarrantExercises', window );">Stock Issued During Period, Shares, Warrant Exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission', window );">Proceeds From Warrants Exercised That Obligated to Pay Commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_CommissionPercentageOfGrossProceeds', window );">Commission Percentage of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right Issued During Period (in shares)</a></td>
<td class="nump">16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sava_BonusShareFractionMember', window );">Bonus Share Fraction [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_CommissionPercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of commission required to be paid from gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_CommissionPercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dollar amount required to be paid for commission from warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_RedemptionPercentageOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Percent of the cost for redemption of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_RedemptionPercentageOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_StockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_StockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_VolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average price of common stock under warrant agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_VolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sava_WarrantRedemptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of warrants if they are redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sava_WarrantRedemptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sava_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sava_BonusShareFractionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sava_BonusShareFractionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MZ.,."!.@YS><JT/'[*C= 2K]!U!+ P04    "  A@%Q88K;_]NL#  !<#0
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M[7KYH%474%J(HK7[@(-5B(JM0J/[@%[=0SU%4)H%I=E0F@.EN5":!Z7Y4%I
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M(,8NC*3#;$G/EO@3ORCXVK3 %7VF-MW[!2T*L=9UFCV9,CW DCC3FJ894 0
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M>V*BJ+IDZA[SE>F?8&P10(99U?DRM@!@E+A5.@=P./7L>TBO[(A?V?U?'Y
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M&[V]2,!V\M]-O&FBY*Z,9P&/PXI?3++!@/=+PVK33T* X0V>?P502P,$%
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M<>.HDKM?EI5RM=V;4FSABP=<$4B_T^5"O-W<[J[3Q'XXT-JRXIMQ$K2@MY3
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M%CYH%#6:E6^'%G*]5J[K&</NT''?=(WFKWK7KC\)LY**[V5)IM'A^"@ T[7
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M;$&HR0D!GD3P62MC7C/T*+UTL!E[,,NRNJP%W7,.K%3:\K_,2\)AW(F'$7R
MPV$2TW"Q,UF',W1H \IAMAV/#Z2-!H&T<0>--=7H($T'G2B*.C0[&;J9S^,@
M25)ON$C*"1Z1:0/HVN9U]3I-^>A#"V\26'+)+1X)$KE\!QMNO'?FBD -L' ;
M%"=(E0T<<DDT5&V(G/DP@O,M6HZ5NXO_::54%4^J#RG<*DN]]**X3=5V]4&X
M)5<EZI4794.774O;*%>[VNK^K)&[9_?FT;AD>L7IYQ"XI-"H.^P'H!LA;@RK
M*B]^"V5)2OVTH+<+M7.@_:4B2=@8[H#V-9S^ U!+ P04    "  A@%Q8W/65
MISD(   7%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R=&&EOVSCV
MKSQX,K,MH,JZ+-FY@*1)9OLA;9"D+1:+_<!(M"U$$EV2LI/Y]?L>*<GR$6]F
M84#F\?CNBSQ="?FLYIQK>"F+2IT-YEHOCH=#E<YYR90K%KS"G:F0)=,XE;.A
M6DC.,G.H+(:!Y\7#DN75X/S4K-W)\U-1ZR*O^)T$59<EDZ^7O!"KLX$_:!?N
M\]E<T\+P_'3!9OR!Z^^+.XFS88<ERTM>J5Q4(/GT;'#A'U]&!&\ ?N1\I7IC
M($F>A'BFR9?L;. 10[S@J28,#/^6_#,O"D*$;/QJ< XZDG2P/VZQWQC9498G
MIOAG4?S,,ST_&XP'D/$IJPM]+U;_Y(T\(\*7BD*9+ZPL;)P,(*V5%F5S&#DH
M\\K^LY=&#[T#8^^- T%S(#!\6T*&RRNFV?FI%"N0!(W8:&!$-:>1N;PBHSQH
MB;LYGM/G7X7FD, G>- B?9Z+(N-2_0.N?]6Y?@5697;C$TF>P6=1HC<H9A1Z
M_4)C?CK4R =A&Z8-S4M+,WB#IA_ K:CT7,%UE?%L$\$0!>BD"%HI+H.#&*]X
MZD+H.Q!X07@ 7]AI)33XP@-:4: %W.05J]*<%:@&ICEZHU;[!+;HHOWH*+".
MU8*E_&R D:.X7/+!^1^_^;%W<H#9J&,V.H3]_&'.)-]K.=KX=&DL=\=>#?/P
M[T?^HN&R0*/^9Y\D!VGMER1QX0YCB4O)&W>!QSDWSL*JUS]^&P=^<J+@4C"9
M@9C"52XQ)H54\$$C' $$WHG9-F/_Y"/,&>H?-UFMYT*21&B-7*F:PZ*CI0RM
MO )1<3)] -\J^"J6O'SB$H+ ^(/]^K1UPY]DC:D'_&;1@0MMR-PR^8P9\,/%
MX^U'8KQ$_[:2?$&:Z *<SM\R/&J=S.E/H!*:1)8<5O2I!*06A^50L0+=J49G
MEX8:4H&LEGDU,]-7SB1P"@5 1[;,M\[LPA>B*],Y33VGU19-# LC ^>YY@L7
M"YD7$,1[F'2)+0.$"7L,WSMNMNUDMM>?CJ7 \]'2FE<T&A\RL02&F5'ELPIC
MQF2-,M>:<S(^4;1@N<*LKA8"$_Q3P6%*QS),<;G2TF:8!GR707^\_>G86NO$
MV!A7?LYY:PBQ(+R*.%QP:4H:F9:MD!\%&"W 7[A,<XJ8"OVA8:!=1-?+"1QC
M2[,7KARS6]5&/0BK*."4&5G/)']M!,WJ%(=/K_N/\%\UYAAT<>/SI:@K2YRH
M@%BM3QI6$5V:+W*,9\O+G.E=E"1-2N(5!<_<OKFP?KPVWOVM40CM3D6!)9J<
MTE;H_"_$DE>V\)L*^H15?4.3MJA2=#;N3(YV##]-+42F+Y9<8FG?7?C:<;NS
M=<^IER!DG[%(2*1 JKF8S22?H3MA/&@DI?(4?K "TT$KPG5KI#MCI$<N2TH-
M_\+@(C'@-B\* _BMUDJCWH@$,];:CKH  F<43)PH&L,1)@O7#R%T)Q%.HHD;
M>QW-F605\>X[?APXGN>!/W8G?K>_]J8/L1<X$0;?1QB[X;B#0.U.>8XXAM96
M!!I-G,ED@I!AX(XF[^ 7N7.\<.)XP<3D!S\XZ?Z/NM$/KHA7\AB.I3NE"7K<
M$I<!'>@04G]$*HA=3*-'$'IN,&[5S2AT]Y[VG7$8.WY"6O-]UYN0"DF?0>QB
M5'ZSH;49EVM]O3,].I34_D_G5?OY;BTC>FK?LJ<1NG-<MNWDW6#MY;)S:K83
M >W*/:MF)D5NIIM-3M)>3'1P2VO9;GXC10F/HI.SR*<</F ,D"K5QR:-M;MV
M=@2>.QF1>=T@@K$7H?DBB%QC,==/NJ5FBJ% -D7;AJX70#R*G2#$VN+2&KHX
MNDN48%@D=FJ\(+(.Y,<42Q@P,2[[Y@ N8? T2^T4_Q-W%'7_8\\S,38Q3-FU
M*,(H#7J@@>_Z1"1)"$7BCYPP]"%Q"29$V9#%)'&\B9' =]&YUVX>&RCK[+ON
MV\^@M4*[7!8,.^.'%'LOVRVB&?*2<A2Y[93E$I8F1:%-Q6;&<+<.IU0%J8'#
MRKG.Y%-FVB0''3DMZJP-B-(V*XT5]]?(?O_APHU%!+7."XR,C/+A#O>65\ZP
MU=C(\0W+3E-KJ,?9\OR#HFZ'LGH[EFWJI6;-1.)Z^D,4C%C'0N./@M^)6W\T
M^AT_?C.)<!(ES007[W/U_&DJL>?(D0E).0Z;"A0T=,<60>2&"(_N-S;3T(TG
M-/4;]&Z$@^LV3YH(ZF3KQU)B?E=8!3.4"UYS7F3P%Y>B][FQ2;[&BDQ,;&_O
M9))-?6[FK%:K1U1J;#Y&?XWQ/QZYX["O*NP[[+7-W)^7=*%MW66.31:VU2EF
MD>7ZP+M\Z4W-4L/1T3-Z,.2^NP_8-4K.5(V==V5N5J@^/IVB:BD%$\F,U(+
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MQ'-X*)*:;K79V K1P:L4RLZBRKGZ*HYM7J%D=J!K5'12:B.9(].L8UL;9$4
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MZ=GY%V419G *GV2J*H0[\8CF?&@)F@6&:0MSU<!$+\"$$7Q6TJX,?) 99H<
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MRXJ^A-"Q ;U?66KU?L,!AF^K^7]02P,$%     @ (8!<6'>DG(Z? P  '@@
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MDV@2?]J+NKPN-]XTX7V1&T^9#,N*GH=H^0#QYX9NU7[#!H8'Y_1_4$L#!!0
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MZ! +MK.XZ? P[J,)P4"E/B+<TM3P&T_\-V9P%88]J?>>89.DSMY2ZX"\>,)
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MQ-,(!#')LK HT>O&QNI9,9QPU0:H\C>Q-?R0==RT0O[EO/:;#F.(G&;VPN3
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MQ/*C<#E?WIV[HG I/ZZ,AC^C!?B^<*ZH?Q""YCKWU?\ 4$L#!!0    ( "&
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MC@90,#<T\='X"_1^I:E-=AOOH/N'3/\!4$L#!!0    ( "& 7%CN@\"GMP(
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M4%D'>K^2U,FM82_H_F;17U!+ P04    "  A@%Q8.)=AA[(%  !(#P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RM5VUOVS80_BN$FW8MH,@B]=XF
M!IPTZ?JA;9!T*89A'QCI; N11)>D[:2_?D=25MS$$S)T,&#QJ..]\;D[W=%&
MR%NU -#DKJE;=3Q::+U\.QZK8@$-5[Y80HMO9D(V7",IYV.UE,!+>ZBIQRP(
MDG'#JW8T.;)[%W)R)%:ZKEJXD$2MFH;+^Q.HQ>9X1$?;C<MJOM!F8SPY6O(Y
M7('^8WDAD1KW4LJJ@595HB429L>C*7U[DAE^RW!=P4;MK(GQY$:(6T-\+(]'
M@3$(:BBTD<#QL893J&LC",WXWLD<]2K-P=WU5OJY]1U]N>$*3D7]K2KUXGB4
MC4@),[ZJ]:78_ Z=/[&15XA:V7^RZ7B#$2E62HNF.XP6-%7KGORNB\-S#K#N
M +-V.T76RO=<\\F1%!LB#3=*,POKJCV-QE6MN90K+?%MA>?TY+/00%)R2*ZT
M*&X7HBY!JM_(V?=5I>\);TOWXM!X7I)3T2 :%+<!/;LS:R"OO_*;&M2;H[%&
M@XS8<=$I/W'*V;\HIXQ\$JU>*'+6EE#^+&",GO3NL*T[)VQ0XGLH?!)2C["
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M2B- WU-!C4&S,1>T??'\/U!+ P04    "  A@%Q89$'#)Q0"  !'!   &0
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M    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;,59;6_B.!#^*R-N=6HE6I)
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M%&([<WSG?>">K7-M!MQX6M$U/(!^K)82>VZGDK$2N&*"$PFKF7/M7R4C@[>
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M@I+MQ+:"%I7KX8W09B+<L3!+#J0U,/=;8?JX$ZR#?FTF?P%02P,$%     @
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M@C G:ZDJBL94&U]O%=#"D2KNAT$P]BO*A)<F;F^ATD36R)F A2*ZKBJJ?L^
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M5ZUR-=$B+[O-5&C3N\IA9OXN0%J >3X3IN-4$]O ZO^5^!]02P,$%     @
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MB H&5PA7S?/0!$96KL-6TF"_NF&!+RHHFX#K:XE=U@:V:;LW.OT%4$L#!!0
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ML/8#>A\$],J WJDU],N _EZ -?@@8% &#$ZM85@&#$\-&)4!HU,#QF7 ^-2
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MXZJ _'R1IN)]1U6P??W>]9]02P,$%     @ (8!<6$_/MZ!.!   91(  !D
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M'\VL3J7@P&O EL(P6,-V6#M)50=[A4'47\.#%39TPG9T.I>J#H]))3& (NV
MTL(:K=MO5=NMG"BLQ""+6"&K*V'5WG:$%4$'-MRJ$H,I8O40U96P:F]UE 8-
MSU3$0(J<;W6*["]/!;"/<5/B:LM37WM]JMU?</P"%3'<(M]TB4I['];?MV.G
M0<"( 1LYWR(5V5^E0D'@#9N*U0"*?--E*K(/* *=O<56M[;6GC#Q5'Q1D*ER
M7*6R7':OCE9?+7PLU^I-\_*3ASLJGB(UH)C-55?/"=1DBO(K@G)'\F6Q<C_E
M4O*DV%PP&C*1-U#GYYS+[4[NH/J68_(?4$L#!!0    ( "& 7%BZ;;@6XP,
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M8N*,'))"1E=<WXO-KU )ZAN^1'!E?\FFBO4<DJR4%GD%Q@QR5I3_]*4JQ![
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MAKA[RO)64CYHL;3G]">A\=1OFPN\R8$T ?@^$WA6KQ[,!^J[X?1?4$L#!!0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;*U9VV[C-A#]%4(MBEW
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M %ZX6$!1;0T)T1U6LMY!Q&A$$H+SFNPA+-$'B('C!-U++#/)^,NN4P_= H^
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M<H/YDE"!$E@H2.=LI 3@Y?>&\D2R=?%"_9%)R=+B< 4X!IX;J/L+QN3K23Y
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M886]-"AK@-]+B=U2.[$;=-WY\A]02P,$%     @ (8!<6.UX^1Y6 P  YPH
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M0*[*5!1 ;ND3*!PN<;]D6PY$K,@"5B E9&:27"H%6A%:9N0;HP^,,\U0<;H
M31E79ZB]6R[(Z<D9.2&L)+>YV"JT5A-7(Z]9U4T;ML\U6W"$;0'I.0G]3R3P
M@M BGW]<'KR5NYBE-E5!FZJ@\C<\EBH\5'A\)-6L7!,NE"(IE?(9S]*.2GN
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MA*/.V@,;HL4,&;W SCAN&<?OWE,?S.2X ^ =('8M@B-'WO=>2X[7O_M>+U'
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M+ #WYQ++;3NQ'^BZ^^0O4$L#!!0    ( "& 7%B+4O+9T (  /H'   9
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MFC:HM_9BV 4C'=M$*=$C*3O]]R4E1;$2F[%6YL86*;X//UX=4CJ3'>/?Q!I
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MU8<9KY/*=4&R394$O6-2LKRZ7 -6FX-NH.XO&9,/!=U!F]J?_0!02P,$%
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M&EF^4R@_$727[3M942%HE!UN"?8)2V^0WZ\I%8>3M(!RO];\7U!+ P04
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M!OMNY8VBS?[-E?U;-Q__!5!+ P04    "  A@%Q8?'[I&]0!  #&'P  &@
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MI[4NFT,^Z_[)3SX!4$L! A0#%     @ (8!<6 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  A@%Q8
M(_:<Z.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  A@%Q8F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "& 7%A2G#F(:P@
M /TZ   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  A@%Q8';&N3Z0%  #Y%@  &               @(&N
M$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ (8!<6.'2
MX=.E @  3 D  !@              ("!B!8  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( "& 7%ABMO_VZP,  %P-   8
M  " @6,9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  A
M@%Q8]]+Q'L,)  !2;@  &               @(&$'0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ (8!<6"-<'R>&!@  81\  !@
M         ("!?2<  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( "& 7%B 3&@(=@,  (\'   8              " @3DN  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  A@%Q8 WP!!"P-  !K)
M&               @('E,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ (8!<6&4GI$W5 @  >08  !@              ("!1S\  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "& 7%AI,.@!!0,
M ),&   9              " @5)"  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ (8!<6#3EF\$A P  ]@8  !D              ("!
MCD4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  A@%Q8
MM'+)U1P#   9!P  &0              @('F2   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( "& 7%C<]96G.0@  !<5   9
M      " @3E,  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ (8!<6,K$*0!K @  4 4  !D              ("!J50  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  A@%Q8I/,_SIT%  #"#0
M&0              @(%+5P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( "& 7%A!1NIBXP,  &((   9              " @1]=  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ (8!<6 .R*_0^
M!   9PD  !D              ("!.6$  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  A@%Q8=Z2<CI\#   >"   &0
M@(&N90  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "&
M7%C.)[+&T 0  'P*   9              " @81I  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ (8!<6$?BJ0R> @  J <  !D
M         ("!BVX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  A@%Q8+O>FSH(.  #:+0  &0              @(%@<0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "& 7%AQ_Q-1Z@(  $\&
M   9              " @1F   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ (8!<6.Z#P*>W @  V 4  !D              ("!.H,
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  A@%Q8C]76
M_HX"  "0!0  &0              @($HA@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( "& 7%C8L3:-R@(  !(&   9
M  " @>V(  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M(8!<6*"&@,K4 @  V08  !D              ("![HL  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  A@%Q8.)=AA[(%  !(#P  &0
M            @('YC@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( "& 7%C?Y +%; 0  ",+   9              " @>*4  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ (8!<6&1!PR<4 @
M1P0  !D              ("!A9D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  A@%Q8VJ\,F!(%  ""&0  &0              @('0
MFP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "& 7%@4
M%G(C:P,  .H)   9              " @1FA  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ (8!<6-L3#G:4 @  \08  !D
M     ("!NZ0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "& 7%CJ;EKS, (  %$%   9              "
M@7FS  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ (8!<
M6/.E>WC+ @  NP@  !D              ("!X+4  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  A@%Q8D*@OQD,"  "O!0  &0
M        @('BN   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( "& 7%BA>CGY4 @  (I/   9              " @5R[  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ (8!<6$_/MZ!.!   91(
M !D              ("!X\,  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  A@%Q8G[7[BZH%  #7(0  &0              @(%HR
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "& 7%BZ;;@6
MXP,  "<.   9              " @4G.  !X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ (8!<6+;A5?5[ @  @08  !D
M ("!8](  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  A
M@%Q8,3)M,O\"  #X"0  &0              @($5U0  >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "& 7%@3J:YWT@0   $:   9
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M970U,"YX;6Q02P$"% ,4    "  A@%Q8S<Q7:4L$   "$P  &0
M    @(&7Z@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M "& 7%@[S=HFQ ,  .87   9              " @1GO  !X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ (8!<6!ME8Z5V!@  NS4  !D
M             ("!%/,  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    "  A@%Q8P')>P4H#  #*%   #0              @ '!^0  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "& 7%B7BKL<P    !,"   +
M      "  3;]  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "& 7%ALB9(;A 0
M /DC   /              "  1_^  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    "  A@%Q8?'[I&]0!  #&'P  &@              @ '0 @$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  A@%Q8*F32ILH!  ";
M'P  $P              @ '<! $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    /0 ] *(0  #7!@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>148</ContextCount>
  <ElementCount>269</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation</Role>
      <ShortName>Note 1 - General, Liquidity and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Prepaid and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets</Role>
      <ShortName>Note 3 - Prepaid and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Real Property and Other Income, Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets</Role>
      <ShortName>Note 6 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Employee 401(k) Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan</Role>
      <ShortName>Note 8 - Employee 401(k) Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Leases and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments</Role>
      <ShortName>Note 10 - Leases and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan</Role>
      <ShortName>Note 11 - 2020 Cash Incentive Bonus Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies</Role>
      <ShortName>Note 12 - Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution</Role>
      <ShortName>Note 13 - Subsequent Event - Warrant Dividend Distribution</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables</Role>
      <ShortName>Note 3 - Prepaid and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995468 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995469 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995470 - Disclosure - Note 6 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables</Role>
      <ShortName>Note 6 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995471 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995472 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual</Role>
      <ShortName>Note 1 - General, Liquidity and Basis of Presentation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual</Role>
      <ShortName>Note 4 - Real Property and Other Income, Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995478 - Disclosure - Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details</Role>
      <ShortName>Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details</Role>
      <ShortName>Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995488 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995489 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995490 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995491 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995492 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995494 - Disclosure - Note 10 - Leases and Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual</Role>
      <ShortName>Note 10 - Leases and Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual</Role>
      <ShortName>Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995496 - Disclosure - Note 12 - Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual</Role>
      <ShortName>Note 12 - Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sava20231231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual</Role>
      <ShortName>Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sava-20231231.xsd</File>
    <File>sava-20231231_cal.xml</File>
    <File>sava-20231231_def.xml</File>
    <File>sava-20231231_lab.xml</File>
    <File>sava-20231231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sava20231231_10k.htm">sava20231231_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>alz.jpg</File>
    <File>cab1ac4300e0img001.jpg</File>
    <File>chgbsl.jpg</File>
    <File>deccog.jpg</File>
    <File>pg01.jpg</File>
    <File>pic1.jpg</File>
    <File>pic2.jpg</File>
    <File>slide02.jpg</File>
    <File>slide03.jpg</File>
    <File>slide04.jpg</File>
    <File>slide05.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="553">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sava20231231_10k.htm": {
   "nsprefix": "sava",
   "nsuri": "http://www.cassavasciences.com/20231231",
   "dts": {
    "schema": {
     "local": [
      "sava-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sava-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sava-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sava-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sava-20231231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sava20231231_10k.htm"
     ]
    }
   },
   "keyStandard": 242,
   "keyCustom": 27,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 21,
   "hidden": {
    "total": 52,
    "http://www.cassavasciences.com/20231231": 4,
    "http://fasb.org/us-gaap/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 148,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 406,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 553,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 5
   },
   "report": {
    "R1": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
     "longName": "006 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation",
     "shortName": "Note 1 - General, Liquidity and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
     "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
     "longName": "008 - Disclosure - Note 3 - Prepaid and Other Current Assets",
     "shortName": "Note 3 - Prepaid and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
     "longName": "009 - Disclosure - Note 4 - Real Property and Other Income, Expense",
     "shortName": "Note 4 - Real Property and Other Income, Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:RealEstateOwnedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
     "longName": "010 - Disclosure - Note 5 - Property and Equipment",
     "shortName": "Note 5 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
     "longName": "011 - Disclosure - Note 6 - Intangible Assets",
     "shortName": "Note 6 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
     "longName": "012 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
     "longName": "013 - Disclosure - Note 8 - Employee 401(k) Benefit Plan",
     "shortName": "Note 8 - Employee 401(k) Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
     "longName": "014 - Disclosure - Note 9 - Income Taxes",
     "shortName": "Note 9 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
     "longName": "015 - Disclosure - Note 10 - Leases and Commitments",
     "shortName": "Note 10 - Leases and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:LeasesAndCommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
     "longName": "016 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan",
     "shortName": "Note 11 - 2020 Cash Incentive Bonus Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:CashIncentiveBonusPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
     "longName": "017 - Disclosure - Note 12 - Contingencies",
     "shortName": "Note 12 - Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
     "longName": "018 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution",
     "shortName": "Note 13 - Subsequent Event - Warrant Dividend Distribution",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies",
     "longName": "995465 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
     "longName": "995466 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
     "longName": "995467 - Disclosure - Note 3 - Prepaid and Other Current Assets (Tables)",
     "shortName": "Note 3 - Prepaid and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
     "longName": "995468 - Disclosure - Note 4 - Real Property and Other Income, Expense (Tables)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
     "longName": "995469 - Disclosure - Note 5 - Property and Equipment (Tables)",
     "shortName": "Note 5 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
     "longName": "995470 - Disclosure - Note 6 - Intangible Assets (Tables)",
     "shortName": "Note 6 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "longName": "995471 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables",
     "longName": "995472 - Disclosure - Note 9 - Income Taxes (Tables)",
     "shortName": "Note 9 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
     "longName": "995473 - Disclosure - Note 1 - General, Liquidity and Basis of Presentation (Details Textual)",
     "shortName": "Note 1 - General, Liquidity and Basis of Presentation (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "longName": "995474 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistancePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistancePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "longName": "995475 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "shortName": "Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "longName": "995476 - Disclosure - Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "sava:PrepaidExpensesAndOtherCurrentAssetsTextBock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
     "longName": "995477 - Disclosure - Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "shortName": "Note 4 - Real Property and Other Income, Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX",
      "name": "us-gaap:NetRentableArea",
      "unitRef": "SquareFoot",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
     "longName": "995478 - Disclosure - Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)",
     "shortName": "Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OtherNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:RealEstateOwnedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual",
     "longName": "995479 - Disclosure - Note 5 - Property and Equipment (Details Textual)",
     "shortName": "Note 5 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "longName": "995480 - Disclosure - Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "shortName": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual",
     "longName": "995481 - Disclosure - Note 6 - Intangible Assets (Details Textual)",
     "shortName": "Note 6 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "longName": "995482 - Disclosure - Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "longName": "995483 - Disclosure - Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "shortName": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
     "longName": "995484 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
     "longName": "995485 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
     "longName": "995486 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
     "longName": "995487 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "longName": "995488 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2022-12-31_AwardTypeAxis-PerformanceSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-12-31_AwardTypeAxis-PerformanceSharesMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "longName": "995489 - Disclosure - Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "shortName": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
     "longName": "995490 - Disclosure - Note 9 - Income Taxes (Details Textual)",
     "shortName": "Note 9 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
     "longName": "995491 - Disclosure - Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "995492 - Disclosure - Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
     "longName": "995493 - Disclosure - Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "i_2022-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual",
     "longName": "995494 - Disclosure - Note 10 - Leases and Commitments (Details Textual)",
     "shortName": "Note 10 - Leases and Commitments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:LeasesAndCommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-01-01_2023-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:LeasesAndCommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
     "longName": "995495 - Disclosure - Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "shortName": "Note 11 - 2020 Cash Incentive Bonus Plan (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember",
      "name": "sava:CashBonusIncentiveIncrementalAmounts",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "sava:CashIncentiveBonusPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual",
     "longName": "995496 - Disclosure - Note 12 - Contingencies (Details Textual)",
     "shortName": "Note 12 - Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual",
     "longName": "995497 - Disclosure - Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual)",
     "shortName": "Note 13 - Subsequent Event - Warrant Dividend Distribution (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "i_2023-12-22",
      "name": "sava:VolumeWeightedAveragePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-22",
      "name": "sava:VolumeWeightedAveragePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sava20231231_10k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and other accrued expenses",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent",
        "terseLabel": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r50",
      "r452"
     ]
    },
    "sava_AccruedDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "AccruedDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued development expense",
        "documentation": "Amount of accrued development expense, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r111",
      "r335"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r467",
      "r559"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r355",
      "r499",
      "r500",
      "r501",
      "r546",
      "r560"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation for stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r253"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
        "terseLabel": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "terseLabel": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r32",
      "r36"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive securities excluded from net loss per share, diluted (in shares)",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r113",
      "r131",
      "r158",
      "r166",
      "r168",
      "r172",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r284",
      "r286",
      "r297",
      "r328",
      "r392",
      "r467",
      "r479",
      "r511",
      "r512",
      "r548"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r118",
      "r131",
      "r172",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r284",
      "r286",
      "r297",
      "r467",
      "r511",
      "r512",
      "r548"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_AtthemarketCommonStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "AtthemarketCommonStockOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-the-market Common Stock Offering [Member]",
        "documentation": "Represents the At-the-Market Common Stock Offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "sava_BonusShareFractionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "BonusShareFractionMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus Share Fraction [Member]",
        "documentation": "Represents the bonus share fraction member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of property and equipment included in accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "sava_CarryforwardSubjectToExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CarryforwardSubjectToExpirationMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carryforward Subject to Expiration [Member]",
        "documentation": "Relating to tax carryforwards subject to expiration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r109",
      "r450"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "sava_CashBonusIncentiveIncrementalAmounts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CashBonusIncentiveIncrementalAmounts",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashBonusIncentiveIncrementalAmounts",
        "terseLabel": "Cash Bonus Incentive, Incremental Amounts",
        "documentation": "The number of incremental amounts for cash bonus incentive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r71",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71"
     ]
    },
    "sava_CashIncentiveBonusAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CashIncentiveBonusAward",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAward",
        "terseLabel": "Cash Incentive Bonus Award",
        "documentation": "Amount of cash incentive bonus award."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusAwardExceedsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CashIncentiveBonusAwardExceedsMaximum",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CashIncentiveBonusAwardExceedsMaximum",
        "terseLabel": "Cash Incentive Bonus Award, Exceeds Maximum",
        "documentation": "Amount of cash incentive bonus award if the maximum milestone is exceeded."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CashIncentiveBonusPlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Member]",
        "documentation": "Represents the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_CashIncentiveBonusPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CashIncentiveBonusPlanTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Incentive Bonus Plan [Text Block]",
        "documentation": "The entire disclosure for the cash incentive bonus plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r115",
      "r116",
      "r131",
      "r147",
      "r148",
      "r150",
      "r152",
      "r156",
      "r157",
      "r172",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r297",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r380",
      "r401",
      "r419",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r492",
      "r497",
      "r502"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sava_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)",
        "documentation": "Represents the warrants or rights exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class Of Warrant Or Right Issued During Period (in shares)",
        "documentation": "The number of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "sava_CommissionPercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "CommissionPercentageOfGrossProceeds",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_CommissionPercentageOfGrossProceeds",
        "terseLabel": "Commission Percentage of Gross Proceeds",
        "documentation": "Represents the percentage of commission required to be paid from gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Notes 10, 11 and 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r54",
      "r329",
      "r379"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r473",
      "r474",
      "r475",
      "r476",
      "r499",
      "r500",
      "r546",
      "r558",
      "r560"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r380"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r380",
      "r398",
      "r560",
      "r561"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 120,000,000 shares authorized; 42,236,919 and 41,735,557 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r331",
      "r467"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r94",
      "r271"
     ]
    },
    "sava_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset (liability)",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r544"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOther",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r544"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r544"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r544"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r544"
     ]
    },
    "us-gaap_DepositContractsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositContractsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract research organization and other deposits",
        "documentation": "Carrying amount of assets as of the balance sheet date pertaining to amounts paid by the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r37"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r487"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share, basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r150",
      "r151",
      "r152",
      "r154",
      "r295",
      "r296",
      "r326",
      "r338",
      "r454"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax at federal statutory rate",
        "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r260",
      "r280"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Section 162(m) limitation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r105",
      "r122",
      "r123",
      "r124",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r155",
      "r173",
      "r174",
      "r209",
      "r246",
      "r247",
      "r248",
      "r277",
      "r278",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r314",
      "r340",
      "r341",
      "r342",
      "r355",
      "r419"
     ]
    },
    "sava_EquityOfferingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "EquityOfferingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingMaximumAmount",
        "terseLabel": "Equity Offering, Maximum Amount",
        "documentation": "The maximum amount to be issued in the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_EquityOfferingPercentageOfCommission": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "EquityOfferingPercentageOfCommission",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_EquityOfferingPercentageOfCommission",
        "terseLabel": "Equity Offering, Percentage of Commission",
        "documentation": "Percentage of commission in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r14"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r180"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "2024",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r324",
      "r325"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r325"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsNet",
        "totalLabel": "Total amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r324"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r403"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAmount",
        "terseLabel": "Government Assistance, Amount",
        "documentation": "Amount of government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r307"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r404"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r404"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r256",
      "r261",
      "r268",
      "r275",
      "r279",
      "r281",
      "r282",
      "r283",
      "r354"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r258",
      "r259",
      "r268",
      "r269",
      "r274",
      "r276",
      "r348"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable and other accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "sava_IncreaseDecreaseInDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "IncreaseDecreaseInDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInDevelopmentExpense",
        "terseLabel": "Accrued development expense",
        "documentation": "Amount of increase (decrease) in development expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Accrued compensation and benefits",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet",
        "negatedLabel": "Operating lease right-of-use assets and liabilities",
        "documentation": "Amount of increase (decrease) in operating lease right of use assets and liabilities, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities",
        "terseLabel": "Other liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "sava_IndefiniteLifeCarryforwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "IndefiniteLifeCarryforwardsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite Life Carryforwards [Member]",
        "documentation": "Relating to indefinite life tax carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r320",
      "r321",
      "r322",
      "r324",
      "r453"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r34"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "sava_LeaseForOfficeSpaceInAustinTexasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "LeaseForOfficeSpaceInAustinTexasMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease for Office Space in Austin, Texas [Member]",
        "documentation": "Relating to the lease for office space in Austin, Texas."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_LeasesAcquiredInPlaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAcquiredInPlaceMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Acquired-in-Place [Member]",
        "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired."
       }
      }
     },
     "auth_ref": []
    },
    "sava_LeasesAndCommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "LeasesAndCommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases And Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure regarding leases and commitments."
       }
      }
     },
     "auth_ref": []
    },
    "sava_LeasingCommissionsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "LeasingCommissionsAndOtherMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasing Commissions and Other [Member]",
        "documentation": "Represents leasing commissions and other."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r131",
      "r172",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r285",
      "r286",
      "r287",
      "r297",
      "r378",
      "r455",
      "r479",
      "r511",
      "r548",
      "r549"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r95",
      "r333",
      "r467",
      "r498",
      "r506",
      "r547"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r108",
      "r131",
      "r172",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r285",
      "r286",
      "r287",
      "r297",
      "r467",
      "r511",
      "r548",
      "r549"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LossContingencyNewClaimsFiledNumber",
        "terseLabel": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r211",
      "r319",
      "r339",
      "r370",
      "r371",
      "r422",
      "r424",
      "r426",
      "r427",
      "r429",
      "r446",
      "r447",
      "r458",
      "r460",
      "r462",
      "r468",
      "r513",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r211",
      "r319",
      "r339",
      "r370",
      "r371",
      "r422",
      "r424",
      "r426",
      "r427",
      "r429",
      "r446",
      "r447",
      "r458",
      "r460",
      "r462",
      "r468",
      "r513",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r73",
      "r96",
      "r106",
      "r119",
      "r120",
      "r124",
      "r131",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r144",
      "r145",
      "r149",
      "r158",
      "r165",
      "r167",
      "r169",
      "r172",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r296",
      "r297",
      "r337",
      "r400",
      "r417",
      "r418",
      "r456",
      "r477",
      "r511"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetRentableArea",
        "terseLabel": "Net Rentable Area (Square Foot)",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "sava_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]"
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r165",
      "r167",
      "r169",
      "r456"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r312"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r466"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r92",
      "r345",
      "r346"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAssetsCurrent",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r467"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r467"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherNonoperatingExpense",
        "negatedLabel": "Property operating expenses",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease revenue",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income, net",
        "totalLabel": "Other income, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "sava_PaymentsForCashIncentiveBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PaymentsForCashIncentiveBonus",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PaymentsForCashIncentiveBonus",
        "terseLabel": "Payments for Cash Incentive Bonus",
        "documentation": "Amount of payments for cash incentive bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "sava_PercentageOfOccupancy": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PercentageOfOccupancy",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageOfOccupancy",
        "terseLabel": "Percentage of Occupancy",
        "documentation": "Percentage of occupancy."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment",
        "terseLabel": "Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment",
        "documentation": "the percentage of valuation milestone cash bonus award subject to approval and adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained",
        "terseLabel": "Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)",
        "documentation": "The minimum number of days valuation milestone must be achieved and maintained in performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_PerformancePlanValuationMilestoneAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PerformancePlanValuationMilestoneAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_PerformancePlanValuationMilestoneAmount",
        "terseLabel": "Performance Plan, Valuation Milestone Amount",
        "documentation": "Amount of valuation milestone for performance plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r203"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r380"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r203"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r380",
      "r398",
      "r560",
      "r561"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r330",
      "r467"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "sava_PrepaidExpensesAndOtherCurrentAssetsTextBock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Bock]",
        "documentation": "The entire disclosure of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r459",
      "r507"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities",
        "terseLabel": "Proceeds from Insurance Settlement, Operating Activities",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r448"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from common stock offering, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock upon exercise of 2018 warrants",
        "terseLabel": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_ProceedsFromWarrantsExercisedThatObligatedToPayCommission",
        "terseLabel": "Proceeds From Warrants Exercised That Obligated to Pay Commission",
        "documentation": "Dollar amount required to be paid for commission from warrants exercised during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r99",
      "r102",
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r110",
      "r336"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r327",
      "r336",
      "r467"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r99",
      "r102",
      "r334"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r240",
      "r241",
      "r242",
      "r318",
      "r319",
      "r339",
      "r370",
      "r371",
      "r422",
      "r424",
      "r426",
      "r427",
      "r429",
      "r446",
      "r447",
      "r458",
      "r460",
      "r462",
      "r468",
      "r471",
      "r508",
      "r513",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "sava_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Five [Member]",
        "documentation": "Relating to range five."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RangeFourMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Four [Member]",
        "documentation": "Relating to range four."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r191",
      "r210",
      "r211",
      "r240",
      "r241",
      "r242",
      "r318",
      "r319",
      "r339",
      "r370",
      "r371",
      "r422",
      "r424",
      "r426",
      "r427",
      "r429",
      "r446",
      "r447",
      "r458",
      "r460",
      "r462",
      "r468",
      "r471",
      "r508",
      "r513",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "sava_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RangeOneMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Relating to range one."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Relating to range three."
       }
      }
     },
     "auth_ref": []
    },
    "sava_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Relating to range two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateOwnedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstateOwnedTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Owned [Text Block]",
        "documentation": "The entire disclosure for real estate owned (as defined). Generally, the largest component of real estate owned by lenders is assets taken in settlement of troubled loans through surrender or foreclosure. Real estate investments, real estate loans that qualify as investments in real estate, and premises that are no longer used in operations may also be included in real estate owned."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "sava_RedemptionPercentageOfWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "RedemptionPercentageOfWarrants",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_RedemptionPercentageOfWarrants",
        "terseLabel": "Redemption Percentage of Warrants",
        "documentation": "The Percent of the cost for redemption of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development, net of grant reimbursement",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r255",
      "r556"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RetainedEarningsAccumulatedDeficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r81",
      "r332",
      "r343",
      "r344",
      "r353",
      "r381",
      "r467"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r173",
      "r174",
      "r246",
      "r247",
      "r248",
      "r277",
      "r278",
      "r288",
      "r290",
      "r291",
      "r293",
      "r294",
      "r340",
      "r342",
      "r355",
      "r560"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r45"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r42"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r367",
      "r368",
      "r369",
      "r423",
      "r425",
      "r428",
      "r430",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r449",
      "r461",
      "r471",
      "r514",
      "r557"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r170",
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedLabel": "Forfeited/canceled, awards (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, awards (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Outstanding, awards (in shares)",
        "periodEndLabel": "Outstanding, awards (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested, awards (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeiture rate",
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rates",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2023 (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Options forfeited/canceled (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value of stock options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding as of December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Outstanding, options (in shares)",
        "periodEndLabel": "Outstanding, options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2023 (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options forfeited/canceled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r218",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, exercise price, lower limit (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable (in shares)",
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding (in shares)",
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, exercise price, upper limit (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of option (in years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable at December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding as of December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest at December 31, 2022, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable, weighted average exercise price (in dollars per share)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding, weighted average exercise price (in dollars per share)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options outstanding, weighted average contractual life (Year)",
        "label": "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sava_ShareholderDerivativeActionsDelawareCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ShareholderDerivativeActionsDelawareCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Delaware Court [Member]",
        "documentation": "Represents shareholder derivative actions in Delaware court."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ShareholderDerivativeActionsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions [Member]",
        "documentation": "Represents shareholder derivative actions."
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ShareholderDerivativeActionsTexasCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas Court [Member]",
        "documentation": "Represents shareholder derivative actions in Texas Court"
       }
      }
     },
     "auth_ref": []
    },
    "sava_ShareholderDerivativeActionsTexasStateCourtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ShareholderDerivativeActionsTexasStateCourtMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder Derivative Actions, Texas State Court Member",
        "documentation": "Represents shareholder derivative actions in Texas State Court."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r85"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r130"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r115",
      "r116",
      "r131",
      "r147",
      "r148",
      "r150",
      "r152",
      "r156",
      "r157",
      "r172",
      "r194",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r297",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r380",
      "r401",
      "r419",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r492",
      "r497",
      "r502"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20",
      "r105",
      "r122",
      "r123",
      "r124",
      "r133",
      "r134",
      "r135",
      "r137",
      "r143",
      "r145",
      "r155",
      "r173",
      "r174",
      "r209",
      "r246",
      "r247",
      "r248",
      "r277",
      "r278",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r314",
      "r340",
      "r341",
      "r342",
      "r355",
      "r419"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r367",
      "r368",
      "r369",
      "r423",
      "r425",
      "r428",
      "r430",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r449",
      "r461",
      "r471",
      "r514",
      "r557"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r155",
      "r323",
      "r347",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r472"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation",
      "http://www.cassavasciences.com/20231231/role/statement-note-1-general-liquidity-and-basis-of-presentation-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments",
      "http://www.cassavasciences.com/20231231/role/statement-note-10-leases-and-commitments-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-11-2020-cash-incentive-bonus-plan-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-components-of-intangible-assets-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-8-employee-401k-benefit-plan",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables",
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r155",
      "r323",
      "r347",
      "r366",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r419",
      "r472"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in conjunction with registered direct offering, net of issuance costs (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r60",
      "r81",
      "r349",
      "r419",
      "r432"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards (in shares)",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r60",
      "r81",
      "r224"
     ]
    },
    "sava_StockIssuedDuringPeriodSharesWarrantExercises": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercises",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of warrants (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrant Exercises (in shares)",
        "documentation": "Number of shares of stock issued attributable to warrant exercises."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued in conjunction with registered direct offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r59",
      "r60",
      "r81",
      "r355",
      "r419",
      "r432",
      "r478"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
        "negatedLabel": "Expiration of restricted stock Performance Awards",
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20",
      "r81"
     ]
    },
    "sava_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock pursuant to exercise of warrants",
        "documentation": "Value of shares of stock issued attributable to exercises of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_StockOptionsExercisedNetSettledSatisfactionOfExercisePrice",
        "terseLabel": "Stock Options Exercised Net Settled Satisfaction Of Exercise Price (in shares)",
        "documentation": "Represents the number of stock options exercised net settled in satisfaction of the exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets",
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r63",
      "r64",
      "r75",
      "r382",
      "r398",
      "r420",
      "r421",
      "r467",
      "r479",
      "r498",
      "r506",
      "r547",
      "r560"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r316"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r316"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r316"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r90",
      "r91"
     ]
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "TX",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-3-prepaid-and-other-current-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-4-real-property-and-other-income-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-5-property-and-equipment-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-6-intangible-assets-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "sava_The2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "The2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2018 Equity Incentive Plan [Member]",
        "documentation": "Represents the 2018 Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "sava_The2021RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "The2021RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 Registered Direct Offering [Member]",
        "documentation": "Relating to the 2021 Registered Direct Offering."
       }
      }
     },
     "auth_ref": []
    },
    "sava_The2022RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "The2022RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense",
      "http://www.cassavasciences.com/20231231/role/statement-note-7-stockholders-equity-and-stockbased-compensation-expense-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2022 Registered Direct Offering [Member]",
        "documentation": "Represents the 2022 Registered Direct Offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual",
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r264"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions based on tax positions related to the current year",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
        "negatedLabel": "Expired research and development tax credits",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
        "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r97",
      "r98",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-9-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "sava_ViolationsOfFederalSecuritiesLawsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "ViolationsOfFederalSecuritiesLawsMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies",
      "http://www.cassavasciences.com/20231231/role/statement-note-12-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Violations of Federal Securities Laws [Member]",
        "documentation": "Represents the violations of federal securities laws."
       }
      }
     },
     "auth_ref": []
    },
    "sava_VolumeWeightedAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "VolumeWeightedAveragePrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_VolumeWeightedAveragePrice",
        "terseLabel": "Volume Weighted Average Price (in dollars per share)",
        "documentation": "Average price of common stock under warrant agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "sava_WarrantRedemptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "WarrantRedemptionPrice",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "sava_WarrantRedemptionPrice",
        "terseLabel": "Warrant Redemption Price (in dollars per share)",
        "documentation": "Price of warrants if they are redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "sava_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution",
      "http://www.cassavasciences.com/20231231/role/statement-note-13-subsequent-event-warrant-dividend-distribution-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Stock [Member]",
        "documentation": "Represents the warrants used to purchase common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.cassavasciences.com/20231231/role/statement-consolidated-statements-of-operations",
      "http://www.cassavasciences.com/20231231/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares used in computing net loss per share, basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r152"
     ]
    },
    "sava_statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-calculation-of-net-loss-per-share-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-2-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-and-other-current-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-3-prepaid-and-other-current-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-3-prepaid-expenses-and-other-current-assets-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-4-real-property-acquisitions-components-of-other-income-net-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property Acquisitions - Components of Other Income, Net (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-4-real-property-and-other-income-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-4-real-property-and-other-income-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Real Property and Other Income, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-5-property-and-equipment-components-of-property-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment - Components of Property and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-5-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-5-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-6-intangible-assets-amortization-expense-for-finitelived-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-components-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-6-intangible-assets-components-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets - Components of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-6-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-6-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-schedule-of-stock-options-by-exercise-price-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Schedule of Stock Options by Exercise Price (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-and-performance-award-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stock-option-valuation-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option Valuation Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-7-stockholders-equity-and-stockbased-compensation-expense-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Stock-based Compensation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-effective-income-tax-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Effective Income Tax Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-9-income-taxes-schedule-of-unrecognized-tax-benefits-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-note-9-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-note-9-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sava_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.cassavasciences.com/20231231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "c(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483081/340-30-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483054/340-30-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-20/tableOfContent"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450-30/tableOfContent"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001437749-24-005894-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-005894-xbrl.zip
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M-<F/Z/90S"9:[>GA4),TBFH4O+_UQB![:PNXZ<X]0LEZ^HG40/J1]_&S>I,
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MHVTN%'.4]\KN<N.-4_T^AG]E2WWD%IYZZ048F^YJ$R%<K0* :J^A*'!K3N"
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MEH^_-JSQ4)<R,D/@/CLXU<T2J!MI#V.#&F#$U%M/OG,BW8&0[9 IF4F^3EW
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M^4FW-HN-"(WTD/S56M2GH#%S=V3<63T-K.%?7>HACMD97CE;^Z%S! +U:MT
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M6J0P#AM0;O^]SM.++#C8<=+%OFC9=N[K5$OQHU"?WEOBKE969=FV=JAWX0Q
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M=0(8N(]E'+W$>C9(A[!!Q#0*E U2*N?8XFF.=$]!EZ1P=6P02VR=BPW:>-,
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M&Y1\QF=YSMUL]9KRJOP2@-G\"&*AF)4_P%_/<S-SM>RX]J&44&.?#H2,TUX
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M\\$, 5,A!]G>X<$<M8WGZ$J5= 3KYEY8/QI<$V6[0A&BW6>#8AZCO> )V5\
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M& 9?Q1SR7$<R?F8AOC_2J^G/HT4_7=J8^T (UR6X!&L"4J^^%E.#FH0WA@_
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M?:5-.ZNRS+FN'3<6EFM^9V;0&1<7Y;=Z^ZBX;)9NDJ/G4Y17'B(,QAO??PL
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M9_@<)6L:KOR/]KX\J,ELVS<V*B)B0!0$A(@HJ$PM,BA35 1$!%04- AI182
M$&U!(H1$F>>THM""$)19AH@04 @)$""*C<@4) B9E%'@^Q3P$S(\^IY7[]4]
M]Y[3YU:]\^Z][_4?JRKUU<K.E[777NOWV[76WN:OGP>>2X_ X;7L?^6-ZF8_
MN'"&0;1TZQ?I$8$WS1%K<_ANJW&7T.MPO@YW#$-)<%P0?ZS^20 GN-8W\+!?
M\21'H:F(]A-QPW4CUW,?LR>D,#X2F/MF;3<CA6TF)>/&D?/KWA*U]#ML327]
MA$T0DM\=(]%).=8$5E)8B"WG(*_FM!)<0@M!N6]7IA363-"%TH*?!DJTH1B!
ML7P RB<+F8#7CUKTN+?D/-QU?-JUKW)F9^:TS@1\?9"%CS8PFU8UBCD]$:Y.
M?^A?ZE3858919[[7>.'A%[/L>:BI/]3[Z+H1-:QIXW+CGI[,8T:['#X0S\?J
MN/X8N^/Q>HR#8O*GV$L/[OMNF2W,[&0[?I_S:;IZ-O#](Q?4KX\<=A1.>U(2
M'Y5[5'H4OIPZ6^Y1<'_J3)GNIX-O74]GA+C4788GVFHBOG2W(1-B\:>1W^ K
M3B,ORV1\77D"'?O]Y)3["\,]9RY?_[=QU%%D@-@HA74C%5?LI2,@2]P'L?:P
M/Q7_5/ROI'BMA"71W)F;I[T"F1S;;;D+ZU:BM<!6&R5"0-5\3?]FM+*UFA0F
M-QYCMNQ9P[8V$Y 3LA=K"KE>+Y#3P=A0)QUE!U?(R/?+K.%'.8--CGL3*-<+
M#\Z(B=WC=V;W[CVR!?/VP3F'RCT=)W,M[[K'\G>]V=VYR=4DM0#7:6C*3C,-
MO;@/5[%6'Y[6++B^U>#*)JJUJZIJ;*6[0C+STNY.L]V#3,'NSBT![*(#':%3
M???]Y=I=#9TN2-P)-L26O70C22<!V2@N9/#NHS=+MD-N/G6_< .)/YA%(I5:
MLQ_$GI9_..\MX\&N6)LBZ-*Z0O(7[;"U<O*SQ:A?H>DIVB/ZD-7U(E7WYCP]
M-JMY;IC2&DZL0;#2-GT,X*17EV,LZW)Y+D&>AWYY/I7I^<Z\$I#"W!NS(AV#
M*^1SUYZ4&0[JW!6M(HE+%T0@2BY"=UY;+V\0!_'=ABTD<D/+)H0/HQH9;A"3
M]Z)2Y(NYM$C7@,KX<3%.X+?XX;& 7L/SVJ'LT/:[0T4]9A-A"B;V_OM:5L_J
MN75- R%^OWB4/[RVT3P=W770L^T:'<DYP_\<[!E^BG_&JSQ#$.C-*59YCW&Q
M/UO06<6@FA +2U9#C0\^?5"=?\G'$[=:[UKG-X0@6>MMVZC<8;29V?%C47S)
MH[>5!WBTHZ^ 20MWV3:C\U1+U\H+1K[NBH_EQ%[^X/[6K+IG/N_?5*#/CS"W
MM!>-9,73[,,Q85@3.>T7=0TQSCB]Z-"+.T^WZ[!VF-"N=C8/D*%S!*T66W3B
MC_OO2F'KR,G[(6);@2;I$YOQ0*6/P2LA T>]3[@4O0E?OB!A+@X&F[*C#4_S
M<'9.MYC'OQPJ.#MHJS*UKT X8\Y" 6L^/$4%5'R\>Q1-8U0[BC;G+/XD;C!=
M9V2[!6HQQ2*&A]K#!,A8@E%>WPEP++'#+"C)\//1&=G$^43O.BDL9&(3%_-1
M:9Q:0?E(\MHAQ*^DU/.VF+A*Y@>G-1$OS?T.Z*'V& 4.A1B9,\?.W9Q[;6V=
MZV44>!]3. -H[15O/5!PYPL<2MHFF^M',,'M27K*EF\;E4T+A/"5KF\ST:SS
M:X[1A-'[&ZY?C]>3>W0R7HF=I:N!2,QJH'_M,],/1KW5GSY\S7",^RFET;E<
MGC3R"K1XB(E4:/H-;6G.-=DU^B*L\YFN6->Q='QA1KQOZ?08O5]RZ>\4=J1^
M0?XJ\2;DWRPJM*$7(%Z)<<@\>!,,3UK>C(!J"-JG6EG+APC]NV.6GR(#2$G^
M 7.WG3HB/0?-OEA\]F2U8E7+ILBU_C,.<<0&QQE9</,,Z]"UPP>$.P7TE_^[
M OOO%14PO+O_9I5W/GPP^3]P)9#BEY60@ICLF^;0U<3YQ"MN261%/!&$=R V
MT'QYE6OA:8R:?/%#R4Z6T$;/N]^(9L-OC(KLB,C,$9+7Z*9%!J\M%VA:L@2.
MJ95>S(:/V3=S(G&F^@65G!9,E!_QF\WF55^N% $UPHU9/!P=@0L_(<ZC!?&-
MUX],:&D :V- .^:HX0L9/CV&IV!\N,;6J#]X?-" 0KLNFQR,Q>YLZJ6972Q
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M;'IO1X>FW?G!66-KYXINH[*J0(N.3C8N5+R7W3JB9X$,\,P)1*ZE*TYKF=1
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M3%$QZ6*94?$:TZ7BVY*UVS?I\5S0Z#^J6GC5([YICU.!QJ']5X5&6KC2MJW
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M%S4S,W,DE'U-DLCWA<9TC]$9*V'-?\<HTE^&&=4?3I-HDPWNZCDC,9%ZZ&)
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MVW0WWC0M/T\/!4$W<H5OG#9G$ZNHM]7!M%S-L;C5PJ0_FJUL':H+P0>X\\H
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M2M6;2U]_UGRB1LYICM:FS\(]E<>*DN=C 00\WXO^8;_B$X*OU?O:!:C,_4M
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M/]M/.LQ6%Z0KTHM<U'MMJ>;2'I[<C8\IX)=^?"H-#@[4:OT9TF25&_>TI'U
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MULJ<\YUO>=[G76L!\3MQ$6"^HZ&M 9"1D0%II!= 1 &"ZC G>P#0U04N P!
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M)?R239ZX2.>6ZL3^F:PRC$91(&:+P!,L>/J*((E+X /=Q.FCL_>,DGGJ"ZO
ME%4)(9#MVC/3=O5&3SEY[_I'I%"BN]3$+CY5=2%P+Z/T3]D6HEIQAE-$ --G
MA7-)C! E. =T+.#%MHD [H=UXG?J1<@I"R0<CM,DF0MO_^P$"*:F)F@AVB%X
MH7TB0)"YP0-!3X)HX>L%P210:D\8) ()AD2 P0M=2(AQ^&LJ&W@':201>"^*
M)D4KS2F$",0-$P%Z,C2(\.*_G^T>:'KAMZ2#?TG:0P0B@=_$];8^"D1@.883
M :Y< B?YO\OZ5,6;*0SRJ6_Z^\P@AKP](,U?@5^T[D2%<*W&<8V$GQ%O-[5P
MI!RUJGB#YCL355/[&N'LP(G  @[400!E+G5EFN#\ PO""^-]OT^CS*&7\]ZQ
M7?K5]99,F%8$4+QR.X%G?3!VX=/A]@P:TL8*>VZ)DT(W*-/\E-QA=PNFL_-3
M&36_^U*-6Y.7\DVV-LL-\M9\;TMJ=.VVW_)$7<("B@21NO*;WPY\>W?\/&A,
MG*HZG@P*PVTOJ8@%HS&*TG%)S[Z'W;BNRH,U.TWS=6F[BBO)G^7\&3'>,+"<
M>:OF@]R/R0FV#O(?9<<_R3[YRUS4ZKY:"G_,-$5^%V/77>&&X;D9Z7(JOZO7
MDDA@%:>&#GM*L7W]-I5D%^_QDYW>/9=2@4J,(<@53@:QK2\W8T-#MO>$MXKX
MA+L;KB1\DP)Z:S[?/?I.!-+@0=.?FIC0,UAE7/SB#H?E2##/B>JL4^B%.J@J
M6'/(]W7&TH]75VMIAR-9'SW_P=)DZ_4EAQ'>!J=JM:^(@G/M0_C7%]CWH:IP
MM;=W7F/*,MM\$5/R&?HIEV7XAD^S^[XO/CI*^CDH# JV(MG8 /3K?B@_$4!I
M.A"!'G'>T,]69(/X84@XXA\63<0]8GI*!/9O$T@9!@4J)/E"!D#RB,@ZW'TB
MH"Z#VB6P^</QWHF_/1FR?Q_\K\EX_I-[_$\G2_]'H.S^Y7Y=_S/WN[XPS=JU
M0 9W&J2 X@*ZX.=4F, I'L53FUM\K3%N%Z3D2OME'R>^]HYX166Y+-CB1JIS
MWYVPJJ-K]*DJ$GPAVV=E,075('36C/NO[NSIT)V9O=7 *]  "R(@%^)$"AWR
M?P\=3?Q5IL_P8T$X#8DH))+8 FX ")Y<2OQ>@=7'@&/Y26%'Y[Z@CYZ=K)IW
M-N.K2-PQUITP@K8%K@S2G2>[]_B7BJ7YA[C[7Z>]+)^=7,>I+7IL-R_KZCQ
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M>"KT1>7WS20"G DVWV\PKN(64N+8 (]:&I*4#;*X)GE1];((77-I0:U=VN2
MKU&*C;WNA_R:I\C=4$7,1")ZM+VV8>V%G+(D2'/T_M?ZIL97ZO0"+ZE,CI,!
M/FT!^F1*!YS'LD(XWB8@#[H!%AKVX\F"ZZ<8C3ZN;=06;JZ.3Q+.EJ.6Y&ZJ
M+)&_RO59Y:T!=1BNAW"VV&W9BFLK]$(#+F*I8B?>CK^M/**L %.HS3:DXR;U
M$Z-2P#4M4I]R[;TF3>_W@)!+.>MH7) &\B,RL1]9&2&)NN6#9+E5-#A$BR*E
M41=XI)*Y4G@ZOPJZ]%+>IGB>I<RF]#,/_YE*5I^.X.0@)LE?&MT][S0%DKRO
M\^<V TI_((Q'W *#9M="Y'%ZU,#&:$(.<_[@]\4FDRP^VUM#7\MX8^NI'J93
MV-KRLHQ-Z,?C?7+Q\NB"=^5;T_$%*;D;GF]^[E[)8^ER?UXB#8E:NP%2QJ43
MSJ;FX#(_$UB'[#$7\VH(+- B-Q$+I:%>7H7R3PL2@;<^*O>]&-9F-JJA/:]"
M>Z@?U4KGUL*/B^W*B&CN^CJX-&#H9SIBT>@VY_:HEN8U*,"5=G;E1[P24WPH
M*Z+=[&(C$3A+E<*8LJ3S0E*VY$TYQ:4B71G7&+':Q:I&3S;ZE.D/^,NG[U18
M,21Z8H9$)T;[EH5N=:1(MA0SY#7F?4RJ=3/E^)""K,RNDR6;,E1G(]LCY1*I
M[^^MXL$*&+\.EY<;T\:Q;OO8=/],-[B$S(RZC_O6CUD-S#;L2J@1)VQ%]_/+
M3I[C].U'#3W1361>?LN23]Q J%GT8*%3F8=[9Z;GA@?AY8.O93\:-:6-3H\?
M0\FO'X X\2;HP8XOR+-R.W"MX>614GAUA>6OC0M0';<NBF\F3XM,V"D.!)Z-
M5.(#3N[ F%!1\?MP!I)*GER)+G?9:M2K;JIC1GX_2ORB3QWN$[=OI$J60]]*
M%4S>@':(]&B2.=\H.\_>6C5FN!3D.+ T.V\QX+EWEN82TLA>_5:XY]E!@:-&
M>)M2F16*JA %P>FXVUA8W;=P#WHAJR,.6VZ^R>8D8: 1RRN@QGRK,F)V^YN>
MR?.?EC2X6A0B&DP/%ASR&U!X.#3Y=2[$0]'Q?O_)22;.?UE4\?-J/0[NO!"E
M #IKBYG&=:A[4/=<K5&JS8KUN?#H&=ORJLB;&P#OBHTLV6=8!99M-+'C$+T;
MY4<7R\,33WT;G2+22R^YOP/>R+]VX6&_N9+R%3T.97W."KA>ZEH#:,<%/=F9
MK9S9<3Y4EN1']"Q=XB1H=*)3RBOCUIB!\LKH<#^?R]*\'[-_P^=/J V4VHDF
M H(04KF^'8 ^)+S-J3"K$#[]^"V8"06&K)(.D1/:#0RH/\S.EE6[?NOG=:23
MD?YL<%TXN[W>BB[8%UT;I[YLLM7@FS2U:37%[W*WF+UK,BV99LG:ZZ*1>O?7
MO:0Q;H^>BLAKP?8X]24FNA[8M,^649E[+0]=J8- ?']2/:/\QR]]R3(#P?U+
M$-S%@N:E@5M;AG7C*N(VX.*@()'N],*96>A&FI=Y_H<W%QY>R+"3[RD?.CDN
MN/ZC\T')^>:W[D&!EDQ2%7KZ7!:C(;(>M6L?-EP"$8:PUB4B$(5G8G'9N<.W
M%>)6T,M&/9C&]9-7^/)Z_:6ZI'Y >O .$M4:_002<V_8#4EGU]#\?(=E:D"P
MQY<52+86]?PLI.*59$F>%]K>T/W&3U;H 7IA2F \Q3#LR'>",#%F?'+;\M/<
M .)U ;U37-C5'LZN1QTDI.Q[T\1^,7M>H+)J_&(]TJ9DVI2],9*F^HT$O[#K
M3[(WA\N*G]O6,BQ'D#]S<1D]Y&G>4TM\NZWB3YS*6L]7A$:-9X"B)8)U'+!9
M\L>#!LC9WC7HW2K->CU.]WL:-Q<3QG,*!9NLL"JG;W9;'1B8H(D&]1_K&B8*
MGTU)F-G02EPMO=D*"]VS$:8$&'(EXWNFGDV#=WSOO\KGZ37-UKB6==DOGY9U
M-69J>O*(\?WKGUXCQ1O'!P5E/E[L97/(KVGWCA0NL;V;GL-DE9/UU= H*JK$
M5%&>'Q\.)4'>R_<Q9[L /I=47!0:V@%BDQVX,PD==MU=GI!8^=C@;ZZ%_A+/
M(_;XRY%)7(*&2T%]8T+?7'[&[4BQ;M.YF@^)WD_NF5EVP=VKU 1UZ7Z5QW&9
M/ E3E"5#+7QBPK/Z+.YN7T>_"69![[9+.V7S08_\I-GGQFI'HE=HN)IZ33-Q
M'.2*G!7^.;S#__#:09*G7UO&IIYFX1\N!KEIRP8E,IN52ENJ> A^[A?4.DNS
MCG_5_3 UTIM&P#CW@7'MQXV:9'-S7;XFYN) X:2P]V(KR?H T_T;H O!I'0:
M9KVYP/FCNF%"Y;&=32!_"B3*O?/JO#/$;60M>4DGUCCCYX]5<2%M=RV)6Z>O
M@:N>7'GPMFMR6W :7&S[8;9,F"YU)P>V=E>NJ>&5 LMK]^V?=X0%=[<Q,CSV
M5O+"IE1HGY<!(79YN$'MR>V,U9X'HQYE8^?L:NNU#0!/O0=);8O']W?PIOGS
M+NEFYDIIB"OYUK&2 ^_-A?3=XP]-1Y5?\7<^RP".Y$G1D1C==*;EH@<E_D;"
MQ%Z7T>3TPV^YQ6T^X'SVO$.-GY<&OB"^9OSDXENV?[F=S?;,G$DB;5]_2@>K
M@Q'=1BV7/5G=[9R8QJ:46BQ8NCMY)/N(=/4@4MPG&>SC.&O,Q S>KL6]#*FX
MA\E.R16)M73.</NP>:_TO+W+JSB++QV7DY)#_57#5C*@3)P;2N6U7@73FQEN
MW;G.9[,GQ%\%HH"G 0+*Z13/ONS>X%;+_QN3XP\X,0RF(E4=2;B'I**^%5OV
M+::LQ"DC96[FO.FXFU1.@SA/B;C0QRA'O^OWIM8X*]X2E(A FPBTASNK!W\A
M^PH278X(#&1\)QO@?\Y9(=X_[I<JJC$PO "U$F!O[1WP*]1 ?#L$:H(<*A5N
M:&FHK4*&NR<[K;#T<!Y(:)%C\D;],BVLYRY6-]0V1-XV94&]U"J-/S1A27K^
M?5^6#)-01HK9C'$Y"X>;=6#YD6W4T,'YK*[(%+G2Z1P9X5;WAE1W.NTB?*8*
MJMK5GW.-7;^="*"U5-4ZLKD^CBYCHB)W)B;$2FM,<:%:DMM8":$3HPE(-4+<
MR$.4:B7-7%[>:R^DIS%QX@WE6(!T:5)#+P]#7U^ .).!(]G686#^?[A9MP1W
MA%/ $$M2[7PNFFCWV@*80^=D,>?'\8I](K!#XWMT7MU#5JW>1_#I'?E0X^GO
MRI[!()0QGE5O%S79Y0;J&L+?FJ@.BK5B,'?D,.)6;0+?O6B$],16F>=5O7\C
MD&QL:GEKSUQK)4P+\L#*2JW0K%^UL[*-7LPV69O'62/']H^0T*;*I^R[-3Q
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M/R$$P<2=)Y!^"/X,B5/<1\!(!PV)@$SM0TKQ'U(SZ3U6S"H\F-W/NZA %8>
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M@$@7@.Z?\@ @"OQ--,D1 ,,_?U/^>\/LKH&V\2T= +@#Z !:P"W@ 6!,O>X
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MIS;C0RK@PE35%P7J0OFT7,I^J;97J_OC&\U#:6MWY,Y5]/4 ;XKF:@ZUS"C
M<B'J@A3$%1&/JLDMQZ+Z[\W(E&-R[AN/$HV\'C4:>/CQ-7AG%$8\*U>M"-^,
MGTX: D+2,:#9N>Y</E+E;W"X$J?FI92>Q<LC19.52+:+B-J5U^KS%:AWP@>@
MY&D6;GX5_B8*$+6$-45$HE@I@%N;T/(0*2]:%,?Y =^P;A(VRSGJ7B43\,[C
M9U+QV9I/1M/G&\^<#5I9&V+H:K]*8*""B<(^1%T@7P%'6S3 @7$%";_HW[P>
MK.X[YST'XGJ]WCXQK3J98_@I] E)@]--Q?G@(T@99&'8O5H"Q*]L@WP5IX\[
M+(U/C)&V;QKS\/WIC(YWO_ABE.[ED\2U1S8UQ/QSH%'D[!:9F1:]-,/2;\>.
M7:  X9I"A"D[7)'%=9<&S0NCZ'%1>YHXY6NMN&I(Z\59WM#GNI+IV'XBAU.7
MIBK!X4-@>#<*1)8+C+7 DDLRS2O11DK=AI HWW0_J1HC=]%9P6-]*;[EY7-R
MUP\@.P8XD"7I$\)Y>'JOQXX9!R5>#EJ/K9.^_7/*QDB17]_EB+N!#;-H^ABQ
M*%DV'[@U_KA-F\S$<76$:(B;T\*]GBPH@SF-^8VJFY4MSA_GS59'#<X-,7N8
M\ 4K$O/YZ+6R 8"A&/X-BC4#@\B3 BKU(T0U+'+E=65.;T^#CUM09.0E6[!Q
MYK6#?HT>"S;&:0'FI#?&ERQ>G$#)\[F,I)A6:8%BS-I4/=.NX(OEL;IXR$Z
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MY,)_POE7HW-DAGMSV7%I86$AVMUPB=$LH_&=%65>8MNWHE,=_!_UOWQ9=>I
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M9K^J8W6M+GXDS23N::@Z=$6,R 'N7F)JUW2#LF[#N6$NN*.H5@TOCH4]HJ"
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M7BOM,H+#J.I7.P,V(:7JKN77,BOG!OQ1,N>7QZ."#&HU6@/KHBVWQ6D9NI=
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M8E3+UEUP(P>Y((XVC<E70A6</U8V3Q%_CU* O?$\HAFO'_)XHY@"+)5#"!^
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M<C\O0\[!SF/;\W :,"GR=>QD.D./6-,H3*=T[DMT"&C.X@Y;9[#73UT8LF:
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M.@]7?V_=17Z%3'>3619P-ABNG?7EI9>0.H;MM0^P"Y-D(6M#I4C'Y%VKHJ;
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M 35:.O?Z\%2O[=N?"5ZGW]P\]_C)]\FFKW_90?7/>A!RQW0(70VDI.FO(^D
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M%EM"3FQ^?$E#1__DQ=V/.LD6+^MCQTM,'B[T'_.0]5T)0KMN<D+%&*U(@4V
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M%$HJ5SXUE.8^Y_@SI=YNM$#9TUBB.F6J1&#'OH\.. =^<F)X%[&!"*L?7TZ
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M\FG (4]D#V.V]D[2 G?=*#RS<"(7O,W.F0X '=;06%S!I$C Q*=R.%:VB@Y
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M.SW?9#,ZGG\7(,W:'\,FFD;V+A/& ]JQ<%Q8V^1L8!)[S U0SU//^]=T+XW
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MZJ,#G! RU$+'6H.U436)7C(Z'2#R7S2#_U.%'R2=@T^OJ^NH _QX.Q'?AMJ
M7*R3'%-TP%-\/#OI\/.1N\B]17+)(>>:M9)X</-UVI>#!)TZT&7"!OKBV1+W
MTZA&VTT$/L]A'U5V56G1D;WW)7&B65-V8?:,/]J\;3[$;24OZZ DNV$W<*BD
MS[=/,"QGU]+0^ <=<$F]OUG?B^QEA6 FZ9)]?"%=\9J.I9*^]@;/)3BKUSPP
MFPLN=,!K&R+*_7-#T,_A2T&/OX?>2;1]TML^*;^"YD';R9RD0,PN-XXF=1N^
M=0]T#%\:*F*OQX0/-?F&[+?*1&+*Y]:3K=G'Q"8KY552QCG[#P+-S_F3N^ "
MVXQ^WYS->]"5/"$A<^"G:ZY#>;B&K]2$[UEKI@9,>4.*QN%;/[,:+6CK^];Q
M8X>+P10SRA4#- FQ!%&%2E/1E6K/<)) [BE=[(:.BEB:1/P8!W4QYA?7#&4N
M0 5^W>U3\]'3Z9,L"NCS>V6;Q,L6K1:.RNWUI)RP9X-RJTNO/6OZ?1<B!QUT
M>;NX-;5EXUB+L:^'Q3C0'M3]?0 5-UB0..$M=64EU<XO0SC);ZIOM^B Z:Q?
MP$E7!RC^'4#>7  ,XZ:*WBL8>\@$1>_E_RJ69W#[S/];\9$W7JV'(Y\VS,W_
M^7VQ^-'FQ]22M_#V3KCM!]Y-N",I_7H 8ETP@=(9J/<KXH5LI=E .\U)%NT%
M_[B)LP,CPGX.[62RY_]E5<.MWB&3\4<TV@49#F;=T9\Q:C5!\\M<,VKUEPF]
M/%ZY)J7!D]*U:!"0);*OFV.5),=WYJVBUW(M. 8-1-NKV7>*,$V N.9];?1(
MB%Q2GG;UY\#3[>LWK<QGK;J/]\L>,S:-[OC^MF6A,"[:E.&OJR8W7B^ &5#M
MG.8-W46QS?EV=\$NUCA6N@A,MTG8U44KC)*GW(6>7/_9/GFBL0C[LX[HLXC8
MN*ZJHA@* U* (Q0UYSS?^.6Y:Q_'O2W6'%TOL0#?9VJRE+U._!S?T,5V)Y.]
MZL??5F<D5S S[#0]\3U].J"\*) .R ='%OVX^F=1BH##T_^9^*)4V>0'I[VY
MCFR)4WAD]N2)O!M19.F9'_,L!%IRD6_;D&E-QK3%AZ<U\2PO@ ,LU]X\U3.]
MRGYKM1,62/EU$B$+!4:<[-"Y!75TMUL(E.[6N]Y:9(Z_;M7X[/HQ]^>1NG2
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M5MWPQI(8U>P,<,JL'QP6C285=.](4F&$44[:?KLT,OV:%:17N[L;Q$L'!$>
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M%7QT)SQ"EKBSU(;EB2B=P."%?-K\38N-O46G;1N3I D\&]=CSW.-KKBG'/T
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MZ4+Q,?I?K?'_3S:1PXE_ 5!+ P04    "  B@%Q8Z0]#/[P"  "/#0  #0
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MQ?AV399,;"GNGPK-.1)&ES??KE?>M(:Y\6QXZ"@<<P/2FT]Y$?L%4$L#!!0
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M36%4QIPE,$@260J#'Q!.F<J[M;C_8IFYR\(OU!X(QX*18*84F$BD*J0B]KA
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MX@S(EWPHE?03(LNKU%+4"9 ,:"L#Q@/1N?UOH!MWU8#RPN9 NPOD/HH BV!
MV G?"@W.K@!ZU(B<H@F)8)=? AM11^;(^%MH;PJTH_6!=G?$51$R'/F]2!)Z
M03>"Q[H5.\I[9OZ$C%T^KMYD!B2C(;*M*[>R0U/XQRUX"J?@]]*"]NG)CT^=
MV'!Z A""DRAG O:TJ?,M&#<$C/'Z@/%=Z>?+>*%3X6J#&&I6@O(9V978L8FB
MPA(JYJCHBEXSXSS*Z?4H^G)P$?:M )-%U[N/-$D ;^2]!>G*\ B@"P?:=-8=
M7N24=KTNK4JYN^?ME#%#.!!QH!)A/JHT/V%*?A6J.MU>D*\M#.;5,R9G"_Y-
M.@0[7!_P_[Y#L/!^-)[&C=HLIU&*G<?N++T1^I[!X9?VR?>F\2)<!7+WM#D4
MH,LLD]X+\1T",30@YE0?2]@7.MD%PI&O'?$!?-*.?1J6Q+="POP0@@H=;A"Y
MU]NSKDW)T&MTUM51V .B5@*#=/!*1[CAHH&L*._]F=-8\*_$8<L]86"Q83<;
MWMQ.7^(\"XK5\5!Y[+TB#?(8#9VXSX*/PK;: Z,)L >_K95$VM%,%1G&BSD*
M@ZG8Q\K77=L\N4D07*/#J ZX<&*1:FH A C9$9 *5Q J[-5**BGUR*B1(#ZI
M^6UUD\)6"55DN3(3@=IQ:LHLRA\@&TC\0\CVTL2N&4967R'\'9=QY\$V@]8C
MKO;V\->G@.<PB!T7IWMNC_6[GWKLK-,_ZW7[QWO%Z<*$_U':'ER#_$DZSE,N
ML9YZRJ#.IG3IW90N_2S-UW0%FF)@2 #GJ10)Z]Z)J* S&795<L^?I'OWNCP+
M!7R65+Y^+GS^MZO:RY'G_K+VP>'_PWW<=XAU+78AAK:@.U[[1S6VW]A_^R=>
MQ(WEB$6*.W>R\[%S,ZA?=]YWZV?];N<WNCX_5WO]_F+07RA+D[HUX^5""D+L
M^OWEYT\S;9"@WP6L^( 5>_0[ 4 ]_%SAOU!+ P04    "  B@%Q8'S)/Y* '
M   L,   #0   &5X7S4W,S,T-2YH=&WM6]%RV[82?4Z^ N,[39T9R9;M^%Z/
M)'M&<>1$;6I[9&6F?81(4$0# @P 2E&_OF=!RI(E.7%ZVV:DT8,CDEA@%^">
MW;,@TDY]IB[:J>#QQ?-G;2^]$A?O!K^\9]U8>F/;A^4CM&7"<Q:EW#KAS_<*
MG]3/]B[*IYIGXGPO,3;COAX++R(OC=YCD=%>:$A[H42>&BW.M=F[>-X^+!6V
MAR:>,N>G*G37OI[P3*IID[WX5!C?&LA,.'8M)JQO,J[+AS46'M>8$U8F+1;Z
M.?F':+*C1NY;+.=Q+/6HR1I2L\;!D=0M%A76&=MDO/"F11;DZ]0NZ6O-APXC
MA]LQMY)KW]0T6]7RXK.O<R5'NFGE*/6MC-N1U$W(L]G?&77>N^C^^J[WNC=@
M)T<'Q^W#_.+Y(U;\N&3&CT^Q8ZX6FE[HH<M;7]+!EJ>ZNHP/M+!*#5N8+XOP
M;H5ML4HW*Y7?]GO7E[W;SGMVU;ONX!)7-U=7O<MNG^%OT,-E9]"[N6:W'_IW
M'SK7 S:X^4ZVWG4O@R4GC6/8R ;ONNRNTW_=N>[>U6]^?=_]C74N!]1RW&AL
MQSO[O7!>)M/EA>C56-?*B/UTP.ZBU A=PXI9DF0^Y;[Y+\[=\Z$2;&AL+.SY
M7@-11"A58?K^WN4\FMU7)DUD[%-:B,8/U92EC@6M0R/_3)A_]OP9(IR=R8]I
M?A%7LY7Q)@]2)!0O#WKVP$X??UDN-*Y_ARN+M13.EE_I5V+.['4^6,ZC@["4
M9,3CILXBX?<UM<=2/A;,BK$4$Q'#V:1C':T+KEA?Y,9Z9C2[PF#04?^9F81=
M<N?XF,-/I= 1F=/3T4%K><KXM?3.\4L.M?/>3?'>X\WQWM?<P6?AH-F4?=1F
MHD0\$K72B6WIO;&!$=KXP(4X" G74U9H;PL!L[D7&5XRN35'1$:&DG#\A$=X
M9)G)I,>++>56!+2 \SMNIR22\8\">A?&='@6PQBH5$1,2 <)1-)&108QP@XL
M@9^R22JCE+F"_IGWGP@KJD%H IET"JP-?LLFTJ>8H,M!]$@[C9O#-!-CFO!,
M+,IPNK@,.W1N"SI/M@"=@B52P_\)2G-_KP&:$$>S76B7NBQK4,_@.E)%C#&!
MJ07GK@&/TJHIRP$)0C.A7*DY7"NDN"75B BHL3!PC20*!0%@U !(09T+]D3<
MI2Q19N)F +9B))VW6 C&Z6%I-ZRL+>#0S8Q9L78'Q6V!XJO-@>+@@=^^^,_9
M\='_6JX"6U5H4&(Q22)Q&SRZQ[@5 3O @B1G@8\SX<AQI$M)G,0R)%5*K'0?
M2Q<IXPKTHW1KC2I!E%L3B1B/'=L'9F(!$); Z'Z.4JY'@G60R?J%@L31":\?
MG>Z+EZ'KT6E<WI6WDJI(78*7QF>4[A8P76*,;'FRHN2!H@2*:)[+2(<$,>7F
M#KV/HO?DOYN$7KXYZ'TC'-K@QX$A?AUD-2*O$2_<T[L0BQP* *;25/)24\ 1
M"F2TL70A3T)*Z# .[4K,,^QBEK9"\8# BIC.452K,C@U2F1;V.*,DC'WP="A
MD['$RM $9$F? V_0-%+AB-*&@.4"_PU9U3@!@SRR.'7*.3EKH3B1 4PK&#&G
MQNA1$NW%^@!70T&"R-?H+^)=?MX6A \W%>%/3G(K0']Z>GPRWA$CQC(F&'-G
M='!*[A "J'XE;',;SW &Y$L^E$KZ*9'E=6HIZ@1(!K25 >.!Z$+]&^C&YVI"
M>6%SH-T%<A]%@$4P(%3"(Z'!V15 CQ:14S0A$53Y); 1=62.C+^#]K9 .]H<
M:'?'7!4APY'?BR2ACW-C>*Q;4U'>,_,G9.SR=GV1&9",CLBVKBQEAZ;PCUOP
M%$[![Z4%U>G)UW>=V'"V Q""DRA7 O:T:/ =&+<$C/'F@/%-Z>>K>*%=X:I
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M:GD\J,..GK/]RV&[W;0<D6:$+TRK9>U6(::2SA:8?HG[8Q@G%1.#3T^:T=Q
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MO=&6>>J4^@H7.HL!.@P6!C6I9R=49$BD-R3PNH2GX$WX\4%99\H9"Y>X@IG
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M4?,%M3]E++Z\C ,6KX<J)W\;2.[.G7='A-']C'U"8@?KCL(W"Y0_H@QA_A1
M'!]0/M[?<[,OV]JZ T32MUA'"4+D::7['7!<=Z5AZGUN)_8B&7];88TQ2<\4
M]HJWN[-[=P'KHZY_Q[/]W?'Y:0S0%BICCP0ZZR\OU!(<"!4,$CZ4 -[35XOI
M+&PE$S3]B&?#KJ9MYX?/00Z2KQ..<#"1F&H^UX!3*)]!'::[X^;#B'^Q]_6&
MASO.X?GQQ4^ZZ,"/XW/TS/PNV@ET$6\E'JE@6:"#JE&OGG:M$);!.4;W0U1"
M1;C1)V!< W:1&Y=?[VQJ[B0'VQ-"QL6G5J+4#06W.S(W(2S^SL/YOE4B.M90
M2!@$_J'O^$"4%4DY1ZSYICN_K4O^@*'F#W3$O<QY3P<F,6GAVQI]7+8' [;[
MTPM-871=8%[!J[&/S_VON'G#Z^1=]Y+@4^?>]GQ7H56W(QW>P.^)C'Q&H0"G
M1KWAX_%Q[U1<ZZG&%LN)TZC[O#_@]P?5!YSZGC]4NT4D3+OBQCA9;6/9R\*Q
MHSMGJ;&I,>VRX'<X\S=>5FI;K*(1NN]3/8FS"%BHW)G/0KFS2"- ]L%'O+#/
MN5V$;?%?E/OPU-'YQ4$K=+_!H6VQVK&90&!B+.7-)'^8ROI*0"C9^2.,H_L:
M $"['K_>.[Y^A.5X4^8;;O_PG]"1;8+T5[T4'X-81%1C&C]X+@85W'[%+K<E
M!GG9M9MYDT8K)'3AU]T!:5^X# [.6/J@*6SVMY[\UCIR,+KX3;71I?Q_&HM4
MW[!S_N71_UY]^CS]</7F>OKKQ^NKO^.7:Z.[']Z\_OQQZ]HJFUJS'EY,L.3X
MX<W[?[SK9H,G\ .[(W^ BL?8K0<J3Y\-_A=02P,$%     @ (H!<6!>OU5^A
M'@  =K    T   !E>%\V,S V,#$N:'1M[3UK<]M&DI^37S'G[&;E*HBF)-N)
M+<=5LJPXOCBV2Y*3NT]70V!(SAH$&#Q$<W_]]6L& Q"D9">1985;NVN1!&9Z
M9OK=/=U/IM4L??ID:G3R].NOGE2V2LU3\^'_'AX,'P[W!O#KDWO\)?SZ7[N[
MZH7)3*$KDZC14IU/ZRPQQ?-\9M3;O*ATJG;5_KW]A_?VA_OWU8/'>_#?1^KM
M+VIW]^F3F:FTBJ>Z*$WUPYVZ&N]^?T>^S?3,_'!GG!<S7>TFIC)Q9?/LCHKS
MK#(9/%V9U,RG>69^R/([3[]^<H\A?C+*DZ4JJV5*KV?5;FG_8QZKO>&\.E3T
MQ5C/;+I\K+[]O<ZKPW,[,Z5Z;1;J-)_IC+\\5'.=)#:;/%9#FZGA8,]FARJN
MBS(O'BM=5_DASCEO323C=@8\;( @&.CCA2ZLSJK'&:XO/:S,AVI7IW:2/2[L
M9%H=SG0QL=EC>%ZY_WVW#R_3@Q9V&-X]> A?P':-GIY\F-J1K=3]P?Z3>Z.G
M3^[-GWZ]!KA_=:#[UU7 :Z"!^;[-1N7\<-,<JKL#JO\<W"Q*IE'!-J@8EFB*
M0R5SJZ%;[/.3L^/3EV_/7[YYK=[\J,Y_.E&G)R]>GIV?'KT^Q^5_^\WW^WO?
M'<*C9^KLY/C=Z<OSER=GEVW,7PLT0WAR>O)<O7UW>O8.0%7G;Q \6L?>OEM*
M [ Z^9_CGXY>OSA11\?G^//>HX/[-^%X/P&_@QEZ,/A\:F!OTS1? ,$I6RJM
M1H4U8Y68,B[L' E?Y6.U8^^J"IZ-\]D,OBFK/'X?J7\,!\/A'M!KH2YT6ALU
M-X4J@:<8M:,0%_:'A\?\QAF^05_M'=Z-<,AC79;Z0JNSV)HL-F6D7F;Q0.W@
M-,V[<YTMW6M*9PE (J L=%' .N$]H^.I6DSSU'^IS =3Q+;4HQ37)T"5-&T
MC]J1B7Z3L5H XB0"@<P!7RZF%OZ C2K,Q): <<![Y\";:IRURM49,TM$*QD"
MOJD+6UF8_N0#,-QL8M117.'/B%:1TK#K,P/'DK06'S[LX!I\;@3\B_E+&^G"
MH_KBJ<\+DT9VL/1.KVMIWW[S\,'^=X\^)X,IZQD\OG2D ?J%@;%2-3:ZJH5
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MBPBTJ8>@PW0VG'9SY)>IF9R$3<(5,D: ,]KD6V^E?2(G?#@\;)(_UP9K.);
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M'[;,7,YIA>T8P4[@01_IDNU$\N?[?$F7)!3P%N]KNQOQ]4:)8G3;NZ_?&Z;
MYD[FQ@S#3L(-[PR^M2#]$&4U;)*>>%<9KE4Z#!!RE*L+!Q9;BU-2TG=:"4N?
MI[WNJB7PZNCL?+?1G7MU^S]59W<J*_PQRI,ER.YI-4N?_C]02P,$%     @
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MDV)[710)A/6#*4\M-Z4,19;JF>V&'RV([R(6'C<]S9_J&ZO]+HI!/>G'U"L
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M*L\"GB)2]\:]3FG2Y)N]=B/[V$HC:Z0H" SL%K0/MCC>OU/1U\"UVO)G'<%
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M-;YTK]:/T-77V<3#?4GM8AV*V=GXU$.?PH2(;T52.DB!YA:2Y 0)FGZ')AI
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M_;[OW#/&/7^L,1+&N^:::Y;GF3-KD:!$)E>11@5;1I*TO7JUK:$K8&G#>(C
MU#+7M72?XEOB0F )5V$/)YMLM\N"JQ:!J%2I;FAM;/W2Z6#SEF) %-_FG9.U
M+F[Q77705]R?O=V6Y+_>+4P*"4($V6"I#GWQLL7B]:YQE_4OVZIP'^94+.*E
M!AN-H?1*O#,%M,=89*!AL/L0:;Y@?EXWZN1&D-^^59W8QP]%S_=[S>)'C%'W
M)MWGY078IZZ&'4@:(2("CWT8$EZD#EOQ"O,\HY=W.:&9G=[85F"IB5Z=%S*=
M;JT2R&Z,&KI6G1',?TZQX'.7:..X[_4B'X7\R_H=$:E2R-\!9=WA_^P-+(>I
M/H3IL(GNT?PL0&M([";MH>L,I;#%,_EW=X=\$<B<H[O3RQ@@=+ 0_ZIYPVI\
MGY!K\;K+ RXBNMMV:*)?\*!*]\-D1",SM$>'<@&9^*(*^6J9>QY:V)"A8;#M
M1&Y>HJHM__8<@-+XQH;ZRU@MZ]R9L6UX_DJ@E(.(3,IS9SB@OQ]LLA)([@]N
M0$QEN*V04R6G=<'[1>;[V0:>Y!T<H^O7FQ$R1OG3VO?S7B<1.\W'6ARV;GUL
M_(EEW_#_+/;]C_W4K<CH:OAK_OT;?;WJ2C,;C\%=>@S0&_X]T;&/I-J(RN\H
M=OD\L]OF2"LQ?KIO_B'J-V-?XGD(TC,!8FZRHGBS7ID"*@HVI^Q8X:H&S74/
MQFI]:YH"P0F7!\MH8#]>CWA5IH&^I<Y4(FN7!!2#:H\,T_,;?(Y]P%?TU/DA
MY2Q+Z WFOCW;HAJ3C- "T-?OBZ;F!>:_GU:2#S+"7HA-?7JE3/WLG[9[0L[B
M;SM^*M.>XZT"0JKYJXKZN,R:KJ]&M\+Y)F(/8@+42NWT,NQ<V\VT\NO'O+$5
M$VLLXD))LJ$DTWHP*,I4S&E!>W%4U7/_P)GO(])ER=RR:^$^EGBCCUC(9]?8
MJH?DVDGLLSJZ=9Y"B?8O8KFC+ B06CYNI=@.W/KH,70?3*'6O@Q[S<CWU)V>
M^:X,SG%Y_4:S:\/F,WIO:7?SV07+;\<G.UIIDU@&L?#YG_Y4\#]B_"-WV$[]
M8Z.CP"CV]\6\(2MLU8D4Z>8\=39+(FE1H2Y]F771=AF[;D;PXUH%J7*[923'
MU-YDO9.9?=;TLR$8P2^Y]KV!=[G8 ,G^)SU!SC'RR GY D37I-D;ZH_'FDAR
MFJ;_FD&U<$$? RB*03L:D%4K%O[Z1[?=_V252)O$*9S*X%N=@:,A9_*6*\/"
ME_-H.CI)JVEQ 0?-T9P3CVB-L0[9_SOZRJB,D9<(#* V5UPLG_,  PS(T#.<
M8 #<1Y93E:>+,[T=%%J;NRG2F3 9YOJZNC]8Y_B_:CW:.3AU KQU.J^UXY?W
MY6>F\[[=L@,?U@P$5IL2WIG+O^"Z^GD1*XGU]6ZY0[HWW_)":6#TA2/W'$6
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M84HHD)[2#SXF]SY34"+]T2?7S?%0F2M<5SK!H2=VKW_YQ?"[LU)/W #N< S
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MDTXLW6$U])6CV>A=/J_! %"C)NS3ZB-GWT&AJ8DW-X\-,8"?7CH&, %7%V&
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M!X!1*1@@@?S' /H#=KM!HE^Q9=!FCN15,[>AT_6;+)0Y"-%8/84!C++MAS#
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MM/*/>XY("N^^8@[>T/I%1EXW] IJ[9V%#A:&+H)OHMTE^OD]X_([([B>ZQZ
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M^W6ULIKUYD5D]BO3Q!,R'[$X;RM%&-W*[)/Q',8X=J2J'>--(?.:^ON33;>
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M^;3@\*'Z+2-N9[CSG"X!08A<<U9'*Q,&L(KB+150GIW5L;G+(@\]-7C],OQ
MCS[@E[Z@).':6M \4U?@/2>*%^KWRX:L[S>)Q>X=08B[V*]QLIS9\ [(P,V?
M7"+WLE;(0\>&91+]A%5/)!_,:(\ T35]U@II.<3>]Q6RO4KOR'3YOBTMLK"[
M<C_6D8NZ5<?G="^:/LCS,L23MA,O2+V=,!]PD><Z8BVW/E(9T8BRN);+GPFE
MWQ,PI$UW(F74IZXX<-_Q_S.?1.P_^O..F5=HDWG1-IKD-V3?__&HK+1X7D/
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M.>>=M"FYJM;40:;]1.9%W55?C:-$);.)'Y1D$5M?LWYE:6E@3],.G>?X/'-
M^GN>)&C6ZX*O%A0+\Q7']@E>BX13Z/4SDK0;B5W]^I.AN6GX [,NTI(\66&9
M+($X'N(7=;('=\Q3PF2E6UC1XY1S/@,!OHY)3Q1E<]9561<>@7=.XH!-^I6:
MPFPR!U5$3Z[#BN5^J9MQK'Y=:-^?6?J][D:BF<XJ#26* PWN!Y0J3,22+DZ=
M)M1HYM_N^[Q"''6A8_?5Z=L,\CC7U2Y_9K]9<\N4HM^T_X__BN/_MP,S\U\
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MGCA2Q@#*$]VZ**XF=[3IU'\6+70RAQXKRN*W[D\P%U+B88!WCH@B#%"TNRZ
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M=4??(^X.L');GJ \FV:B<REKT&SM)8L5! /TG<1PT)R+WAOJSN>>08G>+UU
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M@[%I6LK%^ _(X J*EHOWU?I6!'DB#)?(MP[QZA6Q?A-2WH0!#&6]=O$Z@A+
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M]04#P" H&2S/N.'! +CI*"<\'\?%6X,>YK_]T ZVBAML<.J>015($ ;8ULQ
MZ<.F?M<Z80 D7<$6EDR2*O8IGK--=<&$% =#N3% 9(3,#6D^=J!NIR[D#@>L
M[A4&*/+$>GAR1@QPN\)HTS?J9V^BI]HKNU""V:""\:^*81B@Q;%G#:JS9I+=
MW44MS[?IAU+T1Y"K5+EG#GQ$"HP&;7T4#E$-E4M&&C_' ).MF[HH0JS'2S(
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M1[(6FF<&^=IBKDK;6)L_B,>I]TT#F2M_V[&ZO]OZ:ICWLC8<Z%ZZJ59TK,0
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M6_QZ) O4<I[Z'KUD[NH4"USQIV&/4M=87NDD></UW*%)0/9D-CF0\\@6C8B
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M35QU>/#M%970<_N'HEE58NL]/)Q$-+ 0NZJ?47[I^8H#)_-'T-5': 0>:"0
MO(4'?L14QX#U(@" )9'P5TK3#'FKXLPJ O 5V@W%GD/@0I)4;'@/>/\U(I>^
M2L&Q6?0UV($ O"( 42>\!\CO1,,\P^1$<(!0_$ZG6KC;39C9^!!&:XA$TS6T
M1T-:\:BBY>,U!NRIQ&#Q<1"O>./5S9N\6FOA@97WM:K"" #11XFI<HD&BOE%
MVW+"N_^GR3B7B"B.S\'""0#X%PB?@:QR&(&<HKV#;^+'P:PS")-Q9"MKB_Y\
M8<HYC!ZTU@[^H^0-4]?2!?.:H*4G-RR'9_MQ_;_/B J5) #]&Z3E(^R5#T9F
MB7$#M S#D7CA05HPFS%B;HCZ0NQU_U 3R8QC:DEGF>65^ 5+IWF3]=EVK;-:
M-P( (G;(QX?0OE!)0Q-H@R1T?0V!QU=AQ\^J_^NE7KTSZ,<:_/?+KXJ9#PB
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M#]Q;2\*3_#:0*N7?Y@;]C;^J8.6;#/AV&G^VH[$BEW]"C.&O4L'^?Z1"U!W
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M42Y9<Z:AYTCK;P( P#R5.R]&^H)H'#,LL6ZYN_T9BM6?AV):8KWF I9C2PE
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MG12V;WS$E">C\O!5X=#T^Z9R2%E_JD'LSX=D3%M +W/IY[_M3_K?KA>.J;&
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M!!-.ZNWB37RPGA0P!NK\03HH(K_Z3C"I[]+5]VN2MU1N5J#-BP_K;I<4C$;
M<'3 M?J">!6MR'BE3\S_JZY\#B'7J-(V89Y;SM7ANFYD60\PO^%O;$BNH0,X
MW;MA+!YG!JLYWNWSY B ?LV0+,_^#*^:?1Z\]F/FW3O?7W<TG<N!&=4O5]@D
MS2"WMD;Q4,\TR3*]3$LR;-Q!J>#3IX)X)<#_>7_2';TT^@IX(W2J"QN'R8\#
M>0"!(8_7_F!G4)*UH^ZUYR2%,EJ2<$7S,Z?>=3>U2ZQ5A:EY.[PK,\\(GP&U
MG46SW[@4[[4U&/&KXX:(S8UH$:O+;/^EWW.Q5 VXS%]00+D,C1VK?TX'U)KV
M& PEYC,C-19;M[S#5=K".M17(CG<DL[*$XJ;Y9+VRXL5+28<SV8.SF/3Y'+/
M?0D,A@6B![8]"N*_UWR+P!R6PWA"QKK1#>[="/)UI',)V>[:)S+$F:<*X)7O
MJ4BY]D@R6RWG^<Q6[ES-T&CU<Y4W!/=."D( $DS,CU]N;DR=ZL9 T]UYN06R
M>!PB*OQ=AV,H5Y> <Q<1IDQQ]UT?; 1+JQ2-08CA.I,__KY8]+R4Q%,0-C-;
MB*]>1AD1IM[M#_%Y9F X$NKP//<:54BS/_8$&A76?D0UR&F%AOKE;.M="A^>
MER+F4Y41?SH6\?HTH5^@Q>#C2$/X?@[\2#$7WKQ#!U1M[8;;^L5K.O4+ZXI*
MJYVD2= N>2'S\DQ0O?I^SB_GZ(#\I>9N,D^7B_8(1*W,86M>;:Q^T&8I>!KQ
M:?C&^Z#0V^KKD+7=\W2 _KS3WE*5#=D6IR$;XGV_*:T'JCM*M?*6/WTZ9JPK
MZK;'D[G4E>Z=OZS^C2Q31A7H'HD2XCTOL^)MO[]]A#'+]-=6\0U'H>@^9ZC[
MQQ!P!TQ0!PN,:'Q 7$TK]Y!]5OFR":FN5J(TBZRGF&*DTW\N_SELR&,/,;18
M0+QM@<-I<R4A!S?'(*"UZW3 S(L0)Z<!.6E(-^-9VXRN1PV0YG5_%WB\IN56
M^L5FO#0&R^MSX#"UBQT VT8W!VX30;M4O0L"\5 AXEI<O6.HX;DE'XU.4AR7
MV><6PL+XP#=?^0L!AHZ797PZ-CY.P($AWKW9V!B=V0B6'DQ0=-FL#\7GSQ$G
M*FF7*V96,-<0V3AXD,,"#\,3KW%;]5@H%66V-K8"^RR@P=*%XA'[N["8%DB2
M##F@UQ1G2G*G*F >$MV/.4!?36?H@$E?.@!N"0(&K- !CE.KI"*">"SD:0'9
M\5[C%!)<LM52W.%7X]+Q*4'BSVO&V;\96GV$\D,VR_A/-J%GI8!B&&!L,$I\
M,G"+)QPFN6'EU1#FW 3#\YBIN]H;DKA_?3WCIRKN<5$Z::+CD 0\2;U"7/OS
M@W+%RT5R''7&4_.FZQ@2Z <]^$:.F7+]4#P."XF\B20]'NF,XI)1GK9>MJG)
M->M ! UB<4FTAA87\VMZA9*!(\&P-?+?"#"AMG/>@/"KX@5-A=B0OICC_D;^
M/";DI6>,I/Z39G]_]053Z>=& 0^H:@O;;\-@C"LK#Z&8CB-!:[<85^9/=G*T
M6,F==X@HQ*O]7'DQ:^Q3^CK/6(^L2:0L86-H*N0H:Z):Z5O\7@+%T5EC<**N
MM?78X!J%LZT^O*<AP=M@_C?FW,^OG7/7^TY5AZ%E:%-T0!W[YX6YIU5("908
MBJ+;EYRR+F[;>,FQP[-XSD!<U37'OP7Y%O!JE>G=MZ]5"LJ_7I C5MS_"4;3
MU<J!I3]_&L<&:9>V=HWSB* HX].;4"-]#!B^%Z%_>;?P4?$/G'_ ^1NSJQH8
MXU%D@S2'>W_3<_]!1'R> '$[;M_<$Z*X%*'224KIM/901U[0U<NVF.&7^6U:
MQ]3[&^@T];-%$:]);,3]>KWXX?,8"*<@4.85%I,54>DIOD'R8$=.]HLMW&JI
MKU!-K@CU*A<15]FUG89Q&CX(74)$TTY.UO-(5VE1;,=\MM5]U'VR,=Z>\G'.
MA1X)FN_*Y$55;ZZ;]5ROF"A94C&U$&\%]CB";8,\/G/->5>WHKN<C4V"X88:
M2Q;!G1B?QE@JN&3=H0J%;9C_[7'FR&#@+/\T<F]G!ZL__^SEP2>R:V\4SI8$
MIBJT!%,5/M !R6LD3LK%X]5M\MYNS8$Q>+\-ZN>%KS%188O/CH\W-X7%@'+K
M72PMY2Q=I1L1/MA#FL%'RU<0W24CZ2ZI](:V1;R!\X2ZOK3!M([@XXS0VWPC
MH?\>P.$3X&BH"'$MICX\R]"6@;\>L=2K8A)J$#V=WAB+]DQU=?G?G$N^'$ZK
M;2PBC^,>EQRF9[:A6X%=%L8V;";*DZ@\/^(4.&M-5I+@WFVAWT<'^$X8AA9Y
MN<CN%L/^-%$9[#$]LS.&!WJZIO]<:8!,KVN;QD,DB<+6Q(/9.H3LAI1[+'4Z
MGZ(%YDG("E+':D)'2-$7(7K\0YG/%Y;R37LDRH]6[OB&FY :NZ0C)NNI![N*
MF\25E=;M5CH U.7ZBESZ#_/E/&A(Z\QC,)^F5W)Z-@^"G\^B)"WH6JR^H _
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M?5F(M)6S\KQ&PZ9X?UE"1=W=]MZ$E4-O.9F3AQCM2.]/7X\1J/,0;<8Q"$%
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MJQH]U'D]DRU\[V^J_J1AH?]:*"T(^VUI8!<=VBJ)W74WG+H \QN:49TUYR)
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M 3?".QF&:](!O1L@'($.J+6!+2-"P'3 61!YSG5?QI)*R?S=?S0(7&48DU6
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M&1& RRC$403BQ2Q\V--@CW!SQA2[> O0E=15C&/@R_M75#A';:\+&1QZW+1
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MZ56^0.SU!Z-RY5_8UQX-^/3<,:?]JAR2RW!Y:UQ/>WX7$)IANR0O'R,LC6%
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M01:U"_"X/[Q1?P]W1K*%L%S[:[GLX(<!^-/&.T+M<SXG^_D?(HYI#MQA<W0
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MGKM;$.U4Z\O,&7FZ*.9-KWS?2&85">.9^CA$;43_\NZKC,F)\J+H3V^X!%X
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M'B?91H1)!>5ZRX0X(OM(R9Q7.[C5]A2]C=UGYJ*U3&@CU73@F_[15FH/)NE
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M.D\FDW$EJ^/(9_L'C)3,XBM%V>T5G&@M7HZ::[NQOP]/+:RN386@PT7KHXV
M*3R^[MJZKNI?Z]-55SPM6HW/SD='V/[3\K,)%MVTV^/B36K[$$%VW5^>_% Z
M1Q=(1G&98@>0.G^9>.YTNOE)A!W7-2DA\[$S(VEV QO==G,+4B>?V@3I1F3;
MBH*-0^'6B=P:-L<G1P;#<:5Z$9_UD7P+CET![@[%QAYHA.HCBL@>ZP2&E4$
ML#*$X9 N40!!3<6[H*O$'O2QR%80YE_L:++HC1/DX=-]S/:M"K'W42[H>V9
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M:I!>U"]KQ/]EVDQ__Y<)+WD:X=8WO[6<H9294P2W199/TW*'=[ET<0G1J7;
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M&A"$;_?+/2(ZUSB5)=V$8D6!)C))]RL/#90#RDL3^0)E[W<(=0!L1R=Q-AO
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MO[_1CNDC2?49I&(F@LX-%VUB=':LGSN=CF5;ES&O[,^>[UI7DJUU,V?[J;W
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ML-B,':;I5XFFOD?WA7>$ 5X=XXXKK(=N)M$XD8MVPOK7W2$)ZVV,^87U)=*
M)S"KJ6)$LT\L_WDN*OUH[79U(@)O-M?&Y<+\?F/4YVK\3:]6JB*^X.2>)SSE
MK"2WT6ZG04.>XB+\:KR]1+?$/'Z-@N(8P70V?\_^.^>/)#&S'"*75'$*4]]\
M .+>?%"@O&:*RWA[ ,^>:#*/,^=))X"0W8#^G(W'C-J6:=TP$53.G]A,,<JS
MH;=(H8PD\$)[6Q.'E,JYD3%Y)C!/K:MLSW8=HSD#UR&?&7C"Q!CV@A7Q!E;=
M1<<8LP#BQ8 V@%C90\<(KQ6;$0Z+JC%3BL5++P<6(F/<:7]WZRQT@LC8N6LE
M'SE$%1^?P?^!D?O,!1$4QF5(8<'E&MCZ'6# =RX>P<[O@,_1 09\:[UJBL_1
MP8\$YBLNP?]D@?N='%*(&!0#<8( T^?KA(@4U-S$$5FP;(%0OX.P^)2DC,7Z
M,ZPRS[6>FT,35^.1G$ZEN$TE_=,&R[==9V@R+JYFV?[)V1-3E,/T]T#C;-<9
MFM^(4L2LR'*&; KCTR0HAML)4>PC>,H8YH9QC:[XU4V,,Y7;P,K*%H*G!BFW
M_>5$VY9!_9@*68IN!VDX7)XOR&.\8[Z/?(VO6-ZB'WL?^^>+]AUZM#47_;[
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M.I!>4D&G:TWP[7)\9?F!^><>["P\^1]02P,$%     @ (H!<6-O$![*)/P
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M2D,UB35M>J?KFBP2@8QFA0)$T37KG;J;)4E3D]"I:]0_9:LP34_*G"NMN?J
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M.5R@,X!2[^H"J1\H^_-]D)>K5<@V,EPUX?K0/(FX0 W"***E2%E=!&N:)GS
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M7'/]5(D?8IKM*7 _PW=F07EGMLZ?GO/O=!/:ZPO'.G_/UL8U$= ?/VF$2U;
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M0MK 7X?QZ;HT/S;#Z>:%_*W9''/!\^7L&$B3WYNP>_6EP;W)I<$=+M;OAB[
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M=F"X4]?J?7%R?H-JTJA#&S'B7H50D[G$C&/>EJ:VL.5B6ST0*M4O UOXX<;
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MR!B]-K0P9(B7FK5]L8/#_/(F1UT8@Y'1\H9 R3GNT+?(A(R 'F GT>=1B#B
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MY94U7& 34C<>>TB.+DV8F9H6](L)%XRH28]4W:&H)!2$#Q\?[I.BUF8B:F*
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M20Z'QBDQ5I+% $?$$?GU7!4!#D?$$3'V')HC!$?&$8D6&HH-=YTZ(MOJUBV
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M6MV&G;RNF*0@<Z6QPN *2";,5*.WY7HS55&_:'0U5WOFJ@],%'T?T(X+EL6
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M!1>?N.,=0HTO:X=I@EWX@UX8]5$45^A<9GE"<;TG89QD\PE;VG-44Z:^UC7
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M7 %%S2YN)(^XLGRT\-'2RYW*W-&"2:G,]6#%'QLT8KVK/XO[@%>6OJ$%#--
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M5NMA?QP?ICU%-O:8]V3^6.]ZMBIB,GI,C!H+=HVCAOO+FQH-=ET$S/275^4
MC."0%:>2K]JAV-SMW-]N.$3YL&T8@F-R8@LX]FM3-_?.]J=#6UC"W:#9/";(
ME:3F5DL9'"/FN$D6@L/^&M;SW+MB^^H>/'FT@"O6F.YQ P2_.%71HAL$FX<$
M]ZC)C15,N^DY_>F$UNYK&,!G:9D#V)^*::DR^P@_B;!X^[AKT@"EW&:!O<X(
MM]KLOYBE39*K;=0<X;?6?1>L*C?+]C:ZG-] AYDY+.!DTY9AY6N!MVQVM[T1
M6HQ6.S'-EB^58N?N>B.?>+]LB5U*3*=VXSPI3NDAS?;<7)J<*6]LY7*"6Q0A
M*H4\I.BT E5 NK*]^>+M%7IRL@\;!A^L4+P)%Z@-$Y"S .AI*6]N0]EEEI>$
MV2GD#!PT\RD7/EU!+O(.X3#Q61 ^"\)G0?@L"($Q0GZX.3<KI%A Q%M7O#W0
MV%N0U-R?%^<1D0=L.OH)>"&"4C1WRA^CM9WH"/O6C',_4*FJ"FKATA3:1;30
MGBN<H4WA7$&C9D:X3M]IWMC6 _G>J&;'J-;IIP09SWJ8/*8JVT91N2QY!/!^
MQA/]>XKX5I[%^_D[NJ50NAK>5J&4DY*>&LQ[LZ3?[K$J.?X%L9+P H;5':S0
M#Z+9(IU4,&778T=L$K $'CRG^[P<:4@7HSQ<E"3C?CON]GOB'CPI!^H.1NF_
MHKN2E-[#!F;I8R$J"YS&X,4(Z&&ZM$_]]G:ROJ=TU)R@#7H.@Z//1%S #-9I
M&'R(+X*6=;%F]1>0Q.9(K<C8H*?W#7C?0!O?0+>RLO<!'(\/0.<0Q"WV-E?P
M4CL,M,4*5ZSF#:>22 )VQ73>$!:9 NE*QF9+:%0:B"O9<$T7%E13<R6>NB%.
M4)-!?YD HX );AMRY4 S$1\Q\,/+QT?H.C3A9I@>EHG-2@+ >H=].2_Z6W$#
M]I[#K676W.8_!LFN.MTVZ/"E5>+P>3-G>0=O,N\B[XQH[QCOU3'.A&E6B <O
METF>LZS$;;1*K;=$JT^??OL.YA?(6]_9/#;E6$RHS(^NDD>6^_JR>N;>$;5_
M%(D<CMH#V?*[2R@]67\)_\#D-*5?1N(Q:S#"4#B4^<Z@W8;"RS/2U^%2[H-J
M.,I0.!5["N6=+/D*N<4EWY3 HG11P2Q":F^ZO(?W#7K?8!O?8!<GL_<('H]'
ML,DACSLZ<5S!4&TV:RQ*N6)<;3G-P >G*Y;8AG@U4$1=F6'>?._-]YH653U-
M\"@-^!W8.X[05*^GKEHSUG^BN@"[IR8HPB>4!WFT0'%)U0*J)"!>LI RL-<D
M()L;;BHG3D.[?;<O-6_"[X-^;\VWD^;6[;<$6<[[F#Z&K"_G6_JJVZWNPR=6
MW/2TJN!(!<[G$HX"RPQ\ $L6O7H";U]\@DEQ@>AQ%:;L*"@I4>L7C;58;S3R
MX! YY85NV6TRU=E-&U5GW=<P+2O.TA1_DQ11ZNDM@T/JC*[U2'^%J 89')_7
MF)UFC$HJ]VS2_>OO6#S%N<CFW_V++%V(#F&$J^>[GS:U3F\0B9 P,;BK80>'
M!9>QV95HE*1TUPZU63.J(0>' ?WQE&YR":^SC*B&L&C!O7@P[VWRWJ8VWJ:.
MI5GO>#H>QY,O1^?MM9IFM<Z5*.<F4FOX8()2CR9=\]=9=@=>.VW$E32_[O!4
MR:VN9/QUAYC(-N!*SE]W2,$U8U<2 ;O#KK$I#@SE3\ZX IO;O(?H%BPSIL'-
ML^1O%'.%[@%E:)8T3N+IXE6#<@%J4NT=?X-S_(&_8%MWG^94\48ZDT:ZSNG\
M=>]KTT/@9/.M!00+6K^^K7!4M/\P)-JW]W8RS:),V4US[$[:31'JZFI/VOJ&
M57R7N.NZ'7P(N-SN%(@7M%^%JQQ-9Y/5*DTBMH8JZPK]Z2I9)H74Z]_#FX Y
M=>.RA1DX2+Q]W=O7O7U]$/9U:W<TP]16H !RE#'1)@XTYU(2FB#:2H[JSYQN
MZ2;O=@M7>*FV.>-21+\13I.8K>MG\8;GI.8%COYDQ>L0R7FIVF(-MR0U&]>H
MV:@-B3 ;D< "<L=&O\SS$L5G):$KJ%HVW"N5_Q82$F;%^1,B49(?!%@U'Z #
MTXW@O<S"C%K0+>UO]MJ0..;;5IC>\"O6-I>72^L'@/H8YN*/,B_X9+[' O+J
M7:#\ TU7FP.3SGNZBZ,[1!Z3"%7?ZK;:R"356 R_W?!]'LOEAD[%)1Z"=F9C
M&OG&=;HM-""M4B)M:Y3JSVP;0)5$)JN$(VQGCUHIPI*61BF^1D7E]KH2E^.I
M;6.4REMF)<E0?!Z2C!X4\@M1Y(W-FKYW.]M-N&:;X(0=:W,N6IQ3L0:OD;P<
MC?X @^'OFFX=;5D4CF&>RWQ:%E0LS%B=:QDG^^TL.0.:TVO' ;!3FUX=.[+]
M'M3'N^4@]$YG=WL*3H7GY"'G=^BJ6(#T]<[&6CHE2MLU^L8?B6>03N?A\%4O
MZ%]@,D-4MH^;<*L8TE9I1SG->YK-5L-MQKQLH"'PRW7YAK.YON]@N.IT+D-&
M'-A4KDAN/Y/5XYCG]L5Q)F/G14-;TEX+BD'RWLB=JR 1Y4C<[G"WJ\*>X@H0
M8C9Q>R7<%2=]:Y 4:KPK.&D$,ZBU5E=6&(SE%]<:2:WESDT6*"X:GB7G0A.@
M&$%,O\XE\4'! 3AU7)DXH!-+Z8)Q!0T?9"<#Y9#EUU*-S*3?WW$T=&24^J]S
MRT>*AY5 !^?.,O64:V$+/:YD]);VMN/(1V\;0'<<F><MP_7ZRRD?$DAMG'-@
MA'YV&"&9PP<,T"<7 )($7,'E3;@H/OQ\CDY=P' (74J)Z=+S"$=06[0?=.:&
M,F *#HQ;*2UJUZ*-;!:>E?LQR,OE,B1KGLF14#5JED145@G"*,(EJ_$R#U8X
M3>B >1"%:<3NRV"5+VGS#!4!Q3</*/A!SCY^PR(J_1)AOKR*"7Y\X14[A5?Z
M_;:@DBPFII>I[!M*;9RD):LO=8<B>O(6E.CSIR@MZ=SFR9+TR"VK-3J=;1T7
M]'#FA\UDR?A]!5XO8X\)E9-U_0"2>&$#;QP @LKKAZ'=S&8FO08[S)-(P("T
MK5FJ-Q$->[8T:9Z#LKW/^W$GIG[@T>>_H62^8+?"/2(2SM%UR>;A=':@W\A6
M8J,QW(DSM"K!'$FXHJ\29$ARP4TE!%= 5H=(&!,@70EP,SQO@>*5*^B:J!TV
MEKB, 88U.>M5<@&(%I*K<VM'"A1 V3ZN"*0>+&[6'"/?!P2%:; BF.H9Q9IJ
M)E7H&2]V%^VBB9E&@ME-#-OJIDP]:>8%Z?"-YET>G1/O_1MV_!L=?DB0,Z/S
MB6/(1L2O7[G&&:ZNO\CFF^N2!.8@47-;:<L']%2R#Y3ZEZV'0+DF_"\Z6;JL
MVYMO1ZA4F-O-O!7S>*R8OM:YMU=H*EN@,[F'R3'\6$ZPK-6?N6*PM[GI"4+6
MM.^?ZJI*!V$65[\_L&!<?IYNHW$#M.% ];R9;FZ,'O.:NV'6O%YO1Z\W]IE!
M6K_A26<JZBSE+T)Q?<: 7$75ZVRV;C/*V(7DDRR>Q,LD2UAU*&;CW= DC>O2
MZFN4J^KD>SXVV5O9L2^.D@3T& ('TA!'4!_#U:NKJ['I%#E#CRC%*UZV S"W
M-'IZPXXW[+0Q[)@[L+S9YWC,/I #!3?:NUU!2&T5 A_*KAC*-">-]B'I2A"'
M)DX-!%579I2/EO/69]U0GP;:JC5KHN3JX7CS(?BUPW1<5.1<JDN3\"%)>?Q2
M0Y-AMR\U;Q?L@WYO_.O5^'>V^2[WX=.$?Y5-835VE:94#*@UWK4?K4][9K?3
M$V2T[&-%&-+PM]^RDHGH%[UZ)DR@[\NZ!!FKGV.1C]V<_$S$"9KUC2T%^QP0
MLP?G-1+EL"MZ#847#08&1/5TZP-E$?^G(2'K&2;?0A*#)Y1Z!,L<,F\OF!D>
MD/1Q&)33OYS2?R?%"U2WQPZ4)=@HUCG=_K8Y/_<%:7K ;F_ KI>T3W$.7GL=
MO&HH\X,5YJJHIHK(MY"*M% 0#GO:BL'=(VUO6[]"84YWE+W[(0#;D;R_O;N1
MO!]D='8 HS*P=W8<C[/#Q[AZ*Z.FE;&QP-W?A"D0R=$0(SM-2'O.6?NU$06K
M$\>1^=NIH1 ,F?8%!.-9M+5*.!@8[<L&!ANG#K/=@8&!WR\P_/2&)AHM&"CM
M.P;&,X-J+(]@6. 7"XQJ_FB:#<!PP:\9> G7_= G$\P9 I<^M:7T\2PWN:?"
M1BQ A+,<ITG,9EKP$*9\I\P7"#U;V-2^?< @1GWU8'J\[[U7W_LDB@B[/.)
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M-G^]](M2JA<V)RFY^.)V]N6ZK)3<>!F1]*5L8LE5E[MMNOL/-7%5C\\VWQG
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M"///0JP%H_HOYGF\*SV,?<S]9UWLAAJ#=+"D:,@4S=2>0NQ+:RP[2P_#13<
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M0Q#^2"6#2%;EHCM"Z$J'70[Z0%(140^&-B.35<*V\RFY<D"=I'-PD<)JB3U
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M.K$ZKM66OF7J!D3(^+*/$*S]O1N*^!&Y[ EP354GR-@T".&.WBW]3-AAK.%
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M(\:H'D7]U!TZKKQ*Y3&$JF[:M[IC)>BG U"Z2>9A9I3,D2%+Y;1U6P4]L-$
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M6&$W ;>MI _O RT \[WGV6:4!<!1:1BI,!:1[?6!V0#(F<6KQ06PL(W=?0/
M_99SE32P7;KJ]3A ?]*K8IW2411#D^>M6'$2Z$R;"!0Y T;36B1--+-)$\V5
M2IIX!?BW$:PW$3#,XW:,CVQGE0H=C(L$B&B*J*22?-I#<E7C\6=A5@C+!*-9
M4<QU-MG>EG'@"<E*/A TK[2> VO(98F1D>A1D>H!8I2;5[.8@LL:>$G'"A6.
MO%Z S&WUVF'Q2VC2AD8#<Z7F++I3 [Q0*,5[UN;A[D_6R47%DC6$5K/6$/67
M8(3[09QI,27:Y%+S):2%:$OP/&%&-FAV)SV$\6^L*^[<)) Y.<TC;0?"<DXR
M^G*5F2EYBG3WBFAAJ]/J(Y69ORJ(=&OZEJ<ZS.>@'.%/.JC_]-%T$>(O&0<A
M^7_'.-8+O,9BR-5V$,=!_R@*/!<8R>!1^\1R/OB^ZS@>EV-1KWH)Z2@E6C[5
M8Z2N1*=CC?&*K]7\VL?YA"I]+%]Q#)N7UF=K_R!E"6]C::^%S%S>BNZ_M16]
MQ!QF',\RUO14JQIO;%6O>8B_6),G:(2Y%L/9,;BZG#FK?*D3A;;ZJJ2D5-BW
M0D%:07_553P5]L%;641M2I6+^/3I2#.D7MM[*S-"$S=OUZXN2%"9;C NW:!9
MIAN4Z0;KFV[PG(RL\>_7/N34?>QPVPZZA@/9^.+#- SB-Y&),:VAP?=!X.NP
MDHB6@]803,T4D-7!NF[ 1 :E4%7CH+8GTYUKC10:(W7*8I9TZ@6.LGF@->M;
MYO$C5<CTBL/:-CVGV0"=<>Y7K-9&+)TX5 5GZL&A#O=G,DQ[CCH#=ZPLSLVW
MD9)#6?.I*@\%Y#<5()[*L("Z*O7R?M(I$/*GIP<O_MZ%H]<$&3(I?C$I['H]
M$K MN-I$B, P0JY0%:,,>P51!E&LK2=!,6;*>9CQM2:P3PKM9KYKS/,QO-&L
M[TZ.;Q0$-?9P\>JUG3F#&DTCJ#&MU<7*!C7F/#ERYHN+<V0J^9<0W2@C J\3
M$2 6>JWW>:'1@.7YQ%8F%/#9VJDOVF^]U&5=:AC@L[6]]Z96LPP!E"& A8<
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MII29*>\\,V6^8!Y%H?/Q!K,M^:3XLVLV*\*DT'GD+X7-,_X(V7-FU!$-9J(
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MG75EV9YX)HY]+&?GGO,;2#9%C$& @X=DSE]_ZJM'/T!2DC.))2=<:^^)18)
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M[Q\\>O+DT:-O'MY7T7CN^J*L/!=5K)32-(AB;':11_T&><=_CZ5!3<?$I7H
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MW:*QKU_]C3X' FQ,]_;BXZJHK0\KXLMGTY(+1.@]I<SBE:_$[_:L</$XW@I
MWN#SBDV7QKV7'/FA!SC1.1''1-#4$;F0$ DA0PSCEB/:",%V6(R>:S9*6B60
M3N'^&\A-S4VA,)=48[%<AD\+U 5-!7(LI;W:&9H./^6NR/&/Z0*EMF0C"0K4
M%_@VB.P4&OWO@G!(T4P8/N8ZD#9H<)8^VP!"1371>%\YTZ5HA6>/W=^0#MSM
MY]R^!-P=2701TX?D<MD\E6!-=L'G;(&U#<=I2>?91>&KB1MR/5D)P-9BIA0M
M./.U&8?9L[4G7> @HQH>X7DQ-Q\#=,!@<)B]9I:!;8-$C%:(4X.D>]HWSU'8
MTAG:SBJE,&""CR4(_+@^:@Y2!/P(Q>8(P2I*CZE=F.:AEV(#8)9?2JETYQ("
M1"7G$@B2L$ATTPJH)XCDUH$S>MB3B *C#;LI0]<AMG:P0_#;<B7,+; [-HJW
M?A]'""FN-Y<UO+1JQGKOG2@JG" T!3]N**M]OY#MU@DP 5N=H]CN5DO%.SK%
M2JP^,:0Y2Z!*O>?<4N?(E%87 ["# YBM9?"88J9<[*G6O%TI /-\ OZYXM)W
M>G]$>+KH'E+:Z'J0([0J!]Q]2%X/M5#EE-E)$">PZAW=+=I/Q$/]7*]H#@Z^
MH?CB9Y>"IJS((1TK[SRUZ,+0KJ)RU'(DCAGH#A98A^:5E>C!V'Z@/^1W["?1
MH0N.%S[%]L=2+-(=NK1%<X>5"3*:36!M,+!4EDA=FAQ!(&-Q1A<H!JG3WUY@
M$3$%DCU>Y2T;8L-T'SU?[P^UK*P79&NT"/_H'E S)!:I3/+ YVNM=<3@-'R+
MWHWL&EXG:M$0K+./<0-O,^_V,A6"C#[T?%ET,1>@=F&3:&-9DYHS(#$N#,1I
M_Y)P+Z:\F$*!@8^XJ:IB(H9+9X1-(3$K1,*>9_32M0E6@O.]2=/!XP</OF$S
M8D1Q+*W:U!B.ARG@4DT8)Z-AE0?-Z3[2"2 <49?^I(TD:@%SA8WM(@VC%>1K
MJ'1[)F03/PFA:N"S;=8%4MNAN0??&;G@$'15%))NA4CMCG=:VO%) ZIITZDK
MROZ]TA[MA0M/F19'F=NA#IQ>QP\>/E'J*^W=5Y,!IFV2Q=MG-:*J0](EVC^%
MK4$.#7S*"W(#+:F/X[0%1_XT2#2%\]6JY(S'^3"93"<(W[E$?L+PK]-Q<[9]
M9669XWZHM8=@*&@#_*#%X!L!X)O^%#VK<5)&Q"T+8>*5%BMJ;O.$Z;5_#')2
MZ8%'BQ-3BK]WM-I[LW5,C6^.3>SE]Y@J5'N+NNW8VQ)6@;E4TJ)-N=)/H%3$
MU4RB^H%$>=JT,Z'Z%@^UX38Q$DA0A9^0:?IR[DMD](NT(LZH\ 6@TI?[P,%H
M]5XV0G^."3U=E&Z>O9"B0-((;[BJH,VS=W1.9L^*=L*T,(#1<GWU\>.(G5?C
M7!N]0+A'REH!0AP^PJ-P#T[).+C3HIJZD.F@17>.SV'F_H09-;ZO"4>2EBAH
MO=T!9P"4YS"UM.C&X%DE6>J>2K#>Y_/35@<>'+LJ3/A2UI4T@*(@L,B*$\W_
M-/6-)'A@-IZ%T\(E"9=.@1C%8?9,\ %<B8Q7/ 64]:*P2"W2)PY$-3,4-H.A
M=E&NN#2J\^;/7->8DR<'_J^Y(A3!\.-C>SA"BIHM@Z0KJ]!#7F:NE)<9R$R8
M"O6Q4H>P851,A?EV#P+[K""PL;:(@%_'>^#7'OCUY0*_?NWF9)]0AH[C48[$
MUQH,]P?BWPH,Y^_#JG33/'O]7 [%J.T@-\/V/J17_>P'*!2AOVRX?[IX;5HP
MVP4NH+&B/\R^Y\(CYN$%F0PJ(V9@M'@[IQF@4;VJIX<P@/[[;9[]M6HFR,_;
M^?8#'P[2X:H H(8,,N]X/8\<+_^+[^D7Y@'\&)]7[^RUD"<]S)ZWASH3@L/:
M<1;UY G7S;R4AY23XN"OM$W60*I%!WNGA&;*DP]_NQ "/F8LQ0'(9R>\U^ZZ
M:-OOMM??UM9UI,]F*')Y-K0PBMXN2"K/( KQXB&; K()]NWCE5.;#" %:4VU
MK?^3V6(;J8Q/LFF4L(76%B-S'[-[9C7 5WA1D7$U$@JIOCN9G+NZ'%U^LJ0/
MK^-*_X($X5=HOOF:[+7"5=G_*995T_0L!5B^]\$8?K/2V&+W2S07UP?].ZI+
MI<PLZ\:/1@IIXI9\-(.%A-8A,,\:M^!8>YN]+NH:\:-4'-XADYT%-A:4A9Z0
M"-9%JL-N*'*1GDI^\2.],+S)/4E_Q,JE8O>:G$%Z1BXS^MR+W[M0NWXRGQ=E
MV\4BP:=&1_N;^V])PH=/C5?DCWS,?K"0*'LFK\NJ<G5=#LOQL@E\X6Q-YL]'
M)C!M'?M'=)1U=*6;!5\SH/Q&Q?LQ>86I/*3%#Q"]@.9B_Y%EF@^\Z"TJ?D"X
MD[ZG1?E/V;E:*_\6UY$5 ,(AZ":$5,</CI[L9<J/XZ^N:<]IMSXC'9^]7S1M
MW3=U.-M2K9;[J$)4537;B$NQ5/VM6< "ROZS6*Z>^K^B(!+YM74G4=5)T973
M&/R2! XZUW/(EVXZ*9LHX,!D?P?#*I"< #7*IB1#4!D0V5R4Q7Z]DXA4I/$M
MC&A!<>WQID'%@!DI9A=EA^3-Y:+A2 7,3P98<M3/ _OF);0,GS$+QF]S2?-R
M64J5!=(=C)<2,_,RBJ!OH\R+LA%Q#.K.0)9N,W;^;<EK>6;)4B&.VX?.4U%G
M_MQ2&\E(9Z@MMG7<U\;G=;;Q-YJ>N:(XZ.]NG;G*2#(EL>UCY#ZUC8TP76@Q
M+(W/NG!H4FK/6[9GM+ESC#:3H:PD!P#M7VL@>ZT\W5U6%VW;7%;KM/TR;SIN
MT!3"^5NVX$WSU>+?HM9BO#OWU$Q[0;[9.*V0'["H 9V_T(8GL7840BWYTQ@I
M%Q-+>,P ,C7=PFX7W8=+6%%9ZEQ[X*EP_D%7(3N[%]B]P-YLG("CK$V^8F]K
M6JR$KZ@4*T:+$0SPMF'G*#0FAEMO)6;1&#%8B?92NI?2FXU3B(N8V<B@(!%S
MB;GV<==Z7X1BL!-S"\>%+INRG'NB+W95DRXNOD$Y?GJ5H\K@@;U\[^7[1N-4
MR=6J+:!)N1PFJ5_QQ%8;K8845;W4SO9IR59 P*)E3<OH^P;PD.92>+R8!)++
MEX4JR1)&V&V^+N=7XS?\(T4)?M88LP*.-1:Y,[X)X)''#WO8JD<Z1V"DHNW)
M->D$@KKS?MI+MA-PSW]\\^3PD=(3EE7%,8?_^.J;PP?)9WR3_SA^=/A-^K%%
MVH$6RX3L^;F;NN6$AO/P* ?MRD/^WV.^@["P*.*6&S@?9F?.%[5_6W[W"I0"
M7Q\B$Z0!0T29U#NC[SFO32J\LT&=&*4IB>;+$IU) 1$\!2C6%TR^"_Q6(4EF
M]T5+)::W5L PX\;ZHJPZ+5*S(V;GA(:]] <"TIZ:B]+4^QC@F"#C:F!K %"6
M6\H8VF)5SI!$\E'K%-O/)8V="SZB504CU(>Z&[=<+0K>$752NV55,5Q_,$?3
MEM!N+[X95S\LI06,D46HND^JUE+P)IOO2:XD1AV:LBJ5@DBRU.>8GEI-*..^
MSH.'.U5+K+Q0SE/9?_%-#DD!K+<['E*BI@5H\T$(P"4@J]5H2MY',Q_BK*$&
MP+,9Y[ZJV?5:V.$^EIU1TV#!7*B.#I_P$*3;#U>2!H9 LPBY-_P^5>3'\3UW
M,;,.V+WM)+]?D M$V^?E2BDQ)&R^.XHW6<?Q0,[QRK(P%I"?T*UKE/_Q"9)+
MT?&RN;!F4<7Y.4Z!WJ$E>U_XCM0%6J&QG42FF--F<;4'!3.+0-(5$.\DK;D/
MLQ==Y[0W7FX]/"$;/,9FVK?()2Z8@$#JGJT--DY;-/5>HB$<"$) >(.PY] ;
MJDM[^KU'B'];? E3J#S)*^;C MY7VL-K#97I N3>:.#(EQY(@\P-"U.9CF-:
M!(^;!CATTM38T&Y%=UOI'I'&E,SX BD1CXN>@WN@&;UT!(V:3J'8W,_S>'2;
M2Q^.Z=;%<>$EJ8A*0G!;^R :G;1BOP\\[8*VU0O%L*Z]P5F_1T-_-C3TPST:
M>H^&_G+1T)^)!I.)(HL.;9O3E($_&E#9W5D=9-47M1, %-,1@UOI9APU">^R
M_!9*UU??D*L$-IBAGGK='Y0PG4K"D@R ,)E3,9,96VWMP Z>'S2'H&=HY7AW
M0!IWV,)ZE_"N;)&"W)9;XCW<I$9A=1R(.*^#RZ&\=K:4L)P*'*M%]L&MF0J"
M=HU&"8I '71ENU4T$:>3'IDOV.PY6 '-F:=U9_I1P689HH_]%4@0NCW<_@S?
ME95^,S+E?!OWE$OUG%GYP-%IL1,?W(-%RR7,G&SD2D]M-:];5A8CCX+O,<QX
MHYPS4.%S_\(XB,E;>]2A(X](];8@.:W^O5Q.T&AW:1K"2\B!7.EFD><KE)_Q
MM"1NW=#)&Y"6*7MCJVB=C>*? RW O.0F(&'CU+.(R9TFHFOJVI'@^IGCXO&T
M]7!7]B[EB*0W+!FK8QMF,\ ;(1G!2,;090Y.M;&3$T<+(BJN@JE2V<&I'3QB
M?$#/R6.J"IJALR4<%:XK9#"KF?[FS(=>S7(H",M*3$X?S6X>=9>%GV')P!#.
MA+7=<NLY@2_Q,E1P$221$TE?%$^('Q<$%P885\)#(<@]I)\,UIGN]F>H(:&C
MX9:[VP@]HM]N??9>P22!+M;S$5C!6@ 60H*I;)U& A3314B8A[L2F&.U*X1C
M49OHJ-^*VF2['3&J>69;/Q?D:-R?7/A@K,55KOVMF$C[PM5:4+-J2_RG9[);
M>CJ&S@]C:A$?*\O]]N6MO%AW)4EBS5*VZ@M+"#*]F01_/&5IJKA8[$(X+"FU
M"5S5JV+=6'@_A*^RA@&T0XT[^^[R1MR-?8S61;64@<PW7/R=,;% H^/)URPQ
M)-%[)7F=NTO1%VQ5,+@>"F%F5W9Y^*V?9#8M!-6KA?PUF%"D>TSZX$MA4=1Q
M?B$;\*X4D&VS N(5ER.6"W^"025)G;(-"R&1+HU,\QH-W:AAE%I@?NMES\J&
MMHPW\ JZ$QD RV*2W5O0?Q"1J9MIQ6:=18WN^XQ2X,FGS;+;7+1>6[SE*B?M
M?/R;:,M&E+V#$(>.GK+OTMS-2.HUPZ:,$^Z?@]#1<"S?N(PG:WTW',-_HW?"
M47K\X/A1$JFJF.,M_OYA3M).<^#"''#0GS:,T;46-"G@G=DR-;E:-L*\_H/[
MIUM.2A+%KQ\]O9]K07\I994AYB^E6//L1=D59?:.*R.>1\DU<J,/\^R'?B8<
M7/):4G2:FQT^N\[H_DW63/E^N'N#;#B907LFH^'<+)I1N L;0GS#,6U2!ID#
M^Z(JLQ_*"H.PG]"RR!/%F^FR55-VVMB@B)(JR:;R()"V0Y2QFF,\$)K-/A!2
M1'3%6%]$/#XHJF6^>HUNE]H,+B;LKTHAU)K AYL/W0V:@_]F98]/OCP5*DR*
M?C[]-N0)SRVR/UTTB*MUY$P5[ DMRHD:P0(ZZIH*5D@344IUZ^6J;Y;0KYTV
MMDA%@29BACY/S%F/))B7BO\9R0,LL4UQD8 *ET\UEW&[$K&>N!AJ6?9P_O05
MBBE90I6^R&%VNNN-.%\AVC-S];_62Y<$<6Q*9)&3F^J]<OF*E<B$)N.#9#XN
MZXTA;,[ZSGGV_=AI@[J5^U=99??\KU 1"ATH#X;6DW]YU:?U]O*I%=V?P Q<
M]5[+(A.)]I1+)&B2FUOQ:';R5_SPQ4<Z86K]G?1P+"H2S&+SEW1 (!VT6?1H
M@WA7_*N8K9GO#'>[:ETDV5B[>=DS+7"0)B;DU;I'.ESZ!:PR;DTC)P>K2L[,
M8%0:BL.[LS7//;BUBRMWG6'?'MK/MXH%,10),?*Q"ILW.T!8A[U?ZX5?DF^Z
M :X\,%"M0@H7YR\ZF2$R?Q!['9C8\Z8NI8WDCZ])[X;!)Y/]PU#/)F[Z ?/Z
M8T''PJRP:?TR[,K/%"S69!N30 4&O6:B_!0MV1%N=C"L(N)"86TF8:$1,H-%
M%)/@_AC:(49B)618=:%UBP1N: 7[JVHR1-%]LLMI2?Q?XF_Z&JTME5DW<3.M
M9Q34KO:5C* &4>-CKE\,;9*38(_<*O5/S>WTCJ;ZK+^EOQGG73DW'S%2TJ;F
M.?BW42&B++<!0SX1%_+<=:NRAWI$XY$NKB 64<VC\E&<DN?6_T7RXPO(N%I-
M%5CL>!)%;*S07$0*(6KN/ /3%><[^)C1, SQ,?^2'G#LM*^(#_#1B,WSV&NA
M6 N90<Y;ZCH5LE-MY(GL"J=]$?6242+3ND&<!X2%[)V<>X).WS<A>>JR6$G-
M>(--M;4\C)V*XP='QWGJ&)\LUQ?E3,Z=[)YW,#;8*A*OKBUF95-,X\;CO/'.
M>3N3VI1#VP8+A:.HD555T* /];'<6Z8=D$0=KD3.T+>^,SS &F6[9._9D@#0
MQER%QR>R]3WO<'OIP$0[I*\81U,W.@AVEB2_]Q2[1'H5%:$5'__</]8"U26;
MQFQ%;#-TM_MPX76UR8_U\9. ]A5O;DV8V(!R#7*6??%!0*Z2'\4&UU08EH/S
M&$[MJ73:[3#I<F7($2W+_]OYB(J/R%AGC]VC@UO '3]@P]UZ]?D>E+(+E/)H
M#TK9@U+VH)04-/XZS@!_.;#QNQ*).DL(V)ETB!'$VYP9@X@F_>>3O+*TBU66
M<VDUQQDKJ4#6AG?G:&R8).Z-MH^><6_ZU]=O[UMR7LSN]]J*QW^D%E<O"9X<
M*'60?878._H_YIJZ7_L@3NN8F4NRPJ$0@SN$M.>(G!>^CTG(N1MA@!8_D2TG
ME:IYAMLI#D%;YN*G3*Y>>U./0QI^,AON_.!:[5Y2-7#ED-.6"PP%8STB];:<
M])Y^$#.,RP$+Q)*Y=:1= &RO?2U-%B>#6"V^3< ZNESXLPWPP%1_N4$3AK:6
M+%]75!=DV,1H!V7>B=9.NMVJ=$CVSL^16+4?=I;RDI3X=I C82$Q2!?,O%"R
M>[T%TX@36;2%4D(S77V,[!CZ1=/R6/1']%)]V6'X;$[C?39[]T:0!" 1ALD_
ME,X?]9G-3+W%H0Z=G\E17#E%GTD8O6RCJJ1X3K!CU#&4UXS>7?LKLVWO_6=[
MK^AE;%/$CTU%'67ZVD^*Q@<IDSL&#CTV7M7O5GR,;AF_O=-N#$B6HR5=M[%:
MVFD BY#LW)=%6>$V7#&[!%L?7XX6!D-H_Q66*UEPG79X*M&0N*:0C'MA 9>^
MF8RP#VL^U6"*KRNY+-I:VH B--V)E]ZY\E_\BOCQ5$FL3=#QZW\8G)"W=R=E
MB^3XH]E")2Y=#!JA&691%A'@)D;=0*LC=-SIGADQ&4[+BU(!2RWGU0'ZH?^5
ME3YEE.6T3V:ATU9LY#:A'Q,WV4/<=*BT -.:RT::98VX!+T-8XYZKPWXP?89
M+?#02O GILHGN?,8^@!9\EI22F9$[E$O;;/09AS4[Q1#($CXT#RII*V+=C_U
MUO"2%SS9I4SW6#H?DLZX<ZFZ7YX1B4%>7/'!_UB4JY7BF4S$F7T@4<J1/N(W
MH#.0Q4$J(,:R'H6XDB,)T;:>_I=.E6N+]O:I,&^ G%@:77MT0X"U0<Z8[E_P
M@3N44QJ*W6G$A,@S$"R]G'-U$PYP-"QH8G&S<R/( 2/>.'Z'9SG4^&C3<2>0
MY!XJF&-[.^1#X2\<7MX02*FFTR"#C<NW0;:2FK =XGO)N>,W44L#JV HU(I0
MBWD+E#]5N LTZHNI1EODCM\1]ZVJ?0 Q+K/6+I#6IDZ)G=8C!1^.>VG-Y,OL
MH^+Y$7HUZ;T4=Y-JTF[VOCTEVP6=<V+[L,"S=&/)DX5N+4<<WT:E0;:'MB':
M=C#X R%@:&.M"E7+?6CG.VR\+T1Z[HHZ3-I/V\*1.\$)2MKD)%7:PDF-@C'R
M:&1HQ'[-O=/GK]_<9WUV_/3%15.7']#P::4D /H%F^Q!R:8:%J@ZL81C :,]
MT36',LT2H$9-/HDB1[S8RN0685EQ3N83#Y45YN88(KW$B-F#CBPS%X@H#LZY
M724):MW+]D!1'Y2G=O.1+1;9#ON3^!-$SQ!*S8:7YSD?-[0+%^.@A>@0V#UD
M07@9C=/X[0*:\J'!PF/S?$)G]G@1[Y6'[C#/-#M!5Y$8X=[W-YUJO;2!/\4G
M6-_=-V%$=I?9,U4_[7@IX=9T-2=6H5J!Y#YOU1"5Y&]$-HYW2L>KC>,V@Q[P
MY()9&)<QM<6EMX0#]7/R9@4C_XH9DA6ATIL3K:0:2OY+"RMN/6S_&4-^?PT6
M^#MO8>T[KFV4ZL1>9IN$,:PP.B"XDO2XA8EB]SRNJT-##]+J9WUA)2<@_$F[
M RNI.CKZ\C!<O.-/B[J8%7EV1H;1(OM[PZE^,*^@)I]>L^"=HF7YX^@!?#/Q
M^Y-P@8[-;!K=\"-/F^Y7->M 91L"CX;4"(V#.?:S:@=,:R:]L/@!93L=EK+M
M^:F240TOJKHGDM(H<),T5;XW=\#@57DF31TYM-?0,7<_WS9%>9B?*#H49EQ7
MRJ7=<I';.]>8A\$5\K2*REMVT<&_$2;(/? T]_''*"Z9FREHL<6##\ZMM"JK
M639B\18SYO_J^/,T3+EJNO[ 8UL5N1/L8H0H=8P>.2P&"1J[2U*=_VD&09$V
M. W.U5\-E)%; YFHD) I&OR/D#J>6%$:,#DF':QZF1ASYFBH4F4%>E@21)TW
M*P.181JF36N&8IR.A=4%-X^GJ-7F#:=,: W\KT+GS2VA3D8#31B%.=.NGQP+
M9&/>\ (@F]OU^]]'O_EOR^]XCSW'JL;M.?<4XUM@,::2!%9BBJ13 'A0?B^;
MAN03<RK9@M.F6SKLE!,88B^?GY[</\R>F3W7C39A)R'UT6&D$9L=JE"#Q6[C
M,/+MYPV4=X/23K'DK AC6QB;"QVXP6XRGEP'H_QW'([?-3 [EAAE)W5(L]('
MK**FHWVYE!?=4BB[,W;.D=(0;F<93_,D/<<C^.;:I%KX8#;;K^KDY5&EA$UG
M*_I8-!]'7&W%X,;)\ZT5 H!/H@&%X^8? WI78.D*C:!;NL)_H %A35>D!U9A
M4?<XT].Z^=!ASAI38IF%UN,VQQ*)FY%M+3:_#%9/K2(D*I$MR[F72E]I6\IQ
MCL F3)(#/"4Z&^$1T66:3L!!V_22D^!("Z:!TP!6CQ,%Y(4/*#H#DZ3#O&2F
M&WWSD97F P!\A0<I\J%ZCF8HH12)DPO(E&W)+2!LSV#(=;)PKN;@NJ>B:^H=
M$7P^SSLKRT.L8KB#$9\]I&@7I.CQ'E*TAQ3M(457Z9*WNX$PL3D-N\GWHW1K
M2U(FY<^SQ/OSK(X;IV^ C>L!V6F\'U2ZTNT:!LQ4+(K>K;IK6JW\ZLQA>^KH
M/R!U]"D#JPPBY?%7VZBCA4T$88#K0")Q6,A^K#$<V2_CVS!\+,(T60AG3_&_
ME^.;C?,,X1&A>^ZEM[)X"J]^?&[U$:KAF6/5DU.8?A>J@0V1%XU/;[&7Q+TD
MWFR<)W;R3Q 91$&*@U<KA,[>J>.X ,?P)DW1SK)[K]X]N\_@JGZ!H(JT)NR=
M%U .[0DKE)HA8D"21MW+YEXV;S;.MZ[EL+.:F<6,;$Z+S $7>*!Y <1/=FC$
MJXT 4K>I(3!M!#;%)WS4W4?.=T##3]^B8GZ,"M8\2 )"/S D31R80X[7&+@D
M%K@E0J\)7Z'Y*L\+W8$6Y_&A=X0*&X'06C'Z?G/M-]>_8X*$-%04TY1)O_?C
M\Y/[>_G:R]<-#0LN86Z9HPU"I@$*K?3\ZD$V*]8<42ZY%&;JRE6O5C )FC1V
MY59J4L_.M28AE[B7P[T<WE#/6;&-5!_%\8-"*.)6K3N(&*VLG,6.X:VP6DY6
M1!4U C7QO1T8HC:QE)>4".PH7$']S<BBD(L%"%;H!HB*OI9D=#=:.!5P,@ 1
MF('$F#C'M"9^3#Z/A9YNO23I^];5Y_TB "V$C (I^/T&VV^P&UKI*34<V=V^
M;<<X+.?!)UN)@UG8E6C"2:;<&K\"^ZC(&GQ,!\1>/O?R>;-Q"IQD!$"2W+S*
M4AP ]O"J^ C CX5EKA8KIIA=@)EW'0(?S%342+O!>AT3V0:TF-2S.KNKT<9;
M.F;?17,OUI^8"HF10^@8E@ 88YLB%G'6S%YI1U?%!3GIK32<<KCOC/E+>^?A
M(-.IGEF)B<!&V=V!^1:./BB%RX:1.;1L"6)*X&CGKOO+SE8#!DN[NA%!J@PM
M[^N!8V.46*[\8KO08KE&Y2)J(JOIDNK .D;",:GLE4P/9D$;(RX*!'D@8#)#
M(\#?M#SPEN"B;Z,U.XOZW2).N0>-;MM7L91OV24)C@'UZ#2H*''K2!B'PE,F
M\($\7;@E$''K/&DSK,6S4M::5J;K0B&T*_># _91D-6(/]?EDG%ZDM>SC1^#
M0$=;\S [ 8\BC0J=+, 4CUR@0*H-1&^M7[>9V:5@ ,\=1Z6%<C=Q8LO0I0[[
MMJC60FP(+97+5O6U/F%ZH<)0<(H&. 7O6^G0Z</04<"\Z9LI /L:6J1I A31
M!DSR#. ?R[7PP&$F.@EM*PI<*P:YU.BE!H04YPF$9KTS/$X7<C) MLZ_E4:]
M>SC"6\0@;4-8"-7'UAT5 4W#GC+T<BA #AN)]!\K.71-+/NVT7IZ;)YXCVD8
M)35BI-6Q D$O LEA+7QWTZ)SH]P+N =%<'QE?UNLF*40M"1RAD:5/%L1)ET,
M(E>X]D;)_2XS#+FDY&*N&N5TT)]9?PBUJ)E>ME]4+WR*3H!:^8P:8545^C9;
MNOUL*PO:T!&"A#C,SK!X%?WB )'DC7>2FA_EG0V7>>6K[ZTRQ'_%?*?"LKPI
M-=."'+<:/0/X-M8H5^M-A0]1M9B*@)2Z^"6"8X"YG"KO*I1/%VF?AQK\EEM9
M[%L"Y("$<_<0C^1#!!!(>O9CB[(3=!(95T)OPHI3A&T"OA!>*XYA!E'@>E=F
MDI39X@V1^Y<PD<++XRDL6K#LJ@MA%@!Y "I(U4&69P>HX3B<(S5+OXG^O"7#
M['1LE>VML6W66"0'RLB0-@A7"XP+2**:C1!HN>I,Y[9\ZXSN ;8AYA]J Q5\
M*! B \NU%Z45.P2NH'!S[E\03$/?XD@(6J5"4UL'M_&=)5@IN\7'TWUQXA:L
M@>KX^ !0]EL].D5S1Q[X0ER:0.OL.:BLRET(5D1A"PU#9VRYVM^&NY.5*YE9
MMD#7(VS"878Z/LR*UD6H1WEIL^/07::75LZ[*SL;'F=YX?P9E#XSSV9-IWQ0
MR@>6^_.S<Y4+Y'/N(\T.+Z"V6RQ\[128UI9(+'9:'FL$N$:T[N\8@!5J,AB^
M0EN-!"/5B'LBDYQ9]'TV1K6H7F[8ZU#C>(65^W)H,5-H-90+:F.D+.UN$J)T
MLXTJ21R&[YX%U$<$RX+_&SH=C&YL'G18U)A@0/-*;=E]T,9QLY+$:X!W'@E0
M[2.4&]8/M[^BSY8,*^=1"UE 1UM7^\$S!$8A!@@F\$WQ6M+.02OH\'I2EB>O
MW:DNV)3PI8S<YDRWA+S9EKDU6:"I0^=P_,>UOG);.9NU7Y_Y"B9'6V84Q5J5
MY1!QWK_GK)^O*$R2>%(H9?$V7SW,98*U]+;9G%+/'=G'[I0\W0P\)/>$+UZ[
M*^[;=M^A<J:O]N5,^W*FFZS_'[><Z<0[')>+AH2K6Z1<8,58\\']*&<^;\:E
M2TLTP .=?^U(59+9EB==_Y(84G3OK5I])@$E/J]?S87L@.NK1U>6OF] 8B49
M;I]-1//.I5P9SCE[R;ZSW.B6:CFD*6[)"<C9R/X8F& %#%4(\'7FP/NIQZY!
M8750.P:_>^3*.6EF0W%-]<N&3>O]1H3RF+X/]"X5!_)#%M_:Y!8@$^NDAXF'
MVI3P%!P.>]_&5R@(/1$9E_V&5V+ P#:YH $;;\G;P;4TE'?EM+F*Y^7V-\1=
MV9@;/D%<*QC<I=13X&M:Y[0BD,-Q*S!MD:+Z4'/WLTZHM^0UC_+XKV->C.B#
MAX$T&P9455S7&W5?6+C/IO\*(";FACO:-,DW$DBD@KLE//1Z6$[ U#K?$9K0
MWB8'PHOJ9E$3Q(7X"VJ$T+W!(:1^+-V>! O</DWG&U_5PNJZTH^C*.\H<6JY
MWW*)1JFKH<5] RWRMA!V&E,O)G1\K90<E)S^25.5W3*W%EC<@GWJ":[[!IU.
MH[Y1ZG4SE%S2:7YD>V3+?B]^PEX\WE;,(SLP.IYV;S+MH=5R;TK=*RN0E#>=
M2Y 8BM$52X7LJC:)3YST6J:S=(J#B )+<PGN^,WQ@9[56R,W_6RVK@MI!^<S
M+-AU4Y0M39G1RU/)IU0F7;RA)$[#2H/ANPAHYC[_JKW0-_)OOJ)(:_"LU>%^
M+^[WXJ?LQ8<W.1==C5(\[32P#AN1XW5Z>(G=;K%"[\5$'*[>7_".@.QDH[B3
M*WPNK5;FK?@P1*2T9#K&'I6L,X2(<_Y$-U-9<X,8/EO']7@-=Y.M3 /\&1O/
MAS%!.SU^FC9+X<&#Z\DP^ Q2XK'X*Q7^Y*FH(KB!Y0.DETC9(9_'WA;Z/+A)
M8\!I(USDCB.]-9YE-TSI/(8HH^*[A)>^6<-'G1-$S$OH)3[TI_V@77/XY/9,
M79(<]@C6/?[O%T$GMD$I<T8F]/SXULU=VUJ52.P-/=J20O>T+N:!21I9C<DM
M;>W'\L8]#M3:/$?$Q-H+@G;K(_K+,+&+#UDDS>;]ME;?T&^R&$ 1ZE$YZ6Q
M0&0NF+,T]V&-)7B)=5.OTG+?*Z<!\U3P')2^FB<"=FL$Y?;7_L[((#   O#D
M3DLAH;<-/'(U;B/!BFPFPTC?HR<!-&,]\ DA0:[#[.<65]3>IM&A6&HO2?YV
MVDR=.WP+5; T/!+^=SPG06X('#1TWRAKZ9C5#>?G!GA-F^5 L0>L6.2!>6S^
MKD3?7JZ"7.T,[.0;D9WM0#L#"_NTES:YG@^5$DYJ!ENI9Z7I3PD24/2J%@"P
M#Y5JXBX-PW(+)&G (_6H;C/&''-6DCXQ>FK)H22XK<*$*\JB;B3K8V@"].W$
MX0>QFX\&RU'+$XDAL%0>9F=T,E=%"WY@S?X"4K/]16*MM^6EQ! *&>-RRP[W
MD6T9Y971WU[RM1$K9A0(AN$5U;:@_S1WG2ZZKIE*UPB^2;2+;7/#6V([4&>-
M/"]_*F$>!,>W+0?=L!IP]18&$ZS>*@6!\ ''0S6"8VUX-DX=&_S6QS"+[#GL
M4DCUF2BPUX$A^IG0HCP_>_WL/J2Q[/3A:AIV8U@K9S\$CE<8$@#G(6A%Z<M+
MW([;S4-G2;^-A9M^.%@U)69:6D9KUQQMK*.G;)IO,+A'4UOS0PGB;VAXW\*<
M; -1V[8E8_M@A,?T6?/0Z]=?&CN\ DWC:4Z@H(*\ =\[K3]9H20,PM(;ETA%
M6&L4'H#&3FQ4?O-Y,^ZI$%OGT@_!2K&BIAU;$QNCAG^B5L9](N6Q=C9,BY5E
M ;ETK.LE7^%[@?G:VDG13Q>;H3N:ANV8FK @R0Q;]>\\:BC&I^>-RGKMZ?,R
M@E>-]UI,0ARZ/OK3T%5Z ./<IA%8),+#XX-^MTF*(2BI+U?TNSHS:ILCSE2=
M-ZFVY,A.:1U;N&.68)^ZA:OF&>UU][O!'J(\Z)W4+[X5X=N##\?C>.EY*=,*
M_^W&K%05=X)S_E=2G6\Z^2HP8BF!!./LL?:::GJ,27DD_L! PDZ[9L;F]C9<
M>5*N%1]UG FX"G8F?@]M1Z"A-8!@XPD=$U(=O!,('N'%[-5CA2+:JB5M< %[
M&I,J$&-T:LRMMG9+?8=9+-SFB>FL-5? '6AJGBO@Y2*++SB4X<C13K88&S!5
M\ZU42OS E/] %2'K1!00 !#X/E":\T/BD SW!JK=><")%<M)>3[ :OD%"YG4
M#M'*E"(]ZJ\<BI$AB/.E.N%R$JP/U"890\/D. MQ'>CDJ[BE?'S'3XD**#^L
M<QP!(Q$B%5O+2_L:OTVB3$_K!CLJ0=C2K(8RQ\VH1!Y"?4&B@\?E.SE%3>&T
M2R@?<[\*DY8Z>W$_7OR$G57>61LAA8U6&:&!A[B,$IRQ=AUQ!GT/T;LC$+VO
M]Q"]/41O#]&[RI[ZR=<\O*4C;MJ6C B03C8_T;ME+YV3ABMOG__T\N0^'VJ,
MF8<SP%#L6%G"TQ)G1A#M.'#0;\6IFIUA5((_X/OY[Z4Q;*VA1,FID+?"CAL[
M/DW2HF->HEECMG9%BPZ0CS2&"' 2V3RSH9(R=K78#)%V1EZ% Y9#XU0/<OZQ
M'% V$BU93ZP$\143)+?4RUE-FIECL(%PE'RTOL+_\>CP@3QMB>ZXB)-C1B^+
M\D+1(W3*#]/0.2U4WY4AGI[T 4M#5'(G.__B0=N[B!?8=GWZ;5G9&@G*Q?J4
MC7W$NHD6B4?(!K0$)>BED]17%\<Q"KS?:D%SPPUZ?,%;XA0#4N^9YPMN/:H_
MBG(+M[]/[LI^M?"G%)%T7$$4K"I>#K53REZAI#SA2UXE9=<SW)T9ZSMB.>1T
MBX=4U#%%'_9[N%D$7I7@Q13Y4>]=>7(_M:JB46P2!&J!Y&'VIE:81A>X*[&U
M^%;::FRN54K2#(&FK).@X,&,KED8$5#@_CG,@JY#F\Y.'8,*YF<G[6+9JE;^
M0@'.LI:2AR#(>?0 92/] BUS+/"FKS/3OH-6I].$L)J$9DME8;%Q"07GLJG<
M=*B*]D"B.D(2PM7$\ )\GL+W0=(03/E11[)U(-?</]JDLGE+[L:F@PM+.FN<
MQ(O%!,J6SDF@690W=SN5& ZG;[3WJ&;*]9Z0R=RG?O3U+;BVF:[6V5?15 *1
M[?+)=<>TG^9[-3$>QS/U5=BMD2TO!Y2E8P,$_Y>0(I:ZXKB@EN4T-RM L:((
MRSII*[8C_"JDH<!;-KUOO!6?%7I\ &EO#^E":F9K]%9=\WC8@X]X[QJ.AZW$
M-(O*TQA"OTESK332JYK-8\^LEV+<3([-(1Q^C/EG+KT0S]_P^D. 9I-5\G0\
MF>GY;2O.V(.D@1DO84VS7&V+RHH:T]*Y;%;"TQZJ/BI##Y$85"R:)Z[=M[?P
MIO7KE5;*D]05-3V6%\^?_O+6I1%Z2-A)TSAY1 F;Q^ W0<:A#>@25JE^R#,6
MA_ABTZ=;<'^QN*F.9)RA\"\Q) \WZ"3W6*_#HED&#?X<M%7ZZ,XZP6UY?Q2Q
ME+TGGNO$>AS__I)!P,4'5N4D-YW<M4Y1'CR4JOS@*JW_;)T&.;?EN,18E165
MYFH2S\)Q%7JKD",X'3IYWL3UETBUO=33*#F"XEY_J4(GX6.,"GYF'#F1==S+
M6.E$'USF2DF*A3?3AGB<X,].[?1\QP=AY[(?Y-M[I^]^N,\4#./?6>;-=3MH
M^:)<$V\>W^1T)<[/9!P8G4?]4R.#%.^9T3!\Z%?U4-I%,#9 8ODKNRCCELZM
MM+_SQ%I>/H&IX<IPYPMD;0B6Q)O)&VA-K1_TS$E\;1J5>7"TUJ-+]<@5L<(=
MS30LVR0C.')]HF]6Y07W(=R. >#$Y+WN?HILBQ$:/ ET*J*VJ1N6TE8STL?&
MKP^;:B/(NBT<.\X4:K47KU@GXC?+1S*-MU:1Q.;P="L29I_- *KAD[2J%$$<
M3VR839UC>A8C5:R!XWB5#[,7%XZS]*P%9I9Q3I*I;01)"9I<;6Q_\OT86VH2
MXM1,M]74Q]%X#3S[L.;V P>/C@P_<(&@4%_CXC82!*-;6@ ]NW!(."WC8J_A
MTD67>'0U)Q#^0#WD02L2M6:3M7U;%?4^O;>ME?P66X1K B&.["%"(6ZF&8(?
MQ.0Z2E*HN65!H3 *K%"J&Z];MSQ/]W"-\!(LS6TEBG5CZ9H82UG6T=!"7V+[
M!5W7-369/KG@"<PJ;1ALUQ9=WP[<$IT+18M*8*!Z/VBLLIT=( <(V/5:XBZ@
M_.$[1&>>Q_5&+5_I)6!:L)(1@EOM6[]E HHV.GSFR;U5@)FN3LQU9^E^189L
M7CQ^.6.%9-47(3A\#:+/V6G95!0+D^/C [<]Q,1T3*+'?6)["80)Y.!\+8QZ
M,*]A9[<PE6@HF+V:EF%1KG36*J4U*ST6F[S*<[K7I&RTN(/1KD45034B)/MU
MKQO"A+RB&GZ).\M'*Y>LV!]+29[,N BDLUEY2QNZP3S<DIZ\.VK1.XS>+1IQ
MT''[\7,U1J95TT'8K;6ZNL>QP*UL:HT-L[,@^7:(DH5V-AN0S[D DO1R?] W
M:L YY>B3M62 TW*HO=M)/R\DJC_47LD,G42V9RC7CC/@'6>'V9;EC"_I"LON
M(I%[H;T2DK=*OM.Z%7-87L$@J5U_F/W($(2=.E#(S:*]*6 O>D)(!LMYA%O'
M663S@D(&W&X?YGW*P4H!'C0U&TP-UVT6Y5(M7LU[I.GNJ!I&**32H(2';AH(
M9-PX]C#[G@&HTZ+UM#JM*/P58BJ&-S&/R*EX8)WAVQP_>-K,YP=\>_[[Z"FO
MG6P5]GZ.GZICCY!_9Q'$4?]:=7Q:F4=<80Z,-Z$3,(>]3_J<B9L6P#0DP<I$
M[GU++UKHI4//\=K1'#270#_D&FL,XEPNN8X6.K@^QX2BX7E;:H*& 2/F5]"T
MZ>AV"[B?*L4$O2S*BFF9FB0$%74JL^!G$HQ*!L&S4_*2%48_P>1'@Y3X*EI>
MJ(,,3;&ER[K1$/I#][G#V6CU'W^#9IJZW)#6;Q#@\10,KR102-_]5>K#\(5(
M%C_O>R9</0,_VW0$A2%= L=7?'5I#<\P6@E,C%XF:XM:".9\)WD1KJ1'?.Q,
M1F<I+2:]:T+%R0WJ^<BU#O5S#B-R& DI *4"8_(I[3S/JE06P"*--5=':$3E
MTIE>T&IP.<#=#L6RQX?<%7S(-WM\R!X?LL>';++3HX[1]XM]%YU&^XC%!L>5
M6'J;>MYB%5UBHWN+L(QJ=2-N:3":%C[.IES$$A U(\4?W/Y8VVZS;X90U:#D
M^'=5AN802B^H?CT2$NWL@W,KOK748#$)H3(;!G.V*Y",TKO$GFN>%NU%K(A\
MT,;.P2[')+9Y]IG=(&]7S&N$EF"#*5DX3K;[E.3<X^BWPU^W)"DM)< -8Q3/
M[<FY4P*H[%'XIFE]N)A+W*/DFF&^/$X\&':)P15+EN+K1RE7QJ-;1B*4PWC&
M7H7L>M,]#^4NXCIZ=REPU@;P.=.!"[><4),VDC0N$B_O4%!SB8,@N]@B5W.K
M71DF/#+N5=C%C*+L>LEV])4N'OPL.YD=!O.@[-9J4VL$X)!T=MC1NGB6[_-B
M@2S34*-G(7,?AS\#"* S;TU\ ':,X@?EE@D,W+3\U=KNT>W&#US=*#'"_E5,
MS!Y/ZL;"( "K.:0<L!BWSLU?!B9=_4DX3%W4K<#2QR-ID7*%4FH.MH_M7:31
M@Q_#$^WS/6,R" 7[">+*OB1=2_Y%QP%9'TZ>DY/8C5W$Z!#QP1A.3M-!0C/>
M@(^J9>YHLG.67;3!-_@"<BW?7"%%V0Q=!6I$:/USJ9/T]]#\D_*](<=8=E/4
M8($2-]EP5B(2ID7E1V'R??'!U=>>6)>%\.A*.E?9ICM7_@LN<U@WCA/]@V35
M]_(6VN"9F[8 *4+-<.5"7 0^<N.9/YJK;)7')!)2L =9GW R8X=.2E@,DF(_
M2J 4?#_Z(&KLZ;$%T76Y>J#>F<U39Y1^TKGIK01_[_"9YQ&&XU/(GQS; #,+
M5ZTBV XKBUF*6-FDEO&KAA-C1,PI603-BX<38[K@$(5L1>L!45P6(K. 1WDV
MFJCBB@-DN+XJ'8S$ $K1J* /@_D'>:ZUO6CX<41:R)"2;!LG.SJW5%JP+D,D
M/0H4!YTY5MZ2$(, 1+9Z:I+7B'M+J=C6PR%*;XU[])TZ4=Z(L;Y&C++0!BOR
M1SF+ FDR:%"X=P8WPBW2V-T5@;C-BWV@CX=B ?RW.@-: 8\$MIB6<MU+S3^\
M;XN9V_CVS70ZK"Q*KW?X3_(5GMK(3I*F$/*C%_5%V3:U=O6BY_>*1#QADT(N
M.L&)/F-?_A2SQ*4))Z<G]ZTP63$U50-M(-3L HN[?5F]*WOF)93?1[AN EAF
ML20C@53.&2:PRS=2SS*[NS,Q/@W-IAEOE-AX">MB>:MY6PS:2V "<[XJ+CNC
M+\*_D[X9]J,3>OK!W\OI!T3,>*P#,-=B?"[)Q&!P:%D)[[\EF27GGE9-K.)B
ME[%ST&;W&($F>7;H!RA?06!-W**HYO>YEQ%\'K9/!6Q SQ5P:<>8\CZW"$".
M-(# VE8X1VJ<8LNAMMZSFBQ)2CN1")LZ,1F9(D*HH[B]W*C!Y]!.%]SE)T42
MPLJ;Z5/CMY6Z4&[\ %@XOWVN-!6,^"S6K!E\@2,M@I)(^X58)"DDK'S(<7L%
MYI592=;B?Y>-I5A88Y7(Z%Q*VFD@3; 0SD%DV$I>K30^GR=M9$ 0S684F_I1
M9B!M*<* D(T>*;O?@03P==.ZAA-#K&Q.3P*MAX=;!:4B9@$Y,:WU<Y'\7;1"
MM*L$G-&I!E9/C)TAC*_(+FQJ/&7#5>+.UBZ3O'"]S)PD0DMZ:4,-E709Q!@8
MV"^TL/Z4>,E7GTJ.D53GYTY%W"(K5CD-T:X)\UTD*BO65I@I?_+JU2G[341#
M_F99EZ3!LF?#[-SUY!D"*D<^KJSHB33G.GKRY(' /BQIS"Y)=$M5PR1QC%7T
MY53<>P5;,-2%P;<PH"OGS=NPOBHY9W!%UMF9UL+9UY:J,VM@XQB.,)VLA,==
M[=B761^:<:!SQU4A40ISNBBKV0')><F-92-FD>1>H=T23^3;!AL?98B(;#%$
MSO\.HIJ]_B4FG6_9$J.)MO3R"]:#AS"L@@4B\'#RRX61T?5B</*A=?O"?5<V
MV?N-4-T\&^&GO%RG'14CN=N2^_;9^?CH"[!UB5<?^( UB2&^81DA*QS]R7AU
MR:_6(J=DWX4S=R6B)]6@=;3'K)?[CI?9BT B O,=&(?:6!K,Q&N2B%&R+)Y>
M;5ZV2P';&7>R&'?-EF@3(Q@T.--H+ZNT<#8:VEAI[1H)<#HA>+HM4),KA,!#
MVZ/@3A*G2FK:)/*7;P]O]0RG;[3#&\(:'*ORD7T?O\PSFOU2KK7(HX3Q=X0?
M0S0+KBY3W$E FUU0; >A\J@T'%I,TUZFD?'COT<MAJU!5H!HM&/\!EYS;-SH
MVN><OT#,Y-*E/( SLG,9BR&W@1DM&0$!^@S:PXSV<A+?$ZG@.+ 5?<U0&"VD
M4R3NI 8P:H\G EI4CAF/&_9Q/P.%A9)H.O 6Y<2R%NU&.%& G1N+D'8][P);
M"!FZ@R%>(IB)D)LGSY:V?CZ==EFL_S!&VRD'UCII+Q<= IU8PITADWR)0:!#
M_ZC9S1C:);,MF*"-*6:[6U9K8AJ CY!Y<);_HJ$^%D$5JRAL7+2,56*U\=0?
M:5*,TLQ"_5^@HN\CJB:&9,^D^LN"D$^UP@J:0J%%&LA,Q-3$ZVF6ULJF!^.H
M2/#5/""P[;4NG>A&!"$9!R=%,FN=.I7!(*=7;YK;1NON<4^[<$]/]KBG/>YI
MCWO:P#W!>OT>Y)T'/Q<?$38_\<UA]\"G\3AHOK[M5F KCK;D#$<.'P=_$?\>
M.^=I]J?OW@B.]UG3?,A^D,/YVS_CY]_)S-[VV]R5606MHG,?TL(V>!;;:Q2B
M7GM<IVHU69,440*P5P".,&L3VO.B7B"N.I@:OZJ$Q#VVYJ<5X[&LU&$KGHUO
M:J <OG?'CPUYS(1]B$VWLI,'E5RS7 MDO5O(3^):ZA/+RC+"QD>?^(W>1^T(
M7M KTVBX$N^%YP@0BMTE5UEXG!)&I/4,D6P>:DF#B,-SKGQ(WR(69%H(2: ,
M+?T#M2*E&O<^VB3M4VAH%C<"X&?4!#(%7Q63"7 9A?+Y,%CCA!%9)S7_(X2D
MA1$YJFXODH63F/1"7Y9+;PLAQ*++23*,==%_:WS"ZC\U'6(GC'C2>^A4"%DS
MES4J[W>WP+2:-$[*QD4KX<F+V;+LPWI)1S2[TK,T1D\YS-[TGH-(C.'00AVO
MO_U1N4R4+^X.]<SQKE .E%S &USP'6@^T\)RIIJQ>G;VX;7^3VF*-FDP/-@K
MW4HB4G%=/V^#R\*Z+:J<CCJ%J*2:,(4YZZP&9W/N%%J"-IR,,I7^!IH[$"F5
M>%;9^6ALG"FB46D;!Z-Z:<@HYNA'O$*WKS/OBNZ&^9#*70*Y9%C9!Q=(W8"!
M3;Q"*&>D#[2=N#97BE6IK<1&\?)(8<8J+3LS^AGF@QFQ'G#R@T?"-?MD=MXK
M[\N,1OMM9N=%C&'![A>B"J=\<D_IQ_&O==3Z6USO/JYP.[[PZBNU;%NZM W*
M'"(?,&XTR6%:>CD0&77@LB636T&:>F/^/8^>G>5[Y<7.,7!"EKO;2EQ'B8D8
MH#/GZC#?42"B0!+(T$@*/'J("=6YID_438&H-$8C@[B@.9$LA 389%E\ PIA
M %&29WZ$E);YPC<C2D;Z>EJT@!4U0W^?!:DB@1B@ST-Q6CBJ45#/;/,'S?P
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MK;*0N@>&'AF-K],__?D>_8#;,C:M/@ %=#OGF*,89G[RB_"C!FEUJU/&NU]
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MRW>1CZC"DB-0Q7MB*CVLV%6V:(;YO[B&!!D7!+_T\0-L:7"]6@%0G;D#VG\
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ME\'9#!44 P90'MP-92$E?S-_,?V%<NQ2&NUV-,!W3G+]/)V]/]-YF%P],;E
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M>6@VI80!S%F(8)%?+L;@M[D8F1)WC6)G.=7 U6!;\*%T[;KUKR;\MA'IA9P
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M=Z] U^^O_,F?7KSZ-+'9I P?+GPW$'L(\(UE/6816LU\-?-K2/]W+"K/^/G
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M"/E1 5/@8FCWF<?.^P_5;O"_=V(N$&C]917 ?CJ0]A0+C6$MG* -P%,1F<0
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MW0,;A^8R0=;1NITK"1%(Q=^<"1V:$S72 \*%>@RWJ-'=O"WRO]Q]7J'MC"I
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M@HT858G6$)1)EKD]&_&Z6XZ!&/Z!S8L,AJV\%=I+$':=Y:S]IV]?69[&C:,
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MOT V0#Z/HYUV)8R@P5>%)IRR5!9+ZS[H-H:&4E8(YATG$26.R<>>/8R3W\N
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M7V'_\\BU9/,&E>&%H!QSSZ QQHR-^A@C%>7T!?!#AR1[12G\;M>66\%EE43
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M!"Z6N26*F3\<'//QS_+WPY +8>\.G W^ZM]?D )M\X<H:4#?\N..'?%6-V-
M3N>$U9)H88E0!LR3/ZIM\O1':1M@:8]]V1YE@/I4*DVB+>D-I8*FS?98@S0S
M9]<'NESO"[T3O:$+J?J&ZH,P9TMY'/8^ICJFTXA;E=V\! +$X*D&S2V=WB<S
M9<8&*]A4K1<]AKR'[=G<G_V$N!JK7C91&&XX+4Q%_<R/N<K/&?N@JI\J9++
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M;^6+Z'"6DG@YQLJAGS3&TZQ\BVQT><3)QI!-$WI(KS(BY-Z>#><*A1I;RE[
M(8=HVS\-2/F:F!.)R4B:*WX>]JY&9CS=X^>K7YFPH'.L03\=A91Y\0L^F@BJ
MY?NTUM;EE?NY19Y7=.$"NO!WGZWHPA5=^(M %_[L=/8+XN%*PC%;EW[@< 09
MXZ8*$.\N!"BFOM#4=V@,0N&("=$CN;8<D1("[M;=E^XA]FK'#TDY+X+N4IIH
MU528'1EMH9#V2$=GJI(TP)/?"&\"E64R7N09'RSN"OPH:'\*/>#SM7@Z'U!6
M"]$T2OHTOMEQ:K9"]E5^2YO+.UDXMU#V>:WQSV4\ZO.<(<O![I$5L& Y>)%J
M&WJ@(Y@1Q4X@\-DW6G)!B95* Y+/8@NC)#.TN! Z3_@:;99+LIHC\]PWQ,]S
M,YQB*C@)/,N]*2O@-'=>!O]DHDJP)5P1R,5VK_,[YN^RU>ZX_ @4T7!>")_H
MRXZ_Z0/ QC!E^I-JL7GMW$D8P.)TS+@+L"AT(\^3ZLD3R3E%AT"U] R:0&\(
MB#N]]VB&SD^62L?XX?@-X=A%Z06ZMX5C4"&&3C1XI7RJRD<%_CUI^8542<$*
M&RB%$1D3XVO.@?PL#HEA8^G%S!B;+7%%L'X0R>AHD$ZD3WE+=8RI8I"F>5HZ
M1%>EN^<1DUF5=0/V_4&,1K5G-D< SP@"H,)!.BOCQ': "!B[-@YQ;R8P @U4
M"#X]<H37'+BK^4+KV3[AZ_=+-)RBDL2W%;<P^Y1I4+0@8'$MKLY!:FFJ(@HT
M0^6KRF==X274Z=\)1E0#@=02D))QAB ;*@]-4V2A2-;R\L6Y5(U^=K@QH^8G
ML)-B+D..J1I7=BKVX,VY\&:-XR=@*WP(S92,T+;3TX>E#LXR/:JN-$E3F F(
M:/V0PDH=$H2/*!KI:!.70:6&/K>UQ-,\J6-5@)"Y\E]22Y2_$=^;U=F)*P]K
M2X0=Z=.44.34PG-VX@R8$H^2ON<AD&^$91O?;!?BCI TL-)!'UG9Z6M9+3CH
M3\U/2A5<?&#'3ADK[RK/XOTZ5G530,#C60:3E 6IIK#=$DA#+':46U_./ZRE
MK<DX_J(O[]Z-=7T4IFE>M?XJJ@W1VS :U-V9A."6W&A<7X][T2PL;X/S<QS0
MA6\;A6#R93'_:.)_PK:7A%(G4 K5!N;J53;V)-DHMJ3I>->=.(SC9=Q(.!(.
M_<ZO_)OSKICYZ;Y"Y&,$1WA[_K8I2&!7$N:A0_JSWVP^2:XU^=RGL>> 8;KF
MOGG;\^Q\%6@!I:F$^/D*0P5/;QO!J]IP/1 ;  T"9T+3(;25U#S'G$Q(YG>@
MD_/;RXX31/B- V2,@^WEX2>@9FQ$H/I& :FI0[[WWB')/&I4L.5!94IC $9K
MR\%Z#ML#?A).,"'QJAO;K7]3H:E<C_Q\1(I/$&X:(BU,J3"GVC,=G>%=KS-:
MML38,#/,3F)GS$ =!.FY2K:QY!'8DT_)$-?UET3"KP3\J_P#<H)\OO>OOL"V
M^$(("$ CGQ.!-(.JC93$"RV6?>VM@@WU>R)GVGD7:NRVX<0+JXX2]368N6?O
M-$/YJ>R_J<8FDP]L]L[1R2ERI$FP&XA(4/X"E=1FV^9XAI-U,G-!^,N>DQ"2
M+NB2^HBA^^%".HZ$\T-'A.QJ".LQLT,@U9?:7::Q"6<G*/26,)OT!/N#(>+G
M7?+$1-XD5'% \8^.ZHQ%E_*:V5-'Q(R4.V U05"JG/Q'_$EZ7E_#7(6^/QXW
M>,H[]#FR5Q;<JCD[R5>DTMTZDA' A\\QCY=(J :AO'"&EUTYU5%%)=)VWP3_
M:^4$V]"MD,46HKHZP\75E.#9.JX$!CW<#,F)!=L<'=T+[Z&H/@9C@@84V1*!
M'_,=W#LL!> 4?P?20>'D$H.#D[TG<+1JM"JJR :'8T(K[Q&]1<G)(IQG4%1<
M/5SBX99<F2IB\%(U=LXFNCGZ:1^"6A@,9^M<'5X/ %C-J8]*U!SB3F&+=,WR
MKH$V9=@,O>>!F2O@W*R86:,*AY;%37J\.]MLD:2@O.4!H$W&) $Y(NR!W!UG
M;&,<,=IYL9=:HF%IY8RY!K'@<>T\#SMT<O6+FS1BH)* JU"2UO(U8AUQQ[AE
M>$EA/),7*8D=4BIJCJ6L)!/=LX!/'V8BH[JZ@#L0]@O^OET^:\IXY]P%4+0$
M]JG. :9\*MW.B1AJ./=*\HCK+MS' "BMA5TQS!YI(3@0J!TQ1-@@^L@0JTK5
MIQ/P)J94&EL#3=W<L$>^%M/+O^*"QX=?VM>XF+<K8XX*HS*P>;8!4V ,_[OY
M/%0;E>W!N"'0J+;D+>Z:F*M]6>\K#9AT;8 X]N7W+*/X[+-GS\B(J/H!4)BQ
M;X:0T/)_3@@7;QFZ"7-NN..4>1JLY"5))>9R9*!- _EB#2CT^[3IJ!8PARSI
MKD9BQK2;T>9;:2SG!TW!$!8%88>H_XQ]5NWN&H&A".J$8@T].LWPP &-Q]]Q
M*GEPS-^4Q^%(B,I6$CBB?L!U!BGW6/(Y($0$?(6X[Z;.:;.G9ZO<#2/-Y<"F
M9S3>FY,SX>:/F!?\^-6HXJ,/#ABZMZ9.W+3NW+Q'NS<^,"U"KY+TG0)_U=0:
MDLZ.BWT+IO;I^Q(:YB.^(TL0LKNA;34.0V$E7.;]).Q2P-!<,]>,+YM=W5\$
M%[&(AKGD;E;DT-7(H<]7Y-"*'%J10[,-.PQ7;XA]]23E]9W_AC_!MB&OMH *
M,@R1B19#-LT/V+R Y6TQP<<<*U*6'.>3-J%06 M<W=EF!QT8T[[EW@CK 9\)
M3#A@;JRGC"QT&PY0(3SZ4Q5R_@K'I=P#NA!'Y4PY.@OVM,3?#GQLVI=]4JUP
M>4L,]RO 9V8<?TY>">1KJ *;,N>*-9*CHG9D02>WI"8G>W&0I3/2DC8Q!Z6Z
MQ^LMZ!19K+EL:.E(J 'X"+]>%LF3C!?6DHP7P5%85JPT8HP9^;SJ;%?46/OD
MZC43R_)IWL^&3[$Y)ADQ7\GZ@_[0<I=9G!::BTSK5@6CRLOMT"^T7;W=M'[M
M3\R;V-EF0DOX'[0*-4S8KZHN74QE<B93A5M(+I>^%'02#0%N)C^5Q4BMPHJZ
M>.N;:M(\-OLG/AQ( ]#<6U34^[]O$'-UD\X08P5"4Q53E-];@ $?+*S1\' S
MTX6LG!Z/C1L)PMEJI9+*R:DC6FUH::+N(5-%^J^?UY>$B/HWOQ\YEIMY#[>2
M,'Z$)(PV+7"=>.MC>H^Z9+D#U>JW1G77H.3ZCD*NN[P[2*/5:_^GS"BY H*
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M/X4CMH56$[TB)L1@3@[BC)25%^(\,76K'1,<"@17ZUQ8OU,#Y/.:AC=:?/'
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M@XP^S8X21G4J&VMRL9#%4 ])VYR[#"V'=I=0;*:*M'\-DU8K_"WA8 Q&FLQ
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M5&XO$U:NU;^,@1MG#UV&PS-4@F5JDF)<+^W\FF31IF\FAA920X!+"OTW%>.
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MD805CMP%YOG=+#<*HG#I%ZS%^T&)@W#0M$H4+[))6N X39$-FA@YGJ2F!$[
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M(B^V/[]?LW3GO$%WSF>?+-TY2W?.->___>S.&2WM:T^X1_/5/K^CD!V%I&W
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MZJI? T87@Z R2_CDOLCO2R[Z:'6/EH#=!H6T CG_-KY=<29 NK8I7(Y<(6B
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M9[19V@OO-IP"97<0C&_9QM<,N.@!1R#?*9S(57W/F^6;O'F=K?[REY=T7PS
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MG)L8N!4CV*NZN@.0G\5J**Y%,'H6<TA_*H]K(JZUW@:TV[)%JJ3]%S ^OUD
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M)AX\N^2:M\&4LX9T\!?*1KC%G(F-KY46+M16Z3,1<B?'"'D:..=H'TC3>A0
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MUV8O@O,%_+?!/!M/E#!(C(O^Y\A H1)%Z/87=D7D&&M)YXU,M*I<*43HZH1
M./%J8:;NN!P1A4!L\3:S>]3O-%F9&4LGPIYW-9\M>+(Z]<W#%K)]6?P<[F;<
MN[B=XZ3$2],N27&AQ Q3"M\J3[2"?D;?ERLP26':2D_C0O+\$G6-T(" 7(/
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MQU2?.]G?$B;2UR4/J"B7=[4RW[%C]HK!+6%BRISX?#M**+><?4@A#OF!^_N
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M*L5QDIF.<*U&HG\<$@GAEVQPI='9[? Z;-.RPEKHU%##> ?+N.(TC^00@Z6
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MYY+C<1HGD.<SWDH#WH: ^<"/$MD$NGXFK8_Q_XCNP*O)#UWJ/F$*#5!8E'3
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M9*Z _%554K!:_V5HF;_:3=76E6@.'$#M/II95.=/0/]R/V(J2$(FBY.&3&3
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M["*C6L?!("LY75$ZF&8JI'@U.-]E9IH9888TCH0TKSF/V_4N42_->A'I4:N
MP=O!65H'7>R^TP^P63ZP'C]'0M#Q)U>T3VPF9>:R"R<.>IMEH%,^,<A)&6B4
M#<H19[<T?APQ6W.K?.*A9*88YY=X@=WAVD;KJSA2-QJ(VNFMM@41E:?0<,7D
MTQ4>%E;,]Z[!%K@1BH*B^DJ-FH8>$T^D,G#D6U@QW7M*$/*$TITY[ 93:@5#
MZ@7&DR*.B@Q@2HU7T3<8)2%W.)($+Z;'*H5*O@:L]4TE)PO^W4QXNV"G#)6
M? O['9U^]I!VB.9<FJ1 #WBD;*3N[JUYJZ-T%B".BH7E<&Q(.\X@IY,GVO*]
M7>^W-*-V5U\:PTTV48,BDXW@0#_4J8!PB9#$ 26CH7A'8EYF.F01X34%@("P
M,VN!)Q +85?T[4T:9_<^ :5ISGGFZRES5;<;*N";KE.I48[O+3.;/YS:JJ,%
MJXX.VZJCMNKHGE5'^ -=R+MLD9JD-85M R\*__HB@K.CVW\!YVV!S]6_ROS#
ME?":Y_!'K_LS(D'T13M,_Y?=C]\33@AS6><0IVLTXNEZ7KAY'].'1WK?:!;
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MD+^<N&'C#1TDQIGA-!6WY("'J(+PWR7!?>K^-QT&8 8TR_R%2>S1* UUCBY
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M#AD2DWM92-M]I5Y5(%_8:I#S+XX5(<K>1$0C+KA(+@Z@4_Y*@"6V:E];.$F
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M8&G7C57O7R 9J U1  <:O%9OJ[SB?\-1BEDBAF @STF.D'P04:5U-' 3)P@
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M^)C2H2K4,4\#$?73Z><OWOGY-L#&;&/[S$%ECQTT[;&#W06V6)!]9=9E[#+
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MA=3%0=[PW.L(K)N,M@*^?09VW(!I?%!N4IAY(>.MS_2M0X9,AA>:/:D0&X,
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MB5R2G8+U,CLDZ-K&T6Y=U01#?C6J-P,OL1Z9S:_!9I0GL7E(S\!#@_1>',!
M+@?7*;'*TM<]B7C"3UCX%U/%5A!3?:1J>'SET3[<6L<,\8=8[<A=V2@DMMY
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M+O%:[WW&@ GY+M_A=%A(F_PPRN!,?MDS\3J\;?6-_,K[1!I& NR$*QW7!(L
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MV%<1##C 'NG0F5B-01S$ \EU.O$+-R AK^'/'U,2_EG OND19G[<F:"AP%C
M"\C2?IH9]3=;"]BWBQ(,<$_X &=7&[0C:(1$Q1B7)468JREWE,?]*KIY[:KC
M4/00%H25_1RVE*)F[7G*A+ ;[-#O)7]8 46T DFH9<P6L'#X?P/NQM8<\H\J
M-OH!N^O1B(2U4\F B,O[#W 0N'&^7*=,4"BQH*&,,! %5GPT0I$'W_9*US7*
M,8FJ^,H WNCT;1Z-RF$4!R-N* ]N@K??=KU3#!GADO2= &?W/A%.@E5SAB$X
M6#@\A/F)0RGVH_1,2%N7;DL[<:!F1I'<4!O&&BS,5_5@("#MZ#I-:;\%!(E
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M]AI%NI(FC?7=S=!X=CMWG] /$5UZ,--O:;+/.1_]0P59[BF0O&K)HLO].44
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M#MIV+-@SD9%Y,87%&/[^^4L&FD(I#*F5'#_3R)<J_!1,,,IVFL$U5QQP$]W
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M><$7S.T(SZT/V]X6.RS&7YQT7V.G?O!U>(4?PTXQMUQ-,H,6WFN-$5W+?T.
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M:J*6,,N6-4M<[ZC13AS!+X8,2Z%LP-]_IK/_W7DCX.*K4;]-^MH0<!3Q:#A
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M-*/G8AV/X]IGE_9JK^"D.ZX7874_NR3LFPHJ:PE"/48,6-XYC>/PHSI</HH
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MT=WGES$V%GZ/&=0SK[??/@..L9G=EZM!1Z'5K]1Y3J%@B /!FF-X(28Q]MU
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M(2Y*RS'+E41P0"Z2!Q:!ZAF,6(ZPZ$K[-)RXK'QP34M+MMM7[<?H'4\)+PK
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M,*M*6!X3_A)IGHG)- =,E1C@/S!-PB2,3%2JG#!8CFT9P[@/>P%?7.ZY).(
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MKLQK#'GVH(YCO]$ZY&V#R&QV$MPLGI]QZL.<&SW/."0)BG1*3-"XOS*, >E
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MDR"?T-+8DR]F#7<ETOC8[>A[8NLS(-$[LEZU-O5]YU>O>HABU3RUJK).55;
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MF_ZBM.WU"6^!J/,=ZF9E)8OW=7L((9?50!/[]HTJD((0$?PD8I)GY"$N7&D
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M(Z7"LSBMYGL6)![QUP_U-CHY3K$%%_4#E[N@B7 +C!!1>0Q\@H-).G2)"BR
MK(5;#WR<TO; #6+UB1H,5=H ENMJ]6$I3%0,[Q=[^"8CU-P;HX2M?)),Z!39
MV:2X.'IM ^P2#&[-[_' <?7O>0Y_)O%4 Z]4N_=).^R,M"^4&*_W#M&U7,?7
M'E\2#E*'[^>D,_Z0[,J3SMQ+K=V>K!(91]DLZ@A6V/T'BP-D7C?/+7Q7WZ2-
MG;U&+-Q:WAH'JG)215!)+<G ,9,7D8.8="MLJQE6[TCXHE\ALT;E><D0<KS(
MQ\+JKD]E)\!)"4B$V&!@!V2B )-Z1NJ'2JDD\8?Q#8,?(_")V65.Z0=^QD64
M1/O\1-MX!40[2_%PT4B&Y,CY8%\!+9M HBK#/!DJ,1FAE_%@K?,$_5))_02D
M?.JM'BA$,$+(Z'@)^XZP<&ZV)-C7,/!'><]5XZ\M,RK,6H9XXS8B"G*X08T_
M_8!_+_EMV?S6?.7\EAIZP$.8;/2XW\CXJHFJ^P+:&P::5HDWP&.-U>CX(2+'
MT'!>HQJRFH'YQ27 /)Z:GM:LL:.CRXCF\F[U,42_]D[#43J$GJ<D8MDX"!??
M _FIFQZ*&\U84*O&(-^I\D$F%02EMLY*M/PXI C/?Z1K!!QFVV4FBIIU=D&P
M=X<H1$V<Q^$)6?\Q@)-8%QE_UV2E8ERXJK:D6<RP9C,W/GUU-TU=V@B4&HZ0
M>M8D)C-5SGH ?H\1U.3>:.\@C&SG !^,[X\]$W9S4$EW)O#I62.NT@A$&A[$
M^ "BI["_7[$58$Z$\X&Q$-Z-B8 (!4 ,Z2T]'[O '(:5PW]8M&SY%+4JE,V0
MJ4A!0:C+O6$['T:=3- NC14"SVIH.F] =$58]L5-)1.4JWM_' X<6N,!N'(<
M8^E8=Q^G6G\$LOX[ZG0*5H]=7WG8NDL!9Y-!?G;IR>%:"P)H"*J*,TVG$>(4
M_]WI#SZ(_P'GY%9\^7*)+@E-XZ.N,:N/"P=4*<B3U)7I>E&?VIU(3^O,B1?I
M"#K#&WFQCHR!Q2:QYV+.H8N)EM=YIFE.TX]5-5"6JQ0O5ZF7Y2IEN<H#RU66
MP\0+JM#\N?WQRHP$.K,DXU4J&2]9,EK5B9] ,LXO9GGNUOZ7[TZZ88_IVN[Z
MU@F;(QU9.M&1):(M8"3GSA'7."7)Q>,_"]PY"N#U[0M0R<4 F#(DL*SQQ*2X
M0(6=5EU<:87]%DGDFU1Q&65JY!. <>$*&S>JOS;?PJGD9)]-KITMD_%#H14T
M/N3FC%6'RS-EK54*VKBD"AF0_%2]VLTJ+!"M/=4YP,14F;)[Z@9<YKYIB@C0
M5O=H*.=$'R=\T=B6&@O@F3=^XIW>')=_PV'L<9BA[TI>))Y:%Q('H8XZAC*4
MEM!-(I:VN*"!<(CMP#+TW>\!L<XUFM4QD,OE<>OB:+,R&=9L.SX]E::IC$\1
MFNH.H,3F64HJ)T_WR@Z733,<Z(4,5"LM:F]+]O^$.$F8RS=H)ET_O(]3I%JU
M(!JL*T;2B<PH6U7Z-L4KK1BMHE<7A+ 5:8\])TQ(+_."TYZG ]6>*'\0GA2/
M\!D&".C$!5Z*N00!7H3SO)'71Z:@C(Z<V.-C4&KI+6J:#$"G4B>SRZ_L:JLG
MBD.N]:,0N!6%U"6>8V[\HQYAG&;%,2ADZ&5Q]6D1VT]/JENC$A>S35R8X\6,
M,<-P;, \86K:Y,'0%8]/&%U!^1P4H%7QC:M"G2GQ!3L"860KR4,2$>,%I83]
MGAKID_.EK"Z]?+E-,RWSQYBFMJX%GYS6?L)*AV/C4.<7D9I;TCN].5GTC106
M3DR5G?34B^M,VA1Q0P55Z:?JQ$VI\ !'S5&9E8QH& V=$3T)#CUL4VE+;M;2
M:2-@E49Y?II,N*?XJ3;%IEIB;^Z,+ZQC52*+MYS+^3@U0X?'X\,>N+D5)6!-
M#:%)UUFIWWOI?"=A2X/=L1]7QJ:<4&<(U0VX=I%KXMFPL=7!U"+9C*%K"FQQ
M-16;]FC8'99],YI(M@7@/H4F09O&%*!H^&0+FBLFT:BFHJ;Y*MYHE8F/">73
MD'7;:/UQ1^+-T1S8.">R2V$P)4._I/EG.+ZT#0FN7&M_O*7AFAZAKY=;\KNH
M*M\G[5#QFE_QKKXI7KK.DKRM>7666H"E'J/:@ _B76-S]N$^2UG="U;23:^B
MR[[JXXOJQ@KJ.G:T,[.7!!?;G+.?+UHV92TG4S/QD#*JZ953"Q%?BQ:797G3
MZI0WO0)E"\_8CK?SD^EOX>5:6+H  N9&_G#BEWW41 1ORN.FYK5GIC_MY&)9
M$%"\(*!1%@24!0'/BE_QZ.'9TNV\/T\BGV#2+[HW4:<51?F3LQO+GYQM06>T
ML] 9[3SHC%FP[4<\:7L^M,8%A1S.TG[S<5"-%9NW_6)]C@?Y)78GT\HB"TV.
M3I-3?!P%D"H;>QN%KFON%+QNM^!U>P@&;":UYOY?"EYA'!B$&2= B%B\(T#U
MKHYD7@W]F:B!]3V'-F5K[FB-=UTSL- &<MA4, GPN&'JI';4=!LT/-&3#(PA
M[)B)+_-65FOO%ER:F?U'V'#LXRED65R!>B .='CAAU;T4QT=6$AH- 0-J[ .
MQ20<Q/76;Q4Q3Y#LU ZT))D!.+<\#+'5 SURLY+;S04].D9XS?9'%L$I$AT>
MCW+M/X61Q)#SKR!_XHZG'#QRI2Z58W@64'8@1V:_]28"1+"#O:N^R#LOW&&"
M-[EL7=V(L[.S53C$5>2J>BW#5?CK)%?5:P6@Q-)*0\ZNCL$>\9^/PVA T0;Q
M&<,T'&Q=$I.M>/N!C524!B:S1L([SFO19%D:PN"%MY$SZ&&PAX:[;U80N5B=
MA+8G*N8.X/H9/:Y3"R:M3LDMUZZW2RM+N8] 'R95YP'58'0.SI,08S?FT<.&
M[JNYC,(?(ZZO,L/F\>_I]#"%P74N)0\@ZV:*7M>GPZO]\<@ZX$QU;_X>+YNK
M=@IOUT3<HRC6?FZ;]9RY,]0L]_>_[.TV]@\_7,F^)XZ<J.W)""51!C[:1.J[
M-!8^JE#[3BRC.\ZO@,6 "61$O)L%]W;<<SQ8;I!EHLP!QAYG=/)*>C#=0H!E
M@:@?'AY4<92OGF&'$6#8NHHXCZKZ-41/^H.T6.DV"N^3GB# Y:%._.-*?>\'
M,#(6L59,S8\_VE+#(CK1\!8LW#N0(P/5L4D+JXA6]$^PN2OFF].NY+R(0M,[
MEY'[785EC\,JIXE.@_\;G6/AIKZ5VX/CB)-HE'N/EM_&/YV'OL2A)A&8=;%T
M(K>G2G'M/:!\:1(!28#PDFA3)ZDS<^Q$@;SU))IZH/Z&"<FW;PZ!@24T\@0K
MAH#2'/')NHK_WF+\ZE%ZCE2L%'A4.\JYU6.L< RCP'.L9Z!H^^<0)^)A^@*(
M!/@Y5M7$7$(EX%M2J+_AT0_;3L)3TR>?T8J^8^Z/$[&PC8C%8*J3L[M!J3@D
M6D0J/*JVJBRE+\"7]H%,CD/?E[<\51&O.*^FU^2\6P^>=!LNM5]PE47+516V
M"+R+)!R@>CX.P^^$29>5'=<R0"[^ Z<I&3E")_"94ZWPQ6$02U_)A@L0%!CZ
MP&KAJOB%4O1W7CB,<;8<W;6BKFS4ZOMF]-EG/VS#O7Z1#E'J%R]!''Q=J<%F
M6)^]GCNLT[E5V56DJ9;O(B^DLD$/DNDK8@.FQ^53AKWGP+:Y<DB0(*FPH$H;
MW]?+R7E=/=QQXKUQ"=\<'[8\$<=P-7[6(N_80=D&["E^#3';>AS&P*A7\'>F
M>MQQ51N*->(XB2V!/4+G#CLON?@96.I7<'=B<>+ ,N^I\;?'O;_(AF:;$,$T
MX*E,G(.-^C_%&5EQ<JRD/+&%LK-B/",]]UV?.:RX%>.X+X2[SU26BU8"?!Y(
M2GSK.^%=0=]W&/*4N/$7)[I#H?/%N0=6[X6A7[+A%#;\U<$'?JN*WX8#3[J@
M(JLG# [YGY#"-F,5J'JF#C!8'0^+-?HQR$>BZ!-+P=G*/<O5*;*K%LCZ6N9-
M$\%D-CZ)]/+R%J6GGF%RMR-=I\-FWX2^Q=J*B%4&AC&ZL*=@J@!_A%V/2=-K
M.UN?I7<[RCQR0H+@&V0YM*(%B-F'+R!)) ]ON'2B[UX0AX$Q5DZ\F$;"T4/U
M-[3LH8%2<AAIG6?4-[$"WU&MG>T!9 6GWXZ\SBU:."T2>VJ?^$J\I%&KU=16
M$8\K_J;\-^^!JDFY#^V/TCT1EQG9!9RK@M.H"NO[6_@EX3IP"I&]O]9&]IP.
M#XN,4:O?&M^V8LT>3L^K@L6HG*3'=?FTH31,-E/][:$,L1XBT6A1&OR:W^&7
M, BYCP,LB=1V@D6"AP0$=!2!)+2UMU'P)ZER!ZM*@H0]Q0%\TC(&0D7#L'[:
M>*HMD(E:@B(0EW2"JB]-5$=B%&)9O.R'5,/R2QC3]+#*F!EQA2O&<G(ER.P'
M\HG!8W",,+>*J XPI0""U/@R)869U6:$KF=T&SJ7 =8-@86IZ3/!9:+'W,7A
MCE101546UAB3,>T&PF:(.UW*WBFR]Q3SB7BL,L@Q?:9!7QOSQ?9QD-]UINA8
M6Q6HY?GV^K9 N &&SD&<6=4_-F^%5&%X#K8"F<-!XL.->G*&Z,LUT2IJX5(K
M?7@5NX%,O0O:YS&.IQ3?0F!Z(R%!&/K N=PZ2%D6K!G\ S,J--"(9=]FQB,#
M?ZXC[C.WZ?%MC)E%W P[5\<M0P.P:N\1F4%M>0NL@+RK91FLGVTCV&!IRT::
M2W^/16@]V$\)]M1 IOUB'!HB?T77SE7L.D3:44_[-+>L/UPU0K!/(P1QP!!>
M;!P5M= Q/^6ZBL_4^TWOR$[9,7A_CB5/5H\1RSJ6J74LS;*.I:QC>;W %DL(
M*(1DH;6H>0=5Q*]1E0'S<;59W>JDT?U)CT//4T>)J^]&NMGR+DR#,98?IXX%
MEI^.VCC)F-KH0.60RL-A;PF0KW<K20U(-\2D EBKH/Q"K,[FAF3LO&/+R?44
MFA&9NE)![^LZ;M8&9FV6A^)CW"'D3C,T^G'>H_AT="8DF*7A2')7#Z5!AI%T
MAD95IC'9U/?6@5<3$(P\S(2 C7J,+UE!UR1=WK769T>H['H*KH#]F; JFL(4
M>NLI>!8<P=@;H?I%8# T/Z8$AE.[8C*<C)R$*X1C[4I<WQ>G337W>JK>B%LU
MNZ$[U"@,V6,SD8XQF^ST0A',.;ED8$,<9H/7_*GE)3?&7@T3,DB 1PX8]CYO
MK@I'JNCFN4/V/NR2QFGIP+:CT\*Q%M+PWSR_SZ&5X@I^P3RYHF+"<WM(/[]2
MW#<:Y5C>$]+AUV$@*>(!)IC]A_JN22G 8=,<"PJEY=T)CQDLR@'898B?YPS(
M38JU%_^.ATB_%]=7ES>;U;';IFYS5M@DE -%MXU"'%:GAW:IR<WC<)U);/19
MU&%^ TBM'0[!9;:F5YM[?/ERS"ZF_4+T.=Y%!R(O5>B/IF.%4=(-P4)7MXF8
M6.N'AX=H<F.#@AF? ]M7LSR8="GVGO+*)V^+#S,KL>44:P%DM.M$#GJP:RIF
M2V]T/B9"U0[GL&0+)_O0XB]E$,0C_\[!- 7%(7]N?Z0"&HOQ=*)LR4!Q*\)C
MEYX$X2T^1\Z=2A@^0@DSJ_$7?QWZ(U7*B,>F;IS"! (?\(73G&8XT<N;XUS.
MFPS<M[TPD6XO 'OWUN38JN*3\AZ;2*Y35H3T:JGC21)53,N>*;J8F'D<#FB!
MH')\'UQAZ06P"[>:LU!SD8^.-U*.HHT9D-5IE.TT[;:D-.2MYU92?U\%^LBS
M5(-FE>D2!H%JWB('5U5%D,2(;GDA:1,7.ZY<7&&J'%0L7ST5_-;4E#*'IKB-
MU5P:%.7VG'%/]O3Z^%(<Z?B@BH%E]*2E/SG$)P/8<LD#=J<DYV[2XR6KNS_P
M_OZ71K/QX7;N<-)2B::V]O_"J0ZQT;TB+GO5$V3TZCQ=VJC5FARQY:\*1)C"
M:S'3U,,XN<I_Z]\PXMW8X\!+!8Q;*S*5ALF( C &ZF9K"DPIU434RC*Y+&I0
MZNI@3^BYY1S&3> E&*2%0^F9-U!OJ_H/)P<64!'#\,^AC ,Y'F?FJF'%P/15
MDW_/^XH*PH]L3I@D[W.P<3R,8Z7Y;KKZ!)M:$PW\HNY%+YYYG\GX$JE;_(&;
MZ)CU3ZK7;I4E18]#[+1[T]X4;X940M$J^]G3F%2_107G"X)";H=1R9OS>?/8
M=X8=\+G@X#W,^^J$WJ/]X F3%TE%W?YYC=[K<>>I/ODP^SFI(3N=\3YC][K]
M</T8[<$]QT..>[(/I]O./$A\23K5B5M3F%IG5;85! \R_W@47BB,ZSOLN8Z'
MO@(LKN^( (B)TILT:_$.TS+P 5(0QO4[G%VDXGN'>G^QXQ^586"E%;,+\S@F
MH JXZ(UTWN<J7:'V\*D&265?V=+@:8!D1Z OK;]K@0SA]_M.DF"$'&&/<DRL
MU%RPE\9'83#]4F=_7*);"X5]NX!594_#5$^IE=/VJH1CS,4::&1P:64TP/B)
MV4I]^)C$2],(N_@FAHR:.8MG]R6_B(4J-)5UELF;4\D)FWG6.[6ZB)Q %1DM
M7_Y (VTL(ZO753M0Z8T=9;."/FORGVH'65I/TT*:>C*X"T Z2$,\IC,#N06K
M.*+B'7_K?(1G>@UV8;MM4UO,;YW>D$!F)A)(Q*/\MN.;@!=N92[\%D9^YQZQ
M"6RRM%2YVM%1SEEDM!H*Q1R]@T9@\X/XXK6I<07><?@#;')N+#^2_JTW[*]>
M%F5%% _J:T?Z&%FYR$XJ/4''P@?'XS3^LY"1R!6<Z#5<J+NH6UC(\.,U1[YS
MSQX0T,E%%'GN]XKX!?Q0%25CH_)ZF(!TZG8E]KM/1G>*?8^WW_A8OKPEY#45
M_LRBME6I88;=P4KN&]V/:9GS$)Z=FL&?0L2B@H]PP6,)3%QRWBUI9RG2:QPS
M"D1CO1A\T:2 -8(=8;]X=X2IX(5C:7RJOK *+F-+7#_XY;YY/L5F4)0$GO@<
MAIT(,??Y7:_"V$F\_'?*L.^OP+X5X0[[@HR=2K;L*\?P3"LUCX;N=[IA>I4:
MOIS>KV3Q*2Q^[6##14=<5=- 6Y$ :LK/:7PNAY.!0#YA\L"+W3 3_;!LA?9P
MA AX7;!4*NG=#ZU(HHESYMTKNX9[)VOX4!;&2C>8*RMI.%%79^O237MQ5BRV
M[03?11SZ!#]U!+\<@>=JUZ=/KB0-'.DA)Y*LPC%[&M01' *8<,"'DQ402BS1
MM92$!LX&[>?ZX9!&=P\XHJ, (4DSCZ]EL@Z:_3_Z47N Y/>!@01W<].TQ'0O
MKN2I:<%2)T&E@VKSVG6" (GMG.0;><M%V L,NWTVZ-4=T* / ]./I,B;;+I_
M76")H(IEUO:4J;A7R7S]?J:ES2&7HXP);P5:K2< I6O+<^P)XW5.5@"'B&VL
M+E3?-C7K](TX-J,*?_$:Y74H[#?S9Q-HS/'@.!NQEWMWBQ5,]((SEZ[5B#&M
M"< T.%3 ?(R^2U]:Y849&U2_L558^%G"@^;"DB^D)[.LTLFOTMDIJW3**IW7
M6Z7S,@V8URJ)5-][YVR"W LD"''*QMT'*L)E$$S)D.(Z[V4W8JY6>W-V$W,
M2#2H-+=33'8PCX$]*L3?&",Q][U0A/>!52D$](R?HD 4[^JUOVTR9(F%94XL
MKB%8U!0%"VT<[6X/T<7I8/E"<]K*K-8(?>D'!G[O^O2X:ED<DUW8JDPVDDYB
MFKDGUAQGQOR,(:UWAZ"'XQZBM=!CW7"@.H01]3J[W5AR3)[!B-XJ@VR,5^MM
MF+?IC#2HD>#QFQ80.]R9(VNT1L8457,0*9RX;+6_0(EQ''9(LIXF/0S5EI+
M7H<94(3@0F@SB['M8FQQ)"QF1(M"#2E6LB1JR@'MB"U^06'44EGC&''K.)'Z
M/.T?4)\3E[ S"AN@@F!C"^6<ZB",#;@Y 6^.](R%>]D&VUE61 8TBC:E@Y"]
MY+"^9X1V-"4^B(V/O209O-_>OK^_K[H\?4A'JM!#5N!1M+A[#W:FPX W<NR1
MA%UZ[Y#U#DLF[% 'F++#C)F$/"@T^T9+Y]&5A$NI9^%2ZKEP*?4"<"FI0D K
M009Q+D9<*2$FH5!2.( $74W:\OEX)"0Q%$K]G9P ':&KE3;% 64,>X,C*>!B
MKICU2!!1CTPZX+JG:I<V\L^3Y HC 9YSAK"Z4?)5#E\ULGS5R.6K1C7%]M+C
M7$:6Y8W^B\)TG[#,T[+*%"[\2LVSLM!D]#&5C/@X1DR1BG3!N642(SZU.I]V
M>CYA>C[9B5%+YNBG$=C+\GG>=-1"(>"WX8I/(<]NZ/OA/5E?Y(50Z@L1^CD3
M8KET%G8_30Z+XR'59:H:D=0-=&UACJ.-8I[DI\*IXW"D[Q>,,\[OR:&U?VS4
M-@3&J 9.!RG8_ Y&HFM^YV@6< V%?/+CG;-CAC-"2^/$E$D+U 8_=!3LYZ0=
M=D8ZII1$UK)^8?8S"[O#_F_7\375M<,D"?N/7])D[$N'N9).+L<\X=XZW+@#
MFYH>7=)9P"/KTY_HAD@1P3\V&O,#Q\^QHLGHN;W&:8+J*4^<G\72+YE%H@?+
MXNM0I?.-\E_^@2WBD.Q5_&S&-=$>K,CK+^U5%[+O>TO=^)79AI+\2O);4?*#
M'R/PFTN3I3195LMDP>J/VMZ'ZTS"JBU+ V95-$A)O3.H]QN5/( ?W@*QZ=R6
M9%N2[6L@6^,G6F/%2](MC:;2:'H=_*N,IK,X'H+N^7V J=>2>TO%\UH(]_2'
MC%QL?B"DQC)>69+OJR+?*]E7F,&M.\?S,155$G!I/976TZOB8J.$2O53JI_7
M1+@7PP1A0%&$EH1;$N[K(5PL5OHT3'"BZ9FJ62H)N+2;2KOI57%QJ7Y*]?,Z
M"9?F4,:5DFI+JGT]5/L[%76?4D%W2;FEM51:2Z^*?;72$=^<*'((FZ+DX5+[
MO!;R+:FVI-K71[79IO22<DN;J;29#/MRO^46'R5<-OB!:)A>1T2W[7>UBL#_
M-E\#EU,3/-;?+DX[J>94>_->$^.7-%_2?$GS)<V_+IJ_1.""DMP?9]LMR)#+
M 3I%,FO4=BJBT3R _]G=W5R@N;<X2LY2[>ETX T:"<-8,#8<XBRB3@_\&2WN
MF?2[O"?N_2TK%0B=^"4%Y,;'9J6VLU>I[]<7MQEYRUCT@>3HBARQM?'Q77US
MY:CDA8_BKZM'I/7=:KU6$F@N@3;>-(&NKN!L5 [W]BK[M=V2+G/ILKFYNA;9
M[BX98Z5%!M<GZVN5%70/'R"#EN_*3DK!#9YUUECDQN8ZD ^57HO/2I1475)U
M2=4E59=4O9I4O6)FY+(">^O'[4W@H$XX1*C<Q[+[0MW#XNM?1OQMG..;C^'X
ME]S/-5-M3R"?E0O6%5_ZHH-Z)=6O%M6OC8A?1J3P=1.[9>?!CP9I'GY&G!'^
M>47A^<?.E-#X"X/H3[%GDW"0:UWJAQP49V"^U-J]F<,AGE.^4"9M;D#1&2;A
MC 4^&_GE#43>^'A&T\8D#BTT_9T<$A4A]S#0C!#GWHDZL<!6[GJEWJQ7F@<-
MWOVXY]#,0YYOYH;]/DX3IAND\TD:M=J!P((.NEF]<EC?J>P?-GEWEO+>#UI\
MG1=?'3_-(DQ;LM.SL5/C%;$3$LZ]AHEU&"964=: T,^0E:;S'%#D7^OU:OV
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M<7Z2\-J^AT']P14YW/UH];F;A"XL;3,GNY(&5M;?B@MXNTT5/:M08+HP-'O
MM+_#;%E9<\)#8XU5NFOZB>(D-2UE,$^LS-F^@.N0I8,*EYWOFCL)"N"Q;9Y
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MV5F+L[-B<^;*%9)#ZA]*;78\1.FRYNQ<UL4M-N^G!DP#1;I==6YWU81_>5A
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M[#F:OV614GT2%-R8K'%,X3@NB=<UU^98X9%FF-SM[ATHA$E*?"ST+]3 R_C
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MA_E/QM(],.\"4U=L1%*/44W>DM-SL+_>/#HC<H<3[^X2T133>M)9AG_SYB]
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M^?CCZ/\EY,H^.NYVR\OI+^_$\6/LME&-B+;[-#^(FI#0<35]GYP%30J9BK#
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M97(-7I'"EG.UPHZNEV #!CQF?[)L84&V\N?QYP'\_\$S!?!W[G]02P,$%
M  @ (H!<6"+[X(-W8@  ^&T   L   !S;&ED93 S+FIP9^R[=52<S;(O/ 27
M0""XNT-PET" 08([@P5W=\D$"!J<X.[N[A#<'8*[NSMSR3[W[ON^>]VS[SG?
MNG]^/:O6FIZGNJI^U=75U?,\#^0W9 WP3EI"2@( !04%T'_] ""+@$\ !#@X
M>#A8!'AX>$1$!"04S+<HR,@H>!COT3")\$F(B? )"4DIF6E(R1DI" EIN>D8
M65@Y.#A(:'@%>=@$F-DYV/X(@4)$1$1!1L%]^Q:7C8R0C.V_W2 = '0$*'2H
M1V@H<L ;="AH="A(-X $ (""A?I' _S/!O4&&@86#AX!$0GYE:'V'> -%#3T
M&QAH6%@8F->KWJ_7 3#HL!ADK")P[Q6_P)/;8[+Y1&4B4(A6=F(I39Q1LALX
M^"(B8>/@XN%34=/0TM%S<')Q\_#R?1(3EP!*2DDKJZBJJ6MH:AD:&9N8FIE;
M.#HYN[BZN7OX??</" P*#HF.^1D;%Y^0F)25G9.;EU]06%1575-;5]_0V/2K
MJ[NGMZ]_8'!R:GIF=N[W_,+ZQN;6]L[NWO[!^<7EU?7-[=W]PQ]<4 !HJ/_5
M_H^XT%]QO8&!@8:!_X,+ZHWK'P9T&%@R5C@,$47X+_;OR=E\$#!%HS(K.Q$I
MV)7.L P<)I"P*3G6J<[_0/L'LO\:,-__3\C^">Q_XUH H$!#O4X>-#I &'#[
M0)OU#>F_0@Q=7YF%HH6HS1'+=707]TUEJ=6J#4CX5VWX;OLL_-:75L]5#]'O
M+ Y5&\XZII;Z;^<W/MM'?&T+Q"M++WY,F6._2?I]F\30*8"U:>WX:_5MZ37L
M>-M\=J?3D*,SU2SAB9?7CS%H4J/;<LESFA_.Q7C6..(3Y V^EN :P>WKP<XW
MT!.N8(\L%2H\#0OSXM14K)U/&POI@84;PD<5S%JW1T(B"0C=Z2L?PG&PZM?;
ML2S5!]SM2\WCWFF ?IG@U''OV^-U#. 2[N+E[(TP5!;FN:BHQP+/'6Z/S@[5
M\0G1[US,OUO2MB@[%(',7"*F!(NGJ=$X<WQ7%*+Y2)@_VR!)KFVV?MX?)'E'
M1U/)A+4& ?R><E/?D/ QMMQX*[&IE;;IDNOHLLBT'7I9Z^!NP+,8,\JG7G=@
M<%R3W#,U6+KNWPW;!-^Y^+!1Y#1M;=H@H<XTH<<*ZLM?_"8@7G*7+'JN$,_D
M:5=R!C=6/Q+1=U6VV^LQ%IQU[NK'='6?T1HNAB$Z8&<8\J"03=6QU]JG6YO=
MI3G/IBK+)1@=LN64CJ-C02PTT\+-F:*8ZU_BZ%ZT%6>"'!7Q4>JI.*W^KIKF
MB8P;?[DWKM3U.6O!N[2$C62E'9<RJL]C0#%Y\:%1>^_J@:&GEDB^&R<=JX6$
MN#8W+]FEF$XE9',XY*-('T4#!8RZ.$[WK5[@0UFSNR&F5EJJPVRT)B(J2O,W
MQ113>-ZGM\J95):6]G39$WM%2=ISZGRR.;?C.=Q*W>6,DE((W4:AZ=)GIV^>
M!*>>3$U+5O4L\%-P6"W8/^'Y>M%"1]J)C-',_J3+2XZI#=B:*?'<QMI,>W^^
M/>;_1+-!ZSR0.VTT?NJ?VXQ]O[,DJ4KY6+AUA36Q!WYGNWV.51:V\99Y=M3R
M=Y*,)A/SK#.5A#07'Q?=X/>9[KS$/4SU>+/5]\ZKZ#J(3JGP\FG#HP87(&6Q
M)B14;DQ!^I?LPGG0DTF%KR6 !A\T:/NV*RR$V]BK\B(M,*TF%8_&1,CI1A I
MY"+^KKAL8/WQ%&/!38=$)#B1-+7,GHQTTY%:Z,1M,U>O[2ZJL--QW=-2$(-A
M*,QA:$PCSCM9#^ 3S5KC3'F#^?R]9S0"F-6P"N<V^*@WX^Q-H#Z%T:4\A2?V
M [/-@,5JS>_N:^V\FL./']5T_/Z8BDHL62&T@/\'!!TTX_6A0/=):^+I(YG_
MU1 (D32A.?24__SB]O%7TV&RW8)W]SOR0K=Y%:A76]7,BAQM5D2E* ;(SE#;
MTF&8O1C'19Z+*1=G!-;KB2WJ5QZ@E0[:D,^YGRB;;'*MC7,/(H%Y/69,UWB(
MX;,? <PX,-P"YR,>M5CY];$00%G.!<60@/ ZVON]-)AI#I>I&LO%0D[X!*";
MS"<!V?"/)$Y;]FFQ\/YMA!:*;B&W"LT55>,EIE71,T=6S/B*=/:^?0(HIE=8
MARJ*Q]OE"0X4W1SM_@MM:5^F\L_J VRSPC]SY=LS)F]%"(Z3M$9<KK3&'8R-
M3>Y4A:C7K2(&4P:M9_=W,)S0SV"Q%],U5Q;DN*T^D;8)S8*KG03!"E7QP*F3
MGHXV5*T-_9S-<MY.0;"V>HE%'8W2I,U1W ;()(TZS,0_I,4H'!=]2760-E6=
MP?U-"#!<Q\UR(W8TF"; QF3BU$KGLYYM@\'DD>#]+L]IZ.-L7.T:D\TO87C9
M#.^T!V\H:0Y7-G>#SSZCWNQI0K$''*J>[BZB6\ D'3?'G@?;B'*!3UF+^]5A
M2I,\ICCOV7ZX HQ"T1+>"./W5-WIE9,$3II7#UBC5EH7$TG,U)^$RP$Z^SZO
MO<0>U2@4#U@_:_"B;^=WK7#-MGBNK[ZSY/)PKL$FF%FO2ZG\*'+?>!CM@9I0
M\E9>-%#U;J5))VS:T=SU W8Q&,6Z44VRDX2+/QKX?*V[J<D'#'"2A;,,KFEE
M6YD%^27J<F[?C^E]OBD*<VD[1.R8+<<=KT$+?L&.4*B99'1RM'5VI>J(=G=E
MBQ-T(W6"KO44Q$JAYZ$N]?RYZ3@(_\NR\2O) 9_U;"9FTO;S[[8X![0X(WC_
MZSZ:%&?.#]^]T,'&Y2+N[NLDJ.;!-CDE-Y/]%XDL'QE& 3><!RJJ?)?F^=/:
M0>>V[[P$SVF";+: 9[N!5C9I^EWJU:D3L8XI1R?>A_FM9U^S/W1[$NDJ44VN
M31*/NL]# &[#JC[\WI>Z_N*H+6D^_1&I-B8SK['B419L7K2GKH4B'NIJOV3B
MCMD@I!%1;72[QZXS$N'/"2HU7#\IQU1,%N260W;0O*F*B_B&TZYU:'0'7J=S
M_G",*""L/R=^&\_J;*OM],R0 X#ZQ@*K?9C7NBK<+4TT2M'5AC=]=1JL2SU[
M8ABJ<8"(6V\<B<W_<11H<;R75?$S)77>7(,V*R3J=3E_A/TWA+<Z?PN^PDQ^
MN=.2/SH<>T"2AP"\F,P5M2$ U?S=V_9+KIO+B\?X>[SV^;GT*\ST5S[AZG+A
M/3KAY[/:7'&2_V!"LQ7^T B.DB!@2%B*GZ:*-,2EIP>3Z]W?@?M5KA2O+;Z"
M/2$ -L)%5R-BL?;+,P@@,KL__N4KR066(*:W5GKZ"@0PK#WL]Q^_8;IC0 !C
M72^B^5D1Q<J7CZOW@>QTG*D#!N)/&>^GS#9BCM2%K]#C7^ZQ/$+V97.-C/9[
M(("NJHC?9> ]B@_/%[2/6&//,,800)NX;E8Z.TYUQ-4\\'^-P2PVM2M!;(_]
M=J2BND"[8WAC_Y+,</]'X="+:,2KR??@?M40.IV(6*RG8/#N-@1 !HSZ\/34
MOD7?@ZD32/]/WH)E<]>I4:,?F@T^=G ]89(/EUK3RDIFO(J!SS\*P>.=SA#
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MQ:/5JW%'BJRLQM7C4O"+OR,$X(=0\+(P!P'LJ0O?L81$F$  >7Z)1%A8HQ#
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MRR1]PC"%[;#P]RB?A>+?$HN!-::5]V%[WGRJGB,2J_)521<7QKX+6,N4Y1/
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M'J"]D$<<>0-? EJ57YY%((!NU3'AE0CAE7R]?;)E3 B@\IKD ?]:_O$:'@)
M!]X(94, GW0+(8"O&:_;"0--3QN+'HJ(P2+3BDSCL,Q-\+!B!I*40<?[\-3F
M&2;YWJ:XY+RR+"<-D\J0969F&\,68LVEW\B(BX^]?0(;A:*V#Z([0.!SQ)^[
M9G-%X-4"X;L0X;]I5*D5Q@AC5Y[(B"9<.&#<,S7I#/:U!83?[[8Z-H&[U\%Y
M0,?G%+(D67$F;)IDZ"'C%6H:(BZCS>N\3*ZR^"W"_L/_&P(^$D*S]XO:2[GW
M&M;CDCN2J<@4A RT%,R(:^@I2<7"$4Y;Z;(7&@26A=L!&YJWHK-Y',RN#"A^
MX7U$Y@[R]6N$_8LO?=/@/<L9X=-IDB=QDM\/$<]O/?*?'_P@@*"2 2_7S(]U
M.Z#"^&-TQ&D"<[;*F&\GK!=T@H@][#TK#,E=:FK*H/D>5ZKE_GK5N#71;'HY
M&6)XN2M:N9OZ-;]$_-6_B<O^EUD>V&_'H&R-7D"LZ5]/O48WY(YWJ>I-%%V?
MF?[20!BR6'\^ZN-X4QJ_#5M#[8YOEL9B"$\P74$0X!EZC;E$W?05@3<J^]_Y
M7K/R[E T>N1$[42;LACQ^V(_-7,7F9C;DA3A&9\J0WI0DDY;KCFVE@Q!,G<C
M*"%JV4=M07T(29YP5Y!UA%GJY@DZD0 "^+< 4ETWP]X,6"_H?&0;>Y>*3[OP
ML3(MO$=DH6T7JR&>@9PA.T "4$S73WI%'J,$*N]@#DG_M^(<QVZSQVYSRZ\B
M3T+ ?^,L]&+G7&^>M3HYS6W%CI<A=) N(C /(R"AA2[D%$X_515@7JP%HZ>#
MIB& "=;Q%QR['S-$3)B*VCN=XI@*\#0;J20JT[6T8;X&O"5;U4G6!R@RE%$G
M^FA*6*#S'L6&<4[/MU("04DOP[J+*SO"].0E18K3S!_WWKTXSVI;W& GY:8E
M"_[J<W4C7.P5>=[I0-:_&D63+EBAF6K9#OA0,T;A'FB$?;(%XQTJ!V^R41N:
M%QM-ENN(O2DZ?<UDS(D=#J**?N!%RBG<$<<7(;>AB8H>&S<-59'*T 7:,K6^
M) MEDJ^T="GZ'HG;W7^F_.';H,_B[P /^.:AKIQ_R(5?7#4O1\6 +VV7\[8\
MM16\+.#2PYQ;HFG.RA$?_5,U1"I\FE&4=(@+7E\X@6AO-_98OVK)K^OF]J9)
MJ:= EK$*D62(G<4<QOT>.JI3GS7F(6EWH[(9=)@7PLZY'%XQE_=F_?.$%)Z"
MB(#1FX]CMP@;36Z</Y +F3"0_2.7.VQ(Z1'1<!?CQN0W]$;+&+(!@X,B>R*'
MRL-3'J@#*;G/>86%%ESU<QYL,L8PT5 &.OA 6):R>^OO?BDH9Z@>Y]KM-UYQ
MW%Q-QD>L*P<!)P.;4<8H-WLY& G"K*I0C0!?1,J0ZP]<K$^6'<MS]:7$1F"Z
ME73N95["W<DB3OP]&H(T3YSOS@2>1%P\5@92,*0ZQ\X$"3I TH&Q$7]4L-S5
M[R>ZPNYSZZF8_F_I7._V8 >?"P9J4#9C29]^C[+8Z_[8H=YHGK,[8._/S!%[
M'"T>Y>79B; FW0*FIR/J+@D^19M/,"K-ZS+EH Y^';U@^ZDXBOF4LV7'/EL#
MKN"4*1ZAWG%-0L1VSVV,IE/WTN_9SA@8=?29FFW2X.27R6UDD33B&CWO+\JW
M,SX G"I+.<,H"E0-%A3B1=T28BD.4"H<2/(J]ELN4!=2]5QH@:3<ZEWJQDM&
MZ.F4"4N&]2A=K$)1EXMB^[[7?JBBK:T-80C&?SQ&I40R4O_)1_=E  5.L%IG
MV/7F$O3)'OF^<KAHX@B/"H3+<[63KZ[&B.5#;_=1D%:5TB^6_?NL +_@N;F5
M@$!<\M%)Z2\3*K)E94M"0H!+Q5KZ;&;+66\A9^E,BPO]!V0=_E7W(J'Q: J8
MB++3#46_COE(#_6,8/1@J.G(5WEHN7!B*%#. SS0'/15(OWA&+?B2;W(AY+6
MDS#MT;W\JD&A[@6.%/I.'=HQJ]:N-6-< @SNP0&/^78[F8$*-0V>L2'KN(M2
MV[)C2U[0?G?HRG2\F-'B271Y8FH+HQD/[X&))$.7Y6.W[H^KTC[A61DU+;X/
M[YF:3Q2.PB)%U)1]$001R/,SWH30_N=49(%OG5=L85U.P2:ZK,*K_2)1.B'+
ME3K.Z8VWNT*L<73UF&P6\#NSK3$,/@/C'0-H]+;LZ^@+,GR[[P'!=LSQ[0?_
MJE@?.%$1&&94<:V7Q0H((,TC\ 5YYW4CL6PM;D[1RGX=DCUZ6Y)^W(QVOUL
M7FNS?:&.^&LGGM:"7R-"J>&=5)Z,?K6$!DOKMP;24#L@_==4RS@AM)DU'?(%
MY&.A7?DI"CA^RYH8RV$I:@GD.9BGC#.&_+^K-/M[UR+&\HN%\GE ('?P%6Q5
MR,[KZ%ACJ2 >):BWH8[]U-4V+6]A>]O?+BPQNB!^N5'S$5END9@H\:M'ZJUO
MKSL2WDW+A !\[]OODH3_UGL?K?;1X=T3;^1^//8MCLLO,#U/Z?:/46%[/^-;
MU@X>0F;6:97\]277*!"P0,IJXKE(YD?!.EMJ1]X,TFA/,"%AC([ZS7+@T^6T
M\)G>ZQGL/?!O/=4QELI1/3=EK5;?_E3I;CU0!U//F12&,>"I!$]RR3ZTV,@T
M[;IV@PG12P0[!N84LT)SN>0R9S^*SY\T%)7-\:I8>-&%Y'), 0+H]%I]DB7Y
M6T_VMX7BM "[+?D^JSF#=;Z(H8N-M#@Q^T^&J/![WMW)QD5PH*LQ#6A$8KJF
MCGHF+YBP_X1(Q\BA^X17 6'-,->%Y-_(YJ0C97'^@'+(-XT^5'" _=85=G $
MQ:Z/TEZ?^A?>SV VCUT!IWU%K3N@ZF1^3>-DN=/>3LBD&96F060V1UACT%::
MX!C/;JD3^-^H()RL_;:S<:9SDVQ.5193N%CBZN'Q>X4@088097NS\_"2&SX\
M=EZCAR@@W=H8G9K?+8Z*:=H?M^C?>83&M<'"TGWERGWE.N:Y_@L$('"-]H0S
M\EKV3?R].WT1H?P:R_EN'T^FO43_XU_W7$,(P/HW>$SP$P0 >PD^YRQ>B[LT
MF6/&IHNFL\7*9A>;B'M#B=<%\/!35-1":7+= 6J*8ZKC3?\Y #@*D9Y=-:W4
MFMW18:I5?6]0XA;AVEO@@BX347YJGI7S6Q^Q6@;)%[;$L2,P?S\UI==O7K+%
M[1= 'ZN7/OI0RV_-/_B^.I&*$H@IJ;/D$^,/B/&9+23!-/_^JY*S^Y31FE;2
M.L<%J;2V'L"6PPU#[*A5*!\W\&ZRM=])]MT^_@P$$(,Z]-[6%A.F38JAW<5S
MEY%7T%%SA;JJL6'&UB#85? FC*FT@.G;ZR;4*/!&!/[EC3?#ER?9//BP+^8G
MGR.1_1\YFX<>JR1ACN$)_?ITZ>=GK(2KU%4>I0DH<*-,B)#2TNYW\[74HUW-
M7-0JNPZ$WLTJ76R\99%HLM08V"JP0U$2B.*(@GJ>1>AVP:/(H_?T1E.M;@YX
MX$?4I4JR IG@SG_Z58!+GUK$_8$4PWW,@2$7C&D>U?LY8)L2@U+W$TB2BO%^
M\<*0AT?@:FWF6%BI;GK=G2FQW66'%WT\FP(UHW"+6.3)(E5J4859(X4J\/LU
M+2/WDOG>1?8\'OE*S@BF?4&TP"[N$KO?-Y<9<P[/B./B9.!$RUQC9:.EI"LU
M8]<@UX4<#OS.O8-ZK0?6;+FA,66AHUUE0A;&0*1=D1R<]\ ::CZADJ;%3?PQ
MF\0DD)$4CR*-*VR:^'L 8&WM\EA^8<@3.<K*/MK-89O95FF'E2CG;)"YO*RE
M_6<LKML2T=T2U,(2BIT;9I)-/-C=UKCDP$/]QJ<UQ)R9B:V=,J)"XK<#'!>U
MH(3WB >440=L_,Y^S&PRY0 ^/V&E^)(JW$[?N*/RL<8]>H>VF[P"URT;:/\\
M=_I6O6284J>7CLSX(T@@;-'M9D0]YM?#\,)WJQM* RELX%OBWN ,(SS*>,/H
M1EU,PV^6XTS7#*!&77YW@2G"L/>Q2J)\FZ1I?4G5.\#JK]>+AVETCYI_MG:0
MF]J35G-92J3\COD&F[2->!!-8B@A ($&NM3V#B3G+42[D2Z)?6O?09%VZ9%>
MP^7."^]H&C<$<"\5!&I73FY)ENG*<P[ZA_,D_HZC_("$IDTR6+*@2[4D9-''
M84AIG40=UDX-V/B93UT+BYFX6[W/[2&4#.:IQ3Y?*-(&"<[%[PK^DM0T1 F\
M#>F('7J[RNV5%*<'MR)CS2]E%*,M96OFU6O?/'*Y(%4AM1EPN&2O&]B(;#T8
M,X=70#/-Q)03P&LJ[K[4A[%+]?M--YH7].O49#A0C#%S:'XY)YJ),<O:-ZYO
MX;(O)M5071 L8?NHF'*UY8+E@O9V57/5/5[+;)H,%!?G3*SW(&6&#KT>!%/,
ML.LB]")AV2*E.(.P5G6"U/4V(E?<T=O:%"U5(-,0M6!DFLX ,,J'$C5"/ N"
M)^<AL(5;77][G*(\S,PH%97"BM[W4BDBL(:*=ENYD@,!?+=5JFL*!WGS<$PL
M#6R5I"DOENB9F>HB+N,A.2!YON'!VE-1NIE$%?OB9B\S4J)3_N2YM%K]:4\T
M*_/+D:96O5E6M<U13LEK0B'[OSU,_=\EW*34UFG\X[A26ZM;<T(,T!"*5>8T
MJQIJ<Q#\STZ\TV/-"0C LF<#P=DR#%]"O3KN _W,>,(EK?';QF^,'[="0U^<
MVPLL(LT+V]:9D:P9M6B)/V8X4Q;P/%D*N+5+&%W"3-V+4$1M/W(D4ZCC*?79
MX%"D>;B6OH^MHUIX3,#^BC4[J9G$,,^QOU5)9OPMFWQX2HKZ%P*E_PHO[JF6
MXGY]Z;IX98Q4'5?6O($W:P[9!<(H-0JP$!YP-0#7Q !:].SBJ8]QK__9]0'&
MV@Z*(KV@H*S6DH FEID9FQW30),-;3#G&.^6YAM?BK)CC"<\/9# ,>M@DAPF
M0C59/OP&<1+YQT]N],VOS^$$_'8* )  _EX+^Q=[0^P,XW"WK(8F]D]$W;Y2
MJM(%_,DTO/J26VOZ:OYQI>9?IRCE]BEYV,0YK DR!!'5 &L/CZHC7>% 0=Y#
M:65K3=^0I4W;FL?$ZU(#G@[+=*')EV6\NN!H 6/VQ5AAT:[9_!F#&>=@TM@K
M!T:FW;"MNMBIT48% CM25IV,6-+W _ +3:4#88OQ1.'FV*KFNBRX6+U22E!C
MF:= _B/"_)\'-TS&YM[6WB8Q\LYH3S+'8D-MPW@)_@IR'EB/B8\-^R'3;6=Y
M.;/U\I8&60<;WI^&[0[P-J- 0S"[F?QNQ\>Z 2[8> L:#H(6R$./ELC IL:?
ME+2JFA5RB*2H:5NJGN9.HEM *,=U694AN[@X<J;)97Z^IHQ8HXL@;;\TT::M
MJ^)*-PO+UJ\$P4X_ Z4N<^Q-F8>!":(VM(AZB<TH5V-:)WYOV!!('_"Y:0^Z
M\CQN<H^-"(/6CI_X2T9RS"T=J )."))5(TN"M'BR1)'?.* -CQRJUQ[3*&D:
M66J4<9)P2S=6H4Z2-T0-QC+=2JP@]!.JRUJ"+3VB!5LR9WFUL'DH=I5]>6\+
MC1/)0J0(4\CC]+-IH'\[F'M*Z7VY*"9\=U964'=T<T:)[[?2C)S:Y=!M'0(=
MZ1AVMWG>(TO];;(LX>:% +O<ZBZ9FEPS%#4Y@" 2MWQD^KH/:[%30)T%*,!,
M&2*.&IX? !]I(?UU]M45:9INMJH!R&Y&KR6G+ :HOW[%()V:,E@U:]1QFJ6#
M0.YHMY1E3QU?R(^<,ZF;9CQZ5%P"9L!%#I.0)+%J&:QU94%[4\*+3M0DX#(!
MI+!Q_HC7*DF8%!W"0/[KWQ7L_Z1-)\_R]P</*OC?9FKNU+R[):PTZ[YU.U_R
M[JNWC6U$/*#NK]XQV[[P:O&YN-A>4J3W[].6V1Z]T$( &2>IKY7L:X&\^=,[
MO8?DBFBJ_4Q[]<DA7%YX[,DO^?]G_'_': 6ZRX@4KG<Z 1\0OEXINS-4:)R^
M0F NQ^=J^$#/+]&L<AP53VJTZ7^=LV[L&29]TMN*J:B@H"B."35RE_CA@PV3
M$P10H3V6*V348H9DHDT2QXA-0G?0UX![JI&4%^$-=B]I,E_X:?) *UXW,$.A
MIMIWJOX5 1X/EQ=K=4)+(CN\NV&I;YRQS&I1E9OUZ/)TQ6Q49"E7P70QTA+C
MYM>.M:6ZY)SW>&--NR^7?IN3_1HFS-4VZ)QBMIF/A3W%44HVWVY[LH^DM*R\
M1(QK[Q@K:X18+)G8!< E-[*( %,&_7YITT?#)>W];'BB4X2-03,(SG=^.PHW
MD[U_4800I;?#2-\QG&&*MDA52^WC6N*.XSP1F^2)L\R7YV3*:*RI'99?R.X?
M;57>5AC"&-H+G+Q)_))Y.&&._1"7:B9^I5;WPZ:J'TK_"VL_*KBY@5O092Z?
MC2&4+X#(3L+<_-'4VK\_0BCB5U-L7$74KV@!11G$^D:%=$HI_$*E[A,\LJH,
M_9/#.9R<LZOS)[8?DA%R:LTL7;N@8OI$7+9XV.K02#3>LM&0>#6YKBT@['-4
M(>@ J% [F2L#M/0/&2#"RES%I[6R68!FP_@H8"HXHEYYUI9M:[BSM/]+2DU&
MF(MI<(2##JDX@W*3H-=.$M[:@PGSN1B'7*#!#:1QL;68WZ)VX9T#6LS_>6PS
M1F=L%??+6/II*+JAE\%B[%/35"WE]*X/>HQRFN>/K,,8&P-2C%> J,*$ZK8B
M@%#T2#-G$*J8@9LTGOY9:[1TB;^?9,&R*MX0[1.F#\A)4;/>U2&ZJN(U1 +^
M]GS!?TJ:'CO%7#%&IK[CRU*C%!BP-,1I;36;.#1&U)/J)FC?<Q?7904\&""
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M<!QI@.LJGCV+W<+WOIWQ(P@1H\>7M)IIV$$.Q&Q1O2MR$:?A&D6M /*@E"@
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M^YGZ!UM[Z.S@"3?994"$M=;A0FI3=2Q6IJ?FZX3!X-0>+'U]!3%G\BD8B<M
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M#*[@YN/$Z_,MFI]GO.YYY^.$!5NH"^<8?KPP-_N3"O]H+O;U8>&,]?EXT_7
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M>MF.[<'6%QW<)R1$4V4/#B^;Q7KE@P+0/*8]ZVN)+MBAK+(L3]4BAE$"L%W
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M&Z%8&(.+_1)B[VHAQ6DZ1SZ-=LST95B>)"&(4CF#R@NX5B(V+/1+KFZ&HU^
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MV@!!?6HYU;=8#Y.AF3 7@W9>:/?\4Y9(=D]UZ*2FSLB>6V+1W)%T-$BDY<M
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MTCN7_YO->4HB,]+3+\KM<5)O"G6 N%3J\F'1]<L:5TAM)JEDZ*4]+ERFT&C
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M&8J4.<4V$RHG;>$C%GY#E07923LH6^^"/8A Z0V5 [KTL9'Y2?#,9:MUMY%
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M</UKQO(K=R:-'WU"KJ@_U(,NR 8H,Y.6TVSJXAO2#L8,<UKN/6Y//#JG/BU
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M'TG-A;YN8A' BH&\0QR9WY;%13#%F]*WY]>"!:,$7@C"_PBS(U/[DXN'09\
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M94;CU/.@+?C4X& N^AXIAI8TF H7U;&/C3T1CD ! 4G=\2IN5\Y.5E+NZA.
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MN]JPN/IH/AZBJJD#N8#TC#XJ5&=:*^,Z%7^HP[5_A%+.\@:TC0U=3U^F-*3
MO6"Z&HL]&5[?^FE=+TC7_.G@O>GK<=&/7 TS>:!*AC2EOZ@'*V*@2*VTSHG
M;&Q[\PDI=G"C;"UW ^%KWFX#!GOGN#[<Z*DDC(+#"^75HF,?2;!.&\*SVZ/]
MY;3UE!DD ']NA;F\.2+9H?FF;L5N U[]$3$*E1!>'5'7PD&I^:U#[T6]93*]
M Z]&GX0\7S=9>.03H.O*,^&9Z1CS&_+>B1,PHV]2M[AICMW)E^.K"@[/W&(5
M0&JMQ].JBLS@E=OE9H,]G%GK:*;?_-\-.N]-0KNZI!BN2]='B"1UU=+?DAT/
M!ZI2<UBJX2,+VOWROKH<Z^12FU=8<B[6'_N\T;[T)?<^5AIK \KHB<!6NK9[
M*%W;JS!1#MJT"AE<$>F\24=Q$;_8T\8R+%-162G)J)J2)/\E)3%S$4>X_YR^
MM!D$MLD,#7>^1TX8*.Y2.<'B6H\4X#X=A,7MK6W8"TX''3;?DDNXRL7FSG'D
MP+5PT=P^VA.@I]:VLL1.V*+/I9)NC"$Q@7=%A.;\UWJ)+UE+9(\$R%/</@P[
MGK$Q+^Y-FO9+:K4A.Q2#R:V.B !"J&S!==Z&$GS>0&Q.WZ\(41CEO_R8G\-Q
M,YMS+6UL0@Q65YMYU&1"X OPR'USZCI#@PIW9@G"AW4?V:;OU9W9E^SD\C"^
M\1^%UL7'7R#3'T;N^;^PBT^%..)[+9O)LL[;?Z58_'+D((TJ'2-6;Z\N!VDW
MI5PV./91)=$TE._\?^Z"TK^[,Y[EH.8ENCP!P/YN#B8G^*-)XWK U\(\5^$[
M\EN/\/O=%FQL.99_OBUV+--GDLN8VA0LXK]CZ[_(VWW>R0B+C@-R!P)?\TG:
M_/NCF%^>),<O)I2: Z#28O_H>DMC7QQ$M[#NOA*-EU.1V+7UD#+8:9(D[VG]
MD*TL@;VJ"[=?KA'?Q_9\R'_S'8ELC"=99-_UJKSVGW=2I]QUG572*D&L'_2R
M])9W"-?PPSO@T8O@T)UIU$7OKLV\GI^]?#>4 V,K#QS2OY\ V"QP>-O/IMFM
MMG$'\WAJ=1N/8$.DIHR'5713X[C_,$I]0=W(DYQ)G54]I"6SK7GRR->N1#;W
MA\18+6? FQV)-XXFCKZZ,NMCX>;=0(]02_M22:CWQ]PNM2+K[SCN3"%98K/.
M3=YQH]%QFK*5FJV+HHQV%,;\\ -P]>_&-#XC;*NFA;O)],NU$+?^\XLJ ^"U
M"7=EWK6).E7M>S<)!U<TWT/[H]:MN_8'NXE:23E*NKSOMLKL_0ZOCYVSN.!,
M62P(^= *[IR&#95OHA$]K<,W(>[]?>K>@F,OI&H0Z/*(M]-DS%/?7S?R6@P$
M]YU8Q[7M&64IE.0S3FN4C:"SDS6=H(!I[U_Z5!I*WBX%@ R].M\;2+3K;92.
M+5=U/0OIOQWX)$V5Q)*H4G*8W@3IN:;^E0 6NP,V^\DX/ 'JB\_>131X^=;T
M:66WW>I:;K->S9[E#ZN?5.^\^YX <L=F.?8ZCH'7<E#XJCOZE3P4K1B)<M 8
M4/'\2'5-3,#&'ZSIZXRZ$5 2\.F@,%8M[L6L;R XBA4^U'.X"1S8B(4<&)L%
M^ 6(270_WCZZ%S>6^BQF*6:@[G2I1(WA[#9@KE.WJLHJ12N0SC1HTR"?'L=Y
M:O:)EIS'A0G;K:M(>G:W,S7#JCXW-^A$/'>T(=/G$@]VX_=_ZW+S^OIP<;_G
M YKOVORZT[+317DLH>)<?>W:34[%?#3>\RM6<G^GN5>>O_-D3+!MM0,]#F-.
M%7L_Q3NF^Z1=OXHF/EO.,,-=&KCWCV5N69\#5DQ&$\N%Z72P7HOG,_9(4?Q$
M>(0()9:@$8KB)+ NQ_3)T^\T5[T:6D,Y-=;#)P!GG>A,U:_C5J;W0>3%7KBX
MB-"'D^XM_Z,F3DCZ.7SO;4?9!T(B'0[]O+8[X*U'[4R)W5+TL]QNJLJ.%R-$
M#KJLI;T*QANYU6_/S/]QJ.8)\!PIC8R<$\*FXN9?UP%KB?K@!!Z"ZQ"C9M@%
MF_Q+D):MPC&:^E\9'F6>])A5>0BZW!*;K-?0R2-W<BYW1QPOJP&FP#\;"<Z]
M\G:3T+EG8M&12?>/1>4+']N.N14SR$,?J1K#!$X(0>/[P7:JVI2O5O#'\+2_
M$[F>.2TOL9^$0I'0PE?MXK#WR;$#')TF*6D4MC:%Q'"RY,5F37:ZG@"26H^W
M)%[/?=+8QV?UH:Q 1P]!5>[PI#ZXCU;8DEL3U+Y$(;<BRVR^ &PZ"OZT,D6+
M,&*-;J=;N"[OTA'[RW,*V!;"(2.^K?6K;R0Q,=MPUO2_T"IL;%_L%WHX4VD^
M+&'D50PV7YN9#?<UJ%8MM17^ICBN./[M](TTMU@0I.%"4+J3'F\@_UH0@IT:
M:;C_P:O)-)B1AG5GX-ZNHP4RQ9,FU!H\N9:_A5-2I;N7E60]^@4'T_R?=Q@L
M;AEYXEO=5"D9*Q7[LB*XHYC_3$HX7/(N#EJZQ8Z5#O3I7%7KGCTSMZS2YX/!
M,A&2OMG-OAHO"55Z=TD=>B52C>DK'-(U/SQ_7%BZ:'L[7=YXI!7]&3VDWN(L
MEC\K0T?VGJFY8=;QN-Z19'DOS3]OJZK25/U'$-,W:@EW$9'^$6_K=/K[<_6[
M7<WMON<0$#_>DAK/>[;U',Z:A\'CNMS@O2E5>SPE?N7JTZ>DOI751$GL,J+B
ML1@[R(66('H,J[H)=UJLN^[$)1 Y;U+8DBGFYD#3F\32@1MOM\W9XK^S:>S]
MWYX^9\#9A/1)KD)#J<=)DX_@W*F^/XXM>0O^I4[N!G9K! - _[UIMT;&!4<K
M5^_;37/!O5NNZ!:KK^:F$D,"R>-,7*^JQN_D^:,SW,K]_TW5OUK^(5-_!"BK
MT="_(6$*W\<GVF^8GXDME$JL6 "4NF.,KHI9.$^Q=D!DUJK#5OYDO7SFI^%&
M, ?!-B/=SQ^&6W5>1COQ>?5M)1JMI&;_?6UXI?].6)@OM!%/SF=N RJZJB]
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M?KZ_NUE>VCJVI4Z6S;K.IS*+3SF)XZ[+<:6F3X!XO]\[*<[_O2CGE)PCL8K
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M_PG _Z8('ILH4:00:]17Q2Q(?__26_C^+/WQ,6W7EHV[\MCS(0M<>#J7?^-
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M@?Z )&P)Q@"37JTM\Y]8,*KT>Q+]7(/Y'7T;WFZJ"]U$3<,/DZV/#S(4*:'
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M*[]DAO&N3R-O+\G#F+YBGPG< >;O13(S7BPSWNQSV9NM.5_!6:PP9/ AZSO
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MIW^#V!U@P@@^Z7[K^FC*@#50IZ+:@,1IB9S(>3+5'?&H7D%MNG((L5O%=7*
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M];*N-L8;)B(I]DR_7<@4RU4B!O?X!7Z7U#TG!R^=LWT_WWM[JE=V,L,%P#M
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M43Q[FU)CSG0J>[2SX75*DK+1.@2EL)C>&9]-&3S8LX2P\[4YI"5^OH*LJ(M
M*P74?;AX8)0D"OA&W-PR*+VE?<!0!GP6WQ$]F@B6T$O(1T-P%F1V%LB\S3)L
M9FOWT9'NA<]R@%]@'@UP#T)>S"]W!SSBB&G<O-NNT7W%:2W</4Q>Z>7U.GPB
M5+76A/UYWM9EZJ1NLET\18:UW>X)J: RLQOAJA+@W?= _?5T1^V21O="Z?B0
M&40V9:R^FH,S3FRPI3+1!S8=II(E IP;KEKD\/$5.*B$J?IUPK/XZ$"G7*TD
MTB5YYV3D)]B>/7/RB*K'AXAQ1 )!)H1">M"HGJQ7[I'WBJ:-,6ZJ?<&X(?5
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MU=L5&.?NBX<*PV$+?.I0M^L^]DCA4AX:B/"-A&?>=%C-36&A4*=^D9E,/*_
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M*?$_#0"WGKL###7*GOWA V3_PRP_*NX _VHM#.VOB[.OM[>,^UG3?67>2NY
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M*QF1Z3=<C0MB8;/&E6$KG%D5M6/4)P[3J?VT+W#6'TC*KVW2G[%?/^LP]39
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MAD/JVM 5JFL1OG!$=@=I@(:WA5.-K;8B\9YV^"36ZH$%_1F%E2$-+TH^,BN
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MH^/\O!#&4O_^6WGI;M'ZTVZG+L\[ !1HXO/F1-((I>M-9XKY.="1BB\ Y;>
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MKAR40CQJC@GZ<IP2H;%!_JA6*0(^I^2SFFJ>(A9Q8'6DMA%C*BS+FP]\[EU
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MOYWNW4W_!U!+ 0(4 Q0    ( "* 7%AYSV(@2^@  /D6 0 '
M  "  0    !A;'HN:G!G4$L! A0#%     @ (H!<6./>*(0H9P  NVX  !8
M             ( !<.@  &-A8C%A8S0S,#!E,&EM9S P,2YJ<&=02P$"% ,4
M    "  B@%Q8SW@RX&Y/  "N5P  "@              @ ',3P$ 8VAG8G-L
M+FIP9U!+ 0(4 Q0    ( "* 7%@H*MG7#IH  #?    *              "
M 6*? 0!D96-C;V<N:G!G4$L! A0#%     @ (H!<6.D/0S^\ @  CPT   T
M             ( !F#D" &5X7S4W,S,T,BYH=&U02P$"% ,4    "  B@%Q8
MW,U,-!L$  !D&   #0              @ %_/ ( 97A?-3<S,S0S+FAT;5!+
M 0(4 Q0    ( "* 7%B/^9,%SP<  +4P   -              "  <5  @!E
M>%\U-S,S-#0N:'1M4$L! A0#%     @ (H!<6!\R3^2@!P  +#    T
M         ( !OT@" &5X7S4W,S,T-2YH=&U02P$"% ,4    "  B@%Q88FMR
MXLT$  "9$P  #0              @ &*4 ( 97A?-3<S,S0V+FAT;5!+ 0(4
M Q0    ( "* 7%@HR0K*\A,  #U8   -              "  8)5 @!E>%\V
M,3$V-#$N:'1M4$L! A0#%     @ (H!<6!>OU5^A'@  =K    T
M     ( !GVD" &5X7S8S,#8P,2YH=&U02P$"% ,4    "  B@%Q8!7/0U/Y[
M  #WEP  "               @ %KB ( <&<P,2YJ<&=02P$"% ,4    "  B
M@%Q8'3HIR_E]  #7AP  "               @ &/! , <&EC,2YJ<&=02P$"
M% ,4    "  B@%Q8P\LE6OJ0  !4F@  "               @ &N@@, <&EC
M,BYJ<&=02P$"% ,4    "  B@%Q8'_O"")H0   7T0  $0
M@ '.$P0 <V%V82TR,#(S,3(S,2YX<V102P$"% ,4    "  B@%Q88RA;9PH+
M  !\G   %0              @ &7) 0 <V%V82TR,#(S,3(S,5]C86PN>&UL
M4$L! A0#%     @ (H!<6-O$![*)/P  YV\% !4              ( !U"\$
M '-A=F$M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "* 7%A-SOJ"G%4
M "/Y!  5              "  9!O! !S879A+3(P,C,Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    "  B@%Q8P7E+E0A#  #SZ@4 %0              @ %?Q00
M<V%V82TR,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ (H!<6%#Z-^?Z%0,
M6&(; !0              ( !F@@% '-A=F$R,#(S,3(S,5\Q,&LN:'1M4$L!
M A0#%     @ (H!<6(Z?!MZ^40  IE<   L              ( !QAX( '-L
M:61E,#(N:G!G4$L! A0#%     @ (H!<6"+[X(-W8@  ^&T   L
M     ( !K7 ( '-L:61E,#,N:G!G4$L! A0#%     @ (H!<6(*^\)8S8@
MBV8   L              ( !3=,( '-L:61E,#0N:G!G4$L! A0#%     @
M(H!<6#*SP_V,I0  "+$   L              ( !J34) '-L:61E,#4N:G!G
64$L%!@     8 !@ F04  %[;"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>sava20231231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sava="http://www.cassavasciences.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sava-20231231.xsd" xlink:type="simple"/>
    <context id="d_2023-01-01_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="i_2024-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2024-02-26</instant>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeasesAcquiredInPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sava:LeasingCommissionsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2022RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2021RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:The2021RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sava:AtthemarketCommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:The2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sava:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:CarryforwardSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sava:IndefiniteLifeCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_LeaseContractualTermAxis-LeaseForOfficeSpaceInAustinTexasMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sava:LeaseForOfficeSpaceInAustinTexasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sava:CashIncentiveBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-28</startDate>
            <endDate>2021-10-26</endDate>
        </period>
    </context>
    <context id="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ViolationsOfFederalSecuritiesLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-04</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsTexasStateCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsDelawareCourtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">sava:ShareholderDerivativeActionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-05</endDate>
        </period>
    </context>
    <context id="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-22</startDate>
            <endDate>2023-12-22</endDate>
        </period>
    </context>
    <context id="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <context id="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2024-01-03_ClassOfWarrantOrRightAxis-BonusShareFractionMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sava:BonusShareFractionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="i_2023-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
        </entity>
        <period>
            <instant>2023-12-22</instant>
        </period>
    </context>
    <context id="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-15</instant>
        </period>
    </context>
    <context id="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001069530</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2023-01-01_2023-12-31"
      id="thunderdome-EntityCentralIndexKey">0001069530</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2023-01-01_2023-12-31"
      id="thunderdome-EntityRegistrantName">CASSAVA SCIENCES INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2023-01-01_2023-12-31" id="ixv-12670">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-01-01_2023-12-31" id="ixv-12671">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-01-01_2023-12-31" id="ixv-12672">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-01-01_2023-12-31" id="ixv-12673">2023</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-12-31"
      id="c107483662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2022-12-31"
      id="c107483663"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483667"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483668"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483669"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483670"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483671"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483673"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483672"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483674"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483677"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483678"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483679"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483680"
      unitRef="Share">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483681"
      unitRef="Share">42236919</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107483683"
      unitRef="Share">42236919</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483682"
      unitRef="Share">41735557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107483684"
      unitRef="Share">41735557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483920"
      unitRef="USD">0</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c107483964">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c107483965">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2022-05-05_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      id="c107484158">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484343"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484346"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484349"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484352"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484355"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484358"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c107484403"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484422"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear contextRef="d_2023-01-01_2023-12-31" id="c107484425">2019 2020 2021 2022</us-gaap:OpenTaxYear>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c107484574"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-08-28_2021-10-26_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c107484575"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-06-30_2022-06-30_LitigationCaseAxis-ViolationsOfFederalSecuritiesLawsMember"
      decimals="INF"
      id="c107484576"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c107484579"
      unitRef="Pure">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasStateCourtMember"
      decimals="INF"
      id="c107484580"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2022-07-05_2022-07-05_LitigationCaseAxis-ShareholderDerivativeActionsMember"
      decimals="INF"
      id="c107484582"
      unitRef="Pure">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2023-12-22_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c107484588"
      unitRef="Share">4</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <sava:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2024-01-03_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c107484590"
      unitRef="Share">16900000</sava:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484592"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sava:RedemptionPercentageOfWarrants
      contextRef="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="3"
      id="c107484606"
      unitRef="Pure">0.001</sava:RedemptionPercentageOfWarrants>
    <sava:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484615"
      unitRef="Share">659000</sava:ClassOfWarrantOrRightExercisedDuringPeriod>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2023-01-01_2023-12-31" id="c107484626">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2023-01-01_2023-12-31" id="c107484634">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2023-01-01_2023-12-31" id="c107484635">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2023-01-01_2023-12-31" id="c107484636">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:DocumentType contextRef="d_2023-01-01_2023-12-31" id="ixv-13877">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2023-01-01_2023-12-31" id="ixv-13878">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-01-01_2023-12-31" id="ixv-13879">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-01-01_2023-12-31" id="ixv-13880">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-01-01_2023-12-31" id="ixv-13881">000-29959</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-01-01_2023-12-31" id="ixv-13882">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2023-01-01_2023-12-31" id="ixv-13883">91-1911336</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-01-01_2023-12-31" id="ixv-13884">6801 N. Capital of Texas Highway, Building 1; Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-01-01_2023-12-31" id="ixv-13885">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2023-01-01_2023-12-31" id="ixv-13886">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-01-01_2023-12-31" id="ixv-13887">78731</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-01-01_2023-12-31" id="ixv-13888">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-01-01_2023-12-31" id="ixv-13889">501-2444</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-13890">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-13891">SAVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-CommonStockMember"
      id="ixv-13892">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-13893">Warrants, exercisable for shares of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-13894">SAVAW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="d_2023-01-01_2023-12-31_StatementClassOfStockAxis-WarrantMember"
      id="ixv-13895">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2023-01-01_2023-12-31" id="ixv-13896">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2023-01-01_2023-12-31" id="ixv-13897">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-01-01_2023-12-31" id="ixv-13898">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-01-01_2023-12-31" id="ixv-13899">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-01-01_2023-12-31" id="ixv-13900">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-01-01_2023-12-31" id="ixv-13901">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-01-01_2023-12-31" id="ixv-13902">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2023-01-01_2023-12-31" id="ixv-13903">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2023-01-01_2023-12-31" id="ixv-13904">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2023-01-01_2023-12-31" id="ixv-13905">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2023-06-30"
      decimals="0"
      id="ixv-13906"
      unitRef="USD">967000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2024-02-26"
      decimals="INF"
      id="ixv-13907"
      unitRef="Share">43225211</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2023-01-01_2023-12-31" id="ixv-13908">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2023-01-01_2023-12-31" id="ixv-13909">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2023-01-01_2023-12-31" id="ixv-13910">Austin, Texas</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483626"
      unitRef="USD">121136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483627"
      unitRef="USD">201015000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483628"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483629"
      unitRef="USD">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483630"
      unitRef="USD">129633000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483631"
      unitRef="USD">211226000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483632"
      unitRef="USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483633"
      unitRef="USD">122000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483634"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483635"
      unitRef="USD">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483636"
      unitRef="USD">176000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483637"
      unitRef="USD">622000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483638"
      unitRef="USD">151663000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483639"
      unitRef="USD">234834000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483643"
      unitRef="USD">10573000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483644"
      unitRef="USD">4017000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483645"
      unitRef="USD">3037000</sava:AccruedDevelopmentExpenseCurrent>
    <sava:AccruedDevelopmentExpenseCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c107483646"
      unitRef="USD">2280000</sava:AccruedDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c107483647"
      unitRef="USD">200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c107483648"
      unitRef="USD">170000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483649"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483650"
      unitRef="USD">104000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483651"
      unitRef="USD">385000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483652"
      unitRef="USD">492000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483653"
      unitRef="USD">14195000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483654"
      unitRef="USD">7063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483655"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483656"
      unitRef="USD">35000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483657"
      unitRef="USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483658"
      unitRef="USD">197000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483659"
      unitRef="USD">14195000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483660"
      unitRef="USD">7295000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483665"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483666"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483675"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483676"
      unitRef="USD">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483685"
      unitRef="USD">518195000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483686"
      unitRef="USD">511049000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483687"
      unitRef="USD">-380769000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483688"
      unitRef="USD">-283552000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483689"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483690"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483691"
      unitRef="USD">151663000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483692"
      unitRef="USD">234834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483700"
      unitRef="USD">89423000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483701"
      unitRef="USD">68032000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483702"
      unitRef="USD">24813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483703"
      unitRef="USD">16534000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483704"
      unitRef="USD">11988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483705"
      unitRef="USD">8055000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483706"
      unitRef="USD">105957000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c107483707"
      unitRef="USD">80020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483708"
      unitRef="USD">32868000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483709"
      unitRef="USD">-105957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c107483710"
      unitRef="USD">-80020000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483711"
      unitRef="USD">-32868000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483712"
      unitRef="USD">7833000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483713"
      unitRef="USD">2777000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483714"
      unitRef="USD">49000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483715"
      unitRef="USD">907000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483716"
      unitRef="USD">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483717"
      unitRef="USD">434000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483718"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483719"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483720"
      unitRef="USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107483721"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c107483722"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c107483723"
      unitRef="USDPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483724"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483725"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483726"
      unitRef="Share">39405000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483727"
      unitRef="Share">35237987</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483728"
      unitRef="USD">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483729"
      unitRef="USD">267086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483730"
      unitRef="USD">-174921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c107483731"
      unitRef="USD">92200000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483734"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483735"
      unitRef="USD">1706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483736"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c107483737"
      unitRef="USD">1706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483739"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483740"
      unitRef="USD">53000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483741"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2021-01-01_2021-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c107483742"
      unitRef="USD">53000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483743"
      unitRef="Share">143153</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483744"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483745"
      unitRef="USD">1824000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483746"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483747"
      unitRef="USD">1824000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483748"
      unitRef="Share">554019</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483749"
      unitRef="USD">1000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483750"
      unitRef="USD">691000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483751"
      unitRef="USD">0</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <sava:StockIssuedDuringPeriodValueWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483752"
      unitRef="USD">692000</sava:StockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483753"
      unitRef="Share">4081633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483754"
      unitRef="USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483755"
      unitRef="USD">189821000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483756"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483757"
      unitRef="USD">189825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483759"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483760"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483761"
      unitRef="USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483762"
      unitRef="USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483763"
      unitRef="Share">40016792</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c107483764"
      unitRef="USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483765"
      unitRef="USD">461181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483766"
      unitRef="USD">-207306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c107483767"
      unitRef="USD">253915000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483770"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483771"
      unitRef="USD">1972000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483772"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c107483773"
      unitRef="USD">1972000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483775"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483776"
      unitRef="USD">94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483777"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2022-01-01_2022-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c107483778"
      unitRef="USD">94000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483779"
      unitRef="Share">57143</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483780"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483781"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483782"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483783"
      unitRef="USD">-0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483784"
      unitRef="Share">109241</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483785"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483786"
      unitRef="USD">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483787"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483788"
      unitRef="USD">475000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483789"
      unitRef="Share">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483790"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483791"
      unitRef="USD">47327000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483792"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483793"
      unitRef="USD">47329000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483795"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483796"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483797"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483798"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483799"
      unitRef="Share">41735557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483800"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483801"
      unitRef="USD">511049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483802"
      unitRef="USD">-283552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483803"
      unitRef="USD">227539000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483806"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483807"
      unitRef="USD">4493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483808"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementEmployeeMember"
      decimals="-3"
      id="c107483809"
      unitRef="USD">4493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483811"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483812"
      unitRef="USD">93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483813"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="d_2023-01-01_2023-12-31_GranteeStatusAxis-ShareBasedPaymentArrangementNonemployeeMember"
      decimals="-3"
      id="c107483814"
      unitRef="USD">93000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483815"
      unitRef="Share">501362</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483816"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c107483817"
      unitRef="USD">2560000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483818"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c107483819"
      unitRef="USD">2560000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483821"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483822"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483823"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483824"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c107483825"
      unitRef="Share">42236919</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107483826"
      unitRef="USD">42000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c107483827"
      unitRef="USD">518195000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c107483828"
      unitRef="USD">-380769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483829"
      unitRef="USD">137468000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483837"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483838"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483839"
      unitRef="USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483841"
      unitRef="USD">4586000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483842"
      unitRef="USD">2066000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483843"
      unitRef="USD">1759000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483844"
      unitRef="USD">1084000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483845"
      unitRef="USD">804000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c107483846"
      unitRef="USD">310000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483847"
      unitRef="USD">446000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483848"
      unitRef="USD">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483849"
      unitRef="USD">224000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483851"
      unitRef="USD">-1714000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483852"
      unitRef="USD">-1189000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483853"
      unitRef="USD">10956000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483854"
      unitRef="USD">17000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483855"
      unitRef="USD">9000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483856"
      unitRef="USD">-28000</sava:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483857"
      unitRef="USD">6896000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483858"
      unitRef="USD">-3449000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483859"
      unitRef="USD">6215000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483860"
      unitRef="USD">757000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483861"
      unitRef="USD">-523000</sava:IncreaseDecreaseInDevelopmentExpense>
    <sava:IncreaseDecreaseInDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483862"
      unitRef="USD">2084000</sava:IncreaseDecreaseInDevelopmentExpense>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c107483863"
      unitRef="USD">30000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483864"
      unitRef="USD">-1707000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483865"
      unitRef="USD">1794000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483866"
      unitRef="USD">-304000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483867"
      unitRef="USD">-136000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483868"
      unitRef="USD">731000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483869"
      unitRef="USD">-82025000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483870"
      unitRef="USD">-77514000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483871"
      unitRef="USD">-30196000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483873"
      unitRef="USD">414000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483874"
      unitRef="USD">2712000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483875"
      unitRef="USD">22214000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483876"
      unitRef="USD">-414000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483877"
      unitRef="USD">-2712000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483878"
      unitRef="USD">-22214000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c107483880"
      unitRef="USD">2560000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483881"
      unitRef="USD">475000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483882"
      unitRef="USD">1824000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483883"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483884"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483885"
      unitRef="USD">692000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483886"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483887"
      unitRef="USD">47329000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483888"
      unitRef="USD">189825000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c107483889"
      unitRef="USD">2560000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483890"
      unitRef="USD">47804000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483891"
      unitRef="USD">192341000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483892"
      unitRef="USD">-79879000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107483893"
      unitRef="USD">-32422000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483894"
      unitRef="USD">139931000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483895"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c107483896"
      unitRef="USD">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c107483897"
      unitRef="USD">93506000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107483898"
      unitRef="USD">121136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107483899"
      unitRef="USD">201015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c107483900"
      unitRef="USD">233437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107483903"
      unitRef="USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-4"
      id="c107483904"
      unitRef="USD">340000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107483905"
      unitRef="USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560565">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt; &lt;b&gt;General, Liquidity and Basis of Presentation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the &#x201c;Company&#x201d;) discovers and develops proprietary pharmaceutical product candidates that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer significant improvements to patients and healthcare professionals. The Company generally focuses its product discovery and development efforts on disorders of the nervous system.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#xfeff;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Liquidity &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $380.8&#160;million at &lt;em style="font: inherit;"&gt; December 31, 2023. &lt;/em&gt;The Company expects its cash requirements to be significant in the future. The amount and timing of the Company&#x2019;s future cash requirements will depend on regulatory and market acceptance of its product candidates and the resources it devotes to researching and developing, formulating, manufacturing, commercializing and supporting its products. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional funding through public or private financing in the future, if such funding is available and on terms acceptable to the Company. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurances that additional financing will be available on favorable terms, or at all. However, management believes that the current working capital position will be sufficient to meet the Company&#x2019;s working capital needs for at least the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c107483907"
      unitRef="USD">-380800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560566">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; there were &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c107483920"&gt;no&lt;/span&gt;&lt;/em&gt; reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company received $0.9 million and&#160;$3.9 million&#160;of reimbursement, respectively, from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c107483964"&gt;three&lt;/span&gt; or &lt;span style="-sec-ix-hidden:c107483965"&gt;four&lt;/span&gt; years.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(32,385&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,405&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,211&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded common stock options and warrants outstanding, along with 57,143 restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;would have been anti-dilutive. The 57,143 restricted stock awards expired during the year ended &lt;em style="font: inherit;"&gt; December 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses and other liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of the Plan.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities.&#160;As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.4 years.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates 0.3 years at &lt;em style="font: inherit;"&gt; December 31, 2023.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-01-01_2023-12-31" id="c107485577">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company makes estimates and assumptions in preparing its consolidated financial statements in conformity with accounting principles generally accepted in the United States. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&#160;its estimates on an ongoing basis, including those estimates related to clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485578">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Proceeds from Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; there were &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c107483920"&gt;no&lt;/span&gt;&lt;/em&gt; reimbursements received pursuant to National Institutes of Health (&#x201c;NIH&#x201d;) research grants. In &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company received $0.9 million and&#160;$3.9 million&#160;of reimbursement, respectively, from the NIH&#160;and National Institute on Drug Abuse. The Company records the proceeds from these grants as reductions to its research and development expenses.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-5"
      id="c107483928"
      unitRef="USD">900000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-5"
      id="c107483931"
      unitRef="USD">3900000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485579">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents and Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company invests in cash and cash equivalents. The Company considers highly-liquid financial instruments with original maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Highly liquid investments that are considered cash equivalents include money market accounts and funds, certificates of deposit and U.S. Treasury securities. The Company maintains&#160;its cash and cash equivalents at &lt;em style="font: inherit;"&gt;one&lt;/em&gt; financial institution.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485580">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; includes quoted prices in active markets.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; includes significant observable inputs, such as quoted prices for identical or similar securities, or other inputs that are observable and can be corroborated by observable market data for similar securities. The Company uses market pricing and other observable market inputs obtained from &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party providers. It uses the bid price to establish fair value where a bid price is available. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; includes unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any financial instruments where the fair value is based on Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs.&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; inputs at &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485581">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Business Segments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company&#x2019;s operations are confined to one business segment: the development of novel drugs and diagnostics.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107483963"
      unitRef="Pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485582">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model (&#x201c;Black-Scholes&#x201d;) to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management&#x2019;s judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally &lt;span style="-sec-ix-hidden:c107483964"&gt;three&lt;/span&gt; or &lt;span style="-sec-ix-hidden:c107483965"&gt;four&lt;/span&gt; years.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has granted share-based awards that vest upon achievement of certain performance criteria (&#x201c;Performance Awards&#x201d;). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485583">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company computes basic net loss per share on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus potential dilutive common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding common stock options and warrants. There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; difference between the Company&#x2019;s net loss and comprehensive loss. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands, except net loss per share data):&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(32,385&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,405&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,211&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company excluded common stock options and warrants outstanding, along with 57,143 restricted stock awards, from the calculation of net loss per share, diluted, because the effect of including outstanding options&#160;would have been anti-dilutive. The 57,143 restricted stock awards expired during the year ended &lt;em style="font: inherit;"&gt; December 31, 2022.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560567">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Numerator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Net loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(97,217&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(76,246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(32,385&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Denominator:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;"&gt;Shares used in computing net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;41,932&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;40,202&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;39,405&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2.32&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.90&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(0.82&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Dilutive common stock options excluded from net loss per share, diluted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,123&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,055&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,211&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484008"
      unitRef="USD">-97217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484009"
      unitRef="USD">-76246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484010"
      unitRef="USD">-32385000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484012"
      unitRef="Share">41932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484013"
      unitRef="Share">40202000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484014"
      unitRef="Share">39405000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484015"
      unitRef="USDPerShare">-2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c107484016"
      unitRef="USDPerShare">-1.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c107484017"
      unitRef="USDPerShare">-0.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484018"
      unitRef="Share">2123000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484019"
      unitRef="Share">2055000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484020"
      unitRef="Share">2211000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c107483968"
      unitRef="Share">57143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockMember"
      decimals="INF"
      id="c107483969"
      unitRef="Share">57143</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2023-01-01_2023-12-31" id="c107485584">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Financial instruments include accounts payable, accrued expenses and other liabilities. The estimated fair value of certain financial instruments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be material to the estimated fair value amounts. The carrying amounts of accounts payable,&#160;accrued expenses and other liabilities&#160;are at cost, which approximates fair value due to the short maturity of those instruments.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-01-01_2023-12-31" id="c107485585">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research Contracts, Prepaids and Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has entered into various research and development contracts with research institutions and other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. These agreements are generally cancelable. Related payments are recorded as research and development expenses as incurred. The Company records prepaids and accruals for estimated ongoing research costs. When evaluating the adequacy of the prepaid expenses and accrued liabilities, the Company analyzes progress of the studies including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. The Company&#x2019;s historical prepaid and accrual estimates have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been materially different from actual costs.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2023-01-01_2023-12-31" id="c107485586">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Incentive Bonus Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company established the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan (the &#x201c;Plan&#x201d;) to incentivize Plan participants. Awards under the Plan are accounted for as liability awards under ASC&#160;&lt;em style="font: inherit;"&gt;718&lt;/em&gt; &#x201c;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&#x201d;.&#160;The fair value of each&#160;potential Plan&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;Plan award, when&#160;a Performance Condition&#160;(as defined below) is considered probable of being met. See Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; for further discussion of the Plan.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485587">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company recognizes&#160;assets and liabilities that arise from leases.&#160;For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the&#160;consolidated balance sheets.&#160;The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize right-of-use assets or lease liabilities.&#160;As the Company`s leases do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485588">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements related to leased space are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.4 years.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      id="c107483980">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      id="c107483981">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2023-12-31" id="c107483982">P0Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2023-01-01_2023-12-31" id="c107485589">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which approximates 0.3 years at &lt;em style="font: inherit;"&gt; December 31, 2023.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      id="c107483984">P0Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2023-01-01_2023-12-31" id="c107485590">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for income taxes under the asset and liability method.&#160;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. &#160;Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse.&#160;The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company accounts for uncertain tax positions in accordance with ASC &lt;em style="font: inherit;"&gt;740,&lt;/em&gt; &#x201c;Income Taxes&#x201d;, which clarifies the accounting for uncertainty in tax positions. These provisions require recognition of the impact of a tax position in the Company&#x2019;s financial statements only if that position is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected as a component of income tax expense.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <sava:PrepaidExpensesAndOtherCurrentAssetsTextBock contextRef="d_2023-01-01_2023-12-31" id="c2560568">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Prepaid and other current assets at&#160;&lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; consisted of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;874&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;160&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,211&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </sava:PrepaidExpensesAndOtherCurrentAssetsTextBock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560569">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Prepaid insurance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;874&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Contract research organization and other deposits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,489&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,177&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Interest receivable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;962&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;287&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;160&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,497&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,211&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484027"
      unitRef="USD">759000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484028"
      unitRef="USD">874000</us-gaap:PrepaidInsurance>
    <us-gaap:DepositContractsAssets
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484029"
      unitRef="USD">6489000</us-gaap:DepositContractsAssets>
    <us-gaap:DepositContractsAssets
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484030"
      unitRef="USD">9177000</us-gaap:DepositContractsAssets>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484031"
      unitRef="USD">962000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484032"
      unitRef="USD">0</us-gaap:InterestReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484033"
      unitRef="USD">287000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c107484034"
      unitRef="USD">160000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484035"
      unitRef="USD">8497000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484036"
      unitRef="USD">10211000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RealEstateOwnedTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560570">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt; Real Property and Other Income, Expense&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company owns a &lt;em style="font: inherit;"&gt;two&lt;/em&gt;-building office complex in Austin, Texas, a portion of which serves as its corporate headquarters. This property is intended to accommodate the Company&#x2019;s anticipated growth and expansion of its operations in the coming years. Maintenance, physical facilities, leasing, property management and other key responsibilities related to property ownership are being outsourced to professional real-estate managers. The office complex measures approximately 90,000 rentable square feet.&#160;At &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company&#160;occupied approximately 25% of the property with the remainder&#160;either leased or available for lease to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company records the net income from building operations and leases as other income, net, as leasing is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; core to the Company&#x2019;s operations. Building depreciation and amortization for space &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occupied by the Company is included in general and administrative expense. Building depreciation and amortization for space occupied by the Company is allocated between general and administrative expense and research and development expense. Components of other income, net, for the periods presented were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,283&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,459&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;911&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,462&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(477&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;907&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;997&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;434&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company had accrued property taxes related to the building totaling $338,000 and $433,000 at&#160;&lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and&#160;&lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively, included in other current liabilities.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;


  </us-gaap:RealEstateOwnedTextBlock>
    <us-gaap:NetRentableArea
      contextRef="i_2021-08-04_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c107484039"
      unitRef="SquareFoot">90000</us-gaap:NetRentableArea>
    <sava:PercentageOfOccupancy
      contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="2"
      id="c107484040"
      unitRef="Pure">0.25</sava:PercentageOfOccupancy>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560571">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,283&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,459&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;911&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Property operating expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,376&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,462&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(477&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Other income, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;907&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;997&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;434&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484055"
      unitRef="USD">2283000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484056"
      unitRef="USD">2459000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484057"
      unitRef="USD">911000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484058"
      unitRef="USD">1376000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484059"
      unitRef="USD">1462000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484060"
      unitRef="USD">477000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484061"
      unitRef="USD">907000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484062"
      unitRef="USD">997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484063"
      unitRef="USD">434000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2023-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c107484045"
      unitRef="USD">338000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="i_2022-12-31_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis-OfficeBuildingMember_StatementGeographicalAxis-TX"
      decimals="INF"
      id="c107484046"
      unitRef="USD">433000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560572">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt; Property and Equipment&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of property and equipment, net, as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Depreciation expense for property and equipment was&#160;$1,084,000, $804,000&#160;and&#160;$310,000&#160;for the years ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560573">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Land&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,734&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Buildings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,980&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Site improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;494&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;470&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tenant improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,062&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Furniture and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;851&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Construction in progress&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,138&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;24,064&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,284&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,200&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;21,854&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;22,864&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c107484077"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LandMember"
      decimals="-3"
      id="c107484078"
      unitRef="USD">3734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c107484079"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember"
      decimals="-4"
      id="c107484080"
      unitRef="USD">15980000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-3"
      id="c107484081"
      unitRef="USD">494000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingImprovementsMember"
      decimals="-4"
      id="c107484082"
      unitRef="USD">470000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c107484083"
      unitRef="USD">3062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c107484084"
      unitRef="USD">3016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c107484085"
      unitRef="USD">868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c107484086"
      unitRef="USD">851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c107484087"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c107484088"
      unitRef="USD">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484089"
      unitRef="USD">24138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484090"
      unitRef="USD">24064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484091"
      unitRef="USD">2284000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c107484092"
      unitRef="USD">1200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484093"
      unitRef="USD">21854000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484094"
      unitRef="USD">22864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484066"
      unitRef="USD">1084000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c107484067"
      unitRef="USD">804000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c107484068"
      unitRef="USD">310000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560574">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Intangible assets&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The components of intangible assets, net, as of&#160;&lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; were as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;622&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for intangible assets was $446,000, $497,000 and $224,000 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Amortization expense for finite-lived intangible assets is expected to be as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;172&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;


  </us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560575">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Lease-in-place agreements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,053&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Leasing commissions and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;293&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;290&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Gross intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,346&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,343&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Accumulated amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,170&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(721&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Intangible assets, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;622&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c107484108"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasesAcquiredInPlaceMember"
      decimals="-3"
      id="c107484109"
      unitRef="USD">1053000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-3"
      id="c107484110"
      unitRef="USD">293000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LeasingCommissionsAndOtherMember"
      decimals="-4"
      id="c107484111"
      unitRef="USD">290000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484112"
      unitRef="USD">1346000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484113"
      unitRef="USD">1343000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c107484114"
      unitRef="USD">1170000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484115"
      unitRef="USD">721000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484116"
      unitRef="USD">176000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484117"
      unitRef="USD">622000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484097"
      unitRef="USD">446000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c107484098"
      unitRef="USD">497000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c107484099"
      unitRef="USD">224000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560576">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;For the year ending December 31,&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;172&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;176&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484119"
      unitRef="USD">172000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484120"
      unitRef="USD">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484121"
      unitRef="USD">176000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560577">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt; Stockholders' Equity and Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) has the authority to issue preferred stock in &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; November&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;22,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; the Company completed a common stock offering pursuant to which certain investors purchased 1,666,667 shares of common stock at a price of $30.00 per share. Net proceeds of the offering were approximately $47.3&#160;million after deducting offering expenses.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Registered Direct Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; February&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;12,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company completed a common stock offering pursuant to which certain investors purchased 4,081,633 shares of common stock at a price of $49.00 per share. Net proceeds of the offering were approximately $189.8&#160;million after deducting offering expenses.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;At the Market (ATM) Common Stock Issuance &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;On &lt;em style="font: inherit;"&gt; May 1, 2023, &lt;/em&gt;the Company entered into an&#160;at-the-market offering program (&#x201c;ATM&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $200 million in common stock pursuant to a shelf registration statement that was filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on &lt;em style="font: inherit;"&gt; May 1, 2023 &lt;/em&gt;and became effective immediately upon filing. The Company is obligated to pay a commission of up to 3% of the gross proceeds from the sale of shares of common stock under&#160;the ATM. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to sell any shares in the offering.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;There were&#160;no&#160;common stock sales under the ATM during the year&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the Company entered into an at-the-market offering program (&lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Program&#x201d;) to sell, from time to time, shares of Company common stock having an aggregate offering price of up to $100 million in transactions pursuant to a shelf registration statement that was declared effective by the SEC on &lt;em style="font: inherit;"&gt; May 5, 2020. &lt;/em&gt;The Company gave notice of termination for the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program on &lt;em style="font: inherit;"&gt; April 26, 2023, &lt;/em&gt;which was effective &lt;em style="font: inherit;"&gt; May 1, 2023. &lt;/em&gt;There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; common stock sales under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Program through its termination.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Under the Company&#x2019;s &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Plan, its employees, directors and consultants received share-based awards, including grants of stock options and performance awards. The &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Plan expired in &lt;em style="font: inherit;"&gt; December 2017. &lt;/em&gt;Share-based awards generally expire &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; years from the date of grant.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s Board or a designated Committee of the Board is responsible for administration of the Company&#x2019;s &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Omnibus Incentive Plan (the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan) and determines the terms and conditions of each option granted, consistent with the terms of the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan. The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, including grants of stock options and performance awards. Share-based awards generally expire &lt;span style="-sec-ix-hidden:c107484158"&gt;ten&lt;/span&gt; years from the date of grant. The &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan, as amended on &lt;em style="font: inherit;"&gt; May 5, 2022, &lt;/em&gt;provides for issuance of up to 5,000,000 shares of common stock, par value $0.001 per share, subject to adjustment as provided in the &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;When stock options or performance awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;then use its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock option activity during &lt;em style="font: inherit;"&gt;2023:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Millions&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,529,448&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.94&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;49.60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;1,162,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;18.91&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(602,420&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(49,999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;32.59&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Vested and expected to vest at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,836,174&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.98&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;26.18&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Of the stock options exercised during the year ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;101,058&#160;stock options were net settled in satisfaction of the exercise price, with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; cash proceeds received.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock options at &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;by a range of exercise prices:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options outstanding&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options exercisable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Range of exercise prices&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;outstanding&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;vested&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;From&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;To&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;804,834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;804,834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13.02&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;656,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.33&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;647,167&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.34&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.94&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;62,634&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;62,634&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;800,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;44,442&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.11&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;77.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;715,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;7.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;33.20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;277,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;41.29&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,836,174&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company uses Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of the Company&#x2019;s common stock. Factors utilized in Black-Scholes to value each stock option granted, and the weighted average fair value of options granted during the years ended&#160;&lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; were as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;152% to 155%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 154%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;147% to 151%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.82% to 4.37%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.98% to 3.69%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.12% to 1.42%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484343"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484346"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484349"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeiture rate&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484352"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484355"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484358"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Weighted average fair value of stock options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;65.83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Volatility is based on reviews of the historical volatility of the Company&#x2019;s common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate paying cash dividends in the foreseeable future.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company expects to recognize compensation expense of $24.2&#160;million related to non-vested options held by equity plan participants over the weighted average remaining recognition period of 2.8&#160;years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Performance Awards&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about performance award activity during &lt;em style="font: inherit;"&gt;2023:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Number of Performance Awards&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;a total of 57,143 shares of restricted stock awards expired as performance criteria related to these Performance Awards were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; attained. These shares of restricted stock were returned to the &lt;em style="font: inherit;"&gt;2008&lt;/em&gt; Equity Incentive Plan, which expired in &lt;em style="font: inherit;"&gt; December 2017, &lt;/em&gt;and thus were retired.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If and when outstanding Performance Awards vest, the Company would recognize $101,000 in stock-based compensation expense. These performance awards expire in &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The following summarizes information about stock-based compensation expense, in thousands:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,302&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;457&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c107484127"
      unitRef="Share">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="INF"
      id="c107484128"
      unitRef="USDPerShare">30</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-11-22_2022-11-22_SubsidiarySaleOfStockAxis-The2022RegisteredDirectOfferingMember"
      decimals="-5"
      id="c107484129"
      unitRef="USD">47300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember"
      decimals="INF"
      id="c107484133"
      unitRef="Share">4081633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember"
      decimals="INF"
      id="c107484134"
      unitRef="USDPerShare">49</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-12_2021-02-12_SubsidiarySaleOfStockAxis-The2021RegisteredDirectOfferingMember"
      decimals="-5"
      id="c107484135"
      unitRef="USD">189800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c107484137"
      unitRef="USD">200000000</sava:EquityOfferingMaximumAmount>
    <sava:EquityOfferingPercentageOfCommission
      contextRef="i_2023-05-01_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="2"
      id="c107484138"
      unitRef="Pure">0.03</sava:EquityOfferingPercentageOfCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-12-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-3"
      id="c107484140"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sava:EquityOfferingMaximumAmount
      contextRef="i_2020-03-31_SubsidiarySaleOfStockAxis-AtthemarketCommonStockOfferingMember"
      decimals="-8"
      id="c107484143"
      unitRef="USD">100000000</sava:EquityOfferingMaximumAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c107484160"
      unitRef="Share">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-05-05_PlanNameAxis-The2018EquityIncentivePlanMember"
      decimals="INF"
      id="c107484161"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560578">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted Average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Remaining Contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Aggregate Intrinsic Value&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise Price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Term in Years&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;in Millions&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,529,448&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.94&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;49.60&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;1,162,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;18.91&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(602,420&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;8.38&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Options forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right; padding: 0; margin: 0"&gt;(49,999&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;32.59&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Vested and expected to vest at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;30.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Exercisable at December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,836,174&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.98&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;26.18&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107484194"
      unitRef="Share">2529448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c107484195"
      unitRef="USDPerShare">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c107484196">P3Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c107484197"
      unitRef="USD">49600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484198"
      unitRef="Share">1162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484199"
      unitRef="USDPerShare">18.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484202"
      unitRef="Share">602420</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484203"
      unitRef="USDPerShare">8.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484206"
      unitRef="Share">49999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484207"
      unitRef="USDPerShare">32.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484210"
      unitRef="Share">3039029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484211"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484214"
      unitRef="Share">3039029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484215"
      unitRef="USDPerShare">15.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2023-01-01_2023-12-31" id="c107484216">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c107484217"
      unitRef="USD">30280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484218"
      unitRef="Share">1836174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484219"
      unitRef="USDPerShare">11.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2023-01-01_2023-12-31" id="c107484220">P3Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2023-12-31"
      decimals="-4"
      id="c107484221"
      unitRef="USD">26180000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484165"
      unitRef="Share">101058</sava:StockOptionsExercisedNetSettledSatisfactionOfExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560579">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options outstanding&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Options exercisable&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Weighted&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;remaining&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Number of&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;average&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="6" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Range of exercise prices&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;outstanding&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;contractual&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;vested&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;exercise&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td colspan="2" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;From&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;To&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;life (in years)&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;options&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;price&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.95&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.24&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;804,834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;804,834&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.17&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;13.02&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;656,230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.33&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;647,167&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.34&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.94&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;62,634&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;62,634&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;800,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;44,442&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;17.54&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;21.11&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;77.00&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;715,331&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;7.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;33.20&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"&gt;277,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;41.29&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,039,029&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.13&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,836,174&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484264"
      unitRef="USDPerShare">0.95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484265"
      unitRef="USDPerShare">3.24</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484266"
      unitRef="Share">804834</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      id="c107484267">P4Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484268"
      unitRef="USDPerShare">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484269"
      unitRef="Share">804834</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c107484270"
      unitRef="USDPerShare">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484271"
      unitRef="USDPerShare">4.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484272"
      unitRef="USDPerShare">13.02</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484273"
      unitRef="Share">656230</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      id="c107484274">P2Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484275"
      unitRef="USDPerShare">8.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484276"
      unitRef="Share">647167</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c107484277"
      unitRef="USDPerShare">8.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484278"
      unitRef="USDPerShare">14.21</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484279"
      unitRef="USDPerShare">16.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484280"
      unitRef="Share">62634</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      id="c107484281">P1Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484282"
      unitRef="USDPerShare">16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484283"
      unitRef="Share">62634</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c107484284"
      unitRef="USDPerShare">16</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484285"
      unitRef="USDPerShare">17.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484286"
      unitRef="USDPerShare">17.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484287"
      unitRef="Share">800000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      id="c107484288">P9Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484289"
      unitRef="USDPerShare">17.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484290"
      unitRef="Share">44442</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c107484291"
      unitRef="USDPerShare">17.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484292"
      unitRef="USDPerShare">21.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484293"
      unitRef="USDPerShare">77</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484294"
      unitRef="Share">715331</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2023-01-01_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      id="c107484295">P7Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484296"
      unitRef="USDPerShare">33.2</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484297"
      unitRef="Share">277097</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c107484298"
      unitRef="USDPerShare">41.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484301"
      unitRef="Share">3039029</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-12-31" id="c107484302">P6Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484303"
      unitRef="USDPerShare">15.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484304"
      unitRef="Share">1836174</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2023-12-31"
      decimals="INF"
      id="c107484305"
      unitRef="USDPerShare">11.09</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560580">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;152% to 155%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;151% to 154%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;147% to 151%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.82% to 4.37%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.98% to 3.69%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.12% to 1.42%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484343"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484346"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484349"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Forfeiture rate&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484352"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484355"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c107484358"&gt;zero&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Weighted average fair value of stock options granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;18.21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;35.16&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;65.83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c107484315"
      unitRef="Pure">1.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c107484317"
      unitRef="Pure">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c107484318"
      unitRef="Pure">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c107484320"
      unitRef="Pure">1.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c107484321"
      unitRef="Pure">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c107484323"
      unitRef="Pure">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c107484324"
      unitRef="Pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c107484326"
      unitRef="Pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c107484327"
      unitRef="Pure">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c107484329"
      unitRef="Pure">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c107484330"
      unitRef="Pure">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c107484332"
      unitRef="Pure">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c107484334">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c107484337">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c107484340">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c107484361"
      unitRef="USDPerShare">18.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c107484364"
      unitRef="USDPerShare">35.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c107484367"
      unitRef="USDPerShare">65.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c107484169"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c107484171"
      unitRef="USD">24200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c107484172">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560581">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Number of Performance Awards&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"&gt;Forfeited/canceled&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Outstanding as of December 31, 2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484369"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484370"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484371"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2023-01-01_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484372"
      unitRef="Share">-0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484373"
      unitRef="Share">7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484175"
      unitRef="Share">57143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2022-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c107484178"
      unitRef="USD">101000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560582">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Years ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,050&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,302&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,536&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;435&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;457&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,586&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,066&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,759&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-4"
      id="c107484380"
      unitRef="USD">2050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c107484381"
      unitRef="USD">1631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c107484382"
      unitRef="USD">1302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c107484383"
      unitRef="USD">2536000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c107484384"
      unitRef="USD">435000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="c107484385"
      unitRef="USD">457000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484386"
      unitRef="USD">4586000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484387"
      unitRef="USD">2066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484388"
      unitRef="USD">1759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560583">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Employee &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Benefit Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company has a defined-contribution savings plan under Section &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; day of the month after hire and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contribute up to the current statutory limits under Internal Revenue Service regulations. The &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan permits the Company to make additional matching contributions on behalf of all employees. Through &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any matching contributions to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560584">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; provide for income taxes during the periods presented because it had book and federal taxable losses in those years and the tax benefit that would have resulted from the pre-tax losses was fully offset by a change in the valuation allowance.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The reconciliation of the statutory federal income tax rate to the Company&#x2019;s effective tax rate for periods presented was as follows:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Section 162(m) limitation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Deferred tax assets and valuation allowance&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company&#x2019;s deferred taxes assets at&#160;&lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; were valued at the corporate tax rate of 21%. The Company offsets its deferred tax assets by a valuation allowance because it is uncertain about the timing and amount of any future profits. Significant components of its deferred tax assets are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,322&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,017&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,706&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development credit carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,681&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,538&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;12,690&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,371&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;934&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,002&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The valuation allowance increased by $23.3&#160;million and $17.8&#160;million in&#160;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; respectively, due primarily to continuing operations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s net operating loss carryforwards of $158.7&#160;million are federal, of which $74.1&#160;million expires between &lt;em style="font: inherit;"&gt;2029&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2037&lt;/em&gt; and $84.6&#160;million carries forward indefinitely. As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;the Company had federal research and development tax credits of approximately $21.1&#160;million, which expire in the years &lt;em style="font: inherit;"&gt;2024&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2043.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Unrecognized tax benefits&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company has unrecognized tax benefits related to tax credits of $8.4&#160;million, $6.5&#160;million and $5.0&#160;million, respectively. None of the unrecognized tax benefits as of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;if recognized, would impact the effective tax rate due to the valuation allowance and &lt;span style="-sec-ix-hidden:c107484422"&gt;no&lt;/span&gt; interest or penalties have been recognized. A reconciliation of the beginning and ending balance of unrecognized tax benefits is as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Expired research and development tax credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,495&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;501&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Ending balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;there were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; unrecognized tax benefits that we expect would change significantly over the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company files U.S. and Texas income tax returns. In the United States, the statute of limitations with respect to the federal income tax returns for tax years after &lt;span style="-sec-ix-hidden:c107484425"&gt;2019&lt;/span&gt;&#160;are open to audit; however, since the Company has net operating losses, the taxing authority has the ability to review tax returns prior to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&#160;tax year and make adjustments to these net operating loss carryforwards.&#160;We are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; under audit in any taxing jurisdiction at this time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560585">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Tax at federal statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;State tax, net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5.1&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Section 162(m) limitation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(0.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(24.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(23.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"&gt;Effective income tax rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c107484438"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-01-01_2022-12-31"
      decimals="2"
      id="c107484439"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="2"
      id="c107484440"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c107484441"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c107484442"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c107484443"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c107484444"
      unitRef="Pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c107484445"
      unitRef="Pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c107484446"
      unitRef="Pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c107484447"
      unitRef="Pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c107484448"
      unitRef="Pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c107484449"
      unitRef="Pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c107484450"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c107484451"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c107484452"
      unitRef="Pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2023-01-01_2023-12-31"
      decimals="3"
      id="c107484453"
      unitRef="Pure">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c107484454"
      unitRef="Pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c107484455"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c107484456"
      unitRef="Pure">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-01-01_2022-12-31"
      decimals="3"
      id="c107484457"
      unitRef="Pure">-0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c107484458"
      unitRef="Pure">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="0"
      id="c107484459"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="0"
      id="c107484460"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c107484461"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-01-01_2023-12-31"
      decimals="2"
      id="c107484401"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560586">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;December 31,&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33,322&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28,017&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Share-based compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,561&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,706&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Research and development credit carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,557&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,681&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Capitalized research and development expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,538&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;12,690&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,371&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;934&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;54,028&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(77,349&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(54,002&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Operating lease right-of-use assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(26&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred tax asset (liability)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484467"
      unitRef="USD">33322000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484468"
      unitRef="USD">28017000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484469"
      unitRef="USD">2561000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484470"
      unitRef="USD">2706000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484471"
      unitRef="USD">12557000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484472"
      unitRef="USD">9681000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484473"
      unitRef="USD">27538000</sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i_2022-12-31"
      decimals="-4"
      id="c107484474"
      unitRef="USD">12690000</sava:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484475"
      unitRef="USD">1371000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484476"
      unitRef="USD">934000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484477"
      unitRef="USD">77349000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484478"
      unitRef="USD">54028000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484479"
      unitRef="USD">77349000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484480"
      unitRef="USD">54002000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484481"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484482"
      unitRef="USD">26000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484484"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484485"
      unitRef="USD">26000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484486"
      unitRef="USD">-0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484487"
      unitRef="USD">26000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484488"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484489"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-2"
      id="c107484402"
      unitRef="USD">23300</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-2"
      id="c107484404"
      unitRef="USD">17800</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c107484407"
      unitRef="USD">158700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-CarryforwardSubjectToExpirationMember"
      decimals="-5"
      id="c107484408"
      unitRef="USD">74100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-IndefiniteLifeCarryforwardsMember"
      decimals="-5"
      id="c107484411"
      unitRef="USD">84600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2023-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c107484412"
      unitRef="USD">21100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-5"
      id="c107484418"
      unitRef="USD">8400000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-5"
      id="c107484419"
      unitRef="USD">6500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-6"
      id="c107484420"
      unitRef="USD">5000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484421"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560587">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;Year ended December 31,&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2023&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,500&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt; &lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;Expired research and development tax credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;(50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Additions based on tax positions related to the current year&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,495&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;501&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Ending balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,413&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,496&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,001&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484496"
      unitRef="USD">6496000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c107484497"
      unitRef="USD">5001000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c107484498"
      unitRef="USD">4500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-4"
      id="c107484499"
      unitRef="USD">50000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484500"
      unitRef="USD">-0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484501"
      unitRef="USD">-0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2023-01-01_2023-12-31"
      decimals="-3"
      id="c107484502"
      unitRef="USD">1967000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2022-01-01_2022-12-31"
      decimals="-3"
      id="c107484503"
      unitRef="USD">1495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c107484504"
      unitRef="USD">501000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2023-12-31"
      decimals="-3"
      id="c107484505"
      unitRef="USD">8413000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2022-12-31"
      decimals="-3"
      id="c107484506"
      unitRef="USD">6496000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c107484507"
      unitRef="USD">5001000</us-gaap:UnrecognizedTaxBenefits>
    <sava:LeasesAndCommitmentsDisclosureTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560588">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Leases and Commitments&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Right-of-use Asset and Liability&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas expiring &lt;em style="font: inherit;"&gt; April 30, 2024. &lt;/em&gt;The Company terminated this lease on &lt;em style="font: inherit;"&gt; February 22, 2023 &lt;/em&gt;with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing obligations.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Cash paid for operating lease liabilities totaled $24,000, $155,000 and $109,000 during the years ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2022&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. It has contractual arrangements with these organizations that are generally cancelable. The Company&#x2019;s obligations under these contracts are largely based on services performed.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company is dependent on contract development and manufacturing organizations for the manufacture of all our materials for clinical studies.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
  </sava:LeasesAndCommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2022-12-31_LeaseContractualTermAxis-LeaseForOfficeSpaceInAustinTexasMember"
      decimals="INF"
      id="c107484509"
      unitRef="SquareFoot">6000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-01-01_2023-12-31"
      decimals="INF"
      id="c107484511"
      unitRef="USD">24000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-01-01_2022-12-31"
      decimals="INF"
      id="c107484513"
      unitRef="USD">155000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c107484514"
      unitRef="USD">109000</us-gaap:OperatingLeasePayments>
    <sava:CashIncentiveBonusPlanTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560589">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the Board approved the Plan. The Plan was established to promote the long-term success of the Company by creating an &#x201c;at-risk&#x201d; cash bonus program that rewards&#160;Plan&#160;participants with additional cash compensation in lockstep with significant increases in the Company&#x2019;s market capitalization. The Plan is considered &#x201c;at-risk&#x201d; because Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; receive a cash bonus&#160;unless&#160;the Company&#x2019;s market capitalization increases&#160;significantly and&#160;certain&#160;other&#160;conditions specified in the Plan&#160;are met.&#160;Specifically, Plan participants&#160;will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be paid&#160;any cash bonuses unless (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Company completes a&#160;merger or acquisition transaction that constitutes a sale of ownership of the Company or its assets (a Merger Transaction) or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the Compensation Committee of the Board&#160;(the Compensation Committee) determines the Company has sufficient cash on hand, as defined in the Plan. Because&#160;of the inherent discretion and uncertainty regarding&#160;these&#160;requirements, the Company has concluded that&#160;a&#160;Plan&#160;grant date has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occurred&#160;as of &lt;em style="font: inherit;"&gt; December 31, 2023.&#160;&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt; text-align: justify;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;the Company&#x2019;s independent directors were participants in the Plan. However, effective &lt;em style="font: inherit;"&gt; March 16, 2023, &lt;/em&gt;the Board&#160;amended the Plan to remove all independent directors as participants in the Plan and the independent directors consented to such removal. The independent directors&#x2019; share of potential benefits under the Plan were completely forfeited to the Company and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be allocated to any other participant under the Plan. The Company&#x2019;s independent directors have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; received, and as a result of such amendment will never receive, any payments under the Plan.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Company&#x2019;s market capitalization for purposes of the Plan&#160;is&#160;determined based on either (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Company&#x2019;s closing price&#160;of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; share&#160;on the Nasdaq Capital&#160;Market&#160;multiplied by the total issued and outstanding shares and options to purchase shares of the Company, or (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the aggregate consideration payable to security holders of the Company in a&#160;Merger Transaction. Any warrants outstanding are excluded from the determination of market capitalization. This constitutes a market condition under applicable accounting guidance.&#160; &#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Plan&#160;triggers a potential cash bonus each time&#160;the&#160;Company&#x2019;s market capitalization increases significantly, up to a maximum&#160;&lt;em style="font: inherit;"&gt;$5&lt;/em&gt;&#160;billion in market capitalization. The Plan specifies 14&#160;incremental&#160;amounts&#160;between&#160;$200&#160;million and&#160;$5&#160;billion&#160;(each increment,&#160;a &#x201c;Valuation Milestone&#x201d;). Each&#160;Valuation Milestone&#160;triggers&#160;a potential cash bonus award in a pre-set amount defined in the Plan. Each&#160;Valuation&#160;Milestone&#160;must be achieved and maintained for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days for&#160;Plan&#160;participants to be eligible for a potential cash bonus award.&#160;Approximately 67% of each&#160;cash bonus award&#160;associated with a Valuation Milestone&#160;is subject to&#160;adjustment and&#160;approval&#160;by the Compensation Committee.&#160;Any amounts&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; awarded by the Compensation Committee&#160;are&#160;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer available for distribution.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;If the Company were to exceed a $5&#160;billion market capitalization&#160;for &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 20 consecutive trading days, all&#160;Valuation&#160;Milestones would be deemed achieved, in which case cash bonus awards would&#160;range from&#160;a minimum of&#160;$111.4&#160;million&#160;up to&#160;a hypothetical maximum of&#160;$289.7&#160;million.&#160;Payment of cash bonuses is deferred until such time as&#160;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&#160;the Company completes a Merger Transaction, or&#160;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&#160;the&#160;Compensation Committee determines the&#160;Company has sufficient cash&#160;on hand&#160;to render payment&#160;(each, a &#x201c;Performance Condition&#x201d;),&#160;neither&#160;of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;ever occur. Accordingly, there can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that&#160;Plan&#160;participants will&#160;ever&#160;be&#160;paid a cash bonus that is awarded under the Plan, even if the Company&#x2019;s market capitalization increases&#160;significantly.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;The Plan is accounted for as a liability award.&#160;The fair value of each&#160;Valuation&#160;Milestone&#160;award&#160;will be&#160;determined&#160;once&#160;a&#160;grant date occurs and&#160;will be&#160;remeasured each reporting period.&#160;Compensation expense associated with the Plan&#160;will be&#160;recognized over the expected achievement period for each&#160;of the 14&#160;Valuation&#160;Milestones, when&#160;a Performance Condition&#160;is considered probable of being met. &#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;In &lt;em style="font: inherit;"&gt; October 2020, &lt;/em&gt;the Company&#160;achieved&#160;the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;&#160;Valuation&#160;Milestone.&#160;Subsequently in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Compensation Committee&#160;approved&#160;a potential cash bonus&#160;award&#160;of&#160;$6.5&#160;million&#160;in total&#160;for&#160;all Plan participants (after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Plan amendment), subject to future satisfaction of a Performance Condition.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company achieved 11 additional Valuation Milestones triggering potential Company obligations to all Plan participants from a minimum of $74.9&#160;million up to a hypothetical maximum of $202.3&#160;million (after taking into account the &lt;em style="font: inherit;"&gt; March 2023 &lt;/em&gt;Plan amendment), to be determined by the Compensation Committee and contingent upon future satisfaction of a Performance Condition. However,&#160;no&#160;compensation expense has been recorded&#160;since &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;grant date has occurred and &lt;em style="font: inherit;"&gt;no&lt;/em&gt;&#160;Performance Conditions are considered probable of being met.&#160;There is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; continuing service requirement for Plan participants once&#160;the Compensation Committee approves a cash&#160;bonus award.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&lt;em style="font: inherit;"&gt;No&lt;/em&gt; Valuation Milestones were achieved during the years&#160;ended &lt;em style="font: inherit;"&gt; December 31, 2023 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;No actual cash payments were authorized or made to participants under the Plan through &lt;em style="font: inherit;"&gt; December 31, 2023&#160;&lt;/em&gt;and the date of filing of this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </sava:CashIncentiveBonusPlanTextBlock>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c107484538"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-8"
      id="c107484539"
      unitRef="USD">200000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c107484540"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c107484542">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="2"
      id="c107484543"
      unitRef="Pure">0.67</sava:PercentageValuationMilestoneCashBonusAwardSubjectToApprovalAndAdjustment>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-9"
      id="c107484546"
      unitRef="USD">5000000000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained
      contextRef="d_2023-01-01_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      id="c107484548">P20D</sava:PerformancePlanMinimumNumberOfDaysValuationMilestoneMustBeAchievedAndMaintained>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c107484549"
      unitRef="USD">111400000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashIncentiveBonusAwardExceedsMaximum
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c107484550"
      unitRef="USD">289700000</sava:CashIncentiveBonusAwardExceedsMaximum>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2023-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c107484554"
      unitRef="Pure">14</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:CashIncentiveBonusAward
      contextRef="i_2020-10-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-5"
      id="c107484557"
      unitRef="USD">6500000</sava:CashIncentiveBonusAward>
    <sava:CashBonusIncentiveIncrementalAmounts
      contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="INF"
      id="c107484558"
      unitRef="Pure">11</sava:CashBonusIncentiveIncrementalAmounts>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MinimumMember"
      decimals="-5"
      id="c107484559"
      unitRef="USD">74900000</sava:PerformancePlanValuationMilestoneAmount>
    <sava:PerformancePlanValuationMilestoneAmount
      contextRef="i_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember_RangeAxis-MaximumMember"
      decimals="-5"
      id="c107484560"
      unitRef="USD">202300000</sava:PerformancePlanValuationMilestoneAmount>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c107484561"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <sava:PaymentsForCashIncentiveBonus
      contextRef="d_2022-01-01_2022-12-31_PlanNameAxis-CashIncentiveBonusPlanMember"
      decimals="-3"
      id="c107484567"
      unitRef="USD">0</sava:PaymentsForCashIncentiveBonus>
    <us-gaap:LossContingencyDisclosures contextRef="d_2023-01-01_2023-12-31" id="c2560590">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;The Company is, and from time to time, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive, inquiries from government authorities relating to matters arising from the ordinary course of business.&#160;The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assessment can be made as to their likely outcome or whether the outcome will be material to the Company. The Company believes that its total provisions for legal matters are adequate based upon currently available information.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;Government Investigations&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 15, 2021, &lt;/em&gt;the Company disclosed that certain government agencies had asked the Company to provide corporate information and documents. These were confidential requests. The Company has been voluntarily cooperating and intends to continue to cooperate with these inquiries. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; government agency has informed the Company that it has found evidence of research misconduct or wrongdoing by the Company or its officers, employees or directors. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; government agency has filed any claims or charges relating to these inquiries. We cannot predict the outcome or impact of these ongoing matters, including whether a government agency &lt;em style="font: inherit;"&gt; may &lt;/em&gt;pursue an enforcement action against the Company or others.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;&lt;i&gt;Securities Class Actions and Shareholder Derivative Actions&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;Between &lt;em style="font: inherit;"&gt; August 27, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 26, 2021, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c107484574"&gt;four&lt;/span&gt; putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; June 30, 2022, &lt;/em&gt;a federal judge consolidated the &lt;span style="-sec-ix-hidden:c107484575"&gt;four&lt;/span&gt; class action lawsuits into &lt;span style="-sec-ix-hidden:c107484576"&gt;one&lt;/span&gt; case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;on behalf of a putative class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; September 14, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; July 26, 2022. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; May 11, 2023, &lt;/em&gt;the court dismissed with prejudice plaintiffs&#x2019; claims against&#160;defendant Nadav Friedmann, PhD, MD,&#160;our former Chief Medical Officer and a Company director, who&#160;is now deceased, but otherwise denied defendants&#x2019; motion to dismiss. Defendants filed an answer to the consolidated amended complaint on &lt;em style="font: inherit;"&gt; July 3, 2023.&#160;&lt;/em&gt;On &lt;em style="font: inherit;"&gt; February 22, 2024, &lt;/em&gt;plaintiffs filed a motion to supplement their complaint to extend the putative class period through &lt;em style="font: inherit;"&gt; October 12, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; November 4, 2021, &lt;/em&gt;a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company&#x2019;s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant&#x2019;s alleged wrongful conduct. Although the plaintiff in this derivative case does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between &lt;em style="font: inherit;"&gt; November 4, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; June 20, 2023, &lt;/em&gt;four additional shareholder derivative actions were filed alleging substantially similar claims, &lt;span style="-sec-ix-hidden:c107484579"&gt;two&lt;/span&gt; in the U.S. District Court for the Western District of Texas, &lt;span style="-sec-ix-hidden:c107484580"&gt;one&lt;/span&gt; in Texas state court (Travis County District Court) and one in the Delaware Court of Chancery. On &lt;em style="font: inherit;"&gt; July 5, 2022, &lt;/em&gt;the &lt;span style="-sec-ix-hidden:c107484582"&gt;three&lt;/span&gt; federal court actions were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above.&#160;On &lt;em style="font: inherit;"&gt; November 9, 2023, &lt;/em&gt;another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas.&#160;The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 18pt;"&gt;On &lt;em style="font: inherit;"&gt; February 2, 2024, &lt;/em&gt;a putative class action lawsuit was filed alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an &lt;em style="font: inherit;"&gt; October 12, 2023 &lt;/em&gt;journal article that describes a purported leaked report of alleged scientific misconduct by a&#160;scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company&#x2019;s securities between &lt;em style="font: inherit;"&gt; August 18, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; October 12, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; August 19, 2022, &lt;/em&gt;a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company&#x2019;s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Cash Incentive Bonus Plan in &lt;em style="font: inherit;"&gt; August 2020. &lt;/em&gt;The complaints seek unspecified compensatory damages and other relief. On &lt;em style="font: inherit;"&gt; January 6, 2023, &lt;/em&gt;the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on &lt;em style="font: inherit;"&gt; March 10, 2023, &lt;/em&gt;and moved to partially dismiss the amended complaint on &lt;em style="font: inherit;"&gt; March 14, 2023. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; January 25, 2024, &lt;/em&gt;the parties entered into a binding settlement term sheet with respect to this action. The settlement is subject to certain conditions, including the filing of a Stipulation of Settlement and final court approval. The proposed settlement resolves the claims asserted against the Company and the individual defendants and would contain provisions that the settlement does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; constitute an admission, concession, or finding of any fault, liability, or wrongdoing of any kind by any defendant. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that the final settlement agreement will be executed or that such agreement will be approved by the court.&#160;&lt;/p&gt;
  </us-gaap:LossContingencyDisclosures>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-04_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsTexasCourtMember"
      decimals="INF"
      id="c107484578"
      unitRef="Pure">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="d_2021-11-01_2023-06-20_LitigationCaseAxis-ShareholderDerivativeActionsDelawareCourtMember"
      decimals="INF"
      id="c107484581"
      unitRef="Pure">1</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560591">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Subsequent Event - Warrant Dividend Distribution&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; January 3, 2024, &lt;/em&gt;the Company&#160;completed&#160;a distribution&#160;to the holders of record of the Company&#x2019;s shares of common stock&#160;in the form of warrants to purchase shares of common stock. Each holder of record of the Company's common stock as of the close of business on &lt;em style="font: inherit;"&gt; December 22, 2023 &lt;/em&gt;received &lt;span style="-sec-ix-hidden:c107484588"&gt;four&lt;/span&gt; warrants for every ten shares of common stock (rounded down&#160;for any fractional warrant) resulting in the issuance of approximately &lt;span style="-sec-ix-hidden:c107484590"&gt;16.9&lt;/span&gt; million&#160;warrants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;Each warrant entitles the holder to purchase, at the holder&#x2019;s sole expense and exclusive election, at an exercise price of $33.00 per warrant, &lt;span style="-sec-ix-hidden:c107484592"&gt;one&lt;/span&gt; share of common stock plus, to the extent described below, the Bonus Share Fraction. Payment for shares of common stock upon exercise of warrants must be in cash.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;A Bonus Share Fraction entitles a holder to receive an additional 0.5 of a share of common stock (rounded down for any fractional share) for each warrant exercised (the &#x201c;Bonus Share Fraction&#x201d;) without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire upon the earlier of (i) the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; business day following the last day of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;30&lt;/em&gt; consecutive trading day period (commencing on or after &lt;em style="font: inherit;"&gt; January 3, 2024) &lt;/em&gt;in which the daily volume weighted average price (the &#x201c;VWAP&#x201d;) of the shares of common stock has been at the then applicable trigger price, initially $26.40, for at least &lt;em style="font: inherit;"&gt;20&lt;/em&gt; trading days (whether or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; consecutive) (the &#x201c;Bonus Price Condition&#x201d;) and (ii) the date specified by the Company upon &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than &lt;em style="font: inherit;"&gt;20&lt;/em&gt; business days&#x2019; public notice (either condition being the &#x201c;Bonus Share Expiration Date&#x201d;). Any warrant exercised with an exercise date after the Bonus Share&#160;Expiration Date will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be entitled to the Bonus Share Fraction. The Company&#160;will make a public announcement of the Bonus Share Expiration Date (i) at least &lt;em style="font: inherit;"&gt;20&lt;/em&gt; business days prior to such date, in the case of the Company&#160;setting a Bonus Share Expiration Date and (ii) prior to market open on the Bonus Share Expiration Date in the case of a Bonus Price Condition.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;Unless earlier redeemed, the warrants will expire and cease to be exercisable&#160;on &lt;em style="font: inherit;"&gt; November 15, 2024 (&lt;/em&gt;the &#x201c;Expiration Date&#x201d;). The warrants are redeemable at the Company&#x2019;s sole option at any time with a redemption date on or after &lt;em style="font: inherit;"&gt; April 15, 2024. &lt;/em&gt;The Company will provide at least &lt;em style="font: inherit;"&gt;20&lt;/em&gt; calendar days&#x2019; notice by press release&#160;of the date selected for redemption (the &#x201c;Redemption Date&#x201d;). The redemption price upon any redemption shall equal to &lt;span style="-sec-ix-hidden:c107484606"&gt;1/10&lt;/span&gt; of $0.01 per warrant. The warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised at any time starting on &lt;em style="font: inherit;"&gt; January 3, 2024&#160;&lt;/em&gt;until the earlier of (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) the Expiration Date and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the business day prior to the Redemption Date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;The number of shares of Common Stock issuable upon exercise is subject to certain anti-dilution adjustments, including for share dividends, splits, subdivisions, spin-offs, consolidations, reclassifications, combinations, non-cash distributions and cash dividends. Terms of the warrants prohibit ownership by warrant exercise&#160;of &lt;em style="font: inherit;"&gt;9.9%&lt;/em&gt; or more of the Company's common stock by a single or affiliated group of stockholders without the Company's prior written consent.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;The right to exercise warrants shall be automatically suspended&#160;in a circumstance while&#160;there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; effective registration statement registering the shares of common stock issuable upon exercise of the warrants.&#160;Such registration statement was declared effective by the SEC on &lt;em style="font: inherit;"&gt; May 1, 2023.&#160;&lt;/em&gt;The warrant Expiration Date or the Redemption Date, as the case &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be, shall be extended by the number of days comprised in the event of a suspension.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;from time to time&#160;and in its sole discretion amend warrants for &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more of the following purposes: (i) to cure any ambiguity, omission, defect or inconsistency; (ii) to provide for the assumption by a successor company in any business combination; (iii) to postpone the Expiration Date; (iv) to decrease the warrant exercise price or increase the basic warrant exercise rate or the Bonus Share Fraction; (v) to reinstate a Bonus Share Period after the Bonus Share Expiration Date;&#160;(vi) to provide for net share settlement upon exercise of the warrants; (vii) to make any change that does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; adversely affect the rights of any warrant holder in any material respect; (viii) to provide for a successor warrant agent or calculation agent; (ix) in connection with any business combination, to provide that the warrants are exercisable for appropriate consideration; or (&lt;em style="font: inherit;"&gt;x&lt;/em&gt;) other conforming changes.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt; text-indent: 18pt; text-align: justify;"&gt;The warrants are listed and traded separately from the Company's common stock on the Nasdaq Capital Market under the ticker &#x201c;SAVAW&#x201d;.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 9pt; text-align: justify;"&gt;From &lt;em style="font: inherit;"&gt; January 3, 2024 &lt;/em&gt;to &lt;em style="font: inherit;"&gt; February 26, 2024, &lt;/em&gt;a total of approximately &lt;span style="-sec-ix-hidden:c107484615"&gt;659,000&lt;/span&gt;&#160;warrants were exercised resulting in gross proceeds to the Company of approximately $21.8&#160;million. The Company issued approximately 989,000&#160;shares of common stock, including Bonus Share Fractions, from the exercise of warrants through &lt;em style="font: inherit;"&gt; February 26, 2024. &lt;/em&gt;After the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; $20 million of gross proceeds, the Company is&#160;obligated to pay a commission of&#160;2.5% of the gross proceeds from the sale of shares of common stock in the offering to the Company's financial advisor for the warrant distribution.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2023-12-22_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember"
      decimals="INF"
      id="c107484589"
      unitRef="Share">10</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484591"
      unitRef="USDPerShare">33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2024-01-03_ClassOfWarrantOrRightAxis-BonusShareFractionMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484593"
      unitRef="Share">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <sava:VolumeWeightedAveragePrice
      contextRef="i_2023-12-22"
      decimals="INF"
      id="c107484597"
      unitRef="USDPerShare">26.4</sava:VolumeWeightedAveragePrice>
    <sava:WarrantRedemptionPrice
      contextRef="i_2024-11-15_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484607"
      unitRef="USDPerShare">0.01</sava:WarrantRedemptionPrice>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c107484616"
      unitRef="USD">21800000</us-gaap:ProceedsFromWarrantExercises>
    <sava:StockIssuedDuringPeriodSharesWarrantExercises
      contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c107484617"
      unitRef="Share">989000</sava:StockIssuedDuringPeriodSharesWarrantExercises>
    <sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission
      contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-7"
      id="c107484619"
      unitRef="USD">20000000</sava:ProceedsFromWarrantsExercisedThatObligatedToPayCommission>
    <sava:CommissionPercentageOfGrossProceeds
      contextRef="d_2024-01-03_2024-02-26_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="3"
      id="c107484621"
      unitRef="Pure">0.025</sava:CommissionPercentageOfGrossProceeds>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2023-01-01_2023-12-31" id="c2560592">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;a href="#" id="item9b" title="item9b"&gt;&lt;/a&gt;Item &lt;em style="font: inherit;"&gt;9B.&lt;/em&gt;&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b&gt;&lt;i&gt;Other Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:18pt;"&gt;During the quarter ended &lt;em style="font: inherit;"&gt; December 31, 2023, &lt;/em&gt;&lt;span style="-sec-ix-hidden:c107484626"&gt;&lt;span style="-sec-ix-hidden:c107484634"&gt;&lt;span style="-sec-ix-hidden:c107484635"&gt;&lt;span style="-sec-ix-hidden:c107484636"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or officers (as defined in Rule &lt;em style="font: inherit;"&gt;16a&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt;(f) of the Exchange Act) informed us of the adoption or termination of a &#x201c;Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement&#x201d; or &#x201c;non-Rule &lt;em style="font: inherit;"&gt;10b5&lt;/em&gt;-&lt;em style="font: inherit;"&gt;1&lt;/em&gt; trading arrangement,&#x201d; as those terms are defined in Regulation S-K, Item &lt;em style="font: inherit;"&gt;408.&lt;/em&gt;&lt;/p&gt;
  </ecd:MtrlTermsOfTrdArrTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
